assay_id,assay_test_type,assay_organism,assay_category,assay_type,relationship_type,curated_by,assay_tissue,assay_tax_id,description,tid,variant_id,src_assay_id,src_id,doc_id,bao_format,confidence_score,chembl_id,cell_id,tissue_id
7524,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL618647,,2113.0
7525,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,50597,,,1,9866,BAO_0000218,1,CHEMBL618648,,2113.0
7526,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL618649,,2113.0
7527,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL618650,,2107.0
7528,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,50597,,,1,9866,BAO_0000218,1,CHEMBL618651,,2107.0
7529,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL876497,,2107.0
7530,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL618652,,2048.0
7531,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,50597,,,1,9866,BAO_0000218,1,CHEMBL618653,,2048.0
7532,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL618654,,2048.0
7533,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,50597,,,1,6351,BAO_0000218,1,CHEMBL618655,,
7534,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was tested for solubility in water,50597,,,1,1465,BAO_0000218,1,CHEMBL618656,,
7535,,,,P,U,Intermediate,,,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),22229,,,1,5182,BAO_0000100,0,CHEMBL618657,,
7536,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Solubility was determined,50597,,,1,17847,BAO_0000218,1,CHEMBL618658,,
7537,,Rattus norvegicus,,A,N,Intermediate,,10116.0,solubility in water (ug/mL) at 37 degree C.,50597,,,1,15339,BAO_0000218,1,CHEMBL618659,,
7538,,Rattus norvegicus,,A,N,Intermediate,,10116.0,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,50597,,,1,5202,BAO_0000218,1,CHEMBL618660,,
7539,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,50597,,,1,1088,BAO_0000218,1,CHEMBL618661,,
7540,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in rats,50597,,,1,3169,BAO_0000218,1,CHEMBL873807,,
7541,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in Dawley rat,50597,,,1,5353,BAO_0000218,1,CHEMBL618662,,
7542,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period after 3 mg/kg iv administration,50597,,,1,2864,BAO_0000218,1,CHEMBL618663,,
7543,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period after 3 mg/kg iv administration in rat,50597,,,1,2864,BAO_0000218,1,CHEMBL618664,,
7544,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period after 3 mg/kg iv administration in the rat,50597,,,1,2864,BAO_0000218,1,CHEMBL618665,,
7545,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period in female Sprague-Dawley rats,50597,,,1,6362,BAO_0000218,1,CHEMBL876498,,
7546,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period in rat,50597,,,1,6249,BAO_0000218,1,CHEMBL618666,,
7547,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life in rats was determined,50597,,,1,3169,BAO_0000218,1,CHEMBL620440,,
7548,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life in rats with metabolic oxidation,50597,,,1,3169,BAO_0000218,1,CHEMBL620441,,
7549,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life in rats,50597,,,1,3169,BAO_0000218,1,CHEMBL620442,,
7550,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,,,1,17260,BAO_0000218,1,CHEMBL620443,,
7551,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,,,1,17260,BAO_0000218,1,CHEMBL620444,,
7552,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,,,1,17260,BAO_0000218,1,CHEMBL620445,,
7553,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,,,1,17260,BAO_0000218,1,CHEMBL620446,,
7554,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Biological half-life measured in plasma of rat,50597,,,1,2879,BAO_0000218,1,CHEMBL620447,,1969.0
7555,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Biological half-life measured in plasma of rat; 22-25,50597,,,1,2879,BAO_0000218,1,CHEMBL621129,,1969.0
7556,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Biological half-life measured in plasma of rat; 9-16,50597,,,1,2879,BAO_0000218,1,CHEMBL621130,,1969.0
7557,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for its half life when administered intravenously in rat,50597,,,1,3184,BAO_0000218,1,CHEMBL873808,,
7558,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,50597,,,1,4891,BAO_0000218,1,CHEMBL876598,,
7559,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,50597,,,1,429,BAO_0000218,1,CHEMBL621131,,
7560,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life (T1/2) after oral administration in rat,50597,,,1,5656,BAO_0000218,1,CHEMBL621132,,
7561,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life of compound after iv administration of 20 mg/kg dose in rat,50597,,,1,4413,BAO_0000218,1,CHEMBL621133,,
7562,In vivo,Rattus norvegicus,,A,N,Expert,,10116.0,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,,,1,3598,BAO_0000218,1,CHEMBL621312,,
7563,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life of compound was determined in rat,50597,,,1,17267,BAO_0000218,1,CHEMBL621313,,
7564,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Half life of compound was determined in rat blood,50597,,,1,4727,BAO_0000218,1,CHEMBL621314,,178.0
7565,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life at 1 mg/kg was determined in rat,50597,,,1,17651,BAO_0000218,1,CHEMBL621315,,
7566,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life at 10 mg/kg was determined in rat,50597,,,1,17651,BAO_0000218,1,CHEMBL621316,,
7567,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in rats,50597,,,1,401,BAO_0000218,1,CHEMBL621317,,
7568,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in rats in hours,50597,,,1,4942,BAO_0000218,1,CHEMBL621318,,
7569,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,50597,,,1,17735,BAO_0000218,1,CHEMBL621319,,
7570,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,50597,,,1,6056,BAO_0000218,1,CHEMBL621377,,
7571,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life was determined,50597,,,1,5213,BAO_0000218,1,CHEMBL621378,,
7572,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life after i.v. administration,50597,,,1,6616,BAO_0000218,1,CHEMBL876599,,
7573,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,50597,,,1,5937,BAO_0000218,1,CHEMBL621379,,
7574,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life in rat plasma,50597,,,1,5819,BAO_0000218,1,CHEMBL621380,,1969.0
7575,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life in rat plasma; Not detected,50597,,,1,5819,BAO_0000218,1,CHEMBL621381,,1969.0
7576,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in rats,50597,,,1,6803,BAO_0000218,1,CHEMBL618515,,
7577,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period of compound was determined after peroral administration,50597,,,1,17804,BAO_0000218,1,CHEMBL618516,,
7578,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,50597,,,1,17804,BAO_0000218,1,CHEMBL618517,,
7579,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period in rat,50597,,,1,5948,BAO_0000218,1,CHEMBL618518,,
7580,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,50597,,,1,1916,BAO_0000218,1,CHEMBL618519,,
7581,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,50597,,,1,1916,BAO_0000218,1,CHEMBL618698,,
7582,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,50597,,,1,1916,BAO_0000218,1,CHEMBL618862,,
7583,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,50597,,,1,4890,BAO_0000218,1,CHEMBL618863,,
7584,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,50597,,,1,17764,BAO_0000218,1,CHEMBL618864,,
7585,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life time in rat the dose of 2 mg/kg,50597,,,1,4727,BAO_0000218,1,CHEMBL618865,,
7586,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life 24 hr after 10 mg/kg iv administration in rats,50597,,,1,17509,BAO_0000218,1,CHEMBL618866,,
7587,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life 24 hr after 2 mg/kg iv administration in rats,50597,,,1,17509,BAO_0000218,1,CHEMBL618867,,
7588,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life consistent with the observed metabolic steady state in rats,50597,,,1,6597,BAO_0000218,1,CHEMBL875828,,
7589,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,50597,,,1,17735,BAO_0000218,1,CHEMBL618868,,
7590,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life for oxidative metabolic stability was determined using male human,50597,,,1,6597,BAO_0000218,1,CHEMBL618869,,
7591,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",50597,,,1,17670,BAO_0000218,1,CHEMBL618870,,
7592,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half-life in rat plasma,50597,,,1,1696,BAO_0000218,1,CHEMBL618871,,1969.0
7593,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half-life in rat plasma was determined,50597,,,1,1742,BAO_0000218,1,CHEMBL618872,,1969.0
7594,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life in rats was determined,50597,,,1,17800,BAO_0000218,1,CHEMBL873816,,
7595,,,,A,U,Autocuration,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,22224,,,1,12923,BAO_0000218,0,CHEMBL618873,,
7596,,,,A,U,Autocuration,,,Area under curve after oral dose of 0.1 mg//kg,22224,,,1,11954,BAO_0000019,0,CHEMBL621602,,
7597,,,,A,U,Autocuration,,,Area under curve after oral dose of 0.3 mg/kg,22224,,,1,11954,BAO_0000218,0,CHEMBL621603,,
7598,,,,A,U,Autocuration,,,Area under curve after oral dose of 1 mg/kg,22224,,,1,11954,BAO_0000218,0,CHEMBL621604,,
7599,,,,A,U,Autocuration,,,Area under curve after oral dose of 10 mg/kg,22224,,,1,11954,BAO_0000218,0,CHEMBL621605,,
7600,,,,A,U,Autocuration,,,Area under curve after oral dose of 23.4 mg/kg,22224,,,1,11954,BAO_0000218,0,CHEMBL621606,,
7601,,,,A,U,Autocuration,,,Area under curve after oral dose of 3 mg/kg,22224,,,1,11954,BAO_0000218,0,CHEMBL621607,,
7602,,,,A,U,Autocuration,,,Area under curve after oral dose of 3.87 mg/kg,22224,,,1,11954,BAO_0000218,0,CHEMBL621608,,
7603,,,,A,U,Autocuration,,,Area under curve was determined,22224,,,1,5237,BAO_0000019,0,CHEMBL621609,,
7604,,,,A,U,Autocuration,,,Area under curve at a dose of 10 mg/kg,22224,,,1,4026,BAO_0000218,0,CHEMBL621610,,
7605,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined; ND=No data,50597,,,1,5237,BAO_0000218,1,CHEMBL621611,,
7606,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,50597,,,1,14793,BAO_0000218,1,CHEMBL621612,,
7607,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,50597,,,1,14793,BAO_0000218,1,CHEMBL622308,,
7608,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,50597,,,1,14793,BAO_0000218,1,CHEMBL622309,,
7609,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,50597,,,1,14793,BAO_0000218,1,CHEMBL622310,,
7610,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,50597,,,1,14793,BAO_0000218,1,CHEMBL622311,,
7611,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,50597,,,1,14793,BAO_0000218,1,CHEMBL622312,,
7612,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,50597,,,1,14793,BAO_0000218,1,CHEMBL622931,,
7613,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,50597,,,1,14793,BAO_0000218,1,CHEMBL622932,,
7614,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,50597,,,1,14793,BAO_0000218,1,CHEMBL622736,,1969.0
7615,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,50597,,,1,14793,BAO_0000218,1,CHEMBL622737,,1969.0
7616,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,50597,,,1,14793,BAO_0000218,1,CHEMBL622738,,1969.0
7617,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,50597,,,1,14793,BAO_0000218,1,CHEMBL622739,,1969.0
7618,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,50597,,,1,14793,BAO_0000218,1,CHEMBL622740,,1969.0
7619,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,50597,,,1,14793,BAO_0000218,1,CHEMBL622741,,1969.0
7620,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,50597,,,1,14793,BAO_0000218,1,CHEMBL622742,,1969.0
7621,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,50597,,,1,14793,BAO_0000218,1,CHEMBL622743,,1969.0
7622,,Mus musculus,,A,N,Intermediate,Plasma,10090.0,AUC in mice,50594,,,1,11637,BAO_0000218,1,CHEMBL622744,,1969.0
7623,,,,A,U,Autocuration,,,Area under curve was measured from the graph obtained from concentration Vs time,22224,,,1,11149,BAO_0000019,0,CHEMBL624134,,
7624,,,,A,U,Autocuration,,,Area under curve value of compound per hour after oral administration,22224,,,1,10016,BAO_0000019,0,CHEMBL624135,,
7625,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined after oral administration in rats,50597,,,1,17796,BAO_0000218,1,CHEMBL624136,,
7626,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined after oral administration in rats; No data,50597,,,1,17796,BAO_0000218,1,CHEMBL624137,,
7627,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined after oral administration in rats;No data,50597,,,1,17796,BAO_0000218,1,CHEMBL624320,,
7628,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,50588,,,1,12923,BAO_0000218,1,CHEMBL624321,,
7629,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,50597,,,1,15372,BAO_0000218,1,CHEMBL624322,,
7630,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined for the compound after iv dose of 5.06 in rats,50597,,,1,15372,BAO_0000218,1,CHEMBL624323,,
7631,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,50597,,,1,15372,BAO_0000218,1,CHEMBL624324,,
7632,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,50597,,,1,15372,BAO_0000218,1,CHEMBL624325,,
7633,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,50597,,,1,15372,BAO_0000218,1,CHEMBL624326,,
7634,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,50597,,,1,15372,BAO_0000218,1,CHEMBL624327,,
7635,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,50597,,,1,15372,BAO_0000218,1,CHEMBL624328,,
7636,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve was determined in Dogs after peroral administration,50588,,,1,14169,BAO_0000218,1,CHEMBL627848,,
7637,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined in Rats after peroral administration,50597,,,1,14169,BAO_0000218,1,CHEMBL627849,,
7638,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined in carotid blood of rat when administered intradermally,50597,,,1,14258,BAO_0000218,1,CHEMBL627850,,
7639,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined in portal blood of rat when administered intradermally,50597,,,1,14258,BAO_0000218,1,CHEMBL627851,,
7640,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,50594,,,1,15011,BAO_0000218,1,CHEMBL627852,,
7641,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,50594,,,1,15011,BAO_0000218,1,CHEMBL627853,,
7642,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),50594,,,1,15011,BAO_0000218,1,CHEMBL627854,,
7643,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,50594,,,1,15011,BAO_0000218,1,CHEMBL627855,,
7644,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),50594,,,1,15011,BAO_0000218,1,CHEMBL627856,,
7645,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,50594,,,1,15011,BAO_0000218,1,CHEMBL875339,,
7646,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),50594,,,1,15011,BAO_0000218,1,CHEMBL627857,,
7647,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL627858,,2106.0
7648,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL627859,,178.0
7649,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL627860,,955.0
7650,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL627019,,948.0
7651,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL627020,,2107.0
7652,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL627021,,2048.0
7653,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL627022,,2385.0
7654,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL627023,,
7655,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL627024,,2106.0
7656,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL627025,,2046.0
7657,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL627026,,2113.0
7658,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL627027,,178.0
7659,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL627028,,955.0
7660,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL627029,,948.0
7661,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL627030,,2113.0
7662,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL627031,,2107.0
7663,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL627032,,2048.0
7664,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL627033,,2385.0
7665,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL627034,,
7666,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL627035,,2106.0
7667,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL627036,,2046.0
7668,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL875340,,178.0
7669,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL627037,,948.0
7670,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL627038,,2113.0
7671,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL627039,,2107.0
7672,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL627040,,2385.0
7673,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL624663,,2106.0
7674,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL625963,,2046.0
7675,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL876799,,955.0
7676,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL626133,,2048.0
7677,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,50597,,,1,10130,BAO_0000218,1,CHEMBL626134,,
7678,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,50597,,,1,6295,BAO_0000218,1,CHEMBL626135,,
7679,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,50597,,,1,6296,BAO_0000218,1,CHEMBL626136,,
7680,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,50597,,,1,6296,BAO_0000218,1,CHEMBL626137,,
7681,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,50597,,,1,6295,BAO_0000218,1,CHEMBL626138,,
7682,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,50597,,,1,6296,BAO_0000218,1,CHEMBL626139,,
7683,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,,,1,17260,BAO_0000218,1,CHEMBL626140,,
7684,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,,,1,17260,BAO_0000218,1,CHEMBL626141,,
7685,,Rattus norvegicus,,A,N,Intermediate,,10116.0,C24h in rat p.o. at 20 mg/kg concentration,50597,,,1,17686,BAO_0000218,1,CHEMBL626142,,
7686,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL627930,,2385.0
7687,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,50597,,,1,9866,BAO_0000218,1,CHEMBL627931,,2385.0
7688,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL627932,,2385.0
7689,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL627933,,2106.0
7690,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,50597,,,1,9866,BAO_0000218,1,CHEMBL627934,,2106.0
7691,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL627935,,2106.0
7692,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,50597,,,1,9866,BAO_0000218,1,CHEMBL627936,,178.0
7693,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,50597,,,1,9866,BAO_0000218,1,CHEMBL627937,,178.0
7694,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,50597,,,1,9866,BAO_0000218,1,CHEMBL627938,,178.0
7695,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,50597,,,1,9866,BAO_0000218,1,CHEMBL627939,,178.0
7696,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,50597,,,1,9866,BAO_0000218,1,CHEMBL627940,,178.0
7697,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,50597,,,1,9866,BAO_0000218,1,CHEMBL627941,,178.0
7698,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,,,1,9866,BAO_0000218,1,CHEMBL876800,,178.0
7699,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,50597,,,1,9866,BAO_0000218,1,CHEMBL627942,,178.0
7700,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,50597,,,1,9866,BAO_0000218,1,CHEMBL627943,,178.0
7701,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,50597,,,1,9866,BAO_0000218,1,CHEMBL627944,,178.0
7702,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL627945,,178.0
7703,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL628584,,178.0
7704,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of GdDTPA at 15 min,50597,,,1,9866,BAO_0000218,1,CHEMBL628585,,178.0
7705,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL628586,,178.0
7706,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of GdDTPA at 30 min,50597,,,1,9866,BAO_0000218,1,CHEMBL628587,,178.0
7707,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL628588,,178.0
7708,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,50597,,,1,9866,BAO_0000218,1,CHEMBL628589,,178.0
7709,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,50597,,,1,9866,BAO_0000218,1,CHEMBL625304,,178.0
7710,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL625305,,178.0
7711,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL625306,,178.0
7712,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,50597,,,1,9866,BAO_0000218,1,CHEMBL625307,,178.0
7713,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,50597,,,1,9866,BAO_0000218,1,CHEMBL625308,,178.0
7714,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL627740,,178.0
7715,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL627741,,178.0
7716,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,,,1,9866,BAO_0000218,1,CHEMBL627742,,178.0
7717,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,50597,,,1,9866,BAO_0000218,1,CHEMBL627743,,178.0
7718,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,50597,,,1,9866,BAO_0000218,1,CHEMBL627744,,178.0
7719,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,50597,,,1,9866,BAO_0000218,1,CHEMBL627745,,10000001.0
7720,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,50597,,,1,9866,BAO_0000218,1,CHEMBL627746,,10000001.0
7721,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,50597,,,1,9866,BAO_0000218,1,CHEMBL627747,,10000001.0
7722,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,50597,,,1,9866,BAO_0000218,1,CHEMBL876810,,10000001.0
7723,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,50597,,,1,9866,BAO_0000218,1,CHEMBL627748,,10000001.0
7724,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,50597,,,1,9866,BAO_0000218,1,CHEMBL627749,,10000001.0
7725,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,,,1,9866,BAO_0000218,1,CHEMBL627750,,10000001.0
7726,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,50597,,,1,9866,BAO_0000218,1,CHEMBL618728,,10000001.0
7727,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,50597,,,1,9866,BAO_0000218,1,CHEMBL618729,,10000001.0
7728,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in rat bone in the presence of GdDTPA at 15 min,50597,,,1,9866,BAO_0000218,1,CHEMBL618730,,10000001.0
7729,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL618731,,10000001.0
7730,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in rat bone in the presence of GdDTPA at 30 min,50597,,,1,9866,BAO_0000218,1,CHEMBL618732,,10000001.0
7731,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL618733,,10000001.0
7732,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,50597,,,1,9866,BAO_0000218,1,CHEMBL618734,,10000001.0
7733,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL618735,,10000001.0
7734,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,50597,,,1,9866,BAO_0000218,1,CHEMBL876602,,10000001.0
7735,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL618736,,10000001.0
7736,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,50597,,,1,9866,BAO_0000218,1,CHEMBL618737,,10000001.0
7737,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL618738,,10000001.0
7738,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,50597,,,1,9866,BAO_0000218,1,CHEMBL618739,,10000001.0
7739,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL618740,,10000001.0
7740,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,,,1,9866,BAO_0000218,1,CHEMBL618741,,10000001.0
7741,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,50597,,,1,9866,BAO_0000218,1,CHEMBL618742,,10000001.0
7742,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,50597,,,1,9866,BAO_0000218,1,CHEMBL618743,,10000001.0
7743,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half-life from rat plasma at a single oral dose of 25 mg/kg,50597,,,1,17752,BAO_0000218,1,CHEMBL618744,,1969.0
7744,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life in male rat,50597,,,1,5610,BAO_0000218,1,CHEMBL618745,,
7745,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life in rat after peroral administration at 10 mg/kg concentration,50597,,,1,5939,BAO_0000218,1,CHEMBL620479,,
7746,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life in rat after peroral administration at 5 mg/kg concentration,50597,,,1,5939,BAO_0000218,1,CHEMBL620480,,
7747,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life in rat at a dose of 3 mg/kg,50597,,,1,17771,BAO_0000218,1,CHEMBL620481,,
7748,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life was evaluated in rats,50597,,,1,1974,BAO_0000218,1,CHEMBL620482,,
7749,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life was measured in rat,50597,,,1,4239,BAO_0000218,1,CHEMBL876603,,
7750,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life period for the compound was determined in rats at 50 mg/kg dose,50597,,,1,6681,BAO_0000218,1,CHEMBL620483,,
7751,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life period in rats after intravenous administration at 5 mg/kg,50597,,,1,17752,BAO_0000218,1,CHEMBL620484,,
7752,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life period in rat at 10 mg/kg,50597,,,1,6046,BAO_0000218,1,CHEMBL620485,,
7753,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",50597,,,1,6685,BAO_0000218,1,CHEMBL620486,,
7754,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",50597,,,1,6685,BAO_0000218,1,CHEMBL620487,,
7755,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",50597,,,1,6685,BAO_0000218,1,CHEMBL620488,,
7756,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life time in rat the dose of 2 mg/kg,50597,,,1,4727,BAO_0000218,1,CHEMBL620489,,
7757,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,50597,,,1,1088,BAO_0000218,1,CHEMBL620490,,
7758,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,50597,,,1,5610,BAO_0000218,1,CHEMBL620491,,
7759,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",50597,,,1,3032,BAO_0000218,1,CHEMBL876604,,1969.0
7760,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral half life was determined,50597,,,1,5199,BAO_0000218,1,CHEMBL620492,,
7761,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",50597,,,1,14941,BAO_0000218,1,CHEMBL620493,,
7762,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (t1/2) in rat,50597,,,1,4408,BAO_0000218,1,CHEMBL620494,,
7763,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma elimination half-life was determined,50597,,,1,2552,BAO_0000218,1,CHEMBL620495,,1969.0
7764,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,50597,,,1,5199,BAO_0000218,1,CHEMBL620496,,1969.0
7765,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma half life was observed after intravenous administration in rat,50597,,,1,15662,BAO_0000218,1,CHEMBL620497,,1969.0
7766,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma half-life was determined,50597,,,1,1465,BAO_0000218,1,CHEMBL620498,,1969.0
7767,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma half-life following oral administration in Fisher rats,50597,,,1,1446,BAO_0000218,1,CHEMBL620499,,1969.0
7768,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma half-life in rat,50597,,,1,6824,BAO_0000218,1,CHEMBL620500,,1969.0
7769,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasmatic Half-life after intravenous administration to rat,50597,,,1,17533,BAO_0000218,1,CHEMBL873809,,1969.0
7770,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,50597,,,1,5979,BAO_0000218,1,CHEMBL620501,,
7771,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Terminal half life after intravenous administration (1 mg/kg) in rat,50597,,,1,4689,BAO_0000218,1,CHEMBL620502,,
7772,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Terminal half life in Rat at a oral dose of 5 mg/kg,50597,,,1,4689,BAO_0000218,1,CHEMBL620503,,
7773,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,50597,,,1,2463,BAO_0000218,1,CHEMBL620504,,
7774,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,50597,,,1,4883,BAO_0000218,1,CHEMBL876605,,
7775,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,50597,,,1,4883,BAO_0000218,1,CHEMBL620505,,
7776,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,plasma half life was observed after intravenous administration in rat,50597,,,1,15662,BAO_0000218,1,CHEMBL873811,,1969.0
7777,In vivo,Rattus norvegicus,,A,N,Expert,,10116.0,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,,,1,3598,BAO_0000218,1,CHEMBL624016,,
7778,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life of compound determined in rat,50597,,,1,4576,BAO_0000218,1,CHEMBL624017,,
7779,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean residence time determined in rat,50597,,,1,4576,BAO_0000218,1,CHEMBL624018,,
7780,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma half life determined in rat,50597,,,1,4576,BAO_0000218,1,CHEMBL624019,,
7781,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Compound was evaluated for Tmax in brain after intravenous administration in male rats,50597,,,1,4910,BAO_0000218,1,CHEMBL624020,,955.0
7782,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for pharmacokinetic parameter maximum time period,50597,,,1,4891,BAO_0000218,1,CHEMBL624201,,
7783,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,50597,,,1,429,BAO_0000218,1,CHEMBL872528,,
7784,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,,,1,5974,BAO_0000218,1,CHEMBL624202,,
7785,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,,,1,5974,BAO_0000218,1,CHEMBL624203,,
7786,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,,,1,5974,BAO_0000218,1,CHEMBL624350,,
7787,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,,,1,5974,BAO_0000218,1,CHEMBL621320,,
7788,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,50597,,,1,17582,BAO_0000218,1,CHEMBL621321,,
7789,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum time (Tmax) required to reach Cmax in rats,50597,,,1,4026,BAO_0000218,1,CHEMBL621322,,
7790,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,50597,,,1,4890,BAO_0000218,1,CHEMBL621323,,
7791,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum time of clearance of compound in rats after peroral administration,50597,,,1,6571,BAO_0000218,1,CHEMBL621324,,
7792,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum time at the dose of 2 mg/kg in rat,50597,,,1,4727,BAO_0000218,1,CHEMBL621325,,
7793,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,50597,,,1,17651,BAO_0000218,1,CHEMBL875837,,1969.0
7794,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,50597,,,1,17651,BAO_0000218,1,CHEMBL621326,,1969.0
7795,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax in Guinea pig (PO dose),50597,,,1,14465,BAO_0000218,1,CHEMBL621327,,
7796,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",50597,,,1,14941,BAO_0000218,1,CHEMBL621328,,
7797,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter (Tmax) in rat,50597,,,1,5960,BAO_0000218,1,CHEMBL621329,,
7798,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter (Tmax) was estimated,50597,,,1,5022,BAO_0000218,1,CHEMBL621330,,
7799,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (Tmax) in rat,50597,,,1,4408,BAO_0000218,1,CHEMBL621331,,
7800,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,50597,,,1,5983,BAO_0000218,1,CHEMBL621332,,
7801,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,T max in Rat at a oral dose of 5 mg/kg,50597,,,1,4689,BAO_0000218,1,CHEMBL621333,,
7802,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,T max was determined at 10 mg/kg po dose in rats,50597,,,1,2792,BAO_0000218,1,CHEMBL621334,,
7803,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),50594,,,1,15011,BAO_0000218,1,CHEMBL621335,,
7804,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,50588,,,1,14180,BAO_0000218,1,CHEMBL621336,,
7805,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,50597,,,1,14180,BAO_0000218,1,CHEMBL621337,,
7806,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve was measured after i.v. administration into Beagle dog.,50588,,,1,14599,BAO_0000218,1,CHEMBL621338,,
7807,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve was measured after iv administration into Beagle dog,50588,,,1,14599,BAO_0000218,1,CHEMBL875838,,
7808,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve was measured after po administration into Beagle dog,50588,,,1,14599,BAO_0000218,1,CHEMBL621339,,
7809,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve was measured after po administration into Beagle dog.,50588,,,1,14599,BAO_0000218,1,CHEMBL621340,,
7810,,,,A,U,Autocuration,,,Area under curve was measured at peroral dose of 3 mg/kg,22224,,,1,15675,BAO_0000218,0,CHEMBL621341,,
7811,,,,A,U,Autocuration,,,Area under curve was measured by using concentration Vs time,22224,,,1,12706,BAO_0000019,0,CHEMBL621342,,
7812,,,,A,U,Autocuration,,,Area under curve was measured by using concentration Vs time; not tested,22224,,,1,12706,BAO_0000019,0,CHEMBL621343,,
7813,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),50594,,,1,9750,BAO_0000218,1,CHEMBL621344,,
7814,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve(AUC) was measured in mice after oral administration.,50594,,,1,9750,BAO_0000218,1,CHEMBL621345,,
7815,,,,A,U,Autocuration,,,Area under curve(AUC) value of the compound,22224,,,1,14691,BAO_0000019,0,CHEMBL621346,,
7816,,,,A,U,Autocuration,,,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,22224,,,1,14691,BAO_0000218,0,CHEMBL621347,,
7817,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,50588,,,1,14691,BAO_0000218,1,CHEMBL621348,,
7818,,,,A,U,Autocuration,Blood,,Area under curve(carotid artery) was determined by the availability in blood,22224,,,1,2939,BAO_0000019,0,CHEMBL621349,,178.0
7819,,,,A,U,Autocuration,Blood,,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,22224,,,1,2939,BAO_0000019,0,CHEMBL621350,,178.0
7820,,,,A,U,Autocuration,Blood,,Area under curve(carotid artery) was determined by the availability in blood; No data,22224,,,1,2939,BAO_0000019,0,CHEMBL875839,,178.0
7821,,,,A,U,Autocuration,Blood,,Area under curve(portal vein) was determined by the availability in blood,22224,,,1,2939,BAO_0000019,0,CHEMBL620211,,178.0
7822,,,,A,U,Autocuration,Blood,,Area under curve(portal vein) was determined by the availability in blood; ND means no data,22224,,,1,2939,BAO_0000019,0,CHEMBL620212,,178.0
7823,,,,A,U,Autocuration,Blood,,Area under curve(portal vein) was determined by the availability in blood; No data,22224,,,1,2939,BAO_0000019,0,CHEMBL620213,,178.0
7824,,Macaca mulatta,,A,N,Intermediate,Plasma,9544.0,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",50797,,,1,9552,BAO_0000218,1,CHEMBL620214,,1969.0
7825,,Macaca mulatta,,A,N,Intermediate,Plasma,9544.0,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",50797,,,1,9552,BAO_0000218,1,CHEMBL620215,,1969.0
7826,,Macaca mulatta,,A,N,Intermediate,Plasma,9544.0,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,50797,,,1,9552,BAO_0000218,1,CHEMBL620216,,1969.0
7827,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",50588,,,1,9552,BAO_0000218,1,CHEMBL620888,,1969.0
7828,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",50588,,,1,9552,BAO_0000218,1,CHEMBL620889,,1969.0
7829,,,,A,U,Autocuration,Plasma,,Area under plasma concentration vs time curve observed in rats for 0-3 h,22224,,,1,9552,BAO_0000019,0,CHEMBL620890,,1969.0
7830,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Area under plasma time curve determined in male rat,50597,,,1,11911,BAO_0000218,1,CHEMBL620891,,1969.0
7831,,,,A,U,Autocuration,,,Area under the MAP curve measured over 5 min.,22224,,,1,16618,BAO_0000019,0,CHEMBL620892,,
7832,,Mus musculus,,A,N,Intermediate,,10090.0,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,50594,,,1,14387,BAO_0000218,1,CHEMBL621079,,
7833,,Mus musculus,,A,N,Intermediate,,10090.0,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,50594,,,1,14387,BAO_0000218,1,CHEMBL621080,,
7834,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,50588,,,1,12836,BAO_0000218,1,CHEMBL621081,,
7835,,Cricetinae,,A,N,Intermediate,,10026.0,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,100712,,,1,12836,BAO_0000218,1,CHEMBL621082,,
7836,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,50597,,,1,12836,BAO_0000218,1,CHEMBL621083,,
7837,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,50588,,,1,14339,BAO_0000218,1,CHEMBL621084,,
7838,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,50588,,,1,14339,BAO_0000218,1,CHEMBL621085,,
7839,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,50588,,,1,14339,BAO_0000218,1,CHEMBL621086,,
7840,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),50588,,,1,10524,BAO_0000218,1,CHEMBL621087,,
7841,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),50588,,,1,9994,BAO_0000218,1,CHEMBL622607,,
7842,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Serum AUC in marmosets (IV dose),50588,,,1,11325,BAO_0000218,1,CHEMBL622608,,
7843,,,,A,U,Autocuration,,,Area under the curve after intravenous administration at a dose of 10 umol/kg,22224,,,1,12536,BAO_0000019,0,CHEMBL624481,,
7844,,,,A,U,Autocuration,,,Area under the curve after intravenous administration at a dose of 2 umol/kg,22224,,,1,12536,BAO_0000019,0,CHEMBL624482,,
7845,,,,A,U,Autocuration,,,Area under the curve after intravenous administration at a dose of 4 umol/kg,22224,,,1,12536,BAO_0000019,0,CHEMBL624483,,
7846,,,,A,U,Autocuration,,,Area under the curve after intravenous administration at a dose of 40 umol/kg,22224,,,1,12536,BAO_0000019,0,CHEMBL624484,,
7847,,,,A,U,Autocuration,,,Area under the curve after intravenous administration at a dose of 5 umol/kg,22224,,,1,12536,BAO_0000019,0,CHEMBL624485,,
7848,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve for fumarate salt was evaluated in F344 Rats.,50597,,,1,15556,BAO_0000218,1,CHEMBL624486,,
7849,,,,A,U,Autocuration,,,Area under the curve for the compound was calculated.,22224,,,1,2809,BAO_0000019,0,CHEMBL624487,,
7850,,,,A,U,Autocuration,,,Area under the curve in concentration/ time,22224,,,1,9511,BAO_0000019,0,CHEMBL624488,,
7851,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve administered intraintestinal in rats.,50597,,,1,12818,BAO_0000218,1,CHEMBL624489,,
7852,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve administered intravenously in rats.,50597,,,1,12818,BAO_0000218,1,CHEMBL625184,,
7853,,,,A,U,Autocuration,,,Area under the curve during intravenous administration,22224,,,1,15118,BAO_0000019,0,CHEMBL625185,,
7854,,,,A,U,Autocuration,,,Area under the curve during intravenous administration; Not determined,22224,,,1,15118,BAO_0000019,0,CHEMBL875954,,
7855,,,,A,U,Autocuration,,,Area under the curve during systemic administration,22224,,,1,15118,BAO_0000019,0,CHEMBL625186,,
7856,,,,A,U,Autocuration,,,Area under the curve during systemic administration; Not determined,22224,,,1,15118,BAO_0000019,0,CHEMBL625187,,
7857,,,,A,U,Autocuration,,,Area under the curve was calculated for the compound.,22224,,,1,2632,BAO_0000019,0,CHEMBL625188,,
7858,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,50588,,,1,14346,BAO_0000218,1,CHEMBL625189,,
7859,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,50588,,,1,14346,BAO_0000218,1,CHEMBL625190,,
7860,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,50597,,,1,14346,BAO_0000218,1,CHEMBL621733,,
7861,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,50597,,,1,14346,BAO_0000218,1,CHEMBL621734,,
7862,,Rattus norvegicus,,A,N,Intermediate,,10116.0,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,50597,,,1,11149,BAO_0000218,1,CHEMBL621735,,
7863,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Clearance of the drug was measured in the plasma of rat; No data,50597,,,1,17796,BAO_0000218,1,CHEMBL621736,,1969.0
7864,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,The pharmacokinetic parameter plasma clearance in vivo in rats,50597,,,1,5247,BAO_0000218,1,CHEMBL621737,,1969.0
7865,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance at the dose of 2 mg/kg in rat,50597,,,1,4727,BAO_0000218,1,CHEMBL621738,,
7866,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,50597,,,1,5654,BAO_0000218,1,CHEMBL622806,,
7867,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,50597,,,1,5654,BAO_0000218,1,CHEMBL623519,,
7868,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,,,1,17260,BAO_0000218,1,CHEMBL623520,,
7869,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,,,1,17065,BAO_0000218,1,CHEMBL623521,,
7870,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,,,1,17671,BAO_0000218,1,CHEMBL623522,,
7871,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance rate in rat,50597,,,1,6672,BAO_0000218,1,CHEMBL623523,,
7872,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance rate in rat,50597,,,1,6673,BAO_0000218,1,CHEMBL623690,,
7873,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL623691,,
7874,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL623692,,
7875,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL623693,,
7876,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL623694,,
7877,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance of compound after iv administration of 20 mg/kg dose in rat,50597,,,1,4413,BAO_0000218,1,CHEMBL623695,,
7878,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,50597,,,1,2661,BAO_0000218,1,CHEMBL623696,,
7879,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,50597,,,1,2661,BAO_0000218,1,CHEMBL623697,,
7880,In vivo,Macaca mulatta,,A,U,Intermediate,Plasma,9544.0,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,,,1,5005,BAO_0000218,0,CHEMBL623698,,1969.0
7881,In vivo,Rattus norvegicus,,A,U,Intermediate,Plasma,10116.0,Compound was tested for its plasma clearance rate in Sprague Dawley rats,22224,,,1,5005,BAO_0000218,0,CHEMBL623699,,1969.0
7882,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean (%CV) PK parameters for CL(mL/min/kg).,50597,,,1,15765,BAO_0000218,1,CHEMBL623700,,
7883,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,50597,,,1,3747,BAO_0000218,1,CHEMBL623701,,
7884,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,50597,,,1,16366,BAO_0000218,1,CHEMBL623702,,1969.0
7885,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,50597,,,1,4199,BAO_0000218,1,CHEMBL623703,,
7886,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rat was determined,50597,,,1,17267,BAO_0000218,1,CHEMBL623704,,
7887,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rat after administration of 2 mg/kg iv,50597,,,1,6535,BAO_0000218,1,CHEMBL623705,,
7888,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rat after administration of 2 mg/kg iv,50597,,,1,6535,BAO_0000218,1,CHEMBL623706,,
7889,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance was determined,50597,,,1,5041,BAO_0000218,1,CHEMBL623707,,
7890,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rat,50597,,,1,5960,BAO_0000218,1,CHEMBL623708,,
7891,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,50597,,,1,5937,BAO_0000218,1,CHEMBL623709,,
7892,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rat by iv administration,50597,,,1,5871,BAO_0000218,1,CHEMBL623710,,
7893,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,50597,,,1,5874,BAO_0000218,1,CHEMBL623711,,
7894,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rat p.o.,50597,,,1,6504,BAO_0000218,1,CHEMBL623712,,
7895,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rats,50597,,,1,6803,BAO_0000218,1,CHEMBL623713,,
7896,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance was determined; ND denotes no data,50597,,,1,5041,BAO_0000218,1,CHEMBL623714,,
7897,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance was determined; ND denotes not determined,50597,,,1,5041,BAO_0000218,1,CHEMBL623715,,
7898,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,50597,,,1,1916,BAO_0000218,1,CHEMBL623716,,
7899,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,50597,,,1,5199,BAO_0000218,1,CHEMBL622980,,
7900,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma administration to rats,50597,,,1,16367,BAO_0000218,1,CHEMBL622981,,
7901,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance of the compound in female Sprague-Dawley rats,50597,,,1,6362,BAO_0000218,1,CHEMBL622982,,
7902,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance was observed after intravenous administration in rat,50597,,,1,15662,BAO_0000218,1,CHEMBL622983,,
7903,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,50597,,,1,6215,BAO_0000218,1,CHEMBL622984,,
7904,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,50597,,,1,1466,BAO_0000218,1,CHEMBL622985,,
7905,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,plasma clearance was observed after intravenous administration in rat,50597,,,1,15662,BAO_0000218,1,CHEMBL623631,,1969.0
7906,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo CL/F determined,50597,,,1,4723,BAO_0000218,1,CHEMBL623632,,
7907,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,50597,,,1,2792,BAO_0000218,1,CHEMBL623633,,1969.0
7908,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,50597,,,1,2792,BAO_0000218,1,CHEMBL623634,,1969.0
7909,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was tested for the lower blood clearance in rat,50597,,,1,5213,BAO_0000218,1,CHEMBL623635,,
7910,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Evaluated for the low clearance in rat (in vivo),50597,,,1,4687,BAO_0000218,1,CHEMBL621195,,
7911,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (CLb)of the compound was determined in rat,50597,,,1,3371,BAO_0000218,1,CHEMBL621196,,
7912,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Rapid clearance after intravenous administration in rat was determined,50597,,,1,4690,BAO_0000218,1,CHEMBL875287,,
7913,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance measured in rat,50597,,,1,5702,BAO_0000218,1,CHEMBL621197,,
7914,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Compound was evaluated for plasma clearance in rat,50597,,,1,740,BAO_0000218,1,CHEMBL621198,,1969.0
7915,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Low plasma clearance was calculated in rat,50597,,,1,4853,BAO_0000218,1,CHEMBL621199,,1969.0
7916,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (Clp) in rat,50597,,,1,5789,BAO_0000218,1,CHEMBL621200,,
7917,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,50597,,,1,4527,BAO_0000218,1,CHEMBL621201,,
7918,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,50597,,,1,4527,BAO_0000218,1,CHEMBL621202,,
7919,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance after IV dosing at 0.5 mg/kg in rat,50597,,,1,6518,BAO_0000218,1,CHEMBL621203,,
7920,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance after IV dosing at 1 mg/kg in rat,50597,,,1,6518,BAO_0000218,1,CHEMBL621204,,
7921,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,50597,,,1,9866,BAO_0000218,1,CHEMBL621205,,948.0
7922,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,50597,,,1,9866,BAO_0000218,1,CHEMBL621206,,948.0
7923,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,50597,,,1,9866,BAO_0000218,1,CHEMBL621207,,948.0
7924,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,50597,,,1,9866,BAO_0000218,1,CHEMBL621208,,948.0
7925,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,50597,,,1,9866,BAO_0000218,1,CHEMBL621209,,948.0
7926,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,50597,,,1,9866,BAO_0000218,1,CHEMBL876484,,948.0
7927,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,,,1,9866,BAO_0000218,1,CHEMBL621210,,948.0
7928,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,50597,,,1,9866,BAO_0000218,1,CHEMBL621211,,948.0
7929,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,50597,,,1,9866,BAO_0000218,1,CHEMBL621212,,948.0
7930,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart in the presence of GdDTPA at 15 min,50597,,,1,9866,BAO_0000218,1,CHEMBL621213,,948.0
7931,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL621214,,948.0
7932,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart in the presence of GdDTPA at 30 min,50597,,,1,9866,BAO_0000218,1,CHEMBL621215,,948.0
7933,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL621216,,948.0
7934,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL621217,,948.0
7935,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,50597,,,1,9866,BAO_0000218,1,CHEMBL621218,,948.0
7936,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL621219,,948.0
7937,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,50597,,,1,9866,BAO_0000218,1,CHEMBL621220,,948.0
7938,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL621221,,948.0
7939,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,50597,,,1,9866,BAO_0000218,1,CHEMBL621222,,948.0
7940,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL621223,,948.0
7941,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,50597,,,1,9866,BAO_0000218,1,CHEMBL876485,,948.0
7942,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,,,1,9866,BAO_0000218,1,CHEMBL621224,,948.0
7943,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,50597,,,1,9866,BAO_0000218,1,CHEMBL621225,,948.0
7944,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,50597,,,1,9866,BAO_0000218,1,CHEMBL621226,,948.0
7945,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,50597,,,1,9866,BAO_0000218,1,CHEMBL621227,,2113.0
7946,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,50597,,,1,9866,BAO_0000218,1,CHEMBL621228,,2113.0
7947,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,50597,,,1,9866,BAO_0000218,1,CHEMBL621229,,2113.0
7948,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,50597,,,1,9866,BAO_0000218,1,CHEMBL621230,,2113.0
7949,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,50597,,,1,9866,BAO_0000218,1,CHEMBL621231,,2113.0
7950,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,50597,,,1,9866,BAO_0000218,1,CHEMBL621232,,2113.0
7951,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,,,1,9866,BAO_0000218,1,CHEMBL621233,,2113.0
7952,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,50597,,,1,9866,BAO_0000218,1,CHEMBL621234,,2113.0
7953,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,50597,,,1,9866,BAO_0000218,1,CHEMBL621235,,2113.0
7954,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,,,1,9866,BAO_0000218,1,CHEMBL621236,,2113.0
7955,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,50597,,,1,9866,BAO_0000218,1,CHEMBL621237,,2113.0
7956,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,50597,,,1,9866,BAO_0000218,1,CHEMBL876486,,2113.0
7957,In vivo,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL622436,,160.0
7958,In vivo,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL622437,,160.0
7959,In vivo,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL622438,,160.0
7960,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,50597,,,1,9866,BAO_0000218,1,CHEMBL622439,,2107.0
7961,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,50597,,,1,9866,BAO_0000218,1,CHEMBL622440,,2107.0
7962,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,50597,,,1,9866,BAO_0000218,1,CHEMBL622441,,2107.0
7963,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,50597,,,1,9866,BAO_0000218,1,CHEMBL622442,,2107.0
7964,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,50597,,,1,9866,BAO_0000218,1,CHEMBL622443,,2107.0
7965,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,50597,,,1,9866,BAO_0000218,1,CHEMBL622444,,2107.0
7966,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,50597,,,1,9866,BAO_0000218,1,CHEMBL622445,,2107.0
7967,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,50597,,,1,9866,BAO_0000218,1,CHEMBL622446,,2107.0
7968,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,50597,,,1,9866,BAO_0000218,1,CHEMBL622447,,2107.0
7969,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,50597,,,1,9866,BAO_0000218,1,CHEMBL622448,,2107.0
7970,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,50597,,,1,9866,BAO_0000218,1,CHEMBL622449,,2107.0
7971,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL622450,,2107.0
7972,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL622451,,2107.0
7973,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver in the presence of GdDTPA at 15 min,50597,,,1,9866,BAO_0000218,1,CHEMBL622452,,2107.0
7974,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL622453,,2107.0
7975,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver in the presence of GdDTPA at 30 min,50597,,,1,9866,BAO_0000218,1,CHEMBL622454,,2107.0
7976,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL622455,,2107.0
7977,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,50597,,,1,9866,BAO_0000218,1,CHEMBL876024,,2107.0
7978,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,T max was determined at 3 mg/kg po dose in rats,50597,,,1,2792,BAO_0000218,1,CHEMBL622456,,
7979,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",50597,,,1,15078,BAO_0000218,1,CHEMBL622457,,
7980,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",50597,,,1,15078,BAO_0000218,1,CHEMBL622458,,
7981,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,50597,,,1,15022,BAO_0000218,1,CHEMBL622459,,
7982,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,50597,,,1,15022,BAO_0000218,1,CHEMBL873343,,
7983,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,50597,,,1,15022,BAO_0000218,1,CHEMBL622460,,
7984,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Time for maximum plasma concentration determined in rat,50597,,,1,4576,BAO_0000218,1,CHEMBL622461,,1969.0
7985,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,50597,,,1,6681,BAO_0000218,1,CHEMBL622462,,1969.0
7986,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,50597,,,1,16365,BAO_0000218,1,CHEMBL622463,,
7987,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,50597,,,1,16365,BAO_0000218,1,CHEMBL622464,,
7988,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,50597,,,1,16365,BAO_0000218,1,CHEMBL622465,,
7989,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,50597,,,1,16365,BAO_0000218,1,CHEMBL622466,,
7990,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,50597,,,1,16365,BAO_0000218,1,CHEMBL622467,,
7991,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Time of maximum plasma concentration in rat,50597,,,1,6824,BAO_0000218,1,CHEMBL622468,,1969.0
7992,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",50597,,,1,6685,BAO_0000218,1,CHEMBL876025,,1969.0
7993,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",50597,,,1,6685,BAO_0000218,1,CHEMBL622469,,1969.0
7994,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",50597,,,1,6685,BAO_0000218,1,CHEMBL622470,,1969.0
7995,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Time required to reach maximum concentration (Cmax) after oral administration in rat,50597,,,1,15662,BAO_0000218,1,CHEMBL622471,,
7996,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Time required to reach maximum concentration in rat plasma,50597,,,1,1742,BAO_0000218,1,CHEMBL622472,,1969.0
7997,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,50597,,,1,2774,BAO_0000218,1,CHEMBL622473,,1969.0
7998,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,50597,,,1,5199,BAO_0000218,1,CHEMBL624282,,1969.0
7999,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,50597,,,1,12873,BAO_0000218,1,CHEMBL624283,,1969.0
8000,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,50597,,,1,12873,BAO_0000218,1,CHEMBL624284,,1969.0
8001,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,50597,,,1,1916,BAO_0000218,1,CHEMBL624285,,1969.0
8002,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Time to reach Cmax after oral administration to rats,50597,,,1,16367,BAO_0000218,1,CHEMBL624286,,
8003,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Time to reach Cmax when a dose of 1 mg/kg is administered orally,50597,,,1,16366,BAO_0000218,1,CHEMBL624287,,
8004,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,50597,,,1,216,BAO_0000218,1,CHEMBL624288,,
8005,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,50597,,,1,6410,BAO_0000218,1,CHEMBL624289,,1969.0
8006,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,50597,,,1,6410,BAO_0000218,1,CHEMBL873344,,1969.0
8007,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax after peroral administration (10 mg/kg) was determined in rat,50597,,,1,6215,BAO_0000218,1,CHEMBL619623,,
8008,In vivo,Rattus norvegicus,,A,N,Expert,,10116.0,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,,,1,3598,BAO_0000218,1,CHEMBL621399,,
8009,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,50597,,,1,4527,BAO_0000218,1,CHEMBL621400,,
8010,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",50597,,,1,17670,BAO_0000218,1,CHEMBL621401,,
8011,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax was determined,50597,,,1,1465,BAO_0000218,1,CHEMBL621402,,
8012,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax was determined,50597,,,1,2552,BAO_0000218,1,CHEMBL621403,,
8013,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax after oral administration in rat,50597,,,1,5656,BAO_0000218,1,CHEMBL621121,,
8014,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax after peroral administration in rats at 2.4 uM/kg,50597,,,1,17764,BAO_0000218,1,CHEMBL872525,,
8015,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax in male rat,50597,,,1,5610,BAO_0000218,1,CHEMBL621122,,
8016,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax in rat at 10 mg/kg,50597,,,1,6046,BAO_0000218,1,CHEMBL621123,,
8017,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax in rat by po administration at a dose of 40 mg/kg,50597,,,1,5874,BAO_0000218,1,CHEMBL621124,,
8018,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax in rats,50597,,,1,17596,BAO_0000218,1,CHEMBL621125,,
8019,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax was measured in rats after peroral administration at 5 mg/kg,50597,,,1,17804,BAO_0000218,1,CHEMBL621126,,
8020,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax value after oral dose at a dose of 10 mg/kg in rats.,50597,,,1,1908,BAO_0000218,1,CHEMBL621127,,
8021,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax value after administration of 20 mg/Kg oral dose in rat,50597,,,1,2959,BAO_0000218,1,CHEMBL621128,,
8022,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax value at a dose of 10 mg/kg in male SD rats,50597,,,1,6757,BAO_0000218,1,CHEMBL618263,,
8023,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax value at a dose of 100 mg/kg in male SD rats,50597,,,1,6757,BAO_0000218,1,CHEMBL618264,,
8024,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax value at a dose of 50 mg/kg in male SD rats,50597,,,1,6757,BAO_0000218,1,CHEMBL618265,,
8025,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,,,1,4186,BAO_0000218,1,CHEMBL618266,,1969.0
8026,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,time required to reach maximum concentration (Cmax) after oral administration in rat,50597,,,1,15662,BAO_0000218,1,CHEMBL618267,,
8027,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),50597,,,1,429,BAO_0000218,1,CHEMBL618450,,1088.0
8028,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),50597,,,1,429,BAO_0000218,1,CHEMBL618451,,1088.0
8029,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,50597,,,1,5546,BAO_0000218,1,CHEMBL618452,,
8030,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,50597,,,1,3173,BAO_0000218,1,CHEMBL618453,,1088.0
8031,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,50597,,,1,3173,BAO_0000218,1,CHEMBL618454,,1088.0
8032,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,50597,,,1,3173,BAO_0000218,1,CHEMBL618455,,1088.0
8033,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,50597,,,1,4257,BAO_0000218,1,CHEMBL618456,,
8034,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound distribution in rat tissues was determined,50597,,,1,6011,BAO_0000218,1,CHEMBL618457,,
8035,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution was evaluated in rat,50597,,,1,5472,BAO_0000218,1,CHEMBL618458,,
8036,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,50597,,,1,14346,BAO_0000218,1,CHEMBL618459,,
8037,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,50597,,,1,14346,BAO_0000218,1,CHEMBL876733,,
8038,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,50588,,,1,14346,BAO_0000218,1,CHEMBL618460,,
8039,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,50597,,,1,14346,BAO_0000218,1,CHEMBL618461,,
8040,,,,A,U,Autocuration,,,Area under the curve was determined after oral administration (300 uM/Kg),22224,,,1,15469,BAO_0000019,0,CHEMBL618462,,
8041,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,50597,,,1,14346,BAO_0000218,1,CHEMBL618463,,
8042,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,50597,,,1,14346,BAO_0000218,1,CHEMBL618464,,
8043,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,50597,,,1,14346,BAO_0000218,1,CHEMBL618465,,
8044,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,50597,,,1,14346,BAO_0000218,1,CHEMBL618466,,
8045,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,50597,,,1,14346,BAO_0000218,1,CHEMBL618467,,
8046,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,50597,,,1,15372,BAO_0000218,1,CHEMBL618468,,
8047,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,50588,,,1,12935,BAO_0000218,1,CHEMBL618469,,1969.0
8048,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,50588,,,1,12935,BAO_0000218,1,CHEMBL618470,,1969.0
8049,,,,A,U,Autocuration,,,Plasma drug AUC in rat (PO dose),22224,,,1,14813,BAO_0000218,0,CHEMBL618471,,
8050,,Mus musculus,,A,N,Intermediate,,10090.0,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,50594,,,1,15792,BAO_0000218,1,CHEMBL618472,,
8051,,,,A,U,Autocuration,,,Area under was determined at a dose of 30 mg/kg,22224,,,1,3579,BAO_0000218,0,CHEMBL618473,,
8052,,Mustela putorius furo,,A,N,Intermediate,,9669.0,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,50506,,,1,12487,BAO_0000218,1,CHEMBL621699,,
8053,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,50597,,,1,12487,BAO_0000218,1,CHEMBL621700,,
8054,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,50597,,,1,12487,BAO_0000218,1,CHEMBL621701,,
8055,,Mustela putorius furo,,A,N,Intermediate,,9669.0,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,50506,,,1,12487,BAO_0000218,1,CHEMBL621702,,
8056,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,50588,,,1,12487,BAO_0000218,1,CHEMBL621703,,
8057,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,50588,,,1,12487,BAO_0000218,1,CHEMBL621704,,
8058,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",50597,,,1,12902,BAO_0000218,1,CHEMBL624259,,
8059,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",50597,,,1,12902,BAO_0000218,1,CHEMBL624260,,
8060,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",50597,,,1,12902,BAO_0000218,1,CHEMBL624430,,
8061,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",50597,,,1,12902,BAO_0000218,1,CHEMBL624431,,
8062,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",50597,,,1,12902,BAO_0000218,1,CHEMBL624432,,
8063,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",50597,,,1,12902,BAO_0000218,1,CHEMBL624433,,
8064,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",50597,,,1,12902,BAO_0000218,1,CHEMBL624434,,
8065,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",50597,,,1,12902,BAO_0000218,1,CHEMBL624435,,
8066,,Mus musculus,,A,N,Intermediate,,10090.0,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,50594,,,1,12745,BAO_0000218,1,CHEMBL618570,,
8067,,Mus musculus,,A,N,Intermediate,,10090.0,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),50594,,,1,12745,BAO_0000218,1,CHEMBL618571,,
8068,,Mus musculus,,A,N,Intermediate,,10090.0,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,50594,,,1,12745,BAO_0000218,1,CHEMBL618572,,
8069,,Mus musculus,,A,N,Intermediate,,10090.0,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),50594,,,1,12745,BAO_0000218,1,CHEMBL618573,,
8070,,Mus musculus,,A,N,Intermediate,,10090.0,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,50594,,,1,12745,BAO_0000218,1,CHEMBL619267,,
8071,,Mus musculus,,A,N,Intermediate,,10090.0,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),50594,,,1,12745,BAO_0000218,1,CHEMBL619431,,
8072,,Mus musculus,,A,N,Intermediate,,10090.0,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,50594,,,1,12745,BAO_0000218,1,CHEMBL619432,,
8073,,Mus musculus,,A,N,Intermediate,,10090.0,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),50594,,,1,12745,BAO_0000218,1,CHEMBL619433,,
8074,,,,A,U,Autocuration,Plasma,,AUC in mice after oral dose (50 mg/kg),22224,,,1,13298,BAO_0000218,0,CHEMBL619434,,1969.0
8075,,Mus musculus,,A,N,Intermediate,Serum,10090.0,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,50594,,,1,12226,BAO_0000218,1,CHEMBL619435,,1977.0
8076,,,,A,U,Autocuration,Plasma,,AUC (0-4 hr) ug/ml/h,22224,,,1,12634,BAO_0000019,0,CHEMBL619436,,1969.0
8077,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,50597,,,1,14810,BAO_0000218,1,CHEMBL619437,,
8078,,,,A,U,Autocuration,,,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,22224,,,1,13889,BAO_0000218,0,CHEMBL619438,,
8079,,Mus musculus,,A,N,Intermediate,,10090.0,Compound was evaluated for Area under curve in mice,50594,,,1,10018,BAO_0000218,1,CHEMBL619439,,
8080,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,50597,,,1,8758,BAO_0000218,1,CHEMBL619440,,
8081,,,,F,U,Autocuration,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,22224,,,1,8758,BAO_0000218,0,CHEMBL619441,,
8082,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,50597,,,1,8758,BAO_0000218,1,CHEMBL619442,,
8083,,,,A,U,Autocuration,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,22224,,,1,2249,BAO_0000019,0,CHEMBL875156,,
8084,,,,A,U,Autocuration,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,22224,,,1,2249,BAO_0000019,0,CHEMBL619443,,
8085,,,,A,U,Autocuration,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,22224,,,1,2249,BAO_0000019,0,CHEMBL619444,,
8086,,,,A,U,Autocuration,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,22224,,,1,2249,BAO_0000019,0,CHEMBL623464,,
8087,,Mus musculus,,A,N,Intermediate,,10090.0,Compound was evaluated for area under curve when administered through oral route in mouse,50594,,,1,15115,BAO_0000218,1,CHEMBL623465,,
8088,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,50597,,,1,6518,BAO_0000218,1,CHEMBL623466,,
8089,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,50597,,,1,6518,BAO_0000218,1,CHEMBL623467,,
8090,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rat,50597,,,1,6249,BAO_0000218,1,CHEMBL623468,,
8091,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,50597,,,1,2463,BAO_0000218,1,CHEMBL622660,,
8092,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance rate in Sprague-Dawley rats,50597,,,1,4969,BAO_0000218,1,CHEMBL622661,,
8093,In vivo,Rattus norvegicus,,F,N,Intermediate,,10116.0,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,,,1,17720,BAO_0000218,1,CHEMBL622662,,
8094,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (total body clearance) in rat,50597,,,1,3457,BAO_0000218,1,CHEMBL622663,,
8095,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,50597,,,1,5983,BAO_0000218,1,CHEMBL622664,,
8096,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,50597,,,1,6295,BAO_0000218,1,CHEMBL622665,,
8097,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,50597,,,1,6296,BAO_0000218,1,CHEMBL622666,,
8098,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cl in rat i.v. at 2 mg/kg concentration,50597,,,1,17686,BAO_0000218,1,CHEMBL621615,,
8099,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance of compound after intravenous administration in rats at 24 uM/kg,50597,,,1,17764,BAO_0000218,1,CHEMBL621616,,
8100,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance was determined,50597,,,1,5503,BAO_0000218,1,CHEMBL621617,,
8101,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance by intravenous administration of 3.4 mg/kg in rat,50597,,,1,4368,BAO_0000218,1,CHEMBL621618,,
8102,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,50597,,,1,6005,BAO_0000218,1,CHEMBL621619,,
8103,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance rate after i.v. administration in rats,50597,,,1,5031,BAO_0000218,1,CHEMBL621620,,
8104,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,50597,,,1,4890,BAO_0000218,1,CHEMBL621786,,
8105,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,50597,,,1,5182,BAO_0000218,1,CHEMBL621787,,
8106,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,50597,,,1,5979,BAO_0000218,1,CHEMBL621788,,
8107,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance (Cl) after oral administration in rat,50597,,,1,5656,BAO_0000218,1,CHEMBL621789,,
8108,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,50597,,,1,17804,BAO_0000218,1,CHEMBL621790,,
8109,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Compound was tested for plasma clearance in rat,50597,,,1,4839,BAO_0000218,1,CHEMBL621791,,1969.0
8110,In vitro,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro microsome metabolism clearance in rat was determined,50597,,,1,5041,BAO_0000218,1,CHEMBL621792,,
8111,In vitro,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,50597,,,1,5041,BAO_0000218,1,CHEMBL621793,,
8112,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,,,1,5974,BAO_0000218,1,CHEMBL621794,,
8113,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,In vivo plasma clearance was determined,50597,,,1,5496,BAO_0000218,1,CHEMBL621795,,1969.0
8114,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,50597,,,1,5739,BAO_0000218,1,CHEMBL621796,,
8115,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,50597,,,1,5676,BAO_0000218,1,CHEMBL621797,401.0,2107.0
8116,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (Plasma clearance) was measured in rat,50597,,,1,4239,BAO_0000218,1,CHEMBL621798,,
8117,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (clearance) in rat i.v.,50597,,,1,5676,BAO_0000218,1,CHEMBL621799,,
8118,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Plasma Clearance was evaluated in rats, iv",50597,,,1,1918,BAO_0000218,1,CHEMBL621800,,
8119,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance (in vivo) in rats was determined,50597,,,1,17800,BAO_0000218,1,CHEMBL621801,,
8120,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,50597,,,1,6056,BAO_0000218,1,CHEMBL621802,,
8121,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance was determined,50597,,,1,5496,BAO_0000218,1,CHEMBL618596,,
8122,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,50597,,,1,5939,BAO_0000218,1,CHEMBL618597,,
8123,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,50597,,,1,5939,BAO_0000218,1,CHEMBL618598,,
8124,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rats,50597,,,1,17752,BAO_0000218,1,CHEMBL618599,,
8125,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance rate determined in rat,50597,,,1,4576,BAO_0000218,1,CHEMBL618600,,
8126,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance was determined in rat,50597,,,1,6011,BAO_0000218,1,CHEMBL618601,,
8127,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance was determined,50597,,,1,5510,BAO_0000218,1,CHEMBL618602,,
8128,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance value in rat,50597,,,1,5948,BAO_0000218,1,CHEMBL618603,,
8129,Ex vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Clearance rate constant using isolated perfused rat liver (IPRL) assay,50597,,,1,6125,BAO_0000218,1,CHEMBL618604,,2107.0
8130,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance in rat,50597,,,1,4839,BAO_0000218,1,CHEMBL618605,,
8131,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Total body clearance in rat i.v. at 2 mg/kg concentration,50597,,,1,17686,BAO_0000218,1,CHEMBL618606,,
8132,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance of compound in rats after intravenous administration,50597,,,1,6571,BAO_0000218,1,CHEMBL618607,,
8133,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance after iv administration to rats,50597,,,1,3364,BAO_0000218,1,CHEMBL618608,,
8134,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,50597,,,1,13569,BAO_0000218,1,CHEMBL618609,,
8135,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,50597,,,1,13569,BAO_0000218,1,CHEMBL618610,,
8136,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,50597,,,1,13569,BAO_0000218,1,CHEMBL618611,,
8137,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,50597,,,1,13569,BAO_0000218,1,CHEMBL618612,,
8138,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,50597,,,1,13569,BAO_0000218,1,CHEMBL618613,,
8139,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,50597,,,1,13569,BAO_0000218,1,CHEMBL621076,,
8140,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,50597,,,1,13569,BAO_0000218,1,CHEMBL621077,,
8141,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",50597,,,1,17670,BAO_0000218,1,CHEMBL621078,,
8142,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance in rat,50597,,,1,5970,BAO_0000218,1,CHEMBL621251,,
8143,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance in rat after oral administration at 10 mg/kg,50597,,,1,6495,BAO_0000218,1,CHEMBL621252,,
8144,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance in rat.,50597,,,1,4590,BAO_0000218,1,CHEMBL621253,,
8145,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance rate following an oral dose of 20 mg/kg in rats,50597,,,1,6193,BAO_0000218,1,CHEMBL621254,,
8146,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,50597,,,1,2832,BAO_0000218,1,CHEMBL621255,,
8147,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,50597,,,1,1052,BAO_0000218,1,CHEMBL621256,,1969.0
8148,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL621257,,2107.0
8149,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,50597,,,1,9866,BAO_0000218,1,CHEMBL621258,,2107.0
8150,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL621259,,2107.0
8151,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,50597,,,1,9866,BAO_0000218,1,CHEMBL621260,,2107.0
8152,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL876494,,2107.0
8153,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,50597,,,1,9866,BAO_0000218,1,CHEMBL621261,,2107.0
8154,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL621262,,2107.0
8155,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,50597,,,1,9866,BAO_0000218,1,CHEMBL621263,,2107.0
8156,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,50597,,,1,9866,BAO_0000218,1,CHEMBL621264,,2107.0
8157,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,50597,,,1,9866,BAO_0000218,1,CHEMBL621265,,2385.0
8158,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,50597,,,1,9866,BAO_0000218,1,CHEMBL621266,,2385.0
8159,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,50597,,,1,9866,BAO_0000218,1,CHEMBL621267,,2385.0
8160,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,50597,,,1,9866,BAO_0000218,1,CHEMBL621268,,2385.0
8161,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL621269,,2385.0
8162,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL621270,,2385.0
8163,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,50597,,,1,9866,BAO_0000218,1,CHEMBL621271,,2385.0
8164,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,50597,,,1,9866,BAO_0000218,1,CHEMBL621272,,2385.0
8165,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL621273,,2385.0
8166,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL621274,,2385.0
8167,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,50597,,,1,9866,BAO_0000218,1,CHEMBL876495,,2385.0
8168,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,50597,,,1,9866,BAO_0000218,1,CHEMBL621275,,2385.0
8169,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,50597,,,1,9866,BAO_0000218,1,CHEMBL621276,,2385.0
8170,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,50597,,,1,9866,BAO_0000218,1,CHEMBL621277,,2385.0
8171,In vivo,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL621278,,160.0
8172,In vivo,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL621279,,160.0
8173,In vivo,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),50597,,,1,9866,BAO_0000218,1,CHEMBL621280,,160.0
8174,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,50597,,,1,9866,BAO_0000218,1,CHEMBL621281,,2106.0
8175,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,50597,,,1,9866,BAO_0000218,1,CHEMBL621282,,2106.0
8176,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,50597,,,1,9866,BAO_0000218,1,CHEMBL621283,,2106.0
8177,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,50597,,,1,9866,BAO_0000218,1,CHEMBL621284,,2106.0
8178,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,50597,,,1,9866,BAO_0000218,1,CHEMBL621285,,2106.0
8179,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL621286,,2106.0
8180,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL623220,,2106.0
8181,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,50597,,,1,9866,BAO_0000218,1,CHEMBL623221,,2106.0
8182,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,50597,,,1,9866,BAO_0000218,1,CHEMBL876029,,2106.0
8183,In vivo,Rattus norvegicus,,A,N,Intermediate,Stomach,10116.0,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,50597,,,1,9866,BAO_0000218,1,CHEMBL623222,,945.0
8184,In vivo,Rattus norvegicus,,A,N,Intermediate,Stomach,10116.0,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,50597,,,1,9866,BAO_0000218,1,CHEMBL623223,,945.0
8185,In vivo,Rattus norvegicus,,A,N,Intermediate,Stomach,10116.0,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,50597,,,1,9866,BAO_0000218,1,CHEMBL621445,,945.0
8186,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL621446,,178.0
8187,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL621447,,178.0
8188,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL619681,,178.0
8189,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL619682,,178.0
8190,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL619683,,178.0
8191,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL619684,,955.0
8192,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL619685,,955.0
8193,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL619686,,955.0
8194,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL619687,,955.0
8195,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL619688,,955.0
8196,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL619689,,948.0
8197,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL619690,,948.0
8198,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL619691,,948.0
8199,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,50597,,,1,6062,BAO_0000218,1,CHEMBL619692,,
8200,,Rattus norvegicus,,A,N,Expert,,10116.0,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,,,1,3598,BAO_0000218,1,CHEMBL619693,,
8201,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Vc value after IV dose at a dose of 5 mg/kg in rats.,50597,,,1,1908,BAO_0000218,1,CHEMBL619694,,
8202,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,50597,,,1,17596,BAO_0000218,1,CHEMBL619695,,
8203,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for pharmacokinetic parameter volume of distribution,50597,,,1,4891,BAO_0000218,1,CHEMBL619696,,
8204,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for volume of distribution in rat,50597,,,1,740,BAO_0000218,1,CHEMBL619697,,
8205,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Steady state volume distribution was determined; steady state(ss),50597,,,1,16366,BAO_0000218,1,CHEMBL619698,,
8206,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Steady state volume of distribution after iv administration to rats,50597,,,1,3364,BAO_0000218,1,CHEMBL619699,,
8207,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Steady state volume of distribution dosing at 3 mg/kg iv,50597,,,1,2552,BAO_0000218,1,CHEMBL619700,,
8208,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,The compound was evaluated for volume of distribution in rat,50597,,,1,406,BAO_0000218,1,CHEMBL619701,,
8209,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,The compound was tested for volume of distribution in rat,50597,,,1,12500,BAO_0000218,1,CHEMBL619702,,
8210,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,50597,,,1,12500,BAO_0000218,1,CHEMBL620335,,
8211,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume distribution (VD) after oral administration in rat,50597,,,1,5656,BAO_0000218,1,CHEMBL620336,,
8212,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,,,1,17671,BAO_0000218,1,CHEMBL620337,,
8213,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume distribution in rat,50597,,,1,1094,BAO_0000218,1,CHEMBL620520,,
8214,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume distribution in rat,50597,,,1,5833,BAO_0000218,1,CHEMBL620521,,
8215,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume distribution in rat after peroral administration at 10 mg/kg,50597,,,1,5939,BAO_0000218,1,CHEMBL875825,,
8216,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume distribution in rat after peroral administration at 5 mg/kg,50597,,,1,5939,BAO_0000218,1,CHEMBL620522,,
8217,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,50597,,,1,6005,BAO_0000218,1,CHEMBL620523,,
8218,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution in rat.,50597,,,1,1696,BAO_0000218,1,CHEMBL620524,,
8219,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution in rat,50597,,,1,6672,BAO_0000218,1,CHEMBL620525,,
8220,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution in rat,50597,,,1,6673,BAO_0000218,1,CHEMBL620526,,
8221,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution in rat by iv administration,50597,,,1,5871,BAO_0000218,1,CHEMBL620527,,
8222,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution in rats,50597,,,1,6803,BAO_0000218,1,CHEMBL620528,,
8223,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,50597,,,1,5199,BAO_0000218,1,CHEMBL620529,,
8224,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume distribution at the dose of 2 mg/kg in rat,50597,,,1,4727,BAO_0000218,1,CHEMBL620530,,
8225,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Steady state volume of distribution was determined,50597,,,1,16367,BAO_0000218,1,CHEMBL620531,,
8226,In vivo,Macaca mulatta,,A,U,Intermediate,,9544.0,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,22224,,,1,5005,BAO_0000218,0,CHEMBL620532,,
8227,In vivo,Rattus norvegicus,,A,U,Intermediate,,10116.0,Compound was tested for its plasma volume distribution in Sprague Dawley rats,22224,,,1,5005,BAO_0000218,0,CHEMBL620533,,
8228,In vivo,Rattus norvegicus,,A,U,Intermediate,,10116.0,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,22224,,,1,5005,BAO_0000218,0,CHEMBL620534,,
8229,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean (%CV) PK parameters for Vdss(mL/kg).,50597,,,1,15765,BAO_0000218,1,CHEMBL620535,,
8230,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,50597,,,1,2792,BAO_0000218,1,CHEMBL875826,,
8231,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,50597,,,1,2792,BAO_0000218,1,CHEMBL620536,,
8232,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,50597,,,1,5334,BAO_0000218,1,CHEMBL620537,,
8233,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,50597,,,1,5334,BAO_0000218,1,CHEMBL618526,,
8234,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,50597,,,1,5739,BAO_0000218,1,CHEMBL618527,,
8235,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (Vdss) in rat,50597,,,1,5789,BAO_0000218,1,CHEMBL618528,,
8236,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (vdss) was measured in rat,50597,,,1,4239,BAO_0000218,1,CHEMBL618529,,
8237,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,50597,,,1,4709,BAO_0000218,1,CHEMBL618530,,
8238,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution in rat,50597,,,1,6642,BAO_0000218,1,CHEMBL618531,,
8239,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,The pharmacokinetic parameter volume of distribution in vivo in rats,50597,,,1,5247,BAO_0000218,1,CHEMBL618532,,
8240,In vivo,Rattus norvegicus,,F,N,Intermediate,,10116.0,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,,,1,17720,BAO_0000218,1,CHEMBL618533,,
8241,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Vdss in rat i.v. at 2 mg/kg concentration,50597,,,1,17686,BAO_0000218,1,CHEMBL618534,,
8242,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume distribution after intravenous administration (1 mg/kg) in rat,50597,,,1,4689,BAO_0000218,1,CHEMBL618535,,
8243,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,50597,,,1,5654,BAO_0000218,1,CHEMBL618536,,
8244,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,50597,,,1,5654,BAO_0000218,1,CHEMBL618537,,
8245,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume distribution at a dose of 10 uM/kg in rat was determined,50597,,,1,4527,BAO_0000218,1,CHEMBL618538,,
8246,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,50597,,,1,4521,BAO_0000218,1,CHEMBL618539,,
8247,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume distribution was calculated in rat,50597,,,1,6057,BAO_0000218,1,CHEMBL618540,,
8248,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume distribution was determined,50597,,,1,5510,BAO_0000218,1,CHEMBL618541,,
8249,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution after intravenous administration was evaluated in rat,50597,,,1,2938,BAO_0000218,1,CHEMBL618542,,
8250,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50597,,,1,6679,BAO_0000218,1,CHEMBL622544,,
8251,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",50597,,,1,6685,BAO_0000218,1,CHEMBL622545,,
8252,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",50597,,,1,6685,BAO_0000218,1,CHEMBL622546,,
8253,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",50597,,,1,6685,BAO_0000218,1,CHEMBL622547,,
8254,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution in steady state was determined in rat,50597,,,1,5145,BAO_0000218,1,CHEMBL622548,,
8255,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,50597,,,1,6467,BAO_0000218,1,CHEMBL622549,,
8256,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,50597,,,1,6467,BAO_0000218,1,CHEMBL622550,,
8257,,Mus musculus,,A,N,Intermediate,,10090.0,Compound was evaluated for area under curve when administered through oral route to mouse,50594,,,1,15115,BAO_0000218,1,CHEMBL622551,,
8258,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,50597,,,1,8758,BAO_0000218,1,CHEMBL622552,,
8259,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,50597,,,1,8758,BAO_0000218,1,CHEMBL622553,,
8260,In vivo,,,F,U,Autocuration,,,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,22224,,,1,8267,BAO_0000218,0,CHEMBL622554,,
8261,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,50588,,,1,8267,BAO_0000218,1,CHEMBL622555,,
8262,,Mus musculus,,A,N,Intermediate,,10090.0,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,50594,,,1,14239,BAO_0000218,1,CHEMBL622556,,
8263,,Mus musculus,,A,N,Intermediate,,10090.0,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,50594,,,1,14239,BAO_0000218,1,CHEMBL622557,,
8264,,Mus musculus,,A,N,Intermediate,Blood,10090.0,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,50594,,,1,10754,BAO_0000218,1,CHEMBL622558,,178.0
8265,,Mus musculus,,A,N,Intermediate,Blood,10090.0,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,50594,,,1,10754,BAO_0000218,1,CHEMBL622559,,178.0
8266,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,50588,,,1,10754,BAO_0000218,1,CHEMBL622560,,
8267,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,50597,,,1,14681,BAO_0000218,1,CHEMBL622561,,
8268,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,50597,,,1,14681,BAO_0000218,1,CHEMBL622562,,
8269,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,50597,,,1,14681,BAO_0000218,1,CHEMBL622563,,
8270,,,,A,U,Autocuration,,,Concentration of compound in Central nervous system,22224,,,1,13118,BAO_0000019,0,CHEMBL622564,,
8271,,,,A,U,Autocuration,,,Concentration of compound in Central nervous system; Not detectable,22224,,,1,13118,BAO_0000019,0,CHEMBL622565,,
8272,,Mus musculus,,A,N,Intermediate,,10090.0,"Concentration of diester in the blood, following oral administration in mice",50594,,,1,13318,BAO_0000218,1,CHEMBL622566,,
8273,,Mus musculus,,A,N,Intermediate,,10090.0,"Concentration of monoester in the blood, following oral administration in mice",50594,,,1,13318,BAO_0000218,1,CHEMBL624515,,
8274,,Mus musculus,,A,N,Intermediate,,10090.0,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,50594,,,1,13318,BAO_0000218,1,CHEMBL624516,,
8275,,,,A,U,Autocuration,,,Evaluated for Pharmacokinetic property: Area under the curve,22224,,,1,15692,BAO_0000019,0,CHEMBL624517,,
8276,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,50594,,,1,14839,BAO_0000218,1,CHEMBL624518,,
8277,,Macaca fascicularis,,A,N,Intermediate,,9541.0,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,100710,,,1,14839,BAO_0000218,1,CHEMBL624519,,
8278,,Macaca fascicularis,,A,N,Intermediate,,9541.0,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,100710,,,1,14839,BAO_0000218,1,CHEMBL624520,,
8279,,Macaca fascicularis,,A,N,Intermediate,,9541.0,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,100710,,,1,14839,BAO_0000218,1,CHEMBL624521,,
8280,,Macaca fascicularis,,A,N,Intermediate,,9541.0,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,100710,,,1,14839,BAO_0000218,1,CHEMBL624522,,
8281,,Macaca fascicularis,,A,N,Intermediate,,9541.0,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,100710,,,1,14839,BAO_0000218,1,CHEMBL624523,,
8282,,Macaca fascicularis,,A,N,Intermediate,,9541.0,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",100710,,,1,14839,BAO_0000218,1,CHEMBL624409,,
8283,,Macaca fascicularis,,A,N,Intermediate,,9541.0,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",100710,,,1,14839,BAO_0000218,1,CHEMBL624410,,
8284,,Macaca fascicularis,,A,N,Intermediate,,9541.0,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",100710,,,1,14839,BAO_0000218,1,CHEMBL624411,,
8285,,Macaca fascicularis,,A,N,Intermediate,,9541.0,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",100710,,,1,14839,BAO_0000218,1,CHEMBL623531,,
8286,,Macaca fascicularis,,A,N,Intermediate,,9541.0,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",100710,,,1,14839,BAO_0000218,1,CHEMBL623532,,
8287,,Macaca fascicularis,,A,N,Intermediate,,9541.0,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",100710,,,1,14839,BAO_0000218,1,CHEMBL623533,,
8288,,Macaca fascicularis,,A,N,Intermediate,,9541.0,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",100710,,,1,14839,BAO_0000218,1,CHEMBL623534,,
8289,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,50594,,,1,14839,BAO_0000218,1,CHEMBL623535,,
8290,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,50594,,,1,14839,BAO_0000218,1,CHEMBL623536,,
8291,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,50594,,,1,14839,BAO_0000218,1,CHEMBL623537,,
8292,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,50594,,,1,14839,BAO_0000218,1,CHEMBL623538,,
8293,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,50594,,,1,14839,BAO_0000218,1,CHEMBL623539,,
8294,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,50594,,,1,14839,BAO_0000218,1,CHEMBL623540,,
8295,,Mus musculus,,A,N,Intermediate,,10090.0,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",50594,,,1,14839,BAO_0000218,1,CHEMBL623541,,
8296,,Mus musculus,,A,N,Intermediate,,10090.0,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",50594,,,1,14839,BAO_0000218,1,CHEMBL623542,,
8297,,Mus musculus,,A,N,Intermediate,,10090.0,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",50594,,,1,14839,BAO_0000218,1,CHEMBL623543,,
8298,,Mus musculus,,A,N,Intermediate,,10090.0,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",50594,,,1,14839,BAO_0000218,1,CHEMBL623544,,
8299,,Mus musculus,,A,N,Intermediate,,10090.0,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",50594,,,1,14839,BAO_0000218,1,CHEMBL623545,,
8300,,Mus musculus,,A,N,Intermediate,,10090.0,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",50594,,,1,14839,BAO_0000218,1,CHEMBL623546,,
8301,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,50597,,,1,5408,BAO_0000218,1,CHEMBL623547,,1969.0
8302,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,High i.v. clearance in Dawley rats,50597,,,1,6827,BAO_0000218,1,CHEMBL623548,,
8303,In vitro,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,In vitro clearance in rat liver microsomes,50597,,,1,17538,BAO_0000218,1,CHEMBL623549,,2107.0
8304,In vitro,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Intrinsic clearance in rat liver microsomes was determined,50597,,,1,6331,BAO_0000218,1,CHEMBL623550,,2107.0
8305,In vitro,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Intrinsic clearance in rat hepatocytes was determined,50597,,,1,5948,BAO_0000218,1,CHEMBL875276,401.0,2107.0
8306,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma Clearance was determined,50597,,,1,4026,BAO_0000218,1,CHEMBL621872,,
8307,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,50597,,,1,6647,BAO_0000218,1,CHEMBL621873,,
8308,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rat.,50597,,,1,1696,BAO_0000218,1,CHEMBL621874,,
8309,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rats,50597,,,1,6597,BAO_0000218,1,CHEMBL621875,,
8310,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,50597,,,1,347,BAO_0000218,1,CHEMBL621876,,
8311,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,50597,,,1,16423,BAO_0000218,1,CHEMBL621877,,
8312,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance was measured in rat,50597,,,1,2879,BAO_0000218,1,CHEMBL621878,,
8313,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,50597,,,1,4883,BAO_0000218,1,CHEMBL621879,,
8314,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",50597,,,1,5328,BAO_0000218,1,CHEMBL621880,,1969.0
8315,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,50597,,,1,5160,BAO_0000218,1,CHEMBL621881,,
8316,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,50597,,,1,17582,BAO_0000218,1,CHEMBL621882,,
8317,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Total clearance at 1 mg/kg was determined in rat,50597,,,1,17651,BAO_0000218,1,CHEMBL875283,,
8318,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Total clearance at 10 mg/kg was determined in rat,50597,,,1,17651,BAO_0000218,1,CHEMBL621883,,
8319,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance in rat,50597,,,1,6596,BAO_0000218,1,CHEMBL621884,,
8320,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance rate determined in rats,50597,,,1,4796,BAO_0000218,1,CHEMBL621885,,
8321,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance of compound in rat was evaluated,50597,,,1,6850,BAO_0000218,1,CHEMBL621886,,
8322,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,50597,,,1,5932,BAO_0000218,1,CHEMBL621887,,1969.0
8323,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (blood clearance) in rat,50597,,,1,3371,BAO_0000218,1,CHEMBL621888,,
8324,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rat,50597,,,1,2083,BAO_0000218,1,CHEMBL621889,,
8325,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rats,50597,,,1,4942,BAO_0000218,1,CHEMBL621890,,
8326,In vitro,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,50597,,,1,6838,BAO_0000218,1,CHEMBL621891,,2107.0
8327,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance in Dawley rat,50597,,,1,5353,BAO_0000218,1,CHEMBL621892,,
8328,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance rat,50597,,,1,6641,BAO_0000218,1,CHEMBL621893,,
8329,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),50597,,,1,6641,BAO_0000218,1,CHEMBL621894,,
8330,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance rat; Not determined,50597,,,1,6641,BAO_0000218,1,CHEMBL621895,,
8331,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance rate was determined in rat at a dose of 1 mpk i.v.,50597,,,1,6444,BAO_0000218,1,CHEMBL875284,,
8332,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,50597,,,1,6444,BAO_0000218,1,CHEMBL618699,,
8333,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,50597,,,1,6444,BAO_0000218,1,CHEMBL618700,,
8334,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,50597,,,1,6211,BAO_0000218,1,CHEMBL618701,,
8335,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",50597,,,1,12873,BAO_0000218,1,CHEMBL876600,,1969.0
8336,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance of compound in rat after 1 mg/kg i.v. administration,50597,,,1,6570,BAO_0000218,1,CHEMBL618702,,
8337,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for Hepatic clearance in rat,50597,,,1,3341,BAO_0000218,1,CHEMBL618703,,
8338,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo clearance after 5 mg/kg dose,50597,,,1,4891,BAO_0000218,1,CHEMBL618704,,
8339,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Compound was tested for plasma clearance in rats,50597,,,1,1094,BAO_0000218,1,CHEMBL618705,,1969.0
8340,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Hepatic clearance after intravenous administration was evaluated in rat,50597,,,1,2938,BAO_0000218,1,CHEMBL618706,,
8341,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Lower clearance in rat (i.v.) at 0.5 mpk,50597,,,1,17853,BAO_0000218,1,CHEMBL618707,,
8342,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Pharmacokinetic parameter expressed as plasma clearance in rat,50597,,,1,6049,BAO_0000218,1,CHEMBL618708,,1969.0
8343,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (Clp) in rat,50597,,,1,5789,BAO_0000218,1,CHEMBL618709,,
8344,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in Sprague-Dawley rats,50597,,,1,4514,BAO_0000218,1,CHEMBL618710,,
8345,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance (Clp) in rat,50597,,,1,6448,BAO_0000218,1,CHEMBL618711,,
8346,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,50597,,,1,6062,BAO_0000218,1,CHEMBL618712,,
8347,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,50597,,,1,5710,BAO_0000218,1,CHEMBL618713,,
8348,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance after intravenous administration of 1 mg/kg in rat,50597,,,1,4709,BAO_0000218,1,CHEMBL618714,,
8349,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,50597,,,1,4521,BAO_0000218,1,CHEMBL618715,,
8350,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rat was determined,50597,,,1,1742,BAO_0000218,1,CHEMBL618716,,
8351,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance measured in rat,50597,,,1,6057,BAO_0000218,1,CHEMBL876601,,
8352,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance was calculated in rat,50597,,,1,6057,BAO_0000218,1,CHEMBL618717,,
8353,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rat,50597,,,1,5145,BAO_0000218,1,CHEMBL618718,,
8354,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rat,50597,,,1,5833,BAO_0000218,1,CHEMBL618719,,
8355,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rat,50597,,,1,6453,BAO_0000218,1,CHEMBL618720,,
8356,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rat,50597,,,1,6640,BAO_0000218,1,CHEMBL618721,,
8357,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rats,50597,,,1,6305,BAO_0000218,1,CHEMBL621477,,
8358,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rat,50597,,,1,6642,BAO_0000218,1,CHEMBL621478,,
8359,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance was evaluated in rat,50597,,,1,5472,BAO_0000218,1,CHEMBL621479,,
8360,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance was evaluated in rat; Not tested,50597,,,1,5472,BAO_0000218,1,CHEMBL621480,,
8361,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance rate was determined for the compound in rat,50597,,,1,5144,BAO_0000218,1,CHEMBL621481,,
8362,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",50597,,,1,6685,BAO_0000218,1,CHEMBL621482,,
8363,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",50597,,,1,6685,BAO_0000218,1,CHEMBL621483,,
8364,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",50597,,,1,6685,BAO_0000218,1,CHEMBL621484,,
8365,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL621485,,948.0
8366,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL621486,,948.0
8367,In vivo,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL621487,,160.0
8368,In vivo,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL621488,,160.0
8369,In vivo,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL621489,,160.0
8370,In vivo,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL621490,,160.0
8371,In vivo,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL621491,,160.0
8372,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL621492,,2113.0
8373,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL621493,,2113.0
8374,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL621494,,2113.0
8375,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL621495,,2113.0
8376,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL621496,,2113.0
8377,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL621497,,2107.0
8378,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL621498,,2107.0
8379,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL621499,,2107.0
8380,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL618634,,2107.0
8381,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL618635,,2107.0
8382,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL618636,,2048.0
8383,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL619737,,2048.0
8384,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL619738,,2048.0
8385,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL624329,,2048.0
8386,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL624330,,2048.0
8387,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL624331,,2385.0
8388,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL624332,,2385.0
8389,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL624333,,2385.0
8390,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL624334,,2385.0
8391,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL624335,,2385.0
8392,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620016,,2106.0
8393,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620169,,2106.0
8394,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620170,,2106.0
8395,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620171,,2106.0
8396,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620172,,2106.0
8397,In vivo,Rattus norvegicus,,A,N,Intermediate,Stomach,10116.0,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620173,,945.0
8398,In vivo,Rattus norvegicus,,A,N,Intermediate,Stomach,10116.0,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620174,,945.0
8399,In vivo,Rattus norvegicus,,A,N,Intermediate,Stomach,10116.0,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620175,,945.0
8400,In vivo,Rattus norvegicus,,A,N,Intermediate,Stomach,10116.0,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620176,,945.0
8401,In vivo,Rattus norvegicus,,A,N,Intermediate,Stomach,10116.0,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620177,,945.0
8402,,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620178,,2037.0
8403,,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620179,,2037.0
8404,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620180,,
8405,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,50597,,,1,6570,BAO_0000218,1,CHEMBL620181,,
8406,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution of compound in rats after intravenous administration,50597,,,1,6571,BAO_0000218,1,CHEMBL620182,,
8407,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution in rat,50597,,,1,6453,BAO_0000218,1,CHEMBL620183,,
8408,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,50597,,,1,6444,BAO_0000218,1,CHEMBL620184,,
8409,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,50597,,,1,6444,BAO_0000218,1,CHEMBL620185,,
8410,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,50597,,,1,6444,BAO_0000218,1,CHEMBL620186,,
8411,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution was determined in Dawley rat,50597,,,1,5353,BAO_0000218,1,CHEMBL620187,,
8412,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,50597,,,1,5334,BAO_0000218,1,CHEMBL620188,,
8413,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution was reported in Sprague-Dawley rat,50597,,,1,5334,BAO_0000218,1,CHEMBL620189,,
8414,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volumes of distribution in rat after peroral administration,50597,,,1,6641,BAO_0000218,1,CHEMBL620190,,
8415,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volumes of distribution in rat after po administration,50597,,,1,6641,BAO_0000218,1,CHEMBL620191,,
8416,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volumes of distribution in rat after po administration; Not determined,50597,,,1,6641,BAO_0000218,1,CHEMBL620192,,
8417,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (Volume) in rat i.v.,50597,,,1,5676,BAO_0000218,1,CHEMBL620193,,
8418,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,50597,,,1,6410,BAO_0000218,1,CHEMBL620194,,
8419,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",50597,,,1,17670,BAO_0000218,1,CHEMBL876730,,
8420,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume distribution in rat after oral administration at 10 mg/kg,50597,,,1,6495,BAO_0000218,1,CHEMBL620195,,
8421,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,50597,,,1,5408,BAO_0000218,1,CHEMBL620196,,
8422,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,50597,,,1,4883,BAO_0000218,1,CHEMBL620197,,
8423,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,50597,,,1,6647,BAO_0000218,1,CHEMBL620198,,
8424,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution in rats,50597,,,1,6495,BAO_0000218,1,CHEMBL620199,,
8425,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,50597,,,1,2661,BAO_0000218,1,CHEMBL620200,,
8426,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,50597,,,1,2661,BAO_0000218,1,CHEMBL620201,,
8427,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,,,1,5974,BAO_0000218,1,CHEMBL620202,,
8428,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,,,1,5974,BAO_0000218,1,CHEMBL620203,,
8429,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,50597,,,1,5974,BAO_0000218,1,CHEMBL620204,,
8430,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,,,1,5974,BAO_0000218,1,CHEMBL620205,,
8431,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter (Vss) in rat,50597,,,1,5960,BAO_0000218,1,CHEMBL624664,,
8432,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (Volume) in rat i.v.,50597,,,1,5676,BAO_0000218,1,CHEMBL624665,,
8433,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (Vss) in rat,50597,,,1,5948,BAO_0000218,1,CHEMBL624666,,
8434,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,50597,,,1,5979,BAO_0000218,1,CHEMBL624667,,
8435,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL624668,,
8436,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL624669,,
8437,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL624670,,
8438,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL624671,,
8439,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Steady state volume distribution in rat,50597,,,1,6448,BAO_0000218,1,CHEMBL624672,,
8440,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",50597,,,1,12873,BAO_0000218,1,CHEMBL624673,,1969.0
8441,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Steady state volume of distribution determined in rat,50597,,,1,4576,BAO_0000218,1,CHEMBL624674,,
8442,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,50597,,,1,17582,BAO_0000218,1,CHEMBL624675,,
8443,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,50597,,,1,1466,BAO_0000218,1,CHEMBL621728,,
8444,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,50597,,,1,5182,BAO_0000218,1,CHEMBL621729,,
8445,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,50597,,,1,5182,BAO_0000218,1,CHEMBL621730,,
8446,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume distribution in rat after administration of 2 mg/kg iv,50597,,,1,6535,BAO_0000218,1,CHEMBL621731,,
8447,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume distribution in rat after administration of 2 mg/kg iv,50597,,,1,6535,BAO_0000218,1,CHEMBL621732,,
8448,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume in steady state distribution value was determined,50597,,,1,5041,BAO_0000218,1,CHEMBL621908,,
8449,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume in steady state distribution value was determined; ND denotes no data,50597,,,1,5041,BAO_0000218,1,CHEMBL875347,,
8450,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume in steady state distribution value was determined; ND denotes not determined,50597,,,1,5041,BAO_0000218,1,CHEMBL621909,,
8451,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,,,1,17065,BAO_0000218,1,CHEMBL621910,,
8452,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution at steady state was evaluated in rats,50597,,,1,6597,BAO_0000218,1,CHEMBL621911,,
8453,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution at steady state was observed after intravenous administration in rat,50597,,,1,15662,BAO_0000218,1,CHEMBL621912,,
8454,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution in steady state was determined in rat,50597,,,1,6485,BAO_0000218,1,CHEMBL621913,,
8455,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution in steady state was determined in rat,50597,,,1,17655,BAO_0000218,1,CHEMBL621914,,
8456,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution after i.v. administration,50597,,,1,6616,BAO_0000218,1,CHEMBL621915,,
8457,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,50597,,,1,1916,BAO_0000218,1,CHEMBL621916,,
8458,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,,,1,16438,BAO_0000218,1,CHEMBL621917,,2107.0
8459,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,,,1,16438,BAO_0000218,1,CHEMBL621918,,2107.0
8460,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution of compound (oxidized form) in spleen tissue,50594,,,1,16438,BAO_0000218,1,CHEMBL621919,,2106.0
8461,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",50594,,,1,16438,BAO_0000218,1,CHEMBL621920,,2106.0
8462,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",50594,,,1,16438,BAO_0000218,1,CHEMBL621921,,2106.0
8463,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,,,1,16438,BAO_0000218,1,CHEMBL622401,,2106.0
8464,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",50594,,,1,16438,BAO_0000218,1,CHEMBL875348,,2106.0
8465,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",50594,,,1,16438,BAO_0000218,1,CHEMBL622402,,2106.0
8466,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,50594,,,1,16438,BAO_0000218,1,CHEMBL622403,,178.0
8467,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,,,1,16438,BAO_0000218,1,CHEMBL622404,,178.0
8468,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,50594,,,1,16438,BAO_0000218,1,CHEMBL622405,,955.0
8469,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",50594,,,1,16438,BAO_0000218,1,CHEMBL622406,,955.0
8470,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,,,1,16438,BAO_0000218,1,CHEMBL622407,,955.0
8471,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,50594,,,1,16438,BAO_0000218,1,CHEMBL622408,,948.0
8472,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",50594,,,1,16438,BAO_0000218,1,CHEMBL622409,,948.0
8473,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,,,1,16438,BAO_0000218,1,CHEMBL622410,,948.0
8474,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,50594,,,1,16438,BAO_0000218,1,CHEMBL622411,,2113.0
8475,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",50594,,,1,16438,BAO_0000218,1,CHEMBL627864,,2113.0
8476,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,,,1,16438,BAO_0000218,1,CHEMBL627865,,2113.0
8477,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,50594,,,1,16438,BAO_0000218,1,CHEMBL627866,,2107.0
8478,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,,,1,16438,BAO_0000218,1,CHEMBL627751,,2107.0
8479,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,50594,,,1,16438,BAO_0000218,1,CHEMBL627752,,2106.0
8480,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",50594,,,1,16438,BAO_0000218,1,CHEMBL627753,,2106.0
8481,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",50594,,,1,16438,BAO_0000218,1,CHEMBL627754,,2106.0
8482,,Mus musculus,,A,N,Intermediate,,10090.0,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,50594,,,1,12467,BAO_0000218,1,CHEMBL627755,,
8483,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL627756,,955.0
8484,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL627757,,955.0
8485,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL627758,,955.0
8486,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL627759,,955.0
8487,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL627760,,955.0
8488,In vivo,Mus musculus,,A,N,Intermediate,Brain,10090.0,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL627761,,955.0
8489,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL876811,,948.0
8490,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL627762,,948.0
8491,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL627763,,948.0
8492,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL627764,,948.0
8493,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL627765,,948.0
8494,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL627766,,948.0
8495,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL627767,,2113.0
8496,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL627768,,2113.0
8497,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL628422,,2113.0
8498,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL628423,,2113.0
8499,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,50597,,,1,5089,BAO_0000218,1,CHEMBL628424,,
8500,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,50597,,,1,5089,BAO_0000218,1,CHEMBL628425,,
8501,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,50597,,,1,4257,BAO_0000218,1,CHEMBL628426,,
8502,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50597,,,1,6679,BAO_0000218,1,CHEMBL628427,,
8503,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,50597,,,1,5546,BAO_0000218,1,CHEMBL626938,,
8504,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,50597,,,1,6141,BAO_0000218,1,CHEMBL626939,,
8505,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,50597,,,1,5334,BAO_0000218,1,CHEMBL626940,,
8506,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,50597,,,1,5334,BAO_0000218,1,CHEMBL626941,,
8507,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance was reported in Sprague-Dawley rat,50597,,,1,5334,BAO_0000218,1,CHEMBL626942,,
8508,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance after intravenous administration (1 mg/kg) in rat,50597,,,1,4689,BAO_0000218,1,CHEMBL876812,,
8509,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance of compound in rats was evaluated,50597,,,1,6848,BAO_0000218,1,CHEMBL626943,,
8510,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance of compound in rats was evaluated; ND indicates not determined,50597,,,1,6848,BAO_0000218,1,CHEMBL626944,,
8511,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,50597,,,1,6467,BAO_0000218,1,CHEMBL626945,,
8512,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,50597,,,1,6467,BAO_0000218,1,CHEMBL626946,,
8513,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance rate in Sprague-Dawley rats,50597,,,1,4956,BAO_0000218,1,CHEMBL626856,,
8514,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),50597,,,1,5529,BAO_0000218,1,CHEMBL626857,,
8515,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,The compound was evaluated for plasma clearance in rat,50597,,,1,406,BAO_0000218,1,CHEMBL626858,,1969.0
8516,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Total plasma clearance in rat,50597,,,1,17655,BAO_0000218,1,CHEMBL627018,,1969.0
8517,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,50597,,,1,3293,BAO_0000218,1,CHEMBL625331,,178.0
8518,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,50597,,,1,4075,BAO_0000218,1,CHEMBL625332,,178.0
8519,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,C max was determined at 10 mg/kg po dose in rats,50597,,,1,2792,BAO_0000218,1,CHEMBL877590,,
8520,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,C max was determined at 3 mg/kg po dose in rats,50597,,,1,2792,BAO_0000218,1,CHEMBL625333,,
8521,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax after repeated oral dose of compound at 1 mg/kg in rats,50597,,,1,17594,BAO_0000218,1,CHEMBL625334,,
8522,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax after single intravenous bolus of 1 mg/kg in rats,50597,,,1,17594,BAO_0000218,1,CHEMBL625335,,
8523,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax of compound at 5 mg/kg after po administration was determined in rat,50597,,,1,4762,BAO_0000218,1,CHEMBL625336,,
8524,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax 24 hr after 10 mg/kg oral administration in rats,50597,,,1,17509,BAO_0000218,1,CHEMBL625337,,
8525,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax 24 hr after 2 mg/kg oral administration in rats,50597,,,1,17509,BAO_0000218,1,CHEMBL625338,,
8526,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,50597,,,1,1466,BAO_0000218,1,CHEMBL625339,,1969.0
8527,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax in rat after administration of 2 mg/kg iv,50597,,,1,6535,BAO_0000218,1,CHEMBL625340,,
8528,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax in rat after administration of 2 mg/kg iv,50597,,,1,6535,BAO_0000218,1,CHEMBL625341,,
8529,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,50597,,,1,3169,BAO_0000218,1,CHEMBL622687,,
8530,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Cmax wa determined in rat plasma at 30 mg/kg after po administration,50597,,,1,6515,BAO_0000218,1,CHEMBL622688,,1969.0
8531,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,50597,,,1,11149,BAO_0000218,1,CHEMBL622689,,178.0
8532,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,50597,,,1,11149,BAO_0000218,1,CHEMBL620295,,178.0
8533,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax after 10 mg/kg oral administration in rat,50597,,,1,17858,BAO_0000218,1,CHEMBL620296,,
8534,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax after IV dosing at 0.5 mg/kg in rat; no data,50597,,,1,6518,BAO_0000218,1,CHEMBL620297,,
8535,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax after IV dosing at 1 mg/kg in rat; no data,50597,,,1,6518,BAO_0000218,1,CHEMBL620298,,
8536,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax after oral administration at 20 mpk in rats,50597,,,1,4426,BAO_0000218,1,CHEMBL620299,,
8537,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax after oral administration at 20 mpk in rats; Not performed.,50597,,,1,4426,BAO_0000218,1,CHEMBL620300,,
8538,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax after oral administration at 20 mpk in rats d; Not performed.,50597,,,1,4426,BAO_0000218,1,CHEMBL620301,,
8539,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax after oral administration in rat,50597,,,1,5656,BAO_0000218,1,CHEMBL620302,,
8540,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax after oral administration at a dose of 2 mg/kg in rat,50597,,,1,6518,BAO_0000218,1,CHEMBL620303,,
8541,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax after oral administration at a dose of 4 mg/kg in rat,50597,,,1,6518,BAO_0000218,1,CHEMBL620304,,
8542,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax in rats after 20 mg/kg oral dose,50597,,,1,6113,BAO_0000218,1,CHEMBL620305,,
8543,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax after peroral administration in rats at 2.4 uM/kg,50597,,,1,17764,BAO_0000218,1,CHEMBL620306,,
8544,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax at the dose of 2 mg/Kg administered perorally in rats,50597,,,1,4756,BAO_0000218,1,CHEMBL620307,,
8545,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax at the dose of 5 mg/Kg administered perorally in rats,50597,,,1,4756,BAO_0000218,1,CHEMBL620308,,
8546,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax by administering at 20 mg/kg p.o. in rats,50597,,,1,6402,BAO_0000218,1,CHEMBL620309,,
8547,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax in male rat,50597,,,1,5610,BAO_0000218,1,CHEMBL620310,,
8548,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax in rat,50597,,,1,5207,BAO_0000218,1,CHEMBL620311,,
8549,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax in rat,50597,,,1,6011,BAO_0000218,1,CHEMBL620312,,
8550,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax in rat,50597,,,1,6504,BAO_0000218,1,CHEMBL620313,,
8551,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax in rat at 10 mg/kg,50597,,,1,6046,BAO_0000218,1,CHEMBL620314,,
8552,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax in rat at the dose of 1 mg/kg i.v.,50597,,,1,6504,BAO_0000218,1,CHEMBL620315,,
8553,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax in rat by po administration at a dose of 40 mg/kg,50597,,,1,5874,BAO_0000218,1,CHEMBL620316,,
8554,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax in rat p.o. at 20 mg/kg concentration,50597,,,1,17686,BAO_0000218,1,CHEMBL620317,,
8555,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax in rats,50597,,,1,5836,BAO_0000218,1,CHEMBL620318,,
8556,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax in rats,50597,,,1,17596,BAO_0000218,1,CHEMBL620319,,
8557,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax was evaluated after 20 uM/kg of peroral administration,50597,,,1,16423,BAO_0000218,1,CHEMBL620320,,
8558,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax was measured in rats after peroral administration at 3 mg/kg,50597,,,1,17804,BAO_0000218,1,CHEMBL620321,,
8559,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax value after oral dose at a dose of 10 mg/kg in rats.,50597,,,1,1908,BAO_0000218,1,CHEMBL620322,,
8560,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620323,,
8561,,Rattus norvegicus,,A,N,Intermediate,Frontal cortex,10116.0,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620324,,1870.0
8562,,Rattus norvegicus,,A,N,Intermediate,Frontal cortex,10116.0,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620325,,1870.0
8563,,Rattus norvegicus,,A,N,Intermediate,Hippocampus,10116.0,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620326,,10000000.0
8564,,Rattus norvegicus,,A,N,Intermediate,Hippocampus,10116.0,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620327,,10000000.0
8565,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620328,,
8566,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620329,,
8567,,Rattus norvegicus,,A,N,Intermediate,Midbrain,10116.0,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620330,,1891.0
8568,,Rattus norvegicus,,A,N,Intermediate,Midbrain,10116.0,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL875286,,1891.0
8569,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620331,,
8570,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620332,,
8571,,Rattus norvegicus,,A,N,Intermediate,Striatum,10116.0,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620333,,2435.0
8572,,Rattus norvegicus,,A,N,Intermediate,Striatum,10116.0,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,50597,,,1,13950,BAO_0000218,1,CHEMBL620334,,2435.0
8573,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL621015,,178.0
8574,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL621016,,178.0
8575,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL621191,,178.0
8576,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL621192,,178.0
8577,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL621193,,178.0
8578,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL621194,,178.0
8579,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL624204,,178.0
8580,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL624205,,178.0
8581,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL624206,,178.0
8582,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL624207,,178.0
8583,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL624208,,178.0
8584,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL624209,,178.0
8585,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL624210,,178.0
8586,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL624211,,178.0
8587,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL624212,,178.0
8588,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL624213,,178.0
8589,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,,,1,16434,BAO_0000218,1,CHEMBL876611,,178.0
8590,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,,,1,16434,BAO_0000218,1,CHEMBL624214,,178.0
8591,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,,,1,16434,BAO_0000218,1,CHEMBL624215,,178.0
8592,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,,,1,16435,BAO_0000218,1,CHEMBL624216,,178.0
8593,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,,,1,16435,BAO_0000218,1,CHEMBL624217,,178.0
8594,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,,,1,16435,BAO_0000218,1,CHEMBL624218,,178.0
8595,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,,,1,16435,BAO_0000218,1,CHEMBL624219,,178.0
8596,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,,,1,16435,BAO_0000218,1,CHEMBL624220,,178.0
8597,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,,,1,16435,BAO_0000218,1,CHEMBL624221,,178.0
8598,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL624222,,
8599,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL624223,,
8600,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL624224,,
8601,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL624225,,
8602,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,50597,,,1,17764,BAO_0000218,1,CHEMBL622420,,
8603,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of steady state distribution after i.v. administration in rats,50597,,,1,5031,BAO_0000218,1,CHEMBL622421,,
8604,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Vss after intravenous administration (5.0 mg/kg) was determined in rat,50597,,,1,6215,BAO_0000218,1,CHEMBL622422,,
8605,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,,,1,17671,BAO_0000218,1,CHEMBL622423,,
8606,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Vss was determined,50597,,,1,17752,BAO_0000218,1,CHEMBL622424,,
8607,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Vss in rat,50597,,,1,6596,BAO_0000218,1,CHEMBL622425,,
8608,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Vss was evaluated after 10 uM/kg of intra arterial administration,50597,,,1,16423,BAO_0000218,1,CHEMBL876612,,
8609,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,volume of distribution at steady state was observed after intravenous administration in rat,50597,,,1,15662,BAO_0000218,1,CHEMBL622426,,
8610,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,50597,,,1,6062,BAO_0000218,1,CHEMBL622427,,
8611,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic (PK) parameter Vz in rat,50597,,,1,5874,BAO_0000218,1,CHEMBL622428,,
8612,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume distribution in rats,50597,,,1,4942,BAO_0000218,1,CHEMBL622429,,
8613,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution in rat; No data,50597,,,1,17796,BAO_0000218,1,CHEMBL622430,,
8614,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,50597,,,1,4890,BAO_0000218,1,CHEMBL622431,,
8615,,Rattus norvegicus,,A,N,Intermediate,Ileum,10116.0,% absorption predicted from in vitro rat ileum transport studies,50597,,,1,15765,BAO_0000218,1,CHEMBL622432,,2116.0
8616,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,50597,,,1,13569,BAO_0000218,1,CHEMBL622433,,
8617,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,50597,,,1,13569,BAO_0000218,1,CHEMBL622434,,
8618,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,50597,,,1,13569,BAO_0000218,1,CHEMBL622435,,
8619,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),50597,,,1,13569,BAO_0000218,1,CHEMBL618748,,
8620,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,50597,,,1,13569,BAO_0000218,1,CHEMBL618749,,
8621,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,50597,,,1,13569,BAO_0000218,1,CHEMBL618750,,
8622,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,50597,,,1,13569,BAO_0000218,1,CHEMBL618751,,
8623,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,50597,,,1,13569,BAO_0000218,1,CHEMBL618752,,
8624,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,4576,BAO_0000218,1,CHEMBL618753,,
8625,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,50597,,,1,750,BAO_0000218,1,CHEMBL618754,,1969.0
8626,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,750,BAO_0000218,1,CHEMBL618755,,
8627,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,4590,BAO_0000218,1,CHEMBL618756,,
8628,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,1716,BAO_0000218,1,CHEMBL618757,,
8629,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat,50597,,,1,1974,BAO_0000218,1,CHEMBL618758,,
8630,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (dose 30 mg/kg),50597,,,1,4502,BAO_0000218,1,CHEMBL621088,,
8631,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (cLogP) in rat,50597,,,1,3371,BAO_0000218,1,CHEMBL621089,,
8632,,Rattus norvegicus,,F,N,Intermediate,Blood,10116.0,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,50597,,,1,9099,BAO_0000218,1,CHEMBL621090,,178.0
8633,,Rattus norvegicus,,F,N,Intermediate,Blood,10116.0,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,50597,,,1,9099,BAO_0000218,1,CHEMBL621091,,178.0
8634,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance in rat.,50597,,,1,4590,BAO_0000218,1,CHEMBL876731,,
8635,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for its clearance when administered intravenously in rat,50597,,,1,3184,BAO_0000218,1,CHEMBL621092,,
8636,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,50597,,,1,16456,BAO_0000218,1,CHEMBL621093,,
8637,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Blood: Brain distribution ratio is determined in rat,50597,,,1,4199,BAO_0000218,1,CHEMBL621094,,
8638,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,50597,,,1,4199,BAO_0000218,1,CHEMBL621095,,
8639,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,50597,,,1,4199,BAO_0000218,1,CHEMBL621096,,
8640,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL621097,,2113.0
8641,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Percent dose excreted in 0-48 hours administered ip to male rat,50597,,,1,7449,BAO_0000218,1,CHEMBL621098,,
8642,,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL621099,,2037.0
8643,,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL621100,,2037.0
8644,,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL621101,,2037.0
8645,,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL621102,,2037.0
8646,,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL876732,,2037.0
8647,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL621103,,
8648,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL621104,,
8649,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL621105,,
8650,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL621106,,
8651,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL621107,,
8652,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL621108,,
8653,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL621109,,
8654,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL621110,,2113.0
8655,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL621111,,2113.0
8656,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL622541,,2107.0
8657,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL622542,,2107.0
8658,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL622543,,2107.0
8659,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL624412,,2107.0
8660,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL624413,,2107.0
8661,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL624414,,2107.0
8662,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL624415,,2048.0
8663,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL624416,,2048.0
8664,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL624417,,2048.0
8665,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL624418,,2048.0
8666,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL624419,,2048.0
8667,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL624420,,2048.0
8668,In vivo,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL624421,,2385.0
8669,In vivo,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL624422,,2385.0
8670,In vivo,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL624423,,2385.0
8671,In vivo,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL625123,,2385.0
8672,In vivo,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL625124,,2385.0
8673,In vivo,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL625125,,2385.0
8674,In vivo,Mus musculus,,A,N,Intermediate,Zone of skin,10090.0,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL625126,,14.0
8675,In vivo,Mus musculus,,A,N,Intermediate,Zone of skin,10090.0,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL626947,,14.0
8676,In vivo,Mus musculus,,A,N,Intermediate,Zone of skin,10090.0,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL626948,,14.0
8677,In vivo,Mus musculus,,A,N,Intermediate,Zone of skin,10090.0,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL626949,,14.0
8678,In vivo,Mus musculus,,A,N,Intermediate,Zone of skin,10090.0,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL626950,,14.0
8679,In vivo,Mus musculus,,A,N,Intermediate,Zone of skin,10090.0,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL626951,,14.0
8680,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL626952,,2106.0
8681,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL626953,,2106.0
8682,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL626954,,2106.0
8683,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL626955,,2106.0
8684,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL626956,,2106.0
8685,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL626957,,2106.0
8686,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL626958,,178.0
8687,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL626959,,178.0
8688,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL626960,,178.0
8689,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL626961,,178.0
8690,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL627589,,178.0
8691,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),50594,,,1,17208,BAO_0000218,1,CHEMBL627590,,178.0
8692,,Mus musculus,,A,N,Intermediate,,10090.0,Time taken for EC90 was determined when tested in mouse,50594,,,1,3132,BAO_0000218,1,CHEMBL627591,,
8693,,Mus musculus,,A,N,Intermediate,,10090.0,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,50594,,,1,3132,BAO_0000218,1,CHEMBL627592,,
8694,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),50594,,,1,16597,BAO_0000218,1,CHEMBL627593,,
8695,,Mus musculus,,A,N,Intermediate,,10090.0,Half life in mice,50594,,,1,5727,BAO_0000218,1,CHEMBL627594,,
8696,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Half life period in mouse after 10 mg/Kg dose,50594,,,1,5302,BAO_0000218,1,CHEMBL876813,,
8697,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Half life period in mouse after 10 mg/kg dose,50594,,,1,5302,BAO_0000218,1,CHEMBL627595,,
8698,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,50594,,,1,6348,BAO_0000218,1,CHEMBL627596,,
8699,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax value at 5 mg/kg po was determined in rat,50597,,,1,5964,BAO_0000218,1,CHEMBL627597,,
8700,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax value evaluated in rat,50597,,,1,6078,BAO_0000218,1,CHEMBL627598,,
8701,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,50597,,,1,5206,BAO_0000218,1,CHEMBL627599,,955.0
8702,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax value after administration of 20 mg/Kg oral dose in rat,50597,,,1,2959,BAO_0000218,1,CHEMBL627600,,
8703,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax value at 1 mg/kg po in rat,50597,,,1,5964,BAO_0000218,1,CHEMBL627601,,
8704,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax value at 5 mg/kg po in rat,50597,,,1,5964,BAO_0000218,1,CHEMBL627776,,
8705,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax value at a dose of 10 mg/kg in male SD rats,50597,,,1,6757,BAO_0000218,1,CHEMBL627777,,
8706,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax value at a dose of 100 mg/kg in male SD rats,50597,,,1,6757,BAO_0000218,1,CHEMBL627778,,
8707,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax value at a dose of 50 mg/kg in male SD rats,50597,,,1,6757,BAO_0000218,1,CHEMBL627779,,
8708,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax value in rats at 10 mg/kg,50597,,,1,17617,BAO_0000218,1,CHEMBL876814,,
8709,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax value was evaluated in rats at a dose of 20 mg/kg,50597,,,1,1445,BAO_0000218,1,CHEMBL627780,,
8710,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax value was determined after peroral administration of 20 mg/kg in rat,50597,,,1,6082,BAO_0000218,1,CHEMBL627781,,
8711,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,50597,,,1,1446,BAO_0000218,1,CHEMBL627782,,
8712,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,50597,,,1,5407,BAO_0000218,1,CHEMBL627783,,1969.0
8713,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,50597,,,1,2690,BAO_0000218,1,CHEMBL627784,,1969.0
8714,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,50597,,,1,2661,BAO_0000218,1,CHEMBL627785,,
8715,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,50597,,,1,2661,BAO_0000218,1,CHEMBL627786,,
8716,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,50597,,,1,4891,BAO_0000218,1,CHEMBL627787,,1969.0
8717,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,50597,,,1,2807,BAO_0000218,1,CHEMBL627788,,1969.0
8718,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,50597,,,1,2807,BAO_0000218,1,CHEMBL626579,,1969.0
8719,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,50597,,,1,2807,BAO_0000218,1,CHEMBL626580,,1969.0
8720,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,50597,,,1,3634,BAO_0000218,1,CHEMBL876815,,
8721,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,50597,,,1,1881,BAO_0000218,1,CHEMBL626581,,1969.0
8722,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,50597,,,1,1881,BAO_0000218,1,CHEMBL626582,,1969.0
8723,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,50597,,,1,429,BAO_0000218,1,CHEMBL626583,,
8724,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,,,1,5974,BAO_0000218,1,CHEMBL626205,,
8725,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,,,1,5974,BAO_0000218,1,CHEMBL626206,,
8726,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,,,1,5974,BAO_0000218,1,CHEMBL626207,,
8727,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,,,1,5974,BAO_0000218,1,CHEMBL623882,,
8728,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,50597,,,1,17582,BAO_0000218,1,CHEMBL623883,,
8729,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,50597,,,1,17582,BAO_0000218,1,CHEMBL623884,,
8730,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",50597,,,1,3032,BAO_0000218,1,CHEMBL623885,,1969.0
8731,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,50597,,,1,6295,BAO_0000218,1,CHEMBL623886,,1969.0
8732,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximal concentration in rat was determined,50597,,,1,6619,BAO_0000218,1,CHEMBL623887,,
8733,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximal concentration after i.v. administration,50597,,,1,6616,BAO_0000218,1,CHEMBL623888,,
8734,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,50597,,,1,3249,BAO_0000218,1,CHEMBL623889,,1969.0
8735,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximal plasma concentration in rat after oral administration at 50 mg/kg,50597,,,1,17791,BAO_0000218,1,CHEMBL623890,,1969.0
8736,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Cmax in rat plasma after oral dose (50 mg/Kg),50597,,,1,17791,BAO_0000218,1,CHEMBL623891,,1969.0
8737,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximal plasma concentration was determined.,50597,,,1,1360,BAO_0000218,1,CHEMBL623892,,1969.0
8738,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximal plasma drug concentration was determined,50597,,,1,2552,BAO_0000218,1,CHEMBL623893,,1969.0
8739,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximal concentration in rats after peroral administration,50597,,,1,6571,BAO_0000218,1,CHEMBL877616,,
8740,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration in rat after 2 mg/kg peroral administration,50597,,,1,6570,BAO_0000218,1,CHEMBL623894,,
8741,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum concentration in rat plasma after 5 mg/kg oral gavage,50597,,,1,6567,BAO_0000218,1,CHEMBL623895,,1969.0
8742,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration of compound in rat was evaluated.,50597,,,1,3031,BAO_0000218,1,CHEMBL623896,,
8743,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,50597,,,1,3436,BAO_0000218,1,CHEMBL623897,,
8744,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,50597,,,1,3436,BAO_0000218,1,CHEMBL623898,,
8745,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,50597,,,1,2083,BAO_0000218,1,CHEMBL623899,,
8746,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,50597,,,1,3436,BAO_0000218,1,CHEMBL623900,,
8747,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,50597,,,1,4527,BAO_0000218,1,CHEMBL623901,,
8748,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration was evaluated in rats,50597,,,1,1974,BAO_0000218,1,CHEMBL623902,,
8749,In vivo,Rattus norvegicus,,A,N,Intermediate,Cerebrospinal fluid,10116.0,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,50597,,,1,3307,BAO_0000218,1,CHEMBL623903,,1359.0
8750,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,50597,,,1,3307,BAO_0000218,1,CHEMBL623904,,1969.0
8751,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,50597,,,1,1916,BAO_0000218,1,CHEMBL877617,,1969.0
8752,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,50597,,,1,1500,BAO_0000218,1,CHEMBL623905,,
8753,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,50597,,,1,1500,BAO_0000218,1,CHEMBL623906,,
8754,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,,,1,4186,BAO_0000218,1,CHEMBL623907,,1969.0
8755,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL623908,,
8756,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL623909,,
8757,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL623910,,
8758,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL623911,,
8759,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL623912,,
8760,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL624616,,
8761,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL624617,,
8762,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL624618,,
8763,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL624619,,
8764,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL624794,,
8765,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL624795,,
8766,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL623921,,
8767,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,,,1,16434,BAO_0000218,1,CHEMBL623922,,
8768,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,,,1,16434,BAO_0000218,1,CHEMBL623923,,
8769,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,,,1,16434,BAO_0000218,1,CHEMBL623924,,
8770,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,,,1,16435,BAO_0000218,1,CHEMBL623925,,
8771,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,,,1,16435,BAO_0000218,1,CHEMBL623926,,
8772,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,,,1,16435,BAO_0000218,1,CHEMBL623927,,
8773,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,,,1,16435,BAO_0000218,1,CHEMBL623928,,
8774,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,,,1,16435,BAO_0000218,1,CHEMBL623929,,
8775,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,,,1,16435,BAO_0000218,1,CHEMBL623930,,
8776,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL623931,,955.0
8777,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622165,,955.0
8778,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL621249,,955.0
8779,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL621250,,955.0
8780,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL621448,,955.0
8781,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL621449,,955.0
8782,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL621450,,955.0
8783,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL621451,,955.0
8784,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL621452,,955.0
8785,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL621453,,955.0
8786,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL621454,,955.0
8787,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL621455,,955.0
8788,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL621456,,955.0
8789,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL625145,,955.0
8790,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL875847,,955.0
8791,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL625146,,955.0
8792,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,,,1,16434,BAO_0000218,1,CHEMBL625147,,955.0
8793,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,,,1,16434,BAO_0000218,1,CHEMBL625148,,955.0
8794,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,,,1,16434,BAO_0000218,1,CHEMBL625149,,955.0
8795,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,,,1,16435,BAO_0000218,1,CHEMBL625150,,955.0
8796,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,,,1,16435,BAO_0000218,1,CHEMBL625151,,955.0
8797,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,,,1,16435,BAO_0000218,1,CHEMBL625152,,955.0
8798,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,,,1,16435,BAO_0000218,1,CHEMBL625153,,955.0
8799,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,,,1,16435,BAO_0000218,1,CHEMBL625154,,955.0
8800,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,,,1,16435,BAO_0000218,1,CHEMBL625155,,955.0
8801,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL625156,,
8802,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL624354,,
8803,,Rattus norvegicus,,A,N,Intermediate,Hippocampus,10116.0,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL624355,,10000000.0
8804,,Rattus norvegicus,,A,N,Intermediate,Hippocampus,10116.0,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL624356,,10000000.0
8805,,Rattus norvegicus,,A,N,Intermediate,Hippocampus,10116.0,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL624357,,10000000.0
8806,,Rattus norvegicus,,A,N,Intermediate,Hippocampus,10116.0,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL624358,,10000000.0
8807,,Rattus norvegicus,,A,N,Intermediate,Striatum,10116.0,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL624359,,2435.0
8808,,Rattus norvegicus,,A,N,Intermediate,Striatum,10116.0,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL624360,,2435.0
8809,,Rattus norvegicus,,A,N,Intermediate,Striatum,10116.0,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL624361,,2435.0
8810,,Rattus norvegicus,,A,N,Intermediate,Striatum,10116.0,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL624362,,2435.0
8811,,Rattus norvegicus,,A,N,Intermediate,Striatum,10116.0,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL624363,,2435.0
8812,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL624364,,178.0
8813,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL624365,,178.0
8814,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL624366,,178.0
8815,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL624367,,178.0
8816,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL624368,,955.0
8817,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL624369,,955.0
8818,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL624370,,955.0
8819,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL625069,,955.0
8820,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL625070,,955.0
8821,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL626051,,948.0
8822,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL626052,,948.0
8823,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL626053,,948.0
8824,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL626054,,948.0
8825,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL626055,,948.0
8826,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL626056,,2113.0
8827,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL626057,,2113.0
8828,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL625193,,2113.0
8829,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL625194,,2113.0
8830,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL625195,,2107.0
8831,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL625196,,2107.0
8832,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL625197,,2107.0
8833,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL625198,,2107.0
8834,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL627929,,2107.0
8835,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL627074,,2048.0
8836,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL627075,,2048.0
8837,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL627076,,2048.0
8838,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL627077,,2048.0
8839,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL627078,,2048.0
8840,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL627079,,2385.0
8841,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,50594,,,1,4573,BAO_0000218,1,CHEMBL873824,,
8842,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Half life in mouse plasma was determined at dose 25 mg/kg,50594,,,1,3132,BAO_0000218,1,CHEMBL627080,,1969.0
8843,,Mus musculus,,A,N,Intermediate,,10090.0,Half life was determined,50594,,,1,17718,BAO_0000218,1,CHEMBL627081,,
8844,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,50594,,,1,17728,BAO_0000218,1,CHEMBL627082,,
8845,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Half-life in male mice after 1 mg/kg intravenous dose,50594,,,1,5961,BAO_0000218,1,CHEMBL627083,,
8847,,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Half life in mice plasma,50594,,,1,17731,BAO_0000218,1,CHEMBL627085,,1969.0
8848,,Mus musculus,,A,N,Intermediate,,10090.0,Half life in mouse,50594,,,1,17592,BAO_0000218,1,CHEMBL627086,,
8849,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Half life in mouse plasma at dose 25 mg/kg,50594,,,1,3132,BAO_0000218,1,CHEMBL627087,,1969.0
8850,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,50594,,,1,17729,BAO_0000218,1,CHEMBL627088,,
8851,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,50594,,,1,17729,BAO_0000218,1,CHEMBL627089,,
8852,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,50594,,,1,17729,BAO_0000218,1,CHEMBL627090,,
8853,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),50594,,,1,3277,BAO_0000218,1,CHEMBL627091,,
8854,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",50594,,,1,3760,BAO_0000218,1,CHEMBL627092,,
8855,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",50594,,,1,3760,BAO_0000218,1,CHEMBL876785,,
8856,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Half-life by iv administration in mouse,50594,,,1,2862,BAO_0000218,1,CHEMBL627093,,
8857,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Half-life by oral administration in mouse,50594,,,1,2862,BAO_0000218,1,CHEMBL627094,,
8858,,Mus musculus,,A,N,Intermediate,,10090.0,Half-life in mice,50594,,,1,5980,BAO_0000218,1,CHEMBL627095,,
8859,,Mus musculus,,A,N,Intermediate,Brain,10090.0,Half-life using mouse brain homogenate,50594,,,1,6159,BAO_0000218,1,CHEMBL627096,,955.0
8860,,Mus musculus,,A,N,Intermediate,,10090.0,Half-life was measured in mice,50594,,,1,6254,BAO_0000218,1,CHEMBL627097,,
8861,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Half-life was measured in mouse after an iv dose of 1 mg/kg,50594,,,1,6062,BAO_0000218,1,CHEMBL627098,,
8862,,Mus musculus,,A,N,Intermediate,Blood,10090.0,Half-life period was determined in mouse blood,50594,,,1,1574,BAO_0000218,1,CHEMBL627099,,178.0
8863,,Mus musculus,,A,N,Intermediate,Brain,10090.0,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",50594,,,1,56,BAO_0000218,1,CHEMBL627100,,955.0
8864,,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Plasma half life in mouse,50594,,,1,993,BAO_0000218,1,CHEMBL627101,,1969.0
8865,,Mus musculus,,A,N,Intermediate,,10090.0,Stability of the peptide in the presence of mouse serum,50594,,,1,6652,BAO_0000218,1,CHEMBL627102,,
8866,,Mus musculus,,A,N,Intermediate,,10090.0,Terminal half life of compound was determined in mouse,50594,,,1,17852,BAO_0000218,1,CHEMBL627103,,
8867,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Terminal half life was evaluated in mice after intravenous administration,50594,,,1,2675,BAO_0000218,1,CHEMBL627104,,
8868,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Terminal half life was evaluated in mice after oral administration,50594,,,1,2675,BAO_0000218,1,CHEMBL627105,,
8869,,Mus musculus,,A,N,Intermediate,,10090.0,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,50594,,,1,499,BAO_0000218,1,CHEMBL876786,,
8870,,Mus musculus,,A,N,Intermediate,,10090.0,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,50594,,,1,499,BAO_0000218,1,CHEMBL873825,,
8871,,Mus musculus,,A,N,Intermediate,,10090.0,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,50594,,,1,499,BAO_0000218,1,CHEMBL627106,,
8872,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,half life period is evaluated by administering intravenously at 25 mg/kg in mice,50594,,,1,14239,BAO_0000218,1,CHEMBL626336,,
8873,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",50594,,,1,5506,BAO_0000218,1,CHEMBL877462,,
8874,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",50594,,,1,5506,BAO_0000218,1,CHEMBL626337,,
8875,,Mus musculus,,A,N,Intermediate,,10090.0,Half life after intraperitoneal administration of 100 mg/kg in mice,50594,,,1,17734,BAO_0000218,1,CHEMBL626338,,
8876,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,50594,,,1,17728,BAO_0000218,1,CHEMBL626339,,
8877,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,50594,,,1,17728,BAO_0000218,1,CHEMBL626340,,
8878,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,50594,,,1,17728,BAO_0000218,1,CHEMBL625377,,
8879,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,50594,,,1,17728,BAO_0000218,1,CHEMBL625378,,
8880,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,50594,,,1,17728,BAO_0000218,1,CHEMBL625379,,
8881,,Sus scrofa,,A,U,Autocuration,,9823.0,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),22224,,,1,14294,BAO_0000251,0,CHEMBL625380,,
8882,,Sus scrofa,,A,U,Autocuration,,9823.0,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),22224,,,1,14294,BAO_0000251,0,CHEMBL625381,,
8883,,Sus scrofa,,A,U,Autocuration,,9823.0,Stability to porcine renal DHP-I,22224,,,1,6056,BAO_0000019,0,CHEMBL625382,,
8884,In vivo,Sus scrofa,,A,U,Autocuration,,9823.0,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,22224,,,1,1317,BAO_0000218,0,CHEMBL873828,,
8885,In vivo,Sus scrofa,,A,U,Autocuration,,9823.0,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,22224,,,1,1317,BAO_0000218,0,CHEMBL625383,,
8886,,Sus scrofa,,A,U,Autocuration,,9823.0,Half-life of the parent prodrug in porcine esterase solution,22224,,,1,5229,BAO_0000019,0,CHEMBL625384,,
8887,,Sus scrofa,,A,U,Autocuration,,9823.0,"First order rate constant, k was determined in in pig liver Esterase",22224,,,1,4231,BAO_0000019,0,CHEMBL625385,,
8888,,Sus scrofa,,A,U,Autocuration,Liver,9823.0,Half life of the in pig liver Esterase,22224,,,1,4231,BAO_0000221,0,CHEMBL625386,,2107.0
8889,,Sus scrofa,,A,U,Autocuration,Liver,9823.0,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,22224,,,1,5318,BAO_0000221,0,CHEMBL623571,,2107.0
8890,,Sus scrofa,,A,U,Autocuration,Liver,9823.0,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,22224,,,1,5318,BAO_0000221,0,CHEMBL623572,,2107.0
8891,,Sus scrofa,,A,U,Autocuration,Liver,9823.0,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,22224,,,1,5318,BAO_0000221,0,CHEMBL623573,,2107.0
8892,,Sus scrofa,,A,U,Autocuration,Liver,9823.0,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,22224,,,1,3305,BAO_0000221,0,CHEMBL623574,,2107.0
8893,,Sus scrofa,,A,U,Autocuration,Liver,9823.0,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,22224,,,1,3305,BAO_0000221,0,CHEMBL623575,,2107.0
8894,,Sus scrofa,,A,U,Autocuration,Liver,9823.0,Half-life in the presence of pig liver esterase(PLE) was evaluated.,22224,,,1,2842,BAO_0000221,0,CHEMBL623749,,2107.0
8895,,Sus scrofa,,A,U,Autocuration,Liver,9823.0,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,22224,,,1,2842,BAO_0000221,0,CHEMBL623750,,2107.0
8896,In vitro,Sus scrofa,,A,U,Autocuration,Liver,9823.0,Half-life in vitro in pig liver,22224,,,1,889,BAO_0000221,0,CHEMBL623751,,2107.0
8897,,Sus scrofa,,A,U,Autocuration,Liver,9823.0,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,22224,,,1,1904,BAO_0000221,0,CHEMBL623752,,2107.0
8898,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,50597,,,1,4186,BAO_0000218,1,CHEMBL623753,,1969.0
8899,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,50597,,,1,2774,BAO_0000218,1,CHEMBL623754,,1969.0
8900,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum concentration in rat plasma was determined,50597,,,1,1742,BAO_0000218,1,CHEMBL623755,,1969.0
8901,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration in rats,50597,,,1,3169,BAO_0000218,1,CHEMBL623756,,
8902,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration in rats at 1-2 hours,50597,,,1,3169,BAO_0000218,1,CHEMBL623757,,
8903,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,50597,,,1,2081,BAO_0000218,1,CHEMBL623758,,
8904,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,50597,,,1,3307,BAO_0000218,1,CHEMBL623759,,955.0
8905,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration at the dose of 2 mg/kg in rat,50597,,,1,4727,BAO_0000218,1,CHEMBL623760,,
8906,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration was evaluated in rats,50597,,,1,6597,BAO_0000218,1,CHEMBL623761,,
8907,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,50597,,,1,16365,BAO_0000218,1,CHEMBL623762,,1969.0
8908,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,50597,,,1,16365,BAO_0000218,1,CHEMBL877594,,1969.0
8909,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,50597,,,1,16365,BAO_0000218,1,CHEMBL623763,,1969.0
8910,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,50597,,,1,16365,BAO_0000218,1,CHEMBL623764,,1969.0
8911,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,50597,,,1,16365,BAO_0000218,1,CHEMBL623765,,1969.0
8912,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,50597,,,1,2591,BAO_0000218,1,CHEMBL623766,,178.0
8913,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,50597,,,1,2591,BAO_0000218,1,CHEMBL623767,,178.0
8914,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,50597,,,1,2591,BAO_0000218,1,CHEMBL623768,,178.0
8915,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL623769,,1969.0
8916,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL623770,,1969.0
8917,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL623771,,1969.0
8918,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL623772,,1969.0
8919,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL623773,,1969.0
8920,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL623774,,1969.0
8921,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL623775,,1969.0
8922,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax in rat (PO dose),50597,,,1,14465,BAO_0000218,1,CHEMBL623776,,
8923,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,,,1,4723,BAO_0000218,1,CHEMBL622191,,1969.0
8924,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,,,1,4723,BAO_0000218,1,CHEMBL622192,,1969.0
8925,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration determined in rat,50597,,,1,4576,BAO_0000218,1,CHEMBL622193,,1969.0
8926,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,50597,,,1,12873,BAO_0000218,1,CHEMBL622194,,1969.0
8927,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,50597,,,1,12873,BAO_0000218,1,CHEMBL622195,,1969.0
8928,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration in rat,50597,,,1,6824,BAO_0000218,1,CHEMBL622196,,1969.0
8929,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,,,1,17065,BAO_0000218,1,CHEMBL622197,,1969.0
8930,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,50597,,,1,2932,BAO_0000218,1,CHEMBL622198,,1969.0
8931,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,50597,,,1,2932,BAO_0000218,1,CHEMBL622199,,1969.0
8932,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration of compound was measured in rat,50597,,,1,2879,BAO_0000218,1,CHEMBL622200,,1969.0
8933,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration after 20 mg/kg oral administration in rat,50597,,,1,2864,BAO_0000218,1,CHEMBL622201,,1969.0
8934,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration after oral administration to rats,50597,,,1,16367,BAO_0000218,1,CHEMBL623990,,1969.0
8935,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,,,1,17717,BAO_0000218,1,CHEMBL623991,,1969.0
8936,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",50597,,,1,17717,BAO_0000218,1,CHEMBL623992,,1969.0
8937,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,,,1,17717,BAO_0000218,1,CHEMBL623993,,1969.0
8938,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,50597,,,1,17717,BAO_0000218,1,CHEMBL623994,,1969.0
8939,In vivo,Rattus norvegicus,,F,N,Intermediate,Plasma,10116.0,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,50597,,,1,17720,BAO_0000218,1,CHEMBL623995,,1969.0
8940,In vivo,Rattus norvegicus,,F,N,Intermediate,Plasma,10116.0,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,,,1,17720,BAO_0000218,1,CHEMBL623996,,1969.0
8941,In vivo,Rattus norvegicus,,F,N,Intermediate,Plasma,10116.0,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,50597,,,1,17720,BAO_0000218,1,CHEMBL623997,,1969.0
8942,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration dosed orally in rats,50597,,,1,4516,BAO_0000218,1,CHEMBL623998,,1969.0
8943,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration dosed orally in rats after 6 hours,50597,,,1,4516,BAO_0000218,1,CHEMBL623999,,1969.0
8944,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,50597,,,1,4516,BAO_0000218,1,CHEMBL624000,,1969.0
8945,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,50597,,,1,5199,BAO_0000218,1,CHEMBL624001,,1969.0
8946,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration in rat after po administration,50597,,,1,17538,BAO_0000218,1,CHEMBL624002,,1969.0
8947,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",50597,,,1,6685,BAO_0000218,1,CHEMBL624003,,1969.0
8948,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",50597,,,1,6685,BAO_0000218,1,CHEMBL624004,,1969.0
8949,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL624005,,948.0
8950,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL624006,,948.0
8951,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL624007,,948.0
8952,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL624008,,948.0
8953,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL624009,,948.0
8954,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL874387,,948.0
8955,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL624010,,948.0
8956,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL624011,,948.0
8957,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL624012,,948.0
8958,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL624013,,948.0
8959,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL624736,,948.0
8960,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL624737,,948.0
8961,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,,,1,16434,BAO_0000218,1,CHEMBL624738,,948.0
8962,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,,,1,16434,BAO_0000218,1,CHEMBL624739,,948.0
8963,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,,,1,16434,BAO_0000218,1,CHEMBL624740,,948.0
8964,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,,,1,16435,BAO_0000218,1,CHEMBL624896,,948.0
8965,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,,,1,16435,BAO_0000218,1,CHEMBL624897,,948.0
8966,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,,,1,16435,BAO_0000218,1,CHEMBL624108,,948.0
8967,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,,,1,16435,BAO_0000218,1,CHEMBL624109,,948.0
8968,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,,,1,16435,BAO_0000218,1,CHEMBL624110,,948.0
8969,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,,,1,16435,BAO_0000218,1,CHEMBL624111,,948.0
8970,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL624112,,948.0
8971,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL624113,,948.0
8972,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL619709,,948.0
8973,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL619710,,948.0
8974,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL619711,,2113.0
8975,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL619712,,2113.0
8976,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL619713,,2113.0
8977,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL619714,,2113.0
8978,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL619715,,2113.0
8979,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL619716,,2113.0
8980,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL619717,,2113.0
8981,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL619718,,2113.0
8982,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL619719,,2113.0
8983,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL875329,,2113.0
8984,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL619720,,2113.0
8985,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL619721,,2113.0
8986,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL619722,,2113.0
8987,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL619723,,2113.0
8988,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL619724,,2113.0
8989,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL619725,,2113.0
8990,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,,,1,16434,BAO_0000218,1,CHEMBL619726,,2113.0
8991,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,,,1,16434,BAO_0000218,1,CHEMBL619727,,2113.0
8992,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,,,1,16434,BAO_0000218,1,CHEMBL619728,,2113.0
8993,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,,,1,16435,BAO_0000218,1,CHEMBL619729,,2113.0
8994,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL619730,,2385.0
8995,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL619731,,2385.0
8996,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL619732,,2385.0
8997,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL619733,,2385.0
8998,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL619734,,2385.0
8999,In vivo,Rattus norvegicus,,A,N,Intermediate,Zone of skin,10116.0,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL619735,,14.0
9000,In vivo,Rattus norvegicus,,A,N,Intermediate,Zone of skin,10116.0,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL875330,,14.0
9001,In vivo,Rattus norvegicus,,A,N,Intermediate,Zone of skin,10116.0,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL628465,,14.0
9002,In vivo,Rattus norvegicus,,A,N,Intermediate,Zone of skin,10116.0,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL628466,,14.0
9003,In vivo,Rattus norvegicus,,A,N,Intermediate,Zone of skin,10116.0,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL628467,,14.0
9004,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL628468,,2106.0
9005,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL628469,,2106.0
9006,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL628470,,2106.0
9007,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL628471,,2106.0
9008,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL628472,,2106.0
9009,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL625191,,2046.0
9010,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL625192,,2046.0
9011,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL875337,,2046.0
9012,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL626341,,2046.0
9013,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL626342,,2046.0
9014,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),50597,,,1,11977,BAO_0000218,1,CHEMBL621943,,2107.0
9015,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in rats,50597,,,1,3748,BAO_0000218,1,CHEMBL621944,,
9016,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,50597,,,1,15765,BAO_0000218,1,CHEMBL621945,,
9017,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),50597,,,1,4871,BAO_0000218,1,CHEMBL621946,,
9018,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,50597,,,1,4871,BAO_0000218,1,CHEMBL621947,,
9019,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),50597,,,1,4872,BAO_0000218,1,CHEMBL621948,,
9020,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,50597,,,1,4872,BAO_0000218,1,CHEMBL621949,,
9021,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),50597,,,1,5413,BAO_0000218,1,CHEMBL621950,,
9022,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,50597,,,1,5413,BAO_0000218,1,CHEMBL621951,,
9023,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,50597,,,1,15272,BAO_0000218,1,CHEMBL621952,,178.0
9024,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Stability (%) in rat liver microsomes,50597,,,1,4689,BAO_0000218,1,CHEMBL621953,,2107.0
9025,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was calculated after intravenous administration,50597,,,1,6057,BAO_0000218,1,CHEMBL621954,,
9026,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve was calculated after iv administration in rat,50597,,,1,6057,BAO_0000218,1,CHEMBL621955,,
9027,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve was calculated in rat after peroral administration,50597,,,1,6057,BAO_0000218,1,CHEMBL621956,,
9028,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,50597,,,1,6211,BAO_0000218,1,CHEMBL621957,,
9029,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,50597,,,1,5710,BAO_0000218,1,CHEMBL621958,,
9030,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,50597,,,1,5710,BAO_0000218,1,CHEMBL621959,,
9031,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,50597,,,1,17853,BAO_0000218,1,CHEMBL621960,,
9032,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,50597,,,1,17853,BAO_0000218,1,CHEMBL621961,,
9033,,Rattus norvegicus,,A,N,Intermediate,,10116.0,p value of the compound,50597,,,1,15765,BAO_0000218,1,CHEMBL621962,,
9034,,Rattus norvegicus,,F,N,Intermediate,,10116.0,p value of the compound,50597,,,1,15765,BAO_0000218,1,CHEMBL876787,,
9035,,Rattus norvegicus,,A,N,Intermediate,,10116.0,p value of the compound,50597,,,1,15765,BAO_0000218,1,CHEMBL621963,,
9036,,Rattus norvegicus,,A,N,Intermediate,Stomach,10116.0,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,,,1,6175,BAO_0000218,1,CHEMBL622637,,945.0
9037,,Rattus norvegicus,,A,N,Intermediate,Stomach,10116.0,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,,,1,6175,BAO_0000218,1,CHEMBL622638,,945.0
9038,,Rattus norvegicus,,A,N,Intermediate,Stomach,10116.0,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,,,1,6175,BAO_0000218,1,CHEMBL626561,,945.0
9039,,Oryctolagus cuniculus,,F,U,Autocuration,,9986.0,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),22224,,,1,7991,BAO_0000019,0,CHEMBL626562,,
9040,,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),22224,,,1,429,BAO_0000218,0,CHEMBL626563,,
9041,,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),22224,,,1,429,BAO_0000218,0,CHEMBL626564,,
9042,In vivo,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,22224,,,1,6253,BAO_0000218,0,CHEMBL626565,,
9043,In vivo,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,22224,,,1,6253,BAO_0000218,0,CHEMBL626566,,
9044,In vivo,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,Clearance rate in rabbits,22224,,,1,3615,BAO_0000218,0,CHEMBL626567,,
9045,In vivo,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,22224,,,1,4059,BAO_0000218,0,CHEMBL626568,,
9046,In vivo,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,22224,,,1,5124,BAO_0000218,0,CHEMBL626569,,
9047,In vivo,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,22224,,,1,5124,BAO_0000218,0,CHEMBL626570,,
9048,In vivo,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,22224,,,1,5124,BAO_0000218,0,CHEMBL626571,,
9049,In vivo,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,22224,,,1,429,BAO_0000218,0,CHEMBL626572,,
9050,In vivo,Oryctolagus cuniculus,,A,U,Autocuration,Plasma,9986.0,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,22224,,,1,4059,BAO_0000218,0,CHEMBL626573,,1969.0
9051,,Oryctolagus cuniculus,,A,U,Autocuration,Liver,9986.0,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,22224,,,1,9659,BAO_0000251,0,CHEMBL626574,,2107.0
9052,,Oryctolagus cuniculus,,A,U,Autocuration,Liver,9986.0,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,22224,,,1,9659,BAO_0000251,0,CHEMBL626575,,2107.0
9053,,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,Dose at which bioavailability of intravenously administered compound was tested in rabbit,22224,,,1,3639,BAO_0000218,0,CHEMBL626576,,
9054,,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,Dose at which bioavailability of perorally administered compound was tested in rabbit,22224,,,1,3639,BAO_0000218,0,CHEMBL626577,,
9055,In vivo,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,The compound was tested for its bioavailability in rabbit (by oral dosage).,22224,,,1,3639,BAO_0000218,0,CHEMBL626578,,
9056,In vivo,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,22224,,,1,5124,BAO_0000218,0,CHEMBL625263,,
9057,In vivo,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,22224,,,1,5124,BAO_0000218,0,CHEMBL625264,,
9058,In vivo,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,22224,,,1,5124,BAO_0000218,0,CHEMBL625265,,
9059,,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),22224,,,1,14294,BAO_0000251,0,CHEMBL625266,,
9060,,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),22224,,,1,14294,BAO_0000251,0,CHEMBL876796,,
9061,In vivo,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,22224,,,1,429,BAO_0000218,0,CHEMBL625267,,
9062,In vivo,Oryctolagus cuniculus,,A,U,Autocuration,Plasma,9986.0,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,22224,,,1,5124,BAO_0000218,0,CHEMBL625268,,1969.0
9063,In vivo,Oryctolagus cuniculus,,A,U,Autocuration,Plasma,9986.0,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,22224,,,1,5124,BAO_0000218,0,CHEMBL625269,,1969.0
9064,In vivo,Oryctolagus cuniculus,,A,U,Autocuration,Plasma,9986.0,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,22224,,,1,5124,BAO_0000218,0,CHEMBL624689,,1969.0
9065,In vivo,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,22224,,,1,429,BAO_0000218,0,CHEMBL624690,,
9066,,Oryctolagus cuniculus,,A,U,Autocuration,Urine,9986.0,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),22224,,,1,429,BAO_0000218,0,CHEMBL624691,,1088.0
9067,,Oryctolagus cuniculus,,A,U,Autocuration,Urine,9986.0,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),22224,,,1,429,BAO_0000218,0,CHEMBL624692,,1088.0
9068,In vivo,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,22224,,,1,4059,BAO_0000218,0,CHEMBL624693,,
9069,In vivo,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,22224,,,1,4137,BAO_0000218,0,CHEMBL624694,,
9070,In vitro,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,In vitro Biological half-life in crude homogenate of rabbit renal cortex,22224,,,1,11672,BAO_0000221,0,CHEMBL877596,,
9071,,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,Time within which only 10% of the drug was degraded,22224,,,1,12886,BAO_0000019,0,CHEMBL624695,,
9072,,Oryctolagus cuniculus,,A,U,Autocuration,Liver,9986.0,Half life period in rabbit liver homogenate,22224,,,1,3853,BAO_0000221,0,CHEMBL624696,,2107.0
9073,,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,Half life value in rabbits,22224,,,1,3615,BAO_0000019,0,CHEMBL624697,,
9074,In vivo,Oryctolagus cuniculus,,A,U,Autocuration,Blood,9986.0,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,22224,,,1,6253,BAO_0000218,0,CHEMBL624698,,178.0
9075,In vivo,Oryctolagus cuniculus,,A,U,Autocuration,Blood,9986.0,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,22224,,,1,6253,BAO_0000218,0,CHEMBL624699,,178.0
9076,In vivo,Oryctolagus cuniculus,,A,U,Autocuration,,9986.0,Half-life period in rabbits following intravenous administration at 2 mg/kg,22224,,,1,6077,BAO_0000218,0,CHEMBL624700,,
9077,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC 0-8 hr value in rats at 10 mg/kg,50597,,,1,17617,BAO_0000218,1,CHEMBL622903,,1969.0
9078,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC after administration at 2000 mg/kg/day in rats,50597,,,1,17594,BAO_0000218,1,CHEMBL622904,,1969.0
9079,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,50597,,,1,6149,BAO_0000218,1,CHEMBL622905,,1969.0
9080,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,50597,,,1,17260,BAO_0000218,1,CHEMBL622906,,1969.0
9081,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,,,1,17260,BAO_0000218,1,CHEMBL622907,,1969.0
9082,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC in rat after oral administration at 10.5 mg/kg dose,50597,,,1,6644,BAO_0000218,1,CHEMBL622908,,1969.0
9083,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC in rat after oral administration at 11.2 mg/kg dose,50597,,,1,6644,BAO_0000218,1,CHEMBL622909,,1969.0
9084,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC in rat after oral administration at 9.7 mg/kg dose,50597,,,1,6644,BAO_0000218,1,CHEMBL622910,,1969.0
9085,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,AUC in rat brain after oral administration at 10 mg/kg,50597,,,1,6495,BAO_0000218,1,CHEMBL622911,,955.0
9086,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC in rat p.o.,50597,,,1,6504,BAO_0000218,1,CHEMBL622912,,1969.0
9087,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC in rat p.o. at 20 mg/kg concentration,50597,,,1,17686,BAO_0000218,1,CHEMBL622913,,1969.0
9088,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC in rat plasma after oral administration at 10 mg/kg,50597,,,1,6495,BAO_0000218,1,CHEMBL622914,,1969.0
9089,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC in rats,50597,,,1,216,BAO_0000218,1,CHEMBL622915,,1969.0
9090,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC value after IV dose at a dose of 5 mg/kg in rats.,50597,,,1,1908,BAO_0000218,1,CHEMBL622916,,1969.0
9091,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC value after oral dose at a dose of 10 mg/kg in rats.,50597,,,1,1908,BAO_0000218,1,CHEMBL622917,,1969.0
9092,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",50597,,,1,6685,BAO_0000218,1,CHEMBL622918,,1969.0
9093,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,50597,,,1,216,BAO_0000218,1,CHEMBL622919,,1969.0
9094,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration was evaluated in rat,50597,,,1,6049,BAO_0000218,1,CHEMBL622920,,1969.0
9095,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,50597,,,1,2463,BAO_0000218,1,CHEMBL622921,,1969.0
9096,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,50597,,,1,6679,BAO_0000218,1,CHEMBL622922,,1969.0
9097,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,50597,,,1,6681,BAO_0000218,1,CHEMBL622923,,1969.0
9098,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,50597,,,1,4890,BAO_0000218,1,CHEMBL877604,,1969.0
9099,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,50597,,,1,6410,BAO_0000218,1,CHEMBL622924,,1969.0
9100,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,50597,,,1,6410,BAO_0000218,1,CHEMBL622925,,1969.0
9101,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,50597,,,1,16366,BAO_0000218,1,CHEMBL622926,,1969.0
9102,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,50597,,,1,6227,BAO_0000218,1,CHEMBL623625,,1969.0
9103,In vivo,Rattus norvegicus,,A,N,Expert,Plasma,10116.0,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,,,1,3598,BAO_0000218,1,CHEMBL623626,,1969.0
9104,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma drug concentration was determined,50597,,,1,1465,BAO_0000218,1,CHEMBL623627,,1969.0
9105,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,50597,,,1,4368,BAO_0000218,1,CHEMBL623628,,
9106,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Mean peak plasma concentration was observed after intravenous administration in rat,50597,,,1,15662,BAO_0000218,1,CHEMBL623629,,1969.0
9107,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Mean peak plasma concentration was observed after oral administration in rat,50597,,,1,15662,BAO_0000218,1,CHEMBL623630,,1969.0
9108,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,50597,,,1,5355,BAO_0000218,1,CHEMBL623804,,
9109,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,50597,,,1,5355,BAO_0000218,1,CHEMBL623805,,
9110,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Peak oral plasma concentration was determined in rats by oral administration,50597,,,1,1567,BAO_0000218,1,CHEMBL623806,,1969.0
9111,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Peak plasma concentration (Cmax) was determined,50597,,,1,4026,BAO_0000218,1,CHEMBL623807,,1969.0
9112,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,50597,,,1,6193,BAO_0000218,1,CHEMBL623808,,1969.0
9113,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Peak plasma concentration (Cmax) in rats,50597,,,1,4026,BAO_0000218,1,CHEMBL623809,,1969.0
9114,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Peak plasma concentration at 1 mg/kg peroral administration,50597,,,1,6485,BAO_0000218,1,CHEMBL623810,,1969.0
9115,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Peak plasma concentration in rat,50597,,,1,17655,BAO_0000218,1,CHEMBL623811,,1969.0
9116,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",50597,,,1,14941,BAO_0000218,1,CHEMBL623812,,1969.0
9117,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,50597,,,1,5394,BAO_0000218,1,CHEMBL877605,,
9118,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (Cmax) in rat,50597,,,1,4408,BAO_0000218,1,CHEMBL623813,,
9119,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,50597,,,1,5983,BAO_0000218,1,CHEMBL623814,,
9120,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax in rat after 3mg/kg oral dose,50597,,,1,4878,BAO_0000218,1,CHEMBL623815,,
9121,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,50597,,,1,5862,BAO_0000218,1,CHEMBL623816,,
9122,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax in rats after 20 mg/kg oral dose,50597,,,1,4517,BAO_0000218,1,CHEMBL623145,,
9123,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Cmax in rat plasma after 30mg/kg oral dose,50597,,,1,5932,BAO_0000218,1,CHEMBL623146,,1969.0
9124,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma concentration after oral administration of 100 mg/kg to rats,50597,,,1,5436,BAO_0000218,1,CHEMBL623147,,1969.0
9125,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,50597,,,1,4910,BAO_0000218,1,CHEMBL623042,,955.0
9126,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for the Cmax in rat at 10 mg/kg per orally,50597,,,1,4950,BAO_0000218,1,CHEMBL623043,,
9127,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",50597,,,1,15078,BAO_0000218,1,CHEMBL623044,,
9128,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",50597,,,1,15078,BAO_0000218,1,CHEMBL623045,,
9129,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability as oral Cmax in rats at 30 mins,50597,,,1,3360,BAO_0000218,1,CHEMBL623046,,
9130,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability as oral Cmax in rats at 6hr,50597,,,1,3360,BAO_0000218,1,CHEMBL623226,,
9131,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,The maximum concentration of compound was measured at the dose of 100 umol/kg,50597,,,1,15022,BAO_0000218,1,CHEMBL623227,,
9132,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,The maximum concentration of compound was measured at the dose of 300 umol/kg,50597,,,1,15022,BAO_0000218,1,CHEMBL623228,,
9133,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,The maximum concentration of compound was measured at the dose of 30 umol/kg,50597,,,1,15022,BAO_0000218,1,CHEMBL623229,,
9134,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,The maximum plasma levels for the compounds were determined by LC-MS.,50597,,,1,5160,BAO_0000218,1,CHEMBL623230,,1969.0
9135,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,mean peak plasma concentration was observed after intravenous administration in rat,50597,,,1,15662,BAO_0000218,1,CHEMBL623231,,1969.0
9136,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,mean peak plasma concentration was observed after oral administration in rat,50597,,,1,15662,BAO_0000218,1,CHEMBL623232,,1969.0
9137,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,50597,,,1,4709,BAO_0000218,1,CHEMBL623233,,
9138,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,50597,,,1,3535,BAO_0000218,1,CHEMBL623234,,
9139,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Concentration in plasma (portal) following oral dose in rats at 1 hr,50597,,,1,3535,BAO_0000218,1,CHEMBL623235,,
9140,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Concentration in plasma (portal) following oral dose in rats at 2 hr,50597,,,1,3535,BAO_0000218,1,CHEMBL623236,,
9141,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,50597,,,1,3535,BAO_0000218,1,CHEMBL623237,,
9142,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Concentration in plasma (systemic) following oral dose in rats at 1 hr,50597,,,1,3535,BAO_0000218,1,CHEMBL623238,,
9143,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Concentration in plasma (systemic) following oral dose in rats at 2 hr,50597,,,1,3535,BAO_0000218,1,CHEMBL623239,,
9144,In vivo,Rattus norvegicus,,A,U,Intermediate,Plasma,10116.0,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,22224,,,1,5005,BAO_0000218,0,CHEMBL623240,,1969.0
9145,,Rattus norvegicus,,A,N,Intermediate,Hypothalamus,10116.0,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",50597,,,1,6326,BAO_0000218,1,CHEMBL623241,,1898.0
9146,,Rattus norvegicus,,A,N,Intermediate,Hypothalamus,10116.0,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",50597,,,1,6326,BAO_0000218,1,CHEMBL623242,,1898.0
9147,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",50597,,,1,6326,BAO_0000218,1,CHEMBL874394,,
9148,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",50597,,,1,6326,BAO_0000218,1,CHEMBL623243,,
9149,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,,,1,17411,BAO_0000218,1,CHEMBL623244,,
9150,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,,,1,16435,BAO_0000218,1,CHEMBL623245,,2113.0
9151,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,,,1,16435,BAO_0000218,1,CHEMBL623246,,2113.0
9152,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,,,1,16435,BAO_0000218,1,CHEMBL623247,,2113.0
9153,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,,,1,16435,BAO_0000218,1,CHEMBL623248,,2113.0
9154,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,,,1,16435,BAO_0000218,1,CHEMBL623249,,2113.0
9155,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL625072,,2107.0
9156,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL625073,,2107.0
9157,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL625074,,2107.0
9158,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL625075,,2107.0
9159,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL625076,,2107.0
9160,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL625077,,2107.0
9161,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL625078,,2107.0
9162,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL874395,,2107.0
9163,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL625079,,2107.0
9164,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL625080,,2107.0
9165,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL625081,,2107.0
9166,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL625082,,2107.0
9167,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL625083,,2107.0
9168,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL625084,,2107.0
9169,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL625085,,2107.0
9170,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL625086,,2107.0
9171,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,,,1,16434,BAO_0000218,1,CHEMBL625087,,2107.0
9172,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,,,1,16434,BAO_0000218,1,CHEMBL625088,,2107.0
9173,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,,,1,16434,BAO_0000218,1,CHEMBL622205,,2107.0
9174,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,,,1,16435,BAO_0000218,1,CHEMBL622206,,2107.0
9175,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,,,1,16435,BAO_0000218,1,CHEMBL622207,,2107.0
9176,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,,,1,16435,BAO_0000218,1,CHEMBL622366,,2107.0
9177,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,,,1,16435,BAO_0000218,1,CHEMBL622367,,2107.0
9178,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,,,1,16435,BAO_0000218,1,CHEMBL875331,,2107.0
9179,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,,,1,16435,BAO_0000218,1,CHEMBL622368,,2107.0
9180,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622369,,2048.0
9181,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622370,,2048.0
9182,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622371,,2048.0
9183,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622372,,2048.0
9184,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622373,,2048.0
9185,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622374,,2048.0
9186,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622375,,2048.0
9187,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622376,,2048.0
9188,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL622377,,2048.0
9189,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL622378,,2048.0
9190,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL622379,,2048.0
9191,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL622380,,2048.0
9192,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL622381,,2048.0
9193,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL622382,,2048.0
9194,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,50597,,,1,16434,BAO_0000218,1,CHEMBL622383,,2048.0
9195,,Rattus norvegicus,,A,N,Intermediate,Stomach,10116.0,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,,,1,6175,BAO_0000218,1,CHEMBL875332,,945.0
9196,,Rattus norvegicus,,A,N,Intermediate,Stomach,10116.0,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,,,1,6175,BAO_0000218,1,CHEMBL622384,,945.0
9197,,Rattus norvegicus,,A,N,Intermediate,Stomach,10116.0,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,,,1,6175,BAO_0000218,1,CHEMBL622385,,945.0
9198,,Rattus norvegicus,,A,N,Intermediate,Stomach,10116.0,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),50597,,,1,6175,BAO_0000218,1,CHEMBL622386,,945.0
9199,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The compound was tested for the plasma binding in rat,50597,,,1,10839,BAO_0000218,1,CHEMBL622387,,
9200,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",50597,,,1,16459,BAO_0000218,1,CHEMBL622388,,
9201,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",50597,,,1,16459,BAO_0000218,1,CHEMBL622389,,
9202,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",50597,,,1,16459,BAO_0000218,1,CHEMBL622390,,
9203,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),50597,,,1,16459,BAO_0000218,1,CHEMBL622391,,
9204,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),50597,,,1,16459,BAO_0000218,1,CHEMBL622392,,
9205,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),50597,,,1,16459,BAO_0000218,1,CHEMBL622393,,
9206,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma level at 2 hr after administration of the compound,50597,,,1,3278,BAO_0000218,1,CHEMBL622394,,
9207,,Rattus norvegicus,,A,N,Intermediate,,10116.0,plasma level at 2 hr after administration of the compound,50597,,,1,3278,BAO_0000218,1,CHEMBL622395,,
9208,,Rattus norvegicus,,A,N,Intermediate,Serum,10116.0,Stability in rat serum measured as % recovery at 1 min,50597,,,1,4684,BAO_0000218,1,CHEMBL622396,,1977.0
9209,,Rattus norvegicus,,A,N,Intermediate,Serum,10116.0,Stability in rat serum measured as % recovery at 10 min,50597,,,1,4684,BAO_0000218,1,CHEMBL624894,,1977.0
9210,,Rattus norvegicus,,A,N,Intermediate,Serum,10116.0,Stability in rat serum measured as % recovery at 10 mins,50597,,,1,4684,BAO_0000218,1,CHEMBL624895,,1977.0
9211,,Rattus norvegicus,,A,N,Intermediate,Serum,10116.0,Stability in rat serum measured as % recovery at 2 hr,50597,,,1,4684,BAO_0000218,1,CHEMBL624058,,1977.0
9212,,Rattus norvegicus,,A,N,Intermediate,Serum,10116.0,Stability in rat serum measured as % recovery at 3 min,50597,,,1,4684,BAO_0000218,1,CHEMBL624059,,1977.0
9213,,Rattus norvegicus,,A,N,Intermediate,Serum,10116.0,Stability in rat serum measured as % recovery at 3 mins,50597,,,1,4684,BAO_0000218,1,CHEMBL624060,,1977.0
9214,,Rattus norvegicus,,A,N,Intermediate,Serum,10116.0,Stability in rat serum measured as % recovery at 5 min,50597,,,1,4684,BAO_0000218,1,CHEMBL624061,,1977.0
9215,,Rattus norvegicus,,A,N,Intermediate,Serum,10116.0,Stability in rat serum measured as % recovery at 5 mins,50597,,,1,4684,BAO_0000218,1,CHEMBL624062,,1977.0
9216,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,50597,,,1,16456,BAO_0000218,1,CHEMBL624063,,
9217,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,50597,,,1,16456,BAO_0000218,1,CHEMBL624064,,
9218,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,50597,,,1,723,BAO_0000218,1,CHEMBL624065,,1969.0
9219,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,50597,,,1,723,BAO_0000218,1,CHEMBL624066,,1969.0
9220,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life tested in mature male rat at a dose of 30 mg/kg,50597,,,1,5160,BAO_0000218,1,CHEMBL877490,,
9221,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life after intravenous administration of 1 mg/kg in rat,50597,,,1,4709,BAO_0000218,1,CHEMBL874442,,
9222,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period after administration (30 mg/kg) in rat,50597,,,1,5633,BAO_0000218,1,CHEMBL626890,,
9223,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period in rat after 5 mg/Kg dose,50597,,,1,5302,BAO_0000218,1,CHEMBL626891,,
9224,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period in rat after 5 mg/kg dose,50597,,,1,5302,BAO_0000218,1,CHEMBL626892,,
9225,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period was determined,50597,,,1,17791,BAO_0000218,1,CHEMBL626893,,
9226,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period was evaluated in rat,50597,,,1,17791,BAO_0000218,1,CHEMBL626894,,
9227,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period was evaluated in rat; 0.5-1.0,50597,,,1,17791,BAO_0000218,1,CHEMBL626895,,
9228,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period was evaluated in rat; 5.9-7.5,50597,,,1,17791,BAO_0000218,1,CHEMBL626896,,
9229,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half-life in rat plasma,50597,,,1,14512,BAO_0000218,1,CHEMBL626897,,1969.0
9230,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life time in rat was determined,50597,,,1,6230,BAO_0000218,1,CHEMBL626898,,
9231,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Terminal half-life after iv administration to rats,50597,,,1,3364,BAO_0000218,1,CHEMBL626899,,
9232,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,50597,,,1,6874,BAO_0000218,1,CHEMBL626900,,
9233,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,50597,,,1,857,BAO_0000218,1,CHEMBL626901,,
9234,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),50597,,,1,858,BAO_0000218,1,CHEMBL626902,,
9235,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),50597,,,1,858,BAO_0000218,1,CHEMBL626903,,
9236,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,50597,,,1,5355,BAO_0000218,1,CHEMBL874443,,
9237,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,50597,,,1,5355,BAO_0000218,1,CHEMBL626904,,
9238,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in rats,50597,,,1,6305,BAO_0000218,1,CHEMBL626905,,
9239,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,50597,,,1,13501,BAO_0000218,1,CHEMBL873830,,1969.0
9240,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,50597,,,1,17594,BAO_0000218,1,CHEMBL626906,,
9241,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,,,1,4186,BAO_0000218,1,CHEMBL631076,,1969.0
9242,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Biological half-life was measured in plasma of rats,50597,,,1,2932,BAO_0000218,1,CHEMBL631077,,1969.0
9243,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,,,1,17065,BAO_0000218,1,CHEMBL631078,,
9244,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,50597,,,1,15765,BAO_0000218,1,CHEMBL631079,,
9245,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,50597,,,1,2713,BAO_0000218,1,CHEMBL631080,,
9246,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,50597,,,1,2661,BAO_0000218,1,CHEMBL631081,,
9247,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,50597,,,1,2661,BAO_0000218,1,CHEMBL631239,,
9248,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Compound was evaluated for plasma half life in rat,50597,,,1,740,BAO_0000218,1,CHEMBL631240,,1969.0
9249,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC value at a dose of 5 mg/kg (p.o.) in rats,50597,,,1,6597,BAO_0000218,1,CHEMBL631241,,1969.0
9250,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC value after administration of 20 mg/Kg oral dose in rat,50597,,,1,2959,BAO_0000218,1,CHEMBL631242,,1969.0
9251,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,50597,,,1,17594,BAO_0000218,1,CHEMBL631243,,1969.0
9252,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC0-96 after administration at 50 mg/kg,50597,,,1,17596,BAO_0000218,1,CHEMBL874444,,1969.0
9253,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,50597,,,1,17594,BAO_0000218,1,CHEMBL631244,,1969.0
9254,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",50597,,,1,3293,BAO_0000218,1,CHEMBL631245,,
9255,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,50597,,,1,6757,BAO_0000218,1,CHEMBL627162,,
9256,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,50597,,,1,6757,BAO_0000218,1,CHEMBL627163,,
9257,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,50597,,,1,6757,BAO_0000218,1,CHEMBL627164,,
9258,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,50597,,,1,5979,BAO_0000218,1,CHEMBL627165,,2113.0
9259,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,50597,,,1,5979,BAO_0000218,1,CHEMBL627166,,
9260,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,50597,,,1,5979,BAO_0000218,1,CHEMBL627167,,
9261,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve (AUC) at a dose of 30 mg/kg in rats,50597,,,1,4026,BAO_0000218,1,CHEMBL627822,,
9262,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,50597,,,1,5355,BAO_0000218,1,CHEMBL627823,,
9263,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,50597,,,1,5355,BAO_0000218,1,CHEMBL627824,,
9264,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,50597,,,1,5355,BAO_0000218,1,CHEMBL627825,,
9265,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,50597,,,1,5633,BAO_0000218,1,CHEMBL627826,,
9266,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve (Pharmacokinetic property) was determined,50597,,,1,1716,BAO_0000218,1,CHEMBL627827,,
9267,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve (Pharmacokinetic property) of the compound; Not determined,50597,,,1,1716,BAO_0000218,1,CHEMBL627828,,
9268,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve after intravenous administration (1 mg/kg) in rat,50597,,,1,4689,BAO_0000218,1,CHEMBL627829,,
9269,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,50597,,,1,4527,BAO_0000218,1,CHEMBL627830,,
9270,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,50597,,,1,4527,BAO_0000218,1,CHEMBL627831,,
9271,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve in male SD rats was observed after oral administration in rat,50597,,,1,15662,BAO_0000218,1,CHEMBL627832,,
9272,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve of compound after iv administration of 20 mg/kg dose in rat,50597,,,1,4413,BAO_0000218,1,CHEMBL627833,,
9273,,Rattus norvegicus,,A,N,Expert,,10116.0,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,,,1,3598,BAO_0000218,1,CHEMBL627834,,
9274,,Rattus norvegicus,,A,N,Expert,,10116.0,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,50597,,,1,3598,BAO_0000218,1,CHEMBL628004,,
9275,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve at 5 mg/kg po was determined in rat,50597,,,1,5964,BAO_0000218,1,CHEMBL628005,,
9276,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve in Rat at a oral dose of 5 mg/kg,50597,,,1,4689,BAO_0000218,1,CHEMBL628006,,
9277,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,50597,,,1,4186,BAO_0000218,1,CHEMBL628007,,
9278,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined,50597,,,1,5510,BAO_0000218,1,CHEMBL625676,,
9279,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,50597,,,1,17858,BAO_0000218,1,CHEMBL631309,,
9280,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve after intravenous administration at 3 mg/kg,50597,,,1,17804,BAO_0000218,1,CHEMBL631310,,
9281,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,50597,,,1,6106,BAO_0000218,1,CHEMBL631311,,
9282,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve at 4 hr in rat,50597,,,1,5964,BAO_0000218,1,CHEMBL631312,,
9283,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve at a dose of 30 mg/kg,50597,,,1,4026,BAO_0000218,1,CHEMBL631313,,
9284,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve at the dose of 2 mg/Kg administered perorally in rats,50597,,,1,4756,BAO_0000218,1,CHEMBL631314,,
9285,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve at the dose of 5 mg/Kg administered perorally in rats,50597,,,1,4756,BAO_0000218,1,CHEMBL631315,,
9286,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve for a 2-mpk po dose in SD rats,50597,,,1,5862,BAO_0000218,1,CHEMBL631316,,
9287,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve in SD rats,50597,,,1,5862,BAO_0000218,1,CHEMBL631317,,
9288,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve in rat after oral administration at 13 mg/kg dose,50597,,,1,6644,BAO_0000218,1,CHEMBL874471,,
9289,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve in rat by po administration at 0-24 hr,50597,,,1,5871,BAO_0000218,1,CHEMBL631318,,
9290,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Area under curve in rat plasma,50597,,,1,5919,BAO_0000218,1,CHEMBL631319,,1969.0
9291,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,50597,,,1,5939,BAO_0000218,1,CHEMBL631320,,
9292,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,50597,,,1,5939,BAO_0000218,1,CHEMBL631321,,
9293,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,50597,,,1,10,BAO_0000218,1,CHEMBL631322,,
9294,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,50597,,,1,11149,BAO_0000218,1,CHEMBL631323,,
9295,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve value in rat at a dose of 5 mg/kg,50597,,,1,5302,BAO_0000218,1,CHEMBL631324,,
9296,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined after oral administration in rats,50597,,,1,17796,BAO_0000218,1,CHEMBL631325,,
9297,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,50597,,,1,4890,BAO_0000218,1,CHEMBL631326,,
9298,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined after peroral administration in rat,50597,,,1,6011,BAO_0000218,1,CHEMBL631327,,
9299,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined at a dose 30 mpk administered orally.,50597,,,1,5375,BAO_0000218,1,CHEMBL631328,,
9300,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,50597,,,1,17764,BAO_0000218,1,CHEMBL631329,,
9301,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,50597,,,1,4368,BAO_0000218,1,CHEMBL627217,,
9302,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined in male rat,50597,,,1,5610,BAO_0000218,1,CHEMBL626352,,
9303,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined in rat after PO administration,50597,,,1,5833,BAO_0000218,1,CHEMBL626353,,
9304,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined in rat after a 3 mg/kg of oral dose,50597,,,1,4257,BAO_0000218,1,CHEMBL626354,,
9305,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,50597,,,1,5937,BAO_0000218,1,CHEMBL626355,,
9306,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,50597,,,1,5932,BAO_0000218,1,CHEMBL626356,,
9307,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,50597,,,1,5932,BAO_0000218,1,CHEMBL626357,,
9308,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,,,1,17411,BAO_0000218,1,CHEMBL626358,,
9309,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,,,1,17411,BAO_0000218,1,CHEMBL626359,,
9310,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Peak plasma concentration in rat at a dose of 3 mg/kg,50597,,,1,17771,BAO_0000218,1,CHEMBL626360,,1969.0
9311,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration at 2 hr in rats was evaluated.,50597,,,1,1628,BAO_0000218,1,CHEMBL626361,,
9312,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration at 2 hr in rats was evaluated; Not available,50597,,,1,1628,BAO_0000218,1,CHEMBL626362,,
9313,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,,,1,17411,BAO_0000218,1,CHEMBL626363,,
9314,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,50597,,,1,4910,BAO_0000218,1,CHEMBL626970,,
9315,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,50597,,,1,4910,BAO_0000218,1,CHEMBL626971,,
9316,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,50597,,,1,4910,BAO_0000218,1,CHEMBL626972,,1969.0
9317,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,50597,,,1,4910,BAO_0000218,1,CHEMBL626973,,1969.0
9318,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,50597,,,1,4910,BAO_0000218,1,CHEMBL626974,,1969.0
9319,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,50597,,,1,4910,BAO_0000218,1,CHEMBL874592,,1969.0
9320,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,50597,,,1,5510,BAO_0000218,1,CHEMBL626975,,
9321,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,50597,,,1,5510,BAO_0000218,1,CHEMBL626976,,
9322,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,50597,,,1,5510,BAO_0000218,1,CHEMBL626977,,
9323,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,50597,,,1,5510,BAO_0000218,1,CHEMBL626978,,
9324,,Rattus norvegicus,,A,N,Intermediate,,10116.0,PK study was carried to determine the relative absorption ranking in rat.,50597,,,1,16427,BAO_0000218,1,CHEMBL626979,,
9325,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,50597,,,1,4689,BAO_0000218,1,CHEMBL626980,,1969.0
9326,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL626981,,178.0
9327,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL626982,,178.0
9328,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL626983,,178.0
9329,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL622522,,178.0
9330,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL622523,,178.0
9331,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL622524,,178.0
9332,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL622525,,955.0
9333,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL622526,,955.0
9334,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL619849,,955.0
9335,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL619850,,955.0
9336,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL623864,,955.0
9337,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL623865,,955.0
9338,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL623866,,948.0
9339,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL623867,,948.0
9340,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL877615,,948.0
9341,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL623868,,948.0
9342,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL623869,,948.0
9343,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL623870,,948.0
9344,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,50597,,,1,16434,BAO_0000218,1,CHEMBL623871,,2048.0
9345,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,,,1,16434,BAO_0000218,1,CHEMBL623872,,2048.0
9346,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,,,1,16435,BAO_0000218,1,CHEMBL622129,,2048.0
9347,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,,,1,16435,BAO_0000218,1,CHEMBL622130,,2048.0
9348,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,,,1,16435,BAO_0000218,1,CHEMBL622131,,2048.0
9349,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,,,1,16435,BAO_0000218,1,CHEMBL622132,,2048.0
9350,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,,,1,16435,BAO_0000218,1,CHEMBL622133,,2048.0
9351,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,,,1,16435,BAO_0000218,1,CHEMBL622134,,2048.0
9352,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL622135,,2048.0
9353,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL622136,,2048.0
9354,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622137,,2385.0
9355,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622138,,2385.0
9356,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL623017,,2385.0
9357,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL623018,,2385.0
9358,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL623019,,2385.0
9359,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL623020,,2385.0
9360,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL623021,,2385.0
9361,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL623022,,2385.0
9362,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL623023,,2385.0
9363,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL623024,,2385.0
9364,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL623025,,2385.0
9365,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL620545,,2385.0
9366,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL620546,,2385.0
9367,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL620547,,2385.0
9368,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL620548,,2385.0
9369,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL620549,,2385.0
9370,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,,,1,16434,BAO_0000218,1,CHEMBL620550,,2385.0
9371,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,50597,,,1,16434,BAO_0000218,1,CHEMBL620551,,2385.0
9372,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,,,1,16434,BAO_0000218,1,CHEMBL620552,,2385.0
9373,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,,,1,16435,BAO_0000218,1,CHEMBL620553,,2385.0
9374,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,,,1,16435,BAO_0000218,1,CHEMBL620554,,2385.0
9375,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,,,1,16435,BAO_0000218,1,CHEMBL875845,,2385.0
9376,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,,,1,16435,BAO_0000218,1,CHEMBL620555,,2385.0
9377,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,,,1,16435,BAO_0000218,1,CHEMBL620556,,2385.0
9378,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,,,1,16435,BAO_0000218,1,CHEMBL620557,,2385.0
9379,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL620558,,
9380,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL620559,,
9381,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622939,,
9382,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622940,,
9383,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622941,,
9384,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622942,,
9385,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622943,,
9386,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622944,,
9387,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL622945,,
9388,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL622946,,
9389,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for terminal half life in rat,50597,,,1,3341,BAO_0000218,1,CHEMBL622947,,
9390,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,50597,,,1,3634,BAO_0000218,1,CHEMBL622948,,1969.0
9391,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,50597,,,1,3634,BAO_0000218,1,CHEMBL622949,,1969.0
9392,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was tested for its half life in rat,50597,,,1,4839,BAO_0000218,1,CHEMBL622950,,
9393,In vivo,Macaca mulatta,,A,U,Intermediate,Plasma,9544.0,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,22224,,,1,5005,BAO_0000218,0,CHEMBL622951,,1969.0
9394,,Rattus norvegicus,,A,U,Intermediate,Plasma,10116.0,Compound was tested for its plasma half life in Sprague Dawley rats,22224,,,1,5005,BAO_0000366,0,CHEMBL622952,,1969.0
9395,,Rattus norvegicus,,A,U,Intermediate,Plasma,10116.0,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,22224,,,1,5005,BAO_0000366,0,CHEMBL622953,,1969.0
9396,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Compound was tested for plasma half-life period in rat,50597,,,1,1094,BAO_0000218,1,CHEMBL873818,,1969.0
9397,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Elimination half life after i.v. administration of compound in rats,50597,,,1,5031,BAO_0000218,1,CHEMBL622954,,
9398,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Elimination half-life after IV dosing at 0.5 mg/kg in rat,50597,,,1,6518,BAO_0000218,1,CHEMBL622955,,
9399,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Elimination half-life after IV dosing at 1 mg/kg in rat,50597,,,1,6518,BAO_0000218,1,CHEMBL875229,,
9400,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,50597,,,1,6518,BAO_0000218,1,CHEMBL622956,,
9401,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,50597,,,1,6518,BAO_0000218,1,CHEMBL622957,,
9402,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,50597,,,1,5408,BAO_0000218,1,CHEMBL622958,,955.0
9403,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,50597,,,1,5408,BAO_0000218,1,CHEMBL622959,,1969.0
9404,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,50597,,,1,5408,BAO_0000218,1,CHEMBL622960,,955.0
9405,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,50597,,,1,5408,BAO_0000218,1,CHEMBL622961,,1969.0
9406,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Evaluated for the half life in rat (in vivo),50597,,,1,4687,BAO_0000218,1,CHEMBL622962,,
9407,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Hafl life in rat,50597,,,1,6640,BAO_0000218,1,CHEMBL622963,,
9408,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Hafl life rat,50597,,,1,6640,BAO_0000218,1,CHEMBL622964,,
9409,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Hafl life rat,50597,,,1,6641,BAO_0000218,1,CHEMBL622965,,
9410,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Hafl life rat; Not determined,50597,,,1,6640,BAO_0000218,1,CHEMBL622966,,
9411,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Hafl life rat; Not determined,50597,,,1,6641,BAO_0000218,1,CHEMBL622967,,
9412,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,,,1,17411,BAO_0000218,1,CHEMBL622968,,2113.0
9413,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,,,1,17411,BAO_0000218,1,CHEMBL622969,,2107.0
9414,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,,,1,17411,BAO_0000218,1,CHEMBL875327,,2048.0
9415,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in rat after 1 mg/kg i.v. administration,50597,,,1,6570,BAO_0000218,1,CHEMBL628638,,
9416,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in rat after 2 mg/kg peroral administration,50597,,,1,6570,BAO_0000218,1,CHEMBL628639,,
9417,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,,,1,17411,BAO_0000218,1,CHEMBL625840,,
9418,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life of 10 mg/kg oral dose determined in rats,50597,,,1,4722,BAO_0000218,1,CHEMBL625841,,
9419,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL625842,,
9420,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL625843,,
9421,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL625844,,
9422,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL873822,,
9423,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL625845,,
9424,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL627059,,
9425,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL627060,,
9426,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL627061,,
9427,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life of compound at 5 mg/kg after po administration was determined in rat,50597,,,1,4762,BAO_0000218,1,CHEMBL627709,,
9428,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life of compound determined after intravenous administration to rat,50597,,,1,5327,BAO_0000218,1,CHEMBL627710,,
9429,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life of compound was determined in rat,50597,,,1,4847,BAO_0000218,1,CHEMBL627711,,
9430,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,,,1,17720,BAO_0000218,1,CHEMBL627712,,1969.0
9431,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,,,1,4723,BAO_0000218,1,CHEMBL627713,,
9432,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,,,1,4723,BAO_0000218,1,CHEMBL627714,,
9433,In vivo,Macaca fascicularis,,A,U,Intermediate,,9541.0,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,22224,,,1,4256,BAO_0000218,0,CHEMBL627889,,
9434,In vivo,Rattus norvegicus,,A,U,Intermediate,,10116.0,Half life determined in rat by intravenous administration,22224,,,1,4256,BAO_0000218,0,CHEMBL627890,,
9435,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life determined in rats after iv administration,50597,,,1,4722,BAO_0000218,1,CHEMBL627891,,
9436,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life in rat plasma after administration of 2 mg/kg iv,50597,,,1,6535,BAO_0000218,1,CHEMBL627892,,1969.0
9437,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life in rat plasma after administration of 2 mg/kg iv,50597,,,1,6535,BAO_0000218,1,CHEMBL627893,,1969.0
9438,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life in rat plasma was determined,50597,,,1,1435,BAO_0000218,1,CHEMBL627894,,1969.0
9439,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life in rat plasma was determined; NA means not applicable,50597,,,1,1435,BAO_0000218,1,CHEMBL627895,,1969.0
9440,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in rat was tested,50597,,,1,5206,BAO_0000218,1,CHEMBL627896,,
9441,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life measured in rat plasma,50597,,,1,6080,BAO_0000218,1,CHEMBL627897,,1969.0
9442,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life recorded in rats,50597,,,1,4449,BAO_0000218,1,CHEMBL627898,,
9443,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life was calculated,50597,,,1,6057,BAO_0000218,1,CHEMBL627899,,
9444,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life was calculated in rat,50597,,,1,6057,BAO_0000218,1,CHEMBL873823,,
9445,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life was determined,50597,,,1,3747,BAO_0000218,1,CHEMBL627900,,
9446,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life after 10 mg/kg oral administration in rat,50597,,,1,17858,BAO_0000218,1,CHEMBL627901,,
9447,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life after administering orally a dose of 10 mg/kg to a fasting rat,50597,,,1,16365,BAO_0000218,1,CHEMBL627902,,
9448,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life after administering orally a dose of 30 mg/kg,50597,,,1,16365,BAO_0000218,1,CHEMBL627903,,
9449,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,50597,,,1,5031,BAO_0000218,1,CHEMBL627904,,
9450,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,50597,,,1,4722,BAO_0000218,1,CHEMBL627905,,
9451,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,50597,,,1,6078,BAO_0000218,1,CHEMBL627906,,
9452,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,50597,,,1,6078,BAO_0000218,1,CHEMBL627907,,
9453,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,50597,,,1,6078,BAO_0000218,1,CHEMBL876783,,
9454,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,50597,,,1,6078,BAO_0000218,1,CHEMBL627908,,
9455,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,50597,,,1,17065,BAO_0000218,1,CHEMBL627909,,
9456,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,50597,,,1,1353,BAO_0000218,1,CHEMBL627910,,
9457,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),50597,,,1,1353,BAO_0000218,1,CHEMBL627911,,
9458,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),50597,,,1,1353,BAO_0000218,1,CHEMBL627912,,
9459,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),50597,,,1,1353,BAO_0000218,1,CHEMBL627913,,
9460,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),50597,,,1,1353,BAO_0000218,1,CHEMBL627914,,
9461,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,50597,,,1,16423,BAO_0000218,1,CHEMBL627915,,
9462,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve was evaluated after 20 uM/kg of peroral administration,50597,,,1,16423,BAO_0000218,1,CHEMBL627916,,
9463,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve was measured in rat after an iv dose of 1 mg/kg,50597,,,1,6062,BAO_0000218,1,CHEMBL627917,,
9464,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,50597,,,1,6056,BAO_0000218,1,CHEMBL627918,,
9465,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,50597,,,1,5182,BAO_0000218,1,CHEMBL627919,,
9466,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,50597,,,1,6410,BAO_0000218,1,CHEMBL627920,,
9467,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve was evaluated at an oral dose of 30 mg/kg,50597,,,1,6410,BAO_0000218,1,CHEMBL627921,,
9468,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,,,1,4723,BAO_0000218,1,CHEMBL627922,,
9469,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,,,1,4723,BAO_0000218,1,CHEMBL876784,,
9470,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,,,1,4723,BAO_0000218,1,CHEMBL627923,,
9471,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,,,1,4723,BAO_0000218,1,CHEMBL626208,,
9472,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,,,1,4723,BAO_0000218,1,CHEMBL626209,,
9473,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,,,1,4723,BAO_0000218,1,CHEMBL626210,,
9474,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,50597,,,1,2463,BAO_0000218,1,CHEMBL627994,,1969.0
9475,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,50597,,,1,4709,BAO_0000218,1,CHEMBL627995,,
9476,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,50597,,,1,4075,BAO_0000218,1,CHEMBL627996,,
9477,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,50597,,,1,5394,BAO_0000218,1,CHEMBL627997,,
9478,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,50597,,,1,2661,BAO_0000218,1,CHEMBL627998,,
9479,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,50597,,,1,2661,BAO_0000218,1,CHEMBL628640,,
9480,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,50597,,,1,2661,BAO_0000218,1,CHEMBL628641,,
9481,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,50597,,,1,2661,BAO_0000218,1,CHEMBL628642,,
9482,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for area under the curve expressed as (h*ug/ml),50597,,,1,17791,BAO_0000218,1,CHEMBL628643,,
9483,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was tested for area under curve in rat,50597,,,1,2591,BAO_0000218,1,CHEMBL628644,,
9484,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,50597,,,1,6567,BAO_0000218,1,CHEMBL628645,,
9485,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,50597,,,1,6211,BAO_0000218,1,CHEMBL628646,,
9486,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),50597,,,1,5529,BAO_0000218,1,CHEMBL628647,,
9487,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,50597,,,1,5408,BAO_0000218,1,CHEMBL628648,,
9488,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,50597,,,1,5408,BAO_0000218,1,CHEMBL625358,,
9489,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,50597,,,1,5408,BAO_0000218,1,CHEMBL625359,,
9490,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,50597,,,1,5408,BAO_0000218,1,CHEMBL625360,,
9491,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),50597,,,1,429,BAO_0000218,1,CHEMBL625361,,
9492,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),50597,,,1,429,BAO_0000218,1,CHEMBL625362,,
9493,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),50597,,,1,429,BAO_0000218,1,CHEMBL625363,,
9494,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,50597,,,1,4796,BAO_0000218,1,CHEMBL625364,,
9495,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,,,1,5974,BAO_0000218,1,CHEMBL625365,,
9496,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,,,1,5974,BAO_0000218,1,CHEMBL625366,,
9497,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,,,1,5974,BAO_0000218,1,CHEMBL625367,,
9498,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL625368,,2113.0
9499,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL625369,,2113.0
9500,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL625370,,2113.0
9501,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL625371,,2113.0
9502,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL625372,,2113.0
9503,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL625373,,2113.0
9504,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL625374,,2107.0
9505,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL877593,,2107.0
9506,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL625375,,2107.0
9507,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL625376,,2107.0
9508,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL621973,,2107.0
9509,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL621974,,2107.0
9510,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL621975,,2048.0
9511,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL622166,,2048.0
9512,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL622167,,2048.0
9513,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL622168,,2048.0
9514,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL622169,,2048.0
9515,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL622170,,2048.0
9516,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL622171,,2046.0
9517,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL622172,,2046.0
9518,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL622173,,2046.0
9519,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL622174,,2046.0
9520,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL622175,,2046.0
9521,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL622176,,2046.0
9522,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL622177,,2046.0
9523,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL622178,,2046.0
9524,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL622179,,2046.0
9525,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL622180,,2046.0
9526,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL622181,,
9527,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL622182,,
9528,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL622183,,
9529,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL622184,,
9530,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL622185,,
9531,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL622186,,
9532,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,,,1,16434,BAO_0000218,1,CHEMBL622187,,
9533,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,50597,,,1,16434,BAO_0000218,1,CHEMBL625002,,
9534,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,50597,,,1,16434,BAO_0000218,1,CHEMBL622090,,
9535,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,,,1,16435,BAO_0000218,1,CHEMBL622091,,
9536,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,,,1,16435,BAO_0000218,1,CHEMBL622092,,
9537,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,,,1,16435,BAO_0000218,1,CHEMBL622093,,
9538,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,,,1,16435,BAO_0000218,1,CHEMBL622094,,
9539,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,,,1,16435,BAO_0000218,1,CHEMBL622095,,
9540,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,,,1,16435,BAO_0000218,1,CHEMBL622264,,
9541,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622265,,2106.0
9542,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622266,,2106.0
9543,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622267,,2106.0
9544,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622268,,2106.0
9545,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622269,,2106.0
9546,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL625071,,2106.0
9547,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL621621,,2106.0
9548,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL621622,,2106.0
9549,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL621623,,2106.0
9550,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL621624,,2106.0
9551,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL621625,,2106.0
9552,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL621626,,2106.0
9553,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL621627,,2106.0
9554,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL621628,,2106.0
9555,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL875328,,2106.0
9556,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL621629,,2106.0
9557,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,,,1,16434,BAO_0000218,1,CHEMBL621630,,2106.0
9558,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,,,1,16434,BAO_0000218,1,CHEMBL621631,,2106.0
9559,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,,,1,16434,BAO_0000218,1,CHEMBL621632,,2106.0
9560,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,,,1,16435,BAO_0000218,1,CHEMBL621633,,2106.0
9561,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,,,1,16435,BAO_0000218,1,CHEMBL621634,,2106.0
9562,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,,,1,16435,BAO_0000218,1,CHEMBL621635,,2106.0
9563,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,,,1,16435,BAO_0000218,1,CHEMBL621636,,2106.0
9564,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,,,1,16435,BAO_0000218,1,CHEMBL621637,,2106.0
9565,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,,,1,16435,BAO_0000218,1,CHEMBL621638,,2106.0
9566,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL618883,,
9567,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL618884,,
9568,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL628627,,
9569,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL628628,,
9570,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL628629,,
9571,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life after administering orally a dose of 3 mg/kg,50597,,,1,16365,BAO_0000218,1,CHEMBL628630,,
9572,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life after administering orally a dose of 3 mg/kg to a fasting rat,50597,,,1,16365,BAO_0000218,1,CHEMBL628631,,
9573,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life after administering intravenously a dose of 1 mg/kg,50597,,,1,16365,BAO_0000218,1,CHEMBL628632,,
9574,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life after oral dosing in rats,50597,,,1,526,BAO_0000218,1,CHEMBL628633,,
9575,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,50597,,,1,16365,BAO_0000218,1,CHEMBL628634,,
9576,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life by intravenous administration of 3.4 mg/kg in rat,50597,,,1,4368,BAO_0000218,1,CHEMBL627789,,
9577,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in rat,50597,,,1,3371,BAO_0000218,1,CHEMBL627790,,
9578,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in rat,50597,,,1,6448,BAO_0000218,1,CHEMBL627791,,
9579,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in rat,50597,,,1,6453,BAO_0000218,1,CHEMBL627792,,
9580,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in rat after intravenous administration of the compound,50597,,,1,4353,BAO_0000218,1,CHEMBL627793,,
9581,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,50597,,,1,4353,BAO_0000218,1,CHEMBL627794,,1969.0
9582,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in rat after po administration of the compound,50597,,,1,4353,BAO_0000218,1,CHEMBL627795,,
9583,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in rat after po administration of the compound; ND means Not determined,50597,,,1,4353,BAO_0000218,1,CHEMBL627796,,
9584,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,50597,,,1,4353,BAO_0000218,1,CHEMBL875335,,1969.0
9585,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,50597,,,1,4353,BAO_0000218,1,CHEMBL627797,,1969.0
9586,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in rat i.v.,50597,,,1,5789,BAO_0000218,1,CHEMBL627798,,
9587,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in rat i.v. at 2 mg/kg concentration,50597,,,1,17686,BAO_0000218,1,CHEMBL627799,,
9588,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in rats,50597,,,1,6495,BAO_0000218,1,CHEMBL627800,,
9589,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in rats after intravenous administration,50597,,,1,484,BAO_0000218,1,CHEMBL627801,,
9590,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in rats at the dose of 1.0 mpk by i.v. administration,50597,,,1,6467,BAO_0000218,1,CHEMBL627802,,
9591,,Rattus norvegicus,,A,N,Expert,,10116.0,Half life in rat,50597,,,1,6642,BAO_0000218,1,CHEMBL627803,,
9592,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life was evaluated after intravenous administration to rats,50597,,,1,16367,BAO_0000218,1,CHEMBL873820,,
9593,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),50597,,,1,1369,BAO_0000218,1,CHEMBL627804,,
9594,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life was evaluated in rat,50597,,,1,5472,BAO_0000218,1,CHEMBL627805,,
9595,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life was evaluated in rat,50597,,,1,6049,BAO_0000218,1,CHEMBL627806,,
9596,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life was evaluated in rat; Not tested,50597,,,1,5472,BAO_0000218,1,CHEMBL627107,,
9597,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,50597,,,1,16366,BAO_0000218,1,CHEMBL627108,,
9598,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,50597,,,1,11149,BAO_0000218,1,CHEMBL627109,,
9599,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,50597,,,1,11149,BAO_0000218,1,CHEMBL627110,,178.0
9600,In vivo,Primates,,A,U,Intermediate,,9443.0,Half life was measured in monkey at dose of 10 mg/kg by po administration,22224,,,1,2891,BAO_0000218,0,CHEMBL627111,,
9601,In vivo,Primates,,A,U,Intermediate,,9443.0,Half life was measured in monkey at dose of 10 mg/kg by po administration,22224,,,1,2891,BAO_0000218,0,CHEMBL627112,,
9602,In vivo,Rattus norvegicus,,A,U,Intermediate,,10116.0,Half life was measured in rat at dose of 30 mg/kg by iv administration,22224,,,1,2891,BAO_0000218,0,CHEMBL627113,,
9603,In vivo,Rattus norvegicus,,A,U,Intermediate,,10116.0,Half life was measured in rat at dose of 30 mg/kg by po administration,22224,,,1,2891,BAO_0000218,0,CHEMBL627114,,
9604,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life (t1/2) was determined,50597,,,1,4026,BAO_0000218,1,CHEMBL627115,,
9605,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period at a dose of 10 uM/kg in rat was determined,50597,,,1,4527,BAO_0000218,1,CHEMBL627116,,
9606,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,50597,,,1,4527,BAO_0000218,1,CHEMBL627117,,
9607,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period was determined,50597,,,1,5503,BAO_0000218,1,CHEMBL627118,,
9608,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period after intravenous administration at 20 mpk in rats,50597,,,1,4426,BAO_0000218,1,CHEMBL627119,,
9609,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period after intravenous administration at 20 mpk in rats; Not performed.,50597,,,1,4426,BAO_0000218,1,CHEMBL627120,,
9610,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period after intravenous administration in rat,50597,,,1,6109,BAO_0000218,1,CHEMBL626922,,
9611,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,50597,,,1,5654,BAO_0000218,1,CHEMBL626923,,
9612,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,50597,,,1,5654,BAO_0000218,1,CHEMBL626924,,
9613,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life period in 80% rat plasma at 37 degree Centigrade,50597,,,1,4755,BAO_0000218,1,CHEMBL626925,,1969.0
9614,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period in SD rats,50597,,,1,5862,BAO_0000218,1,CHEMBL626926,,
9615,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),50597,,,1,1515,BAO_0000218,1,CHEMBL626927,,1969.0
9616,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),50597,,,1,1515,BAO_0000218,1,CHEMBL626928,,1969.0
9617,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,50597,,,1,1515,BAO_0000218,1,CHEMBL626929,,1969.0
9618,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,50597,,,1,1515,BAO_0000218,1,CHEMBL626930,,1969.0
9619,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period in rat,50597,,,1,5960,BAO_0000218,1,CHEMBL626931,,
9620,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period in rat,50597,,,1,6103,BAO_0000218,1,CHEMBL626932,,
9621,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period in rat,50597,,,1,6317,BAO_0000218,1,CHEMBL626933,,
9622,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period in rat after oral administration at 10.5 mg/kg dose,50597,,,1,6644,BAO_0000218,1,CHEMBL873826,,
9623,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period in rat after oral administration at 11.2 mg/kg dose,50597,,,1,6644,BAO_0000218,1,CHEMBL626934,,
9624,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period in rat after oral administration at 13 mg/kg dose,50597,,,1,6644,BAO_0000218,1,CHEMBL626935,,
9625,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period in rat after oral administration at 9.7 mg/kg dose,50597,,,1,6644,BAO_0000218,1,CHEMBL626936,,
9626,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,,,1,5974,BAO_0000218,1,CHEMBL626937,,
9627,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,50597,,,1,6295,BAO_0000218,1,CHEMBL625906,,
9628,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,50597,,,1,6296,BAO_0000218,1,CHEMBL625907,,
9629,,Rattus norvegicus,,A,N,Intermediate,,10116.0,PK study was carried to determine AUC (area under curve) value in rat,50597,,,1,16427,BAO_0000218,1,CHEMBL625908,,
9630,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter AUC after intravenous administration to rats,50597,,,1,16367,BAO_0000218,1,CHEMBL625909,,
9631,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter AUC after oral administration to rats,50597,,,1,16367,BAO_0000218,1,CHEMBL625910,,
9632,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,50597,,,1,16365,BAO_0000218,1,CHEMBL625911,,
9633,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,50597,,,1,16365,BAO_0000218,1,CHEMBL625912,,
9634,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,50597,,,1,16365,BAO_0000218,1,CHEMBL626538,,
9635,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,50597,,,1,16365,BAO_0000218,1,CHEMBL876794,,
9636,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,50597,,,1,16365,BAO_0000218,1,CHEMBL626539,,
9637,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,50597,,,1,16365,BAO_0000218,1,CHEMBL626540,,
9638,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,50597,,,1,5394,BAO_0000218,1,CHEMBL626541,,
9639,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,50597,,,1,5394,BAO_0000218,1,CHEMBL626542,,
9640,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,50597,,,1,2792,BAO_0000218,1,CHEMBL626543,,
9641,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,50597,,,1,2792,BAO_0000218,1,CHEMBL626544,,
9642,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,50597,,,1,2792,BAO_0000218,1,CHEMBL626545,,
9643,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,50597,,,1,2792,BAO_0000218,1,CHEMBL626546,,
9644,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter area under curve was reported,50597,,,1,5334,BAO_0000218,1,CHEMBL626547,,
9645,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (AUC) in rat,50597,,,1,4408,BAO_0000218,1,CHEMBL626548,,
9646,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,50597,,,1,5983,BAO_0000218,1,CHEMBL626549,,
9647,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,50597,,,1,4397,BAO_0000218,1,CHEMBL626550,,
9648,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,50597,,,1,4397,BAO_0000218,1,CHEMBL626551,,
9649,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property was determined,50597,,,1,5491,BAO_0000218,1,CHEMBL623777,,
9650,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,50597,,,1,5491,BAO_0000218,1,CHEMBL623778,,
9651,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,50597,,,1,5491,BAO_0000218,1,CHEMBL623779,,
9652,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,50597,,,1,4199,BAO_0000218,1,CHEMBL623780,,1969.0
9653,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,50597,,,1,4199,BAO_0000218,1,CHEMBL622015,,1969.0
9654,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,50597,,,1,4199,BAO_0000218,1,CHEMBL622016,,1969.0
9655,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",50597,,,1,5173,BAO_0000218,1,CHEMBL622017,,
9656,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",50597,,,1,5173,BAO_0000218,1,CHEMBL622018,,
9657,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",50597,,,1,5173,BAO_0000218,1,CHEMBL622019,,
9658,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",50597,,,1,5173,BAO_0000218,1,CHEMBL622020,,
9659,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,50597,,,1,16366,BAO_0000218,1,CHEMBL622021,,
9660,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,50597,,,1,16366,BAO_0000218,1,CHEMBL622022,,
9661,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,50597,,,1,5327,BAO_0000218,1,CHEMBL622023,,
9662,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,50597,,,1,6681,BAO_0000218,1,CHEMBL622024,,
9663,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),50597,,,1,12873,BAO_0000218,1,CHEMBL622693,,
9664,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),50597,,,1,12873,BAO_0000218,1,CHEMBL622694,,
9665,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",50597,,,1,6685,BAO_0000218,1,CHEMBL622695,,
9666,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",50597,,,1,6685,BAO_0000218,1,CHEMBL622696,,
9667,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",50597,,,1,6685,BAO_0000218,1,CHEMBL622697,,
9668,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",50597,,,1,6619,BAO_0000218,1,CHEMBL622874,,
9669,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",50597,,,1,6619,BAO_0000218,1,CHEMBL622875,,
9670,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,50597,,,1,10363,BAO_0000218,1,CHEMBL622876,,
9671,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,50597,,,1,4796,BAO_0000218,1,CHEMBL622877,,
9672,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,50597,,,1,4910,BAO_0000218,1,CHEMBL622878,,
9673,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,50597,,,1,4910,BAO_0000218,1,CHEMBL622879,,1969.0
9674,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,50597,,,1,4839,BAO_0000218,1,CHEMBL877602,,
9675,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",50597,,,1,15078,BAO_0000218,1,CHEMBL622880,,
9676,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",50597,,,1,15078,BAO_0000218,1,CHEMBL622881,,
9677,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",50597,,,1,15078,BAO_0000218,1,CHEMBL622882,,
9678,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",50597,,,1,15078,BAO_0000218,1,CHEMBL622883,,
9679,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL622884,,2046.0
9680,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",50597,,,1,11450,BAO_0000218,1,CHEMBL622885,,2046.0
9681,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,50597,,,1,8151,BAO_0000218,1,CHEMBL622886,,
9682,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,50597,,,1,8151,BAO_0000218,1,CHEMBL622887,,
9683,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,50597,,,1,8151,BAO_0000218,1,CHEMBL622888,,1088.0
9684,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622889,,178.0
9685,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622890,,178.0
9686,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622891,,178.0
9687,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL877603,,178.0
9688,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622892,,955.0
9689,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622893,,955.0
9690,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622894,,955.0
9691,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622895,,955.0
9692,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,50597,,,1,8677,BAO_0000218,1,CHEMBL622896,,955.0
9693,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622897,,948.0
9694,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622898,,948.0
9695,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622899,,948.0
9696,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622900,,2113.0
9697,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL624114,,2113.0
9698,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL624115,,2113.0
9699,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL624116,,2113.0
9700,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL624117,,2107.0
9701,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL624118,,2107.0
9702,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL624119,,2107.0
9703,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL624120,,2107.0
9704,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL624121,,2048.0
9705,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL624122,,2048.0
9706,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL624123,,2048.0
9707,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL624124,,2048.0
9708,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL624125,,2385.0
9709,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL624126,,2385.0
9710,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL624127,,2385.0
9711,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL624128,,2385.0
9712,In vivo,Rattus norvegicus,,A,N,Intermediate,Zone of skin,10116.0,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL624129,,14.0
9713,In vivo,Rattus norvegicus,,A,N,Intermediate,Zone of skin,10116.0,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL624130,,14.0
9714,In vivo,Rattus norvegicus,,A,N,Intermediate,Zone of skin,10116.0,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622340,,14.0
9715,In vivo,Rattus norvegicus,,A,N,Intermediate,Zone of skin,10116.0,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622341,,14.0
9716,In vivo,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622342,,160.0
9717,In vivo,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622343,,160.0
9718,In vivo,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622344,,160.0
9719,In vivo,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622345,,160.0
9720,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622346,,2106.0
9721,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622347,,2106.0
9722,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622348,,2106.0
9723,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622349,,2106.0
9724,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622350,,
9725,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622351,,
9726,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL622352,,
9727,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL622353,,
9728,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL622354,,
9729,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL622355,,
9730,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL622356,,
9731,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL622357,,
9732,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL622358,,
9733,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL622359,,
9734,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,50597,,,1,16435,BAO_0000218,1,CHEMBL874393,,
9735,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,,,1,16434,BAO_0000218,1,CHEMBL622872,,
9736,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,,,1,16434,BAO_0000218,1,CHEMBL622873,,
9737,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,,,1,16434,BAO_0000218,1,CHEMBL623047,,
9738,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,,,1,16435,BAO_0000218,1,CHEMBL623048,,
9739,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,,,1,16435,BAO_0000218,1,CHEMBL623049,,
9740,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,,,1,16435,BAO_0000218,1,CHEMBL623050,,
9741,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,,,1,16435,BAO_0000218,1,CHEMBL623051,,
9742,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,,,1,16435,BAO_0000218,1,CHEMBL623052,,
9743,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,,,1,16435,BAO_0000218,1,CHEMBL626343,,
9744,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL626344,,
9745,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL626345,,
9746,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,50597,,,1,16434,BAO_0000218,1,CHEMBL626346,,
9747,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,50597,,,1,16434,BAO_0000218,1,CHEMBL626347,,
9748,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,50597,,,1,16434,BAO_0000218,1,CHEMBL626348,,
9749,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,50597,,,1,16434,BAO_0000218,1,CHEMBL626349,,
9750,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,50597,,,1,16435,BAO_0000218,1,CHEMBL626350,,
9751,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,50597,,,1,16435,BAO_0000218,1,CHEMBL626351,,
9752,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,50597,,,1,16435,BAO_0000218,1,CHEMBL627650,,
9753,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,50597,,,1,16435,BAO_0000218,1,CHEMBL627651,,
9754,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,50597,,,1,16435,BAO_0000218,1,CHEMBL627652,,
9755,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,50597,,,1,16435,BAO_0000218,1,CHEMBL627653,,
9756,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL627654,,
9757,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL627835,,
9758,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL627836,,
9759,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL627837,,
9760,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL627838,,
9761,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL875338,,
9762,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL627839,,
9763,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL627840,,
9764,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL627841,,
9765,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL627842,,
9766,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL627843,,
9767,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL627844,,
9768,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL627845,,
9769,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period in rat by iv administration at a dose of 3 mg/kg,50597,,,1,5874,BAO_0000218,1,CHEMBL627846,,
9770,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),50597,,,1,1515,BAO_0000218,1,CHEMBL627847,,1969.0
9771,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),50597,,,1,1515,BAO_0000218,1,CHEMBL873821,,1969.0
9772,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,50597,,,1,1515,BAO_0000218,1,CHEMBL626079,,1969.0
9773,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,50597,,,1,1515,BAO_0000218,1,CHEMBL626080,,1969.0
9774,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life period was evaluated in rat plasma,50597,,,1,5491,BAO_0000218,1,CHEMBL626081,,1969.0
9775,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life period was evaluated in rat plasma; Not tested,50597,,,1,5491,BAO_0000218,1,CHEMBL875344,,1969.0
9776,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period was evaluated in rats,50597,,,1,1918,BAO_0000218,1,CHEMBL626082,,
9777,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Half life period was evaluated in rats, iv",50597,,,1,1918,BAO_0000218,1,CHEMBL626250,,
9778,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period after intravenous administration at 5 mg/kg in rat,50597,,,1,6113,BAO_0000218,1,CHEMBL626251,,
9779,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,50597,,,1,5546,BAO_0000218,1,CHEMBL626252,,
9780,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,50597,,,1,5553,BAO_0000218,1,CHEMBL626253,,
9781,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life stability of compound was evaluated in rat plasma,50597,,,1,4188,BAO_0000218,1,CHEMBL626254,,1969.0
9782,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,50597,,,1,6215,BAO_0000218,1,CHEMBL626255,,
9783,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,50597,,,1,6141,BAO_0000218,1,CHEMBL626256,,
9784,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,50597,,,1,5182,BAO_0000218,1,CHEMBL626257,,
9785,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,50597,,,1,5182,BAO_0000218,1,CHEMBL626258,,
9786,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,50597,,,1,5710,BAO_0000218,1,CHEMBL626259,,
9787,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half in rat i.v.,50597,,,1,5789,BAO_0000218,1,CHEMBL626260,,
9788,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half period in rat after intravenous administration,50597,,,1,6011,BAO_0000218,1,CHEMBL875345,,
9789,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life after repeated oral dose of compound at 1 mg/kg in rats,50597,,,1,17594,BAO_0000218,1,CHEMBL626261,,
9790,In vitro,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Half-life measured in in vitro Cathepsin B assay in rat liver,50597,,,1,12357,BAO_0000218,1,CHEMBL626262,,2107.0
9791,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life of compound was determined in rats,50597,,,1,5210,BAO_0000218,1,CHEMBL626263,,
9792,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life at 10 mg/kg in rat upon intravenous administration,50597,,,1,17596,BAO_0000218,1,CHEMBL625270,,
9793,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life determined in rat,50597,,,1,6672,BAO_0000218,1,CHEMBL625271,,
9794,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life determined in rat,50597,,,1,6673,BAO_0000218,1,CHEMBL625272,,
9795,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,50597,,,1,4910,BAO_0000218,1,CHEMBL625273,,955.0
9796,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",50597,,,1,3741,BAO_0000218,1,CHEMBL625274,,1969.0
9797,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,,,1,17671,BAO_0000218,1,CHEMBL625275,,
9798,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,50597,,,1,4910,BAO_0000218,1,CHEMBL625276,,1969.0
9799,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half-life in rat plasma,50597,,,1,17537,BAO_0000218,1,CHEMBL625277,,1969.0
9800,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half-life in rat plasma was determined,50597,,,1,4965,BAO_0000218,1,CHEMBL625278,,1969.0
9801,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half-life in rat plasma; Not tested,50597,,,1,17537,BAO_0000218,1,CHEMBL625279,,1969.0
9802,,Rattus norvegicus,,A,N,Intermediate,Serum,10116.0,Half-life in rat serum,50597,,,1,6124,BAO_0000218,1,CHEMBL625280,,1977.0
9803,,Rattus norvegicus,,A,N,Intermediate,Serum,10116.0,Half-life in rat serum; na is not available,50597,,,1,6124,BAO_0000218,1,CHEMBL876797,,1977.0
9804,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life was calculated in rat,50597,,,1,6078,BAO_0000218,1,CHEMBL625281,,
9805,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half-life was calculated in rat plasma,50597,,,1,17668,BAO_0000218,1,CHEMBL873827,,1969.0
9806,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life was determined,50597,,,1,3185,BAO_0000218,1,CHEMBL625282,,
9807,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life was determined,50597,,,1,4883,BAO_0000218,1,CHEMBL625283,,
9808,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life after administration of 20 mg/Kg oral dose in rat,50597,,,1,2959,BAO_0000218,1,CHEMBL625284,,
9809,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life after administration of 3.2 mg/kg intravenously in male rat,50597,,,1,4029,BAO_0000218,1,CHEMBL625285,,
9810,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life after intravenous administration in female rat,50597,,,1,4029,BAO_0000218,1,CHEMBL625286,,
9811,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life after intravenous administration in male rat,50597,,,1,4029,BAO_0000218,1,CHEMBL625287,,
9812,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life after intravenous dose in rat,50597,,,1,6180,BAO_0000218,1,CHEMBL625288,,
9813,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Half-life in a rat liver homogenate preparation,50597,,,1,1557,BAO_0000218,1,CHEMBL625289,,2107.0
9814,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half-life in plasma of rat,50597,,,1,12500,BAO_0000218,1,CHEMBL625290,,1969.0
9815,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half-life in plasma of rat at dose of 3-10 mgkg,50597,,,1,12500,BAO_0000218,1,CHEMBL876798,,1969.0
9816,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life in rat,50597,,,1,5064,BAO_0000218,1,CHEMBL625291,,
9817,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life in rat,50597,,,1,5145,BAO_0000218,1,CHEMBL625292,,
9818,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life in rat,50597,,,1,5147,BAO_0000218,1,CHEMBL625293,,
9819,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life in rat,50597,,,1,5833,BAO_0000218,1,CHEMBL622832,,
9820,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life in rat,50597,,,1,6596,BAO_0000218,1,CHEMBL622833,,
9821,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life in rat,50597,,,1,17655,BAO_0000218,1,CHEMBL622834,,
9822,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life in rat after oral administration at 10 mg/kg,50597,,,1,6495,BAO_0000218,1,CHEMBL622835,,
9823,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life in rat after po administration at a dose of 10 mg/kg,50597,,,1,17538,BAO_0000218,1,CHEMBL622836,,
9824,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,50597,,,1,17538,BAO_0000218,1,CHEMBL622837,,
9825,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life in rat at 3 mg/kg dose administered intravenously,50597,,,1,10,BAO_0000218,1,CHEMBL622838,,
9826,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Half-life in rat brain homogenate,50597,,,1,17669,BAO_0000218,1,CHEMBL622839,,955.0
9827,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half-life in rat plasma,50597,,,1,17065,BAO_0000218,1,CHEMBL622840,,1969.0
9828,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life in rats,50597,,,1,4333,BAO_0000218,1,CHEMBL622841,,
9829,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life in Dawley rats,50597,,,1,6827,BAO_0000218,1,CHEMBL622842,,
9830,In vitro,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half-life in vitro in rat plasma,50597,,,1,889,BAO_0000218,1,CHEMBL622843,,1969.0
9831,In vitro,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,50597,,,1,889,BAO_0000218,1,CHEMBL622844,,1969.0
9832,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",50597,,,1,3747,BAO_0000218,1,CHEMBL622845,,
9833,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The area under the curve of compound was measured at the dose of 100 umol/kg,50597,,,1,15022,BAO_0000218,1,CHEMBL622846,,
9834,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The area under the curve of compound was measured at the dose of 300 umol/kg,50597,,,1,15022,BAO_0000218,1,CHEMBL622847,,
9835,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The area under the curve of compound was measured at the dose of 30 umol/kg,50597,,,1,15022,BAO_0000218,1,CHEMBL622848,,
9836,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability as oral AUC in rats,50597,,,1,3360,BAO_0000218,1,CHEMBL622849,,
9837,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,The plasma concentration versus time curve (AUC) was determined,50597,,,1,5334,BAO_0000218,1,CHEMBL622850,,1969.0
9838,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,,,1,17411,BAO_0000218,1,CHEMBL876807,,
9839,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,,,1,17411,BAO_0000218,1,CHEMBL622851,,
9840,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,,,1,17411,BAO_0000218,1,CHEMBL622852,,
9841,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,50597,,,1,6570,BAO_0000218,1,CHEMBL622853,,
9842,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,50597,,,1,6570,BAO_0000218,1,CHEMBL622854,,
9843,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,50597,,,1,17411,BAO_0000218,1,CHEMBL622855,,
9844,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",50597,,,1,14941,BAO_0000218,1,CHEMBL622856,,1969.0
9845,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",50597,,,1,14941,BAO_0000218,1,CHEMBL622857,,1969.0
9846,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC in rat after po administration at a dose of 10 mg/kg,50597,,,1,17538,BAO_0000218,1,CHEMBL622858,,1969.0
9847,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,50597,,,1,17752,BAO_0000218,1,CHEMBL622859,,1969.0
9848,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve value 24 hr after 10 mg/kg iv administration in rats,50597,,,1,17509,BAO_0000218,1,CHEMBL622860,,
9849,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve value 24 hr after 10 mg/kg oral administration in rats,50597,,,1,17509,BAO_0000218,1,CHEMBL622861,,
9850,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve value 24 hr after 2 mg/kg iv administration in rats,50597,,,1,17509,BAO_0000218,1,CHEMBL622862,,
9851,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve value 24 hr after 2 mg/kg oral administration in rats,50597,,,1,17509,BAO_0000218,1,CHEMBL622863,,
9852,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve value 6 hr after po administration in rat,50597,,,1,17509,BAO_0000218,1,CHEMBL623817,,
9853,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,,,1,17717,BAO_0000218,1,CHEMBL623818,,
9854,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",50597,,,1,17717,BAO_0000218,1,CHEMBL623819,,
9855,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,,,1,17717,BAO_0000218,1,CHEMBL623820,,
9856,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,50597,,,1,17717,BAO_0000218,1,CHEMBL623821,,
9857,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC normalized for dose (AUCN) in rat,50597,,,1,6642,BAO_0000218,1,CHEMBL623822,,1969.0
9858,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve in rat after p.o. administration,50597,,,1,6640,BAO_0000218,1,CHEMBL623823,,
9859,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve in rat after p.o. administration,50597,,,1,6641,BAO_0000218,1,CHEMBL623824,,
9860,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve in rat after p.o. administration; Not determined,50597,,,1,6641,BAO_0000218,1,CHEMBL623825,,
9861,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve in rat after peroral administration,50597,,,1,6641,BAO_0000218,1,CHEMBL622070,,
9862,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve (carotid artery) value of the compound,50597,,,1,3603,BAO_0000218,1,CHEMBL622071,,
9863,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability expressed as the area under curve of rat carotid artery,50597,,,1,3550,BAO_0000218,1,CHEMBL622072,,
9864,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve in male SD rats was observed after intravenous administration in rat,50597,,,1,15662,BAO_0000218,1,CHEMBL622073,,
9865,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve of the compound was determined,50597,,,1,17720,BAO_0000218,1,CHEMBL622074,,
9866,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,50597,,,1,5407,BAO_0000218,1,CHEMBL622075,,
9867,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,50597,,,1,17752,BAO_0000218,1,CHEMBL622076,,1969.0
9868,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,50597,,,1,17752,BAO_0000218,1,CHEMBL622077,,1969.0
9869,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve (portal vein) value of the compound,50597,,,1,3603,BAO_0000218,1,CHEMBL622078,,
9870,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability expressed as the area under curve of rat portal vein,50597,,,1,3550,BAO_0000218,1,CHEMBL622079,,
9871,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Area Under plasma concentration time curve in rat upon peroral administration,50597,,,1,17655,BAO_0000218,1,CHEMBL622080,,1969.0
9872,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,50597,,,1,17582,BAO_0000218,1,CHEMBL877612,,
9873,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,50597,,,1,17582,BAO_0000218,1,CHEMBL622081,,
9874,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for oral bioavailability in rats,50597,,,1,17791,BAO_0000218,1,CHEMBL622082,,
9875,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for oral bioavailability in rats after iv administration,50597,,,1,17791,BAO_0000218,1,CHEMBL622083,,
9876,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for oral bioavailability in rats; 30-80,50597,,,1,17791,BAO_0000218,1,CHEMBL622084,,
9877,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for oral bioavailability in rats; 50-60,50597,,,1,17791,BAO_0000218,1,CHEMBL622085,,
9878,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for oral bioavailability in rats; no data,50597,,,1,17791,BAO_0000218,1,CHEMBL622086,,
9879,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for oral bioavailability in rats; peptide,50597,,,1,17791,BAO_0000218,1,CHEMBL622087,,
9880,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",50597,,,1,7768,BAO_0000218,1,CHEMBL622088,,178.0
9881,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",50597,,,1,7768,BAO_0000218,1,CHEMBL622089,,178.0
9882,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",50597,,,1,7768,BAO_0000218,1,CHEMBL623685,,178.0
9883,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",50597,,,1,7768,BAO_0000218,1,CHEMBL623686,,178.0
9884,In vivo,Rattus norvegicus,,A,N,Intermediate,Stomach,10116.0,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL623687,,945.0
9885,In vivo,Rattus norvegicus,,A,N,Intermediate,Stomach,10116.0,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL623688,,945.0
9886,In vivo,Rattus norvegicus,,A,N,Intermediate,Stomach,10116.0,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL623689,,945.0
9887,In vivo,Rattus norvegicus,,A,N,Intermediate,Stomach,10116.0,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622485,,945.0
9888,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622486,,2046.0
9889,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL877613,,2046.0
9890,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622487,,2046.0
9891,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622488,,2046.0
9892,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622489,,948.0
9893,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,50597,,,1,6899,BAO_0000218,1,CHEMBL622490,,1088.0
9894,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,50597,,,1,6899,BAO_0000218,1,CHEMBL622491,,1088.0
9895,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,50597,,,1,6899,BAO_0000218,1,CHEMBL622492,,2107.0
9896,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,50597,,,1,6899,BAO_0000218,1,CHEMBL622493,,1088.0
9897,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,50597,,,1,6899,BAO_0000218,1,CHEMBL622494,,1088.0
9898,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",50597,,,1,8677,BAO_0000218,1,CHEMBL622495,,2385.0
9899,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,50597,,,1,6899,BAO_0000218,1,CHEMBL622496,,
9900,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,50597,,,1,6899,BAO_0000218,1,CHEMBL622497,,1088.0
9901,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,50597,,,1,2189,BAO_0000218,1,CHEMBL622498,,
9902,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,50597,,,1,2189,BAO_0000218,1,CHEMBL624918,,1088.0
9903,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,50597,,,1,2189,BAO_0000218,1,CHEMBL624919,,1088.0
9904,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of compound in rat blood after 5 min of administration,50597,,,1,10839,BAO_0000218,1,CHEMBL624920,,178.0
9905,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of compound in rat blood after 5 min of administration.,50597,,,1,10839,BAO_0000218,1,CHEMBL624921,,178.0
9906,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of compound in rat brain after 5 min of administration,50597,,,1,10839,BAO_0000218,1,CHEMBL624922,,955.0
9907,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of compound in rat heart after 5 min of administration,50597,,,1,10839,BAO_0000218,1,CHEMBL624923,,948.0
9908,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of compound in rat heart after 5 min of administration.,50597,,,1,10839,BAO_0000218,1,CHEMBL624924,,948.0
9909,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution of compound in rat kidney after 5 min of administration,50597,,,1,10839,BAO_0000218,1,CHEMBL624925,,2113.0
9910,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution of compound in rat kidney after 5 min of administration.,50597,,,1,10839,BAO_0000218,1,CHEMBL624926,,2113.0
9911,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of compound in rat liver after 5 min of administration,50597,,,1,10839,BAO_0000218,1,CHEMBL624927,,2107.0
9912,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of compound in rat liver after 5 min of administration.,50597,,,1,10839,BAO_0000218,1,CHEMBL874402,,2107.0
9913,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of compound in rat lung after 5 min of administration,50597,,,1,10839,BAO_0000218,1,CHEMBL624928,,2048.0
9914,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of compound in rat lung after 5 min of administration.,50597,,,1,10839,BAO_0000218,1,CHEMBL624929,,2048.0
9915,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of compound in rat muscle after 5 min of administration,50597,,,1,10839,BAO_0000218,1,CHEMBL624930,,2385.0
9916,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of compound in rat muscle after 5 min of administration.,50597,,,1,10839,BAO_0000218,1,CHEMBL624931,,2385.0
9917,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,,,1,4043,BAO_0000218,1,CHEMBL624932,,948.0
9918,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,,,1,4043,BAO_0000218,1,CHEMBL624933,,948.0
9919,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,,,1,4043,BAO_0000218,1,CHEMBL624934,,2107.0
9920,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,,,1,4043,BAO_0000218,1,CHEMBL624935,,2107.0
9921,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,,,1,4043,BAO_0000218,1,CHEMBL624936,,
9922,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,,,1,4043,BAO_0000218,1,CHEMBL624937,,
9923,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,,,1,4043,BAO_0000218,1,CHEMBL624938,,2106.0
9924,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,,,1,4043,BAO_0000218,1,CHEMBL624939,,2106.0
9925,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,,,1,4043,BAO_0000218,1,CHEMBL624940,,
9926,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,50597,,,1,4043,BAO_0000218,1,CHEMBL874403,,
9927,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,50597,,,1,1446,BAO_0000218,1,CHEMBL624941,,
9928,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Dose required to lower urine osmolality to 300 mOsm/kg in rat,50597,,,1,9971,BAO_0000218,1,CHEMBL624942,,1088.0
9929,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,50597,,,1,9971,BAO_0000218,1,CHEMBL624943,,1088.0
9930,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,% Bioavailability after 1 day of the drug administration in rats,50597,,,1,5765,BAO_0000218,1,CHEMBL624944,,
9931,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,% Bioavailability after 4 day of the drug administration in rats,50597,,,1,5765,BAO_0000218,1,CHEMBL624945,,
9932,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Absolute bioavailability was evaluated in rat,50597,,,1,4257,BAO_0000218,1,CHEMBL624946,,
9933,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL624947,,
9934,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL624948,,
9935,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL624949,,
9936,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL622025,,2113.0
9937,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL622026,,2113.0
9938,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL622027,,2113.0
9939,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL622028,,2113.0
9940,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL622029,,2107.0
9941,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL622208,,2107.0
9942,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL622209,,2107.0
9943,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL622210,,2107.0
9944,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL622211,,
9945,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL622212,,
9946,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL622213,,
9947,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL874404,,
9948,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL620452,,2385.0
9949,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL620453,,2385.0
9950,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL620454,,2385.0
9951,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL624067,,2385.0
9952,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL624068,,
9953,,Rattus norvegicus,,A,N,Intermediate,Female gonad,10116.0,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL624069,,992.0
9954,,Rattus norvegicus,,A,N,Intermediate,Female gonad,10116.0,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL624070,,992.0
9955,,Rattus norvegicus,,A,N,Intermediate,Female gonad,10116.0,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL624071,,992.0
9956,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL624072,,995.0
9957,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL624073,,995.0
9958,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL624788,,995.0
9959,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL624789,,995.0
9960,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL624790,,
9961,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL624791,,
9962,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL624792,,
9963,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL624793,,
9964,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL877491,,2385.0
9965,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL624957,,2385.0
9966,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL624958,,2385.0
9967,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,50597,,,1,13091,BAO_0000218,1,CHEMBL624959,,2385.0
9968,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Dissociation constant was determined,50597,,,1,11977,BAO_0000218,1,CHEMBL624960,,
9969,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",50597,,,1,14941,BAO_0000218,1,CHEMBL624961,,
9970,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",50597,,,1,15078,BAO_0000218,1,CHEMBL624962,,
9971,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",50597,,,1,15078,BAO_0000218,1,CHEMBL624963,,
9972,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Observed rate constant in 80% rat plasma at 37 degree Centigrade,50597,,,1,4755,BAO_0000218,1,CHEMBL624964,,
9973,,Rattus norvegicus,,A,N,Intermediate,,10116.0,LogP value was evaluated in the in situ rat gut perfusion assay,50597,,,1,589,BAO_0000218,1,CHEMBL624965,,
9974,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,50597,,,1,17582,BAO_0000218,1,CHEMBL624966,,
9975,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,50597,,,1,5031,BAO_0000218,1,CHEMBL624967,,
9976,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,50597,,,1,17764,BAO_0000218,1,CHEMBL624968,,
9977,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,,,1,17720,BAO_0000218,1,CHEMBL624969,,
9978,,Rattus norvegicus,,F,N,Expert,,10116.0,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,50597,,,1,2862,BAO_0000218,1,CHEMBL624970,,
9979,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life was evaluated after 10 uM/kg of intra arterial administration,50597,,,1,16423,BAO_0000218,1,CHEMBL624971,,
9980,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life was evaluated after 20 uM/kg of peroral administration,50597,,,1,16423,BAO_0000218,1,CHEMBL624972,,
9981,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,50597,,,1,6005,BAO_0000218,1,CHEMBL624973,,
9982,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half-life was evaluated in plasma of rat,50597,,,1,2938,BAO_0000218,1,CHEMBL624974,,1969.0
9983,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,50597,,,1,6410,BAO_0000218,1,CHEMBL624975,,
9984,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life was evaluated in rats at an oral dose of 30 mg/kg,50597,,,1,6410,BAO_0000218,1,CHEMBL877492,,
9985,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life was measured in rat after an iv dose of 1 mg/kg,50597,,,1,6062,BAO_0000218,1,CHEMBL624976,,
9986,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life period of compound in rats after peroral administration,50597,,,1,6571,BAO_0000218,1,CHEMBL624977,,
9987,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half-life period of compound was measured in rat plasma.,50597,,,1,3136,BAO_0000218,1,CHEMBL626848,,1969.0
9988,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half-life period of compound was measured in rat plasma; ND is not determined,50597,,,1,3136,BAO_0000218,1,CHEMBL626849,,1969.0
9989,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half-life period of compound was measured in rat plasma; not determined,50597,,,1,3136,BAO_0000218,1,CHEMBL626850,,1969.0
9990,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,50597,,,1,4521,BAO_0000218,1,CHEMBL626851,,
9991,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life period in rat by iv administration,50597,,,1,5871,BAO_0000218,1,CHEMBL626852,,
9992,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life period in rats following intravenous administration at 2 mg/kg,50597,,,1,6077,BAO_0000218,1,CHEMBL626853,,
9993,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50597,,,1,6679,BAO_0000218,1,CHEMBL626854,,
9994,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life period was determined for the compound in rat,50597,,,1,5144,BAO_0000218,1,CHEMBL627486,,
9995,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",50597,,,1,4498,BAO_0000218,1,CHEMBL627487,,
9996,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",50597,,,1,4498,BAO_0000218,1,CHEMBL627488,,
9997,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life value after IV dose at a dose of 5 mg/kg in rats.,50597,,,1,1908,BAO_0000218,1,CHEMBL627489,,
9998,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,50597,,,1,6211,BAO_0000218,1,CHEMBL627490,,
9999,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life was determined in rat after intravenous administration (0.5 mg/kg),50597,,,1,5529,BAO_0000218,1,CHEMBL873829,,
10000,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life was determined in rat at a dose of 1 mpk i.v.,50597,,,1,6444,BAO_0000218,1,CHEMBL627655,,
10001,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,50597,,,1,6444,BAO_0000218,1,CHEMBL625994,,
10002,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,50597,,,1,6444,BAO_0000218,1,CHEMBL625995,,
10003,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life in rat,50597,,,1,5207,BAO_0000218,1,CHEMBL625996,,
10004,In vitro,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,In vitro half life in rat plasma,50597,,,1,530,BAO_0000218,1,CHEMBL625850,,1969.0
10005,In vitro,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",50597,,,1,1116,BAO_0000218,1,CHEMBL625851,,1969.0
10006,In vitro,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro half life in rat,50597,,,1,3219,BAO_0000218,1,CHEMBL625852,,
10007,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo half life period after intravenous administration in rat,50597,,,1,6109,BAO_0000218,1,CHEMBL625853,,
10008,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,50597,,,1,17582,BAO_0000218,1,CHEMBL625854,,
10009,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,50597,,,1,17582,BAO_0000218,1,CHEMBL874450,,
10010,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,,,1,5974,BAO_0000218,1,CHEMBL625855,,
10011,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,,,1,5974,BAO_0000218,1,CHEMBL625856,,
10012,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,,,1,5974,BAO_0000218,1,CHEMBL625857,,
10013,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,,,1,5974,BAO_0000218,1,CHEMBL873831,,
10014,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Longer half-life in rat (i.v.) at 0.5 mpk,50597,,,1,17853,BAO_0000218,1,CHEMBL625858,,
10015,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Longer half-life in rat (p.o.) at 2.0 mpk,50597,,,1,17853,BAO_0000218,1,CHEMBL625859,,
10016,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (half life) in rat,50597,,,1,3457,BAO_0000218,1,CHEMBL625860,,
10017,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,50597,,,1,2792,BAO_0000218,1,CHEMBL625861,,
10018,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,50597,,,1,2792,BAO_0000218,1,CHEMBL625862,,
10019,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,50597,,,1,2792,BAO_0000218,1,CHEMBL625863,,
10020,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,50597,,,1,2792,BAO_0000218,1,CHEMBL625864,,
10021,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,50597,,,1,5739,BAO_0000218,1,CHEMBL625865,,
10022,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic half time was determined intravenously in rats.,50597,,,1,15765,BAO_0000218,1,CHEMBL625866,,
10023,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,50597,,,1,6567,BAO_0000218,1,CHEMBL625867,,1969.0
10024,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma half life of hydrolysis of the compound,50597,,,1,2448,BAO_0000218,1,CHEMBL625868,,1969.0
10025,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,50597,,,1,5423,BAO_0000218,1,CHEMBL625869,,1969.0
10026,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma half life period was calculated in rat,50597,,,1,4853,BAO_0000218,1,CHEMBL874451,,1969.0
10027,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma half-life in Sprague-Dawley rats,50597,,,1,4514,BAO_0000218,1,CHEMBL625870,,1969.0
10028,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma half-life in Sprague-Dawley rats; Not determined,50597,,,1,4514,BAO_0000218,1,CHEMBL625871,,1969.0
10029,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma half-life in rats,50597,,,1,1500,BAO_0000218,1,CHEMBL625872,,1969.0
10030,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma half-life in rats; <MQL,50597,,,1,1500,BAO_0000218,1,CHEMBL625873,,1969.0
10031,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma half-life period (0-8 h) was determined,50597,,,1,5334,BAO_0000218,1,CHEMBL625874,,1969.0
10032,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,50597,,,1,5334,BAO_0000218,1,CHEMBL625875,,1969.0
10033,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,50597,,,1,5334,BAO_0000218,1,CHEMBL625876,,1969.0
10034,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,50597,,,1,5334,BAO_0000218,1,CHEMBL631258,,1969.0
10035,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,50597,,,1,4956,BAO_0000218,1,CHEMBL631259,,1969.0
10036,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,50597,,,1,4956,BAO_0000218,1,CHEMBL631260,,1969.0
10037,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",50597,,,1,7768,BAO_0000218,1,CHEMBL631261,,178.0
10038,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",50597,,,1,7768,BAO_0000218,1,CHEMBL631262,,178.0
10039,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",50597,,,1,7768,BAO_0000218,1,CHEMBL631263,,178.0
10040,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",50597,,,1,7768,BAO_0000218,1,CHEMBL631264,,
10041,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",50597,,,1,7768,BAO_0000218,1,CHEMBL631265,,
10042,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",50597,,,1,7768,BAO_0000218,1,CHEMBL631266,,
10043,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",50597,,,1,7768,BAO_0000218,1,CHEMBL631267,,
10044,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",50597,,,1,7768,BAO_0000218,1,CHEMBL631268,,
10045,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",50597,,,1,7768,BAO_0000218,1,CHEMBL631269,,
10046,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",50597,,,1,7768,BAO_0000218,1,CHEMBL631270,,
10047,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",50597,,,1,7768,BAO_0000218,1,CHEMBL631271,,948.0
10048,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",50597,,,1,7768,BAO_0000218,1,CHEMBL631272,,948.0
10049,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",50597,,,1,7768,BAO_0000218,1,CHEMBL631273,,948.0
10050,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",50597,,,1,7768,BAO_0000218,1,CHEMBL631274,,948.0
10051,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",50597,,,1,7768,BAO_0000218,1,CHEMBL631275,,948.0
10052,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",50597,,,1,7768,BAO_0000218,1,CHEMBL626984,,948.0
10053,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",50597,,,1,7768,BAO_0000218,1,CHEMBL626985,,948.0
10054,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",50597,,,1,7768,BAO_0000218,1,CHEMBL626986,,2107.0
10055,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",50597,,,1,7768,BAO_0000218,1,CHEMBL626987,,2107.0
10056,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",50597,,,1,7768,BAO_0000218,1,CHEMBL626988,,2107.0
10057,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",50597,,,1,7768,BAO_0000218,1,CHEMBL626989,,2107.0
10058,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",50597,,,1,7768,BAO_0000218,1,CHEMBL626990,,2107.0
10059,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",50597,,,1,7768,BAO_0000218,1,CHEMBL626991,,2107.0
10060,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",50597,,,1,7768,BAO_0000218,1,CHEMBL626992,,2107.0
10061,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",50597,,,1,7768,BAO_0000218,1,CHEMBL626993,,2048.0
10062,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",50597,,,1,7768,BAO_0000218,1,CHEMBL874593,,2048.0
10063,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",50597,,,1,7768,BAO_0000218,1,CHEMBL626994,,2048.0
10064,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",50597,,,1,7768,BAO_0000218,1,CHEMBL626995,,2048.0
10065,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",50597,,,1,7768,BAO_0000218,1,CHEMBL626190,,2048.0
10066,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",50597,,,1,7768,BAO_0000218,1,CHEMBL626191,,2048.0
10067,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",50597,,,1,7768,BAO_0000218,1,CHEMBL626364,,2048.0
10068,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",50597,,,1,7768,BAO_0000218,1,CHEMBL626365,,2046.0
10069,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",50597,,,1,7768,BAO_0000218,1,CHEMBL626366,,2046.0
10070,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",50597,,,1,7768,BAO_0000218,1,CHEMBL626367,,2046.0
10071,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",50597,,,1,7768,BAO_0000218,1,CHEMBL626368,,2046.0
10072,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",50597,,,1,7768,BAO_0000218,1,CHEMBL626369,,2046.0
10073,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",50597,,,1,7768,BAO_0000218,1,CHEMBL626370,,2046.0
10074,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",50597,,,1,4498,BAO_0000218,1,CHEMBL626371,,
10075,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",50597,,,1,4498,BAO_0000218,1,CHEMBL626372,,
10076,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability after a dose of 10 mg/kg p.o.,50597,,,1,3603,BAO_0000218,1,CHEMBL626373,,
10077,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability after peroral administration (10 mg/kg) was determined in rat,50597,,,1,6215,BAO_0000218,1,CHEMBL626374,,
10078,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,50597,,,1,5710,BAO_0000218,1,CHEMBL626375,,
10079,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),50597,,,1,5710,BAO_0000218,1,CHEMBL626376,,
10080,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat po was determined,50597,,,1,5676,BAO_0000218,1,CHEMBL626377,,
10081,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability of compound at 10 mg/kg in rat after oral administration,50597,,,1,17667,BAO_0000218,1,CHEMBL626378,,
10082,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,50597,,,1,17667,BAO_0000218,1,CHEMBL626379,,
10083,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),50597,,,1,6848,BAO_0000218,1,CHEMBL626380,,
10084,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),50597,,,1,6848,BAO_0000218,1,CHEMBL626381,,
10085,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat,50597,,,1,17267,BAO_0000218,1,CHEMBL626382,,
10086,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (Sprague-Dawley) (female),50597,,,1,6362,BAO_0000218,1,CHEMBL626383,,
10087,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,50597,,,1,17671,BAO_0000218,1,CHEMBL874652,,
10088,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),50597,,,1,17671,BAO_0000218,1,CHEMBL626384,,
10089,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,50597,,,1,4333,BAO_0000218,1,CHEMBL626385,,
10090,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat at an oral dose of 2 mg/kg,50597,,,1,6077,BAO_0000218,1,CHEMBL626386,,
10091,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat,50597,,,1,3278,BAO_0000218,1,CHEMBL626387,,
10092,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat,50597,,,1,5964,BAO_0000218,1,CHEMBL626388,,
10093,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat,50597,,,1,4884,BAO_0000218,1,CHEMBL626389,,
10094,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat,50597,,,1,4905,BAO_0000218,1,CHEMBL626390,,
10095,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,50597,,,1,4884,BAO_0000218,1,CHEMBL626391,,
10096,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat,50597,,,1,6850,BAO_0000218,1,CHEMBL626392,,
10097,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,2864,BAO_0000218,1,CHEMBL626393,,
10098,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability was determined in rat,50597,,,1,5780,BAO_0000218,1,CHEMBL623026,,
10099,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability,50597,,,1,1465,BAO_0000218,1,CHEMBL623027,,
10100,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability,50597,,,1,5199,BAO_0000218,1,CHEMBL623028,,
10101,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat after 1 day dosing,50597,,,1,5765,BAO_0000218,1,CHEMBL623029,,
10102,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat after 4 day dosing,50597,,,1,5765,BAO_0000218,1,CHEMBL623030,,
10103,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,50597,,,1,6518,BAO_0000218,1,CHEMBL623031,,
10104,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability after IV dosing at 1 mg/kg in rat; no data,50597,,,1,6518,BAO_0000218,1,CHEMBL623032,,
10105,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability after oral administration at a dose of 2 mg/kg in rat,50597,,,1,6518,BAO_0000218,1,CHEMBL623033,,
10106,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability after oral administration at a dose of 4 mg/kg in rat,50597,,,1,6518,BAO_0000218,1,CHEMBL623034,,
10107,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,50597,,,1,2083,BAO_0000218,1,CHEMBL623035,,
10108,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,50597,,,1,17260,BAO_0000218,1,CHEMBL623036,,
10109,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),50597,,,1,4956,BAO_0000218,1,CHEMBL623037,,
10110,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability by intravenous administration of 3.4 mg/kg in rat,50597,,,1,4368,BAO_0000218,1,CHEMBL623038,,
10111,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,50597,,,1,17752,BAO_0000218,1,CHEMBL874385,,1969.0
10112,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (Fisher) (fasted),50597,,,1,1446,BAO_0000218,1,CHEMBL623039,,
10113,In vivo,Primates,,A,U,Intermediate,,9443.0,Bioavailability in monkey after po administration of 10 mg/kg dose,22224,,,1,2891,BAO_0000218,0,CHEMBL623040,,
10114,In vivo,Primates,,A,U,Intermediate,,9443.0,Oral bioavailability in monkey (dose 10 mg/kg),22224,,,1,2891,BAO_0000218,0,CHEMBL623041,,
10115,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat,50597,,,1,6672,BAO_0000218,1,CHEMBL623741,,
10116,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat,50597,,,1,6673,BAO_0000218,1,CHEMBL623742,,
10117,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat,50597,,,1,17655,BAO_0000218,1,CHEMBL623743,,
10118,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat,50597,,,1,17796,BAO_0000218,1,CHEMBL623744,,
10119,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (dose 2.0 mg/kg p.o.),50597,,,1,17853,BAO_0000218,1,CHEMBL623745,,
10120,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),50597,,,1,4521,BAO_0000218,1,CHEMBL623746,,
10121,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (dose 5 mg/kg p.o.),50597,,,1,4940,BAO_0000218,1,CHEMBL623747,,
10122,In vivo,Rattus norvegicus,,A,U,Intermediate,,10116.0,Bioavailability in rat after po administration of 30 mg/kg dose,22224,,,1,2891,BAO_0000218,0,CHEMBL623748,,
10123,In vivo,Rattus norvegicus,,A,U,Intermediate,,10116.0,Bioavailability in rat after po administration of 30 mg/kg dose,22224,,,1,2891,BAO_0000218,0,CHEMBL623916,,
10124,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,50597,,,1,4521,BAO_0000218,1,CHEMBL623917,,
10125,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (dose 2 mg/kg i.v.),50597,,,1,17686,BAO_0000218,1,CHEMBL623918,,
10126,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat,50597,,,1,17796,BAO_0000218,1,CHEMBL874386,,
10127,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Bioavailability in rat; Only traces detected in rat plasma,50597,,,1,17796,BAO_0000218,1,CHEMBL623919,,1969.0
10128,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat,50597,,,1,5064,BAO_0000218,1,CHEMBL623920,,
10129,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability upon oral administration of compound,50597,,,1,5147,BAO_0000218,1,CHEMBL623148,,
10130,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),50597,,,1,1916,BAO_0000218,1,CHEMBL623149,,
10131,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat,50597,,,1,6049,BAO_0000218,1,CHEMBL623150,,
10132,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",50597,,,1,1445,BAO_0000218,1,CHEMBL623151,,
10133,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",50597,,,1,1445,BAO_0000218,1,CHEMBL623152,,
10134,,Rattus norvegicus,,F,N,Expert,,10116.0,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,50597,,,1,2862,BAO_0000218,1,CHEMBL623153,,
10135,,Rattus norvegicus,,F,N,Expert,,10116.0,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,50597,,,1,2862,BAO_0000218,1,CHEMBL623154,,
10136,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro and metabolic stability was determined,50597,,,1,4194,BAO_0000218,1,CHEMBL623155,,
10137,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro metabolic stability in rat hepatocytes,50597,,,1,4194,BAO_0000218,1,CHEMBL623156,,
10138,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,50597,,,1,5486,BAO_0000218,1,CHEMBL623157,,
10139,In vitro,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Metabolic rate for compound was observed in rat hepatocytes,50597,,,1,17582,BAO_0000218,1,CHEMBL623158,401.0,2107.0
10140,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,50597,,,1,5600,BAO_0000218,1,CHEMBL623159,,
10141,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),50597,,,1,14294,BAO_0000218,1,CHEMBL874390,,
10142,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),50597,,,1,14294,BAO_0000218,1,CHEMBL623160,,
10143,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Metabolism of compound in rat S9 microsomes; Trace,50597,,,1,14294,BAO_0000218,1,CHEMBL623161,,
10144,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,50597,,,1,17847,BAO_0000218,1,CHEMBL623162,,
10145,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,50597,,,1,11020,BAO_0000218,1,CHEMBL623163,,
10146,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,50597,,,1,11020,BAO_0000218,1,CHEMBL623164,,
10147,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,50597,,,1,11020,BAO_0000218,1,CHEMBL623165,,
10148,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,50597,,,1,11020,BAO_0000218,1,CHEMBL623166,,
10149,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,50597,,,1,11020,BAO_0000218,1,CHEMBL624983,,
10150,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,50597,,,1,11020,BAO_0000218,1,CHEMBL624984,,
10151,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,50597,,,1,11020,BAO_0000218,1,CHEMBL624985,,
10152,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,50597,,,1,11020,BAO_0000218,1,CHEMBL622970,,
10153,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,50597,,,1,11020,BAO_0000218,1,CHEMBL622971,,
10154,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,50597,,,1,11020,BAO_0000218,1,CHEMBL622972,,
10155,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,50597,,,1,11020,BAO_0000218,1,CHEMBL622973,,
10156,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,50597,,,1,11020,BAO_0000218,1,CHEMBL622974,,
10157,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,50597,,,1,11020,BAO_0000218,1,CHEMBL622975,,
10158,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,50597,,,1,11020,BAO_0000218,1,CHEMBL622976,,
10159,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,50597,,,1,11020,BAO_0000218,1,CHEMBL622977,,
10160,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,50597,,,1,11020,BAO_0000218,1,CHEMBL624351,,
10161,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,50597,,,1,11020,BAO_0000218,1,CHEMBL624352,,
10162,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,50597,,,1,11020,BAO_0000218,1,CHEMBL624353,,
10163,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,50597,,,1,11020,BAO_0000218,1,CHEMBL622397,,
10164,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,50597,,,1,11020,BAO_0000218,1,CHEMBL622398,,
10165,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,50597,,,1,11020,BAO_0000218,1,CHEMBL622399,,
10166,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,50597,,,1,11020,BAO_0000218,1,CHEMBL622400,,
10167,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,50597,,,1,11020,BAO_0000218,1,CHEMBL628428,,
10168,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,50597,,,1,11020,BAO_0000218,1,CHEMBL628590,,
10169,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,50597,,,1,11020,BAO_0000218,1,CHEMBL628591,,
10170,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,50597,,,1,11020,BAO_0000218,1,CHEMBL628592,,
10171,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,50597,,,1,11020,BAO_0000218,1,CHEMBL628593,,
10172,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,50597,,,1,11020,BAO_0000218,1,CHEMBL875333,,
10173,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,50597,,,1,11020,BAO_0000218,1,CHEMBL628594,,
10174,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,50597,,,1,4969,BAO_0000218,1,CHEMBL628595,,1969.0
10175,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Stability in rat plasma was determined,50597,,,1,6737,BAO_0000218,1,CHEMBL628596,,1969.0
10176,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Stability in rat plasma was determined; ND= no data,50597,,,1,6737,BAO_0000218,1,CHEMBL628597,,1969.0
10177,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Tested for plasma half life period in rat (0-8 hr),50597,,,1,5089,BAO_0000218,1,CHEMBL628598,,1969.0
10178,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Tested for plasma half life period in rat (0-8 hr); Not determined,50597,,,1,5089,BAO_0000218,1,CHEMBL628599,,1969.0
10179,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,50597,,,1,1466,BAO_0000218,1,CHEMBL628600,,
10180,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,50597,,,1,1466,BAO_0000218,1,CHEMBL628601,,
10181,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for the half life in rat,50597,,,1,4950,BAO_0000218,1,CHEMBL628602,,
10182,In vitro,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,50597,,,1,2412,BAO_0000218,1,CHEMBL628603,,
10183,In vitro,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,50597,,,1,2412,BAO_0000218,1,CHEMBL628604,,
10184,In vitro,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,50597,,,1,2412,BAO_0000218,1,CHEMBL628605,,
10185,In vitro,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,50597,,,1,2412,BAO_0000218,1,CHEMBL628606,,
10186,In vitro,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,50597,,,1,2412,BAO_0000218,1,CHEMBL628607,,
10187,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The biological half life the compound was measured at the dose of 100 umol/kg,50597,,,1,15022,BAO_0000218,1,CHEMBL628608,,
10188,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The biological half life the compound was measured at the dose of 30 umol/kg,50597,,,1,15022,BAO_0000218,1,CHEMBL628609,,
10189,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,The compound was evaluated for plasma half life period in rat,50597,,,1,406,BAO_0000218,1,CHEMBL628610,,1969.0
10190,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",50597,,,1,15078,BAO_0000218,1,CHEMBL873819,,
10191,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",50597,,,1,15078,BAO_0000218,1,CHEMBL628611,,
10192,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,The pharmacokinetic parameter half-life period in vivo in rats,50597,,,1,5247,BAO_0000218,1,CHEMBL628612,,
10193,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"The pharmacokinetic property, Half-life was determined",50597,,,1,5041,BAO_0000218,1,CHEMBL628613,,
10194,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"The pharmacokinetic property, Half-life in rat in vivo",50597,,,1,5041,BAO_0000218,1,CHEMBL628614,,
10195,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"The pharmacokinetic property, Half-life was determined; ND denotes no data",50597,,,1,5041,BAO_0000218,1,CHEMBL628615,,
10196,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",50597,,,1,5041,BAO_0000218,1,CHEMBL628616,,
10197,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,The plasma half life period in rats,50597,,,1,3918,BAO_0000218,1,CHEMBL627924,,1969.0
10198,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,50597,,,1,2906,BAO_0000218,1,CHEMBL627925,,2107.0
10199,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,50597,,,1,6467,BAO_0000218,1,CHEMBL627926,,
10200,,Rattus norvegicus,,A,N,Intermediate,,10116.0,t1/2 (apparent elimination)of the compound was determined,50597,,,1,5510,BAO_0000218,1,CHEMBL627927,,
10201,,Rattus norvegicus,,A,N,Intermediate,,10116.0,t1/2 value in rat,50597,,,1,3788,BAO_0000218,1,CHEMBL627928,,
10202,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life in rat,50597,,,1,17796,BAO_0000218,1,CHEMBL627539,,
10203,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",50597,,,1,12873,BAO_0000218,1,CHEMBL876790,,1969.0
10204,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,50597,,,1,5983,BAO_0000218,1,CHEMBL858186,,
10205,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half-life period in fasted rats,50597,,,1,15765,BAO_0000218,1,CHEMBL627540,,
10206,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,50597,,,1,2661,BAO_0000218,1,CHEMBL627541,,
10207,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,50597,,,1,2661,BAO_0000218,1,CHEMBL627715,,
10208,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,50597,,,1,429,BAO_0000218,1,CHEMBL627716,,
10209,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum time required to achieve Cmax was determined in rat,50597,,,1,17655,BAO_0000218,1,CHEMBL627717,,
10210,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,,,1,17717,BAO_0000218,1,CHEMBL627718,,
10211,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,50597,,,1,17717,BAO_0000218,1,CHEMBL627719,,
10212,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,50597,,,1,17717,BAO_0000218,1,CHEMBL627720,,
10213,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,50597,,,1,6570,BAO_0000218,1,CHEMBL627721,,
10214,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,50597,,,1,6570,BAO_0000218,1,CHEMBL627722,,
10215,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL627723,,
10216,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL626058,,
10217,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL626059,,
10218,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL626060,,
10219,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,50597,,,1,17720,BAO_0000218,1,CHEMBL626061,,1969.0
10220,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,50597,,,1,4723,BAO_0000218,1,CHEMBL876791,,
10221,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,50597,,,1,4723,BAO_0000218,1,CHEMBL626062,,
10222,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax at the dose of 2 mg/Kg administered perorally in rats,50597,,,1,4756,BAO_0000218,1,CHEMBL626063,,
10223,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tmax at the dose of 5 mg/Kg administered perorally in rats,50597,,,1,4756,BAO_0000218,1,CHEMBL626064,,
10224,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,50597,,,1,17720,BAO_0000218,1,CHEMBL626065,,1969.0
10225,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,50597,,,1,17720,BAO_0000218,1,CHEMBL626066,,1969.0
10226,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,tmax upon peroral administration of 10.0 mg/Kg dose in rat,50597,,,1,1466,BAO_0000218,1,CHEMBL626067,,
10227,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,50597,,,1,7449,BAO_0000218,1,CHEMBL626068,,
10228,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,50597,,,1,7449,BAO_0000218,1,CHEMBL626069,,
10229,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Percent total excretion of 3-methoxyacetaminophen glucuronide,50597,,,1,7449,BAO_0000218,1,CHEMBL626070,,
10230,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Percent total excretion of N-methoxyacetaminophen glucuronide,50597,,,1,7449,BAO_0000218,1,CHEMBL626071,,
10231,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Percent total excretion of N-methoxyacetaminophen sulfate,50597,,,1,7449,BAO_0000218,1,CHEMBL626072,,
10232,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Percent total excretion of acetaminophen,50597,,,1,7449,BAO_0000218,1,CHEMBL626073,,
10233,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",50597,,,1,7768,BAO_0000218,1,CHEMBL626741,,2046.0
10234,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",50597,,,1,17655,BAO_0000218,1,CHEMBL626742,,
10235,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,50597,,,1,17735,BAO_0000218,1,CHEMBL626743,,
10236,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,50597,,,1,5960,BAO_0000218,1,CHEMBL876792,,
10237,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,50597,,,1,17735,BAO_0000218,1,CHEMBL626744,,
10238,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was tested for antidiuretic activity in rats,50597,,,1,7116,BAO_0000218,1,CHEMBL626745,,
10239,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC in rat after 3mg/kg oral dose,50597,,,1,4878,BAO_0000218,1,CHEMBL626746,,1969.0
10240,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,50597,,,1,5939,BAO_0000218,1,CHEMBL626747,,
10241,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,50597,,,1,5939,BAO_0000218,1,CHEMBL626748,,
10242,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability administered orally at a dose of 10 mg/kg to rats,50597,,,1,16367,BAO_0000218,1,CHEMBL626749,,
10243,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral Bioavailability was determined,50597,,,1,16366,BAO_0000218,1,CHEMBL626750,,
10244,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,4426,BAO_0000218,1,CHEMBL626751,,
10245,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat; Not performed.,50597,,,1,4426,BAO_0000218,1,CHEMBL626913,,
10246,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability,50597,,,1,5041,BAO_0000218,1,CHEMBL626914,,
10247,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability was determined; ND denotes no data,50597,,,1,5041,BAO_0000218,1,CHEMBL626915,,
10248,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,50597,,,1,1500,BAO_0000218,1,CHEMBL626916,,
10249,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,50597,,,1,1500,BAO_0000218,1,CHEMBL626917,,
10250,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Binding towards rat plasma protein at 10 uM,50597,,,1,17409,BAO_0000218,1,CHEMBL626918,,
10251,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Binding towards rat plasma protein at 100 uM,50597,,,1,17409,BAO_0000218,1,CHEMBL626919,,
10252,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (dose 20 mg/kg p.o.),50597,,,1,2959,BAO_0000218,1,CHEMBL626920,,
10253,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,50597,,,1,13501,BAO_0000218,1,CHEMBL621976,,
10254,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat after 5 mg/kg oral gavage,50597,,,1,6567,BAO_0000218,1,CHEMBL877599,,
10255,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat,50597,,,1,6571,BAO_0000218,1,CHEMBL621977,,
10256,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (dose 1 mg/kg i.v.),50597,,,1,6715,BAO_0000218,1,CHEMBL621978,,
10257,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (dose 3 mg/kg p.o.),50597,,,1,6715,BAO_0000218,1,CHEMBL621979,,
10258,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,2932,BAO_0000218,1,CHEMBL621980,,
10259,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability of the compound in rats after administration of 30 mg/kg,50597,,,1,4171,BAO_0000218,1,CHEMBL621981,,
10260,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability after administration of 10 mg/kg in rats,50597,,,1,17509,BAO_0000218,1,CHEMBL621982,,
10261,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability after administration of 2 mg/kg in rats,50597,,,1,17509,BAO_0000218,1,CHEMBL882953,,
10262,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,50597,,,1,4527,BAO_0000218,1,CHEMBL621983,,
10263,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in dogs was determined; high,50597,,,1,4026,BAO_0000218,1,CHEMBL621984,,
10264,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in monkey after intravenous administration at 1 mpk,50597,,,1,6659,BAO_0000218,1,CHEMBL621985,,
10265,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in monkey after peroral administration at 10 mpk,50597,,,1,6659,BAO_0000218,1,CHEMBL621986,,
10266,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat after intravenous administration at 1 mpk,50597,,,1,6659,BAO_0000218,1,CHEMBL621987,,
10267,In vivo,Rattus norvegicus,,F,N,Intermediate,,10116.0,Bioavailability in rat after intravenous administration at 2 mpk,50597,,,1,6659,BAO_0000218,1,CHEMBL877600,,
10268,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat after peroral administration at 30 mpk,50597,,,1,6659,BAO_0000218,1,CHEMBL621988,,
10269,In vivo,Rattus norvegicus,,F,N,Intermediate,,10116.0,Bioavailability in rat after peroral administration at at 100 mpk,50597,,,1,6659,BAO_0000218,1,CHEMBL621989,,
10270,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rats was evaluated,50597,,,1,6597,BAO_0000218,1,CHEMBL621990,,
10271,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,50597,,,1,1202,BAO_0000218,1,CHEMBL621991,,
10272,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,50597,,,1,1202,BAO_0000218,1,CHEMBL621992,,
10273,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,50597,,,1,1202,BAO_0000218,1,CHEMBL621993,,
10274,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,50597,,,1,1202,BAO_0000218,1,CHEMBL621994,,
10275,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat,50597,,,1,5207,BAO_0000218,1,CHEMBL621995,,
10276,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat,50597,,,1,5970,BAO_0000218,1,CHEMBL621996,,
10277,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (dose 10 mg/kg),50597,,,1,17538,BAO_0000218,1,CHEMBL621997,,
10278,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,50597,,,1,17538,BAO_0000218,1,CHEMBL621998,,
10279,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,50597,,,1,1466,BAO_0000218,1,CHEMBL621999,,
10280,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,2879,BAO_0000218,1,CHEMBL622000,,
10281,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability was measured in rat after oral administration; 2-4,50597,,,1,2879,BAO_0000218,1,CHEMBL622001,,
10282,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability was measured in rat after oral administration; 3-7,50597,,,1,2879,BAO_0000218,1,CHEMBL622002,,
10283,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (intraduodenal administration),50597,,,1,3777,BAO_0000218,1,CHEMBL622003,,
10284,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (intraduodenal administration),50597,,,1,3777,BAO_0000218,1,CHEMBL877601,,
10285,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,3777,BAO_0000218,1,CHEMBL624871,,
10286,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,3777,BAO_0000218,1,CHEMBL622004,,
10287,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),50597,,,1,5423,BAO_0000218,1,CHEMBL882954,,
10288,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,50597,,,1,16365,BAO_0000218,1,CHEMBL622005,,
10289,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,50597,,,1,16365,BAO_0000218,1,CHEMBL622006,,
10290,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability was measured in rat,50597,,,1,4239,BAO_0000218,1,CHEMBL622007,,
10291,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability was reported,50597,,,1,5438,BAO_0000218,1,CHEMBL622008,,
10292,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,,,1,5334,BAO_0000218,1,CHEMBL622009,,
10293,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),50597,,,1,5334,BAO_0000218,1,CHEMBL622010,,
10294,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,50597,,,1,4199,BAO_0000218,1,CHEMBL622011,,
10295,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),50597,,,1,4199,BAO_0000218,1,CHEMBL622012,,
10296,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),50597,,,1,4199,BAO_0000218,1,CHEMBL622013,,
10297,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,50597,,,1,4890,BAO_0000218,1,CHEMBL622014,,
10298,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability was determined at 3 mg/kg po dose in rats,50597,,,1,2792,BAO_0000218,1,CHEMBL624749,,
10299,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (dose 2 mg/kg),50597,,,1,5529,BAO_0000218,1,CHEMBL624750,,
10300,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",50597,,,1,6685,BAO_0000218,1,CHEMBL624751,,
10301,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",50597,,,1,6685,BAO_0000218,1,CHEMBL624752,,
10302,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",50597,,,1,6685,BAO_0000218,1,CHEMBL624753,,
10303,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,50597,,,1,6005,BAO_0000218,1,CHEMBL624754,,
10304,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,50597,,,1,6410,BAO_0000218,1,CHEMBL624755,,
10305,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,50597,,,1,6410,BAO_0000218,1,CHEMBL624756,,
10306,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat,50597,,,1,6103,BAO_0000218,1,CHEMBL624757,,
10307,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,50597,,,1,6410,BAO_0000218,1,CHEMBL624758,,
10308,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,50597,,,1,6410,BAO_0000218,1,CHEMBL622270,,
10309,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (Sprague-Dawley),50597,,,1,5353,BAO_0000218,1,CHEMBL622271,,
10310,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat at the dose of 2 mg/kg,50597,,,1,4727,BAO_0000218,1,CHEMBL622272,,
10311,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,17804,BAO_0000218,1,CHEMBL622273,,
10312,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (cannulated) (dose 2 mg/kg),50597,,,1,5809,BAO_0000218,1,CHEMBL622274,,
10313,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability value of compound in rats was determined after peroral administration,50597,,,1,17804,BAO_0000218,1,CHEMBL622275,,
10314,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (dose 20 mg/kg),50597,,,1,3634,BAO_0000218,1,CHEMBL622276,,
10315,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,3341,BAO_0000218,1,CHEMBL622277,,
10316,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (dose 5 mg/kg),50597,,,1,2690,BAO_0000218,1,CHEMBL622278,,
10317,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,3184,BAO_0000218,1,CHEMBL622279,,
10318,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,740,BAO_0000218,1,CHEMBL622280,,
10319,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for oral bioavailability in rats; 15-27 %,50597,,,1,1806,BAO_0000218,1,CHEMBL624083,,
10320,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,50597,,,1,4891,BAO_0000218,1,CHEMBL624084,,
10321,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),50597,,,1,3634,BAO_0000218,1,CHEMBL624085,,
10322,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was tested for bioavailability in rats,50597,,,1,64,BAO_0000218,1,CHEMBL624086,,
10323,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat,50597,,,1,4839,BAO_0000218,1,CHEMBL624087,,
10324,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,1094,BAO_0000218,1,CHEMBL624088,,
10325,In vivo,Macaca mulatta,,A,U,Intermediate,,9544.0,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,22224,,,1,5005,BAO_0000218,0,CHEMBL624089,,
10326,In vivo,Rattus norvegicus,,A,U,Intermediate,,10116.0,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),22224,,,1,5005,BAO_0000218,0,CHEMBL624090,,
10327,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Evaluated for the bioavailability in rat (in vivo),50597,,,1,4687,BAO_0000218,1,CHEMBL624091,,
10328,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,F value of compound in rats was determined after peroral administration,50597,,,1,17804,BAO_0000218,1,CHEMBL624092,,
10329,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,50597,,,1,5974,BAO_0000218,1,CHEMBL624093,,
10330,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,50597,,,1,5974,BAO_0000218,1,CHEMBL624094,,
10331,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,50597,,,1,5974,BAO_0000218,1,CHEMBL624095,,
10332,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,50597,,,1,5974,BAO_0000218,1,CHEMBL624096,,
10333,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",50597,,,1,1088,BAO_0000218,1,CHEMBL624097,,
10334,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum fall in carotid flow in rat,50597,,,1,1742,BAO_0000218,1,CHEMBL624098,,
10335,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,50597,,,1,4689,BAO_0000218,1,CHEMBL874392,,
10336,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (dose 5 mg/kg),50597,,,1,2463,BAO_0000218,1,CHEMBL624099,,
10337,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,50597,,,1,5654,BAO_0000218,1,CHEMBL624100,,
10338,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,50597,,,1,5654,BAO_0000218,1,CHEMBL624101,,
10339,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (male Wistar),50597,,,1,6874,BAO_0000218,1,CHEMBL624102,,
10340,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability after administration (30 mg/kg) in rat; good,50597,,,1,5633,BAO_0000218,1,CHEMBL624103,,
10341,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability at the dose of 2 mg/kg in rat,50597,,,1,5496,BAO_0000218,1,CHEMBL624104,,
10342,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability determined in rats,50597,,,1,2358,BAO_0000218,1,CHEMBL624105,,
10343,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),50597,,,1,16456,BAO_0000218,1,CHEMBL624106,,
10344,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (dose single 10 mg/kg),50597,,,1,5302,BAO_0000218,1,CHEMBL624107,,
10345,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (dose single 10 mg/kg),50597,,,1,5302,BAO_0000218,1,CHEMBL623943,,
10346,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (dose 5 mg/kg,50597,,,1,5302,BAO_0000218,1,CHEMBL623944,,
10347,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,50597,,,1,11020,BAO_0000218,1,CHEMBL623945,,
10348,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,50597,,,1,11020,BAO_0000218,1,CHEMBL623946,,
10349,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,50597,,,1,11020,BAO_0000218,1,CHEMBL623947,,
10350,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,50597,,,1,11020,BAO_0000218,1,CHEMBL623948,,
10351,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,50597,,,1,11020,BAO_0000218,1,CHEMBL623949,,
10352,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,50597,,,1,11020,BAO_0000218,1,CHEMBL623950,,
10353,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,50597,,,1,11020,BAO_0000218,1,CHEMBL874398,,
10354,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,50597,,,1,11020,BAO_0000218,1,CHEMBL623951,,
10355,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,50597,,,1,11020,BAO_0000218,1,CHEMBL623952,,
10356,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,50597,,,1,11020,BAO_0000218,1,CHEMBL623953,,
10357,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,50597,,,1,11020,BAO_0000218,1,CHEMBL623954,,
10358,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,50597,,,1,11020,BAO_0000218,1,CHEMBL623955,,
10359,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,50597,,,1,11020,BAO_0000218,1,CHEMBL623956,,
10360,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,50597,,,1,11020,BAO_0000218,1,CHEMBL627807,,
10361,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,50597,,,1,11020,BAO_0000218,1,CHEMBL627808,,
10362,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,50597,,,1,11020,BAO_0000218,1,CHEMBL627809,,
10363,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,50597,,,1,11020,BAO_0000218,1,CHEMBL627810,,
10364,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",50597,,,1,11020,BAO_0000218,1,CHEMBL627811,,
10365,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",50597,,,1,11020,BAO_0000218,1,CHEMBL627812,,
10366,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",50597,,,1,11020,BAO_0000218,1,CHEMBL627813,,
10367,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",50597,,,1,11020,BAO_0000218,1,CHEMBL627814,,
10368,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",50597,,,1,11020,BAO_0000218,1,CHEMBL875336,,
10369,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",50597,,,1,11020,BAO_0000218,1,CHEMBL627815,,
10370,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",50597,,,1,11020,BAO_0000218,1,CHEMBL627816,,
10371,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",50597,,,1,11020,BAO_0000218,1,CHEMBL627817,,
10372,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",50597,,,1,11020,BAO_0000218,1,CHEMBL627818,,
10373,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",50597,,,1,11020,BAO_0000218,1,CHEMBL627819,,
10374,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",50597,,,1,11020,BAO_0000218,1,CHEMBL627820,,
10375,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",50597,,,1,11020,BAO_0000218,1,CHEMBL627821,,
10376,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,50597,,,1,11020,BAO_0000218,1,CHEMBL628464,,
10377,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,50597,,,1,11020,BAO_0000218,1,CHEMBL626239,,
10378,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,50597,,,1,11020,BAO_0000218,1,CHEMBL626240,,
10379,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,50597,,,1,11020,BAO_0000218,1,CHEMBL626241,,
10380,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,50597,,,1,11020,BAO_0000218,1,CHEMBL626242,,
10381,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,50597,,,1,11020,BAO_0000218,1,CHEMBL626243,,
10382,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,50597,,,1,11020,BAO_0000218,1,CHEMBL626244,,
10383,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,50597,,,1,11020,BAO_0000218,1,CHEMBL626907,,
10384,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,50597,,,1,11020,BAO_0000218,1,CHEMBL626908,,
10385,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,50597,,,1,11020,BAO_0000218,1,CHEMBL626909,,
10386,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,50597,,,1,11020,BAO_0000218,1,CHEMBL626910,,
10387,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Percent total excretion of acetaminophen cysteine conjugate,50597,,,1,7449,BAO_0000218,1,CHEMBL875342,,
10388,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Percent total excretion of acetaminophen glucuronide,50597,,,1,7449,BAO_0000218,1,CHEMBL626911,,
10389,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Percent total excretion of acetaminophen sulfate,50597,,,1,7449,BAO_0000218,1,CHEMBL626912,,
10390,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Percent total excretion of acetaminophen-mercapturic acid,50597,,,1,7449,BAO_0000218,1,CHEMBL627065,,
10391,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,50597,,,1,3172,BAO_0000218,1,CHEMBL627066,,1088.0
10392,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,50597,,,1,16456,BAO_0000218,1,CHEMBL627067,,
10393,In vivo,ratrat,,A,U,Autocuration,Muscle tissue,8656.0,Biodistribution of compound in rat muscle after 5 min of administration,22224,,,1,10839,BAO_0000218,0,CHEMBL627068,,2385.0
10394,In vivo,ratrat,,A,U,Autocuration,Muscle tissue,8656.0,Biodistribution of compound in rat muscle after 5 min of administration.,22224,,,1,10839,BAO_0000218,0,CHEMBL627069,,2385.0
10395,In vivo,Ovis aries,,A,U,Autocuration,,9940.0,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),22224,,,1,5334,BAO_0000218,0,CHEMBL627070,,
10396,In vivo,Ovis aries,,A,U,Autocuration,,9940.0,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),22224,,,1,5334,BAO_0000218,0,CHEMBL627071,,
10397,In vivo,Ovis aries,,A,U,Autocuration,,9940.0,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),22224,,,1,5334,BAO_0000218,0,CHEMBL627072,,
10398,In vivo,Ovis aries,,A,U,Autocuration,,9940.0,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),22224,,,1,5334,BAO_0000218,0,CHEMBL627073,,
10399,In vivo,Ovis aries,,A,U,Autocuration,,9940.0,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),22224,,,1,5334,BAO_0000218,0,CHEMBL625387,,
10400,In vivo,Ovis aries,,A,U,Autocuration,,9940.0,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),22224,,,1,5334,BAO_0000218,0,CHEMBL625388,,
10401,In vivo,Ovis aries,,A,U,Autocuration,Plasma,9940.0,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),22224,,,1,5334,BAO_0000218,0,CHEMBL625389,,1969.0
10402,In vivo,Ovis aries,,A,U,Autocuration,Plasma,9940.0,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),22224,,,1,5334,BAO_0000218,0,CHEMBL875343,,1969.0
10403,,Serpentes,,A,N,Intermediate,,8570.0,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),50497,,,1,1735,BAO_0000218,1,CHEMBL876795,,
10404,,Serpentes,,A,N,Intermediate,,8570.0,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,50497,,,1,1469,BAO_0000218,1,CHEMBL626552,,
10405,,Serpentes,,A,N,Intermediate,,8570.0,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,50497,,,1,1336,BAO_0000218,1,CHEMBL626553,,
10406,,Homo sapiens,,A,U,Autocuration,Plasma,9606.0,The human biological plasma half life of the compound,22224,,,1,12403,BAO_0000366,0,CHEMBL626554,,1969.0
10407,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,50597,,,1,8151,BAO_0000218,1,CHEMBL626555,,1088.0
10408,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,50597,,,1,8004,BAO_0000218,1,CHEMBL626556,,
10409,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,50597,,,1,8004,BAO_0000218,1,CHEMBL626557,,
10410,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,50597,,,1,8004,BAO_0000218,1,CHEMBL626558,,
10411,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,50597,,,1,8004,BAO_0000218,1,CHEMBL626559,,
10412,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,50597,,,1,8004,BAO_0000218,1,CHEMBL626560,,
10413,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,50597,,,1,8004,BAO_0000218,1,CHEMBL876803,,
10414,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,50597,,,1,8004,BAO_0000218,1,CHEMBL627964,,
10415,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,50597,,,1,8004,BAO_0000218,1,CHEMBL627965,,
10416,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,50597,,,1,8004,BAO_0000218,1,CHEMBL627966,,
10417,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,50597,,,1,8004,BAO_0000218,1,CHEMBL627967,,
10418,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,50597,,,1,8004,BAO_0000218,1,CHEMBL627968,,
10419,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,50597,,,1,8004,BAO_0000218,1,CHEMBL627969,,
10420,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,50597,,,1,8004,BAO_0000218,1,CHEMBL627970,,
10421,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,50597,,,1,8004,BAO_0000218,1,CHEMBL627971,,178.0
10422,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,50597,,,1,8004,BAO_0000218,1,CHEMBL627972,,178.0
10423,,Homo sapiens,,B,D,Expert,,9606.0,Dissociation constant against binding to human cyclophilin A,180,,,1,15917,BAO_0000357,9,CHEMBL856029,,
10424,,Bos taurus,,B,H,Expert,,9913.0,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,11591,,,1,12396,BAO_0000019,8,CHEMBL627973,,
10425,,,,A,U,Autocuration,,,-Log C was determined by performing the electroshock minimum test,22224,,,1,7065,BAO_0000019,0,CHEMBL627974,,
10426,,,,A,U,Autocuration,,,-Log C was determined by performing the foot shock test,22224,,,1,7065,BAO_0000019,0,CHEMBL627975,,
10427,,,,A,U,Autocuration,,,-Log C was determined by performing the incl screen test,22224,,,1,7065,BAO_0000019,0,CHEMBL627976,,
10428,,,,A,U,Autocuration,,,-Log C was determined by performing the maximum electroshock test,22224,,,1,7065,BAO_0000019,0,CHEMBL627977,,
10429,,,,A,U,Autocuration,,,-Log C was determined by performing the pentylenetetrazole test,22224,,,1,7065,BAO_0000019,0,CHEMBL627978,,
10430,,,,A,U,Autocuration,,,Tested for experimental arotinoid inhibitory dose,22224,,,1,12415,BAO_0000019,0,CHEMBL627979,,
10431,,,,A,U,Autocuration,,,Negative log transformed activity,22224,,,1,10256,BAO_0000019,0,CHEMBL876804,,
10432,,,,A,U,Autocuration,,,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",22224,,,1,7991,BAO_0000019,0,CHEMBL627980,,
10433,,Cavia porcellus,,A,N,Intermediate,,10141.0,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,50512,,,1,14342,BAO_0000218,1,CHEMBL627981,,
10434,,Cavia porcellus,,A,N,Intermediate,,10141.0,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,50512,,,1,14342,BAO_0000218,1,CHEMBL627982,,
10435,,Cavia porcellus,,A,N,Intermediate,,10141.0,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,50512,,,1,14342,BAO_0000218,1,CHEMBL627983,,
10436,,Cavia porcellus,,A,N,Intermediate,Ileum,10141.0,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,50512,,,1,14342,BAO_0000218,1,CHEMBL627984,,2116.0
10437,,,,P,U,Autocuration,,,Solubility in water was determined; values expressed as -log,22229,,,1,6047,BAO_0000100,0,CHEMBL627985,,
10438,,,,A,U,Autocuration,,,Ratio of Kcat to that of Km was determined,22224,,,1,17269,BAO_0000019,0,CHEMBL627986,,
10439,,,,A,U,Autocuration,,,Observed first order rate constant,22224,,,1,10026,BAO_0000019,0,CHEMBL627987,,
10440,,,,A,U,Autocuration,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,22224,,,1,14583,BAO_0000019,0,CHEMBL627988,,
10441,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,50597,,,1,2661,BAO_0000218,1,CHEMBL627989,,
10442,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,50597,,,1,2661,BAO_0000218,1,CHEMBL627990,,
10443,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral Bioavailability after administration of 10 mg/kg in male rat,50597,,,1,4029,BAO_0000218,1,CHEMBL876805,,
10444,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),50597,,,1,17735,BAO_0000218,1,CHEMBL627991,,
10445,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,4576,BAO_0000218,1,CHEMBL627992,,
10446,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,50597,,,1,17582,BAO_0000218,1,CHEMBL627993,,
10447,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability at 1 mg/kg was determined in rat,50597,,,1,17651,BAO_0000218,1,CHEMBL622817,,
10448,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability at 10 mg/kg was determined in rat,50597,,,1,17651,BAO_0000218,1,CHEMBL622818,,
10449,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",50597,,,1,17670,BAO_0000218,1,CHEMBL622819,,
10450,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,5045,BAO_0000218,1,CHEMBL872267,,
10451,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,1696,BAO_0000218,1,CHEMBL622820,,
10452,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability after intravenous administration in rats at 24 uM/kg,50597,,,1,17764,BAO_0000218,1,CHEMBL622821,,
10453,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,6448,BAO_0000218,1,CHEMBL622822,,
10454,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,6596,BAO_0000218,1,CHEMBL622823,,
10455,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,17547,BAO_0000218,1,CHEMBL622824,,
10456,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat at a dose of 3 mg/kg,50597,,,1,17771,BAO_0000218,1,CHEMBL622825,,
10457,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat after oral administration at 10 mg/kg,50597,,,1,6495,BAO_0000218,1,CHEMBL622901,,
10458,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,4558,BAO_0000218,1,CHEMBL622902,,
10459,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,17596,BAO_0000218,1,CHEMBL621844,,
10460,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in Dawley rats,50597,,,1,6827,BAO_0000218,1,CHEMBL621845,,
10461,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability,50597,,,1,4026,BAO_0000218,1,CHEMBL621846,,
10462,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (dose 30 mg/kg),50597,,,1,10,BAO_0000218,1,CHEMBL621847,,
10463,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,50597,,,1,17717,BAO_0000218,1,CHEMBL877609,,
10464,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (dose 3 mg/kg i.v.),50597,,,1,17717,BAO_0000218,1,CHEMBL621848,,
10465,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,50597,,,1,17717,BAO_0000218,1,CHEMBL621849,,
10466,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (dose 60 mg/kg p.o.),50597,,,1,17717,BAO_0000218,1,CHEMBL622030,,
10467,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Percent oral bioavailability determined in rats,50597,,,1,4796,BAO_0000218,1,CHEMBL622031,,
10468,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,50597,,,1,4883,BAO_0000218,1,CHEMBL622032,,
10469,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,The compound was evaluated for bioavailability in rats; 32-51,50597,,,1,2137,BAO_0000218,1,CHEMBL622033,,
10470,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (dose 20 mg/kg p.o.),50597,,,1,2959,BAO_0000218,1,CHEMBL622034,,
10471,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,1361,BAO_0000218,1,CHEMBL622035,,
10472,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability percent in rat at the dose of 2 mg/kg,50597,,,1,4727,BAO_0000218,1,CHEMBL882966,,
10473,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability was evaluated after 20 uM/kg of peroral administration,50597,,,1,16423,BAO_0000218,1,CHEMBL622036,,
10474,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,5206,BAO_0000218,1,CHEMBL622037,,
10475,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,6448,BAO_0000218,1,CHEMBL622038,,
10476,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rats,50597,,,1,17723,BAO_0000218,1,CHEMBL622039,,
10477,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL622040,,178.0
10478,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL622041,,178.0
10479,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL622042,,178.0
10480,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL622043,,178.0
10481,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL622044,,178.0
10482,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL622045,,10000001.0
10483,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL622046,,10000001.0
10484,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL622047,,10000001.0
10485,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL877610,,10000001.0
10486,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL622048,,955.0
10487,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL622049,,955.0
10488,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL622050,,955.0
10489,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL622051,,955.0
10490,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL622052,,
10491,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL622053,,
10492,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL622054,,
10493,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL622055,,
10494,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rats was determined; High,50597,,,1,5237,BAO_0000218,1,CHEMBL622056,,
10495,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in the rat was determined,50597,,,1,5503,BAO_0000218,1,CHEMBL622057,,
10496,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,50597,,,1,15765,BAO_0000218,1,CHEMBL628008,,
10497,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),50597,,,1,15660,BAO_0000218,1,CHEMBL622058,,
10498,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL622059,,
10499,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL622060,,
10500,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL622061,,
10501,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,50597,,,1,5978,BAO_0000218,1,CHEMBL622062,,
10502,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,50597,,,1,5656,BAO_0000218,1,CHEMBL622063,,
10503,In vivo,Rattus norvegicus,,A,N,Expert,,10116.0,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,50597,,,1,3598,BAO_0000218,1,CHEMBL877611,,
10504,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability of compound in Sprague Dawley rats,50597,,,1,4216,BAO_0000218,1,CHEMBL622064,,
10505,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability of compound in rat,50597,,,1,17839,BAO_0000218,1,CHEMBL622065,,
10506,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (dose 2 mg/kg),50597,,,1,6570,BAO_0000218,1,CHEMBL622066,,
10507,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability of compound in rat was determined,50597,,,1,5334,BAO_0000218,1,CHEMBL622067,,
10508,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability of compound in rats,50597,,,1,6886,BAO_0000218,1,CHEMBL622068,,
10509,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability of compound was determined in rats,50597,,,1,5210,BAO_0000218,1,CHEMBL622069,,
10510,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability at a dose of 30 mg/kg in rats,50597,,,1,4170,BAO_0000218,1,CHEMBL624796,,
10511,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (dose 10 mg/kg),50597,,,1,6028,BAO_0000218,1,CHEMBL624797,,
10512,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (dose 10 mg/kg),50597,,,1,6028,BAO_0000218,1,CHEMBL623053,,
10513,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability evaluated in rat,50597,,,1,6078,BAO_0000218,1,CHEMBL623054,,
10514,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in fasted rat,50597,,,1,6168,BAO_0000218,1,CHEMBL623055,,
10515,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in fed rat,50597,,,1,6168,BAO_0000218,1,CHEMBL623056,,
10516,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (mature male) (dose 30 mg/kg),50597,,,1,5160,BAO_0000218,1,CHEMBL623057,,
10517,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,6057,BAO_0000218,1,CHEMBL623058,,
10518,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (dose 10 mg/kg p.o.),50597,,,1,6535,BAO_0000218,1,CHEMBL623059,,
10519,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat after administration of 10 mg/kg po,50597,,,1,6535,BAO_0000218,1,CHEMBL623060,,
10520,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,4194,BAO_0000218,1,CHEMBL623061,,
10521,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,6230,BAO_0000218,1,CHEMBL623062,,
10522,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,6619,BAO_0000218,1,CHEMBL623063,,
10523,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,17607,BAO_0000218,1,CHEMBL623064,,
10524,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in ratrs,50597,,,1,4942,BAO_0000218,1,CHEMBL623065,,
10525,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,4942,BAO_0000218,1,CHEMBL623066,,
10526,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,6646,BAO_0000218,1,CHEMBL623067,,
10527,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rats was determined; High,50597,,,1,5237,BAO_0000218,1,CHEMBL623068,,
10528,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,6646,BAO_0000218,1,CHEMBL623069,,
10529,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,4449,BAO_0000218,1,CHEMBL623070,,
10530,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability was calculated in rat,50597,,,1,6057,BAO_0000218,1,CHEMBL623071,,
10531,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability,50597,,,1,2552,BAO_0000218,1,CHEMBL623072,,
10532,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability,50597,,,1,5496,BAO_0000218,1,CHEMBL623073,,
10533,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability,50597,,,1,6484,BAO_0000218,1,CHEMBL623074,,
10534,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability,50597,,,1,6485,BAO_0000218,1,CHEMBL623075,,
10535,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability after i.v. administration,50597,,,1,6616,BAO_0000218,1,CHEMBL623076,,
10536,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,,,1,4969,BAO_0000218,1,CHEMBL623077,,
10537,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (Sprague-Dawley),50597,,,1,5862,BAO_0000218,1,CHEMBL623078,,
10538,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in Sprague-Dawley rats,50597,,,1,4514,BAO_0000218,1,CHEMBL623079,,
10539,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,,,1,4514,BAO_0000218,1,CHEMBL623080,,
10540,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),50597,,,1,4514,BAO_0000218,1,CHEMBL623081,,
10541,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,50597,,,1,5546,BAO_0000218,1,CHEMBL623082,,
10542,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in fasted rat,50597,,,1,6168,BAO_0000218,1,CHEMBL874400,,
10543,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in fed rat,50597,,,1,6168,BAO_0000218,1,CHEMBL623083,,
10544,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,3624,BAO_0000218,1,CHEMBL623084,,
10545,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,5213,BAO_0000218,1,CHEMBL623085,,
10546,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,5496,BAO_0000218,1,CHEMBL623086,,
10547,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,5553,BAO_0000218,1,CHEMBL623087,,
10548,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,5833,BAO_0000218,1,CHEMBL623088,,
10549,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,5836,BAO_0000218,1,CHEMBL623089,,
10550,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,5865,BAO_0000218,1,CHEMBL623090,,
10551,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,5960,BAO_0000218,1,CHEMBL623091,,
10552,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,6249,BAO_0000218,1,CHEMBL623092,,
10553,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,6448,BAO_0000218,1,CHEMBL623093,,
10554,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,6453,BAO_0000218,1,CHEMBL874401,,
10555,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,6640,BAO_0000218,1,CHEMBL623094,,
10556,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,17607,BAO_0000218,1,CHEMBL623095,,
10557,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat after peroral administration at 10 mg/kg,50597,,,1,5939,BAO_0000218,1,CHEMBL623096,,
10558,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat after peroral administration at 5 mg/kg,50597,,,1,5939,BAO_0000218,1,CHEMBL624913,,
10559,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),50597,,,1,6281,BAO_0000218,1,CHEMBL624914,,
10560,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,50597,,,1,5874,BAO_0000218,1,CHEMBL624915,,
10561,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat; Not measured,50597,,,1,5213,BAO_0000218,1,CHEMBL624916,,
10562,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,4964,BAO_0000218,1,CHEMBL624917,,
10563,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,50597,,,1,11020,BAO_0000218,1,CHEMBL625157,,
10564,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,In vitro metabolic potential in rat liver microsomes,50597,,,1,6251,BAO_0000218,1,CHEMBL625158,,2107.0
10565,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",50597,,,1,1568,BAO_0000218,1,CHEMBL625159,,
10566,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",50597,,,1,3032,BAO_0000218,1,CHEMBL625160,,
10567,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,50597,,,1,3748,BAO_0000218,1,CHEMBL625161,,
10568,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,401,BAO_0000218,1,CHEMBL625162,,
10569,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,6512,BAO_0000218,1,CHEMBL625163,,
10570,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rats at 10 mg/kg,50597,,,1,17617,BAO_0000218,1,CHEMBL625164,,
10571,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,50597,,,1,6679,BAO_0000218,1,CHEMBL625165,,
10572,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,6742,BAO_0000218,1,CHEMBL625166,,
10573,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,50597,,,1,589,BAO_0000218,1,CHEMBL625167,,
10574,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,50597,,,1,589,BAO_0000218,1,CHEMBL625168,,
10575,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance of the compound,50597,,,1,3185,BAO_0000218,1,CHEMBL625169,,
10576,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance at 10 mg/kg in rat upon intravenous administration,50597,,,1,17596,BAO_0000218,1,CHEMBL626264,,
10577,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,50597,,,1,2713,BAO_0000218,1,CHEMBL626265,,
10578,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,The compound was tested for plasma clearance in rat,50597,,,1,12500,BAO_0000218,1,CHEMBL626266,,1969.0
10579,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,50597,,,1,12500,BAO_0000218,1,CHEMBL626267,,1969.0
10580,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration upon oral administration of 1 mg/Kg in rats,50597,,,1,2713,BAO_0000218,1,CHEMBL626268,,
10581,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,50597,,,1,1446,BAO_0000218,1,CHEMBL626269,,
10582,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,50597,,,1,6227,BAO_0000218,1,CHEMBL626270,,
10583,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,50597,,,1,4709,BAO_0000218,1,CHEMBL626271,,
10584,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",50597,,,1,5510,BAO_0000218,1,CHEMBL626272,,
10585,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",50597,,,1,5510,BAO_0000218,1,CHEMBL626273,,
10586,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",50597,,,1,5510,BAO_0000218,1,CHEMBL875346,,
10587,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",50597,,,1,5510,BAO_0000218,1,CHEMBL626274,,
10588,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was tested for protein binding in rat plasma,50597,,,1,4514,BAO_0000218,1,CHEMBL626275,,
10589,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,50597,,,1,2713,BAO_0000218,1,CHEMBL624646,,
10590,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,50597,,,1,2713,BAO_0000218,1,CHEMBL624647,,
10591,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,50597,,,1,5340,BAO_0000218,1,CHEMBL624648,,2107.0
10592,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve ratio was determined (po/iv) in rat,50597,,,1,12058,BAO_0000218,1,CHEMBL624649,,
10593,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL624650,,
10594,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL624651,,
10595,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL624652,,
10596,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,50597,,,1,6495,BAO_0000218,1,CHEMBL624653,,
10597,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Ratio of AUCbrain to AUCplasma,50597,,,1,6078,BAO_0000218,1,CHEMBL624654,,
10598,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Ratio of brain to plasma,50597,,,1,5656,BAO_0000218,1,CHEMBL624655,,
10599,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,50597,,,1,4910,BAO_0000218,1,CHEMBL624656,,
10600,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,50597,,,1,4910,BAO_0000218,1,CHEMBL624657,,
10601,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,50597,,,1,4910,BAO_0000218,1,CHEMBL624658,,
10602,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,50597,,,1,10130,BAO_0000218,1,CHEMBL624659,,
10603,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,50597,,,1,10130,BAO_0000218,1,CHEMBL624660,,
10604,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,50597,,,1,10130,BAO_0000218,1,CHEMBL624661,,
10605,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Steady state brain :blood ratio was determined,50597,,,1,5213,BAO_0000218,1,CHEMBL624662,,
10606,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,50597,,,1,4910,BAO_0000218,1,CHEMBL625199,,
10607,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,50597,,,1,4910,BAO_0000218,1,CHEMBL625200,,
10608,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,50597,,,1,4910,BAO_0000218,1,CHEMBL625201,,
10609,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,50597,,,1,4910,BAO_0000218,1,CHEMBL625202,,
10610,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Percentage recovery after 3h incubation with rat hapatocytes was determined,50597,,,1,2083,BAO_0000218,1,CHEMBL625203,,
10611,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,50597,,,1,2082,BAO_0000218,1,CHEMBL625204,,
10612,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,50597,,,1,2082,BAO_0000218,1,CHEMBL625205,,
10613,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,50597,,,1,6351,BAO_0000218,1,CHEMBL625206,,
10614,,,,A,U,Autocuration,,,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",22224,,,1,14583,BAO_0000019,0,CHEMBL625207,,
10615,,,,A,U,Autocuration,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,22224,,,1,14583,BAO_0000019,0,CHEMBL625208,,
10616,,Homo sapiens,,A,N,Intermediate,,9606.0,In vivo absorption in Caco-2 cell line monolayers was determined,50587,,,1,4608,BAO_0000218,1,CHEMBL625209,495.0,
10617,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,13668,BAO_0000100,0,CHEMBL625210,,
10618,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determine after peroral administration at 10 mpk in Rat,50597,,,1,5669,BAO_0000218,1,CHEMBL625211,,
10619,,Macaca mulatta,,A,N,Intermediate,,9544.0,Area under curve was determine after peroral administration at 10 mpk in Rhesus,50797,,,1,5669,BAO_0000218,1,CHEMBL625212,,
10620,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determine after peroral administration at 160 mpk in Rat,50597,,,1,5669,BAO_0000218,1,CHEMBL625213,,
10621,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determine after peroral administration at 20 mpk in Rat,50597,,,1,5669,BAO_0000218,1,CHEMBL625214,,
10622,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve was determine after peroral administration at 50 mpk in Rat,50597,,,1,5669,BAO_0000218,1,CHEMBL874542,,
10623,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP) (AlogP),22229,,,1,6472,BAO_0000100,0,CHEMBL625215,,
10624,,,,A,U,Autocuration,,,Activated partial thromboplastin time measured,22224,,,1,15106,BAO_0000019,0,CHEMBL625216,,
10625,,,,P,U,Autocuration,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),22224,,,1,15207,BAO_0000100,0,CHEMBL625217,,
10626,,,,P,U,Autocuration,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),22224,,,1,15207,BAO_0000100,0,CHEMBL625218,,
10627,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,50588,,,1,13941,BAO_0000218,1,CHEMBL622864,,1969.0
10628,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,50597,,,1,13941,BAO_0000218,1,CHEMBL622865,,1969.0
10629,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,50597,,,1,13941,BAO_0000218,1,CHEMBL622866,,1969.0
10630,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,50588,,,1,13941,BAO_0000218,1,CHEMBL622867,,1969.0
10631,,Cavia porcellus,,A,N,Intermediate,Plasma,10141.0,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,50512,,,1,15240,BAO_0000218,1,CHEMBL876808,,1969.0
10632,,,,A,U,Autocuration,Brain,,AUC in brain,22224,,,1,10655,BAO_0000019,0,CHEMBL627725,,955.0
10633,,,,A,U,Autocuration,Serum,,AUC in serum,22224,,,1,10655,BAO_0000019,0,CHEMBL627726,,1977.0
10634,,,,A,U,Autocuration,Plasma,,AUC was determined,22224,,,1,6504,BAO_0000019,0,CHEMBL627727,,1969.0
10635,,,,A,U,Autocuration,Plasma,,AUC of the compound.,22224,,,1,10615,BAO_0000019,0,CHEMBL627728,,1969.0
10636,,,,A,U,Autocuration,Plasma,,AUC value (0-4 hr),22224,,,1,10353,BAO_0000019,0,CHEMBL627729,,1969.0
10637,,,,A,U,Autocuration,Plasma,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",22224,,,1,14907,BAO_0000019,0,CHEMBL627730,,1969.0
10638,,,,A,U,Autocuration,Plasma,,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,22224,,,1,14907,BAO_0000019,0,CHEMBL627731,,1969.0
10639,,,,A,U,Autocuration,Plasma,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",22224,,,1,14907,BAO_0000019,0,CHEMBL627732,,1969.0
10640,,,,A,U,Autocuration,Plasma,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",22224,,,1,14907,BAO_0000019,0,CHEMBL627733,,1969.0
10641,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC(area under curve) was determined after intravenous administration in rats,50597,,,1,16359,BAO_0000218,1,CHEMBL627734,,1969.0
10642,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC(area under curve) was determined after oral administration in rats,50597,,,1,16359,BAO_0000218,1,CHEMBL627735,,1969.0
10643,,Cavia porcellus,,A,N,Intermediate,Plasma,10141.0,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,50512,,,1,15240,BAO_0000218,1,CHEMBL627736,,1969.0
10644,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,50597,,,1,15240,BAO_0000218,1,CHEMBL876809,,1969.0
10645,,,,A,U,Autocuration,,,Area Under Curve after oral dosing of 100 uM/Kg,22224,,,1,15469,BAO_0000019,0,CHEMBL627737,,
10646,,,,A,U,Autocuration,,,Area Under Curve after oral dosing of 30 uM/Kg,22224,,,1,15469,BAO_0000019,0,CHEMBL627738,,
10647,,,,A,U,Autocuration,,,Area Under Curve was measured by ploting the graph between concentration verses time,22224,,,1,13520,BAO_0000019,0,CHEMBL627739,,
10648,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,50588,,,1,17025,BAO_0000218,1,CHEMBL626143,,
10649,,Simiiformes,,A,U,Autocuration,,314293.0,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,22224,,,1,17025,BAO_0000218,0,CHEMBL626144,,
10650,,Oryctolagus cuniculus,,A,N,Intermediate,,9986.0,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,50592,,,1,17025,BAO_0000218,1,CHEMBL626145,,
10651,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,50597,,,1,17025,BAO_0000218,1,CHEMBL626146,,
10652,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,50597,,,1,12032,BAO_0000218,1,CHEMBL626147,,178.0
10653,,,,A,U,Autocuration,,,Area under curve (AUC) was determined,22224,,,1,10291,BAO_0000019,0,CHEMBL626148,,
10654,,,,A,U,Autocuration,,,Area under curve (AUC) following ip administration at 1 mg/kg,22224,,,1,5767,BAO_0000218,0,CHEMBL626149,,
10655,,,,A,U,Autocuration,,,Area under curve (AUC) was determined; ND is Not determined,22224,,,1,1434,BAO_0000019,0,CHEMBL626150,,
10656,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,50588,,,1,14925,BAO_0000218,1,CHEMBL626151,,
10657,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,50588,,,1,14925,BAO_0000218,1,CHEMBL626152,,
10658,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,50588,,,1,14925,BAO_0000218,1,CHEMBL626153,,
10659,,,,A,U,Autocuration,,,Area under curve (AUR) was determined,22224,,,1,1434,BAO_0000019,0,CHEMBL626154,,
10660,,,,A,U,Autocuration,,,Area under curve at 1 uM/dg administered intravenously,22224,,,1,11883,BAO_0000019,0,CHEMBL626155,,
10661,,,,A,U,Autocuration,,,Area under curve at 10 uM/dg administered perorally,22224,,,1,11883,BAO_0000019,0,CHEMBL626156,,
10662,,,,A,U,Autocuration,,,Area under curve at 2 uM/dg administered intravenously,22224,,,1,11883,BAO_0000019,0,CHEMBL626157,,
10663,,,,A,U,Autocuration,,,Area under curve at 20 uM/dg administered perorally,22224,,,1,11883,BAO_0000019,0,CHEMBL626158,,
10664,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve at a peroral dose of 3 mg/kg in dog,50588,,,1,15233,BAO_0000218,1,CHEMBL626159,,
10665,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve at a peroral dose of 3 mg/kg in rat,50597,,,1,15233,BAO_0000218,1,CHEMBL626160,,
10666,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve at an iv dose of 1 mg/kg in dog,50588,,,1,15233,BAO_0000218,1,CHEMBL626161,,
10667,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under curve at an iv dose of 1 mg/kg in rat,50597,,,1,15233,BAO_0000218,1,CHEMBL626162,,
10668,,,,A,U,Autocuration,,,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,22224,,,1,12978,BAO_0000019,0,CHEMBL626163,,
10669,,,,A,U,Autocuration,,,Area under curve gives the effective duration for the angiotensin II antagonist effect.,22224,,,1,12978,BAO_0000019,0,CHEMBL626164,,
10670,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve measured as conc vs time after intravenous administration to mice.,50594,,,1,11355,BAO_0000218,1,CHEMBL626165,,
10671,,Mus musculus,,A,N,Intermediate,,10090.0,Area under curve measured as conc vs time after peroral administration to mice.,50594,,,1,11355,BAO_0000218,1,CHEMBL626166,,
10672,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,50588,,,1,12923,BAO_0000218,1,CHEMBL626167,,
10673,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,50588,,,1,12923,BAO_0000218,1,CHEMBL626168,,
10674,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,50588,,,1,12923,BAO_0000218,1,CHEMBL877463,,
10675,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,50588,,,1,12923,BAO_0000218,1,CHEMBL626169,,
10676,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL626170,,948.0
10677,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL626171,,948.0
10678,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL626172,,948.0
10679,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL626173,,948.0
10680,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL626174,,2113.0
10681,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL626175,,2113.0
10682,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL626176,,2113.0
10683,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL626177,,2113.0
10684,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL622499,,2113.0
10685,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL622500,,2107.0
10686,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL622501,,2107.0
10687,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL622502,,2107.0
10688,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL622503,,2107.0
10689,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL877614,,2107.0
10690,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL624839,,2048.0
10691,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL624840,,2048.0
10692,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL624841,,2048.0
10693,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL624842,,2048.0
10694,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL624843,,2385.0
10695,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL624844,,2385.0
10696,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL624845,,2385.0
10697,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,50597,,,1,17738,BAO_0000218,1,CHEMBL621904,,2385.0
10698,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL621905,,178.0
10699,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL874382,,178.0
10700,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL621906,,178.0
10701,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL621907,,955.0
10702,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL622096,,955.0
10703,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL622097,,955.0
10704,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL622098,,948.0
10705,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL622099,,948.0
10706,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL622100,,948.0
10707,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL622101,,2113.0
10708,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL622102,,2113.0
10709,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL622103,,2113.0
10710,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL622104,,2107.0
10711,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL622105,,2107.0
10712,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL622106,,2107.0
10713,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL622107,,2048.0
10714,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL622108,,2048.0
10715,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL622109,,2048.0
10716,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL622110,,2385.0
10717,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL622111,,2385.0
10718,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL874383,,2385.0
10719,In vivo,Rattus norvegicus,,A,N,Intermediate,Zone of skin,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL622112,,14.0
10720,In vivo,Rattus norvegicus,,A,N,Intermediate,Zone of skin,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL622113,,14.0
10721,In vivo,Rattus norvegicus,,A,N,Intermediate,Zone of skin,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL622114,,14.0
10722,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL622115,,2106.0
10723,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,50597,,,1,11195,BAO_0000218,1,CHEMBL622116,,2106.0
10724,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,6193,BAO_0000218,1,CHEMBL622117,,
10725,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,6803,BAO_0000218,1,CHEMBL622118,,
10726,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rats at 6 mg/kg,50597,,,1,6647,BAO_0000218,1,CHEMBL622119,,
10727,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (dose 6 mg/kg),50597,,,1,6647,BAO_0000218,1,CHEMBL622120,,
10728,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rats at 6 mg/kg dose; Not tested,50597,,,1,6647,BAO_0000218,1,CHEMBL622121,,
10729,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,6640,BAO_0000218,1,CHEMBL622122,,
10730,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,6641,BAO_0000218,1,CHEMBL622123,,
10731,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,6641,BAO_0000218,1,CHEMBL622124,,
10732,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat,50597,,,1,6642,BAO_0000218,1,CHEMBL622125,,
10733,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability,50597,,,1,5472,BAO_0000218,1,CHEMBL622126,,
10734,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),50597,,,1,6141,BAO_0000218,1,CHEMBL620455,,
10735,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,4390,BAO_0000218,1,CHEMBL620456,,
10736,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,5472,BAO_0000218,1,CHEMBL620457,,
10737,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability was evaluated; Not tested,50597,,,1,5472,BAO_0000218,1,CHEMBL620458,,
10738,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability,50597,,,1,5438,BAO_0000218,1,CHEMBL620459,,
10739,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat by oral dosing,50597,,,1,4883,BAO_0000218,1,CHEMBL620460,,
10740,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (dose 10 mg/kg p.o.),50597,,,1,1908,BAO_0000218,1,CHEMBL620461,,
10741,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (Sprague-Dawley),50597,,,1,4853,BAO_0000218,1,CHEMBL620462,,
10742,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,,,1,4853,BAO_0000218,1,CHEMBL620463,,
10743,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),50597,,,1,4853,BAO_0000218,1,CHEMBL620464,,
10744,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),50597,,,1,4853,BAO_0000218,1,CHEMBL620465,,
10745,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),50597,,,1,4853,BAO_0000218,1,CHEMBL620466,,
10746,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,50597,,,1,4853,BAO_0000218,1,CHEMBL620467,,
10747,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,50597,,,1,4853,BAO_0000218,1,CHEMBL620468,,
10748,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,50597,,,1,12873,BAO_0000218,1,CHEMBL620469,,
10749,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,50597,,,1,12873,BAO_0000218,1,CHEMBL620470,,
10750,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,3169,BAO_0000218,1,CHEMBL620471,,
10751,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,6305,BAO_0000218,1,CHEMBL620472,,
10752,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,50597,,,1,4762,BAO_0000218,1,CHEMBL620473,,
10753,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,17847,BAO_0000218,1,CHEMBL620474,,
10754,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),50597,,,1,6211,BAO_0000218,1,CHEMBL620475,,
10755,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,6011,BAO_0000218,1,CHEMBL620476,,
10756,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,6317,BAO_0000218,1,CHEMBL620477,,
10757,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,50597,,,1,6644,BAO_0000218,1,CHEMBL620478,,
10758,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,50597,,,1,6644,BAO_0000218,1,CHEMBL618768,,
10759,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat after oral administration at 13 mg/kg dose,50597,,,1,6644,BAO_0000218,1,CHEMBL618769,,
10760,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,50597,,,1,6644,BAO_0000218,1,CHEMBL618770,,
10761,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability (dose 20 mg/kg p.o.),50597,,,1,6113,BAO_0000218,1,CHEMBL618771,,
10762,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,50597,,,1,5937,BAO_0000218,1,CHEMBL618772,,
10763,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat at 10 mg/kg of the compound,50597,,,1,5711,BAO_0000218,1,CHEMBL618773,,
10764,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,50597,,,1,17717,BAO_0000218,1,CHEMBL875842,,
10765,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (dose 3 mg/kg i.v.),50597,,,1,17717,BAO_0000218,1,CHEMBL618774,,
10766,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,50597,,,1,17717,BAO_0000218,1,CHEMBL618775,,
10767,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (dose 60 mg/kg p.o.),50597,,,1,17717,BAO_0000218,1,CHEMBL618776,,
10768,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Percent bioavailability (F) in rats after iv administration,50597,,,1,4722,BAO_0000218,1,CHEMBL618777,,
10769,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,50597,,,1,4722,BAO_0000218,1,CHEMBL618778,,
10770,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (dose 5 uM/kg p.o.),50597,,,1,4353,BAO_0000218,1,CHEMBL618779,,
10771,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability,50597,,,1,15662,BAO_0000218,1,CHEMBL618780,,
10772,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat (dose 2 mg/kg p.o.),50597,,,1,4756,BAO_0000218,1,CHEMBL618781,,
10773,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,50597,,,1,4756,BAO_0000218,1,CHEMBL618782,,
10774,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (dose 20 mg/kg),50597,,,1,3436,BAO_0000218,1,CHEMBL618783,,
10775,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,17800,BAO_0000218,1,CHEMBL618784,,
10776,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Percent oral bioavailability evaluated in rat,50597,,,1,15762,BAO_0000218,1,CHEMBL618785,,
10777,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,5089,BAO_0000218,1,CHEMBL618786,,
10778,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Percent oral bioavailability in rat; Not determined,50597,,,1,5089,BAO_0000218,1,CHEMBL618787,,
10779,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat,50597,,,1,3185,BAO_0000218,1,CHEMBL618788,,
10780,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability in rat,50597,,,1,5145,BAO_0000218,1,CHEMBL618789,,
10781,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),50597,,,1,3457,BAO_0000218,1,CHEMBL618790,,
10782,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),50597,,,1,3457,BAO_0000218,1,CHEMBL618791,,
10783,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,50597,,,1,5983,BAO_0000218,1,CHEMBL875843,,
10784,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat (dose 20 mg/kg p.o.),50597,,,1,5739,BAO_0000218,1,CHEMBL618792,,
10785,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax at a dose of 30 mg/kg in rat,50597,,,1,3579,BAO_0000218,1,CHEMBL623395,,
10786,In vivo,Simiiformes,,A,U,Autocuration,,314293.0,Cmax in monkeys at a dose of 1 mg/kg,22224,,,1,17788,BAO_0000218,0,CHEMBL623396,,
10787,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax in rat,50597,,,1,14956,BAO_0000218,1,CHEMBL623397,,
10788,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax in rats at a dose of 1 mg/kg,50597,,,1,17788,BAO_0000218,1,CHEMBL623398,,
10789,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Cmax was measured in mice after an oral dose of 50 mg/kg.,50594,,,1,9750,BAO_0000218,1,CHEMBL623399,,
10790,In vivo,,,A,U,Autocuration,,,"Cmax value at a dose of 12.7 uM/kg, po",22224,,,1,12767,BAO_0000218,0,CHEMBL623400,,
10791,In vivo,,,A,U,Autocuration,,,"Cmax value at a dose of 6.3 uM/kg, iv",22224,,,1,12767,BAO_0000218,0,CHEMBL623401,,
10792,In vivo,,,A,U,Autocuration,,,"Cmax value at a dose of 7.1 uM/kg, iv",22224,,,1,12767,BAO_0000218,0,CHEMBL623402,,
10793,In vivo,,,A,U,Autocuration,,,Cmax value of compound was determined after 1 hr,22224,,,1,12703,BAO_0000218,0,CHEMBL623403,,
10794,In vivo,,,A,U,Autocuration,,,Cmax value of the compound,22224,,,1,15778,BAO_0000218,0,CHEMBL623404,,
10795,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax value administered intraintestinal in rats.,50597,,,1,12818,BAO_0000218,1,CHEMBL625997,,
10796,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax value administered perorally was determined in rat; Not determined,50597,,,1,14964,BAO_0000218,1,CHEMBL625998,,
10797,In vivo,,,A,U,Autocuration,,,Cmax value at the dose of 2.3 mg/kg,22224,,,1,15808,BAO_0000218,0,CHEMBL625999,,
10798,In vivo,,,A,U,Autocuration,,,Cmax value at the dose of 5 mg/kg,22224,,,1,15808,BAO_0000218,0,CHEMBL626000,,
10799,In vivo,,,A,U,Autocuration,,,Cmax value in the period of 8 hr after dosing. ,22224,,,1,15778,BAO_0000218,0,CHEMBL626001,,
10800,In vivo,,,A,U,Autocuration,,,Cmax value at a oral dose of 20 mg/kg; Not tested,22224,,,1,3715,BAO_0000218,0,CHEMBL626002,,
10801,In vivo,,,A,U,Autocuration,,,Cmax value at a oral dose of 20 mg/kg,22224,,,1,3715,BAO_0000218,0,CHEMBL626003,,
10802,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,50597,,,1,1446,BAO_0000218,1,CHEMBL626004,,
10803,In vivo,Cavia porcellus,,A,N,Intermediate,,10141.0,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,50512,,,1,15240,BAO_0000218,1,CHEMBL626005,,
10804,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,50597,,,1,15240,BAO_0000218,1,CHEMBL626006,,
10805,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,50597,,,1,14810,BAO_0000218,1,CHEMBL626007,,1969.0
10806,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,50594,,,1,14239,BAO_0000218,1,CHEMBL626008,,1969.0
10807,In vivo,Canis lupus familiaris,,A,N,Intermediate,Liver,9615.0,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,50588,,,1,12555,BAO_0000218,1,CHEMBL626009,,2107.0
10808,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,50588,,,1,10754,BAO_0000218,1,CHEMBL626010,,
10809,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,50594,,,1,10754,BAO_0000218,1,CHEMBL626011,,178.0
10810,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,50594,,,1,10754,BAO_0000218,1,CHEMBL626012,,178.0
10811,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,50594,,,1,10754,BAO_0000218,1,CHEMBL626013,,178.0
10812,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,50594,,,1,10754,BAO_0000218,1,CHEMBL626014,,178.0
10813,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,50594,,,1,10754,BAO_0000218,1,CHEMBL877496,,178.0
10814,In vivo,Canis lupus familiaris,,F,N,Intermediate,,9615.0,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,50588,,,1,14600,BAO_0000218,1,CHEMBL626015,,
10815,In vivo,Canis lupus familiaris,,F,N,Intermediate,,9615.0,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,50588,,,1,14600,BAO_0000218,1,CHEMBL626016,,
10816,In vivo,Canis lupus familiaris,,F,N,Intermediate,,9615.0,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,50588,,,1,14600,BAO_0000218,1,CHEMBL626017,,
10817,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Bioavailability as maximal plasma concentration in dogs,50588,,,1,13543,BAO_0000218,1,CHEMBL626018,,1969.0
10818,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Bioavailability as maximal plasma concentration in dogs,50588,,,1,13543,BAO_0000218,1,CHEMBL626692,,1969.0
10819,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Bioavailability as maximal plasma concentration in rats,50597,,,1,13543,BAO_0000218,1,CHEMBL626693,,1969.0
10820,In vivo,Rattus norvegicus,,A,U,Autocuration,Plasma,10116.0,Bioavailability as maximal plasma concentration in rats,22224,,,1,13543,BAO_0000218,0,CHEMBL626694,,1969.0
10821,In vivo,Canis lupus familiaris,,A,N,Intermediate,Blood,9615.0,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,,,1,14600,BAO_0000218,1,CHEMBL626695,,178.0
10822,In vivo,Canis lupus familiaris,,A,N,Intermediate,Blood,9615.0,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,,,1,14600,BAO_0000218,1,CHEMBL626696,,178.0
10823,In vivo,Canis lupus familiaris,,A,N,Intermediate,Blood,9615.0,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,,,1,14600,BAO_0000218,1,CHEMBL626697,,178.0
10824,In vivo,Canis lupus familiaris,,A,N,Intermediate,Blood,9615.0,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,50588,,,1,14600,BAO_0000218,1,CHEMBL626859,,178.0
10825,In vivo,Canis lupus familiaris,,A,N,Intermediate,Blood,9615.0,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,,,1,14600,BAO_0000218,1,CHEMBL626860,,178.0
10826,In vivo,Canis lupus familiaris,,A,N,Intermediate,Blood,9615.0,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,50588,,,1,14600,BAO_0000218,1,CHEMBL626861,,178.0
10827,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,50597,,,1,14681,BAO_0000218,1,CHEMBL626296,,
10828,In vivo,,,A,U,Autocuration,,,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,22224,,,1,15905,BAO_0000218,0,CHEMBL626297,,
10829,In vivo,,,A,U,Autocuration,Plasma,,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,22224,,,1,15905,BAO_0000218,0,CHEMBL626298,,1969.0
10830,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",50597,,,1,13304,BAO_0000218,1,CHEMBL626299,,1969.0
10831,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,50597,,,1,15137,BAO_0000218,1,CHEMBL626300,,1969.0
10832,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,50597,,,1,15137,BAO_0000218,1,CHEMBL626301,,1969.0
10833,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,50597,,,1,15137,BAO_0000218,1,CHEMBL626962,,1969.0
10834,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,50597,,,1,15137,BAO_0000218,1,CHEMBL626963,,1969.0
10835,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,50597,,,1,15137,BAO_0000218,1,CHEMBL626964,,1969.0
10836,In vivo,Macaca fascicularis,,A,N,Intermediate,Plasma,9541.0,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,100710,,,1,14839,BAO_0000218,1,CHEMBL626965,,1969.0
10837,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,,,1,14839,BAO_0000218,1,CHEMBL626966,,1969.0
10838,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,,,1,14839,BAO_0000218,1,CHEMBL626967,,1969.0
10839,In vivo,Macaca fascicularis,,A,N,Intermediate,Plasma,9541.0,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,100710,,,1,14839,BAO_0000218,1,CHEMBL626968,,1969.0
10840,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,50597,,,1,8418,BAO_0000218,1,CHEMBL626969,,948.0
10841,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,50597,,,1,8418,BAO_0000218,1,CHEMBL627126,,948.0
10842,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,50597,,,1,8418,BAO_0000218,1,CHEMBL631276,,948.0
10843,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,50597,,,1,8418,BAO_0000218,1,CHEMBL631277,,948.0
10844,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,50597,,,1,8418,BAO_0000218,1,CHEMBL631278,,948.0
10845,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,50597,,,1,8418,BAO_0000218,1,CHEMBL874457,,948.0
10846,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,50597,,,1,8418,BAO_0000218,1,CHEMBL631279,,948.0
10847,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,50597,,,1,8418,BAO_0000218,1,CHEMBL631280,,948.0
10848,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,50597,,,1,8418,BAO_0000218,1,CHEMBL631281,,948.0
10849,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,50597,,,1,8418,BAO_0000218,1,CHEMBL631968,,948.0
10850,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,50597,,,1,8418,BAO_0000218,1,CHEMBL631969,,948.0
10851,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,50597,,,1,8418,BAO_0000218,1,CHEMBL631970,,948.0
10852,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,50597,,,1,8418,BAO_0000218,1,CHEMBL631971,,948.0
10853,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,50597,,,1,8418,BAO_0000218,1,CHEMBL631972,,948.0
10854,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,50597,,,1,8418,BAO_0000218,1,CHEMBL630435,,948.0
10855,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,50597,,,1,8418,BAO_0000218,1,CHEMBL630436,,948.0
10856,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,50597,,,1,8418,BAO_0000218,1,CHEMBL630437,,948.0
10857,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,50597,,,1,8418,BAO_0000218,1,CHEMBL630438,,948.0
10858,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,50597,,,1,8418,BAO_0000218,1,CHEMBL630439,,948.0
10859,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,50597,,,1,8418,BAO_0000218,1,CHEMBL630440,,2113.0
10860,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,50597,,,1,8418,BAO_0000218,1,CHEMBL630441,,2113.0
10861,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,50597,,,1,8418,BAO_0000218,1,CHEMBL630442,,2113.0
10862,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,50597,,,1,8418,BAO_0000218,1,CHEMBL625234,,2113.0
10863,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,50597,,,1,8418,BAO_0000218,1,CHEMBL625235,,2113.0
10864,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,50597,,,1,8418,BAO_0000218,1,CHEMBL625236,,2113.0
10865,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,50597,,,1,8418,BAO_0000218,1,CHEMBL625237,,2113.0
10866,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,50597,,,1,8418,BAO_0000218,1,CHEMBL626125,,2113.0
10867,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,50597,,,1,8418,BAO_0000218,1,CHEMBL626126,,2113.0
10868,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,50597,,,1,8418,BAO_0000218,1,CHEMBL626127,,2113.0
10869,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,50597,,,1,8418,BAO_0000218,1,CHEMBL626128,,2113.0
10870,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,50597,,,1,8418,BAO_0000218,1,CHEMBL626129,,2113.0
10871,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,50597,,,1,8418,BAO_0000218,1,CHEMBL626130,,2113.0
10872,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,50597,,,1,8418,BAO_0000218,1,CHEMBL626131,,2113.0
10873,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,50597,,,1,8418,BAO_0000218,1,CHEMBL626132,,2113.0
10874,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,50597,,,1,8418,BAO_0000218,1,CHEMBL626752,,2113.0
10875,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,50597,,,1,8418,BAO_0000218,1,CHEMBL626753,,2113.0
10876,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,50597,,,1,8418,BAO_0000218,1,CHEMBL626754,,2113.0
10877,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,50597,,,1,8418,BAO_0000218,1,CHEMBL626755,,2113.0
10878,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,50597,,,1,8418,BAO_0000218,1,CHEMBL626756,,2107.0
10879,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,50597,,,1,8418,BAO_0000218,1,CHEMBL626757,,2107.0
10880,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,50597,,,1,8418,BAO_0000218,1,CHEMBL626758,,2107.0
10881,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,50597,,,1,8418,BAO_0000218,1,CHEMBL626759,,2107.0
10882,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,50597,,,1,8418,BAO_0000218,1,CHEMBL626760,,2107.0
10883,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL626394,,
10884,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,50588,,,1,6996,BAO_0000218,1,CHEMBL626395,,
10885,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL626396,,
10886,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL626397,,
10887,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),50588,,,1,6996,BAO_0000218,1,CHEMBL626398,,
10888,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL626399,,
10889,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,50597,,,1,6996,BAO_0000218,1,CHEMBL874653,,
10890,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL626400,,
10891,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL626401,,
10892,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL626402,,
10893,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),50597,,,1,6996,BAO_0000218,1,CHEMBL626403,,
10894,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL626404,,
10895,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,50597,,,1,6996,BAO_0000218,1,CHEMBL626405,,
10896,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL625529,,
10897,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL625530,,
10898,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL625531,,
10899,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),50597,,,1,6996,BAO_0000218,1,CHEMBL625532,,
10900,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL625533,,
10901,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,50597,,,1,6996,BAO_0000218,1,CHEMBL875474,,
10902,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL625534,,
10903,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL625535,,
10904,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL625536,,
10905,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),50597,,,1,6996,BAO_0000218,1,CHEMBL625537,,
10906,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL625538,,
10907,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,50597,,,1,6996,BAO_0000218,1,CHEMBL625539,,
10908,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL625540,,
10909,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL625541,,
10910,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL625542,,
10911,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),50597,,,1,6996,BAO_0000218,1,CHEMBL625543,,
10912,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL625544,,
10913,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,50588,,,1,6996,BAO_0000218,1,CHEMBL625545,,
10914,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL625546,,
10915,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,50588,,,1,6996,BAO_0000218,1,CHEMBL625547,,
10916,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL625548,,
10917,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL625549,,
10918,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL625550,,
10919,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL625551,,
10920,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL875475,,
10921,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL625552,,
10922,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL625553,,
10923,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL625554,,
10924,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),50588,,,1,6996,BAO_0000218,1,CHEMBL625555,,
10925,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL625556,,
10926,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,50588,,,1,6996,BAO_0000218,1,CHEMBL624986,,
10927,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL624987,,
10928,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL624988,,
10929,In vivo,Canis lupus familiaris,,A,N,Intermediate,Artery,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,50588,,,1,9025,BAO_0000218,1,CHEMBL624989,,1637.0
10930,In vivo,Canis lupus familiaris,,A,N,Intermediate,Artery,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,50588,,,1,9025,BAO_0000218,1,CHEMBL624990,,1637.0
10931,In vivo,Canis lupus familiaris,,A,N,Intermediate,Artery,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,50588,,,1,9025,BAO_0000218,1,CHEMBL874391,,1637.0
10932,In vivo,Canis lupus familiaris,,A,N,Intermediate,Artery,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,50588,,,1,9025,BAO_0000218,1,CHEMBL624991,,1637.0
10933,In vivo,Canis lupus familiaris,,A,N,Intermediate,Artery,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,50588,,,1,9025,BAO_0000218,1,CHEMBL624992,,1637.0
10934,In vivo,Canis lupus familiaris,,A,N,Intermediate,Artery,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,50588,,,1,9025,BAO_0000218,1,CHEMBL624993,,1637.0
10935,In vivo,Canis lupus familiaris,,A,N,Intermediate,Artery,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,50588,,,1,9025,BAO_0000218,1,CHEMBL624994,,1637.0
10936,In vivo,Canis lupus familiaris,,A,N,Intermediate,Artery,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,50588,,,1,9025,BAO_0000218,1,CHEMBL624995,,1637.0
10937,In vivo,Canis lupus familiaris,,A,N,Intermediate,Artery,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,50588,,,1,9025,BAO_0000218,1,CHEMBL624996,,1637.0
10938,In vivo,Canis lupus familiaris,,A,N,Intermediate,Artery,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,50588,,,1,9025,BAO_0000218,1,CHEMBL624997,,1637.0
10939,In vivo,Canis lupus familiaris,,A,N,Intermediate,Artery,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,50588,,,1,9025,BAO_0000218,1,CHEMBL624998,,1637.0
10940,In vivo,Canis lupus familiaris,,A,N,Intermediate,Artery,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,50588,,,1,9025,BAO_0000218,1,CHEMBL624999,,1637.0
10941,In vivo,Canis lupus familiaris,,A,N,Intermediate,Artery,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,50588,,,1,9025,BAO_0000218,1,CHEMBL882955,,1637.0
10942,In vivo,Canis lupus familiaris,,A,N,Intermediate,Artery,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,50588,,,1,9025,BAO_0000218,1,CHEMBL625000,,1637.0
10943,In vivo,Canis lupus familiaris,,A,N,Intermediate,Artery,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,50588,,,1,9025,BAO_0000218,1,CHEMBL625001,,1637.0
10944,In vivo,Canis lupus familiaris,,A,N,Intermediate,Artery,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,50588,,,1,9025,BAO_0000218,1,CHEMBL625089,,1637.0
10945,In vivo,Canis lupus familiaris,,A,N,Intermediate,Artery,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,50588,,,1,9025,BAO_0000218,1,CHEMBL625090,,1637.0
10946,In vivo,Canis lupus familiaris,,A,N,Intermediate,Artery,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,50588,,,1,9025,BAO_0000218,1,CHEMBL625091,,1637.0
10947,In vivo,Canis lupus familiaris,,A,N,Intermediate,Artery,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,50588,,,1,9025,BAO_0000218,1,CHEMBL625092,,1637.0
10948,In vivo,Canis lupus familiaris,,A,N,Intermediate,Artery,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,50588,,,1,9025,BAO_0000218,1,CHEMBL625093,,1637.0
10949,In vivo,Canis lupus familiaris,,A,N,Intermediate,Artery,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,50588,,,1,9025,BAO_0000218,1,CHEMBL625094,,1637.0
10950,In vivo,Canis lupus familiaris,,A,N,Intermediate,Artery,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,50588,,,1,9025,BAO_0000218,1,CHEMBL625095,,1637.0
10951,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for its bioavailability in the dogs,50588,,,1,2249,BAO_0000218,1,CHEMBL625096,,
10952,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for its bioavailability in the rats,50597,,,1,2249,BAO_0000218,1,CHEMBL625097,,
10953,In vivo,,,A,U,Autocuration,,,Compound was evaluated for oral bioavailability,22224,,,1,17515,BAO_0000218,0,CHEMBL882956,,
10954,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for percentage of Oral bioavailability in rats,50597,,,1,14541,BAO_0000218,1,CHEMBL625098,,
10955,In vivo,Cavia porcellus,,A,U,Autocuration,,10141.0,Bioavailability in guinea pig,22224,,,1,12797,BAO_0000218,0,CHEMBL625099,,
10956,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for the oral bioavailability in rat,50597,,,1,12797,BAO_0000218,1,CHEMBL625100,,
10957,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for the oral bioavailability in dog,50588,,,1,12797,BAO_0000218,1,CHEMBL625101,,
10958,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for the oral bioavailability in rat,50597,,,1,12797,BAO_0000218,1,CHEMBL874396,,
10959,In vivo,Canis lupus familiaris,,F,U,Autocuration,,9615.0,Bioavailability in dog (dosed i.v.),22224,,,1,11727,BAO_0000218,0,CHEMBL625102,,
10960,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was tested for in vivo bioavailability in dog,50588,,,1,13249,BAO_0000218,1,CHEMBL625103,,
10961,In vivo,Cricetinae,,A,N,Intermediate,,10026.0,Compound was tested for in vivo bioavailability in hamsters,100712,,,1,13249,BAO_0000218,1,CHEMBL625104,,
10962,In vivo,Simiiformes,,A,U,Autocuration,,314293.0,Compound was tested for in vivo bioavailability in monkey,22224,,,1,13249,BAO_0000218,0,CHEMBL625105,,
10963,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was tested for in vivo bioavailability in rat,50597,,,1,13249,BAO_0000218,1,CHEMBL625106,,
10964,In vivo,Mus musculus,,A,U,Autocuration,,10090.0,Oral bioavailability in mouse,22224,,,1,9552,BAO_0000218,0,CHEMBL625107,,
10965,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Compound was tested for percent of oral bioavailability in mice; 56-74,50594,,,1,9552,BAO_0000218,1,CHEMBL625108,,
10966,In vivo,Mus musculus,,A,U,Autocuration,,10090.0,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),22224,,,1,14839,BAO_0000218,0,CHEMBL625109,,
10967,In vivo,Macaca fascicularis,,A,U,Autocuration,,9541.0,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),22224,,,1,14839,BAO_0000218,0,CHEMBL625110,,
10968,In vivo,Macaca fascicularis,,A,U,Autocuration,,9541.0,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),22224,,,1,14839,BAO_0000218,0,CHEMBL625111,,
10969,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),50594,,,1,14839,BAO_0000218,1,CHEMBL625112,,
10970,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Oral bioavailability in nude mice,50594,,,1,14839,BAO_0000218,1,CHEMBL875334,,
10971,In vivo,Primates,,A,U,Autocuration,,9443.0,Bioavailability in monkey (i.d. dosing),22224,,,1,11219,BAO_0000218,0,CHEMBL628617,,
10972,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,Bioavailability in rat,22224,,,1,9552,BAO_0000218,0,CHEMBL628618,,
10973,In vivo,,,A,U,Autocuration,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,22224,,,1,11732,BAO_0000218,0,CHEMBL628619,,
10974,In vivo,,,A,U,Autocuration,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,22224,,,1,11732,BAO_0000218,0,CHEMBL628620,,
10975,In vivo,Macaca fascicularis,,A,N,Intermediate,,9541.0,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",100710,,,1,14839,BAO_0000218,1,CHEMBL628621,,
10976,In vivo,Macaca fascicularis,,A,N,Intermediate,,9541.0,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",100710,,,1,14839,BAO_0000218,1,CHEMBL628622,,
10977,In vivo,Macaca fascicularis,,A,N,Intermediate,,9541.0,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",100710,,,1,14839,BAO_0000218,1,CHEMBL628623,,
10978,In vivo,Macaca fascicularis,,A,N,Intermediate,Plasma,9541.0,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,100710,,,1,14839,BAO_0000218,1,CHEMBL628624,,1969.0
10979,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,,,1,14839,BAO_0000218,1,CHEMBL628625,,1969.0
10980,In vivo,Macaca fascicularis,,A,N,Intermediate,Plasma,9541.0,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,100710,,,1,14839,BAO_0000218,1,CHEMBL628626,,1969.0
10981,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,,,1,14839,BAO_0000218,1,CHEMBL627041,,1969.0
10982,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,,,1,14839,BAO_0000218,1,CHEMBL627042,,1969.0
10983,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,50594,,,1,14839,BAO_0000218,1,CHEMBL627043,,1969.0
10984,In vivo,,,A,U,Autocuration,Plasma,,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,22224,,,1,13932,BAO_0000218,0,CHEMBL627044,,1969.0
10985,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Cmax in mouse plasma,50594,,,1,11637,BAO_0000218,1,CHEMBL627045,,1969.0
10986,In vivo,,,A,U,Autocuration,Plasma,,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,22224,,,1,11637,BAO_0000218,0,CHEMBL627046,,1969.0
10987,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximal plasma concentration in rat,50597,,,1,13960,BAO_0000218,1,CHEMBL627047,,1969.0
10988,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,50597,,,1,15905,BAO_0000218,1,CHEMBL627048,,1969.0
10989,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,50597,,,1,14062,BAO_0000218,1,CHEMBL627049,,
10990,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,50597,,,1,14062,BAO_0000218,1,CHEMBL627050,,
10991,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,50597,,,1,14062,BAO_0000218,1,CHEMBL627051,,
10992,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,50597,,,1,14062,BAO_0000218,1,CHEMBL627052,,
10993,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,50597,,,1,14062,BAO_0000218,1,CHEMBL627053,,
10994,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,50597,,,1,14062,BAO_0000218,1,CHEMBL627054,,
10995,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,50594,,,1,15011,BAO_0000218,1,CHEMBL627055,,
10996,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,50594,,,1,15011,BAO_0000218,1,CHEMBL627056,,
10997,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),50594,,,1,15011,BAO_0000218,1,CHEMBL627057,,
10998,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,50594,,,1,15011,BAO_0000218,1,CHEMBL627058,,
10999,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,50594,,,1,15011,BAO_0000218,1,CHEMBL626211,,
11000,In vivo,,,A,U,Autocuration,,,Maximum Concentration of the compound.,22224,,,1,10291,BAO_0000218,0,CHEMBL626212,,
11001,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Maximum Concentration was measured after iv administration into Beagle dog,50588,,,1,14599,BAO_0000218,1,CHEMBL626213,,
11002,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Maximum Concentration was measured after iv administration into Beagle dog.,50588,,,1,14599,BAO_0000218,1,CHEMBL626214,,
11003,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Maximum Concentration was measured after po administration into Beagle dog,50588,,,1,14599,BAO_0000218,1,CHEMBL626215,,
11004,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Maximum Concentration was measured after po administration into Beagle dog.,50588,,,1,14599,BAO_0000218,1,CHEMBL626216,,
11005,In vivo,,,A,U,Autocuration,Blood,,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,22224,,,1,12767,BAO_0000218,0,CHEMBL626217,,178.0
11006,In vivo,,,A,U,Autocuration,Blood,,Maximum blood level reached after an iv dose of 12.2 uM/kg,22224,,,1,12767,BAO_0000218,0,CHEMBL626218,,178.0
11007,In vivo,,,A,U,Autocuration,Blood,,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,22224,,,1,12767,BAO_0000218,0,CHEMBL626219,,178.0
11008,In vivo,,,A,U,Autocuration,Blood,,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,22224,,,1,12767,BAO_0000218,0,CHEMBL626220,,178.0
11009,In vivo,,,A,U,Autocuration,Blood,,Maximum blood level reached after an oral dose of 5.0 mg/kg,22224,,,1,12767,BAO_0000218,0,CHEMBL626221,,178.0
11010,In vivo,,,A,U,Autocuration,Blood,,Maximum blood level reached at dose of 10.6 uM/kg orally,22224,,,1,12767,BAO_0000218,0,CHEMBL626222,,178.0
11011,In vivo,Cavia porcellus,,A,N,Intermediate,,10141.0,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,50512,,,1,14706,BAO_0000218,1,CHEMBL626223,,
11012,In vivo,Cavia porcellus,,A,N,Intermediate,,10141.0,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,50512,,,1,14706,BAO_0000218,1,CHEMBL626224,,
11013,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,50597,,,1,14793,BAO_0000218,1,CHEMBL626225,,955.0
11014,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,50597,,,1,14793,BAO_0000218,1,CHEMBL626226,,955.0
11015,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,50597,,,1,14793,BAO_0000218,1,CHEMBL626227,,955.0
11016,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,50597,,,1,14793,BAO_0000218,1,CHEMBL626228,,955.0
11017,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,50597,,,1,14793,BAO_0000218,1,CHEMBL626229,,
11018,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,50597,,,1,14793,BAO_0000218,1,CHEMBL626921,,
11019,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,50597,,,1,14793,BAO_0000218,1,CHEMBL876793,,
11020,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,50597,,,1,14793,BAO_0000218,1,CHEMBL625309,,
11021,In vivo,Bacillus subtilis,,A,N,Intermediate,,1423.0,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),50278,,,1,10524,BAO_0000218,1,CHEMBL625310,,
11022,In vivo,Simiiformes,,A,U,Autocuration,,314293.0,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,22224,,,1,11871,BAO_0000218,0,CHEMBL625311,,
11023,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,50597,,,1,11871,BAO_0000218,1,CHEMBL625312,,
11024,In vivo,,,A,U,Autocuration,,,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,22224,,,1,3437,BAO_0000218,0,CHEMBL625313,,
11025,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,50594,,,1,12038,BAO_0000218,1,CHEMBL625314,,
11026,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration in male rats after iv administration of 20 mg/kg,50597,,,1,12038,BAO_0000218,1,CHEMBL625315,,
11027,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,50597,,,1,8418,BAO_0000218,1,CHEMBL625316,,2107.0
11028,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,50597,,,1,8418,BAO_0000218,1,CHEMBL625317,,2107.0
11029,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,50597,,,1,8418,BAO_0000218,1,CHEMBL625318,,2107.0
11030,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,50597,,,1,8418,BAO_0000218,1,CHEMBL625319,,2107.0
11031,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,50597,,,1,8418,BAO_0000218,1,CHEMBL625320,,2107.0
11032,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,50597,,,1,8418,BAO_0000218,1,CHEMBL625321,,2107.0
11033,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,50597,,,1,8418,BAO_0000218,1,CHEMBL625322,,2107.0
11034,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,50597,,,1,8418,BAO_0000218,1,CHEMBL876801,,2107.0
11035,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,50597,,,1,8418,BAO_0000218,1,CHEMBL625323,,2107.0
11036,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,50597,,,1,8418,BAO_0000218,1,CHEMBL625324,,2107.0
11037,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,50597,,,1,8418,BAO_0000218,1,CHEMBL625325,,2107.0
11038,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,50597,,,1,8418,BAO_0000218,1,CHEMBL625326,,2107.0
11039,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,50597,,,1,8418,BAO_0000218,1,CHEMBL625327,,2107.0
11040,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,50597,,,1,8418,BAO_0000218,1,CHEMBL625328,,2107.0
11041,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,50597,,,1,8418,BAO_0000218,1,CHEMBL625329,,2048.0
11042,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,50597,,,1,8418,BAO_0000218,1,CHEMBL625330,,2048.0
11043,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,50597,,,1,8418,BAO_0000218,1,CHEMBL627774,,2048.0
11044,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,50597,,,1,8418,BAO_0000218,1,CHEMBL627775,,2048.0
11045,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,50597,,,1,8418,BAO_0000218,1,CHEMBL627949,,2048.0
11046,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,50597,,,1,8418,BAO_0000218,1,CHEMBL627950,,2048.0
11047,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,50597,,,1,8418,BAO_0000218,1,CHEMBL627951,,2048.0
11048,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,50597,,,1,8418,BAO_0000218,1,CHEMBL627952,,2048.0
11049,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,50597,,,1,8418,BAO_0000218,1,CHEMBL627953,,2048.0
11050,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,50597,,,1,8418,BAO_0000218,1,CHEMBL627954,,2048.0
11051,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,50597,,,1,8418,BAO_0000218,1,CHEMBL627955,,2048.0
11052,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,50597,,,1,8418,BAO_0000218,1,CHEMBL627956,,2048.0
11053,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,50597,,,1,8418,BAO_0000218,1,CHEMBL876802,,2048.0
11054,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,50597,,,1,8418,BAO_0000218,1,CHEMBL627957,,2048.0
11055,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,50597,,,1,8418,BAO_0000218,1,CHEMBL627958,,2048.0
11056,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,50597,,,1,8418,BAO_0000218,1,CHEMBL627959,,2048.0
11057,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,50597,,,1,8418,BAO_0000218,1,CHEMBL627960,,2048.0
11058,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,50597,,,1,8418,BAO_0000218,1,CHEMBL627961,,2048.0
11059,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,50597,,,1,8418,BAO_0000218,1,CHEMBL627962,,2048.0
11060,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,50597,,,1,9796,BAO_0000218,1,CHEMBL627963,,
11061,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,50597,,,1,9796,BAO_0000218,1,CHEMBL624759,,
11062,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,50597,,,1,9796,BAO_0000218,1,CHEMBL624760,,
11063,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,50597,,,1,9796,BAO_0000218,1,CHEMBL624761,,
11064,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,50597,,,1,9796,BAO_0000218,1,CHEMBL877607,,
11065,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,50597,,,1,9796,BAO_0000218,1,CHEMBL624762,,2107.0
11066,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,50597,,,1,9796,BAO_0000218,1,CHEMBL624763,,2107.0
11067,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,50597,,,1,9796,BAO_0000218,1,CHEMBL624764,,2107.0
11068,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,50597,,,1,9796,BAO_0000218,1,CHEMBL624765,,2107.0
11069,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,50597,,,1,9796,BAO_0000218,1,CHEMBL624766,,2107.0
11070,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL624767,,
11071,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,50588,,,1,6996,BAO_0000218,1,CHEMBL624768,,
11072,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL624769,,
11073,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL624770,,
11074,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),50588,,,1,6996,BAO_0000218,1,CHEMBL624771,,
11075,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL624772,,
11076,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,50597,,,1,6996,BAO_0000218,1,CHEMBL624773,,
11077,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL624774,,
11078,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL624775,,
11079,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL624776,,
11080,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),50597,,,1,6996,BAO_0000218,1,CHEMBL624777,,
11081,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL624778,,
11082,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,50597,,,1,6996,BAO_0000218,1,CHEMBL624779,,
11083,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL624780,,
11084,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),50597,,,1,6996,BAO_0000218,1,CHEMBL624781,,
11085,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL877608,,
11086,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL624782,,
11087,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL624783,,
11088,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,50597,,,1,6996,BAO_0000218,1,CHEMBL624784,,
11089,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL624785,,
11090,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL624786,,
11091,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),50597,,,1,6996,BAO_0000218,1,CHEMBL624787,,
11092,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL628676,,
11093,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,50597,,,1,6996,BAO_0000218,1,CHEMBL621842,,
11094,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL621843,,
11095,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL623873,,
11096,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL623874,,
11097,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),50597,,,1,6996,BAO_0000218,1,CHEMBL623875,,
11098,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL623876,,
11099,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,50588,,,1,6996,BAO_0000218,1,CHEMBL623877,,
11100,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL623878,,
11101,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,50588,,,1,6996,BAO_0000218,1,CHEMBL623879,,
11102,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL623880,,
11103,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL623881,,
11104,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL623957,,
11105,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL623958,,
11106,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL623959,,
11107,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL623960,,
11108,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL623961,,
11109,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL623962,,
11110,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),50588,,,1,6996,BAO_0000218,1,CHEMBL624676,,
11111,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL624677,,
11112,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,50588,,,1,6996,BAO_0000218,1,CHEMBL624678,,
11113,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL624679,,
11114,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL624680,,
11115,In vivo,,,A,U,Autocuration,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,22224,,,1,11732,BAO_0000218,0,CHEMBL624849,,
11116,In vivo,,,A,U,Autocuration,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,22224,,,1,11732,BAO_0000218,0,CHEMBL624850,,
11117,In vivo,,,A,U,Autocuration,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,22224,,,1,11732,BAO_0000218,0,CHEMBL874399,,
11118,In vivo,,,A,U,Autocuration,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,22224,,,1,11732,BAO_0000218,0,CHEMBL624851,,
11119,In vivo,,,A,U,Autocuration,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,22224,,,1,11732,BAO_0000218,0,CHEMBL624852,,
11120,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,Oral bioavailability in rat (dose 10 mg/kg),22224,,,1,13359,BAO_0000218,0,CHEMBL624853,,
11121,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,Oral bioavailability in rat (Sprague-Dawley),22224,,,1,16618,BAO_0000218,0,CHEMBL624854,,
11122,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,Oral bioavailability in rat,22224,,,1,13960,BAO_0000218,0,CHEMBL624855,,
11123,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,Oral bioavailability in rats was determined in vivo,22224,,,1,13917,BAO_0000218,0,CHEMBL624856,,
11124,In vivo,Canis lupus familiaris,,A,U,Autocuration,,9615.0,Oral bioavailability in dog,22224,,,1,14266,BAO_0000218,0,CHEMBL882957,,
11125,In vivo,Simiiformes,,A,U,Autocuration,,314293.0,Oral bioavailability of compound in monkey,22224,,,1,12359,BAO_0000218,0,CHEMBL624857,,
11126,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability of compound in rat,50597,,,1,12359,BAO_0000218,1,CHEMBL622202,,
11127,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,Bioavailability in rat of PMEA prodrug,22224,,,1,12359,BAO_0000218,0,CHEMBL622203,,
11128,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,50597,,,1,12359,BAO_0000218,1,CHEMBL625522,,
11129,In vivo,Macaca mulatta,,A,U,Autocuration,,9544.0,Serum conc at 3 hours following 25 mg/kg dose,22224,,,1,10791,BAO_0000218,0,CHEMBL622868,,
11130,In vivo,Macaca mulatta,,A,U,Autocuration,Urine,9544.0,Urine conc 0-5 hours following 25 mg/kg dose,22224,,,1,10791,BAO_0000218,0,CHEMBL622869,,1088.0
11131,In vivo,Macaca mulatta,,A,U,Autocuration,Urine,9544.0,Urine conc 0-24 hours following 25 mg/kg dose,22224,,,1,10791,BAO_0000218,0,CHEMBL622870,,1088.0
11132,In vivo,Chlorocebus aethiops,,A,U,Autocuration,,9534.0,Oral bioavailability in African green monkeys; 20-25,22224,,,1,138,BAO_0000218,0,CHEMBL622871,,
11133,In vivo,Macaca fascicularis,,A,N,Intermediate,,9541.0,Oral bioavailability in cynomolgus monkey.,100710,,,1,14521,BAO_0000218,1,CHEMBL620560,,
11134,In vivo,Canis lupus familiaris,,A,U,Autocuration,,9615.0,Oral bioavailability in dog,22224,,,1,13953,BAO_0000218,0,CHEMBL620561,,
11135,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in dog at 10 mg/kg oral dose,50588,,,1,12836,BAO_0000218,1,CHEMBL620562,,
11136,In vivo,Cricetinae,,A,N,Intermediate,,10026.0,Oral bioavailability in hamster at 10 mg/kg oral dose,100712,,,1,12836,BAO_0000218,1,CHEMBL620563,,
11137,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability in rat at 10 mg/kg oral dose,50597,,,1,12836,BAO_0000218,1,CHEMBL620564,,
11138,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,Oral bioavailability in rat,22224,,,1,14521,BAO_0000218,0,CHEMBL872265,,
11139,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,Oral bioavailability in rat,22224,,,1,13953,BAO_0000218,0,CHEMBL620565,,
11140,In vivo,Eutheria,,A,U,Autocuration,,9347.0,Oral bioavailability,22224,,,1,6799,BAO_0000218,0,CHEMBL620566,,
11141,In vivo,,,A,U,Autocuration,,,Oral bioavailability was determined; range 49-102%,22224,,,1,11311,BAO_0000218,0,CHEMBL620567,,
11142,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability was determined in dogs,50588,,,1,4013,BAO_0000218,1,CHEMBL620568,,
11143,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,Oral bioavailability in rat,22224,,,1,4013,BAO_0000218,0,CHEMBL620569,,
11144,In vivo,Eutheria,,A,U,Autocuration,,9347.0,Oral bioavailability,22224,,,1,17591,BAO_0000218,0,CHEMBL620570,,
11145,In vivo,,,A,U,Autocuration,,,Oral bioavailability was determined; Not orally available,22224,,,1,17591,BAO_0000218,0,CHEMBL620571,,
11146,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),50594,,,1,15011,BAO_0000218,1,CHEMBL620572,,
11147,In vivo,Mus musculus,,A,U,Autocuration,,10090.0,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),22224,,,1,15011,BAO_0000218,0,CHEMBL620573,,
11148,In vivo,Mus musculus,,A,U,Autocuration,,10090.0,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,22224,,,1,15011,BAO_0000218,0,CHEMBL620574,,
11149,In vivo,Macaca mulatta,,A,U,Autocuration,,9544.0,Oral bioavailability in Rhesus monkey,22224,,,1,9552,BAO_0000218,0,CHEMBL620575,,
11150,In vivo,Canis lupus familiaris,,A,U,Autocuration,,9615.0,Oral bioavailability in dog (female mongrel),22224,,,1,9552,BAO_0000218,0,CHEMBL620576,,
11151,In vivo,,,A,U,Autocuration,,,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,22224,,,1,3639,BAO_0000218,0,CHEMBL875846,,
11152,In vivo,Canis lupus familiaris,,A,U,Autocuration,,9615.0,Oral bioavailability in dog,22224,,,1,13397,BAO_0000218,0,CHEMBL620577,,
11153,In vivo,,,A,U,Autocuration,,,Percentage Bioavailability was evaluated.,22224,,,1,3031,BAO_0000218,0,CHEMBL620578,,
11154,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,Bioavailability in rat administered i.d.,22224,,,1,12818,BAO_0000218,0,CHEMBL620579,,
11155,In vivo,Eutheria,,A,U,Autocuration,,9347.0,Bioavailability,22224,,,1,4847,BAO_0000218,0,CHEMBL621248,,
11156,In vivo,Canis lupus familiaris,,A,U,Autocuration,,9615.0,Bioavailability in dog (male Beagle) i.v. administration,22224,,,1,12421,BAO_0000218,0,CHEMBL625390,,
11157,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",22224,,,1,11966,BAO_0000218,0,CHEMBL625391,,
11158,In vivo,Primates,,A,U,Autocuration,,9443.0,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),22224,,,1,11218,BAO_0000218,0,CHEMBL872266,,
11159,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,Oral bioavailability in rat (Sprague-Dawley) (male),22224,,,1,13129,BAO_0000218,0,CHEMBL625392,,
11160,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,The oral bioavailability was measured on rats after oral administration,50597,,,1,12350,BAO_0000218,1,CHEMBL625393,,
11161,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,50597,,,1,2231,BAO_0000218,1,CHEMBL625394,,
11162,In vivo,Macaca mulatta,,A,N,Intermediate,,9544.0,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,50797,,,1,2231,BAO_0000218,1,CHEMBL625395,,
11163,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,Bioavailability in rat (dose 10 mg/kg i.d.),22224,,,1,12187,BAO_0000218,0,CHEMBL625396,,
11164,In vivo,Canis lupus familiaris,,A,U,Autocuration,,9615.0,Bioavailability in dog (male Beagle) i.v. administration,22224,,,1,12421,BAO_0000218,0,CHEMBL625397,,
11165,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL625398,,
11166,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL625399,,178.0
11167,In vivo,Mus musculus,,A,N,Intermediate,Cerebellum,10090.0,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL626074,,2037.0
11168,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL626075,,
11169,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,50597,,,1,2231,BAO_0000218,1,CHEMBL626076,,1969.0
11170,In vivo,Macaca mulatta,,A,N,Intermediate,Plasma,9544.0,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,50797,,,1,2231,BAO_0000218,1,CHEMBL626077,,1969.0
11171,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),50597,,,1,12178,BAO_0000218,1,CHEMBL626078,,178.0
11172,In vivo,,,A,U,Autocuration,Blood,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),22224,,,1,12178,BAO_0000218,0,CHEMBL625846,,178.0
11173,In vivo,,,A,U,Autocuration,Blood,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),22224,,,1,12178,BAO_0000218,0,CHEMBL625847,,178.0
11174,In vivo,Rattus norvegicus,,A,N,Expert,,10116.0,Maximum concentration observed in rats at an oral dose of 50 mg/kg,50597,,,1,15633,BAO_0000218,1,CHEMBL625848,,
11175,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum concentration of compound in plasma administered orally to rats,50597,,,1,14258,BAO_0000218,1,CHEMBL625849,,1969.0
11176,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",50588,,,1,14224,BAO_0000218,1,CHEMBL626023,,1969.0
11177,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",50588,,,1,14224,BAO_0000218,1,CHEMBL626024,,1969.0
11178,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",50588,,,1,14224,BAO_0000218,1,CHEMBL626025,,1969.0
11179,In vivo,,,A,U,Autocuration,,,Maximum concentration after 10 mg/kg by oral administration,22224,,,1,5566,BAO_0000218,0,CHEMBL626026,,
11180,In vivo,,,A,U,Autocuration,,,Maximum concentration at a dose of 1.5 mg/kg,22224,,,1,16935,BAO_0000218,0,CHEMBL626027,,
11181,In vivo,,,A,U,Autocuration,,,Maximum concentration at a dose of 2.0 mg/kg,22224,,,1,16935,BAO_0000218,0,CHEMBL626028,,
11182,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum concentration in dog plasma,50588,,,1,14224,BAO_0000218,1,CHEMBL626029,,1969.0
11183,In vivo,,,A,U,Autocuration,Plasma,,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,22224,,,1,12536,BAO_0000218,0,CHEMBL626030,,1969.0
11184,In vivo,,,A,U,Autocuration,Plasma,,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,22224,,,1,12536,BAO_0000218,0,CHEMBL626031,,1969.0
11185,In vivo,,,A,U,Autocuration,Plasma,,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,22224,,,1,12536,BAO_0000218,0,CHEMBL626032,,1969.0
11186,In vivo,,,A,U,Autocuration,Plasma,,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,22224,,,1,12536,BAO_0000218,0,CHEMBL626033,,1969.0
11187,In vivo,,,A,U,Autocuration,Plasma,,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,22224,,,1,12536,BAO_0000218,0,CHEMBL626034,,1969.0
11188,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum concentration in plasma after oral administration in dog (25 mg/kg),50588,,,1,9994,BAO_0000218,1,CHEMBL626035,,1969.0
11189,In vivo,,,A,U,Autocuration,Plasma,,Maximum concentration in plasma at Tmax,22224,,,1,1434,BAO_0000218,0,CHEMBL626036,,1969.0
11190,In vivo,Canis lupus familiaris,,A,N,Expert,Plasma,9615.0,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,50588,,,1,12836,BAO_0000218,1,CHEMBL626037,,1969.0
11191,In vivo,Cricetinae,,A,N,Intermediate,Plasma,10026.0,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,100712,,,1,12836,BAO_0000218,1,CHEMBL626038,,1969.0
11192,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,50597,,,1,12836,BAO_0000218,1,CHEMBL626039,,1969.0
11193,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,50597,,,1,12545,BAO_0000218,1,CHEMBL626040,,1969.0
11194,In vivo,Oryctolagus cuniculus,,A,N,Intermediate,Plasma,9986.0,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,50592,,,1,13856,BAO_0000218,1,CHEMBL626041,,1969.0
11195,In vivo,,,A,U,Autocuration,,,Maximum concentration was calculated,22224,,,1,3550,BAO_0000218,0,CHEMBL626042,,
11196,In vivo,,,A,U,Autocuration,,,Maximum concentration was calculated.,22224,,,1,2632,BAO_0000218,0,CHEMBL626043,,
11197,In vivo,,,A,U,Autocuration,,,Maximum concentration at a peroral dose of 10 mg/kg,22224,,,1,5566,BAO_0000218,0,CHEMBL626044,,
11198,In vivo,,,A,U,Autocuration,,,Maximum concentration of the drug at 10 uM/dg administered perorally,22224,,,1,11883,BAO_0000218,0,CHEMBL626045,,
11199,In vivo,,,A,U,Autocuration,,,Maximum concentration of the drug at 2 uM/dg administered intravenously,22224,,,1,11883,BAO_0000218,0,CHEMBL626046,,
11200,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",50588,,,1,14122,BAO_0000218,1,CHEMBL626047,,1969.0
11201,In vivo,Cricetinae,,A,N,Intermediate,Plasma,10026.0,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",100712,,,1,14122,BAO_0000218,1,CHEMBL626048,,1969.0
11202,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",50597,,,1,14122,BAO_0000218,1,CHEMBL626049,,1969.0
11203,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,50597,,,1,12542,BAO_0000218,1,CHEMBL626050,,1969.0
11204,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,50588,,,1,12542,BAO_0000218,1,CHEMBL874541,,1969.0
11205,In vivo,Cricetinae,,A,N,Intermediate,Plasma,10026.0,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,100712,,,1,12542,BAO_0000218,1,CHEMBL622826,,1969.0
11206,In vivo,Cricetinae,,A,N,Intermediate,Plasma,10026.0,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,100712,,,1,12542,BAO_0000218,1,CHEMBL622827,,1969.0
11207,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,50597,,,1,12542,BAO_0000218,1,CHEMBL622828,,1969.0
11208,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,50597,,,1,14080,BAO_0000218,1,CHEMBL622829,,1969.0
11209,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration reached following intravenous administration in male rat,50597,,,1,11911,BAO_0000218,1,CHEMBL876806,,
11210,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,50588,,,1,13204,BAO_0000218,1,CHEMBL622830,,
11211,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,50597,,,1,13204,BAO_0000218,1,CHEMBL622831,,
11212,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,50588,,,1,14346,BAO_0000218,1,CHEMBL626794,,
11213,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,50597,,,1,14346,BAO_0000218,1,CHEMBL626795,,
11214,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,50597,,,1,14346,BAO_0000218,1,CHEMBL626796,,
11215,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,50597,,,1,14346,BAO_0000218,1,CHEMBL626797,,
11216,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum drug concentration is determined after oral dosing in rats.,50597,,,1,14127,BAO_0000218,1,CHEMBL626798,,
11217,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Maximum observed concentration in oral (5 mg/kg) fasted dogs,50588,,,1,14339,BAO_0000218,1,CHEMBL626799,,
11218,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Maximum observed concentration in oral (5 mg/kg) fed dogs,50588,,,1,14339,BAO_0000218,1,CHEMBL626800,,
11219,In vivo,,,A,U,Autocuration,Plasma,,Maximum plasma concentration,22224,,,1,13494,BAO_0000218,0,CHEMBL626801,,1969.0
11220,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,50597,,,1,14925,BAO_0000218,1,CHEMBL876816,,1969.0
11221,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,50597,,,1,14474,BAO_0000218,1,CHEMBL626802,,1969.0
11222,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,50588,,,1,14474,BAO_0000218,1,CHEMBL626803,,1969.0
11223,In vivo,,,A,U,Autocuration,Plasma,,Maximum plasma concentration following oral administration of 30 umol/kg,22224,,,1,13917,BAO_0000218,0,CHEMBL626804,,1969.0
11224,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,50597,,,1,9796,BAO_0000218,1,CHEMBL626805,,1969.0
11225,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,50597,,,1,9796,BAO_0000218,1,CHEMBL626309,,1969.0
11226,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,50597,,,1,9796,BAO_0000218,1,CHEMBL626310,,1969.0
11227,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,50597,,,1,9796,BAO_0000218,1,CHEMBL626311,,1969.0
11228,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,50597,,,1,9796,BAO_0000218,1,CHEMBL626312,,1969.0
11229,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,50597,,,1,9796,BAO_0000218,1,CHEMBL626313,,995.0
11230,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,50597,,,1,9796,BAO_0000218,1,CHEMBL626314,,995.0
11231,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,50597,,,1,9796,BAO_0000218,1,CHEMBL626315,,995.0
11232,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,50597,,,1,9796,BAO_0000218,1,CHEMBL626316,,995.0
11233,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,50597,,,1,9796,BAO_0000218,1,CHEMBL626317,,995.0
11234,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),50597,,,1,8363,BAO_0000218,1,CHEMBL626318,,
11235,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),50597,,,1,8363,BAO_0000218,1,CHEMBL626319,,
11236,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),50597,,,1,8363,BAO_0000218,1,CHEMBL626320,,
11237,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),50597,,,1,8363,BAO_0000218,1,CHEMBL875053,,
11238,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),50597,,,1,8363,BAO_0000218,1,CHEMBL626321,,
11239,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),50597,,,1,8363,BAO_0000218,1,CHEMBL626322,,
11240,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),50597,,,1,8363,BAO_0000218,1,CHEMBL626323,,
11241,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),50597,,,1,8363,BAO_0000218,1,CHEMBL626324,,
11242,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),50597,,,1,8363,BAO_0000218,1,CHEMBL626325,,
11243,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),50597,,,1,8363,BAO_0000218,1,CHEMBL626326,,
11244,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),50597,,,1,8363,BAO_0000218,1,CHEMBL626327,,
11245,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),50597,,,1,8363,BAO_0000218,1,CHEMBL626328,,
11246,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL626329,,178.0
11247,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL626330,,178.0
11248,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL626331,,178.0
11249,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL626332,,178.0
11250,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL626333,,178.0
11251,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL626334,,178.0
11252,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL626335,,178.0
11253,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624798,,178.0
11254,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624799,,955.0
11255,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624800,,955.0
11256,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624801,,955.0
11257,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624802,,955.0
11258,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624803,,955.0
11259,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624804,,955.0
11260,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624805,,955.0
11261,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624806,,955.0
11262,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624807,,
11263,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624808,,
11264,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624809,,
11265,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624810,,
11266,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL877618,,
11267,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624811,,
11268,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624812,,
11269,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624813,,
11270,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624814,,
11271,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624815,,
11272,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624816,,
11273,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624817,,
11274,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL624818,,
11275,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,50588,,,1,6996,BAO_0000218,1,CHEMBL624819,,
11276,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL624820,,
11277,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL624821,,
11278,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),50588,,,1,6996,BAO_0000218,1,CHEMBL624822,,
11279,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL624823,,
11280,,Escherichia coli,,A,N,Intermediate,,562.0,Observed diffusion coefficient in organic solvent for Escherichia coli,50212,,,1,15599,BAO_0000218,1,CHEMBL624824,,
11281,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",50597,,,1,9614,BAO_0000218,1,CHEMBL624825,,178.0
11282,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",50597,,,1,9614,BAO_0000218,1,CHEMBL624826,,178.0
11283,,Rattus norvegicus,,A,N,Intermediate,Cardiac atrium,10116.0,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",50597,,,1,9614,BAO_0000218,1,CHEMBL876817,,2081.0
11284,,Rattus norvegicus,,A,N,Intermediate,Cardiac atrium,10116.0,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",50597,,,1,9614,BAO_0000218,1,CHEMBL624827,,2081.0
11285,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",50597,,,1,9614,BAO_0000218,1,CHEMBL624828,,
11286,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",50597,,,1,9614,BAO_0000218,1,CHEMBL624829,,
11287,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",50597,,,1,9614,BAO_0000218,1,CHEMBL624830,,2107.0
11288,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",50597,,,1,9614,BAO_0000218,1,CHEMBL624831,,2107.0
11289,,Rattus norvegicus,,A,N,Intermediate,Cardiac atrium,10116.0,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",50597,,,1,9614,BAO_0000218,1,CHEMBL624832,,2081.0
11290,,Rattus norvegicus,,A,N,Intermediate,Cardiac atrium,10116.0,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",50597,,,1,9614,BAO_0000218,1,CHEMBL624833,,2081.0
11291,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",50597,,,1,9614,BAO_0000218,1,CHEMBL624834,,
11292,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",50597,,,1,9614,BAO_0000218,1,CHEMBL624835,,
11293,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",50597,,,1,9614,BAO_0000218,1,CHEMBL624836,,2106.0
11294,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",50597,,,1,9614,BAO_0000218,1,CHEMBL624837,,2106.0
11295,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,50597,,,1,9071,BAO_0000218,1,CHEMBL624838,,178.0
11296,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,50597,,,1,9071,BAO_0000218,1,CHEMBL622188,,178.0
11297,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,50597,,,1,9071,BAO_0000218,1,CHEMBL622189,,948.0
11298,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,50597,,,1,9071,BAO_0000218,1,CHEMBL622190,,948.0
11299,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,50597,,,1,9071,BAO_0000218,1,CHEMBL625170,,948.0
11300,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,50597,,,1,9071,BAO_0000218,1,CHEMBL625171,,2113.0
11301,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,50597,,,1,9071,BAO_0000218,1,CHEMBL625172,,2113.0
11302,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,50597,,,1,9071,BAO_0000218,1,CHEMBL625173,,2113.0
11303,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,50597,,,1,9071,BAO_0000218,1,CHEMBL625174,,2107.0
11304,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,50597,,,1,9071,BAO_0000218,1,CHEMBL625175,,2107.0
11305,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,50597,,,1,9071,BAO_0000218,1,CHEMBL625176,,2107.0
11306,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,50597,,,1,9071,BAO_0000218,1,CHEMBL625177,,2048.0
11307,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,50597,,,1,9071,BAO_0000218,1,CHEMBL625178,,2048.0
11308,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,50597,,,1,9071,BAO_0000218,1,CHEMBL625179,,2048.0
11309,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,50597,,,1,9071,BAO_0000218,1,CHEMBL625180,,2048.0
11310,,,,A,U,Autocuration,,,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",22224,,,1,10677,BAO_0000218,0,CHEMBL625181,,
11311,,Mus musculus,,A,N,Intermediate,Urine,10090.0,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,50594,,,1,9750,BAO_0000218,1,CHEMBL625182,,1088.0
11312,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,50597,,,1,8319,BAO_0000218,1,CHEMBL625183,,
11313,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,50597,,,1,8319,BAO_0000218,1,CHEMBL875848,,
11314,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,50597,,,1,8319,BAO_0000218,1,CHEMBL622260,,
11315,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,50597,,,1,8319,BAO_0000218,1,CHEMBL622261,,
11316,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,50597,,,1,8319,BAO_0000218,1,CHEMBL622262,,
11317,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,50597,,,1,8319,BAO_0000218,1,CHEMBL622263,,2113.0
11318,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,50597,,,1,8319,BAO_0000218,1,CHEMBL622418,,2113.0
11319,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,50597,,,1,8319,BAO_0000218,1,CHEMBL622419,,2107.0
11320,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL623388,,
11321,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL623389,,2107.0
11322,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL623390,,
11323,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL623391,,
11324,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL623392,,178.0
11325,In vivo,Mus musculus,,A,N,Intermediate,Cerebellum,10090.0,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL623393,,2037.0
11326,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL623394,,
11327,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL618885,,
11328,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL618886,,2107.0
11329,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL618887,,
11330,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL619535,,
11331,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL619536,,178.0
11332,In vivo,Mus musculus,,A,N,Intermediate,Cerebellum,10090.0,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL619537,,2037.0
11333,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL619705,,
11334,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL619706,,
11335,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL619707,,2107.0
11336,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL619708,,
11337,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL625219,,
11338,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL625220,,178.0
11339,In vivo,Mus musculus,,A,N,Intermediate,Cerebellum,10090.0,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL625221,,2037.0
11340,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL625222,,
11341,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL625223,,
11342,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL625224,,2107.0
11343,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),50594,,,1,13256,BAO_0000218,1,CHEMBL625225,,
11344,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in Rat blood after 24 hours of iv administration,50597,,,1,8829,BAO_0000218,1,CHEMBL625226,,178.0
11345,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,50597,,,1,8829,BAO_0000218,1,CHEMBL625227,,178.0
11346,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in Rat blood after 30 minutes of iv administration,50597,,,1,8829,BAO_0000218,1,CHEMBL625228,,178.0
11347,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,50597,,,1,8829,BAO_0000218,1,CHEMBL875354,,178.0
11348,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in Rat blood after 5 minutes of iv administration,50597,,,1,8829,BAO_0000218,1,CHEMBL625229,,178.0
11349,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,50597,,,1,8829,BAO_0000218,1,CHEMBL625230,,178.0
11350,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in Rat heart after 24 hours of iv administration,50597,,,1,8829,BAO_0000218,1,CHEMBL625231,,948.0
11351,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,50597,,,1,8829,BAO_0000218,1,CHEMBL625900,,948.0
11352,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in Rat heart after 30 minutes of iv administration,50597,,,1,8829,BAO_0000218,1,CHEMBL625901,,948.0
11353,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,50597,,,1,8829,BAO_0000218,1,CHEMBL625902,,948.0
11354,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in Rat heart after 5 minutes of iv administration,50597,,,1,8829,BAO_0000218,1,CHEMBL625903,,948.0
11355,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,50597,,,1,8829,BAO_0000218,1,CHEMBL625904,,948.0
11356,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in Rat liver after 24 hours of iv administration,50597,,,1,8829,BAO_0000218,1,CHEMBL625905,,2107.0
11357,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,50597,,,1,8829,BAO_0000218,1,CHEMBL627861,,2107.0
11358,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in Rat liver after 30 minutes of iv administration,50597,,,1,8829,BAO_0000218,1,CHEMBL627862,,2107.0
11359,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,50597,,,1,8829,BAO_0000218,1,CHEMBL627863,,2107.0
11360,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in Rat liver after 30 minutes of iv administration,50597,,,1,8829,BAO_0000218,1,CHEMBL627769,,2107.0
11361,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,50588,,,1,13249,BAO_0000218,1,CHEMBL627770,,1969.0
11362,In vivo,Macaca fascicularis,,A,N,Intermediate,,9541.0,Cmax in cynomolgus monkey (PO dose),100710,,,1,13622,BAO_0000218,1,CHEMBL627771,,
11363,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax in rat (PO dose),50597,,,1,13622,BAO_0000218,1,CHEMBL627772,,
11364,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax in rat (PO dose),50597,,,1,13622,BAO_0000218,1,CHEMBL627773,,
11365,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,50597,,,1,13494,BAO_0000218,1,CHEMBL621922,,1969.0
11366,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Cmax in rat plasma after oral dose (10 mg/kg),50597,,,1,12170,BAO_0000218,1,CHEMBL621923,,1969.0
11367,In vivo,,,A,U,Autocuration,Plasma,,Cmax in plasma after oral dose (10 mg/kg),22224,,,1,12170,BAO_0000218,0,CHEMBL621924,,1969.0
11368,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,50588,,,1,17025,BAO_0000218,1,CHEMBL621925,,1969.0
11369,In vivo,Simiiformes,,A,U,Autocuration,Plasma,314293.0,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,22224,,,1,17025,BAO_0000218,0,CHEMBL621926,,1969.0
11370,In vivo,Oryctolagus cuniculus,,A,N,Intermediate,Plasma,9986.0,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,50592,,,1,17025,BAO_0000218,1,CHEMBL621927,,1969.0
11371,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,50597,,,1,17025,BAO_0000218,1,CHEMBL621928,,1969.0
11372,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,50597,,,1,14187,BAO_0000218,1,CHEMBL621929,,1969.0
11373,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,50594,,,1,14816,BAO_0000218,1,CHEMBL621930,,1969.0
11374,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration after oral dosing in rat,50597,,,1,17820,BAO_0000218,1,CHEMBL621931,,1969.0
11375,In vivo,,,A,U,Autocuration,Plasma,,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,22224,,,1,14380,BAO_0000218,0,CHEMBL621932,,1969.0
11376,In vivo,,,A,U,Autocuration,Plasma,,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,22224,,,1,14380,BAO_0000218,0,CHEMBL621933,,1969.0
11377,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,50588,,,1,14691,BAO_0000218,1,CHEMBL621934,,1969.0
11378,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,50588,,,1,14691,BAO_0000218,1,CHEMBL621935,,1969.0
11379,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,50597,,,1,13375,BAO_0000218,1,CHEMBL621936,,1969.0
11380,In vivo,,,A,U,Autocuration,Plasma,,Maximum plasma concentration was determined,22224,,,1,6236,BAO_0000218,0,CHEMBL621937,,1969.0
11381,In vivo,,,A,U,Autocuration,Plasma,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,22224,,,1,14380,BAO_0000218,0,CHEMBL621938,,1969.0
11382,In vivo,,,A,U,Autocuration,Plasma,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,22224,,,1,14380,BAO_0000218,0,CHEMBL621939,,1969.0
11383,In vivo,,,A,U,Autocuration,Plasma,,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,22224,,,1,14380,BAO_0000218,0,CHEMBL621940,,1969.0
11384,In vivo,,,A,U,Autocuration,Plasma,,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,22224,,,1,14380,BAO_0000218,0,CHEMBL621941,,1969.0
11385,In vivo,,,A,U,Autocuration,Plasma,,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,22224,,,1,14380,BAO_0000218,0,CHEMBL621942,,1969.0
11386,In vivo,,,A,U,Autocuration,Plasma,,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,22224,,,1,14380,BAO_0000218,0,CHEMBL626178,,1969.0
11387,In vivo,,,A,U,Autocuration,Plasma,,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,22224,,,1,14380,BAO_0000218,0,CHEMBL626179,,1969.0
11388,In vivo,,,A,U,Autocuration,Plasma,,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,22224,,,1,14380,BAO_0000218,0,CHEMBL626180,,1969.0
11389,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma Cmax in rat (PO dose),50597,,,1,13622,BAO_0000218,1,CHEMBL626181,,1969.0
11390,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum serum concentration after po dose of 5.22 mg/kg in rats,50597,,,1,15372,BAO_0000218,1,CHEMBL626182,,
11391,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum serum concentration after po dose of 5.46 mg/kg in rats,50597,,,1,15372,BAO_0000218,1,CHEMBL626183,,
11392,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,50597,,,1,15372,BAO_0000218,1,CHEMBL626184,,
11393,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,50597,,,1,15372,BAO_0000218,1,CHEMBL626185,,
11394,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,50588,,,1,14925,BAO_0000218,1,CHEMBL626186,,1969.0
11395,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,50588,,,1,14925,BAO_0000218,1,CHEMBL877589,,1969.0
11396,In vivo,,,A,U,Autocuration,,,Maximum concentration of the drug at 1 uM/dg administered intravenously,22224,,,1,11883,BAO_0000218,0,CHEMBL626187,,
11397,In vivo,,,A,U,Autocuration,,,Maximum concentration of the drug at 20 uM/dg administered perorally,22224,,,1,11883,BAO_0000218,0,CHEMBL626188,,
11398,In vivo,,,A,U,Autocuration,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,22224,,,1,13391,BAO_0000218,0,CHEMBL626189,,
11399,In vivo,,,A,U,Autocuration,Blood,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,22224,,,1,13391,BAO_0000218,0,CHEMBL626855,,178.0
11400,In vivo,,,A,U,Autocuration,Blood,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,22224,,,1,13391,BAO_0000218,0,CHEMBL623781,,178.0
11401,In vivo,,,A,U,Autocuration,Blood,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,22224,,,1,13391,BAO_0000218,0,CHEMBL623782,,178.0
11402,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,50597,,,1,16360,BAO_0000218,1,CHEMBL623783,,1969.0
11403,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Cmax in dog plasma after 1mg/kg oral dose,50588,,,1,3673,BAO_0000218,1,CHEMBL623784,,1969.0
11404,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,50588,,,1,14431,BAO_0000218,1,CHEMBL623785,,1969.0
11405,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,50597,,,1,14431,BAO_0000218,1,CHEMBL623786,,1969.0
11406,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral maximum concentration in rat,50597,,,1,14964,BAO_0000218,1,CHEMBL623787,,
11407,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral maximum concentration in rat,50597,,,1,14964,BAO_0000218,1,CHEMBL623788,,
11408,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,50594,,,1,14209,BAO_0000218,1,CHEMBL623789,,1969.0
11409,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Peak concentration in blood after intravenous administration to mice,50594,,,1,11355,BAO_0000218,1,CHEMBL623790,,178.0
11410,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Peak concentration in blood after peroral administration to mice,50594,,,1,11355,BAO_0000218,1,CHEMBL623791,,178.0
11411,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Peak concentration in rat plasma was determined,50597,,,1,11966,BAO_0000218,1,CHEMBL623792,,1969.0
11412,In vivo,Simiiformes,,A,U,Autocuration,Plasma,314293.0,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,22224,,,1,8918,BAO_0000218,0,CHEMBL623793,,1969.0
11413,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,50594,,,1,8918,BAO_0000218,1,CHEMBL623794,,1969.0
11414,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,50597,,,1,8918,BAO_0000218,1,CHEMBL623795,,1969.0
11415,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL623796,,
11416,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL623797,,
11417,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL623798,,
11418,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL623799,,
11419,,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624490,,160.0
11420,,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624491,,160.0
11421,,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624492,,160.0
11422,,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624493,,160.0
11423,,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL877595,,160.0
11424,,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624494,,160.0
11425,,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624495,,160.0
11426,,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624681,,160.0
11427,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624682,,
11428,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624683,,
11429,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624684,,
11430,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624685,,
11431,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624686,,
11432,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624687,,
11433,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624688,,
11434,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL627161,,
11435,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL622127,,
11436,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL622128,,
11437,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL874384,,
11438,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624898,,
11439,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624899,,
11440,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624900,,
11441,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624901,,
11442,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624902,,
11443,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624903,,
11444,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624904,,
11445,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624905,,
11446,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624906,,
11447,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624907,,
11448,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624908,,
11449,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624909,,
11450,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624910,,
11451,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624911,,2385.0
11452,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL874388,,2385.0
11453,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL624912,,2385.0
11454,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL622930,,2385.0
11455,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL623121,,2385.0
11456,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL623122,,2385.0
11457,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL623123,,2385.0
11458,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL623124,,2385.0
11459,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL623125,,
11460,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL623126,,
11461,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL623127,,
11462,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL623128,,
11463,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL623129,,
11464,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL623130,,
11465,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL623131,,
11466,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL623132,,
11467,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,50597,,,1,8319,BAO_0000218,1,CHEMBL623133,,2107.0
11468,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,50597,,,1,8319,BAO_0000218,1,CHEMBL623134,,
11469,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,50597,,,1,8319,BAO_0000218,1,CHEMBL874389,,
11470,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,50597,,,1,8319,BAO_0000218,1,CHEMBL623135,,
11471,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,50597,,,1,8319,BAO_0000218,1,CHEMBL623136,,
11472,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,50597,,,1,8319,BAO_0000218,1,CHEMBL623137,,
11473,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,50597,,,1,8319,BAO_0000218,1,CHEMBL623138,,
11474,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,50597,,,1,8319,BAO_0000218,1,CHEMBL623139,,2113.0
11475,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,50597,,,1,8319,BAO_0000218,1,CHEMBL623140,,2113.0
11476,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,50597,,,1,8319,BAO_0000218,1,CHEMBL623141,,2107.0
11477,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,50597,,,1,8319,BAO_0000218,1,CHEMBL623142,,2107.0
11478,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,50597,,,1,8319,BAO_0000218,1,CHEMBL623143,,
11479,,Mus musculus,,A,N,Intermediate,Urine,10090.0,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,50594,,,1,14571,BAO_0000218,1,CHEMBL623144,,1088.0
11480,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,50597,,,1,14571,BAO_0000218,1,CHEMBL623405,,1088.0
11481,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,50597,,,1,8319,BAO_0000218,1,CHEMBL624074,,
11482,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,50597,,,1,8319,BAO_0000218,1,CHEMBL624075,,
11483,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,50597,,,1,8319,BAO_0000218,1,CHEMBL624076,,
11484,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,50597,,,1,8319,BAO_0000218,1,CHEMBL624077,,
11485,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,50597,,,1,8319,BAO_0000218,1,CHEMBL624078,,
11486,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,50597,,,1,8319,BAO_0000218,1,CHEMBL624079,,2113.0
11487,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,50597,,,1,8319,BAO_0000218,1,CHEMBL624261,,2113.0
11488,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,50597,,,1,8319,BAO_0000218,1,CHEMBL624262,,
11489,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,50597,,,1,8319,BAO_0000218,1,CHEMBL624263,,
11490,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,50597,,,1,8319,BAO_0000218,1,CHEMBL624264,,
11491,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,50597,,,1,8319,BAO_0000218,1,CHEMBL624265,,
11492,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,50597,,,1,8319,BAO_0000218,1,CHEMBL624266,,
11493,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,50597,,,1,8319,BAO_0000218,1,CHEMBL624267,,
11494,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,50597,,,1,8319,BAO_0000218,1,CHEMBL624268,,
11495,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,50597,,,1,8319,BAO_0000218,1,CHEMBL875227,,
11496,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,50597,,,1,8319,BAO_0000218,1,CHEMBL624269,,2113.0
11497,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,50597,,,1,8319,BAO_0000218,1,CHEMBL624270,,2113.0
11498,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,50597,,,1,8319,BAO_0000218,1,CHEMBL624271,,
11499,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,50597,,,1,8319,BAO_0000218,1,CHEMBL624272,,
11500,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,50597,,,1,8319,BAO_0000218,1,CHEMBL624273,,
11501,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,50597,,,1,12064,BAO_0000218,1,CHEMBL624274,,1088.0
11502,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,50597,,,1,12064,BAO_0000218,1,CHEMBL624275,,1088.0
11503,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,50597,,,1,12064,BAO_0000218,1,CHEMBL624276,,1088.0
11504,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,50597,,,1,12038,BAO_0000218,1,CHEMBL624277,,1088.0
11505,,,,A,U,Autocuration,,,% dose converted to 2-amino-5-chlorophenyl sulfate,22224,,,1,14314,BAO_0000019,0,CHEMBL624278,,
11506,,,,A,U,Autocuration,,,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),22224,,,1,14314,BAO_0000019,0,CHEMBL624279,,
11507,,Rattus norvegicus,,A,N,Intermediate,Feces,10116.0,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",50597,,,1,11488,BAO_0000218,1,CHEMBL624280,,1988.0
11508,,Rattus norvegicus,,A,N,Intermediate,Feces,10116.0,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",50597,,,1,11488,BAO_0000218,1,CHEMBL624281,,1988.0
11509,,Rattus norvegicus,,A,N,Intermediate,Feces,10116.0,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",50597,,,1,11488,BAO_0000218,1,CHEMBL622933,,1988.0
11510,,Rattus norvegicus,,A,N,Intermediate,Feces,10116.0,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",50597,,,1,11488,BAO_0000218,1,CHEMBL622934,,1988.0
11511,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,50597,,,1,8829,BAO_0000218,1,CHEMBL622935,,2107.0
11512,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in Rat liver after 5 minutes of iv administration,50597,,,1,8829,BAO_0000218,1,CHEMBL622936,,2107.0
11513,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,50597,,,1,8829,BAO_0000218,1,CHEMBL875228,,2107.0
11514,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in Rat lung after 24 hours of iv administration,50597,,,1,8829,BAO_0000218,1,CHEMBL622937,,2048.0
11515,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,50597,,,1,8829,BAO_0000218,1,CHEMBL622938,,2048.0
11516,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in Rat lung after 30 minutes of iv administration,50597,,,1,8829,BAO_0000218,1,CHEMBL619736,,2048.0
11517,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,50597,,,1,8829,BAO_0000218,1,CHEMBL625117,,2048.0
11518,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in Rat lung after 5 minutes of iv administration,50597,,,1,8829,BAO_0000218,1,CHEMBL625118,,2048.0
11519,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,50597,,,1,8829,BAO_0000218,1,CHEMBL625119,,2048.0
11520,In vivo,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",50597,,,1,14972,BAO_0000218,1,CHEMBL625120,,2037.0
11521,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",50597,,,1,14972,BAO_0000218,1,CHEMBL625121,,
11522,In vivo,Rattus norvegicus,,A,N,Intermediate,Thalamus,10116.0,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",50597,,,1,14972,BAO_0000218,1,CHEMBL625122,,10000006.0
11523,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,,,1,14608,BAO_0000218,1,CHEMBL622204,,178.0
11524,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,,,1,14608,BAO_0000218,1,CHEMBL877503,,178.0
11525,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,,,1,14608,BAO_0000218,1,CHEMBL627127,,178.0
11526,In vivo,,,A,U,Autocuration,Hippocampus,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,22224,,,1,14608,BAO_0000218,0,CHEMBL627128,,10000000.0
11527,In vivo,,,A,U,Autocuration,Hippocampus,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,22224,,,1,14608,BAO_0000218,0,CHEMBL627129,,10000000.0
11528,In vivo,,,A,U,Autocuration,Hippocampus,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,22224,,,1,14608,BAO_0000218,0,CHEMBL627130,,10000000.0
11529,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,,,1,14608,BAO_0000218,1,CHEMBL627131,,955.0
11530,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,,,1,14608,BAO_0000218,1,CHEMBL627132,,955.0
11531,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,,,1,14608,BAO_0000218,1,CHEMBL627133,,955.0
11532,In vivo,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,,,1,14608,BAO_0000218,1,CHEMBL627134,,2037.0
11533,In vivo,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,,,1,14608,BAO_0000218,1,CHEMBL627135,,2037.0
11534,In vivo,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,,,1,14608,BAO_0000218,1,CHEMBL627136,,2037.0
11535,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,,,1,14608,BAO_0000218,1,CHEMBL628435,,
11536,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,,,1,14608,BAO_0000218,1,CHEMBL628436,,
11537,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,,,1,14608,BAO_0000218,1,CHEMBL628437,,
11538,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,,,1,14608,BAO_0000218,1,CHEMBL628438,,948.0
11539,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,,,1,14608,BAO_0000218,1,CHEMBL628439,,948.0
11540,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,,,1,14608,BAO_0000218,1,CHEMBL628440,,948.0
11541,In vivo,Rattus norvegicus,,A,N,Intermediate,Hippocampus,10116.0,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,,,1,14608,BAO_0000218,1,CHEMBL628441,,10000000.0
11542,In vivo,Rattus norvegicus,,A,N,Intermediate,Hippocampus,10116.0,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,,,1,14608,BAO_0000218,1,CHEMBL628442,,10000000.0
11543,In vivo,Rattus norvegicus,,A,N,Intermediate,Hippocampus,10116.0,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,,,1,14608,BAO_0000218,1,CHEMBL628443,,10000000.0
11544,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,,,1,14608,BAO_0000218,1,CHEMBL628444,,2113.0
11545,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,,,1,14608,BAO_0000218,1,CHEMBL628445,,2113.0
11546,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,,,1,14608,BAO_0000218,1,CHEMBL877504,,2113.0
11547,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,,,1,14608,BAO_0000218,1,CHEMBL628446,,2107.0
11548,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,,,1,14608,BAO_0000218,1,CHEMBL626874,,2107.0
11549,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,,,1,14608,BAO_0000218,1,CHEMBL626875,,2107.0
11550,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,,,1,14608,BAO_0000218,1,CHEMBL626876,,2048.0
11551,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,,,1,14608,BAO_0000218,1,CHEMBL626877,,2048.0
11552,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,,,1,14608,BAO_0000218,1,CHEMBL626878,,2048.0
11553,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,,,1,14608,BAO_0000218,1,CHEMBL626879,,2385.0
11554,In vivo,Simiiformes,,A,U,Autocuration,Plasma,314293.0,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,22224,,,1,8918,BAO_0000218,0,CHEMBL626880,,1969.0
11555,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,50594,,,1,8918,BAO_0000218,1,CHEMBL626881,,1969.0
11556,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,50597,,,1,8918,BAO_0000218,1,CHEMBL626882,,1969.0
11557,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Peak plasma concentration was measured in dogs,50588,,,1,14470,BAO_0000218,1,CHEMBL626883,,1969.0
11558,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,50597,,,1,14393,BAO_0000218,1,CHEMBL626884,,
11559,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,50597,,,1,14886,BAO_0000218,1,CHEMBL626885,,
11560,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,50597,,,1,14886,BAO_0000218,1,CHEMBL626886,,
11561,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,50597,,,1,14886,BAO_0000218,1,CHEMBL626887,,
11562,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,50597,,,1,14393,BAO_0000218,1,CHEMBL626888,,
11563,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,50588,,,1,13465,BAO_0000218,1,CHEMBL626889,,
11564,In vivo,Simiiformes,,A,U,Autocuration,,314293.0,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,22224,,,1,13465,BAO_0000218,0,CHEMBL626761,,
11565,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,50588,,,1,13465,BAO_0000218,1,CHEMBL626762,,
11566,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,50588,,,1,13465,BAO_0000218,1,CHEMBL626763,,
11567,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,50597,,,1,13465,BAO_0000218,1,CHEMBL626764,,
11568,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,50597,,,1,13465,BAO_0000218,1,CHEMBL626765,,
11569,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,50588,,,1,13465,BAO_0000218,1,CHEMBL626766,,
11570,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,50597,,,1,13465,BAO_0000218,1,CHEMBL626767,,
11571,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,50597,,,1,13465,BAO_0000218,1,CHEMBL626768,,
11572,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,50588,,,1,13465,BAO_0000218,1,CHEMBL626769,,
11573,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,50588,,,1,13465,BAO_0000218,1,CHEMBL874463,,
11574,In vivo,Simiiformes,,A,U,Autocuration,,314293.0,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,22224,,,1,13465,BAO_0000218,0,CHEMBL626770,,
11575,In vivo,Simiiformes,,A,U,Autocuration,,314293.0,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,22224,,,1,13465,BAO_0000218,0,CHEMBL626771,,
11576,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,50597,,,1,13465,BAO_0000218,1,CHEMBL626772,,
11577,In vivo,Macaca fascicularis,,A,N,Intermediate,,9541.0,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,100710,,,1,14731,BAO_0000218,1,CHEMBL626773,,
11578,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,50594,,,1,14731,BAO_0000218,1,CHEMBL626774,,
11579,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,50588,,,1,13376,BAO_0000218,1,CHEMBL626775,,
11580,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,50588,,,1,13376,BAO_0000218,1,CHEMBL626776,,
11581,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Maximum concentration (Cmax) in rat when administered orally,50597,,,1,14443,BAO_0000218,1,CHEMBL626777,,
11582,In vivo,Simiiformes,,A,U,Autocuration,Plasma,314293.0,Maximal concentration in monkey plasma after 25 mg/kg oral dose,22224,,,1,13465,BAO_0000218,0,CHEMBL626778,,1969.0
11583,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",22224,,,1,16359,BAO_0000218,0,CHEMBL626779,,
11584,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",22224,,,1,16359,BAO_0000218,0,CHEMBL626780,,
11585,In vivo,,,A,U,Autocuration,Plasma,,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,22224,,,1,15618,BAO_0000218,0,CHEMBL626781,,1969.0
11586,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic profile Cmax was evaluated in rats,50597,,,1,14554,BAO_0000218,1,CHEMBL632164,,
11587,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),50588,,,1,11537,BAO_0000218,1,CHEMBL632165,,
11588,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),50594,,,1,11537,BAO_0000218,1,CHEMBL632166,,
11589,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),50588,,,1,11537,BAO_0000218,1,CHEMBL632167,,
11590,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),50594,,,1,11537,BAO_0000218,1,CHEMBL632168,,
11591,In vivo,Rattus norvegicus,,A,U,Autocuration,Plasma,10116.0,Cmax in rat plasma,22224,,,1,2021,BAO_0000218,0,CHEMBL632169,,1969.0
11592,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Cmax in dog plasma after 30mg/kg oral dose,50588,,,1,5932,BAO_0000218,1,CHEMBL632170,,1969.0
11593,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Cmax in rat plasma after 30mg/kg oral dose,50597,,,1,5932,BAO_0000218,1,CHEMBL632171,,1969.0
11594,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma level in rats at 30 mg/kg,50597,,,1,17320,BAO_0000218,1,CHEMBL632172,,1969.0
11595,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Tested for maximum plasma concentration in mice,50594,,,1,15831,BAO_0000218,1,CHEMBL632173,,1969.0
11596,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",50597,,,1,15078,BAO_0000218,1,CHEMBL632174,,
11597,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,The Cmax values in female wistar rats.,50597,,,1,14941,BAO_0000218,1,CHEMBL632175,,
11598,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,50588,,,1,15343,BAO_0000218,1,CHEMBL632176,,1969.0
11599,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,50597,,,1,15343,BAO_0000218,1,CHEMBL632177,,1969.0
11600,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,50597,,,1,14856,BAO_0000218,1,CHEMBL632178,,1969.0
11601,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,50597,,,1,13129,BAO_0000218,1,CHEMBL632179,,
11602,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,50597,,,1,13098,BAO_0000218,1,CHEMBL632180,,178.0
11603,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,50597,,,1,13098,BAO_0000218,1,CHEMBL632181,,178.0
11604,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,50597,,,1,13098,BAO_0000218,1,CHEMBL632182,,178.0
11605,In vivo,Mus musculus,,A,U,Autocuration,Blood,10090.0,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,22224,,,1,15478,BAO_0000218,0,CHEMBL632183,,178.0
11606,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,50588,,,1,15341,BAO_0000218,1,CHEMBL632184,,
11607,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,50597,,,1,15341,BAO_0000218,1,CHEMBL874470,,
11608,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL631302,,
11609,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL631303,,
11610,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL631304,,
11611,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL631305,,
11612,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL631306,,
11613,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL631307,,
11614,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL631308,,
11615,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL625557,,
11616,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL625558,,2106.0
11617,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL625559,,2106.0
11618,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL625560,,2106.0
11619,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL625561,,2106.0
11620,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL625562,,2106.0
11621,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL875320,,2106.0
11622,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL625563,,2106.0
11623,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL625564,,2106.0
11624,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL625565,,995.0
11625,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL625566,,995.0
11626,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL625567,,995.0
11627,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL625568,,995.0
11628,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL628217,,995.0
11629,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL628218,,995.0
11630,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL628219,,995.0
11631,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",50597,,,1,8684,BAO_0000218,1,CHEMBL628220,,995.0
11632,,,,A,U,Autocuration,,,Distribution in the blood after 120 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628221,,
11633,,,,A,U,Autocuration,,,Distribution in the blood after 15 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628222,,
11634,,,,A,U,Autocuration,,,Distribution in the blood after 30 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628223,,
11635,,,,A,U,Autocuration,,,Distribution in the blood after 5 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628224,,
11636,,,,A,U,Autocuration,,,Distribution in the blood after 60 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628225,,
11637,,,,A,U,Autocuration,,,Distribution in the blood after 90 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628226,,
11638,,,,A,U,Autocuration,,,Distribution in the bone after 120 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628227,,
11639,,,,A,U,Autocuration,,,Distribution in the bone after 15 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL875481,,
11640,,,,A,U,Autocuration,,,Distribution in the bone after 30 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628228,,
11641,,,,A,U,Autocuration,,,Distribution in the bone after 5 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628229,,
11642,,,,A,U,Autocuration,,,Distribution in the bone after 60 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628230,,
11643,,,,A,U,Autocuration,,,Distribution in the bone after 90 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628231,,
11644,,,,A,U,Autocuration,,,Distribution in the heart after 120 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628232,,
11645,,,,A,U,Autocuration,,,Distribution in the heart after 15 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628233,,
11646,,,,A,U,Autocuration,,,Distribution in the heart after 30 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628234,,
11647,,,,A,U,Autocuration,,,Distribution in the heart after 5 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628235,,
11648,,,,A,U,Autocuration,,,Distribution in the heart after 60 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628236,,
11649,,,,A,U,Autocuration,,,Distribution in the heart after 90 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628237,,
11650,,,,A,U,Autocuration,,,Distribution in the kidneys after 120 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628238,,
11651,,,,A,U,Autocuration,,,Distribution in the kidneys after 15 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628239,,
11652,,,,A,U,Autocuration,,,Distribution in the kidneys after 30 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628240,,
11653,,,,A,U,Autocuration,,,Distribution in the kidneys after 5 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628241,,
11654,,,,A,U,Autocuration,,,Distribution in the kidneys after 60 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628242,,
11655,,,,A,U,Autocuration,,,Distribution in the kidneys after 90 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL875482,,
11656,,,,A,U,Autocuration,,,Distribution in the liver after 120 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628243,,
11657,,,,A,U,Autocuration,,,Distribution in the liver after 15 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628244,,
11658,,,,A,U,Autocuration,,,Distribution in the liver after 30 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628245,,
11659,,,,A,U,Autocuration,,,Distribution in the liver after 5 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628246,,
11660,,,,A,U,Autocuration,,,Distribution in the liver after 60 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628247,,
11661,,,,A,U,Autocuration,,,Distribution in the liver after 90 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628248,,
11662,,,,A,U,Autocuration,,,Distribution in the lung after 120 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628249,,
11663,,Mus musculus,,A,N,Intermediate,,10090.0,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",50594,,,1,14839,BAO_0000218,1,CHEMBL625452,,
11664,,Mus musculus,,A,N,Intermediate,,10090.0,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",50594,,,1,14839,BAO_0000218,1,CHEMBL625453,,
11665,,Mus musculus,,A,N,Intermediate,,10090.0,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",50594,,,1,14839,BAO_0000218,1,CHEMBL625454,,
11666,,Mus musculus,,A,N,Intermediate,,10090.0,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",50594,,,1,14839,BAO_0000218,1,CHEMBL623844,,
11667,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,50597,,,1,12178,BAO_0000218,1,CHEMBL623845,,
11668,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,50597,,,1,12178,BAO_0000218,1,CHEMBL623846,,
11669,,,,A,U,Autocuration,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,22224,,,1,12178,BAO_0000218,0,CHEMBL623847,,
11670,,Macaca fascicularis,,A,N,Intermediate,,9541.0,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,100710,,,1,12186,BAO_0000218,1,CHEMBL623848,,
11671,,Macaca fascicularis,,A,N,Intermediate,,9541.0,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,100710,,,1,12186,BAO_0000218,1,CHEMBL623849,,
11672,,Macaca fascicularis,,A,N,Intermediate,,9541.0,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,100710,,,1,12186,BAO_0000218,1,CHEMBL623850,,
11673,,Macaca fascicularis,,A,N,Intermediate,,9541.0,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,100710,,,1,12186,BAO_0000218,1,CHEMBL623851,,
11674,,Simiiformes,,A,U,Autocuration,,314293.0,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,22224,,,1,12187,BAO_0000218,0,CHEMBL623852,,
11675,,Mustela putorius furo,,A,N,Intermediate,,9669.0,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,50506,,,1,12187,BAO_0000218,1,CHEMBL624551,,
11676,,Mustela putorius furo,,A,N,Intermediate,,9669.0,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",50506,,,1,12187,BAO_0000218,1,CHEMBL624552,,
11677,,Simiiformes,,A,U,Autocuration,,314293.0,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,22224,,,1,12187,BAO_0000218,0,CHEMBL624553,,
11678,,Simiiformes,,A,U,Autocuration,,314293.0,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,22224,,,1,12187,BAO_0000218,0,CHEMBL624554,,
11679,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,50597,,,1,12187,BAO_0000218,1,CHEMBL624555,,
11680,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",50597,,,1,12187,BAO_0000218,1,CHEMBL624741,,
11681,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",50588,,,1,14122,BAO_0000218,1,CHEMBL624742,,
11682,,Cricetinae,,A,N,Intermediate,,10026.0,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",100712,,,1,14122,BAO_0000218,1,CHEMBL624743,,
11683,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",50597,,,1,14122,BAO_0000218,1,CHEMBL877606,,
11684,,,,A,U,Autocuration,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,22224,,,1,13391,BAO_0000218,0,CHEMBL624744,,
11685,,,,A,U,Autocuration,Blood,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,22224,,,1,13391,BAO_0000218,0,CHEMBL624745,,178.0
11686,,,,A,U,Autocuration,Blood,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,22224,,,1,13391,BAO_0000218,0,CHEMBL624746,,178.0
11687,,,,A,U,Autocuration,Blood,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,22224,,,1,13391,BAO_0000218,0,CHEMBL624747,,178.0
11688,,,,A,U,Autocuration,,,Oral absorption expressed as Area under curve was determined,22224,,,1,16360,BAO_0000019,0,CHEMBL624748,,
11689,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,50588,,,1,3673,BAO_0000218,1,CHEMBL622504,,
11690,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",50588,,,1,14122,BAO_0000218,1,CHEMBL622505,,
11691,,Cricetinae,,A,N,Intermediate,,10026.0,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",100712,,,1,14122,BAO_0000218,1,CHEMBL622506,,
11692,,Cricetinae,,A,N,Intermediate,,10026.0,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",100712,,,1,14122,BAO_0000218,1,CHEMBL622507,,
11693,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",50597,,,1,14122,BAO_0000218,1,CHEMBL622508,,
11694,,,,A,U,Autocuration,,,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,22224,,,1,13889,BAO_0000019,0,CHEMBL622509,,
11695,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,50597,,,1,14393,BAO_0000218,1,CHEMBL622510,,
11696,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),50597,,,1,17279,BAO_0000218,1,CHEMBL622511,,
11697,,Macaca fascicularis,,A,N,Intermediate,,9541.0,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,100710,,,1,14548,BAO_0000218,1,CHEMBL622512,,
11698,,Macaca fascicularis,,A,N,Intermediate,,9541.0,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,100710,,,1,14548,BAO_0000218,1,CHEMBL622513,,
11699,,Macaca fascicularis,,A,N,Intermediate,,9541.0,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,100710,,,1,14548,BAO_0000218,1,CHEMBL622514,,
11700,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,50588,,,1,14548,BAO_0000218,1,CHEMBL622515,,
11701,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,50588,,,1,14548,BAO_0000218,1,CHEMBL622516,,
11702,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,50597,,,1,14548,BAO_0000218,1,CHEMBL622517,,
11703,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,50597,,,1,14548,BAO_0000218,1,CHEMBL622518,,
11704,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,50597,,,1,14548,BAO_0000218,1,CHEMBL622519,,
11705,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,,,1,14608,BAO_0000218,1,CHEMBL622520,,2385.0
11706,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,,,1,14608,BAO_0000218,1,CHEMBL622521,,2385.0
11707,In vivo,Mus musculus,,A,N,Intermediate,Zone of skin,10090.0,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,50594,,,1,14608,BAO_0000218,1,CHEMBL625113,,14.0
11708,In vivo,Rattus norvegicus,,A,N,Intermediate,Zone of skin,10116.0,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,,,1,14608,BAO_0000218,1,CHEMBL625114,,14.0
11709,In vivo,Rattus norvegicus,,A,N,Intermediate,Zone of skin,10116.0,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,,,1,14608,BAO_0000218,1,CHEMBL874397,,14.0
11710,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,,,1,14608,BAO_0000218,1,CHEMBL625115,,2106.0
11711,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,,,1,14608,BAO_0000218,1,CHEMBL625116,,2106.0
11712,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,,,1,14608,BAO_0000218,1,CHEMBL623932,,2106.0
11713,In vivo,Rattus norvegicus,,A,N,Intermediate,Striatum,10116.0,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,,,1,14608,BAO_0000218,1,CHEMBL623933,,2435.0
11714,In vivo,Rattus norvegicus,,A,N,Intermediate,Striatum,10116.0,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,,,1,14608,BAO_0000218,1,CHEMBL623934,,2435.0
11715,In vivo,Rattus norvegicus,,A,N,Intermediate,Striatum,10116.0,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,,,1,14608,BAO_0000218,1,CHEMBL623935,,2435.0
11716,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,50597,,,1,14608,BAO_0000218,1,CHEMBL623936,,2046.0
11717,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,50597,,,1,14608,BAO_0000218,1,CHEMBL623937,,2046.0
11718,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,50597,,,1,14608,BAO_0000218,1,CHEMBL623938,,2046.0
11719,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,50594,,,1,15383,BAO_0000218,1,CHEMBL623939,,
11720,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL623940,,
11721,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL623941,,
11722,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL627216,,
11723,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL623942,,
11724,,Mus musculus,,A,N,Intermediate,Brain,10090.0,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,50594,,,1,15383,BAO_0000218,1,CHEMBL618793,,955.0
11725,,Mus musculus,,A,N,Intermediate,Brain,10090.0,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL618794,,955.0
11726,,Mus musculus,,A,N,Intermediate,Brain,10090.0,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL618795,,955.0
11727,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL618796,,
11728,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL618797,,
11729,,Mus musculus,,A,N,Intermediate,Kidney,10090.0,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,50594,,,1,15383,BAO_0000218,1,CHEMBL618798,,2113.0
11730,,Mus musculus,,A,N,Intermediate,Kidney,10090.0,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,50594,,,1,15383,BAO_0000218,1,CHEMBL618799,,2113.0
11731,,Mus musculus,,A,N,Intermediate,Kidney,10090.0,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL618800,,2113.0
11732,,Mus musculus,,A,N,Intermediate,Kidney,10090.0,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL618801,,2113.0
11733,,Mus musculus,,A,N,Intermediate,Kidney,10090.0,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL618802,,2113.0
11734,,Mus musculus,,A,N,Intermediate,Kidney,10090.0,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL618803,,2113.0
11735,,Mus musculus,,A,N,Intermediate,Liver,10090.0,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,50594,,,1,15383,BAO_0000218,1,CHEMBL618804,,2107.0
11736,,Mus musculus,,A,N,Intermediate,Liver,10090.0,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,50594,,,1,15383,BAO_0000218,1,CHEMBL618805,,2107.0
11737,,Mus musculus,,A,N,Intermediate,Liver,10090.0,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL618806,,2107.0
11738,,Mus musculus,,A,N,Intermediate,Liver,10090.0,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL618807,,2107.0
11739,,Mus musculus,,A,N,Intermediate,Liver,10090.0,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL618808,,2107.0
11740,,Mus musculus,,A,N,Intermediate,Liver,10090.0,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL618809,,2107.0
11741,,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,50594,,,1,15383,BAO_0000218,1,CHEMBL618810,,2385.0
11742,,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL618811,,2385.0
11743,,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL875844,,2385.0
11744,,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL618812,,2385.0
11745,,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL618813,,2385.0
11746,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,50594,,,1,15383,BAO_0000218,1,CHEMBL618814,,
11747,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL618815,,
11748,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL618816,,
11749,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL618817,,
11750,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL620544,,
11751,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,50597,,,1,15341,BAO_0000218,1,CHEMBL626230,,
11752,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,50597,,,1,15341,BAO_0000218,1,CHEMBL626231,,
11753,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,50597,,,1,15341,BAO_0000218,1,CHEMBL626232,,
11754,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,50588,,,1,14906,BAO_0000218,1,CHEMBL626233,,1969.0
11755,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,50597,,,1,14906,BAO_0000218,1,CHEMBL626234,,1969.0
11756,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,50597,,,1,14906,BAO_0000218,1,CHEMBL875341,,1969.0
11757,In vivo,Homo sapiens,,A,N,Intermediate,Plasma,9606.0,The maximum plasma concentration (100 mg/kg) administered orally in human,50587,,,1,14215,BAO_0000218,1,CHEMBL626235,,1969.0
11758,In vivo,Callithrix,,A,U,Autocuration,Plasma,9481.0,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,22224,,,1,14215,BAO_0000218,0,CHEMBL626236,,1969.0
11759,In vivo,Simiiformes,,A,U,Autocuration,Plasma,314293.0,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,22224,,,1,14215,BAO_0000218,0,CHEMBL626237,,1969.0
11760,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,50588,,,1,14215,BAO_0000218,1,CHEMBL626238,,1969.0
11761,In vivo,Homo sapiens,,A,N,Intermediate,Plasma,9606.0,The maximum plasma concentration (200 mg/kg) administered orally in human,50587,,,1,14215,BAO_0000218,1,CHEMBL622412,,1969.0
11762,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,50597,,,1,14215,BAO_0000218,1,CHEMBL623114,,1969.0
11763,In vivo,Callithrix,,A,U,Autocuration,Plasma,9481.0,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,22224,,,1,14215,BAO_0000218,0,CHEMBL623115,,1969.0
11764,In vivo,Simiiformes,,A,U,Autocuration,Plasma,314293.0,The maximum plasma concentration (25 mg/kg) administered orally in monkey,22224,,,1,14215,BAO_0000218,0,CHEMBL623116,,1969.0
11765,In vivo,Canis lupus familiaris,,A,U,Autocuration,Plasma,9615.0,The maximum plasma concentration (30 mg/kg) administered orally in dog,22224,,,1,14215,BAO_0000218,0,CHEMBL623117,,1969.0
11766,In vivo,Homo sapiens,,A,N,Intermediate,Plasma,9606.0,The maximum plasma concentration (400 mg/kg) administered orally in human,50587,,,1,14215,BAO_0000218,1,CHEMBL623118,,1969.0
11767,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,50597,,,1,14215,BAO_0000218,1,CHEMBL623119,,1969.0
11768,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,The maximum plasma concentration (50 mg/kg) administered orally in rat,50597,,,1,14215,BAO_0000218,1,CHEMBL623120,,1969.0
11769,In vivo,Homo sapiens,,A,N,Intermediate,Plasma,9606.0,The maximum plasma concentration (800 mg/kg) administered orally in human,50587,,,1,14215,BAO_0000218,1,CHEMBL623286,,1969.0
11770,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,The maximum plasma concentration was measured on rats,50597,,,1,14067,BAO_0000218,1,CHEMBL623287,,1969.0
11771,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,The maximum plasma concentration was measured on rats after oral administration,50597,,,1,12350,BAO_0000218,1,CHEMBL623288,,1969.0
11772,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma drug Cmax in rat (PO dose),50597,,,1,14813,BAO_0000218,1,CHEMBL623289,,1969.0
11773,In vivo,,,A,U,Autocuration,,,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,22224,,,1,12536,BAO_0000218,0,CHEMBL623290,,
11774,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,maximum Plasma concentration in Dog was determined after Peroral administration,50588,,,1,14169,BAO_0000218,1,CHEMBL623291,,1969.0
11775,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,maximum Plasma concentration in Rats was determined after Peroral administration,50597,,,1,14169,BAO_0000218,1,CHEMBL623292,,1969.0
11776,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,50588,,,1,15604,BAO_0000218,1,CHEMBL623293,,1969.0
11777,In vivo,Simiiformes,,A,U,Autocuration,Plasma,314293.0,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,22224,,,1,15604,BAO_0000218,0,CHEMBL623294,,1969.0
11778,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,50597,,,1,15604,BAO_0000218,1,CHEMBL623295,,1969.0
11779,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,maximum concentration was measured when administered through oral route in mice,50594,,,1,14387,BAO_0000218,1,CHEMBL623296,,
11780,,Mus musculus,,A,N,Intermediate,,10090.0,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,50594,,,1,15115,BAO_0000218,1,CHEMBL875349,,
11781,,Simiiformes,,A,U,Autocuration,,314293.0,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,22224,,,1,15115,BAO_0000019,0,CHEMBL623297,,
11782,,Simiiformes,,A,U,Autocuration,,314293.0,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,22224,,,1,15115,BAO_0000019,0,CHEMBL623298,,
11783,,Simiiformes,,A,U,Autocuration,,314293.0,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,22224,,,1,15115,BAO_0000019,0,CHEMBL623299,,
11784,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter was evaluated in rats,50597,,,1,16359,BAO_0000218,1,CHEMBL623300,,
11785,,Mus musculus,,A,N,Intermediate,,10090.0,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,50594,,,1,12829,BAO_0000218,1,CHEMBL623301,,
11786,,Mus musculus,,A,N,Intermediate,,10090.0,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,50594,,,1,12829,BAO_0000218,1,CHEMBL623302,,
11787,,Mus musculus,,A,N,Intermediate,,10090.0,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,50594,,,1,12829,BAO_0000218,1,CHEMBL623303,,
11788,,Mus musculus,,A,N,Intermediate,,10090.0,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,50594,,,1,12829,BAO_0000218,1,CHEMBL623304,,
11789,,Mus musculus,,A,N,Intermediate,,10090.0,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,50594,,,1,12829,BAO_0000218,1,CHEMBL623305,,
11790,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,50597,,,1,15137,BAO_0000218,1,CHEMBL623306,,1969.0
11791,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,50597,,,1,15137,BAO_0000218,1,CHEMBL623307,,1969.0
11792,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,50597,,,1,15137,BAO_0000218,1,CHEMBL623308,,1969.0
11793,,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,50594,,,1,15137,BAO_0000218,1,CHEMBL623309,,1969.0
11794,,Mus musculus,,A,N,Intermediate,,10090.0,Plasma Concentration after 120 min of oral administration to mice,50594,,,1,13509,BAO_0000218,1,CHEMBL623310,,
11795,,Mus musculus,,A,N,Intermediate,,10090.0,Plasma Concentration after 30 min of oral administration to mice,50594,,,1,13509,BAO_0000218,1,CHEMBL623311,,
11796,,Macaca fascicularis,,A,N,Intermediate,,9541.0,Plasma Concentration after 60 min of oral administration to mice,100710,,,1,13509,BAO_0000218,1,CHEMBL623312,,
11797,,Mus musculus,,A,N,Intermediate,,10090.0,Plasma Concentration after 60 min of oral administration to mice; Not determined,50594,,,1,13509,BAO_0000218,1,CHEMBL875350,,
11798,,Mus musculus,,A,N,Intermediate,,10090.0,Plasma Concentration after 90 min of oral administration to mice,50594,,,1,13509,BAO_0000218,1,CHEMBL628635,,
11799,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,50597,,,1,12064,BAO_0000218,1,CHEMBL628636,,
11800,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,50597,,,1,12064,BAO_0000218,1,CHEMBL628637,,
11801,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,50597,,,1,12064,BAO_0000218,1,CHEMBL628058,,
11802,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,50597,,,1,10677,BAO_0000218,1,CHEMBL628059,,
11803,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,50597,,,1,10677,BAO_0000218,1,CHEMBL628060,,
11804,,,,A,U,Autocuration,,,Distribution in the lung after 15 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628061,,
11805,,,,A,U,Autocuration,,,Distribution in the lung after 30 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628062,,
11806,,,,A,U,Autocuration,,,Distribution in the lung after 5 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628063,,
11807,,,,A,U,Autocuration,,,Distribution in the lung after 60 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628064,,
11808,,,,A,U,Autocuration,,,Distribution in the lung after 90 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628065,,
11809,,,,A,U,Autocuration,Muscle tissue,,Distribution in the muscle after 120 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628066,,2385.0
11810,,,,A,U,Autocuration,Muscle tissue,,Distribution in the muscle after 15 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628067,,2385.0
11811,,Mus musculus,,A,N,Intermediate,Muscle tissue,10090.0,Distribution in the muscle after 30 min of intravenous administration,50594,,,1,8926,BAO_0000218,1,CHEMBL874646,,2385.0
11812,,,,A,U,Autocuration,Muscle tissue,,Distribution in the muscle after 5 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628068,,2385.0
11813,,,,A,U,Autocuration,Muscle tissue,,Distribution in the muscle after 60 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628069,,2385.0
11814,,,,A,U,Autocuration,Muscle tissue,,Distribution in the muscle after 90 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628070,,2385.0
11815,,,,A,U,Autocuration,Spleen,,Distribution in the spleen after 120 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628071,,2106.0
11816,,,,A,U,Autocuration,Spleen,,Distribution in the spleen after 15 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628072,,2106.0
11817,,,,A,U,Autocuration,Spleen,,Distribution in the spleen after 30 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628073,,2106.0
11818,,,,A,U,Autocuration,Spleen,,Distribution in the spleen after 5 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628074,,2106.0
11819,,,,A,U,Autocuration,Spleen,,Distribution in the spleen after 60 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628075,,2106.0
11820,,,,A,U,Autocuration,Spleen,,Distribution in the spleen after 90 min of intravenous administration,22224,,,1,8926,BAO_0000019,0,CHEMBL628076,,2106.0
11821,,Rattus norvegicus,,A,N,Intermediate,Adrenal cortex,10116.0,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,50597,,,1,7570,BAO_0000218,1,CHEMBL628077,,1235.0
11822,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,50597,,,1,7570,BAO_0000218,1,CHEMBL628078,,178.0
11823,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,50597,,,1,7570,BAO_0000218,1,CHEMBL628079,,2107.0
11824,,Rattus norvegicus,,A,N,Intermediate,Female gonad,10116.0,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,50597,,,1,7570,BAO_0000218,1,CHEMBL628080,,992.0
11825,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,50597,,,1,7570,BAO_0000218,1,CHEMBL628081,,2046.0
11826,,Rattus norvegicus,,A,N,Intermediate,Adrenal cortex,10116.0,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,50597,,,1,7570,BAO_0000218,1,CHEMBL628082,,1235.0
11827,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,50597,,,1,7570,BAO_0000218,1,CHEMBL874647,,178.0
11828,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,50597,,,1,7570,BAO_0000218,1,CHEMBL626406,,2107.0
11829,,Rattus norvegicus,,A,N,Intermediate,Female gonad,10116.0,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,50597,,,1,7570,BAO_0000218,1,CHEMBL626407,,992.0
11830,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,50597,,,1,7570,BAO_0000218,1,CHEMBL626408,,2046.0
11831,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",50597,,,1,8608,BAO_0000218,1,CHEMBL626409,,178.0
11832,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",50597,,,1,8608,BAO_0000218,1,CHEMBL626410,,178.0
11833,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",50597,,,1,8608,BAO_0000218,1,CHEMBL626411,,178.0
11834,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",50597,,,1,8608,BAO_0000218,1,CHEMBL626412,,178.0
11835,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",50597,,,1,8608,BAO_0000218,1,CHEMBL626413,,178.0
11836,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",50597,,,1,8608,BAO_0000218,1,CHEMBL626414,,178.0
11837,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",50597,,,1,8608,BAO_0000218,1,CHEMBL626415,,178.0
11838,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",50597,,,1,8608,BAO_0000218,1,CHEMBL626416,,178.0
11839,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",50597,,,1,8608,BAO_0000218,1,CHEMBL627062,,178.0
11840,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",50597,,,1,8608,BAO_0000218,1,CHEMBL627063,,178.0
11841,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",50597,,,1,8608,BAO_0000218,1,CHEMBL627064,,178.0
11842,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",50597,,,1,8608,BAO_0000218,1,CHEMBL627227,,178.0
11843,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",50597,,,1,8608,BAO_0000218,1,CHEMBL627228,,178.0
11844,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",50597,,,1,8608,BAO_0000218,1,CHEMBL627229,,178.0
11845,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",50597,,,1,8608,BAO_0000218,1,CHEMBL625792,,178.0
11846,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",50597,,,1,8608,BAO_0000218,1,CHEMBL625793,,178.0
11847,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",50597,,,1,8608,BAO_0000218,1,CHEMBL625794,,178.0
11848,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",50597,,,1,8608,BAO_0000218,1,CHEMBL625795,,178.0
11849,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,50594,,,1,13792,BAO_0000218,1,CHEMBL625796,,
11850,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,50588,,,1,13376,BAO_0000218,1,CHEMBL625797,,
11851,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,50588,,,1,13376,BAO_0000218,1,CHEMBL625798,,
11852,,,,A,U,Autocuration,,,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,22224,,,1,14380,BAO_0000218,0,CHEMBL875613,,
11853,,,,A,U,Autocuration,,,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,22224,,,1,14380,BAO_0000218,0,CHEMBL625799,,
11854,,,,A,U,Autocuration,,,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,22224,,,1,14380,BAO_0000218,0,CHEMBL625800,,
11855,,,,A,U,Autocuration,,,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,22224,,,1,14380,BAO_0000218,0,CHEMBL625801,,
11856,,,,A,U,Autocuration,,,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,22224,,,1,14380,BAO_0000218,0,CHEMBL625802,,
11857,,,,A,U,Autocuration,,,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,22224,,,1,14380,BAO_0000218,0,CHEMBL625803,,
11858,,,,A,U,Autocuration,,,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,22224,,,1,14380,BAO_0000019,0,CHEMBL625804,,
11859,,,,A,U,Autocuration,,,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,22224,,,1,14380,BAO_0000218,0,CHEMBL622530,,
11860,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,50594,,,1,13701,BAO_0000218,1,CHEMBL622531,,
11861,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),50594,,,1,13701,BAO_0000218,1,CHEMBL622532,,
11862,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),50594,,,1,13701,BAO_0000218,1,CHEMBL623176,,
11863,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),50594,,,1,13701,BAO_0000218,1,CHEMBL623177,,
11864,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),50594,,,1,13701,BAO_0000218,1,CHEMBL623178,,
11865,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,50594,,,1,13701,BAO_0000218,1,CHEMBL623179,,
11866,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),50594,,,1,13701,BAO_0000218,1,CHEMBL623180,,
11867,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),50594,,,1,13701,BAO_0000218,1,CHEMBL623181,,
11868,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),50594,,,1,13701,BAO_0000218,1,CHEMBL624131,,
11869,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),50594,,,1,13701,BAO_0000218,1,CHEMBL624132,,
11870,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),50594,,,1,13701,BAO_0000218,1,CHEMBL624133,,
11871,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,50594,,,1,13701,BAO_0000218,1,CHEMBL624846,,
11872,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),50594,,,1,13701,BAO_0000218,1,CHEMBL624847,,
11873,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),50594,,,1,13701,BAO_0000218,1,CHEMBL624848,,
11874,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),50594,,,1,13701,BAO_0000218,1,CHEMBL625012,,
11875,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),50594,,,1,13701,BAO_0000218,1,CHEMBL625013,,
11876,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,50594,,,1,13701,BAO_0000218,1,CHEMBL625014,,
11877,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),50594,,,1,13701,BAO_0000218,1,CHEMBL625015,,
11878,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),50594,,,1,13701,BAO_0000218,1,CHEMBL625016,,
11879,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,50594,,,1,13701,BAO_0000218,1,CHEMBL625017,,
11880,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),50594,,,1,13701,BAO_0000218,1,CHEMBL625018,,
11881,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),50594,,,1,13701,BAO_0000218,1,CHEMBL625019,,
11882,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),50594,,,1,13701,BAO_0000218,1,CHEMBL625020,,
11883,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,50594,,,1,13701,BAO_0000218,1,CHEMBL625021,,
11884,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,50597,,,1,14393,BAO_0000218,1,CHEMBL625022,,
11885,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,50594,,,1,14731,BAO_0000218,1,CHEMBL625023,,
11886,,Macaca fascicularis,,A,N,Intermediate,,9541.0,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,100710,,,1,14731,BAO_0000218,1,CHEMBL625024,,
11887,,Macaca fascicularis,,A,N,Intermediate,,9541.0,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,100710,,,1,14731,BAO_0000218,1,CHEMBL627626,,
11888,,,,A,U,Autocuration,Brain,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,22224,,,1,13758,BAO_0000218,0,CHEMBL627627,,955.0
11889,,,,A,U,Autocuration,Serum,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,22224,,,1,13758,BAO_0000218,0,CHEMBL627628,,1977.0
11890,,,,A,U,Autocuration,Brain,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,22224,,,1,13758,BAO_0000218,0,CHEMBL627629,,955.0
11891,,,,A,U,Autocuration,Serum,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,22224,,,1,13758,BAO_0000218,0,CHEMBL627630,,1977.0
11892,,,,A,U,Autocuration,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),22224,,,1,16359,BAO_0000019,0,CHEMBL627631,,
11893,,,,A,U,Autocuration,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),22224,,,1,16359,BAO_0000218,0,CHEMBL629515,,
11894,,Mus musculus,,A,N,Intermediate,Spleen,10090.0,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,50594,,,1,15383,BAO_0000218,1,CHEMBL629516,,2106.0
11895,,Mus musculus,,A,N,Intermediate,Spleen,10090.0,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL629517,,2106.0
11896,,Mus musculus,,A,N,Intermediate,Spleen,10090.0,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL629518,,2106.0
11897,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,50594,,,1,15383,BAO_0000218,1,CHEMBL877499,,
11898,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL629519,,
11899,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL629520,,
11900,,Mus musculus,,A,N,Intermediate,,10090.0,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,50594,,,1,15383,BAO_0000218,1,CHEMBL629521,,
11901,,Mus musculus,,A,N,Intermediate,,10090.0,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),50594,,,1,14439,BAO_0000218,1,CHEMBL629522,,
11902,,Mus musculus,,A,N,Intermediate,,10090.0,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),50594,,,1,14439,BAO_0000218,1,CHEMBL629523,,
11903,,Mus musculus,,A,N,Intermediate,,10090.0,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),50594,,,1,14439,BAO_0000218,1,CHEMBL629524,,
11904,,Mus musculus,,A,N,Intermediate,,10090.0,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),50594,,,1,14439,BAO_0000218,1,CHEMBL629525,,
11905,,Mus musculus,,A,N,Intermediate,,10090.0,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),50594,,,1,14439,BAO_0000218,1,CHEMBL629526,,
11906,,Mus musculus,,A,N,Intermediate,,10090.0,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),50594,,,1,14439,BAO_0000218,1,CHEMBL629527,,
11907,,Mus musculus,,A,N,Intermediate,,10090.0,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),50594,,,1,14439,BAO_0000218,1,CHEMBL629528,,
11908,,Mus musculus,,A,N,Intermediate,,10090.0,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),50594,,,1,14439,BAO_0000218,1,CHEMBL629529,,
11909,,Mus musculus,,A,N,Intermediate,,10090.0,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),50594,,,1,14439,BAO_0000218,1,CHEMBL629530,,
11910,,Mus musculus,,A,N,Intermediate,,10090.0,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),50594,,,1,14439,BAO_0000218,1,CHEMBL629531,,
11911,,Mus musculus,,A,N,Intermediate,,10090.0,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),50594,,,1,14439,BAO_0000218,1,CHEMBL628656,,
11912,,Mus musculus,,A,N,Intermediate,,10090.0,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),50594,,,1,14439,BAO_0000218,1,CHEMBL628657,,
11913,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL628658,,
11914,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL628659,,
11915,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL877500,,
11916,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL628660,,
11917,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL628661,,
11918,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL628662,,
11919,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL628663,,
11920,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL628664,,
11921,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL628665,,178.0
11922,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL628666,,178.0
11923,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL628667,,178.0
11924,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL628668,,178.0
11925,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL628669,,178.0
11926,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL628670,,178.0
11927,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL628671,,178.0
11928,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL628672,,10000001.0
11929,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL630300,,10000001.0
11930,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL629787,,10000001.0
11931,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL629788,,10000001.0
11932,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL629789,,955.0
11933,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL629790,,955.0
11934,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL629791,,955.0
11935,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL629792,,955.0
11936,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL629793,,955.0
11937,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL629794,,955.0
11938,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,50597,,,1,10677,BAO_0000218,1,CHEMBL874459,,
11939,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,50597,,,1,10677,BAO_0000218,1,CHEMBL629795,,
11940,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,50597,,,1,10677,BAO_0000218,1,CHEMBL629796,,
11941,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,50597,,,1,10677,BAO_0000218,1,CHEMBL629797,,
11942,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,50597,,,1,10677,BAO_0000218,1,CHEMBL629798,,
11943,In vivo,Rattus norvegicus,,A,N,Intermediate,Adrenal gland,10116.0,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL629799,,2369.0
11944,In vivo,Rattus norvegicus,,A,N,Intermediate,Adrenal gland,10116.0,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL629800,,2369.0
11945,In vivo,Rattus norvegicus,,A,N,Intermediate,Adrenal gland,10116.0,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL629801,,2369.0
11946,In vivo,Rattus norvegicus,,A,N,Intermediate,Adrenal gland,10116.0,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,50597,,,1,10911,BAO_0000218,1,CHEMBL629802,,2369.0
11947,In vivo,Rattus norvegicus,,A,N,Intermediate,Adrenal gland,10116.0,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL629803,,2369.0
11948,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL629804,,178.0
11949,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL629805,,178.0
11950,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL629806,,178.0
11951,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL629807,,178.0
11952,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL629808,,178.0
11953,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL629809,,955.0
11954,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL629810,,955.0
11955,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL629811,,955.0
11956,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL629812,,955.0
11957,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL629813,,955.0
11958,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL874460,,955.0
11959,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL629814,,
11960,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL629815,,
11961,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL629816,,
11962,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL629817,,
11963,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL626643,,2113.0
11964,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL626644,,2113.0
11965,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL626806,,2113.0
11966,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL626807,,2113.0
11967,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627261,,2107.0
11968,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627262,,2107.0
11969,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627263,,2107.0
11970,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627264,,2107.0
11971,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627265,,2048.0
11972,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627266,,2048.0
11973,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627267,,2048.0
11974,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627268,,2048.0
11975,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627269,,2385.0
11976,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627270,,2385.0
11977,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",50597,,,1,8608,BAO_0000218,1,CHEMBL627271,,
11978,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",50597,,,1,8608,BAO_0000218,1,CHEMBL627946,,
11979,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",50597,,,1,8608,BAO_0000218,1,CHEMBL875472,,
11980,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",50597,,,1,8608,BAO_0000218,1,CHEMBL627947,,
11981,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",50597,,,1,8608,BAO_0000218,1,CHEMBL627948,,
11982,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",50597,,,1,8608,BAO_0000218,1,CHEMBL628113,,
11983,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",50597,,,1,8608,BAO_0000218,1,CHEMBL628114,,
11984,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",50597,,,1,8608,BAO_0000218,1,CHEMBL628115,,
11985,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",50597,,,1,8608,BAO_0000218,1,CHEMBL628116,,
11986,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",50597,,,1,8608,BAO_0000218,1,CHEMBL628117,,
11987,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",50597,,,1,8608,BAO_0000218,1,CHEMBL628118,,
11988,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",50597,,,1,8608,BAO_0000218,1,CHEMBL628119,,
11989,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",50597,,,1,8608,BAO_0000218,1,CHEMBL628120,,
11990,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",50597,,,1,8608,BAO_0000218,1,CHEMBL628121,,
11991,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",50597,,,1,8608,BAO_0000218,1,CHEMBL628122,,
11992,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",50597,,,1,8608,BAO_0000218,1,CHEMBL627297,,
11993,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",50597,,,1,8608,BAO_0000218,1,CHEMBL627298,,
11994,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",50597,,,1,8608,BAO_0000218,1,CHEMBL627299,,
11995,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",50597,,,1,8608,BAO_0000218,1,CHEMBL627300,,
11996,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",50597,,,1,8608,BAO_0000218,1,CHEMBL627301,,
11997,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",50597,,,1,8608,BAO_0000218,1,CHEMBL627302,,
11998,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",50597,,,1,8608,BAO_0000218,1,CHEMBL627303,,
11999,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",50597,,,1,8608,BAO_0000218,1,CHEMBL627304,,
12000,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",50597,,,1,8608,BAO_0000218,1,CHEMBL627305,,
12001,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",50597,,,1,8608,BAO_0000218,1,CHEMBL627306,,
12002,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",50597,,,1,8608,BAO_0000218,1,CHEMBL623982,,
12003,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",50597,,,1,8608,BAO_0000218,1,CHEMBL623983,,
12004,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",50597,,,1,8608,BAO_0000218,1,CHEMBL623984,,
12005,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",50597,,,1,8608,BAO_0000218,1,CHEMBL623985,,
12006,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",50597,,,1,8608,BAO_0000218,1,CHEMBL623986,,
12007,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",50597,,,1,8608,BAO_0000218,1,CHEMBL623987,,
12008,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",50597,,,1,8608,BAO_0000218,1,CHEMBL623988,,
12009,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",50597,,,1,8608,BAO_0000218,1,CHEMBL623989,,
12010,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",50597,,,1,8608,BAO_0000218,1,CHEMBL622215,,
12011,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",50597,,,1,8608,BAO_0000218,1,CHEMBL622216,,
12012,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",50597,,,1,8608,BAO_0000218,1,CHEMBL877481,,
12013,,,,A,U,Autocuration,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),22224,,,1,16359,BAO_0000218,0,CHEMBL622217,,
12014,,Mus musculus,,A,N,Intermediate,,10090.0,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),50594,,,1,13701,BAO_0000218,1,CHEMBL622218,,
12015,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic profile AUC was evaluated in rats,50597,,,1,14554,BAO_0000218,1,CHEMBL622219,,
12016,,,,A,U,Autocuration,,,Pharmacokinetic property (Area under curve),22224,,,1,6241,BAO_0000019,0,CHEMBL622220,,
12017,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",50588,,,1,11537,BAO_0000218,1,CHEMBL622221,,
12018,,Mus musculus,,A,N,Intermediate,,10090.0,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",50594,,,1,11537,BAO_0000218,1,CHEMBL622222,,
12019,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",50588,,,1,11537,BAO_0000218,1,CHEMBL622223,,
12020,,Mus musculus,,A,N,Intermediate,,10090.0,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",50594,,,1,11537,BAO_0000218,1,CHEMBL622224,,
12021,,,,A,U,Autocuration,,,Plasma concentration (AUC) was determined,22224,,,1,13118,BAO_0000019,0,CHEMBL622225,,
12022,,,,A,U,Autocuration,,,Plasma concentration (AUC) was determined; Not detectable,22224,,,1,13118,BAO_0000019,0,CHEMBL622226,,
12023,,Cavia porcellus,,A,N,Intermediate,,10141.0,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),50512,,,1,9562,BAO_0000218,1,CHEMBL624154,,
12024,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,50597,,,1,10363,BAO_0000218,1,CHEMBL624155,,
12025,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,50597,,,1,10363,BAO_0000218,1,CHEMBL624156,,
12026,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,50597,,,1,10363,BAO_0000218,1,CHEMBL624157,,
12027,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,50597,,,1,10363,BAO_0000218,1,CHEMBL624158,,
12028,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,50597,,,1,12504,BAO_0000218,1,CHEMBL624159,,
12029,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,50597,,,1,12504,BAO_0000218,1,CHEMBL624160,,
12030,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,50597,,,1,12504,BAO_0000218,1,CHEMBL624161,,
12031,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,50597,,,1,12504,BAO_0000218,1,CHEMBL624162,,
12032,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,50588,,,1,13317,BAO_0000218,1,CHEMBL624163,,
12033,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",50597,,,1,15078,BAO_0000218,1,CHEMBL624164,,
12034,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The AUC(0-infinity) values in female wistar rats.,50597,,,1,14941,BAO_0000218,1,CHEMBL624165,,
12035,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",50597,,,1,15078,BAO_0000218,1,CHEMBL624166,,
12036,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",50597,,,1,15078,BAO_0000218,1,CHEMBL624167,,
12037,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The AUC(0-t)values in female wistar rats.,50597,,,1,14941,BAO_0000218,1,CHEMBL624168,,
12038,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The Area under the concentration time curve of compound was measured on rats,50597,,,1,14067,BAO_0000218,1,CHEMBL624169,,
12039,,Homo sapiens,,A,N,Intermediate,,9606.0,The area under curve (100 mg/kg) administered orally in humans,50587,,,1,14215,BAO_0000218,1,CHEMBL624170,,
12040,,Callithrix,,A,U,Autocuration,,9481.0,The area under curve (12.5 mg/kg) administered intravenously in marmoset,22224,,,1,14215,BAO_0000218,0,CHEMBL624171,,
12041,,Simiiformes,,A,U,Autocuration,,314293.0,The area under curve (12.5 mg/kg) administered intravenously in monkey,22224,,,1,14215,BAO_0000218,0,CHEMBL624172,,
12042,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,The area under curve (15 mg/kg) administered intravenously in dog,50588,,,1,14215,BAO_0000218,1,CHEMBL624173,,
12043,,Homo sapiens,,A,N,Intermediate,,9606.0,The area under curve (200 mg/kg) administered orally in humans,50587,,,1,14215,BAO_0000218,1,CHEMBL877488,,
12044,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The area under curve (25 mg/kg) administered intravenously in rat,50597,,,1,14215,BAO_0000218,1,CHEMBL624174,,
12045,,Callithrix,,A,U,Autocuration,,9481.0,The area under curve (25 mg/kg) administered orally in marmoset,22224,,,1,14215,BAO_0000218,0,CHEMBL624175,,
12046,,Simiiformes,,A,U,Autocuration,,314293.0,The area under curve (25 mg/kg) administered orally in monkey,22224,,,1,14215,BAO_0000218,0,CHEMBL624176,,
12047,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,The area under curve (30 mg/kg) administered orally in dog,50588,,,1,14215,BAO_0000218,1,CHEMBL624177,,
12048,,Homo sapiens,,A,N,Intermediate,,9606.0,The area under curve (400 mg/kg) administered orally in humans,50587,,,1,14215,BAO_0000218,1,CHEMBL624178,,
12049,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The area under curve (50 mg/kg) administered orally in fasted rat,50597,,,1,14215,BAO_0000218,1,CHEMBL624179,,
12050,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The area under curve (50 mg/kg) administered orally in rat,50597,,,1,14215,BAO_0000218,1,CHEMBL627689,,
12051,,Homo sapiens,,A,N,Intermediate,,9606.0,The area under curve (800 mg/kg) administered orally in humans,50587,,,1,14215,BAO_0000218,1,CHEMBL627690,,
12052,,,,A,U,Autocuration,,,The compound was evaluated for area under the curve,22224,,,1,11324,BAO_0000019,0,CHEMBL627691,,
12053,,Callithrix,,A,U,Autocuration,,9481.0,The compound was evaluated for area under the curve in marmosets,22224,,,1,11324,BAO_0000019,0,CHEMBL627692,,
12054,,Callithrix,,A,U,Autocuration,,9481.0,The compound was evaluated for area under the curve in marmosets,22224,,,1,11324,BAO_0000019,0,CHEMBL627693,,
12055,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,50597,,,1,13875,BAO_0000218,1,CHEMBL627694,,
12056,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,50597,,,1,13875,BAO_0000218,1,CHEMBL627695,,
12057,,,,A,U,Autocuration,,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),22224,,,1,13875,BAO_0000218,0,CHEMBL627696,,
12058,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,50597,,,1,13875,BAO_0000218,1,CHEMBL627697,,
12059,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,50597,,,1,13875,BAO_0000218,1,CHEMBL627698,,
12060,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,50597,,,1,13875,BAO_0000218,1,CHEMBL627699,,
12061,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,50597,,,1,13807,BAO_0000218,1,CHEMBL627700,,
12062,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Total drug exposure is determined after oral dosing in rats.,50597,,,1,14127,BAO_0000218,1,CHEMBL627701,,
12063,,,,A,U,Autocuration,,,Total drug exposure (5 mg/kg) when administered intravenously,22224,,,1,15116,BAO_0000218,0,CHEMBL627702,,
12064,,,,A,U,Autocuration,,,Total drug exposure (5 mg/kg) when administered orally,22224,,,1,15116,BAO_0000218,0,CHEMBL627703,,
12065,,Simiiformes,,A,U,Autocuration,,314293.0,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,22224,,,1,15604,BAO_0000218,0,CHEMBL626873,,
12066,,Rattus norvegicus,,A,N,Intermediate,,10116.0,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,50597,,,1,15604,BAO_0000218,1,CHEMBL629583,,
12067,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,50588,,,1,15604,BAO_0000218,1,CHEMBL629584,,
12068,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,50588,,,1,15604,BAO_0000218,1,CHEMBL629585,,
12069,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL629586,,955.0
12070,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL629587,,955.0
12071,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL629588,,
12072,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL629589,,
12073,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL629590,,
12074,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL629591,,
12075,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL629592,,
12076,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL629593,,
12077,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL629594,,
12078,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL629595,,948.0
12079,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL630290,,948.0
12080,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627137,,948.0
12081,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627138,,948.0
12082,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627139,,948.0
12083,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627140,,948.0
12084,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627141,,948.0
12085,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627142,,2113.0
12086,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627143,,2113.0
12087,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL874449,,2113.0
12088,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627144,,2113.0
12089,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627145,,2113.0
12090,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627146,,2113.0
12091,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627147,,2113.0
12092,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627148,,2107.0
12093,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627149,,2048.0
12094,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL632160,,2048.0
12095,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL632161,,2048.0
12096,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL632162,,2048.0
12097,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL632163,,2048.0
12098,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL874469,,2048.0
12099,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627182,,2048.0
12100,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627183,,2385.0
12101,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627184,,2385.0
12102,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627185,,2385.0
12103,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627186,,2385.0
12104,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627187,,2385.0
12105,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627188,,2385.0
12106,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627189,,2385.0
12107,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627190,,
12108,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627191,,2107.0
12109,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627192,,2107.0
12110,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL627193,,2107.0
12111,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL874590,,2385.0
12112,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627194,,2385.0
12113,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627195,,2385.0
12114,In vivo,Rattus norvegicus,,A,N,Intermediate,Female gonad,10116.0,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627196,,992.0
12115,In vivo,Rattus norvegicus,,A,N,Intermediate,Female gonad,10116.0,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627197,,992.0
12116,In vivo,Rattus norvegicus,,A,N,Intermediate,Female gonad,10116.0,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627198,,992.0
12117,In vivo,Rattus norvegicus,,A,N,Intermediate,Female gonad,10116.0,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,50597,,,1,10911,BAO_0000218,1,CHEMBL627199,,992.0
12118,In vivo,Rattus norvegicus,,A,N,Intermediate,Female gonad,10116.0,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627200,,992.0
12119,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627201,,1969.0
12120,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627202,,1969.0
12121,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627203,,1969.0
12122,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627204,,1969.0
12123,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627205,,2106.0
12124,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627206,,2106.0
12125,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627207,,2106.0
12126,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627208,,2106.0
12127,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627209,,2046.0
12128,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627210,,2046.0
12129,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627211,,2046.0
12130,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627212,,2046.0
12131,In vivo,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL627213,,995.0
12132,In vivo,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL626599,,995.0
12133,In vivo,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL626600,,995.0
12134,In vivo,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,50597,,,1,10911,BAO_0000218,1,CHEMBL626601,,995.0
12135,,,,A,U,Autocuration,,,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,22224,,,1,8081,BAO_0000019,0,CHEMBL627484,,
12136,,Macaca fascicularis,,A,N,Intermediate,Plasma,9541.0,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),100710,,,1,17248,BAO_0000218,1,CHEMBL627485,,1969.0
12137,,Macaca fascicularis,,A,N,Intermediate,Plasma,9541.0,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,100710,,,1,17248,BAO_0000218,1,CHEMBL628147,,1969.0
12138,,Macaca fascicularis,,A,N,Intermediate,Plasma,9541.0,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,100710,,,1,17248,BAO_0000218,1,CHEMBL628148,,1969.0
12139,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),50588,,,1,17248,BAO_0000218,1,CHEMBL628149,,1969.0
12140,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,50588,,,1,17248,BAO_0000218,1,CHEMBL628150,,1969.0
12141,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,50588,,,1,17248,BAO_0000218,1,CHEMBL628318,,1969.0
12142,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,50588,,,1,17248,BAO_0000218,1,CHEMBL628319,,1969.0
12143,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",50588,,,1,15592,BAO_0000218,1,CHEMBL875609,,
12144,,,,A,U,Autocuration,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,22224,,,1,7040,BAO_0000019,0,CHEMBL628320,,
12145,,,,A,U,Autocuration,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,22224,,,1,7040,BAO_0000019,0,CHEMBL628321,,
12146,,,,A,U,Autocuration,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,22224,,,1,7040,BAO_0000019,0,CHEMBL628322,,
12147,,,,A,U,Autocuration,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,22224,,,1,7040,BAO_0000019,0,CHEMBL628323,,
12148,,,,A,U,Autocuration,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,22224,,,1,7040,BAO_0000019,0,CHEMBL628324,,
12149,,,,A,U,Autocuration,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,22224,,,1,7040,BAO_0000019,0,CHEMBL628325,,
12150,,,,A,U,Autocuration,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,22224,,,1,7040,BAO_0000019,0,CHEMBL628326,,
12151,,Canis lupus familiaris,,A,N,Intermediate,Adrenal medulla,9615.0,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",50588,,,1,9614,BAO_0000218,1,CHEMBL628327,,1236.0
12152,,Canis lupus familiaris,,A,N,Intermediate,Adrenal medulla,9615.0,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",50588,,,1,9614,BAO_0000218,1,CHEMBL628328,,1236.0
12153,,Canis lupus familiaris,,A,N,Intermediate,Blood,9615.0,"Concentration of compound in blood of dog 1, after administering intravenously",50588,,,1,9614,BAO_0000218,1,CHEMBL628329,,178.0
12154,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",50597,,,1,8608,BAO_0000218,1,CHEMBL628330,,2107.0
12155,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",50597,,,1,8608,BAO_0000218,1,CHEMBL628331,,2107.0
12156,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",50597,,,1,8608,BAO_0000218,1,CHEMBL628332,,2107.0
12157,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",50597,,,1,8608,BAO_0000218,1,CHEMBL628333,,2107.0
12158,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",50597,,,1,8608,BAO_0000218,1,CHEMBL628334,,2107.0
12159,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",50597,,,1,8608,BAO_0000218,1,CHEMBL628335,,2107.0
12160,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",50597,,,1,8608,BAO_0000218,1,CHEMBL628336,,2107.0
12161,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",50597,,,1,8608,BAO_0000218,1,CHEMBL628337,,2107.0
12162,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",50597,,,1,8608,BAO_0000218,1,CHEMBL628338,,2107.0
12163,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",50597,,,1,8608,BAO_0000218,1,CHEMBL875610,,2107.0
12164,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",50597,,,1,8608,BAO_0000218,1,CHEMBL628339,,2107.0
12165,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",50597,,,1,8608,BAO_0000218,1,CHEMBL628340,,2107.0
12166,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",50597,,,1,8608,BAO_0000218,1,CHEMBL628341,,2107.0
12167,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",50597,,,1,8608,BAO_0000218,1,CHEMBL622214,,2107.0
12168,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",50597,,,1,8608,BAO_0000218,1,CHEMBL623167,,2107.0
12169,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",50597,,,1,8608,BAO_0000218,1,CHEMBL623168,,2107.0
12170,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",50597,,,1,8608,BAO_0000218,1,CHEMBL623169,,2107.0
12171,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",50597,,,1,8608,BAO_0000218,1,CHEMBL623170,,2107.0
12172,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",50597,,,1,8608,BAO_0000218,1,CHEMBL627224,,2048.0
12173,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",50597,,,1,8608,BAO_0000218,1,CHEMBL875634,,2048.0
12174,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",50597,,,1,8608,BAO_0000218,1,CHEMBL627225,,2048.0
12175,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",50597,,,1,8608,BAO_0000218,1,CHEMBL627226,,2048.0
12176,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",50597,,,1,8608,BAO_0000218,1,CHEMBL626083,,2048.0
12177,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",50597,,,1,8608,BAO_0000218,1,CHEMBL626084,,2048.0
12178,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",50597,,,1,8608,BAO_0000218,1,CHEMBL626085,,2048.0
12179,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",50597,,,1,8608,BAO_0000218,1,CHEMBL626086,,2048.0
12180,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",50597,,,1,8608,BAO_0000218,1,CHEMBL626087,,2048.0
12181,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",50597,,,1,8608,BAO_0000218,1,CHEMBL626088,,2048.0
12182,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",50597,,,1,8608,BAO_0000218,1,CHEMBL626089,,2048.0
12183,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",50597,,,1,8608,BAO_0000218,1,CHEMBL626090,,2048.0
12184,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",50597,,,1,8608,BAO_0000218,1,CHEMBL626091,,2048.0
12185,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",50597,,,1,8608,BAO_0000218,1,CHEMBL626092,,2048.0
12186,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",50597,,,1,8608,BAO_0000218,1,CHEMBL626093,,2048.0
12187,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",50597,,,1,8608,BAO_0000218,1,CHEMBL626094,,2048.0
12188,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",50597,,,1,8608,BAO_0000218,1,CHEMBL626095,,2048.0
12189,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",50597,,,1,8608,BAO_0000218,1,CHEMBL626096,,2048.0
12190,,Simiiformes,,A,U,Autocuration,,314293.0,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,22224,,,1,15604,BAO_0000218,0,CHEMBL626097,,
12191,,Rattus norvegicus,,A,N,Intermediate,,10116.0,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,50597,,,1,15604,BAO_0000218,1,CHEMBL626098,,
12192,,,,A,U,Autocuration,Plasma,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,22224,,,1,1806,BAO_0000218,0,CHEMBL626099,,1969.0
12193,,,,A,U,Autocuration,Plasma,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,22224,,,1,1806,BAO_0000218,0,CHEMBL626100,,1969.0
12194,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,AUC 0-inf in dog,50588,,,1,17237,BAO_0000218,1,CHEMBL626101,,1969.0
12195,,Cavia porcellus,,A,N,Intermediate,Plasma,10141.0,AUC 0-inf in guinea pig,50512,,,1,17237,BAO_0000218,1,CHEMBL626102,,1969.0
12196,,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,AUC 0-t in dog,50588,,,1,17237,BAO_0000218,1,CHEMBL626103,,1969.0
12197,,Cavia porcellus,,A,N,Intermediate,Plasma,10141.0,AUC 0-t in guinea pig,50512,,,1,17237,BAO_0000218,1,CHEMBL628391,,1969.0
12198,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The compound was tested for brain to plasma partition in rat,50597,,,1,15194,BAO_0000218,1,CHEMBL628392,,
12199,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The compound was tested for brain to plasma partition in rat.,50597,,,1,15194,BAO_0000218,1,CHEMBL628393,,
12200,,,,A,U,Autocuration,Blood,,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,22224,,,1,8787,BAO_0000019,0,CHEMBL628394,,178.0
12201,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,50588,,,1,17025,BAO_0000218,1,CHEMBL628395,,
12202,,Simiiformes,,A,U,Autocuration,,314293.0,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,22224,,,1,17025,BAO_0000218,0,CHEMBL628396,,
12203,,Oryctolagus cuniculus,,A,N,Intermediate,,9986.0,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,50592,,,1,17025,BAO_0000218,1,CHEMBL628397,,
12204,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,50597,,,1,17025,BAO_0000218,1,CHEMBL628398,,
12205,,Macaca mulatta,,A,N,Intermediate,,9544.0,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,50797,,,1,4236,BAO_0000218,1,CHEMBL628399,,
12206,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,50588,,,1,15343,BAO_0000218,1,CHEMBL628400,,
12207,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,50597,,,1,15343,BAO_0000218,1,CHEMBL874907,,
12208,,,,A,U,Autocuration,,,Area under curve of the compound was determined,22224,,,1,17720,BAO_0000019,0,CHEMBL628401,,
12209,,Simiiformes,,A,U,Autocuration,Plasma,314293.0,AUC in monkeys at a dose of 1 mg/kg,22224,,,1,17788,BAO_0000218,0,CHEMBL628402,,1969.0
12210,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,AUC in rats at a dose of 1 mg/kg,50597,,,1,17788,BAO_0000218,1,CHEMBL628403,,1969.0
12211,,,,A,U,Autocuration,,,Compound was evaluated for the overall absorbance loss at pH of 2,22224,,,1,8778,BAO_0000019,0,CHEMBL628404,,
12212,,,,A,U,Autocuration,,,Compound was evaluated for the overall absorbance loss at pH of 4,22224,,,1,8778,BAO_0000019,0,CHEMBL628405,,
12213,,,,A,U,Autocuration,,,Compound was evaluated for the overall absorbance loss at pH of 7,22224,,,1,8778,BAO_0000019,0,CHEMBL628406,,
12214,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for its absorption in the rats,50597,,,1,2249,BAO_0000218,1,CHEMBL628407,,
12215,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,50597,,,1,8881,BAO_0000218,1,CHEMBL628408,,1088.0
12216,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,50597,,,1,8881,BAO_0000218,1,CHEMBL629171,,1088.0
12217,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,50597,,,1,8881,BAO_0000218,1,CHEMBL629172,,1088.0
12218,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,50597,,,1,8881,BAO_0000218,1,CHEMBL629173,,1088.0
12219,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro percent permeability into rat ileum,50597,,,1,15286,BAO_0000218,1,CHEMBL629174,,
12220,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro percent permeability into rat ileum; Range is 10-17,50597,,,1,15286,BAO_0000218,1,CHEMBL629175,,
12221,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro percent permeability into rat ileum; Range is 10-18,50597,,,1,15286,BAO_0000218,1,CHEMBL629176,,
12222,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro percent permeability into rat ileum; Range is 10-19,50597,,,1,15286,BAO_0000218,1,CHEMBL629177,,
12223,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro percent permeability into rat ileum; Range is 12-15,50597,,,1,15286,BAO_0000218,1,CHEMBL629178,,
12224,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro percent permeability into rat ileum; Range is 13-19,50597,,,1,15286,BAO_0000218,1,CHEMBL631869,,
12225,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro percent permeability into rat ileum; Range is 14-17,50597,,,1,15286,BAO_0000218,1,CHEMBL631870,,
12226,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro percent permeability into rat ileum; Range is 15-18,50597,,,1,15286,BAO_0000218,1,CHEMBL631871,,
12227,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro percent permeability into rat ileum; Range is 2-5,50597,,,1,15286,BAO_0000218,1,CHEMBL631872,,
12228,,,,A,U,Autocuration,Ileum,,In vitro percent permeability into rat ileum; Range is 23-42,22224,,,1,15286,BAO_0000221,0,CHEMBL875775,,2116.0
12229,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro percent permeability into rat ileum; Range is 28-36,50597,,,1,15286,BAO_0000218,1,CHEMBL631873,,
12230,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro percent permeability into rat ileum; Range is 29-35,50597,,,1,15286,BAO_0000218,1,CHEMBL631874,,
12231,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro percent permeability into rat ileum; Range is 46-66,50597,,,1,15286,BAO_0000218,1,CHEMBL631875,,
12232,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro percent permeability into rat ileum; Range is 50-68,50597,,,1,15286,BAO_0000218,1,CHEMBL631876,,
12233,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro percent permeability into rat ileum; Range is 78-81,50597,,,1,15286,BAO_0000218,1,CHEMBL631877,,
12234,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,50597,,,1,15286,BAO_0000218,1,CHEMBL631878,,
12235,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro percent permeability into rat ileum; nd indicates not detected,50597,,,1,15286,BAO_0000218,1,CHEMBL631879,,
12236,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro percent permeability into rat ileum; nt indicates not detected,50597,,,1,15286,BAO_0000218,1,CHEMBL631880,,
12237,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro percent permeability into rat ileum; nt indicates not tested,50597,,,1,15286,BAO_0000218,1,CHEMBL631881,,
12238,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was tested for oral absorption in bile-duct cannulated rats,50597,,,1,13770,BAO_0000218,1,CHEMBL631882,,
12239,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was tested for oral absorption in bile-duct cannulated rats.,50597,,,1,13770,BAO_0000218,1,CHEMBL630749,,
12240,,Homo sapiens,,A,N,Intermediate,,9606.0,Oral absorption using Caco-2 cell monolayers.,50587,,,1,5202,BAO_0000218,1,CHEMBL630750,,
12241,,Homo sapiens,,A,N,Intermediate,,9606.0,Percent of the drug absorbed after administration to humans was determined,50587,,,1,14920,BAO_0000218,1,CHEMBL630253,,
12242,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,50597,,,1,14103,BAO_0000218,1,CHEMBL630254,,1969.0
12243,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,50597,,,1,14103,BAO_0000218,1,CHEMBL630255,,1969.0
12244,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,50597,,,1,14103,BAO_0000218,1,CHEMBL630256,,1969.0
12245,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL875781,,2107.0
12246,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL630257,,2107.0
12247,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",50597,,,1,13751,BAO_0000218,1,CHEMBL630258,,2107.0
12248,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",50597,,,1,15807,BAO_0000218,1,CHEMBL630259,,
12249,,Rattus norvegicus,,A,N,Intermediate,Striatum,10116.0,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",50597,,,1,15807,BAO_0000218,1,CHEMBL630260,,2435.0
12250,,Rattus norvegicus,,A,N,Intermediate,Striatum,10116.0,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",50597,,,1,15807,BAO_0000218,1,CHEMBL630261,,2435.0
12251,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,50597,,,1,14950,BAO_0000218,1,CHEMBL630262,,
12252,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,50597,,,1,14950,BAO_0000218,1,CHEMBL630263,,
12253,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,50597,,,1,14950,BAO_0000218,1,CHEMBL630264,,
12254,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,50597,,,1,14950,BAO_0000218,1,CHEMBL630265,,
12255,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,50597,,,1,14950,BAO_0000218,1,CHEMBL630266,,
12256,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,50597,,,1,14950,BAO_0000218,1,CHEMBL630267,,2113.0
12257,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,50597,,,1,14950,BAO_0000218,1,CHEMBL630268,,2113.0
12258,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,50597,,,1,14950,BAO_0000218,1,CHEMBL630269,,
12259,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,50597,,,1,14950,BAO_0000218,1,CHEMBL630270,,
12260,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,50597,,,1,14950,BAO_0000218,1,CHEMBL630141,,2048.0
12261,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,50597,,,1,14950,BAO_0000218,1,CHEMBL630142,,2048.0
12262,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,50597,,,1,14950,BAO_0000218,1,CHEMBL630143,,2385.0
12263,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,50597,,,1,14950,BAO_0000218,1,CHEMBL630144,,2385.0
12264,,Rattus norvegicus,,A,N,Intermediate,Prostate gland,10116.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,50597,,,1,14950,BAO_0000218,1,CHEMBL630145,,2367.0
12265,,Rattus norvegicus,,A,N,Intermediate,Prostate gland,10116.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,50597,,,1,14950,BAO_0000218,1,CHEMBL630146,,2367.0
12266,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,50597,,,1,14950,BAO_0000218,1,CHEMBL630147,,
12267,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,50597,,,1,14950,BAO_0000218,1,CHEMBL630148,,
12268,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,50597,,,1,14950,BAO_0000218,1,CHEMBL630149,,
12269,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,50597,,,1,14950,BAO_0000218,1,CHEMBL630150,,2106.0
12270,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,50597,,,1,14950,BAO_0000218,1,CHEMBL630151,,2106.0
12271,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,50597,,,1,14950,BAO_0000218,1,CHEMBL632031,,2046.0
12272,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,50597,,,1,14950,BAO_0000218,1,CHEMBL632032,,2046.0
12273,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,50597,,,1,14950,BAO_0000218,1,CHEMBL632033,,
12274,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,50597,,,1,14950,BAO_0000218,1,CHEMBL632034,,
12275,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,50597,,,1,14950,BAO_0000218,1,CHEMBL632035,,2385.0
12276,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,50597,,,1,14950,BAO_0000218,1,CHEMBL632036,,
12277,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,50597,,,1,14950,BAO_0000218,1,CHEMBL632037,,2046.0
12278,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL632038,,178.0
12279,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL632039,,178.0
12280,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL632040,,178.0
12281,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL632041,,178.0
12282,,Canis lupus familiaris,,A,N,Intermediate,Blood,9615.0,"Concentration of compound in blood of dog 2, after administering intravenously",50588,,,1,9614,BAO_0000218,1,CHEMBL632042,,178.0
12283,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,"Concentration of compound in left ventricle of dog 1, after administering intravenously",50588,,,1,9614,BAO_0000218,1,CHEMBL632043,,
12284,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,"Concentration of compound in left ventricle of dog 2, after administering intravenously",50588,,,1,9614,BAO_0000218,1,CHEMBL632044,,
12285,,Canis lupus familiaris,,A,N,Intermediate,Liver,9615.0,"Concentration of compound in liver of dog 1, after administering intravenously",50588,,,1,9614,BAO_0000218,1,CHEMBL632045,,2107.0
12286,,Canis lupus familiaris,,A,N,Intermediate,Liver,9615.0,"Concentration of compound in liver of dog 2, after administering intravenously",50588,,,1,9614,BAO_0000218,1,CHEMBL632046,,2107.0
12287,,Canis lupus familiaris,,A,N,Intermediate,Lung,9615.0,"Concentration of compound in lung of dog 1, after administering intravenously",50588,,,1,9614,BAO_0000218,1,CHEMBL632047,,2048.0
12288,,Canis lupus familiaris,,A,N,Intermediate,Lung,9615.0,"Concentration of compound in lung of dog 2, after administering intravenously",50588,,,1,9614,BAO_0000218,1,CHEMBL632048,,2048.0
12289,,Canis lupus familiaris,,A,N,Intermediate,Muscle tissue,9615.0,"Concentration of compound in muscle of dog 1, after administering intravenously",50588,,,1,9614,BAO_0000218,1,CHEMBL632049,,2385.0
12290,,Canis lupus familiaris,,A,N,Intermediate,Muscle tissue,9615.0,"Concentration of compound in muscle of dog 2, after administering intravenously",50588,,,1,9614,BAO_0000218,1,CHEMBL876418,,2385.0
12291,,Canis lupus familiaris,,A,N,Intermediate,Spleen,9615.0,"Concentration of compound in spleen of dog 1,after administering intravenously",50588,,,1,9614,BAO_0000218,1,CHEMBL632050,,2106.0
12292,,Canis lupus familiaris,,A,N,Intermediate,Spleen,9615.0,"Concentration of compound in spleen of dog 2, after administering intravenously",50588,,,1,9614,BAO_0000218,1,CHEMBL632051,,2106.0
12293,,,,F,U,Autocuration,,,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,22224,,,1,10353,BAO_0000218,0,CHEMBL632052,,
12294,,,,F,U,Autocuration,,,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,22224,,,1,10353,BAO_0000218,0,CHEMBL632053,,
12295,,,,A,U,Autocuration,,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,22224,,,1,10353,BAO_0000218,0,CHEMBL632054,,
12296,,,,F,U,Autocuration,,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,22224,,,1,10353,BAO_0000218,0,CHEMBL632055,,
12297,,,,F,U,Autocuration,,,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,22224,,,1,10353,BAO_0000218,0,CHEMBL631181,,
12298,,,,A,U,Autocuration,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL631182,,
12299,,,,A,U,Autocuration,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL631183,,
12300,,,,A,U,Autocuration,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL631184,,
12301,,,,A,U,Autocuration,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL629774,,
12302,,,,A,U,Autocuration,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL629775,,
12303,,,,A,U,Autocuration,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL876549,,
12304,,,,A,U,Autocuration,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL628172,,
12305,,,,A,U,Autocuration,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL628173,,
12306,,,,A,U,Autocuration,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL628174,,
12307,,,,A,U,Autocuration,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL628175,,
12308,,,,A,U,Autocuration,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL628176,,
12309,,,,A,U,Autocuration,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL628177,,
12310,,,,A,U,Autocuration,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL628178,,
12311,,,,A,U,Autocuration,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL628179,,
12312,,,,A,U,Autocuration,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,22224,,,1,9196,BAO_0000218,0,CHEMBL628180,,
12313,,,,A,U,Autocuration,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL628181,,
12314,,,,A,U,Autocuration,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL628182,,
12315,,,,A,U,Autocuration,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL628183,,
12316,,,,A,U,Autocuration,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,22224,,,1,9196,BAO_0000218,0,CHEMBL628184,,
12317,,,,A,U,Autocuration,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL628185,,
12318,,,,A,U,Autocuration,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL875617,,
12319,,,,A,U,Autocuration,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,22224,,,1,9196,BAO_0000218,0,CHEMBL628186,,
12320,,,,A,U,Autocuration,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL628187,,
12321,,,,A,U,Autocuration,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL628188,,
12322,,,,A,U,Autocuration,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL628189,,
12323,,,,A,U,Autocuration,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,22224,,,1,9196,BAO_0000218,0,CHEMBL628190,,
12324,,,,A,U,Autocuration,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL628191,,
12325,,,,A,U,Autocuration,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,22224,,,1,9196,BAO_0000218,0,CHEMBL626513,,
12326,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",50597,,,1,8608,BAO_0000218,1,CHEMBL626514,,2046.0
12327,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",50597,,,1,8608,BAO_0000218,1,CHEMBL626515,,2046.0
12328,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",50597,,,1,8608,BAO_0000218,1,CHEMBL626516,,2046.0
12329,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",50597,,,1,8608,BAO_0000218,1,CHEMBL626517,,2046.0
12330,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",50597,,,1,8608,BAO_0000218,1,CHEMBL626518,,2046.0
12331,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",50597,,,1,8608,BAO_0000218,1,CHEMBL626519,,2046.0
12332,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",50597,,,1,8608,BAO_0000218,1,CHEMBL626520,,2046.0
12333,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",50597,,,1,8608,BAO_0000218,1,CHEMBL626521,,2046.0
12334,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",50597,,,1,8608,BAO_0000218,1,CHEMBL626522,,2046.0
12335,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",50597,,,1,8608,BAO_0000218,1,CHEMBL626523,,2046.0
12336,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",50597,,,1,8608,BAO_0000218,1,CHEMBL626524,,2046.0
12337,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",50597,,,1,8608,BAO_0000218,1,CHEMBL626688,,2046.0
12338,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",50597,,,1,8608,BAO_0000218,1,CHEMBL626689,,2046.0
12339,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",50597,,,1,8608,BAO_0000218,1,CHEMBL626690,,2046.0
12340,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",50597,,,1,8608,BAO_0000218,1,CHEMBL626691,,2046.0
12341,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",50597,,,1,8608,BAO_0000218,1,CHEMBL627319,,2046.0
12342,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",50597,,,1,8608,BAO_0000218,1,CHEMBL624052,,2046.0
12343,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",50597,,,1,8608,BAO_0000218,1,CHEMBL624053,,2046.0
12344,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,,,1,8085,BAO_0000218,1,CHEMBL624054,,
12345,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,,,1,8085,BAO_0000218,1,CHEMBL624055,,
12346,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,,,1,8085,BAO_0000218,1,CHEMBL624056,,
12347,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,,,1,8085,BAO_0000218,1,CHEMBL624057,,995.0
12348,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,,,1,8085,BAO_0000218,1,CHEMBL622281,,995.0
12349,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,,,1,8085,BAO_0000218,1,CHEMBL622282,,995.0
12350,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,,,1,8085,BAO_0000218,1,CHEMBL622283,,995.0
12351,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,,,1,8085,BAO_0000218,1,CHEMBL622284,,995.0
12352,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,,,1,8085,BAO_0000218,1,CHEMBL622285,,995.0
12353,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,50597,,,1,8085,BAO_0000218,1,CHEMBL622286,,995.0
12354,,,,P,U,Autocuration,,,Distribution coefficient (D %) between octanol and buffer of pH 7.4,22224,,,1,7657,BAO_0000100,0,CHEMBL622287,,
12355,,Mus musculus,,A,N,Intermediate,,10090.0,Partition coefficient (logD7.4),50594,,,1,8935,BAO_0000218,1,CHEMBL622288,,
12356,,Mus musculus,,A,N,Intermediate,,10090.0,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",50594,,,1,13792,BAO_0000218,1,CHEMBL622289,,
12357,,Mus musculus,,A,N,Intermediate,Brain,10090.0,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",50594,,,1,13792,BAO_0000218,1,CHEMBL622290,,955.0
12358,,Mus musculus,,A,N,Intermediate,,10090.0,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,50594,,,1,13792,BAO_0000218,1,CHEMBL622291,,
12359,,Mus musculus,,A,N,Intermediate,Brain,10090.0,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,50594,,,1,13792,BAO_0000218,1,CHEMBL622292,,955.0
12360,,Mus musculus,,A,N,Intermediate,,10090.0,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",50594,,,1,13792,BAO_0000218,1,CHEMBL622293,,
12361,,Mus musculus,,A,N,Intermediate,Brain,10090.0,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",50594,,,1,13792,BAO_0000218,1,CHEMBL622294,,955.0
12362,,Mus musculus,,A,N,Intermediate,,10090.0,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,50594,,,1,13792,BAO_0000218,1,CHEMBL622295,,
12363,,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,50597,,,1,13792,BAO_0000218,1,CHEMBL622296,,955.0
12364,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,50597,,,1,14103,BAO_0000218,1,CHEMBL874409,,1969.0
12365,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,50597,,,1,14103,BAO_0000218,1,CHEMBL622297,,1969.0
12366,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,50597,,,1,14103,BAO_0000218,1,CHEMBL622298,,1969.0
12367,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,50597,,,1,14103,BAO_0000218,1,CHEMBL622299,,1969.0
12368,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,50597,,,1,14103,BAO_0000218,1,CHEMBL622300,,1969.0
12369,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,50597,,,1,14103,BAO_0000218,1,CHEMBL622301,,1969.0
12370,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,50597,,,1,14103,BAO_0000218,1,CHEMBL622302,,1969.0
12371,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,50597,,,1,14103,BAO_0000218,1,CHEMBL622303,,1969.0
12372,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,50597,,,1,14103,BAO_0000218,1,CHEMBL622304,,1969.0
12373,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,50597,,,1,14103,BAO_0000218,1,CHEMBL622305,,1969.0
12374,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,50597,,,1,14103,BAO_0000218,1,CHEMBL622306,,1969.0
12375,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,50597,,,1,14103,BAO_0000218,1,CHEMBL626864,,1969.0
12376,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,50597,,,1,14103,BAO_0000218,1,CHEMBL626865,,1969.0
12377,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,50597,,,1,14103,BAO_0000218,1,CHEMBL626866,,1969.0
12378,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,50597,,,1,14103,BAO_0000218,1,CHEMBL626867,,1969.0
12379,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,50597,,,1,14103,BAO_0000218,1,CHEMBL626868,,1969.0
12380,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,50597,,,1,14103,BAO_0000218,1,CHEMBL626869,,1969.0
12381,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,50597,,,1,14103,BAO_0000218,1,CHEMBL626870,,1969.0
12382,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,50597,,,1,14103,BAO_0000218,1,CHEMBL626871,,1969.0
12383,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,50597,,,1,14103,BAO_0000218,1,CHEMBL626872,,1969.0
12384,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,50597,,,1,14103,BAO_0000218,1,CHEMBL632185,,1969.0
12385,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,50597,,,1,14103,BAO_0000218,1,CHEMBL632186,,1969.0
12386,,,,A,U,Autocuration,,,Amount of acetic acid produced by the compound,22224,,,1,12904,BAO_0000019,0,CHEMBL629310,,
12387,,,,A,U,Autocuration,,,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,22224,,,1,12904,BAO_0000019,0,CHEMBL629311,,
12388,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Log of (Cbrain/Cblood) in rats,50597,,,1,9663,BAO_0000218,1,CHEMBL629312,,
12389,,,,A,U,Autocuration,,,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),22224,,,1,7652,BAO_0000221,0,CHEMBL629313,,
12390,,,,A,U,Autocuration,,,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),22224,,,1,7652,BAO_0000221,0,CHEMBL629314,,
12391,,,,A,U,Autocuration,,,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),22224,,,1,7652,BAO_0000221,0,CHEMBL629315,,
12392,,,,B,U,Autocuration,,,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),22224,,,1,7652,BAO_0000219,0,CHEMBL629316,,
12393,,,,A,U,Autocuration,,,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),22224,,,1,7652,BAO_0000221,0,CHEMBL629317,,
12394,,,,A,U,Autocuration,,,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),22224,,,1,7652,BAO_0000019,0,CHEMBL629318,,
12395,,,,A,U,Autocuration,,,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),22224,,,1,7652,BAO_0000019,0,CHEMBL877497,,
12396,,,,A,U,Autocuration,,,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),22224,,,1,7652,BAO_0000019,0,CHEMBL629319,,
12397,,,,A,U,Autocuration,,,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),22224,,,1,7652,BAO_0000019,0,CHEMBL629320,,
12398,,,,A,U,Autocuration,,,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),22224,,,1,7652,BAO_0000019,0,CHEMBL629496,,
12399,,,,A,U,Autocuration,,,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),22224,,,1,7652,BAO_0000019,0,CHEMBL629497,,
12400,,,,A,U,Autocuration,,,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),22224,,,1,7652,BAO_0000019,0,CHEMBL629498,,
12401,,,,A,U,Autocuration,,,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),22224,,,1,7652,BAO_0000019,0,CHEMBL629499,,
12402,,,,A,U,Autocuration,,,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),22224,,,1,7652,BAO_0000019,0,CHEMBL629500,,
12403,,,,A,U,Autocuration,,,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),22224,,,1,7652,BAO_0000019,0,CHEMBL629501,,
12404,,,,A,U,Autocuration,,,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),22224,,,1,7652,BAO_0000019,0,CHEMBL629502,,
12405,In vivo,,,F,U,Autocuration,,,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,22224,,,1,8267,BAO_0000218,0,CHEMBL629503,,
12406,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,50588,,,1,8267,BAO_0000218,1,CHEMBL629504,,
12407,,,,A,U,Autocuration,,,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,22224,,,1,14479,BAO_0000019,0,CHEMBL629505,,
12408,,,,A,U,Autocuration,,,Compound was evaluated for total body clearance,22224,,,1,17515,BAO_0000019,0,CHEMBL629506,,
12409,,,,A,U,Autocuration,,,Compound was evaluated for volume of distribution at steady state,22224,,,1,17515,BAO_0000019,0,CHEMBL629507,,
12410,,,,A,U,Autocuration,,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,22224,,,1,8142,BAO_0000019,0,CHEMBL877498,,
12411,,,,A,U,Autocuration,,,Percentage of the diamine which is monoprotonated at pH 7.4,22224,,,1,14849,BAO_0000019,0,CHEMBL629508,,
12412,,,,A,U,Autocuration,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,22224,,,1,7653,BAO_0000019,0,CHEMBL629509,,
12413,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL629510,,178.0
12414,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL629511,,178.0
12415,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL629512,,178.0
12416,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL629513,,178.0
12417,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL629514,,178.0
12418,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL628447,,178.0
12419,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL628448,,178.0
12420,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL628449,,178.0
12421,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL631119,,178.0
12422,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL631120,,178.0
12423,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL631121,,178.0
12424,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,50597,,,1,8631,BAO_0000218,1,CHEMBL874458,,178.0
12425,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL631122,,178.0
12426,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL631123,,178.0
12427,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL631124,,178.0
12428,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL631125,,178.0
12429,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL631290,,178.0
12430,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL631291,,178.0
12431,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL631292,,178.0
12432,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL631293,,178.0
12433,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL631294,,178.0
12434,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL631295,,178.0
12435,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL631296,,178.0
12436,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,50597,,,1,8631,BAO_0000218,1,CHEMBL631297,,178.0
12437,,,,A,U,Autocuration,,,Maximum biodistribution (Bmax) was determined.,22224,,,1,10263,BAO_0000218,0,CHEMBL631298,,
12438,,Mus musculus,,A,N,Intermediate,,10090.0,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,50594,,,1,12364,BAO_0000218,1,CHEMBL631299,,
12439,,Mus musculus,,A,N,Intermediate,,10090.0,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,50594,,,1,12364,BAO_0000218,1,CHEMBL631300,,
12440,,Mus musculus,,A,N,Intermediate,,10090.0,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,50594,,,1,12364,BAO_0000218,1,CHEMBL631301,,
12441,,Mus musculus,,A,N,Intermediate,,10090.0,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,50594,,,1,12364,BAO_0000218,1,CHEMBL630291,,
12442,,,,A,U,Autocuration,,,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,22224,,,1,14793,BAO_0000218,0,CHEMBL630292,,
12443,,,,A,U,Autocuration,,,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,22224,,,1,14793,BAO_0000218,0,CHEMBL630293,,
12444,,,,A,U,Autocuration,,,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,22224,,,1,14793,BAO_0000218,0,CHEMBL630294,,
12445,,,,A,U,Autocuration,,,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,22224,,,1,14793,BAO_0000218,0,CHEMBL630295,,
12446,,,,A,U,Autocuration,,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,22224,,,1,14793,BAO_0000218,0,CHEMBL630296,,
12447,,,,A,U,Autocuration,,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,22224,,,1,14793,BAO_0000218,0,CHEMBL626782,,
12448,,,,A,U,Autocuration,,,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,22224,,,1,14793,BAO_0000218,0,CHEMBL626783,,
12449,,,,A,U,Autocuration,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,22224,,,1,14793,BAO_0000218,0,CHEMBL626784,,
12450,,,,A,U,Autocuration,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,22224,,,1,14793,BAO_0000218,0,CHEMBL626785,,
12451,,,,A,U,Autocuration,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,22224,,,1,14793,BAO_0000218,0,CHEMBL626786,,
12452,,,,A,U,Autocuration,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL626787,,
12453,,,,A,U,Autocuration,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,22224,,,1,9196,BAO_0000218,0,CHEMBL626788,,
12454,,,,A,U,Autocuration,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL625927,,
12455,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,,,1,8374,BAO_0000218,1,CHEMBL625928,,178.0
12456,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,50597,,,1,8374,BAO_0000218,1,CHEMBL625929,,178.0
12457,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,50597,,,1,8374,BAO_0000218,1,CHEMBL625930,,178.0
12458,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",50597,,,1,8374,BAO_0000218,1,CHEMBL625931,,178.0
12459,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,50597,,,1,8374,BAO_0000218,1,CHEMBL627230,,178.0
12460,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,,,1,8374,BAO_0000218,1,CHEMBL627231,,178.0
12461,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,50597,,,1,8374,BAO_0000218,1,CHEMBL627232,,178.0
12462,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,50597,,,1,8374,BAO_0000218,1,CHEMBL627233,,178.0
12463,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,,,1,8374,BAO_0000218,1,CHEMBL875470,,178.0
12464,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,,,1,8374,BAO_0000218,1,CHEMBL627234,,178.0
12465,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,,,1,8374,BAO_0000218,1,CHEMBL627235,,178.0
12466,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,,,1,8374,BAO_0000218,1,CHEMBL627236,,178.0
12467,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,,,1,8374,BAO_0000218,1,CHEMBL627237,,178.0
12468,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,,,1,8374,BAO_0000218,1,CHEMBL627238,,178.0
12469,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,,,1,8374,BAO_0000218,1,CHEMBL627239,,178.0
12470,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,,,1,8374,BAO_0000218,1,CHEMBL627240,,178.0
12471,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,,,1,8374,BAO_0000218,1,CHEMBL627241,,178.0
12472,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,,,1,8374,BAO_0000218,1,CHEMBL627242,,178.0
12473,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,50597,,,1,8374,BAO_0000218,1,CHEMBL627243,,178.0
12474,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,50597,,,1,8374,BAO_0000218,1,CHEMBL627244,,178.0
12475,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,,,1,8374,BAO_0000218,1,CHEMBL627245,,178.0
12476,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,,,1,8374,BAO_0000218,1,CHEMBL627246,,178.0
12477,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,,,1,8374,BAO_0000218,1,CHEMBL627247,,178.0
12478,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,,,1,8374,BAO_0000218,1,CHEMBL627248,,178.0
12479,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,,,1,8374,BAO_0000218,1,CHEMBL627249,,178.0
12480,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,,,1,8374,BAO_0000218,1,CHEMBL625569,,178.0
12481,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,,,1,8374,BAO_0000218,1,CHEMBL625570,,178.0
12482,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,,,1,8374,BAO_0000218,1,CHEMBL625571,,178.0
12483,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,50597,,,1,8374,BAO_0000218,1,CHEMBL625572,,178.0
12484,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,50597,,,1,8374,BAO_0000218,1,CHEMBL625573,,178.0
12485,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,50597,,,1,8374,BAO_0000218,1,CHEMBL625574,,178.0
12486,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,50597,,,1,8374,BAO_0000218,1,CHEMBL626245,,178.0
12487,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,,,1,8374,BAO_0000218,1,CHEMBL626246,,178.0
12488,,,,A,U,Autocuration,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL626247,,
12489,,,,A,U,Autocuration,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL626248,,
12490,,,,A,U,Autocuration,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL626249,,
12491,,,,A,U,Autocuration,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL626420,,
12492,,,,A,U,Autocuration,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL626421,,
12493,,,,A,U,Autocuration,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL626422,,
12494,,,,A,U,Autocuration,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL626423,,
12495,,,,A,U,Autocuration,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL626424,,
12496,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,50588,,,1,12023,BAO_0000218,1,CHEMBL626425,,
12497,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,50597,,,1,12023,BAO_0000218,1,CHEMBL875476,,
12498,,Macaca fascicularis,,A,N,Intermediate,,9541.0,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,100710,,,1,12023,BAO_0000218,1,CHEMBL626426,,
12499,,,,P,U,Autocuration,,,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,22224,,,1,10580,BAO_0000100,0,CHEMBL626427,,
12500,,,,P,U,Autocuration,,,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,22224,,,1,10580,BAO_0000100,0,CHEMBL626428,,
12501,,,,A,U,Autocuration,,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,22224,,,1,16032,BAO_0000019,0,CHEMBL626429,,
12502,,,,A,U,Autocuration,Urine,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,22224,,,1,16032,BAO_0000019,0,CHEMBL625025,,1088.0
12503,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL625026,,178.0
12504,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL625027,,178.0
12505,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL874410,,178.0
12506,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL625028,,178.0
12507,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL625029,,178.0
12508,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL625030,,178.0
12509,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL625031,,178.0
12510,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL625032,,178.0
12511,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL625033,,178.0
12512,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL625034,,178.0
12513,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624872,,948.0
12514,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624873,,948.0
12515,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624874,,948.0
12516,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624875,,948.0
12517,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624876,,948.0
12518,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624877,,948.0
12519,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624878,,948.0
12520,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624879,,948.0
12521,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624880,,948.0
12522,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624881,,948.0
12523,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",50597,,,1,8594,BAO_0000218,1,CHEMBL624882,,948.0
12524,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624883,,2113.0
12525,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624884,,2113.0
12526,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624885,,2113.0
12527,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624886,,2113.0
12528,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624887,,2113.0
12529,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624888,,2113.0
12530,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624889,,2113.0
12531,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624890,,2113.0
12532,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL621964,,2113.0
12533,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL621965,,2113.0
12534,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL621966,,2107.0
12535,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL621967,,2107.0
12536,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL622164,,2107.0
12537,,,,A,U,Autocuration,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),22224,,,1,7653,BAO_0000019,0,CHEMBL623097,,
12538,,,,A,U,Autocuration,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),22224,,,1,7653,BAO_0000019,0,CHEMBL623098,,
12539,,,,A,U,Autocuration,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,22224,,,1,7653,BAO_0000019,0,CHEMBL623099,,
12540,,,,A,U,Autocuration,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,22224,,,1,7653,BAO_0000019,0,CHEMBL623100,,
12541,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",50597,,,1,9104,BAO_0000218,1,CHEMBL628673,,
12542,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",50597,,,1,9104,BAO_0000218,1,CHEMBL628674,,
12543,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",50597,,,1,9104,BAO_0000218,1,CHEMBL628675,,
12544,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",50597,,,1,9104,BAO_0000218,1,CHEMBL627644,,
12545,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",50597,,,1,9104,BAO_0000218,1,CHEMBL627645,,
12546,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",50597,,,1,9104,BAO_0000218,1,CHEMBL627646,,
12547,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",50597,,,1,9104,BAO_0000218,1,CHEMBL627647,,
12548,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",50597,,,1,9104,BAO_0000218,1,CHEMBL627648,,
12549,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Free level in rat plasma,50597,,,1,12902,BAO_0000218,1,CHEMBL627649,,
12550,,,,A,U,Autocuration,,,Level reaching in blood plasma of rat or human was determined,22224,,,1,6614,BAO_0000019,0,CHEMBL628313,,
12551,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Log (Cbrain/Cblood) in rats,50597,,,1,9663,BAO_0000218,1,CHEMBL628314,,
12552,,,,A,U,Autocuration,,,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,22224,,,1,17658,BAO_0000019,0,CHEMBL628315,,
12553,,,,A,U,Autocuration,,,Mean percentage of compound transport through membrane; expressed as membrane transport,22224,,,1,17658,BAO_0000019,0,CHEMBL628316,,
12554,,,,A,U,Autocuration,,,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,22224,,,1,14314,BAO_0000218,0,CHEMBL628317,,
12555,,,,A,U,Autocuration,,,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,22224,,,1,7385,BAO_0000019,0,CHEMBL628473,,
12556,,,,A,U,Autocuration,,,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",22224,,,1,7385,BAO_0000019,0,CHEMBL628474,,
12557,,,,A,U,Autocuration,,,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,22224,,,1,7385,BAO_0000019,0,CHEMBL628475,,
12558,,,,A,U,Autocuration,,,Net water uptake by a carrier mediated transport (%cm) mechanism,22224,,,1,1329,BAO_0000019,0,CHEMBL628476,,
12559,,Simiiformes,,A,U,Autocuration,,314293.0,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,22224,,,1,12187,BAO_0000218,0,CHEMBL628477,,
12560,,Mustela putorius furo,,A,N,Intermediate,,9669.0,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,50506,,,1,12187,BAO_0000218,1,CHEMBL628478,,
12561,,Mustela putorius furo,,A,N,Intermediate,,9669.0,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",50506,,,1,12187,BAO_0000218,1,CHEMBL628479,,
12562,,Simiiformes,,A,U,Autocuration,,314293.0,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,22224,,,1,12187,BAO_0000218,0,CHEMBL628480,,
12563,,Simiiformes,,A,U,Autocuration,,314293.0,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",22224,,,1,12187,BAO_0000218,0,CHEMBL628481,,
12564,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,50597,,,1,12187,BAO_0000218,1,CHEMBL628482,,
12565,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",50597,,,1,12187,BAO_0000218,1,CHEMBL628483,,
12566,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",50597,,,1,9278,BAO_0000218,1,CHEMBL628484,,1969.0
12567,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",50597,,,1,9278,BAO_0000218,1,CHEMBL628485,,1969.0
12568,,Macaca fascicularis,,A,N,Intermediate,Plasma,9541.0,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",100710,,,1,9278,BAO_0000218,1,CHEMBL628486,,1969.0
12569,,Homo sapiens,,A,N,Intermediate,Plasma,9606.0,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",50587,,,1,9278,BAO_0000218,1,CHEMBL628487,,1969.0
12570,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",50597,,,1,9278,BAO_0000218,1,CHEMBL628488,,1969.0
12571,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",50597,,,1,9278,BAO_0000218,1,CHEMBL628489,,1969.0
12572,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",50597,,,1,9278,BAO_0000218,1,CHEMBL628490,,1969.0
12573,,Macaca fascicularis,,A,N,Intermediate,,9541.0,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,100710,,,1,12186,BAO_0000218,1,CHEMBL628491,,
12574,,Macaca fascicularis,,A,N,Intermediate,,9541.0,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,100710,,,1,12186,BAO_0000218,1,CHEMBL877507,,
12575,,,,A,U,Autocuration,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,22224,,,1,12186,BAO_0000218,0,CHEMBL628492,,
12576,,Simiiformes,,A,U,Autocuration,,314293.0,% metabolized in monkey S-9 after 2 hours (10 ug/mL),22224,,,1,12041,BAO_0000019,0,CHEMBL628493,,
12577,,Simiiformes,,A,U,Autocuration,,314293.0,% metabolized in monkey S-9 after 2 hours (1 ug/ml),22224,,,1,12041,BAO_0000019,0,CHEMBL628494,,
12578,,Simiiformes,,A,U,Autocuration,,314293.0,% metabolized in monkey S-9 after 2 hours (10 ug/ml),22224,,,1,12041,BAO_0000019,0,CHEMBL628495,,
12579,,Homo sapiens,,A,N,Intermediate,,9606.0,Permeability in Caco-2 assay at 10E-6,50587,,,1,6737,BAO_0000218,1,CHEMBL628496,,
12580,,,,A,U,Autocuration,Brain,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,22224,,,1,13758,BAO_0000218,0,CHEMBL628497,,955.0
12581,,,,A,U,Autocuration,Brain,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,22224,,,1,13758,BAO_0000218,0,CHEMBL628498,,955.0
12582,,,,A,U,Autocuration,,,Plasma protein binding was determined,22224,,,1,5676,BAO_0000019,0,CHEMBL628499,,
12583,,,,A,U,Autocuration,,,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,22224,,,1,14793,BAO_0000218,0,CHEMBL627656,,
12584,,,,A,U,Autocuration,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,22224,,,1,14793,BAO_0000218,0,CHEMBL627657,,
12585,,,,A,U,Autocuration,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,22224,,,1,14793,BAO_0000218,0,CHEMBL626808,,
12586,,,,A,U,Autocuration,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,22224,,,1,14793,BAO_0000218,0,CHEMBL626809,,
12587,,,,A,U,Autocuration,,,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,22224,,,1,14793,BAO_0000218,0,CHEMBL626810,,
12588,,,,A,U,Autocuration,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,22224,,,1,14793,BAO_0000218,0,CHEMBL626811,,
12589,,,,A,U,Autocuration,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,22224,,,1,14793,BAO_0000218,0,CHEMBL874465,,
12590,,,,A,U,Autocuration,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,22224,,,1,14793,BAO_0000218,0,CHEMBL626812,,
12591,,,,A,U,Autocuration,,,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,22224,,,1,14793,BAO_0000218,0,CHEMBL626813,,
12592,,,,A,U,Autocuration,,,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,22224,,,1,14793,BAO_0000218,0,CHEMBL626814,,
12593,,,,A,U,Autocuration,,,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,22224,,,1,14000,BAO_0000019,0,CHEMBL626815,,
12594,,,,A,U,Autocuration,,,Partition coefficient (logP),22224,,,1,5948,BAO_0000019,0,CHEMBL628566,,
12595,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),22229,,,1,13824,BAO_0000100,0,CHEMBL628567,,
12596,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,10778,BAO_0000100,0,CHEMBL628568,,
12597,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,C max in dog,50588,,,1,17237,BAO_0000218,1,CHEMBL628569,,
12598,In vivo,Cavia porcellus,,A,N,Intermediate,,10141.0,C max in guinea pig,50512,,,1,17237,BAO_0000218,1,CHEMBL628570,,
12599,In vivo,,,A,U,Autocuration,,,C max value was evaluated,22224,,,1,2809,BAO_0000218,0,CHEMBL628571,,
12600,In vivo,,,A,U,Autocuration,,,Cmax value after oral dose of 0.1 mg//kg,22224,,,1,11954,BAO_0000218,0,CHEMBL628572,,
12601,In vivo,,,A,U,Autocuration,,,Cmax value after oral dose of 0.3 mg/kg,22224,,,1,11954,BAO_0000218,0,CHEMBL628573,,
12602,In vivo,,,A,U,Autocuration,,,Cmax value after oral dose of 1 mg/kg,22224,,,1,11954,BAO_0000218,0,CHEMBL628574,,
12603,In vivo,,,A,U,Autocuration,,,Cmax value after oral dose of 10 mg/kg,22224,,,1,11954,BAO_0000218,0,CHEMBL628575,,
12604,In vivo,,,A,U,Autocuration,,,Cmax value after oral dose of 23.4 mg/kg,22224,,,1,11954,BAO_0000218,0,CHEMBL628576,,
12605,In vivo,,,A,U,Autocuration,,,Cmax value after oral dose of 3 mg/kg,22224,,,1,11954,BAO_0000218,0,CHEMBL628577,,
12606,In vivo,,,A,U,Autocuration,,,Cmax value after oral dose of 3.87 mg/kg,22224,,,1,11954,BAO_0000218,0,CHEMBL628578,,
12607,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax value in female Beagle dogs,50588,,,1,12768,BAO_0000218,1,CHEMBL874466,,
12608,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax value in male rats,50597,,,1,12768,BAO_0000218,1,CHEMBL628579,,
12609,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Cmax value in rat plasma when administered 20 mg/kg perorally,50597,,,1,12780,BAO_0000218,1,CHEMBL628580,,1969.0
12610,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,50588,,,1,15592,BAO_0000218,1,CHEMBL628581,,1969.0
12611,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,50588,,,1,15592,BAO_0000218,1,CHEMBL628582,,1969.0
12612,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,50588,,,1,17025,BAO_0000218,1,CHEMBL628583,,
12613,,Simiiformes,,A,U,Autocuration,,314293.0,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,22224,,,1,17025,BAO_0000218,0,CHEMBL625782,,
12614,,Oryctolagus cuniculus,,A,N,Intermediate,,9986.0,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,50592,,,1,17025,BAO_0000218,1,CHEMBL625783,,
12615,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,50597,,,1,17025,BAO_0000218,1,CHEMBL625784,,
12616,,Macaca mulatta,,A,N,Intermediate,Plasma,9544.0,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,50797,,,1,4236,BAO_0000218,1,CHEMBL625785,,1969.0
12617,,Rattus norvegicus,,A,N,Intermediate,,10116.0,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,50597,,,1,15791,BAO_0000218,1,CHEMBL625786,,
12618,,,,A,U,Autocuration,,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,22224,,,1,11149,BAO_0000019,0,CHEMBL874467,,
12619,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",50588,,,1,15592,BAO_0000218,1,CHEMBL625787,,
12620,,Human immunodeficiency virus,,A,N,Intermediate,,12721.0,cytotoxicity against HIV protease enzyme.,50677,,,1,15778,BAO_0000218,1,CHEMBL625964,,
12621,,Mus musculus,,A,N,Intermediate,,10090.0,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,50594,,,1,12745,BAO_0000218,1,CHEMBL625965,,
12622,,Mus musculus,,A,N,Intermediate,,10090.0,Apparent clearance in mice after oral administration of 100 mg/kg of dose,50594,,,1,12745,BAO_0000218,1,CHEMBL625966,,
12623,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,The plasma clearance in dog.,50588,,,1,13941,BAO_0000218,1,CHEMBL625967,,1969.0
12624,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,The plasma clearance in rat.,50597,,,1,13941,BAO_0000218,1,CHEMBL625968,,1969.0
12625,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Clearance from plasma in male Sprague-Dawley rats,50597,,,1,16449,BAO_0000218,1,CHEMBL625969,,1969.0
12626,In vivo,Macaca fascicularis,,A,N,Intermediate,Plasma,9541.0,Clearance from plasma in male cynomolgus monkeys,100710,,,1,16449,BAO_0000218,1,CHEMBL625970,,1969.0
12627,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",50588,,,1,14224,BAO_0000218,1,CHEMBL625971,,1969.0
12628,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Clearance of compound in dog plasma,50588,,,1,14224,BAO_0000218,1,CHEMBL625972,,1969.0
12629,In vivo,Homo sapiens,,A,N,Intermediate,Plasma,9606.0,Clearance of compound in human plasma,50587,,,1,14224,BAO_0000218,1,CHEMBL625973,,1969.0
12630,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,50588,,,1,14317,BAO_0000218,1,CHEMBL625974,,
12631,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Clearance of compound when administered intravenously as an individual dose to a single dog.,50588,,,1,14317,BAO_0000218,1,CHEMBL625975,,
12632,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,"Clearance (10 mg/kg, intravenously) in dog plasma",50588,,,1,14224,BAO_0000218,1,CHEMBL625976,,1969.0
12633,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Clearance value in dog,50588,,,1,17237,BAO_0000218,1,CHEMBL625977,,
12634,In vivo,Cavia porcellus,,A,N,Intermediate,,10141.0,Clearance value in guinea pig,50512,,,1,17237,BAO_0000218,1,CHEMBL625978,,
12635,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance values in rats after iv administration.,50597,,,1,14187,BAO_0000218,1,CHEMBL874468,,
12636,In vivo,,,A,U,Autocuration,Plasma,,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,22224,,,1,4806,BAO_0000218,0,CHEMBL625421,,1969.0
12637,In vivo,Oryctolagus cuniculus,,A,N,Intermediate,,9986.0,In vivo clearance (5 mg/kg) was determined in rabbits,50592,,,1,15025,BAO_0000218,1,CHEMBL625422,,
12638,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma Clearance rate was determined for the compound in rats,50597,,,1,13197,BAO_0000218,1,CHEMBL625423,,
12639,In vivo,Saimiri,,A,U,Autocuration,,9520.0,Plasma Clearance rate was determined for the compound in squirrel monkeys,22224,,,1,13197,BAO_0000218,0,CHEMBL625424,,
12640,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance in rat,50597,,,1,13960,BAO_0000218,1,CHEMBL625425,,
12641,In vivo,,,A,U,Autocuration,,,Plasma clearance of the compound,22224,,,1,17820,BAO_0000218,0,CHEMBL625426,,
12642,In vivo,Cavia porcellus,,A,N,Intermediate,,10141.0,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,50512,,,1,14706,BAO_0000218,1,CHEMBL625427,,
12643,In vivo,Cavia porcellus,,A,N,Intermediate,,10141.0,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,50512,,,1,14706,BAO_0000218,1,CHEMBL625428,,
12644,In vivo,,,A,U,Autocuration,,,Plasma clearance was determined,22224,,,1,6504,BAO_0000218,0,CHEMBL625429,,
12645,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,50588,,,1,14925,BAO_0000218,1,CHEMBL625430,,
12646,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance rate was determined for the compound in rats,50597,,,1,13197,BAO_0000218,1,CHEMBL625431,,
12647,In vivo,Saimiri,,A,U,Autocuration,,9520.0,Plasma clearance rate was determined for the compound in squirrel monkeys,22224,,,1,13197,BAO_0000218,0,CHEMBL627307,,
12648,In vivo,,,A,U,Autocuration,,,Slow clearance (CL) was determined,22224,,,1,3437,BAO_0000218,0,CHEMBL627308,,
12649,,,,A,U,Autocuration,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL627309,,
12650,,,,A,U,Autocuration,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,22224,,,1,9196,BAO_0000218,0,CHEMBL627310,,
12651,,,,A,U,Autocuration,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL627311,,
12652,,,,A,U,Autocuration,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL627312,,
12653,,,,A,U,Autocuration,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL627313,,
12654,,,,A,U,Autocuration,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL627314,,
12655,,,,A,U,Autocuration,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL627315,,
12656,,,,A,U,Autocuration,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL627316,,
12657,,,,A,U,Autocuration,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL627317,,
12658,,,,A,U,Autocuration,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL627318,,
12659,,,,A,U,Autocuration,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL627999,,
12660,,,,A,U,Autocuration,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL628000,,
12661,,,,A,U,Autocuration,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL628001,,
12662,,,,A,U,Autocuration,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL628002,,
12663,,,,A,U,Autocuration,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL625610,,
12664,,,,A,U,Autocuration,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL625611,,
12665,,,,A,U,Autocuration,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL625612,,
12666,,,,A,U,Autocuration,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL625613,,
12667,,,,A,U,Autocuration,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL875479,,
12668,,,,A,U,Autocuration,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL625614,,
12669,,,,A,U,Autocuration,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL625615,,
12670,,,,A,U,Autocuration,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,22224,,,1,9196,BAO_0000218,0,CHEMBL626302,,
12671,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,50597,,,1,8374,BAO_0000218,1,CHEMBL626303,,178.0
12672,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,50597,,,1,8374,BAO_0000218,1,CHEMBL627420,,178.0
12673,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,50597,,,1,13477,BAO_0000218,1,CHEMBL627421,,
12674,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,50597,,,1,13477,BAO_0000218,1,CHEMBL625695,,
12675,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,50597,,,1,13477,BAO_0000218,1,CHEMBL625696,,
12676,,Mus musculus,,A,N,Intermediate,Brain,10090.0,Distribution of compound in mice brain was measured after 1 hr,50594,,,1,10009,BAO_0000218,1,CHEMBL875606,,955.0
12677,,Mus musculus,,A,N,Intermediate,Brain,10090.0,Distribution of compound in mice brain was measured after 24 hr r,50594,,,1,10009,BAO_0000218,1,CHEMBL625697,,955.0
12678,,Mus musculus,,A,N,Intermediate,Brain,10090.0,Distribution of compound in mice brain was measured after 2 hr,50594,,,1,10009,BAO_0000218,1,CHEMBL625698,,955.0
12679,,Mus musculus,,A,N,Intermediate,Brain,10090.0,Distribution of compound in mice brain was measured after 3 hr,50594,,,1,10009,BAO_0000218,1,CHEMBL625699,,955.0
12680,,Mus musculus,,A,N,Intermediate,Brain,10090.0,Distribution of compound in mice brain was measured after 6 hr,50594,,,1,10009,BAO_0000218,1,CHEMBL625700,,955.0
12681,,Mus musculus,,A,N,Intermediate,,10090.0,Distribution of compound in mice liver was measured after 1 hr,50594,,,1,10009,BAO_0000218,1,CHEMBL625701,,
12682,,Mus musculus,,A,N,Intermediate,,10090.0,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,50594,,,1,10009,BAO_0000218,1,CHEMBL625702,,
12683,,Mus musculus,,A,N,Intermediate,,10090.0,Distribution of compound in mice liver was measured after 2 hr,50594,,,1,10009,BAO_0000218,1,CHEMBL625703,,
12684,,Mus musculus,,A,N,Intermediate,,10090.0,Distribution of compound in mice liver was measured after 3 hr,50594,,,1,10009,BAO_0000218,1,CHEMBL625704,,
12685,,Mus musculus,,A,N,Intermediate,,10090.0,Distribution of compound in mice liver was measured after 6 hr,50594,,,1,10009,BAO_0000218,1,CHEMBL625705,,
12686,,Canis lupus familiaris,,A,N,Intermediate,Adrenal medulla,9615.0,Distribution in dog adrenal medulla 30 min after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL625706,,1236.0
12687,,Canis lupus familiaris,,A,N,Intermediate,Adrenal medulla,9615.0,Distribution in dog adrenal medulla 72 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL625707,,1236.0
12688,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Distribution in female dog Ovary 24 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL625708,,
12689,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Distribution in female dog Ovary 72 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL625709,,
12690,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Distribution in female dog adipose 24 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624180,,
12691,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Distribution in female dog adipose 72 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624181,,
12692,,Canis lupus familiaris,,A,N,Intermediate,Adrenal cortex,9615.0,Distribution in female dog adrenal cortex 72 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624182,,1235.0
12693,,Canis lupus familiaris,,A,N,Intermediate,Adrenal cortex,9615.0,Distribution in female dog adrenal cortex 72 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624183,,1235.0
12694,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624184,,2107.0
12695,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL877489,,2107.0
12696,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624185,,2107.0
12697,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624186,,2107.0
12698,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624187,,2107.0
12699,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624188,,2107.0
12700,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624189,,2048.0
12701,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624190,,2048.0
12702,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624191,,2048.0
12703,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624192,,2048.0
12704,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624193,,2048.0
12705,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624194,,2048.0
12706,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624891,,2048.0
12707,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624892,,2048.0
12708,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL624893,,2048.0
12709,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL627632,,2048.0
12710,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL627633,,
12711,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL627634,,
12712,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL627635,,
12713,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL627636,,
12714,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626816,,
12715,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626817,,
12716,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626818,,
12717,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626819,,
12718,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626820,,
12719,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626821,,
12720,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626822,,2046.0
12721,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626823,,2046.0
12722,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626824,,2046.0
12723,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626825,,2046.0
12724,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626826,,2046.0
12725,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626827,,2046.0
12726,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626828,,2046.0
12727,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626829,,2046.0
12728,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626830,,2046.0
12729,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL627150,,
12730,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL627151,,
12731,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL627152,,
12732,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL627153,,
12733,,,,A,U,Autocuration,,,Rate of acetate production by the compound was determined,22224,,,1,12904,BAO_0000019,0,CHEMBL627154,,
12734,,,,A,U,Autocuration,,,Rate of acetate production by the compound was determined; Not determined,22224,,,1,12904,BAO_0000019,0,CHEMBL627155,,
12735,,,,A,U,Autocuration,,,Rate of hydrolysis of nitrocefin by compound was evaluated in water,22224,,,1,3730,BAO_0000019,0,CHEMBL627156,,
12736,,,,A,U,Autocuration,,,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,22224,,,1,3627,BAO_0000019,0,CHEMBL627157,,
12737,,Oryctolagus cuniculus,,A,N,Intermediate,,9986.0,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,50592,,,1,13799,BAO_0000218,1,CHEMBL627158,,
12738,,Oryctolagus cuniculus,,A,N,Intermediate,Plasma,9986.0,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,50592,,,1,13799,BAO_0000218,1,CHEMBL627159,,1969.0
12739,,Mus musculus,,A,N,Intermediate,,10090.0,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,50594,,,1,13799,BAO_0000218,1,CHEMBL627160,,
12740,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,50597,,,1,13799,BAO_0000218,1,CHEMBL628540,,
12741,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,50597,,,1,13799,BAO_0000218,1,CHEMBL628541,,1969.0
12742,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,50597,,,1,13799,BAO_0000218,1,CHEMBL628542,,1969.0
12743,,,,P,U,Autocuration,,,Solubility after at a pH 1.2,22229,,,1,6629,BAO_0000100,0,CHEMBL628543,,
12744,,,,P,U,Autocuration,,,Solubility after at pH 1.2,22229,,,1,6629,BAO_0000100,0,CHEMBL628544,,
12745,,,,P,U,Autocuration,,,Solubility after injection of water,22229,,,1,6629,BAO_0000100,0,CHEMBL628545,,
12746,,,,A,U,Autocuration,,,Statistical significance of IC 50 values; Expressed as R value,22224,,,1,14000,BAO_0000019,0,CHEMBL628546,,
12747,,,,A,U,Autocuration,,,Systemic availability with respect to methyldopa was determined,22224,,,1,8267,BAO_0000019,0,CHEMBL874455,,
12748,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,50597,,,1,13799,BAO_0000218,1,CHEMBL628547,,
12749,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,50597,,,1,13799,BAO_0000218,1,CHEMBL628548,,1969.0
12750,,Oryctolagus cuniculus,,A,N,Intermediate,Feces,9986.0,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",50592,,,1,7132,BAO_0000218,1,CHEMBL628549,,1988.0
12751,,Oryctolagus cuniculus,,A,N,Intermediate,Feces,9986.0,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",50592,,,1,7132,BAO_0000218,1,CHEMBL628550,,1988.0
12752,,Oryctolagus cuniculus,,A,N,Intermediate,Feces,9986.0,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",50592,,,1,7132,BAO_0000218,1,CHEMBL628551,,1988.0
12753,,Oryctolagus cuniculus,,A,N,Intermediate,Urine,9986.0,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",50592,,,1,7132,BAO_0000218,1,CHEMBL628552,,1088.0
12754,,Oryctolagus cuniculus,,A,N,Intermediate,Urine,9986.0,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",50592,,,1,7132,BAO_0000218,1,CHEMBL628553,,1088.0
12755,,Oryctolagus cuniculus,,A,N,Intermediate,Urine,9986.0,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",50592,,,1,7132,BAO_0000218,1,CHEMBL628554,,1088.0
12756,,Oryctolagus cuniculus,,A,N,Intermediate,Urine,9986.0,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",50592,,,1,7132,BAO_0000218,1,CHEMBL628555,,1088.0
12757,,Oryctolagus cuniculus,,A,N,Intermediate,Urine,9986.0,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",50592,,,1,7132,BAO_0000218,1,CHEMBL628556,,1088.0
12758,,Oryctolagus cuniculus,,A,N,Intermediate,Kidney,9986.0,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",50592,,,1,7132,BAO_0000218,1,CHEMBL628557,,2113.0
12759,,Oryctolagus cuniculus,,A,N,Intermediate,Feces,9986.0,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",50592,,,1,7132,BAO_0000218,1,CHEMBL628558,,1988.0
12760,,Oryctolagus cuniculus,,A,N,Intermediate,Feces,9986.0,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",50592,,,1,7132,BAO_0000218,1,CHEMBL628559,,1988.0
12761,,Oryctolagus cuniculus,,A,N,Intermediate,Feces,9986.0,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",50592,,,1,7132,BAO_0000218,1,CHEMBL628560,,1988.0
12762,,Oryctolagus cuniculus,,A,N,Intermediate,Urine,9986.0,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",50592,,,1,7132,BAO_0000218,1,CHEMBL874456,,1088.0
12763,,Oryctolagus cuniculus,,A,N,Intermediate,Feces,9986.0,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",50592,,,1,7132,BAO_0000218,1,CHEMBL628561,,1988.0
12764,,Oryctolagus cuniculus,,A,N,Intermediate,Feces,9986.0,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",50592,,,1,7132,BAO_0000218,1,CHEMBL628562,,1988.0
12765,,Oryctolagus cuniculus,,A,N,Intermediate,Urine,9986.0,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",50592,,,1,7132,BAO_0000218,1,CHEMBL628563,,1088.0
12766,,Oryctolagus cuniculus,,A,N,Intermediate,Urine,9986.0,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",50592,,,1,7132,BAO_0000218,1,CHEMBL628564,,1088.0
12767,,Oryctolagus cuniculus,,A,N,Intermediate,Urine,9986.0,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",50592,,,1,7132,BAO_0000218,1,CHEMBL628565,,1088.0
12768,,Oryctolagus cuniculus,,A,N,Intermediate,Urine,9986.0,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",50592,,,1,7132,BAO_0000218,1,CHEMBL631248,,1088.0
12769,,Oryctolagus cuniculus,,A,N,Intermediate,Urine,9986.0,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",50592,,,1,7132,BAO_0000218,1,CHEMBL631249,,1088.0
12770,,Oryctolagus cuniculus,,A,N,Intermediate,Kidney,9986.0,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",50592,,,1,7132,BAO_0000218,1,CHEMBL627214,,2113.0
12771,,Oryctolagus cuniculus,,A,N,Intermediate,Feces,9986.0,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",50592,,,1,7132,BAO_0000218,1,CHEMBL874591,,1988.0
12772,,Oryctolagus cuniculus,,A,N,Intermediate,Feces,9986.0,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",50592,,,1,7132,BAO_0000218,1,CHEMBL627215,,1988.0
12773,,Oryctolagus cuniculus,,A,N,Intermediate,Feces,9986.0,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,50592,,,1,7132,BAO_0000218,1,CHEMBL625471,,1988.0
12774,,Oryctolagus cuniculus,,A,N,Intermediate,,9986.0,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,50592,,,1,7132,BAO_0000218,1,CHEMBL625472,,
12775,,Oryctolagus cuniculus,,A,N,Intermediate,,9986.0,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,50592,,,1,7132,BAO_0000218,1,CHEMBL625473,,
12776,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,50588,,,1,13317,BAO_0000218,1,CHEMBL625474,,
12777,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,50588,,,1,15341,BAO_0000218,1,CHEMBL625475,,
12778,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,50597,,,1,15341,BAO_0000218,1,CHEMBL625476,,
12779,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,50597,,,1,15341,BAO_0000218,1,CHEMBL625477,,
12780,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,50597,,,1,15341,BAO_0000218,1,CHEMBL625478,,
12781,In vitro,Rattus norvegicus,,A,N,Intermediate,esophageal tunica muscularis mucosae,10116.0,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,50597,,,1,12801,BAO_0000218,1,CHEMBL625479,,
12782,In vitro,Rattus norvegicus,,A,N,Intermediate,esophageal tunica muscularis mucosae,10116.0,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,50597,,,1,12801,BAO_0000218,1,CHEMBL625480,,
12783,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,50597,,,1,14856,BAO_0000218,1,CHEMBL625481,,1969.0
12784,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,50597,,,1,14062,BAO_0000218,1,CHEMBL625482,,
12785,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,50597,,,1,14062,BAO_0000218,1,CHEMBL625483,,
12786,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,50597,,,1,14062,BAO_0000218,1,CHEMBL625484,,
12787,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,50597,,,1,14062,BAO_0000218,1,CHEMBL625485,,
12788,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,50588,,,1,14346,BAO_0000218,1,CHEMBL625486,,1969.0
12789,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,50597,,,1,14346,BAO_0000218,1,CHEMBL625487,,1969.0
12790,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,50597,,,1,14346,BAO_0000218,1,CHEMBL625488,,1969.0
12791,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,50597,,,1,14346,BAO_0000218,1,CHEMBL625489,,1969.0
12792,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,50597,,,1,14346,BAO_0000218,1,CHEMBL625490,,1969.0
12793,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,50588,,,1,14346,BAO_0000218,1,CHEMBL625491,,1969.0
12794,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,50597,,,1,14346,BAO_0000218,1,CHEMBL625492,,1969.0
12795,In vivo,Homo sapiens,,A,N,Intermediate,Plasma,9606.0,plasma clearance in human,50587,,,1,15711,BAO_0000218,1,CHEMBL625493,,1969.0
12796,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,50597,,,1,14886,BAO_0000218,1,CHEMBL625494,,
12797,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,50597,,,1,14886,BAO_0000218,1,CHEMBL625495,,
12798,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,50597,,,1,14886,BAO_0000218,1,CHEMBL625496,,
12799,,,,P,U,Autocuration,,,1-Octanol/water partition coefficient measured at 7.4,22229,,,1,4115,BAO_0000100,0,CHEMBL625497,,
12800,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,13733,BAO_0000100,0,CHEMBL625498,,
12801,,,,A,U,Autocuration,,,Partition coefficient (logP),22224,,,1,12102,BAO_0000019,0,CHEMBL625499,,
12802,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,12676,BAO_0000100,0,CHEMBL625500,,
12803,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,13733,BAO_0000100,0,CHEMBL625501,,
12804,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,13740,BAO_0000100,0,CHEMBL625502,,
12805,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP) (relative to BAY K 8644),22229,,,1,12766,BAO_0000100,0,CHEMBL625503,,
12806,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,2764,BAO_0000100,0,CHEMBL625504,,
12807,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,12355,BAO_0000100,0,CHEMBL625505,,
12808,,,,P,U,Autocuration,,,Calculated partition coefficient of the compound,22229,,,1,11314,BAO_0000100,0,CHEMBL625506,,
12809,,,,A,U,Autocuration,,,Partition coefficient (logP),22224,,,1,12706,BAO_0000019,0,CHEMBL625507,,
12810,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,12645,BAO_0000100,0,CHEMBL625508,,
12811,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,13668,BAO_0000100,0,CHEMBL625509,,
12812,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,12819,BAO_0000100,0,CHEMBL625510,,
12813,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,13668,BAO_0000100,0,CHEMBL883125,,
12814,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,13017,BAO_0000100,0,CHEMBL625511,,
12815,,,,A,U,Autocuration,,,Partition coefficient of the compound,22224,,,1,2448,BAO_0000019,0,CHEMBL874650,,
12816,,,,A,U,Autocuration,,,Partition coefficient of the compound,22224,,,1,11526,BAO_0000019,0,CHEMBL625512,,
12817,,,,A,U,Autocuration,,,Partition coefficient of compound was determined,22224,,,1,12426,BAO_0000019,0,CHEMBL625513,,
12818,,,,A,U,Autocuration,,,Partition coefficient was determined,22224,,,1,2448,BAO_0000019,0,CHEMBL625514,,
12819,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,12001,BAO_0000100,0,CHEMBL625515,,
12820,,,,P,U,Autocuration,,,partition coefficient of compound was determined,22229,,,1,12426,BAO_0000100,0,CHEMBL625516,,
12821,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,The total body administered intravenously in dog,50588,,,1,13204,BAO_0000218,1,CHEMBL625517,,
12822,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,The total body administered intravenously in rats,50597,,,1,13204,BAO_0000218,1,CHEMBL625518,,
12823,,Mus musculus,,A,N,Intermediate,,10090.0,Time taken for the administration to female NIH mice weighing 25-30 g.,50594,,,1,13889,BAO_0000218,1,CHEMBL625519,,
12824,,,,A,U,Autocuration,,,Time taken for the administration,22224,,,1,13889,BAO_0000019,0,CHEMBL625520,,
12825,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,50588,,,1,17025,BAO_0000218,1,CHEMBL874651,,
12826,In vivo,Simiiformes,,A,U,Autocuration,,314293.0,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,22224,,,1,17025,BAO_0000218,0,CHEMBL625521,,
12827,In vivo,Oryctolagus cuniculus,,A,N,Intermediate,,9986.0,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,50592,,,1,17025,BAO_0000218,1,CHEMBL623171,,
12828,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,50597,,,1,17025,BAO_0000218,1,CHEMBL623853,,
12829,,,,A,U,Autocuration,,,Plasma clearance for the compound was determined.,22224,,,1,15067,BAO_0000019,0,CHEMBL623854,,
12830,,,,P,U,Autocuration,,,CLog P value of the compound,22224,,,1,3091,BAO_0000100,0,CHEMBL874405,,
12831,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,15592,BAO_0000100,0,CHEMBL623855,,
12832,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,14738,BAO_0000100,0,CHEMBL623856,,
12833,,,,P,U,Autocuration,,,ClogP value of the compound; nd ='no data',22224,,,1,14738,BAO_0000100,0,CHEMBL623857,,
12834,,,,P,U,Autocuration,,,ClogP value of the compound; nd ='not determined',22224,,,1,14738,BAO_0000100,0,CHEMBL623858,,
12835,,,,P,U,Autocuration,,,CLog P was determined,22224,,,1,6076,BAO_0000100,0,CHEMBL623859,,
12836,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,17840,BAO_0000100,0,CHEMBL839829,,
12837,,,,A,U,Autocuration,,,CLogP was calculated,22224,,,1,13589,BAO_0000019,0,CHEMBL623860,,
12838,,,,A,U,Autocuration,,,CLogP value was determined,22224,,,1,17655,BAO_0000019,0,CHEMBL623861,,
12839,,,,A,U,Autocuration,,,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,22224,,,1,5867,BAO_0000019,0,CHEMBL623862,,
12840,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,5867,BAO_0000100,0,CHEMBL874406,,
12841,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,10783,BAO_0000100,0,CHEMBL623863,,
12842,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,14849,BAO_0000100,0,CHEMBL624021,,
12843,,Canis lupus familiaris,,A,N,Intermediate,Adrenal medulla,9615.0,Distribution in female dog adrenal medulla 24 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624022,,1236.0
12844,,Canis lupus familiaris,,A,N,Intermediate,Adrenal medulla,9615.0,Distribution in female dog adrenal medulla 72 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624023,,1236.0
12845,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Distribution in female dog bile 24 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624024,,
12846,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Distribution in female dog bile 72 hr after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624025,,
12847,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Distribution in female dog blood 24 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624026,,
12848,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Distribution in female dog blood 72 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624027,,
12849,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Distribution in female dog heart 24 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624028,,
12850,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Distribution in female dog heart 72 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624029,,
12851,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Distribution in female dog kidney 24 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624030,,
12852,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Distribution in female dog kidney 72 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624031,,
12853,,Canis lupus familiaris,,A,N,Intermediate,Intestine,9615.0,Distribution in female dog large intestine 24 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624032,,160.0
12854,,Canis lupus familiaris,,A,N,Intermediate,Intestine,9615.0,Distribution in female dog large intestine 72 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL874407,,160.0
12855,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Distribution in female dog liver 24 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624033,,
12856,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Distribution in female dog liver 72 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624034,,
12857,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Distribution in female dog lung 24 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624035,,
12858,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Distribution in female dog lung 72 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624036,,
12859,,Canis lupus familiaris,,A,N,Intermediate,Muscle tissue,9615.0,Distribution in female dog muscle 24 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624037,,2385.0
12860,,Canis lupus familiaris,,A,N,Intermediate,Muscle tissue,9615.0,Distribution in female dog muscle 72 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624038,,2385.0
12861,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Distribution in female dog pancreas 24 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624039,,
12862,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Distribution in female dog pancreas 72 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624040,,
12863,,Canis lupus familiaris,,A,N,Intermediate,Intestine,9615.0,Distribution in female dog small intestine 24 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624041,,160.0
12864,,Canis lupus familiaris,,A,N,Intermediate,Intestine,9615.0,Distribution in female dog small intestine 72 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624042,,160.0
12865,,Canis lupus familiaris,,A,N,Intermediate,Spleen,9615.0,Distribution in female dog spleen 24 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624043,,2106.0
12866,,Canis lupus familiaris,,A,N,Intermediate,Spleen,9615.0,Distribution in female dog spleen 72 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624044,,2106.0
12867,,Canis lupus familiaris,,A,N,Intermediate,Stomach,9615.0,Distribution in female dog stomach 24 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624045,,945.0
12868,,Canis lupus familiaris,,A,N,Intermediate,Stomach,9615.0,Distribution in female dog stomach 72 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624046,,945.0
12869,,Canis lupus familiaris,,A,N,Intermediate,Thyroid gland,9615.0,Distribution in female dog thyroid 24 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624047,,2046.0
12870,,Canis lupus familiaris,,A,N,Intermediate,Thyroid gland,9615.0,Distribution in female dog thyroid 72 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624048,,2046.0
12871,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Distribution in female dog urine 24 hours after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL874408,,1088.0
12872,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Distribution in female dog urine 72 hr after administration.,50588,,,1,8170,BAO_0000218,1,CHEMBL624049,,1088.0
12873,,,,A,U,Autocuration,Plasma,,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,22224,,,1,14283,BAO_0000218,0,CHEMBL624050,,1969.0
12874,,,,A,U,Autocuration,,,Plasma concentration at 7 hr after intravenous dosing,22224,,,1,5623,BAO_0000019,0,CHEMBL624051,,
12875,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,50597,,,1,13477,BAO_0000218,1,CHEMBL623278,,
12876,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,50597,,,1,13477,BAO_0000218,1,CHEMBL623279,,
12877,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration of 3 mg/kg iv after 1 hr in rats,50597,,,1,13477,BAO_0000218,1,CHEMBL623280,,
12878,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration of 3 mg/kg iv after 2 hr in rats,50597,,,1,13477,BAO_0000218,1,CHEMBL623963,,
12879,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration of 3 mg/kg iv after 4 hr in rats,50597,,,1,13477,BAO_0000218,1,CHEMBL623964,,
12880,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration of 3 mg/kg iv after 6 hr in rats,50597,,,1,13477,BAO_0000218,1,CHEMBL623965,,
12881,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,50597,,,1,13477,BAO_0000218,1,CHEMBL623966,,
12882,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,50597,,,1,13477,BAO_0000218,1,CHEMBL874415,,
12883,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,50597,,,1,13477,BAO_0000218,1,CHEMBL623967,,
12884,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,50597,,,1,13477,BAO_0000218,1,CHEMBL623968,,
12885,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,50597,,,1,13477,BAO_0000218,1,CHEMBL623969,,
12886,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,50597,,,1,13477,BAO_0000218,1,CHEMBL628409,,
12887,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,50597,,,1,13477,BAO_0000218,1,CHEMBL628410,,
12888,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,50597,,,1,13477,BAO_0000218,1,CHEMBL628411,,
12889,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,50597,,,1,13477,BAO_0000218,1,CHEMBL628412,,
12890,,,,A,U,Autocuration,,,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,22224,,,1,12553,BAO_0000019,0,CHEMBL628413,,
12891,,,,A,U,Autocuration,Plasma,,The concentration in plasmat; Not determined,22224,,,1,14548,BAO_0000019,0,CHEMBL628414,,1969.0
12892,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue level at 10 mg/kg/po in wistar rats in blood,50597,,,1,14393,BAO_0000218,1,CHEMBL628415,,
12893,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue level at 10 mg/kg/po in wistar rats in brown fat,50597,,,1,14393,BAO_0000218,1,CHEMBL628416,,
12894,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue level at 10 mg/kg/po in wistar rats in heart,50597,,,1,14393,BAO_0000218,1,CHEMBL628417,,
12895,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Tissue level at 10 mg/kg/po in wistar rats in liver,50597,,,1,14393,BAO_0000218,1,CHEMBL874908,,2107.0
12896,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue level at 10 mg/kg/po in wistar rats in plasma,50597,,,1,14393,BAO_0000218,1,CHEMBL628418,,
12897,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,50597,,,1,14393,BAO_0000218,1,CHEMBL628419,,2385.0
12898,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,50597,,,1,14393,BAO_0000218,1,CHEMBL628420,,
12899,,,,A,U,Autocuration,,,Water solubility at 37 degree C.,22224,,,1,1629,BAO_0000019,0,CHEMBL628421,,
12900,,,,P,U,Autocuration,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,22229,,,1,8194,BAO_0000100,0,CHEMBL626726,,
12901,,,,P,U,Autocuration,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,22229,,,1,8194,BAO_0000100,0,CHEMBL626727,,
12902,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626728,,178.0
12903,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626729,,178.0
12904,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626730,,178.0
12905,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626731,,178.0
12906,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626732,,178.0
12907,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626733,,948.0
12908,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626734,,948.0
12909,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626735,,948.0
12910,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL874909,,948.0
12911,,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626736,,948.0
12912,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL626737,,2113.0
12913,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL630999,,2113.0
12914,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL631000,,2113.0
12915,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL631001,,2113.0
12916,,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL631002,,2113.0
12917,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL631003,,2107.0
12918,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL631004,,2107.0
12919,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL631005,,2107.0
12920,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL631006,,2107.0
12921,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL631007,,2107.0
12922,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL631008,,2048.0
12923,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL631009,,2048.0
12924,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL631010,,2048.0
12925,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL631011,,2048.0
12926,,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL631012,,2048.0
12927,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL630271,,2046.0
12928,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL630272,,2046.0
12929,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL630273,,2046.0
12930,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL630274,,2046.0
12931,,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL630275,,2046.0
12932,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL875782,,
12933,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL630276,,
12934,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL630277,,
12935,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL630278,,
12936,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,50597,,,1,8594,BAO_0000218,1,CHEMBL630279,,
12937,,,,A,U,Autocuration,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,22224,,,1,8151,BAO_0000019,0,CHEMBL630280,,
12938,,,,A,U,Autocuration,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,22224,,,1,8151,BAO_0000019,0,CHEMBL630281,,
12939,,Oryctolagus cuniculus,,A,N,Intermediate,,9986.0,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,50592,,,1,7132,BAO_0000218,1,CHEMBL630282,,
12940,,Oryctolagus cuniculus,,A,N,Intermediate,,9986.0,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,50592,,,1,7132,BAO_0000218,1,CHEMBL630283,,
12941,,,,A,U,Autocuration,,,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),22224,,,1,5797,BAO_0000019,0,CHEMBL630284,,
12942,,,,A,U,Autocuration,,,Alkylating activity was determined,22224,,,1,7849,BAO_0000019,0,CHEMBL630285,,
12943,,,,A,U,Autocuration,,,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),22224,,,1,14220,BAO_0000251,0,CHEMBL630286,,
12944,,Oryctolagus cuniculus,,A,N,Intermediate,,9986.0,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",50592,,,1,8650,BAO_0000218,1,CHEMBL630069,,
12945,,Oryctolagus cuniculus,,A,N,Intermediate,,9986.0,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",50592,,,1,8650,BAO_0000218,1,CHEMBL630070,,
12946,,Oryctolagus cuniculus,,A,N,Intermediate,,9986.0,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",50592,,,1,8650,BAO_0000218,1,CHEMBL630071,,
12947,,Oryctolagus cuniculus,,A,N,Intermediate,,9986.0,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",50592,,,1,8650,BAO_0000218,1,CHEMBL630072,,
12948,,Oryctolagus cuniculus,,A,N,Intermediate,,9986.0,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",50592,,,1,8650,BAO_0000218,1,CHEMBL875110,,
12949,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was tested for antidiuretic activity in rats,50597,,,1,7116,BAO_0000218,1,CHEMBL630073,,
12950,,,,A,U,Autocuration,,,Compound was tested for inactivation kinetic values,22224,,,1,14131,BAO_0000019,0,CHEMBL630074,,
12951,In vivo,,,A,U,Autocuration,,,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,22224,,,1,7415,BAO_0000218,0,CHEMBL630075,,
12952,,,,A,U,Autocuration,,,Dissociation rate calculated from the first-order equation using the t1/2 value,22224,,,1,13178,BAO_0000019,0,CHEMBL630076,,
12953,,,,P,U,Autocuration,,,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,22229,,,1,8815,BAO_0000100,0,CHEMBL630077,,
12954,,,,P,U,Autocuration,,,Aqueous solubility was measured,22229,,,1,1450,BAO_0000100,0,CHEMBL630078,,
12955,,,,P,U,Autocuration,,,Aqueous solubility was measured at a pH 4,22229,,,1,1450,BAO_0000100,0,CHEMBL630079,,
12956,,,,P,U,Autocuration,,,Aqueous solubility (pH 7),22229,,,1,1450,BAO_0000100,0,CHEMBL630080,,
12957,,,,P,U,Autocuration,,,Aqueous solubility was measured at a pH 9,22229,,,1,1450,BAO_0000100,0,CHEMBL630081,,
12958,,,,A,U,Autocuration,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",22224,,,1,12711,BAO_0000019,0,CHEMBL630082,,
12959,,,,A,U,Autocuration,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",22224,,,1,12711,BAO_0000019,0,CHEMBL630083,,
12960,,,,A,U,Autocuration,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",22224,,,1,12711,BAO_0000019,0,CHEMBL630084,,
12961,,,,P,U,Autocuration,,,Aqueous solubility of the compound,22229,,,1,15032,BAO_0000100,0,CHEMBL629198,,
12962,,,,P,U,Autocuration,,,Aqueous solubility at 37 degree Celsius at pH 7.38,22229,,,1,9964,BAO_0000100,0,CHEMBL629199,,
12963,,,,P,U,Autocuration,,,Aqueous solubility in pH 7.4 phosphate buffer,22229,,,1,14962,BAO_0000100,0,CHEMBL629200,,
12964,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,50588,,,1,12487,BAO_0000218,1,CHEMBL629201,,
12965,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,50588,,,1,12487,BAO_0000218,1,CHEMBL629202,,
12966,,Homo sapiens,,A,N,Intermediate,,9606.0,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,50587,,,1,10026,BAO_0000218,1,CHEMBL875111,,
12967,,Homo sapiens,,A,N,Intermediate,,9606.0,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,50587,,,1,10026,BAO_0000218,1,CHEMBL629203,,
12968,,Homo sapiens,,A,N,Intermediate,,9606.0,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,50587,,,1,10026,BAO_0000218,1,CHEMBL629204,,
12969,,Homo sapiens,,A,N,Intermediate,,9606.0,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,50587,,,1,10026,BAO_0000218,1,CHEMBL629205,,
12970,,Homo sapiens,,A,N,Intermediate,,9606.0,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,50587,,,1,10026,BAO_0000218,1,CHEMBL629206,,
12971,,,,A,U,Autocuration,,,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,22224,,,1,10026,BAO_0000019,0,CHEMBL631185,,
12972,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for the average bile flow rat in rats,50597,,,1,7415,BAO_0000218,1,CHEMBL631186,,
12973,,Oryctolagus cuniculus,,A,N,Intermediate,,9986.0,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",50592,,,1,17025,BAO_0000218,1,CHEMBL631187,,
12974,,Oryctolagus cuniculus,,A,N,Intermediate,,9986.0,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",50592,,,1,17025,BAO_0000218,1,CHEMBL631188,,
12975,,,,A,U,Autocuration,,,Average half life period was determined,22224,,,1,10184,BAO_0000019,0,CHEMBL876419,,
12976,,,,A,U,Autocuration,,,Average half life period was determined,22224,,,1,10184,BAO_0000019,0,CHEMBL631189,,
12977,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,50602,,,1,8613,BAO_0000218,1,CHEMBL631190,,
12978,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,50602,,,1,8613,BAO_0000218,1,CHEMBL631191,,
12979,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,50602,,,1,8613,BAO_0000218,1,CHEMBL631192,,
12980,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,50602,,,1,8613,BAO_0000218,1,CHEMBL632400,,
12981,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,50602,,,1,8613,BAO_0000218,1,CHEMBL630564,,
12982,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,50602,,,1,8613,BAO_0000218,1,CHEMBL630565,,
12983,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,50602,,,1,8613,BAO_0000218,1,CHEMBL630566,,
12984,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,50602,,,1,8613,BAO_0000218,1,CHEMBL631229,,
12985,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,50602,,,1,8613,BAO_0000218,1,CHEMBL631230,,
12986,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,6030,BAO_0000100,0,CHEMBL876428,,
12987,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,6147,BAO_0000100,0,CHEMBL631231,,
12988,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP) (MacLogP),22229,,,1,14556,BAO_0000100,0,CHEMBL631232,,
12989,,,,A,U,Autocuration,,,Hydrophilicity was determined,22224,,,1,768,BAO_0000019,0,CHEMBL631233,,
12990,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,14452,BAO_0000100,0,CHEMBL631234,,
12991,,,,A,U,Autocuration,,,Increased absorption was determined,22224,,,1,5237,BAO_0000019,0,CHEMBL883126,,
12992,,,,P,U,Autocuration,,,Lipophilicity value was evaluated,22224,,,1,14378,BAO_0000100,0,CHEMBL631235,,
12993,,,,P,U,Autocuration,,,Log P value of the compound.,22224,,,1,14418,BAO_0000100,0,CHEMBL631236,,
12994,,,,A,U,Autocuration,,,Partition coefficient of compound was determined,22224,,,1,5249,BAO_0000019,0,CHEMBL631237,,
12995,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,14621,BAO_0000100,0,CHEMBL631238,,
12996,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,12542,BAO_0000100,0,CHEMBL876429,,
12997,,,,A,U,Autocuration,,,Partition coefficient was measured by medchem software; Not calculated,22224,,,1,12542,BAO_0000019,0,CHEMBL631414,,
12998,,,,P,U,Autocuration,,,Partition coefficient was measured by octanol-water using standard shake-flask method,22224,,,1,12542,BAO_0000100,0,CHEMBL631415,,
12999,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,15462,BAO_0000100,0,CHEMBL631416,,
13000,,,,A,U,Autocuration,,,Partition coefficient (logP),22224,,,1,14884,BAO_0000019,0,CHEMBL631417,,
13001,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,16526,BAO_0000100,0,CHEMBL631418,,
13002,,,,P,U,Autocuration,,,The Octanol/Water partition coefficient CLogP,22229,,,1,13693,BAO_0000100,0,CHEMBL631419,,
13003,,,,A,U,Autocuration,,,The pharmacokinetic parameter C Log p was reported,22224,,,1,13693,BAO_0000019,0,CHEMBL631420,,
13004,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,13779,BAO_0000100,0,CHEMBL631421,,
13005,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,14772,BAO_0000100,0,CHEMBL631422,,
13006,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,14393,BAO_0000100,0,CHEMBL631423,,
13007,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,50597,,,1,14793,BAO_0000218,1,CHEMBL876430,,1969.0
13008,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,50597,,,1,14793,BAO_0000218,1,CHEMBL631424,,1969.0
13009,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Compound was administered intravenously in dog to evaluate plasma clearance values,50588,,,1,13744,BAO_0000218,1,CHEMBL631425,,1969.0
13010,In vivo,Simiiformes,,A,U,Autocuration,Plasma,314293.0,Compound was administered intravenously in monkey to evaluate plasma clearance values,22224,,,1,13744,BAO_0000218,0,CHEMBL631426,,1969.0
13011,In vivo,Mus musculus,,A,N,Intermediate,Plasma,10090.0,Compound was administered intravenously in mouse to evaluate plasma clearance values,50594,,,1,13744,BAO_0000218,1,CHEMBL631427,,1969.0
13012,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,50588,,,1,13207,BAO_0000218,1,CHEMBL631428,,1969.0
13013,In vitro,Macaca mulatta,,A,N,Intermediate,Liver,9544.0,Intrinsic clearance in Rhesus liver microsome,50797,,,1,5669,BAO_0000218,1,CHEMBL631429,,2107.0
13014,In vitro,Canis lupus familiaris,,A,N,Intermediate,Liver,9615.0,Intrinsic clearance in dog liver microsome,50588,,,1,5669,BAO_0000218,1,CHEMBL631430,,2107.0
13015,In vitro,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Intrinsic clearance in rat liver microsome,50597,,,1,5669,BAO_0000218,1,CHEMBL631431,,2107.0
13016,In vivo,Macaca mulatta,,A,N,Intermediate,Plasma,9544.0,Low plasma clearance was calculated in rhesus monkey,50797,,,1,4853,BAO_0000218,1,CHEMBL631432,,1969.0
13017,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,50588,,,1,16452,BAO_0000218,1,CHEMBL631433,,
13018,In vivo,,,A,U,Autocuration,,,Plasma clearance after intravenous dose of 0.3 mg/kg,22224,,,1,11954,BAO_0000218,0,CHEMBL631434,,
13019,In vivo,,,A,U,Autocuration,,,Plasma clearance after intravenous dose of 1 mg/kg,22224,,,1,11954,BAO_0000218,0,CHEMBL631435,,
13020,In vivo,,,A,U,Autocuration,,,Plasma clearance after intravenous dose of 3 mg/kg,22224,,,1,11954,BAO_0000218,0,CHEMBL631436,,
13021,In vivo,,,A,U,Autocuration,,,Plasma clearance after intravenous dose of 3.87 mg/kg,22224,,,1,11954,BAO_0000218,0,CHEMBL631437,,
13022,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance after peroral administration at 10 mpk in Rat,50597,,,1,5669,BAO_0000218,1,CHEMBL631438,,
13023,In vivo,Macaca mulatta,,A,N,Intermediate,,9544.0,Plasma clearance after peroral administration at 10 mpk in Rhesus,50797,,,1,5669,BAO_0000218,1,CHEMBL876431,,
13024,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Plasma clearance after peroral administration at 10 mpk in dog,50588,,,1,5669,BAO_0000218,1,CHEMBL631439,,
13025,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,50597,,,1,13662,BAO_0000218,1,CHEMBL631440,,
13026,,,,A,U,Autocuration,,,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),22224,,,1,8272,BAO_0000019,0,CHEMBL631441,,
13027,,,,A,U,Autocuration,,,Critical Micellar concentration was determined,22224,,,1,13410,BAO_0000019,0,CHEMBL631442,,
13028,,,,A,U,Autocuration,,,Critical Micellar concentration of the compound. was determined,22224,,,1,13410,BAO_0000019,0,CHEMBL626525,,
13029,,,,A,U,Autocuration,,,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,22224,,,1,12628,BAO_0000019,0,CHEMBL627168,,
13030,,,,A,U,Autocuration,,,Critical micellar concentration was measured in water by the dye solubilization method,22224,,,1,9675,BAO_0000019,0,CHEMBL875618,,
13031,,,,B,U,Autocuration,,,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,22224,,,1,12628,BAO_0000019,0,CHEMBL626612,,
13032,,,,A,U,Autocuration,,,CMR value (relative to BAY K 8644),22224,,,1,12766,BAO_0000019,0,CHEMBL626613,,
13033,,,,A,U,Autocuration,,,Carbamoylating activity was determined,22224,,,1,7849,BAO_0000019,0,CHEMBL626614,,
13034,,Simiiformes,,A,U,Autocuration,,314293.0,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,22224,,,1,12187,BAO_0000218,0,CHEMBL626615,,
13035,,,,A,U,Autocuration,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,22224,,,1,2040,BAO_0000019,0,CHEMBL626616,,
13036,,,,A,U,Autocuration,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,22224,,,1,2040,BAO_0000019,0,CHEMBL626617,,
13037,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,50588,,,1,14180,BAO_0000218,1,CHEMBL626618,,1969.0
13038,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,50597,,,1,14180,BAO_0000218,1,CHEMBL626619,,1969.0
13039,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,"Clearance rate at 0.46 mg/kg, iv, in dogs",50588,,,1,14474,BAO_0000218,1,CHEMBL626620,,
13040,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Clearance rate at 5.5 mg/kg, iv, in rat",50597,,,1,14474,BAO_0000218,1,CHEMBL626621,,
13041,In vivo,Macaca fascicularis,,A,N,Intermediate,,9541.0,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,100710,,,1,14548,BAO_0000218,1,CHEMBL626622,,
13042,In vivo,Macaca fascicularis,,A,N,Intermediate,,9541.0,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,100710,,,1,14548,BAO_0000218,1,CHEMBL626623,,
13043,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,50588,,,1,14548,BAO_0000218,1,CHEMBL626624,,
13044,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,50597,,,1,14548,BAO_0000218,1,CHEMBL626625,,
13045,Ex vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Clearance rate constant using isolated perfused rat liver (IPRL) assay,50597,,,1,6125,BAO_0000218,1,CHEMBL626626,,2107.0
13046,In vivo,,,A,U,Autocuration,,,Tested for the total clearance of the compound,22224,,,1,6874,BAO_0000218,0,CHEMBL626627,,
13047,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,50588,,,1,15343,BAO_0000218,1,CHEMBL626628,,
13048,In vivo,,,A,U,Autocuration,,,Total body clearance was determined,22224,,,1,6236,BAO_0000218,0,CHEMBL626629,,
13049,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL626630,,
13050,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL626631,,
13051,,,,P,U,Autocuration,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,22229,,,1,8194,BAO_0000100,0,CHEMBL626632,,
13052,,,,P,U,Autocuration,,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,22229,,,1,8194,BAO_0000100,0,CHEMBL626633,,
13053,,,,P,U,Autocuration,,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,22229,,,1,8194,BAO_0000100,0,CHEMBL626634,,
13054,,,,P,U,Autocuration,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,22229,,,1,8194,BAO_0000100,0,CHEMBL626635,,
13055,,,,P,U,Autocuration,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,22229,,,1,8194,BAO_0000100,0,CHEMBL626636,,
13056,,,,P,U,Autocuration,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,22229,,,1,8194,BAO_0000100,0,CHEMBL626637,,
13057,,Pneumocystis carinii,,A,N,Intermediate,,4754.0,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),50339,,,1,13273,BAO_0000218,1,CHEMBL626638,,
13058,,Pneumocystis carinii,,A,N,Intermediate,,4754.0,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,50339,,,1,13273,BAO_0000218,1,CHEMBL626639,,
13059,,Pneumocystis carinii,,A,N,Intermediate,,4754.0,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,50339,,,1,13273,BAO_0000218,1,CHEMBL626640,,
13060,,Pneumocystis carinii,,A,N,Intermediate,,4754.0,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,50339,,,1,13273,BAO_0000218,1,CHEMBL626641,,
13061,,Pneumocystis carinii,,A,N,Intermediate,,4754.0,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,50339,,,1,13273,BAO_0000218,1,CHEMBL627272,,
13062,,Pneumocystis carinii,,A,N,Intermediate,,4754.0,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,50339,,,1,13273,BAO_0000218,1,CHEMBL627273,,
13063,,Pneumocystis carinii,,A,N,Intermediate,,4754.0,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),50339,,,1,13273,BAO_0000218,1,CHEMBL627441,,
13064,,Pneumocystis carinii,,A,N,Intermediate,,4754.0,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),50339,,,1,13273,BAO_0000218,1,CHEMBL628355,,
13065,,Pneumocystis carinii,,A,N,Intermediate,,4754.0,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),50339,,,1,13273,BAO_0000218,1,CHEMBL628356,,
13066,,Pneumocystis carinii,,A,N,Intermediate,,4754.0,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),50339,,,1,13273,BAO_0000218,1,CHEMBL628357,,
13067,,Pneumocystis carinii,,A,N,Intermediate,,4754.0,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),50339,,,1,13273,BAO_0000218,1,CHEMBL628358,,
13068,,Pneumocystis carinii,,A,N,Intermediate,,4754.0,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),50339,,,1,13273,BAO_0000218,1,CHEMBL622307,,
13069,,,,A,U,Autocuration,,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,22224,,,1,13118,BAO_0000019,0,CHEMBL622527,,
13070,,,,A,U,Autocuration,,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,22224,,,1,13118,BAO_0000019,0,CHEMBL622528,,
13071,,,,A,U,Autocuration,,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,22224,,,1,13118,BAO_0000019,0,CHEMBL622529,,
13072,,,,A,U,Autocuration,,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,22224,,,1,13118,BAO_0000019,0,CHEMBL622992,,
13073,,,,A,U,Autocuration,,,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,22224,,,1,13118,BAO_0000019,0,CHEMBL622993,,
13074,,,,A,U,Autocuration,,,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,22224,,,1,13118,BAO_0000019,0,CHEMBL622994,,
13075,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",50597,,,1,10633,BAO_0000218,1,CHEMBL622995,,
13076,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",50597,,,1,10633,BAO_0000218,1,CHEMBL622996,,
13077,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",50597,,,1,10633,BAO_0000218,1,CHEMBL622997,,
13078,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",50597,,,1,10633,BAO_0000218,1,CHEMBL622998,,
13079,,,,A,U,Autocuration,,,Cp max following ip administration at 1 mg/kg,22224,,,1,5767,BAO_0000218,0,CHEMBL622999,,
13080,In vivo,,,A,U,Autocuration,Plasma,,Maximum concentration in plasma was reported at 0.5 hour,22224,,,1,3302,BAO_0000218,0,CHEMBL623000,,1969.0
13081,In vivo,,,A,U,Autocuration,Plasma,,Maximum concentration in plasma was reported at 2 hour,22224,,,1,3302,BAO_0000218,0,CHEMBL623001,,1969.0
13082,,Mus musculus,,A,N,Intermediate,,10090.0,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,50594,,,1,12467,BAO_0000218,1,CHEMBL623002,,
13083,,,,P,U,Autocuration,,,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),22229,,,1,11778,BAO_0000100,0,CHEMBL623003,,
13084,,,,A,U,Autocuration,,,Steady state concentration was evaluated,22224,,,1,4321,BAO_0000019,0,CHEMBL623004,,
13085,,,,A,U,Autocuration,,,Partition coefficient (logP),22224,,,1,14884,BAO_0000019,0,CHEMBL623005,,
13086,,,,A,U,Autocuration,,,Partition coefficient (logD7.4),22224,,,1,15234,BAO_0000019,0,CHEMBL623006,,
13087,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL623007,,2107.0
13088,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL623008,,10000001.0
13089,In vivo,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL876654,,2037.0
13090,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL623009,,
13091,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL623010,,
13092,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL623011,,948.0
13093,In vivo,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL623012,,160.0
13094,,,,A,U,Autocuration,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,22224,,,1,8151,BAO_0000019,0,CHEMBL623013,,
13095,,,,A,U,Autocuration,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,22224,,,1,8151,BAO_0000019,0,CHEMBL623014,,
13096,,,,A,U,Autocuration,Urine,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,22224,,,1,8151,BAO_0000019,0,CHEMBL623015,,1088.0
13097,,,,A,U,Autocuration,Urine,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,22224,,,1,8151,BAO_0000019,0,CHEMBL623016,,1088.0
13098,,,,A,U,Autocuration,Urine,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,22224,,,1,8151,BAO_0000019,0,CHEMBL624858,,1088.0
13099,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,50597,,,1,8151,BAO_0000218,1,CHEMBL624859,,
13100,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,50597,,,1,8151,BAO_0000218,1,CHEMBL624860,,
13101,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,50597,,,1,8151,BAO_0000218,1,CHEMBL624861,,
13102,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,50597,,,1,8151,BAO_0000218,1,CHEMBL624862,,
13103,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,50597,,,1,8151,BAO_0000218,1,CHEMBL624863,,
13104,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,50597,,,1,8151,BAO_0000218,1,CHEMBL876655,,
13105,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,50588,,,1,6996,BAO_0000218,1,CHEMBL624864,,
13106,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,50588,,,1,6996,BAO_0000218,1,CHEMBL624865,,
13107,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,50588,,,1,6996,BAO_0000218,1,CHEMBL624866,,
13108,,Canis lupus familiaris,,F,N,Expert,,9615.0,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,50588,,,1,6996,BAO_0000218,1,CHEMBL624867,,
13109,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,50588,,,1,6996,BAO_0000218,1,CHEMBL624868,,
13110,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,50588,,,1,6996,BAO_0000218,1,CHEMBL628450,,
13111,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,50588,,,1,6996,BAO_0000218,1,CHEMBL628451,,
13112,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,50588,,,1,6996,BAO_0000218,1,CHEMBL628452,,
13113,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,50588,,,1,6996,BAO_0000218,1,CHEMBL628453,,
13114,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,50588,,,1,6996,BAO_0000218,1,CHEMBL628454,,
13115,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,50588,,,1,6996,BAO_0000218,1,CHEMBL628455,,
13116,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,50588,,,1,6996,BAO_0000218,1,CHEMBL628456,,
13117,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,50588,,,1,6996,BAO_0000218,1,CHEMBL628457,,
13118,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,50588,,,1,6996,BAO_0000218,1,CHEMBL877505,,
13119,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,50588,,,1,6996,BAO_0000218,1,CHEMBL628458,,
13120,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,50588,,,1,6996,BAO_0000218,1,CHEMBL628459,,
13121,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,50588,,,1,6996,BAO_0000218,1,CHEMBL628460,,
13122,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,50588,,,1,6996,BAO_0000218,1,CHEMBL628461,,
13123,,,,B,U,Autocuration,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",22224,,,1,6996,BAO_0000218,0,CHEMBL628462,,
13124,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,50588,,,1,6996,BAO_0000218,1,CHEMBL628463,,
13125,,Rattus norvegicus,,F,N,Expert,,10116.0,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",50597,,,1,6996,BAO_0000218,1,CHEMBL625666,,
13126,,,,B,U,Autocuration,,,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,22224,,,1,6996,BAO_0000218,0,CHEMBL625667,,
13127,,Rattus norvegicus,,A,N,Expert,,10116.0,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,50597,,,1,6996,BAO_0000218,1,CHEMBL625668,,
13128,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,50597,,,1,6996,BAO_0000218,1,CHEMBL625669,,
13129,,,,A,U,Autocuration,,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,22224,,,1,7114,BAO_0000019,0,CHEMBL625670,,
13130,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,50597,,,1,7114,BAO_0000218,1,CHEMBL625671,,
13131,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,50602,,,1,8613,BAO_0000218,1,CHEMBL625672,,
13132,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,50602,,,1,8613,BAO_0000218,1,CHEMBL625673,,
13133,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,50602,,,1,8613,BAO_0000218,1,CHEMBL625674,,
13134,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,50602,,,1,8613,BAO_0000218,1,CHEMBL625675,,
13135,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,50602,,,1,8613,BAO_0000218,1,CHEMBL627637,,
13136,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,50602,,,1,8613,BAO_0000218,1,CHEMBL627638,,
13137,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,50602,,,1,8613,BAO_0000218,1,CHEMBL627639,,
13138,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,50602,,,1,8613,BAO_0000218,1,CHEMBL627640,,
13139,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,50602,,,1,8613,BAO_0000218,1,CHEMBL627641,,
13140,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,50602,,,1,8613,BAO_0000218,1,CHEMBL627642,,
13141,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,50602,,,1,8613,BAO_0000218,1,CHEMBL877506,,
13142,,Mus musculus,,A,N,Intermediate,,10090.0,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,50594,,,1,8613,BAO_0000218,1,CHEMBL627275,,
13143,,Mustela putorius furo,,A,N,Intermediate,,9669.0,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",50506,,,1,11219,BAO_0000218,1,CHEMBL627643,,
13144,,Mustela putorius furo,,A,N,Intermediate,,9669.0,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",50506,,,1,11219,BAO_0000218,1,CHEMBL631246,,
13145,,Mustela putorius furo,,A,N,Intermediate,,9669.0,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",50506,,,1,11219,BAO_0000218,1,CHEMBL631247,,
13146,,Mustela putorius furo,,A,N,Intermediate,,9669.0,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,50506,,,1,11219,BAO_0000218,1,CHEMBL629532,,
13147,,Mustela putorius furo,,A,N,Intermediate,,9669.0,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,50506,,,1,11219,BAO_0000218,1,CHEMBL629533,,
13148,,Mustela putorius furo,,A,N,Intermediate,,9669.0,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,50506,,,1,11219,BAO_0000218,1,CHEMBL629534,,
13149,,Mustela putorius furo,,A,N,Intermediate,,9669.0,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,50506,,,1,11219,BAO_0000218,1,CHEMBL629535,,
13150,,,,A,U,Autocuration,,,Pharmacokinetic parameter :drug bound to plasma was reported,22224,,,1,14837,BAO_0000019,0,CHEMBL625932,,
13151,,,,A,U,Autocuration,,,compound was evaluated for drug bound in plasma,22224,,,1,14837,BAO_0000019,0,CHEMBL625933,,
13152,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,50597,,,1,15343,BAO_0000218,1,CHEMBL625934,,
13153,,Eutheria,,A,U,Autocuration,,9347.0,Bioavailability,22224,,,1,13761,BAO_0000218,0,CHEMBL625935,,
13154,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,50597,,,1,14810,BAO_0000218,1,CHEMBL625936,,
13155,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,50597,,,1,14810,BAO_0000218,1,CHEMBL625937,,
13156,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,50588,,,1,13249,BAO_0000218,1,CHEMBL625938,,
13157,,Rattus norvegicus,,A,N,Intermediate,Bile,10116.0,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,50597,,,1,9267,BAO_0000218,1,CHEMBL625939,,1970.0
13158,,Rattus norvegicus,,A,N,Intermediate,Bile,10116.0,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,50597,,,1,9267,BAO_0000218,1,CHEMBL625940,,1970.0
13159,,Rattus norvegicus,,A,N,Intermediate,Bile,10116.0,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,50597,,,1,9267,BAO_0000218,1,CHEMBL874464,,1970.0
13160,,Rattus norvegicus,,A,N,Intermediate,Bile,10116.0,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,50597,,,1,9267,BAO_0000218,1,CHEMBL625941,,1970.0
13161,,Rattus norvegicus,,A,N,Intermediate,Bile,10116.0,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,50597,,,1,9267,BAO_0000218,1,CHEMBL625942,,1970.0
13162,,Rattus norvegicus,,A,N,Intermediate,Bile,10116.0,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,50597,,,1,9267,BAO_0000218,1,CHEMBL625943,,1970.0
13163,,Homo sapiens,,A,N,Intermediate,Serum,9606.0,In vitro protein binding in human serum at 5 ug/ml,50587,,,1,15549,BAO_0000218,1,CHEMBL625944,,1977.0
13164,,,,A,U,Autocuration,,,Serum protein binding ability was measured,22224,,,1,10929,BAO_0000019,0,CHEMBL625945,,
13165,,,,A,U,Autocuration,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),22224,,,1,15444,BAO_0000019,0,CHEMBL625946,,
13166,In vivo,Canis lupus familiaris,,A,U,Autocuration,,9615.0,Oral bioavailability in dog,22224,,,1,12860,BAO_0000218,0,CHEMBL625947,,
13167,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,50597,,,1,12170,BAO_0000218,1,CHEMBL625948,,
13168,In vivo,,,A,U,Autocuration,,,Absolute oral bioavailability at an iv dose of 14 mg/kg,22224,,,1,15173,BAO_0000218,0,CHEMBL625949,,
13169,In vivo,,,A,U,Autocuration,,,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,22224,,,1,15173,BAO_0000218,0,CHEMBL625950,,
13170,In vivo,Eutheria,,A,U,Autocuration,,9347.0,Oral bioavailability (dose 15 mg/kg i.v.),22224,,,1,15173,BAO_0000218,0,CHEMBL625951,,
13171,In vivo,,,A,U,Autocuration,,,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,22224,,,1,15173,BAO_0000218,0,CHEMBL625952,,
13172,In vivo,,,A,U,Autocuration,,,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,22224,,,1,15173,BAO_0000218,0,CHEMBL625953,,
13173,In vivo,,,A,U,Autocuration,,,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,22224,,,1,15173,BAO_0000218,0,CHEMBL625954,,
13174,In vivo,,,A,U,Autocuration,,,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,22224,,,1,15173,BAO_0000218,0,CHEMBL882959,,
13175,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,50588,,,1,11767,BAO_0000218,1,CHEMBL625955,,
13176,In vivo,Mustela putorius furo,,A,U,Autocuration,,9669.0,Bioavailability in ferret,22224,,,1,11219,BAO_0000218,0,CHEMBL625956,,
13177,In vivo,Macaca fascicularis,,A,N,Intermediate,,9541.0,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,100710,,,1,12186,BAO_0000218,1,CHEMBL625957,,
13178,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL625958,,
13179,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL625959,,
13180,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL626642,,
13181,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL631330,,
13182,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL631331,,
13183,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,50597,,,1,11510,BAO_0000218,1,CHEMBL631332,,
13184,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL631333,,
13185,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL632018,,
13186,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL632019,,
13187,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL632020,,
13188,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL632021,,
13189,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL632022,,
13190,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL632023,,
13191,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL632024,,
13192,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL874472,,
13193,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL632025,,
13194,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL632026,,
13195,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL632027,,
13196,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL632028,,
13197,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL626430,,
13198,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL626431,,
13199,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL626432,,
13200,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL626433,,
13201,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL626434,,
13202,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL627280,,
13203,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL627281,,
13204,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL627282,,
13205,,,,A,U,Autocuration,,,Total body clearance was measured at given dose,22224,,,1,7199,BAO_0000019,0,CHEMBL627283,,
13206,,,,A,U,Autocuration,,,Total body clearance was measured at given dose.,22224,,,1,7199,BAO_0000218,0,CHEMBL627284,,
13207,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Metabolic clearance from the body in rat,50597,,,1,7095,BAO_0000218,1,CHEMBL627285,,
13208,In vivo,,,A,U,Autocuration,,,Renal clearance from the body,22224,,,1,7095,BAO_0000218,0,CHEMBL627286,,
13209,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Renal clearance from the body in rat,50597,,,1,7095,BAO_0000218,1,CHEMBL875477,,
13210,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,50597,,,1,12528,BAO_0000218,1,CHEMBL627287,,
13211,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,50588,,,1,12528,BAO_0000218,1,CHEMBL627288,,
13212,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Total clearance from the body in rat,50597,,,1,7095,BAO_0000218,1,CHEMBL627289,,
13213,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Clearance into cortex from rat plasma or PBS,50597,,,1,14223,BAO_0000218,1,CHEMBL627290,,1969.0
13214,In vivo,,,A,U,Autocuration,,,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,22224,,,1,13569,BAO_0000218,0,CHEMBL627291,,
13215,In vivo,,,A,U,Autocuration,,,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,22224,,,1,13569,BAO_0000218,0,CHEMBL627292,,
13216,In vivo,,,A,U,Autocuration,,,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,22224,,,1,13569,BAO_0000218,0,CHEMBL627293,,
13217,In vivo,,,A,U,Autocuration,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,22224,,,1,13569,BAO_0000218,0,CHEMBL627294,,
13218,In vivo,,,A,U,Autocuration,,,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,22224,,,1,13569,BAO_0000218,0,CHEMBL875478,,
13219,In vivo,,,A,U,Autocuration,,,Clearance was determined,22224,,,1,13979,BAO_0000218,0,CHEMBL627295,,
13220,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,50594,,,1,14315,BAO_0000218,1,CHEMBL627296,,
13221,In vivo,Oryctolagus cuniculus,,A,N,Intermediate,,9986.0,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,50592,,,1,14315,BAO_0000218,1,CHEMBL626119,,
13222,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,50597,,,1,14315,BAO_0000218,1,CHEMBL626120,,
13223,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance in rat after iv dose (100 ug/kg),50597,,,1,12174,BAO_0000218,1,CHEMBL626121,,
13224,In vivo,Cavia porcellus,,A,U,Autocuration,,10141.0,Clearance in guinea pig,22224,,,1,12797,BAO_0000218,0,CHEMBL626122,,
13225,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for clearance in rat,50597,,,1,12797,BAO_0000218,1,CHEMBL626123,,
13226,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for the clearance in dog,50588,,,1,12797,BAO_0000218,1,CHEMBL623456,,
13227,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for the clearance in rat,50597,,,1,12797,BAO_0000218,1,CHEMBL623457,,
13228,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was tested in vivo for clearance after iv administration in the rat,50597,,,1,11500,BAO_0000218,1,CHEMBL623458,,
13229,In vivo,,,A,U,Autocuration,,,IV clearance determined at an iv dose of 14 mg/kg,22224,,,1,15173,BAO_0000218,0,CHEMBL623459,,
13230,In vivo,,,A,U,Autocuration,,,IV clearance determined at an iv dose of 15.2 mg/kg,22224,,,1,15173,BAO_0000218,0,CHEMBL875484,,
13231,In vivo,,,A,U,Autocuration,,,IV clearance determined at an iv dose of 15 mg/kg,22224,,,1,15173,BAO_0000218,0,CHEMBL623460,,
13232,In vivo,,,A,U,Autocuration,,,IV clearance determined at an peroral dose of 30 mg/kg.,22224,,,1,15173,BAO_0000218,0,CHEMBL623461,,
13233,In vivo,,,A,U,Autocuration,,,IV clearance determined at an peroral dose of 30.2 mg/kg.,22224,,,1,15173,BAO_0000218,0,CHEMBL623462,,
13234,In vivo,,,A,U,Autocuration,,,IV clearance determined at an peroral dose of 30.3 mg/kg.,22224,,,1,15173,BAO_0000218,0,CHEMBL627386,,
13235,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL627387,,2113.0
13236,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL627388,,2107.0
13237,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL627389,,2048.0
13238,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL627390,,2385.0
13239,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL627391,,1969.0
13240,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL627392,,
13241,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL627393,,2106.0
13242,In vivo,Rattus norvegicus,,A,N,Intermediate,Trachea,10116.0,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL627394,,3126.0
13243,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL627395,,10000001.0
13244,In vivo,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL875485,,2037.0
13245,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL627396,,
13246,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL627397,,
13247,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL627398,,948.0
13248,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL627399,,10000001.0
13249,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL627400,,2113.0
13250,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL627401,,2107.0
13251,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL627402,,2048.0
13252,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL627403,,2385.0
13253,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL627404,,1969.0
13254,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL623101,,
13255,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL877480,,2106.0
13256,In vivo,Rattus norvegicus,,A,N,Intermediate,Trachea,10116.0,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL623102,,3126.0
13257,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL623103,,10000001.0
13258,In vivo,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL623104,,2037.0
13259,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL623105,,
13260,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL623106,,
13261,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL623107,,948.0
13262,In vivo,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL623108,,160.0
13263,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL623109,,2113.0
13264,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL623110,,2107.0
13265,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL623111,,2048.0
13266,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL625060,,2385.0
13267,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL625061,,1969.0
13268,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL625062,,
13269,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL625063,,2106.0
13270,In vivo,Rattus norvegicus,,A,N,Intermediate,Trachea,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL625064,,3126.0
13271,In vivo,Rattus norvegicus,,A,N,Intermediate,Bone,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL625065,,10000001.0
13272,In vivo,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL625066,,2037.0
13273,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL625067,,
13274,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL625068,,
13275,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL622159,,948.0
13276,In vivo,Rattus norvegicus,,A,N,Intermediate,Intestine,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL622160,,160.0
13277,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL622161,,2113.0
13278,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL622162,,2048.0
13279,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL622163,,2385.0
13280,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL622313,,1969.0
13281,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL622314,,
13282,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL622315,,2106.0
13283,In vivo,Rattus norvegicus,,A,N,Intermediate,Trachea,10116.0,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,50597,,,1,14198,BAO_0000218,1,CHEMBL622316,,3126.0
13284,,Escherichia coli,,A,N,Intermediate,,562.0,Normal diffusion coefficient in water for Escherichia coli,50212,,,1,15599,BAO_0000218,1,CHEMBL877486,,
13285,,,,A,U,Autocuration,,,Average max percent decrease in RVR (renal vascular resistance) was determined,22224,,,1,8204,BAO_0000019,0,CHEMBL622317,,
13286,,,,A,U,Autocuration,,,Average max percent decrease in RVR (renal vascular resistance) was determined.,22224,,,1,8204,BAO_0000019,0,CHEMBL622318,,
13287,,,,A,U,Autocuration,,,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,22224,,,1,6154,BAO_0000019,0,CHEMBL622319,,
13288,,,,A,U,Autocuration,,,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,22224,,,1,6154,BAO_0000019,0,CHEMBL622320,,
13289,,,,A,U,Autocuration,,,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,22224,,,1,6154,BAO_0000019,0,CHEMBL622321,,
13290,,,,A,U,Autocuration,,,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,22224,,,1,6154,BAO_0000019,0,CHEMBL622322,,
13291,,,,A,U,Autocuration,,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,22224,,,1,7114,BAO_0000019,0,CHEMBL622323,,
13292,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,50597,,,1,7114,BAO_0000218,1,CHEMBL622324,,
13293,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL622325,,1088.0
13294,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL622326,,1088.0
13295,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL877487,,1088.0
13296,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL622327,,1088.0
13297,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL622328,,1088.0
13298,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL622329,,1088.0
13299,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL622330,,1088.0
13300,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL622331,,1088.0
13301,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL622332,,1088.0
13302,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL622333,,1088.0
13303,,Simiiformes,,A,U,Autocuration,Urine,314293.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",22224,,,1,8133,BAO_0000218,0,CHEMBL627658,,1088.0
13304,,Simiiformes,,A,U,Autocuration,Urine,314293.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",22224,,,1,8133,BAO_0000218,0,CHEMBL630428,,1088.0
13305,,Simiiformes,,A,U,Autocuration,Urine,314293.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",22224,,,1,8133,BAO_0000218,0,CHEMBL630429,,1088.0
13306,,Simiiformes,,A,U,Autocuration,Urine,314293.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",22224,,,1,8133,BAO_0000218,0,CHEMBL630430,,1088.0
13307,,Simiiformes,,A,U,Autocuration,Urine,314293.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",22224,,,1,8133,BAO_0000218,0,CHEMBL630431,,1088.0
13308,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL630432,,1088.0
13309,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL630433,,1088.0
13310,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL630434,,1088.0
13311,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL629372,,1088.0
13312,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL629553,,1088.0
13313,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL629554,,1088.0
13314,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL874447,,1088.0
13315,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL629555,,1088.0
13316,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL629556,,1088.0
13317,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL629557,,1088.0
13318,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL629558,,1088.0
13319,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL629559,,1088.0
13320,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL629560,,1088.0
13321,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL629561,,1088.0
13322,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL629562,,1088.0
13323,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL629563,,1088.0
13324,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL629564,,1088.0
13325,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL629565,,1088.0
13326,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL629566,,1088.0
13327,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL629567,,1088.0
13328,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL629568,,1088.0
13329,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL629569,,1088.0
13330,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL629570,,1088.0
13331,,Simiiformes,,A,U,Autocuration,Urine,314293.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",22224,,,1,8133,BAO_0000218,0,CHEMBL629571,,1088.0
13332,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,22224,,,1,12170,BAO_0000218,0,CHEMBL629572,,
13333,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,22224,,,1,12170,BAO_0000218,0,CHEMBL629573,,
13334,In vivo,Eutheria,,A,U,Autocuration,,9347.0,Bioavailability (dose 20 mg/kg),22224,,,1,4985,BAO_0000218,0,CHEMBL629574,,
13335,In vivo,Canis lupus familiaris,,A,U,Autocuration,,9615.0,Bioavailability in dog,22224,,,1,15145,BAO_0000218,0,CHEMBL629575,,
13336,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,Bioavailability in rat (Sprague-Dawley) (male),22224,,,1,14080,BAO_0000218,0,CHEMBL874448,,
13337,In vivo,Primates,,A,U,Autocuration,,9443.0,Bioavailability in monkey (dose 10 mg/kg i.d.),22224,,,1,11219,BAO_0000218,0,CHEMBL629576,,
13338,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,Bioavailability in rat,22224,,,1,15145,BAO_0000218,0,CHEMBL629577,,
13339,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,Bioavailability in rat,22224,,,1,15145,BAO_0000218,0,CHEMBL629578,,
13340,In vivo,Canis lupus familiaris,,A,U,Autocuration,,9615.0,Bioavailability in dog (dose 3.0 mg/kg p.o.),22224,,,1,1202,BAO_0000218,0,CHEMBL629579,,
13341,In vivo,Canis lupus familiaris,,A,U,Autocuration,,9615.0,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,22224,,,1,1202,BAO_0000218,0,CHEMBL882958,,
13342,In vivo,Pan troglodytes,,A,N,Intermediate,,9598.0,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,50505,,,1,1202,BAO_0000218,1,CHEMBL629580,,
13343,In vivo,Eutheria,,A,U,Autocuration,,9347.0,Bioavailability,22224,,,1,4026,BAO_0000218,0,CHEMBL629581,,
13344,In vivo,Saimiri,,A,U,Autocuration,,9520.0,Bioavailability in squirrel monkey,22224,,,1,1492,BAO_0000218,0,CHEMBL629582,,
13345,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Bioavailability was evaluated in dog,50588,,,1,12793,BAO_0000218,1,CHEMBL628522,,
13346,In vivo,Cricetinae,,A,N,Intermediate,,10026.0,Bioavailability was evaluated in hamster,100712,,,1,12793,BAO_0000218,1,CHEMBL625432,,
13347,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,Bioavailability in rat,22224,,,1,12793,BAO_0000218,0,CHEMBL625433,,
13348,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,50597,,,1,14793,BAO_0000218,1,CHEMBL625434,,1969.0
13349,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,50597,,,1,14793,BAO_0000218,1,CHEMBL625435,,1969.0
13350,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,Bioavailability in rat (dose 10 mg/kg p.o.),22224,,,1,14793,BAO_0000218,0,CHEMBL625436,,
13351,In vivo,Macaca fascicularis,,A,N,Intermediate,,9541.0,Bioavailability was measured in cynomolgus monkeys.,100710,,,1,14731,BAO_0000218,1,CHEMBL874588,,
13352,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Bioavailability was measured in nude mice.,50594,,,1,14731,BAO_0000218,1,CHEMBL625437,,
13353,In vivo,Mustela putorius furo,,A,U,Autocuration,,9669.0,Bioavailability in ferret (dose 10 mg/kg i.d.),22224,,,1,12187,BAO_0000218,0,CHEMBL625438,,
13354,In vivo,Simiiformes,,A,U,Autocuration,,314293.0,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),22224,,,1,12187,BAO_0000218,0,CHEMBL625439,,
13355,In vivo,Simiiformes,,A,U,Autocuration,,314293.0,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",22224,,,1,12187,BAO_0000218,0,CHEMBL625440,,
13356,In vivo,Simiiformes,,A,U,Autocuration,,314293.0,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),22224,,,1,12187,BAO_0000218,0,CHEMBL625441,,
13357,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,Bioavailability in rat (dose 10 mg/kg i.d.),22224,,,1,12187,BAO_0000218,0,CHEMBL625442,,
13358,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",50597,,,1,12187,BAO_0000218,1,CHEMBL625443,,
13359,In vivo,,,A,U,Autocuration,,,Bioavailability was determined; extremely poor,22224,,,1,17431,BAO_0000218,0,CHEMBL625444,,
13360,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,% bioavailability in mice after oral administration of prodrug,50594,,,1,13318,BAO_0000218,1,CHEMBL625445,,
13361,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,50588,,,1,9025,BAO_0000218,1,CHEMBL625446,,
13362,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,50588,,,1,9025,BAO_0000218,1,CHEMBL882960,,
13363,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,50588,,,1,9025,BAO_0000218,1,CHEMBL625447,,
13364,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,50588,,,1,9025,BAO_0000218,1,CHEMBL625448,,
13365,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,50588,,,1,9025,BAO_0000218,1,CHEMBL625449,,
13366,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),50588,,,1,9025,BAO_0000218,1,CHEMBL874589,,
13367,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,50588,,,1,9025,BAO_0000218,1,CHEMBL625450,,
13368,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,50588,,,1,9025,BAO_0000218,1,CHEMBL625451,,
13369,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,50588,,,1,9025,BAO_0000218,1,CHEMBL626584,,
13370,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,50588,,,1,9025,BAO_0000218,1,CHEMBL626585,,
13371,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,50588,,,1,9025,BAO_0000218,1,CHEMBL626586,,
13372,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,50588,,,1,9025,BAO_0000218,1,CHEMBL626587,,
13373,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,50588,,,1,9025,BAO_0000218,1,CHEMBL626588,,
13374,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,50588,,,1,9025,BAO_0000218,1,CHEMBL626589,,
13375,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,50588,,,1,9025,BAO_0000218,1,CHEMBL626590,,
13376,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,50588,,,1,9025,BAO_0000218,1,CHEMBL626591,,
13377,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,50588,,,1,9025,BAO_0000218,1,CHEMBL627181,,
13378,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,50588,,,1,9025,BAO_0000218,1,CHEMBL628083,,
13379,In vivo,,,A,U,Autocuration,,,IV clearance determined at an peroral dose of 15 mg/kg.,22224,,,1,15173,BAO_0000218,0,CHEMBL628084,,
13380,In vivo,Hymenolepis nana,,F,N,Expert,,102285.0,Mouse oral clearance was measured against Hymenolepiasis nana.,50064,,,1,7732,BAO_0000218,1,CHEMBL628085,,
13381,In vivo,Heligmosomoides polygyrus,,F,N,Expert,,6339.0,Mouse oral clearance was measured against Nematospiroides dubius,50545,,,1,7732,BAO_0000218,1,CHEMBL628086,,
13382,In vivo,,,F,U,Autocuration,,,Mouse oral clearance was measured against N. dubius; NT is Not Tested,22224,,,1,7732,BAO_0000218,0,CHEMBL628087,,
13383,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Mouse oral clearance was measured against N. nana; NT is Not Tested,50594,,,1,7732,BAO_0000218,1,CHEMBL628088,,
13384,In vivo,,,B,U,Autocuration,,,Mouse oral clearance was measured against N. nana; NT is Not Tested,22224,,,1,7732,BAO_0000218,0,CHEMBL628089,,
13385,In vivo,,,A,U,Autocuration,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,22224,,,1,8328,BAO_0000218,0,CHEMBL628090,,
13386,In vivo,,,A,U,Autocuration,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,22224,,,1,8328,BAO_0000218,0,CHEMBL628091,,
13387,In vivo,,,A,U,Autocuration,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,22224,,,1,8328,BAO_0000218,0,CHEMBL628092,,
13388,In vivo,,,A,U,Autocuration,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,22224,,,1,8328,BAO_0000218,0,CHEMBL628093,,
13389,In vivo,,,A,U,Autocuration,,,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,22224,,,1,8328,BAO_0000218,0,CHEMBL875607,,
13390,In vivo,,,A,U,Autocuration,,,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,22224,,,1,8328,BAO_0000218,0,CHEMBL625710,,
13391,In vivo,,,A,U,Autocuration,,,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,22224,,,1,8328,BAO_0000218,0,CHEMBL625711,,
13392,In vivo,,,A,U,Autocuration,,,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,22224,,,1,8328,BAO_0000218,0,CHEMBL625712,,
13393,In vivo,,,A,U,Autocuration,,,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,22224,,,1,8328,BAO_0000218,0,CHEMBL625713,,
13394,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,50588,,,1,13376,BAO_0000218,1,CHEMBL625714,,
13395,In vivo,Macaca mulatta,,A,N,Intermediate,,9544.0,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,50797,,,1,13477,BAO_0000218,1,CHEMBL625715,,
13396,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,50597,,,1,13477,BAO_0000218,1,CHEMBL625716,,
13397,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,50597,,,1,13477,BAO_0000218,1,CHEMBL625717,,
13398,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance was determined for the compound in rats,50597,,,1,13313,BAO_0000218,1,CHEMBL625718,,
13399,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,50597,,,1,12504,BAO_0000218,1,CHEMBL625719,,
13400,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,50597,,,1,12504,BAO_0000218,1,CHEMBL625720,,
13401,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,50597,,,1,12504,BAO_0000218,1,CHEMBL625721,,
13402,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,50597,,,1,12504,BAO_0000218,1,CHEMBL625722,,
13403,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,50597,,,1,13129,BAO_0000218,1,CHEMBL625723,,
13404,In vivo,Heligmosomoides polygyrus,,A,N,Intermediate,,6339.0,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,50545,,,1,7732,BAO_0000218,1,CHEMBL625724,,
13405,In vivo,Heligmosomoides polygyrus,,A,N,Intermediate,,6339.0,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,50545,,,1,7732,BAO_0000218,1,CHEMBL625725,,
13406,In vivo,Heligmosomoides polygyrus,,A,N,Intermediate,,6339.0,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,50545,,,1,7732,BAO_0000218,1,CHEMBL625726,,
13407,In vivo,Heligmosomoides polygyrus,,A,N,Intermediate,,6339.0,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,50545,,,1,7732,BAO_0000218,1,CHEMBL875608,,
13408,In vivo,Heligmosomoides polygyrus,,A,N,Intermediate,,6339.0,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,50545,,,1,7732,BAO_0000218,1,CHEMBL625727,,
13409,In vivo,Rattus norvegicus,,A,U,Autocuration,Urine,10116.0,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,22224,,,1,9278,BAO_0000218,0,CHEMBL625728,,1088.0
13410,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,22224,,,1,9278,BAO_0000218,0,CHEMBL625729,,
13411,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,22224,,,1,9278,BAO_0000218,0,CHEMBL625730,,
13412,In vivo,Rattus norvegicus,,A,U,Autocuration,Urine,10116.0,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,22224,,,1,9278,BAO_0000218,0,CHEMBL625731,,1088.0
13413,In vivo,Rattus norvegicus,,A,U,Autocuration,Urine,10116.0,Urinary clearance was determined in rat at 25 mg/kg os dosage,22224,,,1,9278,BAO_0000218,0,CHEMBL626417,,1088.0
13414,In vivo,Homo sapiens,,A,N,Intermediate,Urine,9606.0,Urinary clearance was determined at 100 mg/kg oral dosage in human,50587,,,1,9278,BAO_0000218,1,CHEMBL626418,,1088.0
13415,In vivo,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,50588,,,1,9278,BAO_0000218,1,CHEMBL626419,,1088.0
13416,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,50588,,,1,5932,BAO_0000218,1,CHEMBL626592,,1969.0
13417,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,50597,,,1,5932,BAO_0000218,1,CHEMBL626593,,1969.0
13418,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,50597,,,1,5182,BAO_0000218,1,CHEMBL626594,,
13419,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Clearance rate in dogs,50588,,,1,10499,BAO_0000218,1,CHEMBL625035,,
13420,In vitro,,,A,U,Autocuration,,,Compound was measured for intrinsic clearance,22224,,,1,6051,BAO_0000019,0,CHEMBL625036,,
13421,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,17508,BAO_0000100,0,CHEMBL625037,,
13422,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,6228,BAO_0000100,0,CHEMBL625038,,
13423,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,6231,BAO_0000100,0,CHEMBL625039,,
13424,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,17740,BAO_0000100,0,CHEMBL625040,,
13425,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,6495,BAO_0000100,0,CHEMBL625041,,
13426,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,2171,BAO_0000100,0,CHEMBL625042,,
13427,,,,A,U,Autocuration,,,Partition coefficient of the compound,22224,,,1,3255,BAO_0000019,0,CHEMBL874411,,
13428,,,,A,U,Autocuration,,,Permeability,22224,,,1,6821,BAO_0000019,0,CHEMBL625043,,
13429,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,2685,BAO_0000100,0,CHEMBL625044,,
13430,,,,A,U,Autocuration,,,Partition coefficient (logD),22224,,,1,17584,BAO_0000019,0,CHEMBL625045,,
13431,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),22229,,,1,13824,BAO_0000100,0,CHEMBL625046,,
13432,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),22229,,,1,13824,BAO_0000100,0,CHEMBL625047,,
13433,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,16479,BAO_0000100,0,CHEMBL625048,,
13434,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,11997,BAO_0000100,0,CHEMBL625049,,
13435,,,,P,U,Autocuration,,,Calculated logarithm of partition coefficient (P) was determined,22229,,,1,2988,BAO_0000100,0,CHEMBL625050,,
13436,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,931,BAO_0000100,0,CHEMBL625051,,
13437,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,4381,BAO_0000100,0,CHEMBL874412,,
13438,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,4397,BAO_0000100,0,CHEMBL625052,,
13439,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,5889,BAO_0000100,0,CHEMBL625053,,
13440,,,,A,U,Autocuration,,,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,22224,,,1,6154,BAO_0000019,0,CHEMBL623250,,
13441,,,,A,U,Autocuration,,,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,22224,,,1,6154,BAO_0000019,0,CHEMBL623251,,
13442,,,,A,U,Autocuration,,,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,22224,,,1,6154,BAO_0000019,0,CHEMBL623252,,
13443,,,,A,U,Autocuration,,,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,22224,,,1,6154,BAO_0000019,0,CHEMBL623253,,
13444,,,,A,U,Autocuration,,,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,22224,,,1,6154,BAO_0000019,0,CHEMBL623254,,
13445,,,,A,U,Autocuration,,,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,22224,,,1,6154,BAO_0000019,0,CHEMBL623255,,
13446,,,,A,U,Autocuration,,,Percent degradation of compound at a pH of 1 over a 18 hr period,22224,,,1,6887,BAO_0000019,0,CHEMBL626831,,
13447,,,,A,U,Autocuration,,,Percent degradation of compound at pH of 1 over an 18 hr period,22224,,,1,6887,BAO_0000019,0,CHEMBL877494,,
13448,,,,A,U,Autocuration,,,Delta Logarithm of Partition Coefficient value was determined.,22224,,,1,14116,BAO_0000019,0,CHEMBL626832,,
13449,,,,A,U,Autocuration,,,Delta logPoct-cyc,22224,,,1,11137,BAO_0000019,0,CHEMBL626833,,
13450,,,,P,U,Autocuration,,,Lipophilicity estimated on reversed phase TLC,22224,,,1,7230,BAO_0000100,0,CHEMBL626834,,
13451,,,,A,U,Autocuration,,,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,22224,,,1,15741,BAO_0000019,0,CHEMBL626835,,
13452,,,,A,U,Autocuration,,,Delta logPoct-cyc,22224,,,1,9663,BAO_0000019,0,CHEMBL626836,,
13453,,,,P,U,Autocuration,,,Change in logarithm of partition coefficient of the compound,22229,,,1,9663,BAO_0000100,0,CHEMBL626837,,
13454,,,,A,U,Autocuration,,,Delta logD (pH 6.5),22224,,,1,13807,BAO_0000019,0,CHEMBL626838,,
13455,,,,P,U,Autocuration,,,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",22224,,,1,13807,BAO_0000100,0,CHEMBL626839,,
13456,,,,A,U,Autocuration,,,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,22224,,,1,17425,BAO_0000019,0,CHEMBL626840,,
13457,,,,A,U,Autocuration,,,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),22224,,,1,12143,BAO_0000019,0,CHEMBL626841,,
13458,,,,A,U,Autocuration,,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,22224,,,1,12608,BAO_0000219,0,CHEMBL626842,,
13459,,,,A,U,Autocuration,,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,22224,,,1,12608,BAO_0000219,0,CHEMBL626843,,
13460,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,50597,,,1,8649,BAO_0000218,1,CHEMBL626844,,
13461,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Amount of deuterium retained was reported after normal workup in rats,50597,,,1,8649,BAO_0000218,1,CHEMBL877495,,
13462,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,50597,,,1,8649,BAO_0000218,1,CHEMBL626845,,
13463,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,50597,,,1,8649,BAO_0000218,1,CHEMBL626846,,
13464,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,50597,,,1,8649,BAO_0000218,1,CHEMBL626847,,
13465,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,50597,,,1,8649,BAO_0000218,1,CHEMBL628677,,
13466,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,50597,,,1,8649,BAO_0000218,1,CHEMBL628678,,
13467,,,,A,U,Autocuration,,,Compound was subjected to electrochemical oxidation,22224,,,1,9659,BAO_0000019,0,CHEMBL628679,,
13468,,,,A,U,Autocuration,,,Compound was subjected to photochemical oxidation,22224,,,1,9659,BAO_0000019,0,CHEMBL628680,,
13469,,,,A,U,Autocuration,,,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,22224,,,1,9659,BAO_0000019,0,CHEMBL628681,,
13470,,,,A,U,Autocuration,,,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,22224,,,1,9659,BAO_0000019,0,CHEMBL628682,,
13471,,,,A,U,Autocuration,,,Oxidation of compound by methemoglobin in presence of hydroperoxide,22224,,,1,9659,BAO_0000019,0,CHEMBL628683,,
13472,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Percent diffusion through fuzzy rat skin after 48 h of incubation,50597,,,1,9607,BAO_0000218,1,CHEMBL628684,,
13473,,,,P,U,Autocuration,,,Dissociation constant (pKa),22229,,,1,7057,BAO_0000100,0,CHEMBL877501,,
13474,,,,P,U,Autocuration,,,Dissociation constant value of the compound; ND means not determined.,22224,,,1,7057,BAO_0000100,0,CHEMBL628685,,
13475,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,50597,,,1,7911,BAO_0000218,1,CHEMBL628686,,178.0
13476,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,50597,,,1,7911,BAO_0000218,1,CHEMBL628687,,178.0
13477,,Rattus norvegicus,,A,N,Intermediate,,10116.0,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,50597,,,1,7911,BAO_0000218,1,CHEMBL628688,,
13478,,Rattus norvegicus,,A,N,Intermediate,,10116.0,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,50597,,,1,7911,BAO_0000218,1,CHEMBL628689,,
13479,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,50597,,,1,7911,BAO_0000218,1,CHEMBL628690,,2107.0
13480,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,50597,,,1,7911,BAO_0000218,1,CHEMBL629363,,2107.0
13481,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,50597,,,1,7911,BAO_0000218,1,CHEMBL629364,,2106.0
13482,,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,50597,,,1,7911,BAO_0000218,1,CHEMBL629365,,2106.0
13483,,Rattus norvegicus,,A,N,Intermediate,,10116.0,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,50597,,,1,7911,BAO_0000218,1,CHEMBL629366,,
13484,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,50597,,,1,7911,BAO_0000218,1,CHEMBL629367,,1088.0
13485,,Rattus norvegicus,,A,N,Intermediate,Feces,10116.0,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,50597,,,1,7911,BAO_0000218,1,CHEMBL629368,,1988.0
13486,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,50597,,,1,7911,BAO_0000218,1,CHEMBL877502,,1088.0
13487,,Mus musculus,,A,N,Intermediate,Cerebellum,10090.0,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,50594,,,1,13792,BAO_0000218,1,CHEMBL629369,,2037.0
13488,,Mus musculus,,A,N,Intermediate,Brain,10090.0,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,50594,,,1,13792,BAO_0000218,1,CHEMBL629370,,955.0
13489,,Simiiformes,,A,U,Autocuration,Urine,314293.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",22224,,,1,8133,BAO_0000218,0,CHEMBL629371,,1088.0
13490,,Simiiformes,,A,U,Autocuration,Urine,314293.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",22224,,,1,8133,BAO_0000218,0,CHEMBL626276,,1088.0
13491,,Simiiformes,,A,U,Autocuration,Urine,314293.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",22224,,,1,8133,BAO_0000218,0,CHEMBL626277,,1088.0
13492,,Simiiformes,,A,U,Autocuration,Urine,314293.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",22224,,,1,8133,BAO_0000218,0,CHEMBL631250,,1088.0
13493,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL631251,,1088.0
13494,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL631252,,1088.0
13495,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL631253,,1088.0
13496,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL631254,,1088.0
13497,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL631255,,1088.0
13498,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL631256,,1088.0
13499,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL631257,,1088.0
13500,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL628009,,1088.0
13501,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL628010,,1088.0
13502,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL628011,,1088.0
13503,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL628012,,1088.0
13504,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL628013,,1088.0
13505,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL628014,,1088.0
13506,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL628015,,1088.0
13507,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL628016,,1088.0
13508,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL874461,,1088.0
13509,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL628017,,1088.0
13510,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL628018,,1088.0
13511,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL628019,,1088.0
13512,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL628020,,1088.0
13513,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL628021,,1088.0
13514,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL628022,,1088.0
13515,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",50588,,,1,8133,BAO_0000218,1,CHEMBL628023,,1088.0
13516,,Simiiformes,,A,U,Autocuration,Urine,314293.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",22224,,,1,8133,BAO_0000218,0,CHEMBL628024,,1088.0
13517,,Simiiformes,,A,U,Autocuration,Urine,314293.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",22224,,,1,8133,BAO_0000218,0,CHEMBL628025,,1088.0
13518,,Simiiformes,,A,U,Autocuration,Urine,314293.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",22224,,,1,8133,BAO_0000218,0,CHEMBL628026,,1088.0
13519,,Simiiformes,,A,U,Autocuration,Urine,314293.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",22224,,,1,8133,BAO_0000218,0,CHEMBL628027,,1088.0
13520,,Simiiformes,,A,U,Autocuration,Urine,314293.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",22224,,,1,8133,BAO_0000218,0,CHEMBL628028,,1088.0
13521,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL628029,,1088.0
13522,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL628030,,1088.0
13523,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL628031,,1088.0
13524,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL628032,,1088.0
13525,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL628033,,1088.0
13526,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL628034,,1088.0
13527,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL628035,,1088.0
13528,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL628036,,1088.0
13529,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL874462,,1088.0
13530,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,50588,,,1,9025,BAO_0000218,1,CHEMBL628037,,
13531,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,50588,,,1,9025,BAO_0000218,1,CHEMBL628123,,
13532,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,50588,,,1,9025,BAO_0000218,1,CHEMBL628124,,
13533,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,50588,,,1,9025,BAO_0000218,1,CHEMBL628125,,
13534,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,50588,,,1,9025,BAO_0000218,1,CHEMBL628126,,
13535,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),50588,,,1,9025,BAO_0000218,1,CHEMBL628127,,
13536,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,50588,,,1,9025,BAO_0000218,1,CHEMBL628128,,
13537,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,50588,,,1,9025,BAO_0000218,1,CHEMBL628129,,
13538,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,50588,,,1,9025,BAO_0000218,1,CHEMBL628130,,
13539,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,50588,,,1,9025,BAO_0000218,1,CHEMBL628131,,
13540,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,50588,,,1,9025,BAO_0000218,1,CHEMBL628132,,
13541,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,50588,,,1,9025,BAO_0000218,1,CHEMBL628133,,
13542,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,50588,,,1,9025,BAO_0000218,1,CHEMBL628134,,
13543,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,50588,,,1,9025,BAO_0000218,1,CHEMBL628135,,
13544,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,50588,,,1,9025,BAO_0000218,1,CHEMBL628136,,
13545,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,50588,,,1,9025,BAO_0000218,1,CHEMBL628137,,
13546,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,50588,,,1,9025,BAO_0000218,1,CHEMBL628138,,
13547,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,50588,,,1,9025,BAO_0000218,1,CHEMBL628139,,
13548,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,50588,,,1,9025,BAO_0000218,1,CHEMBL628140,,
13549,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,50588,,,1,9025,BAO_0000218,1,CHEMBL628141,,
13550,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,50588,,,1,9025,BAO_0000218,1,CHEMBL628142,,
13551,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,50588,,,1,9025,BAO_0000218,1,CHEMBL628143,,
13552,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,50588,,,1,9025,BAO_0000218,1,CHEMBL628144,,
13553,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,50588,,,1,9025,BAO_0000218,1,CHEMBL628145,,
13554,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,50588,,,1,9025,BAO_0000218,1,CHEMBL628146,,
13555,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,50588,,,1,9025,BAO_0000218,1,CHEMBL625355,,
13556,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,50588,,,1,9025,BAO_0000218,1,CHEMBL625356,,
13557,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,50588,,,1,9025,BAO_0000218,1,CHEMBL625357,,
13558,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,50588,,,1,9025,BAO_0000218,1,CHEMBL625527,,
13559,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),50588,,,1,9025,BAO_0000218,1,CHEMBL875473,,
13560,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,50588,,,1,9025,BAO_0000218,1,CHEMBL625528,,
13561,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,50597,,,1,9025,BAO_0000218,1,CHEMBL626304,,
13562,In vivo,Canis lupus familiaris,,A,N,Intermediate,Artery,9615.0,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,50588,,,1,9025,BAO_0000218,1,CHEMBL624138,,1637.0
13563,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,6448,BAO_0000100,0,CHEMBL624139,,
13564,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,17221,BAO_0000100,0,CHEMBL624140,,
13565,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,6545,BAO_0000100,0,CHEMBL624141,,
13566,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,577,BAO_0000100,0,CHEMBL624142,,
13567,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,6285,BAO_0000100,0,CHEMBL624143,,
13568,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,6500,BAO_0000100,0,CHEMBL624144,,
13569,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,6716,BAO_0000100,0,CHEMBL624145,,
13570,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,13658,BAO_0000100,0,CHEMBL624146,,
13571,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,6549,BAO_0000100,0,CHEMBL624147,,
13572,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP) (MacLogP),22229,,,1,14685,BAO_0000100,0,CHEMBL883123,,
13573,,,,A,U,Autocuration,,,Partition coefficient (logP),22224,,,1,6893,BAO_0000019,0,CHEMBL624148,,
13574,,,,A,U,Autocuration,,,Kinetic parameter was determined,22224,,,1,3687,BAO_0000019,0,CHEMBL874416,,
13575,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,4207,BAO_0000100,0,CHEMBL624149,,
13576,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,4626,BAO_0000100,0,CHEMBL624150,,
13577,,,,P,U,Autocuration,,,Lipophilicity was determined,22224,,,1,1021,BAO_0000100,0,CHEMBL624151,,
13578,,,,P,U,Autocuration,,,Lipophilicity was determined,22224,,,1,3777,BAO_0000100,0,CHEMBL624152,,
13579,,,,P,U,Autocuration,,,Lipophilicity was determined,22224,,,1,17533,BAO_0000100,0,CHEMBL622139,,
13580,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,6524,BAO_0000100,0,CHEMBL622140,,
13581,,,,P,U,Autocuration,,,Lipophilicity was determined,22224,,,1,17533,BAO_0000100,0,CHEMBL622141,,
13582,,,,P,U,Autocuration,,,Lipophilicity in octanol-water,22224,,,1,6480,BAO_0000100,0,CHEMBL622142,,
13583,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,17606,BAO_0000100,0,CHEMBL622143,,
13584,,,,P,U,Autocuration,,,Octanol-water partition coefficient was determined,22229,,,1,6863,BAO_0000100,0,CHEMBL622144,,
13585,,,,A,U,Autocuration,,,Partition coefficient (logP),22224,,,1,1356,BAO_0000019,0,CHEMBL877473,,
13586,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,3326,BAO_0000100,0,CHEMBL622145,,
13587,,,,A,U,Autocuration,,,Partition coefficient was determined; ND means not determined,22224,,,1,1356,BAO_0000019,0,CHEMBL622146,,
13588,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP),22229,,,1,12984,BAO_0000100,0,CHEMBL622147,,
13589,,,,A,U,Autocuration,,,Partition coefficient of the compound,22224,,,1,17363,BAO_0000019,0,CHEMBL622148,,
13590,,,,A,U,Autocuration,,,Permeability was determined,22224,,,1,6827,BAO_0000019,0,CHEMBL883124,,
13591,,,,P,U,Autocuration,,,The compound was evaluated for the partition coefficient,22229,,,1,261,BAO_0000100,0,CHEMBL622149,,
13592,,,,A,U,Autocuration,,,Partition coefficient (logP),22224,,,1,2685,BAO_0000019,0,CHEMBL622150,,
13593,,,,P,U,Autocuration,,,The lipophilicity was reported,22224,,,1,414,BAO_0000100,0,CHEMBL622151,,
13594,,,,P,U,Autocuration,,,logarithm of the octanol-water partition coefficient for the compound,22229,,,1,15769,BAO_0000100,0,CHEMBL622152,,
13595,,,,A,U,Autocuration,,,Clogp value was determined,22224,,,1,17248,BAO_0000019,0,CHEMBL622153,,
13596,In vivo,,,A,U,Autocuration,,,Clp at a dose of 1.5 mg/kg,22224,,,1,16935,BAO_0000218,0,CHEMBL877474,,
13597,In vivo,,,A,U,Autocuration,,,Clp at a dose of 2.0 mg/kg,22224,,,1,16935,BAO_0000218,0,CHEMBL622154,,
13598,In vivo,,,A,U,Autocuration,Plasma,,"Clp, plasma clearance at a dose of 10 mg/kg",22224,,,1,14832,BAO_0000218,0,CHEMBL622155,,1969.0
13599,In vivo,,,A,U,Autocuration,Plasma,,"Clp, plasma clearance at a dose of 50 mg/kg",22224,,,1,14832,BAO_0000218,0,CHEMBL622156,,1969.0
13600,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Compound was tested for plasma clearance in rat,50597,,,1,2399,BAO_0000218,1,CHEMBL622157,,1969.0
13601,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Compound was tested for plasma clearance in rat; Not determined,50597,,,1,2399,BAO_0000218,1,CHEMBL622158,,1969.0
13602,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,50597,,,1,6227,BAO_0000218,1,CHEMBL622807,,
13603,In vivo,Macaca mulatta,,A,N,Intermediate,,9544.0,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,50797,,,1,6227,BAO_0000218,1,CHEMBL622808,,
13604,In vivo,,,A,U,Autocuration,,,Plasma clearance by iv administration at a dose 0.003 ug/mL,22224,,,1,5623,BAO_0000218,0,CHEMBL622809,,
13605,In vivo,,,A,U,Autocuration,,,Plasma clearance determined,22224,,,1,4854,BAO_0000218,0,CHEMBL622810,,
13606,In vivo,Cricetinae,,A,N,Intermediate,,10026.0,Plasma clearance after iv administration at 3 mg/kg in hamster,100712,,,1,4493,BAO_0000218,1,CHEMBL876653,,
13607,In vivo,Cricetinae,,A,N,Intermediate,,10026.0,Plasma clearance after iv administration at 4 mg/kg in hamster,100712,,,1,4493,BAO_0000218,1,CHEMBL622811,,
13608,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Rate of clearance in rat was determined,50597,,,1,14956,BAO_0000218,1,CHEMBL622986,,
13609,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,50597,,,1,15372,BAO_0000218,1,CHEMBL622987,,1969.0
13610,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Total plasma clearance after iv dose of 5.10 mg/kg in rats,50597,,,1,15372,BAO_0000218,1,CHEMBL622988,,1969.0
13611,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,50597,,,1,15372,BAO_0000218,1,CHEMBL622989,,1969.0
13612,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,50597,,,1,15372,BAO_0000218,1,CHEMBL622990,,1969.0
13613,In vivo,Simiiformes,,A,U,Autocuration,Plasma,314293.0,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,22224,,,1,15604,BAO_0000218,0,CHEMBL622991,,1969.0
13614,In vivo,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,50597,,,1,15604,BAO_0000218,1,CHEMBL622227,,1969.0
13615,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,50588,,,1,15604,BAO_0000218,1,CHEMBL622228,,1969.0
13616,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Clpl value in rat,50597,,,1,14964,BAO_0000218,1,CHEMBL622229,,
13617,In vivo,Cavia porcellus,,A,N,Intermediate,,10141.0,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,50512,,,1,15240,BAO_0000218,1,CHEMBL622230,,
13618,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,50597,,,1,16449,BAO_0000218,1,CHEMBL622231,,
13619,In vivo,Macaca fascicularis,,A,N,Intermediate,,9541.0,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,100710,,,1,16449,BAO_0000218,1,CHEMBL622232,,
13620,In vivo,,,A,U,Autocuration,,,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,22224,,,1,12902,BAO_0000218,0,CHEMBL622233,,
13621,In vivo,,,A,U,Autocuration,,,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,22224,,,1,12902,BAO_0000218,0,CHEMBL622234,,
13622,In vivo,,,A,U,Autocuration,,,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,22224,,,1,12902,BAO_0000218,0,CHEMBL622235,,
13623,In vivo,,,A,U,Autocuration,,,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,22224,,,1,12902,BAO_0000218,0,CHEMBL622236,,
13624,In vivo,,,A,U,Autocuration,,,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,22224,,,1,12902,BAO_0000218,0,CHEMBL622237,,
13625,In vivo,,,A,U,Autocuration,,,Cmax in minutes at a po dose of 10.0(pmol/g/h).,22224,,,1,12902,BAO_0000218,0,CHEMBL877482,,
13626,In vivo,,,A,U,Autocuration,,,Cmax in minutes at a po dose of 20.0(pmol/g/h).,22224,,,1,12902,BAO_0000218,0,CHEMBL622238,,
13627,In vivo,,,A,U,Autocuration,,,Cmax in minutes at a po dose of 40.0(pmol/g/h).,22224,,,1,12902,BAO_0000218,0,CHEMBL622239,,
13628,In vivo,,,A,U,Autocuration,Blood,,Cmax was calculated as maximum concentration reached in the blood,22224,,,1,11149,BAO_0000218,0,CHEMBL622240,,178.0
13629,In vivo,,,A,U,Autocuration,Blood,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,22224,,,1,11149,BAO_0000218,0,CHEMBL622241,,178.0
13630,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax was determine after peroral administration at 10 mpk in Rat,50597,,,1,5669,BAO_0000218,1,CHEMBL631013,,
13631,In vivo,Macaca mulatta,,A,N,Intermediate,,9544.0,Cmax was determine after peroral administration at 10 mpk in Rhesus,50797,,,1,5669,BAO_0000218,1,CHEMBL631014,,
13632,In vivo,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Cmax was determine after peroral administration at 10 mpk in dog,50588,,,1,5669,BAO_0000218,1,CHEMBL631015,,
13633,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax was determine after peroral administration at 160 mpk in Rat,50597,,,1,5669,BAO_0000218,1,CHEMBL631016,,
13634,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax was determine after peroral administration at 20 mpk in Rat,50597,,,1,5669,BAO_0000218,1,CHEMBL631017,,
13635,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cmax was determine after peroral administration at 50 mpk in Rat,50597,,,1,5669,BAO_0000218,1,CHEMBL631018,,
13636,In vivo,,,A,U,Autocuration,,,Cmax was determined,22224,,,1,4236,BAO_0000218,0,CHEMBL631019,,
13637,,Mus musculus,,A,N,Intermediate,Brain,10090.0,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,50594,,,1,13792,BAO_0000218,1,CHEMBL875761,,955.0
13638,,Mus musculus,,A,N,Intermediate,Brain,10090.0,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,50594,,,1,13792,BAO_0000218,1,CHEMBL631020,,955.0
13639,,Mus musculus,,A,N,Intermediate,Brain,10090.0,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,50594,,,1,13792,BAO_0000218,1,CHEMBL631669,,955.0
13640,,Mus musculus,,A,N,Intermediate,Brain,10090.0,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,50594,,,1,13792,BAO_0000218,1,CHEMBL631670,,955.0
13641,,Mus musculus,,A,N,Intermediate,Striatum,10090.0,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,50594,,,1,13792,BAO_0000218,1,CHEMBL631671,,2435.0
13642,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,50597,,,1,8418,BAO_0000218,1,CHEMBL631672,,178.0
13643,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,50597,,,1,8418,BAO_0000218,1,CHEMBL631673,,178.0
13644,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,50597,,,1,8418,BAO_0000218,1,CHEMBL631856,,178.0
13645,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,50597,,,1,8418,BAO_0000218,1,CHEMBL631857,,178.0
13646,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,50597,,,1,8418,BAO_0000218,1,CHEMBL631858,,178.0
13647,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,50597,,,1,8418,BAO_0000218,1,CHEMBL631859,,178.0
13648,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,50597,,,1,8418,BAO_0000218,1,CHEMBL631860,,178.0
13649,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,50597,,,1,8418,BAO_0000218,1,CHEMBL631861,,178.0
13650,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,50597,,,1,8418,BAO_0000218,1,CHEMBL631862,,178.0
13651,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,50597,,,1,8418,BAO_0000218,1,CHEMBL631863,,178.0
13652,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,50597,,,1,8418,BAO_0000218,1,CHEMBL631864,,178.0
13653,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,50597,,,1,8418,BAO_0000218,1,CHEMBL631865,,178.0
13654,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,50597,,,1,8418,BAO_0000218,1,CHEMBL631866,,178.0
13655,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,50597,,,1,8418,BAO_0000218,1,CHEMBL629360,,178.0
13656,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,50597,,,1,8418,BAO_0000218,1,CHEMBL629361,,178.0
13657,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,50597,,,1,8418,BAO_0000218,1,CHEMBL629362,,178.0
13658,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,50597,,,1,8418,BAO_0000218,1,CHEMBL630740,,178.0
13659,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,50597,,,1,8418,BAO_0000218,1,CHEMBL630741,,178.0
13660,,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,50597,,,1,8418,BAO_0000218,1,CHEMBL630742,,178.0
13661,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,50597,,,1,8418,BAO_0000218,1,CHEMBL630743,,
13662,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,50597,,,1,8418,BAO_0000218,1,CHEMBL630744,,
13663,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,50597,,,1,8418,BAO_0000218,1,CHEMBL630745,,
13664,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,50597,,,1,8418,BAO_0000218,1,CHEMBL630746,,
13665,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,50597,,,1,8418,BAO_0000218,1,CHEMBL630747,,
13666,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,50597,,,1,8418,BAO_0000218,1,CHEMBL630748,,
13667,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,50597,,,1,8418,BAO_0000218,1,CHEMBL632056,,
13668,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,50597,,,1,8418,BAO_0000218,1,CHEMBL632057,,
13669,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,50597,,,1,8418,BAO_0000218,1,CHEMBL632058,,
13670,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,50597,,,1,8418,BAO_0000218,1,CHEMBL632059,,
13671,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,50597,,,1,8418,BAO_0000218,1,CHEMBL632060,,
13672,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,50597,,,1,8418,BAO_0000218,1,CHEMBL632061,,
13673,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,50597,,,1,8418,BAO_0000218,1,CHEMBL629207,,
13674,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,50597,,,1,8418,BAO_0000218,1,CHEMBL629208,,
13675,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,50597,,,1,8418,BAO_0000218,1,CHEMBL629209,,
13676,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,50597,,,1,8418,BAO_0000218,1,CHEMBL629210,,
13677,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,50597,,,1,8418,BAO_0000218,1,CHEMBL629211,,
13678,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,50597,,,1,8418,BAO_0000218,1,CHEMBL629212,,
13679,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,50597,,,1,8418,BAO_0000218,1,CHEMBL629213,,
13680,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL629214,,1088.0
13681,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL629215,,1088.0
13682,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",50597,,,1,8133,BAO_0000218,1,CHEMBL635154,,1088.0
13683,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL629216,,
13684,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,50597,,,1,6996,BAO_0000218,1,CHEMBL629217,,
13685,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL629218,,
13686,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL629219,,
13687,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL629220,,
13688,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),50597,,,1,6996,BAO_0000218,1,CHEMBL629221,,
13689,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL631127,,
13690,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,50597,,,1,6996,BAO_0000218,1,CHEMBL631128,,
13691,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL631129,,
13692,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL631130,,
13693,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL631131,,
13694,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),50597,,,1,6996,BAO_0000218,1,CHEMBL631132,,
13695,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL631133,,
13696,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,50597,,,1,6996,BAO_0000218,1,CHEMBL631134,,
13697,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL875120,,
13698,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL631135,,
13699,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL631136,,
13700,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),50597,,,1,6996,BAO_0000218,1,CHEMBL631137,,
13701,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL631138,,
13702,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,50597,,,1,6996,BAO_0000218,1,CHEMBL631139,,
13703,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL631140,,
13704,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL631141,,
13705,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL631142,,
13706,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),50597,,,1,6996,BAO_0000218,1,CHEMBL631143,,
13707,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),50597,,,1,6996,BAO_0000218,1,CHEMBL631144,,
13708,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,50588,,,1,6996,BAO_0000218,1,CHEMBL631145,,
13709,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL631146,,
13710,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,50588,,,1,6996,BAO_0000218,1,CHEMBL631147,,
13711,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL631148,,
13712,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL631149,,
13713,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL631150,,
13714,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL631151,,
13715,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL631152,,
13716,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL631443,,
13717,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL631444,,
13718,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL631445,,
13719,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),50588,,,1,6996,BAO_0000218,1,CHEMBL631446,,
13720,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL631447,,
13721,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL631448,,
13722,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,50588,,,1,6996,BAO_0000218,1,CHEMBL631449,,
13723,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL631450,,
13724,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),50588,,,1,6996,BAO_0000218,1,CHEMBL629724,,
13725,In vivo,Mus musculus,,A,N,Intermediate,Zone of skin,10090.0,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,,,1,9716,BAO_0000218,1,CHEMBL629725,,14.0
13726,In vivo,Mus musculus,,A,N,Intermediate,Zone of skin,10090.0,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,,,1,9716,BAO_0000218,1,CHEMBL629726,,14.0
13727,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,,,1,9716,BAO_0000218,1,CHEMBL629727,,2106.0
13728,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,,,1,9716,BAO_0000218,1,CHEMBL630404,,2106.0
13729,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,,,1,9716,BAO_0000218,1,CHEMBL630405,,2106.0
13730,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,,,1,9716,BAO_0000218,1,CHEMBL630406,,2106.0
13731,In vivo,Mus musculus,,A,N,Intermediate,Stomach,10090.0,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,,,1,9716,BAO_0000218,1,CHEMBL630407,,945.0
13732,In vivo,Mus musculus,,A,N,Intermediate,Stomach,10090.0,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,,,1,9716,BAO_0000218,1,CHEMBL630573,,945.0
13733,In vivo,Mus musculus,,A,N,Intermediate,Stomach,10090.0,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,,,1,9716,BAO_0000218,1,CHEMBL630574,,945.0
13734,In vivo,Mus musculus,,A,N,Intermediate,Stomach,10090.0,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,,,1,9716,BAO_0000218,1,CHEMBL630575,,945.0
13735,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,,,1,9716,BAO_0000218,1,CHEMBL630576,,
13736,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,,,1,9716,BAO_0000218,1,CHEMBL630577,,
13737,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,,,1,9716,BAO_0000218,1,CHEMBL630578,,
13738,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",50594,,,1,9716,BAO_0000218,1,CHEMBL630579,,
13739,,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),50594,,,1,12192,BAO_0000218,1,CHEMBL630580,,2113.0
13740,,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,50594,,,1,12192,BAO_0000218,1,CHEMBL630581,,2113.0
13741,,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),50594,,,1,12192,BAO_0000218,1,CHEMBL630582,,2113.0
13742,,Mus musculus,,A,N,Intermediate,,10090.0,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,50594,,,1,12192,BAO_0000218,1,CHEMBL630583,,
13743,,Mus musculus,,A,N,Intermediate,,10090.0,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),50594,,,1,12192,BAO_0000218,1,CHEMBL630584,,
13744,,Mus musculus,,A,N,Intermediate,,10090.0,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,50594,,,1,12192,BAO_0000218,1,CHEMBL630585,,
13745,,Mus musculus,,A,N,Intermediate,,10090.0,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),50594,,,1,12192,BAO_0000218,1,CHEMBL630586,,
13746,,Mus musculus,,A,N,Intermediate,,10090.0,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,50594,,,1,12192,BAO_0000218,1,CHEMBL630587,,
13747,,Mus musculus,,A,N,Intermediate,,10090.0,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),50594,,,1,12192,BAO_0000218,1,CHEMBL630588,,
13748,,Mus musculus,,A,N,Intermediate,,10090.0,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,50594,,,1,12192,BAO_0000218,1,CHEMBL630589,,
13749,,Mus musculus,,A,N,Intermediate,,10090.0,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),50594,,,1,12192,BAO_0000218,1,CHEMBL630590,,
13750,,,,A,U,Autocuration,Feces,,Removal of 238-Plutonium(IV) in feces at 24 h,22224,,,1,12192,BAO_0000019,0,CHEMBL630591,,1988.0
13751,,,,A,U,Autocuration,Feces,,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),22224,,,1,12192,BAO_0000019,0,CHEMBL630592,,1988.0
13752,,,,A,U,Autocuration,,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,22224,,,1,12192,BAO_0000019,0,CHEMBL630593,,
13753,,,,A,U,Autocuration,,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),22224,,,1,12192,BAO_0000019,0,CHEMBL630594,,
13754,,,,A,U,Autocuration,Urine,,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),22224,,,1,12192,BAO_0000019,0,CHEMBL630595,,1088.0
13755,,,,A,U,Autocuration,Urine,,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),22224,,,1,12192,BAO_0000019,0,CHEMBL630596,,1088.0
13756,,,,A,U,Autocuration,Urine,,Removal of 238-Plutonium(IV) in urine after 0-24 h,22224,,,1,12192,BAO_0000019,0,CHEMBL630597,,1088.0
13757,,,,A,U,Autocuration,Urine,,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),22224,,,1,12192,BAO_0000019,0,CHEMBL630598,,1088.0
13758,,,,A,U,Autocuration,Urine,,Removal of 238-Plutonium(IV) in urine after 0-4 h,22224,,,1,12192,BAO_0000019,0,CHEMBL630599,,1088.0
13759,,,,A,U,Autocuration,Urine,,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),22224,,,1,12192,BAO_0000019,0,CHEMBL630600,,1088.0
13760,,,,A,U,Autocuration,Urine,,Removal of 238-Plutonium(IV) in urine after 4-24 h,22224,,,1,12192,BAO_0000019,0,CHEMBL630601,,1088.0
13761,,,,A,U,Autocuration,Urine,,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),22224,,,1,12192,BAO_0000019,0,CHEMBL630602,,1088.0
13762,,,,A,U,Autocuration,Urine,,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),22224,,,1,12192,BAO_0000019,0,CHEMBL630603,,1088.0
13763,,,,A,U,Autocuration,Urine,,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),22224,,,1,12192,BAO_0000019,0,CHEMBL630604,,1088.0
13764,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL624869,,178.0
13765,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL624870,,178.0
13766,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL623189,,178.0
13767,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL623190,,178.0
13768,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL623191,,178.0
13769,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL623192,,
13770,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL623193,,
13771,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL623194,,
13772,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL623195,,
13773,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL623196,,
13774,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,50597,,,1,11836,BAO_0000218,1,CHEMBL623197,,
13775,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,50597,,,1,11836,BAO_0000218,1,CHEMBL623198,,
13776,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,50597,,,1,11836,BAO_0000218,1,CHEMBL623199,,
13777,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,50597,,,1,11836,BAO_0000218,1,CHEMBL623200,,2385.0
13778,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,50597,,,1,11836,BAO_0000218,1,CHEMBL623201,,2385.0
13779,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,50597,,,1,11836,BAO_0000218,1,CHEMBL623202,,2385.0
13780,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,50597,,,1,11836,BAO_0000218,1,CHEMBL623203,,2385.0
13781,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,50597,,,1,11836,BAO_0000218,1,CHEMBL623204,,2385.0
13782,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,50597,,,1,11836,BAO_0000218,1,CHEMBL623205,,2385.0
13783,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,50597,,,1,11836,BAO_0000218,1,CHEMBL623206,,2385.0
13784,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,50597,,,1,11836,BAO_0000218,1,CHEMBL623207,,2385.0
13785,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,50597,,,1,11836,BAO_0000218,1,CHEMBL623208,,2385.0
13786,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,50597,,,1,11836,BAO_0000218,1,CHEMBL623209,,2385.0
13787,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,50597,,,1,11836,BAO_0000218,1,CHEMBL623210,,2385.0
13788,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,50597,,,1,11836,BAO_0000218,1,CHEMBL623211,,
13789,,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,50597,,,1,11836,BAO_0000218,1,CHEMBL623212,,995.0
13790,,,,A,U,Autocuration,,,Tested in vitro for intrinsic activity relative to quinpirole,22224,,,1,12640,BAO_0000019,0,CHEMBL623213,,
13791,,,,A,U,Autocuration,,,"Relative ion enhancement, determined in pulsed ultrafiltration",22224,,,1,14218,BAO_0000019,0,CHEMBL623214,,
13792,,,,A,U,Autocuration,,,% ionization at the pH 7.4 at 37 degree Centigrade,22224,,,1,11296,BAO_0000019,0,CHEMBL623215,,
13793,,,,A,U,Autocuration,,,Percentage ionization was measured,22224,,,1,10929,BAO_0000019,0,CHEMBL623216,,
13794,,Bos taurus,,A,N,Intermediate,,9913.0,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,50591,,,1,13841,BAO_0000218,1,CHEMBL623217,,
13795,,,,A,U,Autocuration,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,22224,,,1,10431,BAO_0000019,0,CHEMBL623218,,
13796,,,,A,U,Autocuration,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,22224,,,1,10431,BAO_0000019,0,CHEMBL623913,,
13797,,,,A,U,Autocuration,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,22224,,,1,10431,BAO_0000019,0,CHEMBL623914,,
13798,,,,P,U,Autocuration,,,Compound was evaluated for the partition coefficient in octanol/water,22229,,,1,8826,BAO_0000100,0,CHEMBL623915,,
13799,,,,P,U,Autocuration,,,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),22229,,,1,8826,BAO_0000100,0,CHEMBL624080,,
13800,,,,A,U,Autocuration,,,Equilibrium constant measured by the pulse radiolysis at pH 7,22224,,,1,9884,BAO_0000019,0,CHEMBL624081,,
13801,,Homo sapiens,,A,N,Intermediate,,9606.0,In vitro hydrolytic rate constant determined in human blood,50587,,,1,9827,BAO_0000218,1,CHEMBL624082,,
13802,,Homo sapiens,,A,N,Intermediate,,9606.0,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,50587,,,1,10009,BAO_0000218,1,CHEMBL625054,,
13803,,,,A,U,Autocuration,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,22224,,,1,10009,BAO_0000019,0,CHEMBL877485,,
13804,,Mus musculus,,A,N,Intermediate,,10090.0,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,50594,,,1,10009,BAO_0000218,1,CHEMBL625055,,
13805,,Mus musculus,,A,N,Intermediate,,10090.0,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,50594,,,1,10009,BAO_0000218,1,CHEMBL625056,,
13806,,Homo sapiens,,A,N,Intermediate,,9606.0,In vitro oxidation of compound in presence of human plasma,50587,,,1,10009,BAO_0000218,1,CHEMBL625057,,
13807,,,,A,U,Autocuration,,,In vitro oxidation of compound in presence of hydrogen peroxide,22224,,,1,10009,BAO_0000019,0,CHEMBL625058,,
13808,,Mus musculus,,A,N,Intermediate,,10090.0,In vitro oxidation of compound in presence of mouse brain homogenate,50594,,,1,10009,BAO_0000218,1,CHEMBL625059,,
13809,,Mus musculus,,A,N,Intermediate,,10090.0,In vitro oxidation of compound in presence of mouse liver homogenate,50594,,,1,10009,BAO_0000218,1,CHEMBL629536,,
13810,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629537,,
13811,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629538,,
13812,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629539,,
13813,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL874445,,
13814,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629540,,
13815,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629541,,
13816,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629542,,
13817,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,50597,,,1,11510,BAO_0000218,1,CHEMBL630243,,
13818,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL630244,,
13819,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL630245,,
13820,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL630246,,
13821,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL630247,,
13822,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL630248,,
13823,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood at 240 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630249,,178.0
13824,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood at 30 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630250,,178.0
13825,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood at 360 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630251,,178.0
13826,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood at 3 hr after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630252,,178.0
13827,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood at 60 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630408,,178.0
13828,In vivo,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Biodistribution in rat cerebellum at 120 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630409,,2037.0
13829,In vivo,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL874446,,2037.0
13830,In vivo,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Biodistribution in rat cerebellum at 15 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630410,,2037.0
13831,In vivo,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Biodistribution in rat cerebellum at 240 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630411,,2037.0
13832,In vivo,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Biodistribution in rat cerebellum at 30 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630412,,2037.0
13833,In vivo,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Biodistribution in rat cerebellum at 360 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630413,,2037.0
13834,In vivo,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Biodistribution in rat cerebellum at 3 hr after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630414,,2037.0
13835,In vivo,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Biodistribution in rat cerebellum at 60 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630415,,2037.0
13836,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in rat cortex at 120 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630416,,
13837,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in rat cortex at 1440 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630417,,
13838,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in rat cortex at 15 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630418,,
13839,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in rat cortex at 240 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630419,,
13840,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in rat cortex at 30 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630420,,
13841,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in rat cortex at 360 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630421,,
13842,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in rat cortex at 3 hr after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630422,,
13843,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in rat cortex at 60 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630423,,
13844,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart at 120 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630424,,948.0
13845,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart at 15 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630425,,948.0
13846,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart at 240 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL629462,,948.0
13847,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart at 30 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630426,,948.0
13848,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart at 360 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630427,,948.0
13849,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart at 3 hr after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL625877,,948.0
13850,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart at 60 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL625878,,948.0
13851,In vivo,Rattus norvegicus,,A,N,Intermediate,Hippocampus,10116.0,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL625879,,10000000.0
13852,In vivo,Rattus norvegicus,,A,N,Intermediate,Hippocampus,10116.0,Biodistribution in rat hippocampus at 240 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL625880,,10000000.0
13853,In vivo,Rattus norvegicus,,A,N,Intermediate,Hippocampus,10116.0,Biodistribution in rat hippocampus at 30 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL625881,,10000000.0
13854,In vivo,Rattus norvegicus,,A,N,Intermediate,Hippocampus,10116.0,Biodistribution in rat hippocampus at 360 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL625882,,10000000.0
13855,In vivo,Rattus norvegicus,,A,N,Intermediate,Hippocampus,10116.0,Biodistribution in rat hippocampus at 15 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL625883,,10000000.0
13856,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in rat kidney at 120 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL625884,,2113.0
13857,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in rat kidney at 1440 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL625885,,2113.0
13858,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in rat kidney at 15 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628649,,2113.0
13859,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in rat kidney at 240 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628650,,2113.0
13860,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in rat kidney at 30 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628651,,2113.0
13861,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in rat kidney at 360 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628652,,2113.0
13862,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in rat kidney at 60 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628653,,2113.0
13863,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver at 120 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628654,,2107.0
13864,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver at 1440 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628655,,2107.0
13865,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver at 15 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL625238,,2107.0
13866,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver at 240 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL625239,,2107.0
13867,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver at 30 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL625240,,2107.0
13868,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver at 360 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL625241,,2107.0
13869,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver at 60 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL625242,,2107.0
13870,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in rat lung at 120 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL874587,,2048.0
13871,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in rat lung at 1440 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL625405,,2048.0
13872,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in rat lung at 15 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL625406,,2048.0
13873,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in rat lung at 240 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL625407,,2048.0
13874,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in rat lung at 30 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL625408,,2048.0
13875,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in rat lung at 360 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL625409,,2048.0
13876,,Rattus norvegicus,,A,N,Intermediate,Thoracic aorta,10116.0,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,50597,,,1,12361,BAO_0000218,1,CHEMBL625410,,1515.0
13877,,Rattus norvegicus,,A,N,Intermediate,Thoracic aorta,10116.0,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,50597,,,1,12361,BAO_0000218,1,CHEMBL625411,,1515.0
13878,,Rattus norvegicus,,A,N,Intermediate,Thoracic aorta,10116.0,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,50597,,,1,12361,BAO_0000218,1,CHEMBL625412,,1515.0
13879,,Rattus norvegicus,,A,N,Intermediate,Thoracic aorta,10116.0,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,50597,,,1,12361,BAO_0000218,1,CHEMBL625413,,1515.0
13880,,Rattus norvegicus,,A,N,Intermediate,Thoracic aorta,10116.0,Percent of maximal contractile response to compound in rat thoracic aorta strips v,50597,,,1,12361,BAO_0000218,1,CHEMBL625414,,1515.0
13881,,Rattus norvegicus,,A,N,Intermediate,Thoracic aorta,10116.0,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,50597,,,1,12361,BAO_0000218,1,CHEMBL625415,,1515.0
13882,,Rattus norvegicus,,A,N,Intermediate,Thoracic aorta,10116.0,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,50597,,,1,12361,BAO_0000218,1,CHEMBL625416,,1515.0
13883,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,50597,,,1,12712,BAO_0000218,1,CHEMBL625417,,1088.0
13884,,Rattus norvegicus,,A,N,Intermediate,Feces,10116.0,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,50597,,,1,7415,BAO_0000218,1,CHEMBL625418,,1988.0
13885,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,50597,,,1,7415,BAO_0000218,1,CHEMBL625419,,1088.0
13886,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,50597,,,1,7415,BAO_0000218,1,CHEMBL625420,,
13887,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,50597,,,1,7415,BAO_0000218,1,CHEMBL626996,,
13888,,Rattus norvegicus,,A,N,Intermediate,Feces,10116.0,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",50597,,,1,7415,BAO_0000218,1,CHEMBL626997,,1988.0
13889,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",50597,,,1,7415,BAO_0000218,1,CHEMBL626998,,1088.0
13890,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",50597,,,1,7415,BAO_0000218,1,CHEMBL626999,,
13891,,Mus musculus,,A,N,Intermediate,,10090.0,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,50594,,,1,8050,BAO_0000218,1,CHEMBL627000,,
13892,,Mus musculus,,A,N,Intermediate,,10090.0,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,50594,,,1,8050,BAO_0000218,1,CHEMBL627001,,
13893,,Mus musculus,,A,N,Intermediate,,10090.0,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,50594,,,1,8050,BAO_0000218,1,CHEMBL627002,,
13894,,Mus musculus,,A,N,Intermediate,,10090.0,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,50594,,,1,8050,BAO_0000218,1,CHEMBL627003,,
13895,,Mus musculus,,A,N,Intermediate,Urine,10090.0,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,50594,,,1,8050,BAO_0000218,1,CHEMBL627004,,1088.0
13896,,Mus musculus,,A,N,Intermediate,Urine,10090.0,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,50594,,,1,8050,BAO_0000218,1,CHEMBL627005,,1088.0
13897,,Mus musculus,,A,N,Intermediate,Urine,10090.0,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,50594,,,1,8050,BAO_0000218,1,CHEMBL874594,,1088.0
13898,,Mus musculus,,A,N,Intermediate,Urine,10090.0,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,50594,,,1,8050,BAO_0000218,1,CHEMBL627006,,1088.0
13899,,Mus musculus,,A,N,Intermediate,Urine,10090.0,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,50594,,,1,8050,BAO_0000218,1,CHEMBL627007,,1088.0
13900,,Mus musculus,,A,N,Intermediate,Urine,10090.0,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,50594,,,1,8050,BAO_0000218,1,CHEMBL627884,,1088.0
13901,,Mus musculus,,A,N,Intermediate,Urine,10090.0,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,50594,,,1,8050,BAO_0000218,1,CHEMBL627885,,1088.0
13902,,Mus musculus,,A,N,Intermediate,Urine,10090.0,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,50594,,,1,8050,BAO_0000218,1,CHEMBL627886,,1088.0
13903,,Mus musculus,,A,N,Intermediate,Urine,10090.0,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,50594,,,1,8050,BAO_0000218,1,CHEMBL627887,,1088.0
13904,,Mus musculus,,A,N,Intermediate,Urine,10090.0,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,50594,,,1,8050,BAO_0000218,1,CHEMBL627888,,1088.0
13905,,Mus musculus,,A,N,Intermediate,Urine,10090.0,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,50594,,,1,8050,BAO_0000218,1,CHEMBL628057,,1088.0
13906,,Mus musculus,,A,N,Intermediate,Urine,10090.0,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,50594,,,1,8050,BAO_0000218,1,CHEMBL627405,,1088.0
13907,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL627406,,1088.0
13908,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL627407,,1088.0
13909,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL627408,,1088.0
13910,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL627409,,1088.0
13911,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL875486,,1088.0
13912,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL627410,,1088.0
13913,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL627411,,1088.0
13914,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL627412,,1088.0
13915,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL627413,,1088.0
13916,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL627414,,1088.0
13917,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL627415,,1088.0
13918,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL627416,,1088.0
13919,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL627417,,1088.0
13920,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL627418,,1088.0
13921,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL627419,,1088.0
13922,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL627320,,1088.0
13923,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL627321,,1088.0
13924,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL627322,,2113.0
13925,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL627323,,2113.0
13926,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL627491,,2113.0
13927,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL627492,,2113.0
13928,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL627493,,2113.0
13929,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL627494,,2107.0
13930,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL627495,,2107.0
13931,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL627496,,2107.0
13932,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL627497,,2107.0
13933,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL627498,,2107.0
13934,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL627499,,2048.0
13935,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL627500,,2048.0
13936,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL627501,,2048.0
13937,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL625616,,2048.0
13938,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL625617,,2048.0
13939,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL625618,,2385.0
13940,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL625619,,2385.0
13941,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL625620,,2385.0
13942,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL625621,,2385.0
13943,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL625622,,2385.0
13944,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL625788,,2106.0
13945,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL625789,,2106.0
13946,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL625790,,2106.0
13947,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL625791,,2106.0
13948,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL622334,,2106.0
13949,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL622335,,2046.0
13950,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL622336,,2046.0
13951,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL622337,,2046.0
13952,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL622338,,2046.0
13953,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL622339,,2046.0
13954,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL624153,,
13955,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL628430,,
13956,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL628431,,
13957,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL628432,,
13958,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL628433,,
13959,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",50597,,,1,12017,BAO_0000218,1,CHEMBL628434,,2106.0
13960,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",50597,,,1,12017,BAO_0000218,1,CHEMBL626789,,2106.0
13961,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",50597,,,1,12017,BAO_0000218,1,CHEMBL626790,,2106.0
13962,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",50597,,,1,12017,BAO_0000218,1,CHEMBL626791,,2106.0
13963,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",50597,,,1,12017,BAO_0000218,1,CHEMBL626792,,2106.0
13964,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",50597,,,1,12017,BAO_0000218,1,CHEMBL626793,,2106.0
13965,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL627436,,
13966,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL627437,,
13967,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL627438,,
13968,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL627439,,
13969,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL627440,,
13970,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL627602,,
13971,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL627603,,
13972,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL627604,,
13973,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL627605,,
13974,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL627606,,
13975,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL627607,,
13976,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL627608,,
13977,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL627609,,
13978,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL627610,,
13979,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL627611,,
13980,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL627612,,
13981,,,,P,U,Autocuration,,,Octanol:water partition coefficient is evaluated,22229,,,1,8362,BAO_0000100,0,CHEMBL627613,,
13982,,,,P,U,Autocuration,,,Partition coefficient in 1-octanol/water system,22224,,,1,8257,BAO_0000100,0,CHEMBL627614,,
13983,,,,P,U,Autocuration,,,Partition coefficient in 1-octanol/water system measured using radio active compounds,22224,,,1,8257,BAO_0000100,0,CHEMBL627615,,
13984,,,,P,U,Autocuration,,,Partition coefficient in octanol/water system was determined,22224,,,1,9468,BAO_0000100,0,CHEMBL627616,,
13985,,,,P,U,Autocuration,,,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,22224,,,1,9468,BAO_0000100,0,CHEMBL627617,,
13986,,,,A,U,Autocuration,,,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,22224,,,1,10568,BAO_0000019,0,CHEMBL627618,,
13987,,,,A,U,Autocuration,,,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",22224,,,1,10568,BAO_0000019,0,CHEMBL627619,,
13988,,,,A,U,Autocuration,,,Pseudo-first-order rate constant of the compound,22224,,,1,15359,BAO_0000019,0,CHEMBL627620,,
13989,,,,A,U,Autocuration,,,Pseudo-first-order rate constant with 1-min time point,22224,,,1,15359,BAO_0000019,0,CHEMBL627621,,
13990,,,,A,U,Autocuration,,,Pseudo-first-order rate constant without 1-min time point,22224,,,1,15359,BAO_0000019,0,CHEMBL627622,,
13991,,,,A,U,Autocuration,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,22224,,,1,10431,BAO_0000019,0,CHEMBL627623,,
13992,,,,A,U,Autocuration,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,22224,,,1,10431,BAO_0000019,0,CHEMBL627624,,
13993,,,,A,U,Autocuration,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,22224,,,1,10431,BAO_0000019,0,CHEMBL627625,,
13994,,,,A,U,Autocuration,,,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,22224,,,1,15704,BAO_0000019,0,CHEMBL628523,,
13995,,,,A,U,Autocuration,,,The alkaline hydrolysis second order rate constant(K OH) of the compound,22224,,,1,15287,BAO_0000019,0,CHEMBL628524,,
13996,,,,A,U,Autocuration,,,The efflux rate constant of the compound,22224,,,1,7516,BAO_0000019,0,CHEMBL628525,,
13997,,,,A,U,Autocuration,,,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,22224,,,1,12973,BAO_0000019,0,CHEMBL625732,,
13998,,,,A,U,Autocuration,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,22224,,,1,12973,BAO_0000019,0,CHEMBL625733,,
13999,,,,F,U,Autocuration,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,22224,,,1,12973,BAO_0000019,0,CHEMBL625734,,
14000,,,,A,U,Autocuration,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,22224,,,1,12973,BAO_0000019,0,CHEMBL625913,,
14001,,,,A,U,Autocuration,,,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,22224,,,1,8696,BAO_0000019,0,CHEMBL625914,,
14002,,,,A,U,Autocuration,,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,22224,,,1,15052,BAO_0000019,0,CHEMBL625915,,
14003,,,,A,U,Autocuration,,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,22224,,,1,15052,BAO_0000019,0,CHEMBL625916,,
14004,,,,A,U,Autocuration,,,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),22224,,,1,10503,BAO_0000019,0,CHEMBL625917,,
14005,,,,A,U,Autocuration,,,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL625918,,
14006,,,,A,U,Autocuration,,,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL625919,,
14007,,,,A,U,Autocuration,,,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL625920,,
14008,,,,A,U,Autocuration,,,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL874453,,
14009,,,,A,U,Autocuration,,,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL625921,,
14010,,,,A,U,Autocuration,,,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,22224,,,1,10503,BAO_0000019,0,CHEMBL625922,,
14011,,,,A,U,Autocuration,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL625923,,
14012,,,,A,U,Autocuration,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL625924,,
14013,,,,A,U,Autocuration,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL625925,,
14014,,,,A,U,Autocuration,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL625926,,
14015,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in rat lung at 60 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL627704,,2048.0
14016,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL627705,,
14017,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL627706,,
14018,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL627707,,
14019,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL627708,,
14020,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628361,,
14021,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628362,,
14022,In vivo,Rattus norvegicus,,A,N,Intermediate,Striatum,10116.0,Biodistribution in rat striatum at 120 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628363,,2435.0
14023,In vivo,Rattus norvegicus,,A,N,Intermediate,Striatum,10116.0,Biodistribution in rat striatum at 1440 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628364,,2435.0
14024,In vivo,Rattus norvegicus,,A,N,Intermediate,Striatum,10116.0,Biodistribution in rat striatum at 15 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628365,,2435.0
14025,In vivo,Rattus norvegicus,,A,N,Intermediate,Striatum,10116.0,Biodistribution in rat striatum at 240 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL874454,,2435.0
14026,In vivo,Rattus norvegicus,,A,N,Intermediate,Striatum,10116.0,Biodistribution in rat striatum at 30 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628531,,2435.0
14027,In vivo,Rattus norvegicus,,A,N,Intermediate,Striatum,10116.0,Biodistribution in rat striatum at 360 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628532,,2435.0
14028,In vivo,Rattus norvegicus,,A,N,Intermediate,Striatum,10116.0,Biodistribution in rat striatum at 3 hr after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628533,,2435.0
14029,In vivo,Rattus norvegicus,,A,N,Intermediate,Striatum,10116.0,Biodistribution in rat striatum at 60 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628534,,2435.0
14030,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution in rat thyroid at 120 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628535,,2046.0
14031,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution in rat thyroid at 1440 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628536,,2046.0
14032,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution in rat thyroid at 15 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628537,,2046.0
14033,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution in rat thyroid at 240 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628538,,2046.0
14034,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution in rat thyroid at 30 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628539,,2046.0
14035,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution in rat thyroid at 360 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630297,,2046.0
14036,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution in rat thyroid at 60 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630298,,2046.0
14037,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution in rest of brain of rat 120 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL630299,,955.0
14038,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628094,,955.0
14039,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628095,,955.0
14040,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL874648,,955.0
14041,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628096,,955.0
14042,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628097,,955.0
14043,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,50597,,,1,13100,BAO_0000218,1,CHEMBL628098,,955.0
14044,,,,A,U,Autocuration,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",22224,,,1,13331,BAO_0000019,0,CHEMBL628099,,
14045,,,,A,U,Autocuration,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",22224,,,1,13331,BAO_0000019,0,CHEMBL628100,,
14046,,,,A,U,Autocuration,,,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),22224,,,1,13331,BAO_0000019,0,CHEMBL628101,,
14047,,,,A,U,Autocuration,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",22224,,,1,13331,BAO_0000019,0,CHEMBL628102,,
14048,,,,A,U,Autocuration,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",22224,,,1,13331,BAO_0000019,0,CHEMBL628103,,
14049,,,,A,U,Autocuration,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",22224,,,1,13331,BAO_0000019,0,CHEMBL628104,,
14050,,,,A,U,Autocuration,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",22224,,,1,13331,BAO_0000019,0,CHEMBL628105,,
14051,,,,A,U,Autocuration,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",22224,,,1,13331,BAO_0000019,0,CHEMBL628106,,
14052,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,50597,,,1,10086,BAO_0000218,1,CHEMBL628107,,1088.0
14053,,,,F,U,Autocuration,Urine,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,22224,,,1,10086,BAO_0000218,0,CHEMBL628108,,1088.0
14054,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,50597,,,1,10086,BAO_0000218,1,CHEMBL628109,,1088.0
14055,,,,F,U,Autocuration,Urine,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,22224,,,1,10086,BAO_0000218,0,CHEMBL625299,,1088.0
14056,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,50597,,,1,10086,BAO_0000218,1,CHEMBL625300,,1088.0
14057,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,50597,,,1,10086,BAO_0000218,1,CHEMBL625301,,1088.0
14058,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,50597,,,1,10086,BAO_0000218,1,CHEMBL625302,,1088.0
14059,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,50597,,,1,10086,BAO_0000218,1,CHEMBL874649,,1088.0
14060,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,50597,,,1,13248,BAO_0000218,1,CHEMBL625303,,
14061,,Rattus norvegicus,,A,N,Intermediate,,10116.0,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,50597,,,1,13248,BAO_0000218,1,CHEMBL625463,,
14062,,Homo sapiens,,A,N,Intermediate,Liver,9606.0,In vitro metabolism in human liver microsomes,50587,,,1,14527,BAO_0000218,1,CHEMBL625464,,2107.0
14063,,Homo sapiens,,A,N,Intermediate,,9606.0,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,50587,,,1,3008,BAO_0000218,1,CHEMBL625465,,
14064,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL625466,,1088.0
14065,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL625467,,1088.0
14066,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL625468,,1088.0
14067,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL625469,,1088.0
14068,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL625470,,1088.0
14069,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL632418,,1088.0
14070,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL627250,,1088.0
14071,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL627251,,1088.0
14072,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL627252,,1088.0
14073,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL627253,,1088.0
14074,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL627254,,1088.0
14075,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL875471,,1088.0
14076,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL627255,,1088.0
14077,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL627256,,1088.0
14078,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL627257,,1088.0
14079,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL627258,,1088.0
14080,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL627259,,1088.0
14081,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL627260,,1088.0
14082,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623256,,1088.0
14083,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL874413,,1088.0
14084,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623257,,1088.0
14085,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623258,,1088.0
14086,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623259,,1088.0
14087,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623260,,1088.0
14088,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623261,,1088.0
14089,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623262,,1088.0
14090,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623263,,1088.0
14091,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623264,,1088.0
14092,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623265,,1088.0
14093,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623266,,1088.0
14094,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623267,,1088.0
14095,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623268,,1088.0
14096,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623269,,1088.0
14097,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623270,,1088.0
14098,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623271,,1088.0
14099,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623272,,1088.0
14100,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623273,,1088.0
14101,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623274,,1088.0
14102,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL874414,,1088.0
14103,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623275,,1088.0
14104,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL629150,,1088.0
14105,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623276,,1088.0
14106,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623277,,1088.0
14107,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623112,,1088.0
14108,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623113,,1088.0
14109,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623800,,1088.0
14110,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623801,,1088.0
14111,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",50597,,,1,12017,BAO_0000218,1,CHEMBL623802,,2106.0
14112,In vivo,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL623803,,995.0
14113,In vivo,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL623970,,995.0
14114,In vivo,Rattus norvegicus,,A,N,Intermediate,Uterus,10116.0,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL623971,,995.0
14115,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),50597,,,1,14045,BAO_0000218,1,CHEMBL623972,,178.0
14116,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),50597,,,1,14045,BAO_0000218,1,CHEMBL623973,,178.0
14117,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),50597,,,1,14045,BAO_0000218,1,CHEMBL623974,,178.0
14118,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),50597,,,1,14045,BAO_0000218,1,CHEMBL623975,,178.0
14119,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),50597,,,1,14045,BAO_0000218,1,CHEMBL623976,,955.0
14120,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),50597,,,1,14045,BAO_0000218,1,CHEMBL623977,,955.0
14121,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),50597,,,1,14045,BAO_0000218,1,CHEMBL623978,,955.0
14122,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),50597,,,1,14045,BAO_0000218,1,CHEMBL623979,,955.0
14123,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),50597,,,1,14045,BAO_0000218,1,CHEMBL623980,,
14124,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),50597,,,1,14045,BAO_0000218,1,CHEMBL623981,,
14125,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),50597,,,1,14045,BAO_0000218,1,CHEMBL626278,,
14126,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),50597,,,1,14045,BAO_0000218,1,CHEMBL626279,,
14127,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in mice bladder plus excreted urine was determined,50594,,,1,14045,BAO_0000218,1,CHEMBL626280,,
14128,,Mus musculus,,A,N,Intermediate,,10090.0,"Percentage biodistribution in mouse blood, 10 minutes post injection",50594,,,1,14045,BAO_0000218,1,CHEMBL626281,,
14129,,Mus musculus,,A,N,Intermediate,,10090.0,"Percentage biodistribution in mouse blood, 30 minutes post injection",50594,,,1,14045,BAO_0000218,1,CHEMBL626282,,
14130,,Mus musculus,,A,N,Intermediate,,10090.0,"Percentage biodistribution in mouse blood, 5 minutes post injection",50594,,,1,14045,BAO_0000218,1,CHEMBL626283,,
14131,,Mus musculus,,A,N,Intermediate,,10090.0,"Percentage biodistribution in mouse blood, 60 minutes post injection",50594,,,1,14045,BAO_0000218,1,CHEMBL626284,,
14132,,Mus musculus,,A,N,Intermediate,Brain,10090.0,"Percentage biodistribution in mouse brain, 10 minutes post injection",50594,,,1,14045,BAO_0000218,1,CHEMBL626285,,955.0
14133,,Mus musculus,,A,N,Intermediate,Brain,10090.0,"Percentage biodistribution in mouse brain, 30 minutes post injection",50594,,,1,14045,BAO_0000218,1,CHEMBL626286,,955.0
14134,,Mus musculus,,A,N,Intermediate,Brain,10090.0,"Percentage biodistribution in mouse brain, 5 minutes post injection",50594,,,1,14045,BAO_0000218,1,CHEMBL626287,,955.0
14135,,Mus musculus,,A,N,Intermediate,Brain,10090.0,"Percentage biodistribution in mouse brain, 60 minutes post injection",50594,,,1,14045,BAO_0000218,1,CHEMBL626288,,955.0
14136,,Mus musculus,,A,N,Intermediate,,10090.0,"Percentage biodistribution in mouse heart, 10 minutes post injection",50594,,,1,14045,BAO_0000218,1,CHEMBL626289,,
14137,,Mus musculus,,A,N,Intermediate,,10090.0,"Percentage biodistribution in mouse heart, 30 minutes post injection",50594,,,1,14045,BAO_0000218,1,CHEMBL626290,,
14138,,Mus musculus,,A,N,Intermediate,,10090.0,"Percentage biodistribution in mouse heart, 5 minutes post injection",50594,,,1,14045,BAO_0000218,1,CHEMBL626291,,
14139,,Mus musculus,,A,N,Intermediate,,10090.0,"Percentage biodistribution in mouse heart, 60 minutes post injection",50594,,,1,14045,BAO_0000218,1,CHEMBL839888,,
14140,,Mus musculus,,A,N,Intermediate,Intestine,10090.0,"Percentage biodistribution in mouse intestine, 10 minutes post injection",50594,,,1,14045,BAO_0000218,1,CHEMBL626292,,160.0
14141,,Mus musculus,,A,N,Intermediate,Intestine,10090.0,"Percentage biodistribution in mouse intestine, 30 minutes post injection",50594,,,1,14045,BAO_0000218,1,CHEMBL626293,,160.0
14142,,Mus musculus,,A,N,Intermediate,Intestine,10090.0,"Percentage biodistribution in mouse intestine, 5 minutes post injection",50594,,,1,14045,BAO_0000218,1,CHEMBL626294,,160.0
14143,,Mus musculus,,A,N,Intermediate,Intestine,10090.0,"Percentage biodistribution in mouse intestine, 60 minutes post injection",50594,,,1,14045,BAO_0000218,1,CHEMBL626295,,160.0
14144,,Mus musculus,,A,N,Intermediate,Liver,10090.0,"Percentage biodistribution in mouse liver, 10 minutes post injection",50594,,,1,14045,BAO_0000218,1,CHEMBL627659,,2107.0
14145,,Mus musculus,,A,N,Intermediate,Liver,10090.0,"Percentage biodistribution in mouse liver, 30 minutes of post injection",50594,,,1,14045,BAO_0000218,1,CHEMBL627660,,2107.0
14146,,Mus musculus,,A,N,Intermediate,Liver,10090.0,"Percentage biodistribution in mouse liver, 5 minutes post injection",50594,,,1,14045,BAO_0000218,1,CHEMBL627661,,2107.0
14147,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution in mice liver at 60 minutes of post injection,50594,,,1,14045,BAO_0000218,1,CHEMBL627662,,2107.0
14148,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution in mice lungs at 10 min of post injection,50594,,,1,14045,BAO_0000218,1,CHEMBL627663,,2048.0
14149,,Mus musculus,,A,N,Intermediate,,10090.0,"Percentage biodistribution in mouse lung, 30 minutes post injection",50594,,,1,14045,BAO_0000218,1,CHEMBL627664,,
14150,,Mus musculus,,A,N,Intermediate,,10090.0,"Percentage biodistribution in mousee lung, 5 minutes post injection",50594,,,1,14045,BAO_0000218,1,CHEMBL627665,,
14151,In vivo,Mus musculus,,A,N,Intermediate,Lung,10090.0,Biodistribution in mice lungs at 60 min of post injection,50594,,,1,14045,BAO_0000218,1,CHEMBL627666,,2048.0
14152,,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Percentage biodistribution in mouse spleen,50594,,,1,14045,BAO_0000218,1,CHEMBL627667,,2106.0
14153,,Mus musculus,,A,N,Intermediate,Stomach,10090.0,Percentage biodistribution in mouse stomach,50594,,,1,14045,BAO_0000218,1,CHEMBL627668,,945.0
14154,,Mus musculus,,A,N,Intermediate,Urine,10090.0,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,50594,,,1,11745,BAO_0000218,1,CHEMBL627669,,1088.0
14155,In vivo,,,A,U,Autocuration,Urinary bladder,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,22224,,,1,13257,BAO_0000218,0,CHEMBL627670,,1255.0
14156,In vivo,,,A,U,Autocuration,Blood,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,22224,,,1,13257,BAO_0000218,0,CHEMBL627671,,178.0
14157,In vivo,,,A,U,Autocuration,Bone element,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,22224,,,1,13257,BAO_0000218,0,CHEMBL627672,,1474.0
14158,In vivo,,,A,U,Autocuration,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,22224,,,1,13257,BAO_0000218,0,CHEMBL627673,,
14159,In vivo,,,A,U,Autocuration,Kidney,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,22224,,,1,13257,BAO_0000218,0,CHEMBL627674,,2113.0
14160,In vivo,,,A,U,Autocuration,Liver,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,22224,,,1,13257,BAO_0000218,0,CHEMBL627675,,2107.0
14161,In vivo,,,A,U,Autocuration,Lung,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,22224,,,1,13257,BAO_0000218,0,CHEMBL627676,,2048.0
14162,In vivo,,,A,U,Autocuration,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,22224,,,1,13257,BAO_0000218,0,CHEMBL627677,,2385.0
14163,,,,A,U,Autocuration,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL627678,,
14164,,Rattus norvegicus,,A,N,Intermediate,Serum,10116.0,Affinity for protein binding expressed as association constant in fresh rat serum,50597,,,1,7095,BAO_0000218,1,CHEMBL627679,,1977.0
14165,,,,A,U,Autocuration,,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,22224,,,1,12185,BAO_0000019,0,CHEMBL627680,,
14166,,,,A,U,Autocuration,,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,22224,,,1,12185,BAO_0000019,0,CHEMBL627681,,
14167,,,,A,U,Autocuration,,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,22224,,,1,12185,BAO_0000019,0,CHEMBL627682,,
14168,,,,A,U,Autocuration,,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,22224,,,1,12185,BAO_0000019,0,CHEMBL627683,,
14169,,,,A,U,Autocuration,,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,22224,,,1,12686,BAO_0000019,0,CHEMBL627684,,
14170,,,,A,U,Autocuration,,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",22224,,,1,12686,BAO_0000019,0,CHEMBL874441,,
14171,,,,A,U,Autocuration,,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,22224,,,1,12686,BAO_0000019,0,CHEMBL627685,,
14172,,,,A,U,Autocuration,,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",22224,,,1,12686,BAO_0000019,0,CHEMBL627686,,
14173,,,,A,U,Autocuration,,,Apparent rate constant Koff for inactivation of dTMP synthase.,22224,,,1,8057,BAO_0000019,0,CHEMBL627687,,
14174,,,,A,U,Autocuration,,,The irreversible inhibitor activity by second order rate equation.,22224,,,1,15778,BAO_0000019,0,CHEMBL627688,,
14175,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,50597,,,1,12375,BAO_0000218,1,CHEMBL628038,,
14176,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,50597,,,1,12375,BAO_0000218,1,CHEMBL628039,,
14177,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,50597,,,1,12375,BAO_0000218,1,CHEMBL628040,,
14178,,,,A,U,Autocuration,,,Dissociation rate calculated from the first-order equation using t1/2 value,22224,,,1,13588,BAO_0000019,0,CHEMBL628041,,
14179,,,,A,U,Autocuration,,,The compound was tested for Binding constant against DNA,22224,,,1,15039,BAO_0000019,0,CHEMBL630226,,
14180,,,,A,U,Autocuration,,,First order rate constant for cyclization of the compound,22224,,,1,9500,BAO_0000019,0,CHEMBL628042,,
14181,,,,A,U,Autocuration,,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,22224,,,1,10014,BAO_0000019,0,CHEMBL625232,,
14182,,,,A,U,Autocuration,,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,22224,,,1,10014,BAO_0000019,0,CHEMBL625233,,
14183,,,,A,U,Autocuration,,,Hydrolysis rate constant was determined,22224,,,1,568,BAO_0000019,0,CHEMBL625979,,
14184,,,,A,U,Autocuration,,,Observed first order rate constant,22224,,,1,10026,BAO_0000019,0,CHEMBL625980,,
14185,,,,A,U,Autocuration,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,22224,,,1,10281,BAO_0000019,0,CHEMBL625981,,
14186,,,,A,U,Autocuration,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,22224,,,1,10281,BAO_0000019,0,CHEMBL625982,,
14187,,,,A,U,Autocuration,,,Second-order rate constant for attack on PNPA at 25 degree Centigrade,22224,,,1,9680,BAO_0000019,0,CHEMBL625983,,
14188,,,,A,U,Autocuration,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL625984,,
14189,,,,A,U,Autocuration,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL625985,,
14190,,,,A,U,Autocuration,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL625986,,
14191,,,,A,U,Autocuration,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL625987,,
14192,,,,A,U,Autocuration,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL625988,,
14193,,,,A,U,Autocuration,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL625989,,
14194,,,,A,U,Autocuration,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL625990,,
14195,,,,A,U,Autocuration,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL625991,,
14196,,,,A,U,Autocuration,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL625992,,
14197,,,,A,U,Autocuration,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL625993,,
14198,,,,A,U,Autocuration,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL631973,,
14199,,,,A,U,Autocuration,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL632143,,
14200,,,,A,U,Autocuration,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL632144,,
14201,,,,A,U,Autocuration,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL632145,,
14202,,,,A,U,Autocuration,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL632146,,
14203,,,,A,U,Autocuration,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL632147,,
14204,,,,A,U,Autocuration,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL632148,,
14205,,,,A,U,Autocuration,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL632149,,
14206,,,,A,U,Autocuration,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL632150,,
14207,,,,A,U,Autocuration,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL632151,,
14208,,Homo sapiens,,A,N,Intermediate,,9606.0,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,50587,,,1,3008,BAO_0000218,1,CHEMBL632152,,
14209,,Homo sapiens,,A,N,Intermediate,,9606.0,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,50587,,,1,4509,BAO_0000218,1,CHEMBL632153,,
14210,,Homo sapiens,,A,N,Intermediate,,9606.0,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,50587,,,1,4509,BAO_0000218,1,CHEMBL632154,,
14211,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,50602,,,1,8613,BAO_0000218,1,CHEMBL632155,,
14212,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,50602,,,1,8613,BAO_0000218,1,CHEMBL632156,,
14213,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,50602,,,1,8613,BAO_0000218,1,CHEMBL632157,,
14214,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,50602,,,1,8613,BAO_0000218,1,CHEMBL632158,,
14215,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,50602,,,1,8613,BAO_0000218,1,CHEMBL632159,,
14216,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,50602,,,1,8613,BAO_0000218,1,CHEMBL626305,,
14217,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,50602,,,1,8613,BAO_0000218,1,CHEMBL626306,,
14218,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,50602,,,1,8613,BAO_0000218,1,CHEMBL626307,,
14219,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,50602,,,1,8613,BAO_0000218,1,CHEMBL626308,,
14220,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,50602,,,1,8613,BAO_0000218,1,CHEMBL626479,,
14221,,Human herpesvirus 1,,A,N,Intermediate,,10298.0,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,50602,,,1,8613,BAO_0000218,1,CHEMBL626480,,
14222,,,,P,U,Autocuration,,,Calculated partition coefficient (clogP) (MlogP),22229,,,1,6021,BAO_0000100,0,CHEMBL626481,,
14223,,,,A,U,Autocuration,,,Equipotent potent ratio relative to carbachol (nicotinic activity),22224,,,1,9348,BAO_0000019,0,CHEMBL626482,,
14224,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",50588,,,1,15592,BAO_0000218,1,CHEMBL626483,,
14225,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",50588,,,1,15592,BAO_0000218,1,CHEMBL626484,,
14226,,,,P,U,Autocuration,,,Solubility at pH 7.4 in micro g/mL;NA denotes available,22229,,,1,15592,BAO_0000100,0,CHEMBL626485,,
14227,,,,P,U,Autocuration,,,Solubility at pH 7.4 in micro g/mL;NA denotes not available,22229,,,1,15592,BAO_0000100,0,CHEMBL626486,,
14228,,,,P,U,Autocuration,,,Solubility at pH 7.4 in ug/mL;NA denotes not available,22229,,,1,15592,BAO_0000100,0,CHEMBL626487,,
14229,In vivo,Canis lupus familiaris,,A,N,Intermediate,Plasma,9615.0,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,50588,,,1,15592,BAO_0000218,1,CHEMBL626488,,1969.0
14230,,Rattus norvegicus,,A,N,Intermediate,Serum,10116.0,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,50597,,,1,7095,BAO_0000218,1,CHEMBL626489,,1977.0
14231,,,,A,U,Autocuration,,,Area under the MAP curve measured over 5 min; ND means Not determined,22224,,,1,16618,BAO_0000019,0,CHEMBL626490,,
14232,,,,P,U,Autocuration,,,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,22224,,,1,16835,BAO_0000100,0,CHEMBL626491,,
14233,,,,P,U,Autocuration,,,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,22229,,,1,15284,BAO_0000100,0,CHEMBL626492,,
14234,,,,A,U,Autocuration,,,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,22224,,,1,15750,BAO_0000019,0,CHEMBL626493,,
14235,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,50597,,,1,16618,BAO_0000218,1,CHEMBL626494,,
14236,In vivo,,,A,U,Autocuration,,,Half life after oral tested,22224,,,1,16618,BAO_0000218,0,CHEMBL626495,,
14237,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,Half life was determined in plasma of rat; NT indicates not tested,50597,,,1,15812,BAO_0000218,1,CHEMBL626496,,1969.0
14238,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,50597,,,1,16618,BAO_0000218,1,CHEMBL626497,,
14239,In vivo,,,A,U,Autocuration,,,Oral bioavailability after oral tested,22224,,,1,16618,BAO_0000218,0,CHEMBL626498,,
14240,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),50597,,,1,13098,BAO_0000218,1,CHEMBL626499,,
14241,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),50597,,,1,13098,BAO_0000218,1,CHEMBL626500,,
14242,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,half life was determined in plasma of rat; NT indicates not tested,50597,,,1,15812,BAO_0000218,1,CHEMBL626501,,1969.0
14243,,Rattus norvegicus,,A,N,Intermediate,Plasma,10116.0,half life was determined in plasma of rat; NT means not tested,50597,,,1,15812,BAO_0000218,1,CHEMBL626502,,1969.0
14244,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,50597,,,1,11510,BAO_0000218,1,CHEMBL626503,,
14245,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); inactive,50597,,,1,11510,BAO_0000218,1,CHEMBL626504,,
14246,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,50597,,,1,11510,BAO_0000218,1,CHEMBL626505,,
14247,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,50597,,,1,11510,BAO_0000218,1,CHEMBL626506,,
14248,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,50597,,,1,11510,BAO_0000218,1,CHEMBL626507,,
14249,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,50597,,,1,11510,BAO_0000218,1,CHEMBL626508,,
14250,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,50597,,,1,11510,BAO_0000218,1,CHEMBL626509,,
14251,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,50597,,,1,11510,BAO_0000218,1,CHEMBL875480,,
14252,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,50597,,,1,11510,BAO_0000218,1,CHEMBL626510,,
14253,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,50597,,,1,11510,BAO_0000218,1,CHEMBL626511,,
14254,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,50597,,,1,11510,BAO_0000218,1,CHEMBL626512,,
14255,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,50597,,,1,11510,BAO_0000218,1,CHEMBL628208,,
14256,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,50597,,,1,11510,BAO_0000218,1,CHEMBL628209,,
14257,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,50597,,,1,11510,BAO_0000218,1,CHEMBL628210,,
14258,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,50597,,,1,11510,BAO_0000218,1,CHEMBL628211,,
14259,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,50597,,,1,11510,BAO_0000218,1,CHEMBL628212,,
14260,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,50597,,,1,11510,BAO_0000218,1,CHEMBL628213,,
14261,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628214,,1088.0
14262,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628215,,1088.0
14263,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628216,,1088.0
14264,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626595,,1088.0
14265,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626596,,1088.0
14266,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626597,,1088.0
14267,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626598,,1088.0
14268,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL622242,,1088.0
14269,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL622243,,1088.0
14270,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL622244,,1088.0
14271,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL622245,,1088.0
14272,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL622246,,1088.0
14273,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL622247,,1088.0
14274,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL622248,,1088.0
14275,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL877483,,1088.0
14276,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL622249,,1088.0
14277,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL622250,,1088.0
14278,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL622251,,1088.0
14279,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL622252,,1088.0
14280,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL622253,,1088.0
14281,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL622254,,1088.0
14282,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL622255,,1088.0
14283,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL622256,,1088.0
14284,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL622257,,1088.0
14285,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL622258,,1088.0
14286,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL622259,,1088.0
14287,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL622927,,1088.0
14288,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL622928,,1088.0
14289,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL622929,,1088.0
14290,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL623182,,1088.0
14291,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL623183,,1088.0
14292,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623184,,1088.0
14293,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623185,,1088.0
14294,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL877484,,1088.0
14295,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL627274,,1088.0
14296,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623186,,1088.0
14297,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623187,,1088.0
14298,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL623188,,1088.0
14299,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628055,,1088.0
14300,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628056,,1088.0
14301,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628200,,1088.0
14302,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628201,,1088.0
14303,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628202,,1088.0
14304,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628203,,1088.0
14305,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628204,,1088.0
14306,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628205,,1088.0
14307,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628206,,1088.0
14308,In vivo,,,A,U,Autocuration,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),22224,,,1,13257,BAO_0000218,0,CHEMBL628207,,2367.0
14309,In vivo,,,A,U,Autocuration,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,22224,,,1,13257,BAO_0000218,0,CHEMBL627220,,2367.0
14310,In vivo,,,A,U,Autocuration,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,22224,,,1,13257,BAO_0000218,0,CHEMBL627221,,2385.0
14311,In vivo,,,A,U,Autocuration,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),22224,,,1,13257,BAO_0000218,0,CHEMBL627222,,2367.0
14312,In vivo,,,A,U,Autocuration,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,22224,,,1,13257,BAO_0000218,0,CHEMBL627223,,
14313,In vivo,,,A,U,Autocuration,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,22224,,,1,13257,BAO_0000218,0,CHEMBL632062,,2385.0
14314,In vivo,,,A,U,Autocuration,Spleen,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,22224,,,1,13257,BAO_0000218,0,CHEMBL632063,,2106.0
14315,In vivo,,,A,U,Autocuration,Urinary bladder,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,22224,,,1,13257,BAO_0000218,0,CHEMBL632064,,1255.0
14316,In vivo,,,A,U,Autocuration,Blood,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,22224,,,1,13257,BAO_0000218,0,CHEMBL632065,,178.0
14317,In vivo,,,A,U,Autocuration,Bone element,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,22224,,,1,13257,BAO_0000218,0,CHEMBL632066,,1474.0
14318,In vivo,,,A,U,Autocuration,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,22224,,,1,13257,BAO_0000218,0,CHEMBL632067,,
14319,In vivo,,,A,U,Autocuration,Kidney,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,22224,,,1,13257,BAO_0000218,0,CHEMBL629188,,2113.0
14320,In vivo,,,A,U,Autocuration,Liver,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,22224,,,1,13257,BAO_0000218,0,CHEMBL629189,,2107.0
14321,In vivo,,,A,U,Autocuration,Lung,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,22224,,,1,13257,BAO_0000218,0,CHEMBL629190,,2048.0
14322,In vivo,,,A,U,Autocuration,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,22224,,,1,13257,BAO_0000218,0,CHEMBL629191,,2385.0
14323,In vivo,,,A,U,Autocuration,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),22224,,,1,13257,BAO_0000218,0,CHEMBL629192,,2367.0
14324,In vivo,,,A,U,Autocuration,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,22224,,,1,13257,BAO_0000218,0,CHEMBL629193,,2385.0
14325,In vivo,,,A,U,Autocuration,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),22224,,,1,13257,BAO_0000218,0,CHEMBL629194,,2367.0
14326,In vivo,,,A,U,Autocuration,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,22224,,,1,13257,BAO_0000218,0,CHEMBL629195,,
14327,In vivo,,,A,U,Autocuration,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,22224,,,1,13257,BAO_0000218,0,CHEMBL629373,,2385.0
14328,In vivo,,,A,U,Autocuration,Spleen,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,22224,,,1,13257,BAO_0000218,0,CHEMBL629374,,2106.0
14329,In vivo,,,A,U,Autocuration,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,22224,,,1,13257,BAO_0000218,0,CHEMBL629375,,2367.0
14330,In vivo,,,A,U,Autocuration,Urinary bladder,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,22224,,,1,13257,BAO_0000218,0,CHEMBL629376,,1255.0
14331,In vivo,,,A,U,Autocuration,Blood,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,22224,,,1,13257,BAO_0000218,0,CHEMBL629377,,178.0
14332,In vivo,,,A,U,Autocuration,Bone element,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,22224,,,1,13257,BAO_0000218,0,CHEMBL629378,,1474.0
14333,In vivo,,,A,U,Autocuration,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,22224,,,1,13257,BAO_0000218,0,CHEMBL629379,,
14334,In vivo,,,A,U,Autocuration,Kidney,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,22224,,,1,13257,BAO_0000218,0,CHEMBL629151,,2113.0
14335,In vivo,,,A,U,Autocuration,Liver,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,22224,,,1,13257,BAO_0000218,0,CHEMBL629152,,2107.0
14336,In vivo,,,A,U,Autocuration,Lung,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,22224,,,1,13257,BAO_0000218,0,CHEMBL629153,,2048.0
14337,In vivo,,,A,U,Autocuration,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,22224,,,1,13257,BAO_0000218,0,CHEMBL629154,,2385.0
14338,In vivo,,,A,U,Autocuration,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),22224,,,1,13257,BAO_0000218,0,CHEMBL629155,,2367.0
14339,In vivo,,,A,U,Autocuration,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,22224,,,1,13257,BAO_0000218,0,CHEMBL629156,,2367.0
14340,In vivo,,,A,U,Autocuration,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,22224,,,1,13257,BAO_0000218,0,CHEMBL629157,,2385.0
14341,In vivo,,,A,U,Autocuration,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),22224,,,1,13257,BAO_0000218,0,CHEMBL629158,,2367.0
14342,In vivo,,,A,U,Autocuration,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,22224,,,1,13257,BAO_0000218,0,CHEMBL629159,,
14343,In vivo,,,A,U,Autocuration,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,22224,,,1,13257,BAO_0000218,0,CHEMBL629160,,2385.0
14344,In vivo,,,A,U,Autocuration,Spleen,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,22224,,,1,13257,BAO_0000218,0,CHEMBL629161,,2106.0
14345,In vivo,,,A,U,Autocuration,Urinary bladder,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,22224,,,1,13257,BAO_0000218,0,CHEMBL629162,,1255.0
14346,In vivo,,,A,U,Autocuration,Blood,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,22224,,,1,13257,BAO_0000218,0,CHEMBL629163,,178.0
14347,In vivo,,,A,U,Autocuration,Bone element,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,22224,,,1,13257,BAO_0000218,0,CHEMBL629164,,1474.0
14348,In vivo,,,A,U,Autocuration,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,22224,,,1,13257,BAO_0000218,0,CHEMBL629165,,
14349,In vivo,,,A,U,Autocuration,Liver,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,22224,,,1,13257,BAO_0000218,0,CHEMBL629166,,2107.0
14350,In vivo,,,A,U,Autocuration,Lung,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,22224,,,1,13257,BAO_0000218,0,CHEMBL629167,,2048.0
14351,In vivo,,,A,U,Autocuration,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,22224,,,1,13257,BAO_0000218,0,CHEMBL629168,,2385.0
14352,,,,A,U,Autocuration,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,22224,,,1,2193,BAO_0000019,0,CHEMBL629169,,
14353,,,,A,U,Autocuration,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,22224,,,1,2193,BAO_0000019,0,CHEMBL629170,,
14354,,,,A,U,Autocuration,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,22224,,,1,2193,BAO_0000019,0,CHEMBL631153,,
14355,,,,A,U,Autocuration,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,22224,,,1,2193,BAO_0000019,0,CHEMBL875121,,
14356,,,,A,U,Autocuration,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,22224,,,1,2193,BAO_0000019,0,CHEMBL631154,,
14357,,,,A,U,Autocuration,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,22224,,,1,2193,BAO_0000019,0,CHEMBL631155,,
14358,,,,A,U,Autocuration,,,Hydrolysis rate constant was determined,22224,,,1,568,BAO_0000019,0,CHEMBL631156,,
14359,,,,A,U,Autocuration,,,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",22224,,,1,9680,BAO_0000019,0,CHEMBL631157,,
14360,,,,A,U,Autocuration,,,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",22224,,,1,9680,BAO_0000019,0,CHEMBL631158,,
14361,,,,A,U,Autocuration,,,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",22224,,,1,9680,BAO_0000019,0,CHEMBL631159,,
14362,,,,A,U,Autocuration,,,Observed second order rate constant,22224,,,1,10026,BAO_0000019,0,CHEMBL631160,,
14363,,,,A,U,Autocuration,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,22224,,,1,10281,BAO_0000019,0,CHEMBL631161,,
14364,,,,A,U,Autocuration,,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,22224,,,1,10014,BAO_0000019,0,CHEMBL631162,,
14365,,,,A,U,Autocuration,,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,22224,,,1,10014,BAO_0000019,0,CHEMBL630313,,
14366,,,,A,U,Autocuration,,,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",22224,,,1,9680,BAO_0000019,0,CHEMBL630314,,
14367,,,,A,U,Autocuration,,,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",22224,,,1,9680,BAO_0000019,0,CHEMBL630315,,
14368,,,,A,U,Autocuration,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL630316,,
14369,,,,A,U,Autocuration,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL630986,,
14370,,,,A,U,Autocuration,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL630987,,
14371,,,,A,U,Autocuration,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL630988,,
14372,,,,A,U,Autocuration,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL630989,,
14373,,,,A,U,Autocuration,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL630990,,
14374,,,,A,U,Autocuration,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL630991,,
14375,,,,A,U,Autocuration,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL630992,,
14376,,,,A,U,Autocuration,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL630993,,
14377,,,,A,U,Autocuration,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,22224,,,1,13028,BAO_0000019,0,CHEMBL630994,,
14378,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,50597,,,1,10014,BAO_0000218,1,CHEMBL630995,,
14379,,,,A,U,Autocuration,,,Association constant for compound at 31 degree C was determined,22224,,,1,9962,BAO_0000019,0,CHEMBL629252,,
14380,,,,A,U,Autocuration,,,Calculated antagonist equilibrium dissociation constant of the compound,22224,,,1,12029,BAO_0000019,0,CHEMBL629253,,
14381,,,,A,U,Autocuration,,,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,22224,,,1,12029,BAO_0000019,0,CHEMBL629944,,
14382,,Cavia porcellus,,A,N,Intermediate,Trachea,10141.0,Dissociation constants vs LTE4 on guinea pig trachea,50512,,,1,10583,BAO_0000218,1,CHEMBL629945,,3126.0
14383,,,,A,U,Autocuration,,,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",22224,,,1,568,BAO_0000019,0,CHEMBL629946,,
14384,,,,A,U,Autocuration,,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",22224,,,1,568,BAO_0000019,0,CHEMBL629947,,
14385,,,,A,U,Autocuration,,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",22224,,,1,568,BAO_0000019,0,CHEMBL629948,,
14386,,,,A,U,Autocuration,,,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",22224,,,1,568,BAO_0000019,0,CHEMBL856024,,
14387,,,,A,U,Autocuration,,,Affinity constant KD value was derived from TMP,22224,,,1,7493,BAO_0000019,0,CHEMBL629949,,
14388,,,,A,U,Autocuration,,,Apparent dissociation (binding) rate constant was evaluated,22224,,,1,8371,BAO_0000019,0,CHEMBL629950,,
14389,,,,P,U,Autocuration,,,Dissociation constant (KD) of the compound,22224,,,1,13114,BAO_0000100,0,CHEMBL630127,,
14390,,,,P,U,Autocuration,,,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,22224,,,1,15515,BAO_0000100,0,CHEMBL630128,,
14391,,,,P,U,Autocuration,,,Dissociation constant from ESR titration experiments,22224,,,1,522,BAO_0000100,0,CHEMBL630129,,
14392,,,,,U,Autocuration,,,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),22224,,,1,13888,BAO_0000019,0,CHEMBL630130,,
14393,,,,P,U,Autocuration,,,Dissociation constant was evaluated.,22224,,,1,2616,BAO_0000100,0,CHEMBL875234,,
14394,,,,P,U,Autocuration,,,Dissociation constant was reported,22224,,,1,3798,BAO_0000100,0,CHEMBL630131,,
14395,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Dissociation constant was determined in rat pituitary cells.,50597,,,1,8731,BAO_0000218,1,CHEMBL630132,,
14396,,,,A,U,Autocuration,,,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,22224,,,1,11892,BAO_0000019,0,CHEMBL630133,,
14397,,,,A,U,Autocuration,,,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,22224,,,1,11892,BAO_0000019,0,CHEMBL630134,,
14398,,,,A,U,Autocuration,,,Equilibrium dissociation constant of the compound,22224,,,1,2582,BAO_0000019,0,CHEMBL630135,,
14399,,,,A,U,Autocuration,,,Equilibrium dissociation constant was determined,22224,,,1,11892,BAO_0000019,0,CHEMBL630136,,
14400,,,,A,U,Autocuration,,,Kinetic constant KD was evaluated,22224,,,1,13396,BAO_0000019,0,CHEMBL630137,,
14401,,,,A,U,Autocuration,,,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,22224,,,1,603,BAO_0000019,0,CHEMBL630138,,
14402,,,,A,U,Autocuration,,,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,22224,,,1,15673,BAO_0000019,0,CHEMBL630139,,
14403,,,,A,U,Autocuration,,,Rate constant for hydrolysis in aqueous acetone.,22224,,,1,10368,BAO_0000019,0,CHEMBL630140,,
14404,,,,A,U,Autocuration,,,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,22224,,,1,14228,BAO_0000019,0,CHEMBL875235,,
14405,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,50597,,,1,11510,BAO_0000218,1,CHEMBL876439,,
14406,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,50597,,,1,11510,BAO_0000218,1,CHEMBL630605,,
14407,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,50597,,,1,11510,BAO_0000218,1,CHEMBL630606,,
14408,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,50597,,,1,11510,BAO_0000218,1,CHEMBL630607,,
14409,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,50597,,,1,11510,BAO_0000218,1,CHEMBL630608,,
14410,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,50597,,,1,11510,BAO_0000218,1,CHEMBL630609,,
14411,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,50597,,,1,11510,BAO_0000218,1,CHEMBL630610,,
14412,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,50597,,,1,11510,BAO_0000218,1,CHEMBL630611,,
14413,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,50597,,,1,11510,BAO_0000218,1,CHEMBL629552,,
14414,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629733,,
14415,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629734,,
14416,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629735,,
14417,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629736,,
14418,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629737,,
14419,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629738,,
14420,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629739,,
14421,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,50597,,,1,11510,BAO_0000218,1,CHEMBL629740,,
14422,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629741,,
14423,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629742,,
14424,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629743,,
14425,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629744,,
14426,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629745,,
14427,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629746,,
14428,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629747,,
14429,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629748,,
14430,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629749,,
14431,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629750,,
14432,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629751,,
14433,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629752,,
14434,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629753,,
14435,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629754,,
14436,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629755,,
14437,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629756,,
14438,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629757,,
14439,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629758,,
14440,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629759,,
14441,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL629760,,
14442,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,50597,,,1,11510,BAO_0000218,1,CHEMBL876443,,
14443,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,50588,,,1,8310,BAO_0000218,1,CHEMBL629761,,
14444,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,50588,,,1,8310,BAO_0000218,1,CHEMBL629762,,
14445,,Mus musculus,,A,N,Intermediate,,10090.0,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,50594,,,1,8310,BAO_0000218,1,CHEMBL629763,,
14446,,Mus musculus,,A,N,Intermediate,,10090.0,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,50594,,,1,8310,BAO_0000218,1,CHEMBL629764,,
14447,,Mus musculus,,A,N,Intermediate,,10090.0,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,50594,,,1,8310,BAO_0000218,1,CHEMBL629765,,
14448,,Mus musculus,,A,N,Intermediate,,10090.0,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,50594,,,1,8310,BAO_0000218,1,CHEMBL629766,,
14449,,Mus musculus,,A,N,Intermediate,,10090.0,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,50594,,,1,8310,BAO_0000218,1,CHEMBL629767,,
14450,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,50588,,,1,8310,BAO_0000218,1,CHEMBL629768,,
14451,,Mus musculus,,A,N,Intermediate,,10090.0,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,50594,,,1,8310,BAO_0000218,1,CHEMBL629769,,
14452,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,50588,,,1,8310,BAO_0000218,1,CHEMBL629770,,
14453,,Canis lupus familiaris,,A,N,Intermediate,,9615.0,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,50588,,,1,8310,BAO_0000218,1,CHEMBL629771,,
14454,,Mus musculus,,A,N,Intermediate,,10090.0,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,50594,,,1,8310,BAO_0000218,1,CHEMBL629772,,
14455,,Mus musculus,,A,N,Intermediate,,10090.0,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,50594,,,1,8310,BAO_0000218,1,CHEMBL629773,,
14456,,Mus musculus,,A,N,Intermediate,,10090.0,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,50594,,,1,8310,BAO_0000218,1,CHEMBL625455,,
14457,,Mus musculus,,A,N,Intermediate,,10090.0,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,50594,,,1,8310,BAO_0000218,1,CHEMBL625456,,
14458,,Mus musculus,,A,N,Intermediate,,10090.0,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,50594,,,1,8310,BAO_0000218,1,CHEMBL625457,,
14459,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL625458,,1088.0
14460,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL625459,,1088.0
14461,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL875483,,1088.0
14462,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL634779,,1088.0
14463,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL625460,,1088.0
14464,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626117,,1088.0
14465,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626118,,1088.0
14466,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628342,,1088.0
14467,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628343,,1088.0
14468,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628344,,1088.0
14469,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628345,,1088.0
14470,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628346,,1088.0
14471,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628347,,1088.0
14472,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628348,,1088.0
14473,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628349,,1088.0
14474,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL875611,,1088.0
14475,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628350,,1088.0
14476,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628351,,1088.0
14477,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628352,,1088.0
14478,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628353,,1088.0
14479,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628354,,1088.0
14480,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626667,,1088.0
14481,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626668,,1088.0
14482,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626669,,1088.0
14483,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626670,,1088.0
14484,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626671,,1088.0
14485,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626672,,1088.0
14486,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626673,,1088.0
14487,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626674,,1088.0
14488,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626675,,1088.0
14489,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626676,,1088.0
14490,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626677,,1088.0
14491,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626678,,1088.0
14492,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626679,,1088.0
14493,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL875612,,1088.0
14494,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626680,,1088.0
14495,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626681,,1088.0
14496,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626682,,1088.0
14497,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626683,,1088.0
14498,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626684,,1088.0
14499,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626685,,1088.0
14500,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626686,,1088.0
14501,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626687,,1088.0
14502,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL624978,,1088.0
14503,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL624979,,1088.0
14504,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL624980,,1088.0
14505,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL624981,,1088.0
14506,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL624982,,1088.0
14507,In vivo,,,A,U,Autocuration,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),22224,,,1,13257,BAO_0000218,0,CHEMBL627564,,2367.0
14508,In vivo,,,A,U,Autocuration,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),22224,,,1,13257,BAO_0000218,0,CHEMBL627565,,2367.0
14509,In vivo,,,A,U,Autocuration,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,22224,,,1,13257,BAO_0000218,0,CHEMBL627566,,
14510,In vivo,,,A,U,Autocuration,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,22224,,,1,13257,BAO_0000218,0,CHEMBL627567,,2385.0
14511,In vivo,,,A,U,Autocuration,Spleen,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,22224,,,1,13257,BAO_0000218,0,CHEMBL627568,,2106.0
14512,In vivo,,,A,U,Autocuration,Kidney,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,22224,,,1,13257,BAO_0000218,0,CHEMBL627569,,2113.0
14513,In vivo,,,A,U,Autocuration,Urinary bladder,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,22224,,,1,13257,BAO_0000218,0,CHEMBL627570,,1255.0
14514,In vivo,,,A,U,Autocuration,Blood,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,22224,,,1,13257,BAO_0000218,0,CHEMBL627571,,178.0
14515,In vivo,,,A,U,Autocuration,Bone element,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,22224,,,1,13257,BAO_0000218,0,CHEMBL627572,,1474.0
14516,In vivo,,,A,U,Autocuration,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,22224,,,1,13257,BAO_0000218,0,CHEMBL627573,,
14517,In vivo,,,A,U,Autocuration,Kidney,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,22224,,,1,13257,BAO_0000218,0,CHEMBL627574,,2113.0
14518,In vivo,,,A,U,Autocuration,Liver,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,22224,,,1,13257,BAO_0000218,0,CHEMBL627575,,2107.0
14519,In vivo,,,A,U,Autocuration,Lung,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,22224,,,1,13257,BAO_0000218,0,CHEMBL627576,,2048.0
14520,In vivo,,,A,U,Autocuration,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,22224,,,1,13257,BAO_0000218,0,CHEMBL627577,,2385.0
14521,In vivo,,,A,U,Autocuration,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),22224,,,1,13257,BAO_0000218,0,CHEMBL627578,,2367.0
14522,In vivo,,,A,U,Autocuration,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,22224,,,1,13257,BAO_0000218,0,CHEMBL627579,,2367.0
14523,In vivo,,,A,U,Autocuration,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,22224,,,1,13257,BAO_0000218,0,CHEMBL627580,,2385.0
14524,In vivo,,,A,U,Autocuration,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),22224,,,1,13257,BAO_0000218,0,CHEMBL627581,,2367.0
14525,In vivo,,,A,U,Autocuration,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,22224,,,1,13257,BAO_0000218,0,CHEMBL627582,,
14526,In vivo,,,A,U,Autocuration,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,22224,,,1,13257,BAO_0000218,0,CHEMBL627583,,2385.0
14527,In vivo,,,A,U,Autocuration,Spleen,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,22224,,,1,13257,BAO_0000218,0,CHEMBL627584,,2106.0
14528,In vivo,,,A,U,Autocuration,Prostate gland,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,22224,,,1,13257,BAO_0000218,0,CHEMBL627585,,2367.0
14529,In vivo,,,A,U,Autocuration,Muscle tissue,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,22224,,,1,13257,BAO_0000218,0,CHEMBL627586,,2385.0
14530,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,50597,,,1,15413,BAO_0000218,1,CHEMBL627587,,
14531,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,50597,,,1,15413,BAO_0000218,1,CHEMBL627588,,
14532,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,50597,,,1,15413,BAO_0000218,1,CHEMBL628250,,
14533,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,50597,,,1,15413,BAO_0000218,1,CHEMBL628251,,
14534,In vivo,Rattus norvegicus,,A,N,Intermediate,Hippocampus,10116.0,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,50597,,,1,15413,BAO_0000218,1,CHEMBL628252,,10000000.0
14535,In vivo,Rattus norvegicus,,A,N,Intermediate,Hippocampus,10116.0,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,50597,,,1,15413,BAO_0000218,1,CHEMBL628253,,10000000.0
14536,In vivo,Rattus norvegicus,,A,N,Intermediate,Hypothalamus,10116.0,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,50597,,,1,15413,BAO_0000218,1,CHEMBL628254,,1898.0
14537,In vivo,Rattus norvegicus,,A,N,Intermediate,Hypothalamus,10116.0,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,50597,,,1,15413,BAO_0000218,1,CHEMBL877493,,1898.0
14538,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,50597,,,1,15413,BAO_0000218,1,CHEMBL628255,,
14539,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,50597,,,1,15413,BAO_0000218,1,CHEMBL628256,,
14540,In vivo,Rattus norvegicus,,A,N,Intermediate,Hippocampus,10116.0,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,50597,,,1,15413,BAO_0000218,1,CHEMBL628257,,10000000.0
14541,In vivo,Rattus norvegicus,,A,N,Intermediate,Hypothalamus,10116.0,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,50597,,,1,15413,BAO_0000218,1,CHEMBL628258,,1898.0
14542,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,50597,,,1,15413,BAO_0000218,1,CHEMBL628259,,
14543,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,50597,,,1,15413,BAO_0000218,1,CHEMBL628429,,
14544,In vivo,Rattus norvegicus,,A,N,Intermediate,Hippocampus,10116.0,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,50597,,,1,15413,BAO_0000218,1,CHEMBL626862,,10000000.0
14545,In vivo,Rattus norvegicus,,A,N,Intermediate,Hypothalamus,10116.0,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,50597,,,1,15413,BAO_0000218,1,CHEMBL626863,,1898.0
14546,In vivo,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,50597,,,1,15413,BAO_0000218,1,CHEMBL625886,,2037.0
14547,In vivo,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,50597,,,1,15413,BAO_0000218,1,CHEMBL625887,,2037.0
14548,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of the [11C]-radiolabeled compound in rat cortex,50597,,,1,15413,BAO_0000218,1,CHEMBL625888,,
14549,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,50597,,,1,15413,BAO_0000218,1,CHEMBL625889,,
14550,In vivo,Rattus norvegicus,,A,N,Intermediate,Hippocampus,10116.0,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,50597,,,1,15413,BAO_0000218,1,CHEMBL625890,,10000000.0
14551,In vivo,Rattus norvegicus,,A,N,Intermediate,Hippocampus,10116.0,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,50597,,,1,15413,BAO_0000218,1,CHEMBL625891,,10000000.0
14552,In vivo,Rattus norvegicus,,A,N,Intermediate,Hypothalamus,10116.0,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,50597,,,1,15413,BAO_0000218,1,CHEMBL625892,,1898.0
14553,In vivo,Rattus norvegicus,,A,N,Intermediate,Hypothalamus,10116.0,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,50597,,,1,15413,BAO_0000218,1,CHEMBL625893,,1898.0
14554,In vivo,Rattus norvegicus,,A,N,Intermediate,Cerebellum,10116.0,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,50597,,,1,15413,BAO_0000218,1,CHEMBL625894,,2037.0
14555,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution of the [18F]-radiolabeled compound in rat cortex,50597,,,1,15413,BAO_0000218,1,CHEMBL625895,,
14556,,,,A,U,Autocuration,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,22224,,,1,12404,BAO_0000019,0,CHEMBL625896,,
14557,,,,A,U,Autocuration,,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",22224,,,1,568,BAO_0000019,0,CHEMBL625897,,
14558,,,,A,U,Autocuration,,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",22224,,,1,568,BAO_0000019,0,CHEMBL625898,,
14559,,,,A,U,Autocuration,,,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",22224,,,1,568,BAO_0000019,0,CHEMBL625899,,
14560,,,,A,U,Autocuration,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,22224,,,1,12404,BAO_0000019,0,CHEMBL626124,,
14561,,Escherichia coli,,A,N,Intermediate,,562.0,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,50212,,,1,7624,BAO_0000218,1,CHEMBL628500,,
14562,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",50597,,,1,7624,BAO_0000218,1,CHEMBL857856,,
14563,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",50597,,,1,7624,BAO_0000218,1,CHEMBL628501,,
14564,,,,A,U,Autocuration,,,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",22224,,,1,4643,BAO_0000019,0,CHEMBL628502,,
14565,,,,A,U,Autocuration,,,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,22224,,,1,11532,BAO_0000019,0,CHEMBL628503,,
14566,,,,A,U,Autocuration,,,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,22224,,,1,11018,BAO_0000019,0,CHEMBL628504,,
14567,,,,A,U,Autocuration,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",22224,,,1,2276,BAO_0000019,0,CHEMBL628505,,
14568,,,,A,U,Autocuration,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",22224,,,1,2276,BAO_0000019,0,CHEMBL874452,,
14569,,,,A,U,Autocuration,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",22224,,,1,2276,BAO_0000019,0,CHEMBL628506,,
14570,,,,A,U,Autocuration,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",22224,,,1,2276,BAO_0000019,0,CHEMBL628507,,
14571,,,,A,U,Autocuration,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",22224,,,1,2276,BAO_0000019,0,CHEMBL628508,,
14572,,,,A,U,Autocuration,,,Michaelis constant (KM) was evaluated,22224,,,1,8949,BAO_0000019,0,CHEMBL628509,,
14573,,,,A,U,Autocuration,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,22224,,,1,12404,BAO_0000019,0,CHEMBL628510,,
14574,,,,B,U,Autocuration,,,Substrate concentration for half maximal velocity was reported for rat hexokinase I,22224,,,1,7625,BAO_0000019,0,CHEMBL628511,,
14575,,,,B,U,Autocuration,,,Substrate concentration for half maximal velocity was reported for rat hexokinase II,22224,,,1,7625,BAO_0000019,0,CHEMBL628512,,
14576,,,,B,U,Autocuration,,,Substrate concentration for half maximal velocity was reported for rat hexokinase III,22224,,,1,7625,BAO_0000019,0,CHEMBL628513,,
14577,,,,B,U,Autocuration,,,Substrate concentration for half maximal velocity was reported for yeast hexokinase,22224,,,1,7625,BAO_0000019,0,CHEMBL628514,,
14578,,,,A,U,Autocuration,,,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,22224,,,1,12908,BAO_0000019,0,CHEMBL628515,,
14579,,,,A,U,Autocuration,,,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,22224,,,1,10368,BAO_0000019,0,CHEMBL628516,,
14580,,,,A,U,Autocuration,,,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),22224,,,1,13108,BAO_0000019,0,CHEMBL628517,,
14581,,,,A,U,Autocuration,,,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),22224,,,1,13108,BAO_0000019,0,CHEMBL628518,,
14582,,,,A,U,Autocuration,,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,22224,,,1,15217,BAO_0000019,0,CHEMBL628519,,
14583,,,,A,U,Autocuration,,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,22224,,,1,15217,BAO_0000019,0,CHEMBL628520,,
14584,,,,A,U,Autocuration,,,Binding constant was determined,22224,,,1,10933,BAO_0000019,0,CHEMBL628521,,
14585,,,,A,U,Autocuration,,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,22224,,,1,2363,BAO_0000019,0,CHEMBL630443,,
14586,,,,A,U,Autocuration,,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,22224,,,1,2363,BAO_0000019,0,CHEMBL630444,,
14587,,,,A,U,Autocuration,,,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,22224,,,1,2276,BAO_0000019,0,CHEMBL857732,,
14588,,,,P,U,Autocuration,,,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,22224,,,1,14915,BAO_0000100,0,CHEMBL630445,,
14589,,,,A,U,Autocuration,,,Catalytic rate constant of the compound,22224,,,1,8847,BAO_0000019,0,CHEMBL630446,,
14590,,,,B,U,Autocuration,,,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,22224,,,1,15357,BAO_0000019,0,CHEMBL630447,,
14591,,,,A,U,Autocuration,,,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),22224,,,1,2869,BAO_0000019,0,CHEMBL630448,,
14592,,,,A,U,Autocuration,,,Catalytic rate constant against phospholipase A2 was determined,22224,,,1,3484,BAO_0000019,0,CHEMBL630449,,
14593,,,,A,U,Autocuration,,,"Compound was evaluated for catalytic constant, Kcat",22224,,,1,1373,BAO_0000019,0,CHEMBL630450,,
14594,,,,A,U,Autocuration,,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,22224,,,1,8142,BAO_0000019,0,CHEMBL630451,,
14595,,,,A,U,Autocuration,,,Kcat calculated from 0.693/T1/2,22224,,,1,14131,BAO_0000019,0,CHEMBL630452,,
14596,,,,A,U,Autocuration,,,Kcat was determined,22224,,,1,17269,BAO_0000019,0,CHEMBL630453,,
14597,,,,A,U,Autocuration,,,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,22224,,,1,3485,BAO_0000019,0,CHEMBL630454,,
14598,,,,A,U,Autocuration,,,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,22224,,,1,3485,BAO_0000019,0,CHEMBL630455,,
14599,,,,A,U,Autocuration,,,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,22224,,,1,3485,BAO_0000019,0,CHEMBL631487,,
14600,,,,A,U,Autocuration,,,Kcat value was determined,22224,,,1,5962,BAO_0000019,0,CHEMBL631488,,
14601,,,,A,U,Autocuration,,,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,22224,,,1,3133,BAO_0000019,0,CHEMBL876440,,
14602,,,,A,U,Autocuration,,,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,22224,,,1,3133,BAO_0000019,0,CHEMBL631489,,
14603,,,,A,U,Autocuration,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",22224,,,1,2276,BAO_0000019,0,CHEMBL857742,,
14604,,,,A,U,Autocuration,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",22224,,,1,2276,BAO_0000019,0,CHEMBL631490,,
14605,,,,A,U,Autocuration,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",22224,,,1,2276,BAO_0000019,0,CHEMBL631491,,
14606,,,,A,U,Autocuration,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",22224,,,1,2276,BAO_0000019,0,CHEMBL631492,,
14607,,,,A,U,Autocuration,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",22224,,,1,2276,BAO_0000019,0,CHEMBL631493,,
14608,,,,A,U,Autocuration,,,Kinetic parameter for rate of conversion to PABA was determined,22224,,,1,4892,BAO_0000019,0,CHEMBL631494,,
14609,,,,A,U,Autocuration,,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,22224,,,1,3133,BAO_0000019,0,CHEMBL631495,,
14610,,Rattus norvegicus,,A,N,Intermediate,Feces,10116.0,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",50597,,,1,11488,BAO_0000218,1,CHEMBL631496,,1988.0
14611,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",50597,,,1,11488,BAO_0000218,1,CHEMBL631497,,1088.0
14612,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",50597,,,1,11488,BAO_0000218,1,CHEMBL631498,,1088.0
14613,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",50597,,,1,11488,BAO_0000218,1,CHEMBL629776,,1088.0
14614,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",50597,,,1,11488,BAO_0000218,1,CHEMBL629777,,1088.0
14615,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",50597,,,1,11488,BAO_0000218,1,CHEMBL629778,,1088.0
14616,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,50597,,,1,11488,BAO_0000218,1,CHEMBL630456,,
14617,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,50597,,,1,11488,BAO_0000218,1,CHEMBL630457,,
14618,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,50597,,,1,11488,BAO_0000218,1,CHEMBL630458,,
14619,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,50597,,,1,11488,BAO_0000218,1,CHEMBL630459,,
14620,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,50597,,,1,11488,BAO_0000218,1,CHEMBL630460,,
14621,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,50597,,,1,11488,BAO_0000218,1,CHEMBL876550,,
14622,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,50597,,,1,11488,BAO_0000218,1,CHEMBL630461,,
14623,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,50597,,,1,11488,BAO_0000218,1,CHEMBL630462,,
14624,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,50597,,,1,11488,BAO_0000218,1,CHEMBL630463,,
14625,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,50597,,,1,11488,BAO_0000218,1,CHEMBL630464,,
14626,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,50597,,,1,11488,BAO_0000218,1,CHEMBL630465,,
14627,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,50597,,,1,11488,BAO_0000218,1,CHEMBL630466,,
14628,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,50597,,,1,11488,BAO_0000218,1,CHEMBL630467,,
14629,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,50597,,,1,11488,BAO_0000218,1,CHEMBL630633,,
14630,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,50597,,,1,11488,BAO_0000218,1,CHEMBL630634,,
14631,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,50597,,,1,11488,BAO_0000218,1,CHEMBL630635,,
14632,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,50597,,,1,11488,BAO_0000218,1,CHEMBL630636,,
14633,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,50597,,,1,11488,BAO_0000218,1,CHEMBL630637,,
14634,,Oryctolagus cuniculus,,A,N,Intermediate,Feces,9986.0,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",50592,,,1,7132,BAO_0000218,1,CHEMBL630638,,1988.0
14635,,Oryctolagus cuniculus,,A,N,Intermediate,Feces,9986.0,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",50592,,,1,7132,BAO_0000218,1,CHEMBL630639,,1988.0
14636,,Oryctolagus cuniculus,,A,N,Intermediate,Feces,9986.0,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",50592,,,1,7132,BAO_0000218,1,CHEMBL630640,,1988.0
14637,,Oryctolagus cuniculus,,A,N,Intermediate,Feces,9986.0,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",50592,,,1,7132,BAO_0000218,1,CHEMBL876551,,1988.0
14638,,Oryctolagus cuniculus,,A,N,Intermediate,Urine,9986.0,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",50592,,,1,7132,BAO_0000218,1,CHEMBL630641,,1088.0
14639,,Oryctolagus cuniculus,,A,N,Intermediate,Urine,9986.0,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",50592,,,1,7132,BAO_0000218,1,CHEMBL630642,,1088.0
14640,,Oryctolagus cuniculus,,A,N,Intermediate,Urine,9986.0,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",50592,,,1,7132,BAO_0000218,1,CHEMBL630643,,1088.0
14641,,Oryctolagus cuniculus,,A,N,Intermediate,Urine,9986.0,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",50592,,,1,7132,BAO_0000218,1,CHEMBL630644,,1088.0
14642,,Oryctolagus cuniculus,,A,N,Intermediate,Urine,9986.0,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",50592,,,1,7132,BAO_0000218,1,CHEMBL630645,,1088.0
14643,,Oryctolagus cuniculus,,A,N,Intermediate,Feces,9986.0,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",50592,,,1,7132,BAO_0000218,1,CHEMBL625599,,1988.0
14644,,Oryctolagus cuniculus,,A,N,Intermediate,Feces,9986.0,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",50592,,,1,7132,BAO_0000218,1,CHEMBL625600,,1988.0
14645,,Oryctolagus cuniculus,,A,N,Intermediate,Feces,9986.0,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",50592,,,1,7132,BAO_0000218,1,CHEMBL625601,,1988.0
14646,,Oryctolagus cuniculus,,A,N,Intermediate,Feces,9986.0,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",50592,,,1,7132,BAO_0000218,1,CHEMBL625602,,1988.0
14647,,Oryctolagus cuniculus,,A,N,Intermediate,Urine,9986.0,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",50592,,,1,7132,BAO_0000218,1,CHEMBL627470,,1088.0
14648,,Oryctolagus cuniculus,,A,N,Intermediate,Urine,9986.0,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",50592,,,1,7132,BAO_0000218,1,CHEMBL627471,,1088.0
14649,,Oryctolagus cuniculus,,A,N,Intermediate,Urine,9986.0,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",50592,,,1,7132,BAO_0000218,1,CHEMBL627472,,1088.0
14650,,Oryctolagus cuniculus,,A,N,Intermediate,Urine,9986.0,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",50592,,,1,7132,BAO_0000218,1,CHEMBL627473,,1088.0
14651,,Oryctolagus cuniculus,,A,N,Intermediate,Urine,9986.0,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",50592,,,1,7132,BAO_0000218,1,CHEMBL627474,,1088.0
14652,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,,,1,13925,BAO_0000218,1,CHEMBL627475,,178.0
14653,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,,,1,13925,BAO_0000218,1,CHEMBL627476,,178.0
14654,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL627477,,1088.0
14655,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL627478,,1088.0
14656,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL627479,,1088.0
14657,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL627480,,1088.0
14658,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL627481,,1088.0
14659,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL627482,,1088.0
14660,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL627483,,1088.0
14661,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL875636,,1088.0
14662,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL625764,,1088.0
14663,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL625765,,1088.0
14664,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL625766,,1088.0
14665,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL625767,,1088.0
14666,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL625768,,1088.0
14667,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL625769,,1088.0
14668,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL625770,,1088.0
14669,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL625771,,1088.0
14670,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL625772,,1088.0
14671,,Canis lupus familiaris,,A,N,Intermediate,Urine,9615.0,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,50588,,,1,12582,BAO_0000218,1,CHEMBL625773,,1088.0
14672,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL625774,,1088.0
14673,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL625775,,1088.0
14674,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL625776,,1088.0
14675,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL625777,,1088.0
14676,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL625778,,1088.0
14677,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL625779,,1088.0
14678,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL625780,,1088.0
14679,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL625781,,1088.0
14680,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL875637,,1088.0
14681,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626473,,1088.0
14682,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626474,,1088.0
14683,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626475,,1088.0
14684,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626476,,1088.0
14685,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL634397,,1088.0
14686,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL626477,,1088.0
14687,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631069,,1088.0
14688,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631070,,1088.0
14689,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631071,,1088.0
14690,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631072,,1088.0
14691,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631073,,1088.0
14692,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631074,,1088.0
14693,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631075,,1088.0
14694,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631725,,1088.0
14695,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631726,,1088.0
14696,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631727,,1088.0
14697,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631728,,1088.0
14698,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631729,,1088.0
14699,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631730,,1088.0
14700,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631731,,1088.0
14701,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631910,,1088.0
14702,In vivo,Rattus norvegicus,,A,N,Intermediate,Hippocampus,10116.0,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,50597,,,1,15413,BAO_0000218,1,CHEMBL631911,,10000000.0
14703,In vivo,Rattus norvegicus,,A,N,Intermediate,Hypothalamus,10116.0,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,50597,,,1,15413,BAO_0000218,1,CHEMBL631912,,1898.0
14704,In vivo,Rattus norvegicus,,A,N,Intermediate,Hypothalamus,10116.0,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,50597,,,1,15413,BAO_0000218,1,CHEMBL631913,,1898.0
14705,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL631914,,178.0
14706,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL631915,,178.0
14707,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL875778,,178.0
14708,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL631916,,178.0
14709,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL631917,,178.0
14710,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL631918,,178.0
14711,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL631919,,178.0
14712,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL631920,,178.0
14713,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL631921,,178.0
14714,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL631922,,178.0
14715,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL631923,,178.0
14716,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL631924,,
14717,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630234,,
14718,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL630235,,
14719,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630236,,
14720,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630237,,
14721,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630238,,
14722,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630239,,
14723,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL630303,,
14724,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630304,,
14725,In vivo,Rattus norvegicus,,A,N,Intermediate,,10116.0,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630305,,
14726,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630306,,2113.0
14727,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630307,,2113.0
14728,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL630308,,2113.0
14729,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630309,,2113.0
14730,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL629309,,2113.0
14731,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL629993,,2113.0
14732,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL629994,,2113.0
14733,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL629995,,2113.0
14734,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL631993,,2113.0
14735,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL631994,,2113.0
14736,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL631995,,2113.0
14737,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL631996,,2107.0
14738,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL631997,,2107.0
14739,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL631998,,2107.0
14740,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL631999,,2107.0
14741,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL632000,,2107.0
14742,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL632001,,2107.0
14743,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL874424,,2107.0
14744,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL632002,,2107.0
14745,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL632003,,2107.0
14746,,,,A,U,Autocuration,,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,22224,,,1,3133,BAO_0000019,0,CHEMBL632004,,
14747,,,,A,U,Autocuration,,,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,22224,,,1,2742,BAO_0000019,0,CHEMBL632005,,
14748,,,,A,U,Autocuration,,,Compound was tested for amidase rate in the presence of N62C screen enzyme,22224,,,1,2742,BAO_0000019,0,CHEMBL632006,,
14749,,,,A,U,Autocuration,,,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,22224,,,1,2742,BAO_0000019,0,CHEMBL632007,,
14750,,,,A,U,Autocuration,,,Compound was tested for amidase rate in the presence of S166C screen enzyme,22224,,,1,2742,BAO_0000019,0,CHEMBL632008,,
14751,,,,A,U,Autocuration,,,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,22224,,,1,2742,BAO_0000019,0,CHEMBL632009,,
14752,,,,A,U,Autocuration,,,Compound was tested for esterase rate in the presence of N62C screen enzyme,22224,,,1,2742,BAO_0000019,0,CHEMBL632010,,
14753,,,,A,U,Autocuration,,,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,22224,,,1,2742,BAO_0000019,0,CHEMBL857750,,
14754,,,,A,U,Autocuration,,,Compound was tested for esterase rate in the presence of S166C screen enzyme,22224,,,1,2742,BAO_0000019,0,CHEMBL632011,,
14755,,,,A,U,Autocuration,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",22224,,,1,2276,BAO_0000019,0,CHEMBL632012,,
14756,,,,A,U,Autocuration,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",22224,,,1,2276,BAO_0000019,0,CHEMBL632013,,
14757,,,,A,U,Autocuration,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",22224,,,1,2276,BAO_0000019,0,CHEMBL632014,,
14758,,,,A,U,Autocuration,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",22224,,,1,2276,BAO_0000019,0,CHEMBL629622,,
14759,,,,A,U,Autocuration,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",22224,,,1,2276,BAO_0000019,0,CHEMBL629623,,
14760,,,,A,U,Autocuration,,,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",22224,,,1,2276,BAO_0000019,0,CHEMBL629624,,
14761,,,,A,U,Autocuration,,,Ratio of Kcat to that of Km was determined,22224,,,1,17269,BAO_0000019,0,CHEMBL629625,,
14762,,,,A,U,Autocuration,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",22224,,,1,2276,BAO_0000019,0,CHEMBL629626,,
14763,,,,A,U,Autocuration,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",22224,,,1,2276,BAO_0000019,0,CHEMBL629627,,
14764,,,,A,U,Autocuration,,,"Compound was evaluated for constant, Kd",22224,,,1,15917,BAO_0000019,0,CHEMBL629628,,
14765,,,,A,U,Autocuration,,,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,22224,,,1,10933,BAO_0000019,0,CHEMBL629629,,
14766,,,,A,U,Autocuration,,,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,22224,,,1,10933,BAO_0000019,0,CHEMBL629630,,
14767,,,,A,U,Autocuration,,,Dissociation Constant of compound determined,22224,,,1,14293,BAO_0000019,0,CHEMBL856030,,
14768,,,,B,U,Autocuration,,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,22224,,,1,6698,BAO_0000019,0,CHEMBL629631,,
14769,,,,B,U,Autocuration,,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,22224,,,1,6698,BAO_0000019,0,CHEMBL629632,,
14770,,,,P,U,Autocuration,,,Dissociation constant of compound with Fructose was determined,22224,,,1,4318,BAO_0000100,0,CHEMBL629633,,
14771,,,,P,U,Autocuration,,,Dissociation constant of compound with Fructose was determined; Not determined,22224,,,1,4318,BAO_0000100,0,CHEMBL629634,,
14772,,,,P,U,Autocuration,,,Dissociation constant of compound with Lactulose was determined,22224,,,1,4318,BAO_0000100,0,CHEMBL629635,,
14773,,,,P,U,Autocuration,,,Dissociation constant of compound with Lactulose was determined; Not determined,22224,,,1,4318,BAO_0000100,0,CHEMBL629636,,
14774,,,,P,U,Autocuration,,,Dissociation constant of the Compound,22224,,,1,14959,BAO_0000100,0,CHEMBL629637,,
14775,,,,P,U,Autocuration,,,Dissociation constant by non-linear regression analysis,22224,,,1,5913,BAO_0000100,0,CHEMBL629638,,
14776,,,,P,U,Autocuration,,,Dissociation constant was determined,22224,,,1,14218,BAO_0000100,0,CHEMBL629639,,
14777,,,,P,U,Autocuration,,,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,22224,,,1,10689,BAO_0000100,0,CHEMBL629640,,
14778,,,,P,U,Autocuration,,,Dissociation constant was determined,22224,,,1,13925,BAO_0000100,0,CHEMBL629641,,
14779,,,,P,U,Autocuration,,,Dissociation constant was determined,22224,,,1,16359,BAO_0000100,0,CHEMBL631344,,
14780,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,50597,,,1,10944,BAO_0000218,1,CHEMBL631345,,2385.0
14781,,,,A,U,Autocuration,,,The dissociation constant determined by fluorescence displacement assay,22224,,,1,11080,BAO_0000019,0,CHEMBL631346,,
14782,,,,A,U,Autocuration,,,kd value surface plasmon resonance (SPR) method,22224,,,1,17805,BAO_0000019,0,CHEMBL631524,,
14783,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,50597,,,1,10944,BAO_0000218,1,CHEMBL631525,,2385.0
14784,,,,F,U,Autocuration,,,First dissociation constant of the binding of compound to V30M TTR,22224,,,1,16645,BAO_0000019,0,CHEMBL631526,,
14785,,,,F,U,Autocuration,,,Second dissociation constant of the binding of compound to V30M TTR,22224,,,1,16645,BAO_0000019,0,CHEMBL631527,,
14786,,,,A,U,Autocuration,,,"Compound was evaluated for equilibrium constant, Ke",22224,,,1,7793,BAO_0000019,0,CHEMBL631528,,
14787,,,,A,U,Autocuration,Hypothalamus,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,22224,,,1,12199,BAO_0000019,0,CHEMBL631529,,1898.0
14788,,,,A,U,Autocuration,Hypothalamus,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,22224,,,1,12199,BAO_0000019,0,CHEMBL631530,,1898.0
14789,,,,A,U,Autocuration,,,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,22224,,,1,9680,BAO_0000019,0,CHEMBL631531,,
14790,,,,A,U,Autocuration,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,22224,,,1,9680,BAO_0000019,0,CHEMBL631532,,
14791,,,,A,U,Autocuration,,,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,22224,,,1,9680,BAO_0000019,0,CHEMBL631533,,
14792,,Mus musculus,,A,N,Intermediate,,10090.0,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,50594,,,1,13758,BAO_0000218,1,CHEMBL876552,,
14793,,Mus musculus,,A,N,Intermediate,,10090.0,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,50594,,,1,13758,BAO_0000218,1,CHEMBL631534,,
14794,,Mus musculus,,A,N,Intermediate,,10090.0,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,50594,,,1,13758,BAO_0000218,1,CHEMBL631535,,
14795,,Mus musculus,,A,N,Intermediate,,10090.0,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,50594,,,1,13758,BAO_0000218,1,CHEMBL631536,,
14796,,Mus musculus,,A,N,Intermediate,,10090.0,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,50594,,,1,13758,BAO_0000218,1,CHEMBL631537,,
14797,,Mus musculus,,A,N,Intermediate,,10090.0,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,50594,,,1,13758,BAO_0000218,1,CHEMBL631538,,
14798,,Mus musculus,,A,N,Intermediate,,10090.0,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,50594,,,1,13758,BAO_0000218,1,CHEMBL631539,,
14799,,Mus musculus,,A,N,Intermediate,,10090.0,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,50594,,,1,13758,BAO_0000218,1,CHEMBL631540,,
14800,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,50597,,,1,14393,BAO_0000218,1,CHEMBL625637,,
14801,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,50597,,,1,14393,BAO_0000218,1,CHEMBL625638,,
14802,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",50597,,,1,15078,BAO_0000218,1,CHEMBL625639,,
14803,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,,,1,13925,BAO_0000218,1,CHEMBL625640,,955.0
14804,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,,,1,13925,BAO_0000218,1,CHEMBL625641,,955.0
14805,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,,,1,13925,BAO_0000218,1,CHEMBL625642,,948.0
14806,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,,,1,13925,BAO_0000218,1,CHEMBL625643,,948.0
14807,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,,,1,13925,BAO_0000218,1,CHEMBL625644,,2113.0
14808,In vivo,Rattus norvegicus,,A,N,Intermediate,Kidney,10116.0,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,,,1,13925,BAO_0000218,1,CHEMBL625645,,2113.0
14809,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,,,1,13925,BAO_0000218,1,CHEMBL625646,,2107.0
14810,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,,,1,13925,BAO_0000218,1,CHEMBL625647,,2107.0
14811,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,,,1,13925,BAO_0000218,1,CHEMBL625648,,2048.0
14812,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,50597,,,1,13925,BAO_0000218,1,CHEMBL625649,,2048.0
14813,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,,,1,13925,BAO_0000218,1,CHEMBL625650,,2385.0
14814,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,,,1,13925,BAO_0000218,1,CHEMBL625651,,2385.0
14815,In vivo,Rattus norvegicus,,A,N,Intermediate,Zone of skin,10116.0,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,,,1,13925,BAO_0000218,1,CHEMBL625652,,14.0
14816,In vivo,Rattus norvegicus,,A,N,Intermediate,Zone of skin,10116.0,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,,,1,13925,BAO_0000218,1,CHEMBL625653,,14.0
14817,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,,,1,13925,BAO_0000218,1,CHEMBL625654,,2106.0
14818,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,50597,,,1,13925,BAO_0000218,1,CHEMBL625655,,2106.0
14819,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of Compound in rat blood after 15 minutes of administration,50597,,,1,9712,BAO_0000218,1,CHEMBL625656,,178.0
14820,In vivo,Rattus norvegicus,,A,N,Intermediate,Blood,10116.0,Biodistribution of Compound in rat blood after 2 minutes of administration,50597,,,1,9712,BAO_0000218,1,CHEMBL625657,,178.0
14821,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of Compound in rat brain after 15 minutes of administration,50597,,,1,9712,BAO_0000218,1,CHEMBL625658,,955.0
14822,In vivo,Rattus norvegicus,,A,N,Intermediate,Brain,10116.0,Biodistribution of Compound in rat brain after 2 minutes of administration,50597,,,1,9712,BAO_0000218,1,CHEMBL625659,,955.0
14823,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of Compound in rat heart after 15 minutes of administration,50597,,,1,9712,BAO_0000218,1,CHEMBL625660,,948.0
14824,In vivo,Rattus norvegicus,,A,N,Intermediate,Heart,10116.0,Biodistribution of Compound in rat heart after 2 minutes of administration,50597,,,1,9712,BAO_0000218,1,CHEMBL625661,,948.0
14825,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of Compound in rat liver after 15 minutes of administration,50597,,,1,9712,BAO_0000218,1,CHEMBL625662,,2107.0
14826,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution of Compound in rat liver after 2 minutes of administration,50597,,,1,9712,BAO_0000218,1,CHEMBL625663,,2107.0
14827,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of Compound in rat lung after 15 minutes of administration,50597,,,1,9712,BAO_0000218,1,CHEMBL875621,,2048.0
14828,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution of Compound in rat lung after 2 minutes of administration,50597,,,1,9712,BAO_0000218,1,CHEMBL628382,,2048.0
14829,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of Compound in rat muscle after 15 minutes of administration,50597,,,1,9712,BAO_0000218,1,CHEMBL628383,,2385.0
14830,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution of Compound in rat muscle after 2 minutes of administration,50597,,,1,9712,BAO_0000218,1,CHEMBL628384,,2385.0
14831,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,50597,,,1,13925,BAO_0000218,1,CHEMBL628385,,
14832,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,50597,,,1,13925,BAO_0000218,1,CHEMBL875753,,
14833,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,50597,,,1,13925,BAO_0000218,1,CHEMBL628386,,
14834,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Organ distribution in rat blood 2 minutes after intravenous injection,50597,,,1,6941,BAO_0000218,1,CHEMBL628387,,
14835,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Organ distribution in rat blood 2 hr after intravenous injection,50597,,,1,6941,BAO_0000218,1,CHEMBL628388,,
14836,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Organ distribution in rat blood 30 minutes after intravenous injection,50597,,,1,6941,BAO_0000218,1,CHEMBL628389,,
14837,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Organ distribution in rat blood 30 min after intravenous injection,50597,,,1,6941,BAO_0000218,1,CHEMBL632756,,
14838,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Organ distribution in rat brain 2 minutes after intravenous injection,50597,,,1,6941,BAO_0000218,1,CHEMBL628390,,
14839,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Organ distribution in rat brain 2 hr after intravenous injection,50597,,,1,6941,BAO_0000218,1,CHEMBL631811,,
14840,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Organ distribution in rat brain 30 minutes after intravenous injection,50597,,,1,6941,BAO_0000218,1,CHEMBL631812,,
14841,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Organ distribution in rat heart 2 minutes after intravenous injection,50597,,,1,6941,BAO_0000218,1,CHEMBL631813,,
14842,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Organ distribution in rat heart 2 hr after intravenous injection,50597,,,1,6941,BAO_0000218,1,CHEMBL631814,,
14843,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Organ distribution in rat heart 30 minutes after intravenous injection,50597,,,1,6941,BAO_0000218,1,CHEMBL631815,,
14844,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Organ distribution in rat kidney 2 minutes after intravenous injection,50597,,,1,6941,BAO_0000218,1,CHEMBL631816,,
14845,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Organ distribution in rat kidney 2 hr after intravenous injection,50597,,,1,6941,BAO_0000218,1,CHEMBL875758,,
14846,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Organ distribution in rat kidney 30 minutes after intravenous injection,50597,,,1,6941,BAO_0000218,1,CHEMBL631817,,
14847,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Organ distribution in rat liver 2 minutes after intravenous injection,50597,,,1,6941,BAO_0000218,1,CHEMBL631818,,2107.0
14848,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Organ distribution in rat liver 2 hr after intravenous injection,50597,,,1,6941,BAO_0000218,1,CHEMBL631819,,2107.0
14849,,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Organ distribution in rat liver 30 minutes after intravenous injection,50597,,,1,6941,BAO_0000218,1,CHEMBL631820,,2107.0
14850,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Organ distribution in rat lung 2 minutes after intravenous injection,50597,,,1,6941,BAO_0000218,1,CHEMBL631821,,
14851,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Organ distribution in rat lung 2 hr after intravenous injection,50597,,,1,6941,BAO_0000218,1,CHEMBL631822,,
14852,,Rattus norvegicus,,A,N,Intermediate,,10116.0,Organ distribution in rat lung 30 minutes after intravenous injection,50597,,,1,6941,BAO_0000218,1,CHEMBL631823,,
14853,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Organ distribution in rat muscle 2 minutes after intravenous injection,50597,,,1,6941,BAO_0000218,1,CHEMBL631824,,2385.0
14854,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Organ distribution in rat muscle 2 hr after intravenous injection,50597,,,1,6941,BAO_0000218,1,CHEMBL631825,,2385.0
14855,,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Organ distribution in rat muscle 30 minutes after intravenous injection,50597,,,1,6941,BAO_0000218,1,CHEMBL631826,,2385.0
14856,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),50594,,,1,14439,BAO_0000218,1,CHEMBL631827,,
14857,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),50594,,,1,14439,BAO_0000218,1,CHEMBL631828,,
14858,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),50594,,,1,14439,BAO_0000218,1,CHEMBL631829,,
14859,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL875759,,1088.0
14860,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631830,,1088.0
14861,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631831,,1088.0
14862,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631832,,1088.0
14863,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631833,,1088.0
14864,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631834,,1088.0
14865,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631835,,1088.0
14866,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631836,,1088.0
14867,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631837,,1088.0
14868,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631838,,1088.0
14869,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631839,,1088.0
14870,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631840,,1088.0
14871,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631841,,1088.0
14872,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631842,,1088.0
14873,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631843,,1088.0
14874,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631844,,1088.0
14875,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631845,,1088.0
14876,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631846,,1088.0
14877,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL875760,,1088.0
14878,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL632199,,1088.0
14879,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631847,,1088.0
14880,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL631848,,1088.0
14881,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628707,,1088.0
14882,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628708,,1088.0
14883,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628709,,1088.0
14884,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628710,,1088.0
14885,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628711,,1088.0
14886,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628712,,1088.0
14887,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628713,,1088.0
14888,,Rattus norvegicus,,A,N,Intermediate,Urine,10116.0,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,50597,,,1,12582,BAO_0000218,1,CHEMBL628714,,1088.0
14889,,Rattus norvegicus,,A,N,Intermediate,,10116.0,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",50597,,,1,7415,BAO_0000218,1,CHEMBL628715,,
14890,,,,A,U,Autocuration,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,22224,,,1,7313,BAO_0000019,0,CHEMBL629179,,
14891,,,,A,U,Autocuration,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,22224,,,1,7313,BAO_0000019,0,CHEMBL629180,,
14892,,,,A,U,Autocuration,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,22224,,,1,7313,BAO_0000019,0,CHEMBL875108,,
14893,,,,A,U,Autocuration,Adrenal cortex,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,22224,,,1,7570,BAO_0000019,0,CHEMBL629181,,1235.0
14894,,,,A,U,Autocuration,Adrenal cortex,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,22224,,,1,7570,BAO_0000019,0,CHEMBL629182,,1235.0
14895,,,,A,U,Autocuration,,,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,22224,,,1,7570,BAO_0000019,0,CHEMBL629183,,
14896,,,,A,U,Autocuration,,,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,22224,,,1,7570,BAO_0000019,0,CHEMBL629184,,
14897,,,,A,U,Autocuration,Adrenal cortex,,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,22224,,,1,7570,BAO_0000019,0,CHEMBL629185,,1235.0
14898,,,,A,U,Autocuration,Adrenal cortex,,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,22224,,,1,7570,BAO_0000019,0,CHEMBL629186,,1235.0
14899,,,,A,U,Autocuration,,,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,22224,,,1,7570,BAO_0000019,0,CHEMBL629187,,
14900,,,,A,U,Autocuration,,,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,22224,,,1,7570,BAO_0000019,0,CHEMBL629887,,
14901,,,,A,U,Autocuration,,,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,22224,,,1,7570,BAO_0000019,0,CHEMBL629888,,
14902,,,,A,U,Autocuration,,,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,22224,,,1,7570,BAO_0000019,0,CHEMBL629889,,
14903,,,,A,U,Autocuration,Adrenal cortex,,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,22224,,,1,7570,BAO_0000019,0,CHEMBL629890,,1235.0
14904,,,,A,U,Autocuration,,,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,22224,,,1,7570,BAO_0000019,0,CHEMBL629891,,
14905,,,,A,U,Autocuration,,,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,22224,,,1,7570,BAO_0000019,0,CHEMBL629892,,
14906,,,,A,U,Autocuration,Adrenal cortex,,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,22224,,,1,7570,BAO_0000019,0,CHEMBL629893,,1235.0
14907,,,,A,U,Autocuration,,,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,22224,,,1,7570,BAO_0000019,0,CHEMBL629894,,
14908,,,,A,U,Autocuration,,,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,22224,,,1,7570,BAO_0000019,0,CHEMBL629895,,
14909,In vivo,Canis lupus familiaris,,A,U,Autocuration,,9615.0,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",22224,,,1,14122,BAO_0000218,0,CHEMBL875109,,
14910,In vivo,Macaca fascicularis,,A,U,Autocuration,,9541.0,Absolute bioavailability in male cynomolgus monkeys,22224,,,1,16449,BAO_0000218,0,CHEMBL629896,,
14911,In vivo,Rattus norvegicus,,A,U,Autocuration,,10116.0,Absolute bioavailability in maleSprague-Dawley rats,22224,,,1,16449,BAO_0000218,0,CHEMBL629897,,
14912,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL629898,,2107.0
14913,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630057,,2107.0
14914,In vivo,Rattus norvegicus,,A,N,Intermediate,Liver,10116.0,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630058,,2107.0
14915,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630059,,2048.0
14916,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630060,,2048.0
14917,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL630061,,2048.0
14918,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630062,,2048.0
14919,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630063,,2048.0
14920,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630064,,2048.0
14921,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630065,,2048.0
14922,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL630066,,2048.0
14923,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630067,,2048.0
14924,In vivo,Rattus norvegicus,,A,N,Intermediate,Lung,10116.0,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630068,,2048.0
14925,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL631113,,2385.0
14926,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL631114,,2385.0
14927,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL631115,,2385.0
14928,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL631116,,2385.0
14929,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630528,,2385.0
14930,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630529,,2385.0
14931,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630530,,2385.0
14932,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL630531,,2385.0
14933,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630532,,2385.0
14934,In vivo,Rattus norvegicus,,A,N,Intermediate,Muscle tissue,10116.0,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630533,,2385.0
14935,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution in normal mice blood after 120 hr,50594,,,1,15045,BAO_0000218,1,CHEMBL630534,,178.0
14936,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution in normal mice blood after 24 hr,50594,,,1,15045,BAO_0000218,1,CHEMBL630535,,178.0
14937,In vivo,Mus musculus,,A,N,Intermediate,Blood,10090.0,Biodistribution in normal mice blood after 4 hr,50594,,,1,15045,BAO_0000218,1,CHEMBL630536,,178.0
14938,In vivo,Mus musculus,,A,N,Intermediate,Bone,10090.0,Biodistribution in normal mice bone after 120 hr,50594,,,1,15045,BAO_0000218,1,CHEMBL630537,,10000001.0
14939,In vivo,Mus musculus,,A,N,Intermediate,Bone,10090.0,Biodistribution in normal mice bone after 24 hr,50594,,,1,15045,BAO_0000218,1,CHEMBL630538,,10000001.0
14940,In vivo,Mus musculus,,A,N,Intermediate,Bone,10090.0,Biodistribution in normal mice bone after 4 hr,50594,,,1,15045,BAO_0000218,1,CHEMBL630539,,10000001.0
14941,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution in normal mice heart after 120 hr,50594,,,1,15045,BAO_0000218,1,CHEMBL630540,,948.0
14942,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution in normal mice heart after 24 hr,50594,,,1,15045,BAO_0000218,1,CHEMBL630541,,948.0
14943,In vivo,Mus musculus,,A,N,Intermediate,Heart,10090.0,Biodistribution in normal mice heart after 4 hr,50594,,,1,15045,BAO_0000218,1,CHEMBL630542,,948.0
14944,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution in normal mice kidney after 120 hr,50594,,,1,15045,BAO_0000218,1,CHEMBL630543,,2113.0
14945,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution in normal mice kidney after 24 hr,50594,,,1,15045,BAO_0000218,1,CHEMBL630544,,2113.0
14946,In vivo,Mus musculus,,A,N,Intermediate,Kidney,10090.0,Biodistribution in normal mice kidney after 4 hr,50594,,,1,15045,BAO_0000218,1,CHEMBL630545,,2113.0
14947,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution in normal mice liver after 120 hr,50594,,,1,15045,BAO_0000218,1,CHEMBL630546,,2107.0
14948,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution in normal mice liver after 24 hr,50594,,,1,15045,BAO_0000218,1,CHEMBL630547,,2107.0
14949,In vivo,Mus musculus,,A,N,Intermediate,Liver,10090.0,Biodistribution in normal mice liver after 4 hr,50594,,,1,15045,BAO_0000218,1,CHEMBL630548,,2107.0
14950,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution in normal mice spleen after 120 hr,50594,,,1,15045,BAO_0000218,1,CHEMBL630549,,2106.0
14951,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution in normal mice spleen after 24 hr,50594,,,1,15045,BAO_0000218,1,CHEMBL630550,,2106.0
14952,In vivo,Mus musculus,,A,N,Intermediate,Spleen,10090.0,Biodistribution in normal mice spleen after 4 hr,50594,,,1,15045,BAO_0000218,1,CHEMBL876426,,2106.0
14953,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630551,,2106.0
14954,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630552,,2106.0
14955,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL630553,,2106.0
14956,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630554,,2106.0
14957,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630555,,2106.0
14958,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630556,,2106.0
14959,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630557,,2106.0
14960,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),50597,,,1,12017,BAO_0000218,1,CHEMBL630558,,2106.0
14961,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630559,,2106.0
14962,In vivo,Rattus norvegicus,,A,N,Intermediate,Spleen,10116.0,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL630560,,2106.0
14963,In vivo,Rattus norvegicus,,A,N,Intermediate,Thyroid gland,10116.0,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,50597,,,1,12017,BAO_0000218,1,CHEMBL876427,,2046.0
14964,,Rattus norvegicus,,A,N,Intermediate,,10116.0,The Kel values in female wistar rats.,50597,,,1,14941,BAO_0000218,1,CHEMBL630561,,
14965,,,,A,U,Autocuration,,,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,22224,,,1,4646,BAO_0000019,0,CHEMBL630562,,
14966,,,,A,U,Autocuration,,,Hydrolysis rate constant of the compound,22224,,,1,8847,BAO_0000019,0,CHEMBL630563,,
14967,,,,P,U,Autocuration,,,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,22229,,,1,11778,BAO_0000100,0,CHEMBL629673,,
14968,,,,A,U,Autocuration,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",22224,,,1,2363,BAO_0000019,0,CHEMBL629674,,
14969,,,,A,U,Autocuration,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",22224,,,1,2363,BAO_0000019,0,CHEMBL629675,,
14970,,,,A,U,Autocuration,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",22224,,,1,2363,BAO_0000019,0,CHEMBL629676,,
14971,,,,A,U,Autocuration,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",22224,,,1,2363,BAO_0000019,0,CHEMBL629677,,
14972,,,,A,U,Autocuration,,,Apparent inactivation rate constant was evaluated,22224,,,1,8371,BAO_0000019,0,CHEMBL629678,,
14973,,,,A,U,Autocuration,,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,22224,,,1,14883,BAO_0000019,0,CHEMBL629679,,
14974,,,,A,U,Autocuration,,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,22224,,,1,14883,BAO_0000019,0,CHEMBL629680,,
14975,,,,A,U,Autocuration,,,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,22224,,,1,4643,BAO_0000019,0,CHEMBL629681,,
14976,,,,A,U,Autocuration,,,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,22224,,,1,3519,BAO_0000019,0,CHEMBL629682,,
14977,,,,A,U,Autocuration,,,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,22224,,,1,10600,BAO_0000019,0,CHEMBL629683,,
14978,,,,F,U,Autocuration,,,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,22224,,,1,8501,BAO_0000019,0,CHEMBL629684,,
14979,,,,P,U,Autocuration,,,Dissociation constant was determined,22224,,,1,8505,BAO_0000100,0,CHEMBL629685,,
14980,,,,P,U,Autocuration,,,Dissociation constant was determined,22224,,,1,9778,BAO_0000100,0,CHEMBL629686,,
14981,,,,P,U,Autocuration,,,Dissociation constant at pH 7.4,22224,,,1,9778,BAO_0000100,0,CHEMBL872932,,
14982,,,,P,U,Autocuration,,,Dissociation constant in presence of 1 mM dithiothreitol,22224,,,1,9778,BAO_0000100,0,CHEMBL629687,,
14983,,,,A,U,Autocuration,,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,22224,,,1,13007,BAO_0000019,0,CHEMBL872931,,
14984,,,,A,U,Autocuration,,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,22224,,,1,13007,BAO_0000019,0,CHEMBL628151,,
14985,,,,A,U,Autocuration,,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,22224,,,1,13007,BAO_0000019,0,CHEMBL628152,,
14986,,,,A,U,Autocuration,,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,22224,,,1,13007,BAO_0000019,0,CHEMBL628153,,
14987,,,,A,U,Autocuration,,,Kinetic constant for aromatization of androstenedione,22224,,,1,11482,BAO_0000019,0,CHEMBL628154,,
14988,,,,A,U,Autocuration,,,Kinetic constant for aromatization of testosterone,22224,,,1,11482,BAO_0000019,0,CHEMBL628155,,
14989,,,,A,U,Autocuration,,,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,22224,,,1,2303,BAO_0000019,0,CHEMBL628156,,
14990,,,,A,U,Autocuration,,,Local inhibition constant was determined,22224,,,1,11964,BAO_0000019,0,CHEMBL628157,,
14991,,Saccharomyces cerevisiae,,A,N,Intermediate,,4932.0,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,50347,,,1,3140,BAO_0000218,1,CHEMBL857533,,
14992,,,,P,U,Autocuration,,,Dissociation constant value of the compound,22224,,,1,10650,BAO_0000100,0,CHEMBL628158,,
14993,,,,A,U,Autocuration,Cornea,,In vitro permeability through cornea without epithelium,22224,,,1,4667,BAO_0000019,0,CHEMBL628159,,964.0
14994,,,,A,U,Autocuration,Cornea,,In vitro permeability through intact cornea,22224,,,1,4667,BAO_0000019,0,CHEMBL875616,,964.0
14995,,Oryctolagus cuniculus,,A,N,Intermediate,Cornea,9986.0,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,50592,,,1,9199,BAO_0000218,1,CHEMBL628160,,964.0
14996,,,,A,U,Autocuration,,,Rate of enzyme inactivation for the compound was determined,22224,,,1,11966,BAO_0000019,0,CHEMBL628161,,
14997,,,,A,U,Autocuration,Cornea,,In vitro permeability through cornea without epithelium,22224,,,1,4667,BAO_0000019,0,CHEMBL628162,,964.0
14998,,,,A,U,Autocuration,Cornea,,In vitro permeability through intact cornea,22224,,,1,4667,BAO_0000019,0,CHEMBL628163,,964.0
14999,,,,A,U,Autocuration,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL628164,,
15000,,,,A,U,Autocuration,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL628165,,
15001,,,,A,U,Autocuration,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL628166,,
15002,,,,A,U,Autocuration,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL628167,,
15003,,,,A,U,Autocuration,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL628168,,
15004,,,,A,U,Autocuration,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL628169,,
15005,,,,A,U,Autocuration,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL628170,,
15006,,,,A,U,Autocuration,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL628171,,
15007,,,,A,U,Autocuration,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL627434,,
15008,,,,A,U,Autocuration,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL627435,,
15009,,,,A,U,Autocuration,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL628110,,
15010,,,,A,U,Autocuration,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL628111,,
15011,,,,A,U,Autocuration,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL628112,,
15012,,,,A,U,Autocuration,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL628260,,
15013,,,,A,U,Autocuration,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",22224,,,1,8354,BAO_0000019,0,CHEMBL628261,,
15014,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),50594,,,1,14439,BAO_0000218,1,CHEMBL628262,,
15015,In vivo,Homo sapiens,,A,N,Intermediate,,9606.0,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,50587,,,1,14439,BAO_0000218,1,CHEMBL628263,,
15016,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),50594,,,1,14439,BAO_0000218,1,CHEMBL628264,,
15017,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),50594,,,1,14439,BAO_0000218,1,CHEMBL628265,,
15018,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),50594,,,1,14439,BAO_0000218,1,CHEMBL628266,,
15019,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),50594,,,1,14439,BAO_0000218,1,CHEMBL628267,,
15020,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,50594,,,1,14439,BAO_0000218,1,CHEMBL628268,,
15021,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),50594,,,1,14439,BAO_0000218,1,CHEMBL628269,,
15022,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),50594,,,1,14439,BAO_0000218,1,CHEMBL628270,,
15023,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),50594,,,1,14439,BAO_0000218,1,CHEMBL628271,,
15024,In vivo,Mus musculus,,A,N,Intermediate,,10090.0,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),50594,,,1,14439,BAO_0000218,1,CHEMBL628272,,
1,,,,B,H,Autocuration,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,12052,,,1,11087,BAO_0000019,8,CHEMBL615117,,
2,,,,F,U,Autocuration,,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,22226,,,1,684,BAO_0000219,0,CHEMBL615118,,
3,,,,B,U,Autocuration,,,,22226,,,1,15453,BAO_0000019,0,CHEMBL615119,,
4,,Bos taurus,,B,H,Autocuration,,9913.0,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,104729,,,1,17841,BAO_0000249,4,CHEMBL615120,,
5,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),80001,,,1,17430,BAO_0000219,1,CHEMBL615121,163.0,
6,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),80001,,,1,17430,BAO_0000219,1,CHEMBL615122,163.0,
7,,Mus musculus,,F,N,Intermediate,,10090.0,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,80001,,,1,13799,BAO_0000219,1,CHEMBL615123,163.0,
8,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cell cytotoxicity was determined against 143B cell line,80001,,,1,17774,BAO_0000219,1,CHEMBL615124,163.0,
9,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,80001,,,1,3801,BAO_0000219,1,CHEMBL615125,163.0,
10,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,80001,,,1,17430,BAO_0000219,1,CHEMBL615126,163.0,
11,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,80001,,,1,17430,BAO_0000219,1,CHEMBL615127,163.0,
12,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cell cytotoxicity was determined against 143B-LTK cell line,80001,,,1,17774,BAO_0000219,1,CHEMBL615128,163.0,
13,,Staphylococcus aureus,,F,N,Intermediate,,1280.0,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,,,1,11324,BAO_0000218,1,CHEMBL857900,,
14,,Staphylococcus aureus,,F,N,Intermediate,,1280.0,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,,,1,11324,BAO_0000218,1,CHEMBL615129,,
15,,Staphylococcus aureus,,F,N,Intermediate,,1280.0,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,,,1,11324,BAO_0000218,1,CHEMBL615130,,
16,,Staphylococcus aureus,,F,N,Intermediate,,1280.0,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",50185,,,1,11324,BAO_0000218,1,CHEMBL615131,,
17,,Rattus norvegicus,,A,D,Expert,,10116.0,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,100122,,,1,11347,BAO_0000357,9,CHEMBL884521,,
18,,,,B,H,Autocuration,,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),12054,,,1,16474,BAO_0000357,8,CHEMBL615132,,
19,,,,B,H,Autocuration,,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,12054,,,1,10091,BAO_0000019,8,CHEMBL615133,,
20,,,,B,H,Autocuration,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),12054,,,1,16474,BAO_0000357,8,CHEMBL615134,,
21,,,,B,H,Autocuration,,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),12054,,,1,16474,BAO_0000357,8,CHEMBL615135,,
22,,,,B,H,Autocuration,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),12054,,,1,16474,BAO_0000357,8,CHEMBL615136,,
23,,,,B,H,Autocuration,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,12054,,,1,16474,BAO_0000357,8,CHEMBL615137,,
24,,,,B,H,Autocuration,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,12054,,,1,16474,BAO_0000357,8,CHEMBL615138,,
25,,,,B,U,Autocuration,,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",22226,,,1,14352,BAO_0000219,0,CHEMBL836324,,
26,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,12054,,,1,5646,BAO_0000357,8,CHEMBL615139,,
27,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),12054,,,1,5646,BAO_0000357,8,CHEMBL615140,,
28,,,,B,H,Autocuration,,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,12426,,,1,10997,BAO_0000219,8,CHEMBL615141,,
29,,soya bean,,B,H,Autocuration,,3847.0,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,12054,,,1,6309,BAO_0000357,8,CHEMBL615142,,
30,,Glycine max,,B,H,Autocuration,,3847.0,Inhibitory activity against soybean 15-lipoxygenase was evaluated,12054,,,1,167,BAO_0000357,8,CHEMBL615143,,
31,,Glycine max,,B,H,Autocuration,,3847.0,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,12054,,,1,167,BAO_0000357,8,CHEMBL615144,,
32,,Glycine max,,B,H,Autocuration,,3847.0,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,12054,,,1,11087,BAO_0000357,8,CHEMBL872867,,
33,,Glycine max,,B,H,Autocuration,,3847.0,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,12054,,,1,11087,BAO_0000357,8,CHEMBL615145,,
34,,Glycine max,,B,H,Autocuration,,3847.0,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,12054,,,1,13622,BAO_0000357,8,CHEMBL615146,,
35,,Glycine max,,B,H,Autocuration,,3847.0,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,12054,,,1,13622,BAO_0000357,8,CHEMBL615147,,
36,,Rattus norvegicus,,A,U,Autocuration,,10116.0,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,22226,,,1,11347,BAO_0000019,0,CHEMBL615148,,
37,,Escherichia coli,,B,U,Autocuration,,562.0,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,22226,,,1,5926,BAO_0000019,0,CHEMBL615149,,
38,,,,B,U,Autocuration,,,Dissociation constant with dimeric 16S rRNA RNA construct B,22226,,,1,4567,BAO_0000019,0,CHEMBL615150,,
39,,,,B,M,Intermediate,,,Dissociation constant towards 16S rRNA construct A,22222,,,1,3782,BAO_0000225,3,CHEMBL615151,,
40,,,,B,M,Intermediate,,,Dissociation constant towards 16S rRNA construct B,22222,,,1,3782,BAO_0000225,3,CHEMBL615152,,
41,,Escherichia coli,,B,M,Expert,,562.0,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,100263,,,1,4466,BAO_0000225,3,CHEMBL615153,,
42,,Escherichia coli,,B,M,Expert,,562.0,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,100263,,,1,6592,BAO_0000225,3,CHEMBL615154,,
43,,,,B,H,Autocuration,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),13053,,,1,898,BAO_0000019,8,CHEMBL615155,,
44,,,,B,H,Autocuration,,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),13053,,,1,898,BAO_0000019,8,CHEMBL615156,,
45,,Homo sapiens,,B,H,Autocuration,,9606.0,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,20001,,,1,13163,BAO_0000019,8,CHEMBL615157,,
46,,Homo sapiens,,B,H,Autocuration,,9606.0,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,20001,,,1,13163,BAO_0000019,8,CHEMBL615158,,
47,,Rattus norvegicus,,B,D,Expert,,10116.0,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",12971,,,1,10691,BAO_0000019,9,CHEMBL615159,,
48,,Rattus norvegicus,,B,D,Expert,,10116.0,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",12971,,,1,10691,BAO_0000019,9,CHEMBL615172,,
49,,Rattus norvegicus,,B,D,Expert,,10116.0,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",12971,,,1,10691,BAO_0000019,9,CHEMBL615173,,
50,,Rattus norvegicus,,B,D,Expert,,10116.0,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",12971,,,1,10691,BAO_0000019,9,CHEMBL615174,,
51,,,,B,H,Autocuration,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),13053,,,1,898,BAO_0000019,8,CHEMBL884518,,
52,,,,B,H,Autocuration,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),11512,,,1,912,BAO_0000357,8,CHEMBL615175,,
53,,,,B,H,Autocuration,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,11512,,,1,912,BAO_0000357,8,CHEMBL615176,,
54,,,,B,H,Autocuration,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,11512,,,1,912,BAO_0000357,8,CHEMBL615177,,
55,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,104740,,,1,15103,BAO_0000249,5,CHEMBL615178,,
56,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,80002,,,1,5116,BAO_0000219,1,CHEMBL615179,506.0,
57,,Rattus norvegicus,,F,D,Autocuration,,10116.0,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,104835,,,1,14578,BAO_0000219,7,CHEMBL615180,,
58,,Rattus norvegicus,,F,D,Autocuration,,10116.0,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,104821,,,1,14578,BAO_0000219,7,CHEMBL615181,,
59,,Rattus norvegicus,,F,D,Autocuration,,10116.0,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,104848,,,1,14578,BAO_0000219,7,CHEMBL615182,,
60,,Homo sapiens,,F,N,Expert,,9606.0,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,80002,,,1,4787,BAO_0000219,1,CHEMBL615183,506.0,
61,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,80002,,,1,4787,BAO_0000219,1,CHEMBL615184,506.0,
62,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity against human ovarian cancer (1A9) cell line,80002,,,1,3547,BAO_0000219,1,CHEMBL615185,506.0,
63,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,80002,,,1,3547,BAO_0000219,1,CHEMBL615186,506.0,
64,,Homo sapiens,,F,N,Intermediate,,9606.0,Effective dose of compound against replication of 1A9 cell line was evaluated,80002,,,1,6726,BAO_0000219,1,CHEMBL615187,506.0,
65,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,80002,,,1,3455,BAO_0000219,1,CHEMBL885343,506.0,
66,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),80002,,,1,5726,BAO_0000219,1,CHEMBL615188,506.0,
67,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,80002,,,1,5726,BAO_0000219,1,CHEMBL615189,506.0,
68,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,80002,,,1,5726,BAO_0000219,1,CHEMBL615190,506.0,
69,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory activity against Taxol resistant 1A9 cell lines,80002,,,1,3395,BAO_0000219,1,CHEMBL615191,506.0,
70,,Homo sapiens,,F,N,Expert,,9606.0,Cytotoxicity against human ovarian cancer (1A9) cell lines.,80002,,,1,3415,BAO_0000219,1,CHEMBL615192,506.0,
71,,Homo sapiens,,F,N,Expert,,9606.0,Percentage inhibition of human ovarian cancer (1A9) cell lines.,80002,,,1,3415,BAO_0000219,1,CHEMBL827083,506.0,
72,,Homo sapiens,,F,N,Expert,,9606.0,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,80002,,,1,17099,BAO_0000219,1,CHEMBL615193,506.0,
73,,Homo sapiens,,F,N,Intermediate,,9606.0,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,80002,,,1,17099,BAO_0000219,1,CHEMBL615194,506.0,
74,,Homo sapiens,,F,N,Intermediate,,9606.0,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,80002,,,1,17099,BAO_0000219,1,CHEMBL615195,506.0,
75,,Homo sapiens,,F,N,Intermediate,,9606.0,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,80002,,,1,17099,BAO_0000219,1,CHEMBL615196,506.0,
76,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory concentration against Jurkat cells,81072,,,1,17721,BAO_0000219,1,CHEMBL615197,503.0,
77,,,,F,U,Intermediate,,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,22226,,,1,1229,BAO_0000019,0,CHEMBL615198,,
78,,Rattus norvegicus,,A,D,Expert,,10116.0,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,100121,,,1,11347,BAO_0000357,9,CHEMBL615199,,
79,,,,B,H,Expert,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",11231,,,1,17117,BAO_0000357,8,CHEMBL615200,,
80,,,,B,H,Expert,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",11231,,,1,17117,BAO_0000357,8,CHEMBL615201,,
81,,,,B,H,Expert,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",11231,,,1,17117,BAO_0000357,8,CHEMBL615202,,
82,,Candida albicans,,B,H,Autocuration,,5476.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",11231,,,1,11375,BAO_0000251,8,CHEMBL615203,,
83,,Candida albicans,,B,H,Autocuration,,5476.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",11231,,,1,11375,BAO_0000251,8,CHEMBL615204,,
84,,Saccharomyces cerevisiae,,B,H,Autocuration,,4932.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",11231,,,1,11375,BAO_0000251,8,CHEMBL615205,,
85,,Saccharomyces cerevisiae,,B,H,Autocuration,,4932.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",11231,,,1,11375,BAO_0000251,8,CHEMBL615206,,
86,,Sus scrofa,,B,H,Autocuration,Liver,9823.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",12083,,,1,11375,BAO_0000251,8,CHEMBL615207,,2107.0
87,,Rattus norvegicus,,B,H,Autocuration,,10116.0,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",11231,,,1,791,BAO_0000019,8,CHEMBL827084,,
88,,Rattus norvegicus,,B,H,Autocuration,,10116.0,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",11231,,,1,791,BAO_0000019,8,CHEMBL615208,,
89,,Rattus norvegicus,,B,H,Autocuration,,10116.0,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",11231,,,1,791,BAO_0000019,8,CHEMBL615209,,
90,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",12083,,,1,11375,BAO_0000251,9,CHEMBL615210,,2107.0
91,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",12083,,,1,11375,BAO_0000251,9,CHEMBL615211,,2107.0
92,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",12083,,,1,153,BAO_0000251,9,CHEMBL615212,,2107.0
93,,,,B,H,Expert,,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),11377,,,1,8269,BAO_0000357,8,CHEMBL615213,,
94,,,,B,H,Expert,,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,11377,,,1,8269,BAO_0000357,8,CHEMBL615273,,
95,,Homo sapiens,,F,N,Expert,,9606.0,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,81020,,,1,17653,BAO_0000219,1,CHEMBL615274,726.0,
96,,Homo sapiens,,F,N,Intermediate,,9606.0,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,81020,,,1,14277,BAO_0000219,1,CHEMBL615275,726.0,
97,,Homo sapiens,,F,N,Intermediate,,9606.0,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,81020,,,1,1717,BAO_0000219,1,CHEMBL615276,726.0,
98,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,81020,,,1,14091,BAO_0000219,1,CHEMBL615277,726.0,
99,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,81020,,,1,14091,BAO_0000219,1,CHEMBL615326,726.0,
100,,Hepatitis B virus,,F,N,Expert,,10407.0,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,50606,,,1,17653,BAO_0000218,1,CHEMBL883130,,
101,,Homo sapiens,,F,N,Intermediate,,9606.0,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,81020,,,1,13105,BAO_0000219,1,CHEMBL884519,726.0,
102,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration required to inhibit 50% of 2.2.15 cell line,81020,,,1,1717,BAO_0000219,1,CHEMBL615327,726.0,
103,,Homo sapiens,,A,N,Intermediate,,9606.0,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,81020,,,1,13105,BAO_0000219,1,CHEMBL615328,726.0,
104,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity of compound against uninfected 2.2.15 cells.,50587,,,1,13600,BAO_0000218,1,CHEMBL615329,,
105,,Homo sapiens,,F,N,Intermediate,,9606.0,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,50587,,,1,13467,BAO_0000218,1,CHEMBL615330,,
106,,Hepatitis B virus,,F,N,Expert,,10407.0,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",50606,,,1,17477,BAO_0000218,1,CHEMBL615331,,
107,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro anti-HBV activity in 2.2.15 cells,50587,,,1,1593,BAO_0000218,1,CHEMBL615332,,
108,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro anti-HBV activity in 2.2.15 cells; Not determined,50587,,,1,1593,BAO_0000218,1,CHEMBL615333,,
109,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,50587,,,1,15089,BAO_0000218,1,CHEMBL615334,,
110,,Homo sapiens,,F,N,Intermediate,,9606.0,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,50587,,,1,15089,BAO_0000218,1,CHEMBL615335,,
111,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity in 2.2.15 cells,50587,,,1,1593,BAO_0000218,1,CHEMBL615336,,
112,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity in 2.2.15 cells; Not determined,50587,,,1,1593,BAO_0000218,1,CHEMBL615337,,
113,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,50587,,,1,13600,BAO_0000218,1,CHEMBL615338,,
114,,Homo sapiens,,F,N,Intermediate,,9606.0,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,50587,,,1,13467,BAO_0000218,1,CHEMBL615339,,
115,,Homo sapiens,,F,N,Intermediate,,9606.0,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,50587,,,1,13467,BAO_0000218,1,CHEMBL615340,,
116,,Homo sapiens,,F,N,Intermediate,,9606.0,Antiviral activity against HBV was determined in 2.215 cell line,81020,,,1,14764,BAO_0000219,1,CHEMBL615341,726.0,
117,,Homo sapiens,,B,U,Autocuration,,9606.0,Inhibition of 20-HETE synthesis in human renal microsomes,22226,,,1,6531,BAO_0000251,0,CHEMBL615342,,
118,,,,B,U,Autocuration,,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,22226,,,1,17322,BAO_0000019,0,CHEMBL615343,,
119,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibitory concentration against 2008 (ovarian) cells,80612,,,1,17072,BAO_0000219,1,CHEMBL615344,388.0,
120,,Homo sapiens,,F,N,Intermediate,,9606.0,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,80612,,,1,16936,BAO_0000219,1,CHEMBL615345,388.0,
121,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),80612,,,1,16936,BAO_0000219,1,CHEMBL615346,388.0,
122,,Homo sapiens,,F,N,Intermediate,,9606.0,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,80612,,,1,17146,BAO_0000219,1,CHEMBL615347,388.0,
123,,Homo sapiens,,F,N,Intermediate,,9606.0,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,80612,,,1,17146,BAO_0000219,1,CHEMBL615348,388.0,
124,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibition of 2008/R ovarian cancer cell line,80613,,,1,10797,BAO_0000219,1,CHEMBL827085,561.0,
125,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,80613,,,1,10797,BAO_0000219,1,CHEMBL615349,561.0,
126,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibition of 2008/S ovarian cancer cell line,80614,,,1,10797,BAO_0000219,1,CHEMBL615350,389.0,
127,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,80614,,,1,10797,BAO_0000219,1,CHEMBL615351,389.0,
128,,Homo sapiens,,B,S,Expert,,9606.0,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,100256,,,1,4823,BAO_0000220,2,CHEMBL615352,,
129,,Homo sapiens,,B,S,Intermediate,,9606.0,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,100256,,,1,12912,BAO_0000220,2,CHEMBL615353,,
130,,,,B,S,Expert,,,Inhibition of chymotrypsin-like activity of 20S proteasome,100256,,,1,2957,BAO_0000220,2,CHEMBL615354,,
131,,,,B,S,Expert,,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,100256,,,1,2957,BAO_0000220,2,CHEMBL615355,,
132,,,,B,S,Intermediate,,,Inhibitory activity against 20S proteosome,100256,,,1,3260,BAO_0000220,2,CHEMBL615356,,
133,,Homo sapiens,,B,U,Autocuration,,9606.0,Compound was tested for inhibitory activity against tryptase,22226,,,1,3451,BAO_0000019,0,CHEMBL615357,,
134,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,81020,,,1,13885,BAO_0000219,1,CHEMBL615358,726.0,
135,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,81020,,,1,13885,BAO_0000219,1,CHEMBL827086,726.0,
136,,,,B,U,Autocuration,,,Compound was tested for the inhibition of Alpha-glucosidase,22226,,,1,3676,BAO_0000019,0,CHEMBL615359,,
137,,,,B,H,Autocuration,,,Inhibitory concentration against human neutrophil elastase (HNE),235,,,1,6043,BAO_0000357,8,CHEMBL615360,,
138,,Rattus norvegicus,,F,U,Autocuration,Heart,10116.0,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,22226,,,1,11140,BAO_0000218,0,CHEMBL615361,,948.0
139,,,,F,H,Autocuration,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,19640,,,1,10543,BAO_0000019,8,CHEMBL615362,,
140,,,,F,H,Expert,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,19640,,,1,10543,BAO_0000019,8,CHEMBL615363,,
141,,,,B,H,Autocuration,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,19640,,,1,10543,BAO_0000357,8,CHEMBL615364,,
142,,,,F,H,Expert,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,19640,,,1,10543,BAO_0000019,8,CHEMBL615365,,
143,,Mus musculus,,F,N,Intermediate,,10090.0,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,80360,,,1,11365,BAO_0000219,1,CHEMBL615366,524.0,
144,,Mus musculus,,F,N,Intermediate,,10090.0,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,80360,,,1,11365,BAO_0000219,1,CHEMBL615367,524.0,
145,,Homo sapiens,,F,N,Intermediate,,9606.0,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,80384,,,1,11803,BAO_0000219,1,CHEMBL615368,554.0,
146,,Ovis aries,,F,U,Autocuration,,9940.0,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,22226,,,1,11803,BAO_0000019,0,CHEMBL615369,,
147,,Ovis aries,,F,U,Autocuration,,9940.0,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,22226,,,1,11803,BAO_0000019,0,CHEMBL615370,,
148,,,,B,H,Autocuration,,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),191,,,1,12278,BAO_0000357,8,CHEMBL615673,,
149,,Homo sapiens,,F,U,Autocuration,,9606.0,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,22226,,,1,8249,BAO_0000019,0,CHEMBL615674,,
150,,Homo sapiens,,F,U,Autocuration,,9606.0,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,22226,,,1,8249,BAO_0000019,0,CHEMBL615675,,
151,,Homo sapiens,,F,U,Autocuration,,9606.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,22226,,,1,8249,BAO_0000219,0,CHEMBL615676,635.0,
152,,Homo sapiens,,F,U,Autocuration,,9606.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,22226,,,1,8249,BAO_0000219,0,CHEMBL615677,635.0,
153,,Homo sapiens,,F,U,Autocuration,,9606.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,22226,,,1,8249,BAO_0000219,0,CHEMBL615678,635.0,
154,,Homo sapiens,,F,U,Autocuration,,9606.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,22226,,,1,8249,BAO_0000219,0,CHEMBL615679,635.0,
155,,Homo sapiens,,F,U,Autocuration,,9606.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,22226,,,1,8249,BAO_0000019,0,CHEMBL615680,,
156,,Homo sapiens,,F,U,Autocuration,,9606.0,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,22226,,,1,8249,BAO_0000019,0,CHEMBL615681,,
157,,,,B,H,Autocuration,,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,104290,,,1,16992,BAO_0000249,6,CHEMBL857972,,
158,,Streptococcus pyogenes,,F,N,Intermediate,,1314.0,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,50264,,,1,10543,BAO_0000218,1,CHEMBL857899,,
159,,Human herpesvirus 3,,F,N,Intermediate,,10335.0,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),50527,,,1,17833,BAO_0000218,1,CHEMBL615371,,
160,,vericilla zoster virus,,F,N,Expert,,10335.0,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,50527,,,1,17290,BAO_0000218,1,CHEMBL615372,468.0,
161,,vericilla zoster virus,,F,N,Intermediate,,10335.0,Antiviral activity against 07/1 strain of VZV; ND: No data,50527,,,1,17290,BAO_0000218,1,CHEMBL615373,,
162,,vericilla zoster virus,,F,N,Intermediate,,10335.0,Antiviral activity against 07/1 strain of VZV; ND=No data,50527,,,1,17290,BAO_0000218,1,CHEMBL615374,,
163,,escherichia cloac,,F,N,Intermediate,,561.0,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",50145,,,1,10932,BAO_0000218,1,CHEMBL615375,,
164,,,,B,U,Autocuration,,,Ratio of Ki at A2 to Ki at A1 receptors,22226,,,1,9707,BAO_0000019,0,CHEMBL615376,,
165,,Candida albicans,,B,H,Expert,,5476.0,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",11143,,,1,2346,BAO_0000249,8,CHEMBL615377,,
166,,Candida glabrata CBS 138,,B,H,Expert,,284593.0,"Inhibition of 1,3-beta-glucan synthase",18077,,,1,2205,BAO_0000357,8,CHEMBL615378,,
167,,Homo sapiens,,F,N,Intermediate,,9606.0,Inhibition of growth of 1-87 human tumor cell line,80609,,,1,11900,BAO_0000219,1,CHEMBL615379,832.0,
168,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of 1-lipoxygenase (LOX)in RBL cells,12166,,,1,14864,BAO_0000219,9,CHEMBL615380,,
169,,Glycine max,,B,D,Autocuration,,3847.0,Inhibitory activity against soybean 1-lipoxygenase (SLO),100171,,,1,16474,BAO_0000357,9,CHEMBL615381,,
170,,Glycine max,,B,D,Autocuration,,3847.0,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,100171,,,1,16474,BAO_0000357,9,CHEMBL615382,,
171,,Glycine max,,B,D,Autocuration,,3847.0,% inhibition against soybean 1-lipoxygenase (SLO),100171,,,1,16474,BAO_0000357,9,CHEMBL615383,,
172,,Glycine max,,B,D,Autocuration,,3847.0,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,100171,,,1,16474,BAO_0000357,9,CHEMBL615384,,
173,,Glycine max,,B,D,Autocuration,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,100171,,,1,3094,BAO_0000357,9,CHEMBL615385,,
174,,Glycine max,,B,D,Autocuration,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,100171,,,1,3094,BAO_0000357,9,CHEMBL615386,,
175,,Glycine max,,B,D,Autocuration,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,100171,,,1,3094,BAO_0000357,9,CHEMBL615387,,
176,,Glycine max,,B,D,Autocuration,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,100171,,,1,3094,BAO_0000357,9,CHEMBL615388,,
177,,Glycine max,,B,D,Autocuration,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,100171,,,1,3094,BAO_0000357,9,CHEMBL615214,,
178,,Glycine max,,B,D,Autocuration,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,100171,,,1,3094,BAO_0000357,9,CHEMBL827087,,
179,,Glycine max,,B,D,Autocuration,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,100171,,,1,3094,BAO_0000357,9,CHEMBL615215,,
180,,Glycine max,,B,D,Autocuration,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,100171,,,1,3094,BAO_0000357,9,CHEMBL615216,,
181,,Glycine max,,B,D,Autocuration,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,100171,,,1,3094,BAO_0000357,9,CHEMBL615217,,
182,,Glycine max,,B,D,Autocuration,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,100171,,,1,3094,BAO_0000357,9,CHEMBL615218,,
183,,Glycine max,,B,D,Autocuration,,3847.0,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,100171,,,1,3094,BAO_0000357,9,CHEMBL615219,,
184,,Mus musculus,,B,U,Autocuration,,10090.0,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,22226,,,1,10413,BAO_0000019,0,CHEMBL615220,,
185,,Mus musculus,,F,N,Intermediate,,10090.0,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),80049,,,1,16929,BAO_0000219,1,CHEMBL615221,294.0,
186,,,,F,U,Intermediate,,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,22226,,,1,1229,BAO_0000019,0,CHEMBL615222,,
187,,,,B,H,Autocuration,,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),11489,,,1,16587,BAO_0000357,8,CHEMBL615223,,
188,,,,B,H,Autocuration,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),11862,,,1,16587,BAO_0000357,8,CHEMBL615224,,
189,,,,B,H,Autocuration,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,11862,,,1,16587,BAO_0000357,8,CHEMBL615225,,
190,,,,B,H,Autocuration,,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,11489,,,1,16587,BAO_0000357,8,CHEMBL615226,,
191,,,,B,H,Autocuration,,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,11862,,,1,16587,BAO_0000357,8,CHEMBL615227,,
192,,Bos taurus,,F,D,Expert,,9913.0,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,12347,,,1,8058,BAO_0000019,9,CHEMBL615228,,
193,,Rattus norvegicus,,B,D,Expert,,10116.0,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,100120,,,1,9065,BAO_0000357,9,CHEMBL615229,,
194,,Rattus norvegicus,,B,D,Expert,Adrenal gland,10116.0,Inhibition of 11 beta-hydroxylase from rat adrenal gland,100120,,,1,8865,BAO_0000357,9,CHEMBL615230,,2369.0
195,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of rat adrenal 11-beta-hydroxylase,100120,,,1,9066,BAO_0000357,9,CHEMBL615231,,
196,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of rat adrenal 11-beta-hydroxylase,100120,,,1,8394,BAO_0000357,9,CHEMBL884520,,
197,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,100120,,,1,8394,BAO_0000357,9,CHEMBL615232,,
198,,,,B,H,Autocuration,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,10328,,,1,6431,BAO_0000019,8,CHEMBL615233,,
199,,,,B,H,Autocuration,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,11490,,,1,6431,BAO_0000357,8,CHEMBL827088,,
200,,,,B,H,Autocuration,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,11490,,,1,6431,BAO_0000357,8,CHEMBL615234,,
201,,,,F,H,Autocuration,,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,11134,,,1,9295,BAO_0000019,8,CHEMBL615235,,
202,,,,B,H,Autocuration,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,12052,,,1,10193,BAO_0000019,8,CHEMBL615236,,
203,,,,B,H,Autocuration,,,Compound was tested in vitro for inhibition of 12-LO human platelet,11134,,,1,13622,BAO_0000019,8,CHEMBL615237,,
204,,,,F,H,Autocuration,,,Inhibitory concentration against human platelet 12-lipoxygenase,11134,,,1,12079,BAO_0000019,8,CHEMBL615238,,
205,,,,B,H,Autocuration,,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,11134,,,1,13622,BAO_0000019,8,CHEMBL615239,,
206,,Homo sapiens,,F,D,Autocuration,,9606.0,Inhibitory concentration against human platelet 12-lipoxygenase,11134,,,1,12079,BAO_0000019,9,CHEMBL615240,,
207,,,,B,H,Expert,,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,11835,,,1,13500,BAO_0000019,8,CHEMBL615241,,
208,,,,B,H,Expert,,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,11601,,,1,13723,BAO_0000357,8,CHEMBL615242,,
209,,,,B,H,Autocuration,,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),11134,,,1,16474,BAO_0000019,8,CHEMBL615243,,
210,,,,B,H,Autocuration,,,Inhibitory activity against human platelet 12-lipoxygenase,11134,,,1,1630,BAO_0000019,8,CHEMBL615244,,
211,,,,B,H,Autocuration,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,11134,,,1,167,BAO_0000019,8,CHEMBL615245,,
212,,,,B,H,Autocuration,,,% inhibition against human platelet 12-lipoxygenase (12-HLO),11134,,,1,16474,BAO_0000019,8,CHEMBL615246,,
213,,,,B,H,Autocuration,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,11134,,,1,167,BAO_0000019,8,CHEMBL615247,,
214,,,,B,H,Autocuration,,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,11134,,,1,16474,BAO_0000019,8,CHEMBL615248,,
215,,,,B,H,Autocuration,,,Inhibitory activity towards porcine 12-lipoxygenase,11601,,,1,10091,BAO_0000357,8,CHEMBL615249,,
216,,,,B,H,Autocuration,,,Tested for inhibition against porcine 12-LO,11601,,,1,11966,BAO_0000357,8,CHEMBL615250,,
217,,,,B,H,Autocuration,,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,12052,,,1,951,BAO_0000019,8,CHEMBL615251,,
218,,,,B,H,Autocuration,,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,12052,,,1,10997,BAO_0000019,8,CHEMBL615252,,
219,,,,B,H,Expert,,,In vitro inhibition of rat platelet 12-lipoxygenase,12052,,,1,10193,BAO_0000019,8,CHEMBL828340,,
220,,,,B,H,Autocuration,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,12052,,,1,10193,BAO_0000019,8,CHEMBL615253,,
221,,,,B,H,Autocuration,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,12052,,,1,10193,BAO_0000019,8,CHEMBL615254,,
222,,,,B,H,Autocuration,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,12052,,,1,10193,BAO_0000019,8,CHEMBL615255,,
223,,,,B,H,Autocuration,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,12052,,,1,10193,BAO_0000019,8,CHEMBL615256,,
224,,,,B,H,Autocuration,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,12052,,,1,10193,BAO_0000019,8,CHEMBL615257,,
225,,,,B,H,Autocuration,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,12052,,,1,11087,BAO_0000019,8,CHEMBL615258,,
226,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,80007,,,1,15569,BAO_0000219,1,CHEMBL615259,621.0,
227,,Homo sapiens,,F,N,Expert,,9606.0,In vitro antitumor activity against 41M cell line.,80007,,,1,12989,BAO_0000219,1,CHEMBL615260,621.0,
228,,Homo sapiens,,F,N,Intermediate,,9606.0,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,80007,,,1,16745,BAO_0000219,1,CHEMBL615261,621.0,
229,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,80007,,,1,15569,BAO_0000219,1,CHEMBL615262,621.0,
230,,Homo sapiens,,F,N,Expert,,9606.0,In vitro antitumor activity against 41McisR cell line.,80007,,,1,12989,BAO_0000219,1,CHEMBL615263,621.0,
231,,Homo sapiens,,F,N,Expert,,9606.0,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,80007,,,1,12989,BAO_0000219,1,CHEMBL838393,621.0,
232,,Homo sapiens,,F,N,Intermediate,,9606.0,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,80007,,,1,16745,BAO_0000219,1,CHEMBL615264,621.0,
233,,Homo sapiens,,B,D,Expert,,9606.0,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),84,,,1,6210,BAO_0000357,9,CHEMBL615265,,
234,,Homo sapiens,,B,D,Expert,,9606.0,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),68,,,1,6210,BAO_0000357,9,CHEMBL615266,,
235,,,,B,H,Expert,,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),68,,,1,6226,BAO_0000357,8,CHEMBL615267,,
236,,,,B,H,Expert,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,10201,,,1,17855,BAO_0000357,8,CHEMBL615268,,
237,,,,B,H,Expert,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,10201,,,1,17855,BAO_0000357,8,CHEMBL615269,,
238,,,,B,H,Expert,,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,10201,,,1,17855,BAO_0000357,8,CHEMBL615270,,
239,,,,B,H,Autocuration,,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",12220,,,1,10413,BAO_0000357,8,CHEMBL615271,,
240,,Escherichia coli,,B,H,Autocuration,,562.0,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",11303,,,1,10413,BAO_0000357,8,CHEMBL615272,,
241,,Escherichia coli,,B,H,Autocuration,,562.0,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",11303,,,1,10413,BAO_0000357,8,CHEMBL615103,,
242,,Escherichia coli,,B,H,Autocuration,,562.0,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",11303,,,1,10413,BAO_0000357,8,CHEMBL615104,,
243,,,,B,H,Autocuration,,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",12220,,,1,10413,BAO_0000357,8,CHEMBL615105,,
244,,,,B,H,Autocuration,,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",12220,,,1,10413,BAO_0000357,8,CHEMBL872866,,
245,,Sus scrofa,,B,H,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",11303,,,1,7587,BAO_0000357,8,CHEMBL615106,,
246,,Sus scrofa,,B,H,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",11303,,,1,7587,BAO_0000019,8,CHEMBL615107,,
247,,Sus scrofa,,B,H,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",11303,,,1,7587,BAO_0000357,8,CHEMBL615108,,
248,,Sus scrofa,,B,H,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",11303,,,1,7587,BAO_0000357,8,CHEMBL615109,,
249,,Sus scrofa,,B,H,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",11303,,,1,7587,BAO_0000357,8,CHEMBL615110,,
250,,Sus scrofa,,B,H,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",11303,,,1,7587,BAO_0000019,8,CHEMBL840105,,
251,,Sus scrofa,,B,H,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",11303,,,1,7587,BAO_0000019,8,CHEMBL615111,,
252,,Sus scrofa,,B,H,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",11303,,,1,7587,BAO_0000019,8,CHEMBL615112,,
253,,Sus scrofa,,B,H,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",11303,,,1,7587,BAO_0000019,8,CHEMBL615113,,
254,,Sus scrofa,,B,H,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",11303,,,1,7587,BAO_0000019,8,CHEMBL615114,,
255,,Sus scrofa,,B,H,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",11303,,,1,7587,BAO_0000357,8,CHEMBL615115,,
256,,Sus scrofa,,B,H,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",11303,,,1,7587,BAO_0000019,8,CHEMBL615116,,
257,,,,B,H,Autocuration,,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",11303,,,1,7323,BAO_0000357,8,CHEMBL615698,,
258,,Sus scrofa,,B,U,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",22226,,,1,7587,BAO_0000019,0,CHEMBL615699,,
259,,Sus scrofa,,B,U,Autocuration,,9823.0,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",22226,,,1,7587,BAO_0000019,0,CHEMBL615700,,
260,,Saccharomyces cerevisiae,,B,H,Expert,,4932.0,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,100249,,,1,13750,BAO_0000357,8,CHEMBL615701,,
261,,Rattus norvegicus,,B,U,Autocuration,,10116.0,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,22226,,,1,7662,BAO_0000019,0,CHEMBL615702,,
262,,Rattus norvegicus,,B,U,Autocuration,,10116.0,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,22226,,,1,7662,BAO_0000019,0,CHEMBL615703,,
263,,Rattus norvegicus,,B,U,Autocuration,,10116.0,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",22226,,,1,7662,BAO_0000019,0,CHEMBL615704,,
264,,,,F,H,Autocuration,,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",104698,,,1,12211,BAO_0000019,6,CHEMBL615705,,
265,,,,F,H,Autocuration,,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",104698,,,1,12211,BAO_0000019,6,CHEMBL615706,,
266,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,20033,,,1,12211,BAO_0000221,9,CHEMBL615707,,2116.0
267,,,,F,H,Expert,,,Stimulatory activity of intragastric pressure was tested in the rat,10623,,,1,12211,BAO_0000019,8,CHEMBL615708,,
268,,,,B,H,Autocuration,,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,121,,,1,15453,BAO_0000357,8,CHEMBL615709,,
269,,Rattus norvegicus,,F,U,Autocuration,,10116.0,Dose to reduce neuronal firing against 5-HT cells in rats (iv),22226,,,1,11884,BAO_0000218,0,CHEMBL615710,,
270,,,,F,H,Autocuration,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,12688,,,1,7185,BAO_0000019,8,CHEMBL615711,,
271,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,121,,,1,6876,BAO_0000357,9,CHEMBL615712,,
272,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,121,,,1,6876,BAO_0000357,9,CHEMBL836325,,
273,,,,F,H,Autocuration,,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,12198,,,1,11863,BAO_0000019,8,CHEMBL615713,,
274,,,,B,H,Autocuration,,,Inhibition constant of high-affinity 5-HT uptake,12198,,,1,11863,BAO_0000357,8,CHEMBL615714,,
275,,,,F,H,Autocuration,,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,12198,,,1,11863,BAO_0000019,8,CHEMBL615715,,
276,,,,F,H,Autocuration,,,Maximum rate was determined for high affinity transport of 5-HT,12198,,,1,11863,BAO_0000019,8,CHEMBL615716,,
277,,,,F,H,Autocuration,,,Compound was tested for agonistic activity against 5-HT uptake,104714,,,1,4639,BAO_0000019,4,CHEMBL615717,,
278,,,,B,H,Expert,,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,10577,,,1,15796,BAO_0000019,8,CHEMBL881818,,
279,,Bos taurus,,B,H,Expert,,9913.0,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,105,,,1,15796,BAO_0000357,8,CHEMBL884540,,
280,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,104744,,,1,12801,BAO_0000224,5,CHEMBL615718,,
281,,,,B,H,Autocuration,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,104744,,,1,12801,BAO_0000224,4,CHEMBL615719,,
282,,,,B,H,Autocuration,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,104744,,,1,12120,BAO_0000249,4,CHEMBL615720,,
283,,,,B,H,Autocuration,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,104744,,,1,12120,BAO_0000249,4,CHEMBL615721,,
284,,,,B,H,Autocuration,,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,,,1,11963,BAO_0000019,4,CHEMBL615722,,
285,,,,F,H,Autocuration,,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,51,,,1,11701,BAO_0000019,8,CHEMBL615723,,
286,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,8,CHEMBL615724,,10000000.0
287,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,8,CHEMBL615725,,10000000.0
288,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,8,CHEMBL615726,,10000000.0
289,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),10576,,,1,16394,BAO_0000218,8,CHEMBL615727,,
290,,Cavia porcellus,,F,D,Intermediate,,10141.0,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,105570,,,1,11574,BAO_0000019,9,CHEMBL615728,,
291,,,,B,H,Autocuration,,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,279,,,1,15779,BAO_0000219,8,CHEMBL857971,449.0,
292,,,,B,H,Autocuration,,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,107,,,1,15363,BAO_0000357,8,CHEMBL615729,,
293,,Rattus norvegicus,,F,D,Expert,,10116.0,Efficacy against 5-hydroxytryptamine 2A receptor,12687,,,1,15363,BAO_0000019,9,CHEMBL615730,,
294,,,,F,H,Expert,,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,12687,,,1,15329,BAO_0000019,8,CHEMBL615731,,
295,,,,F,H,Expert,,,Relative potency towards 5-HT2A receptor of rat tail artery,12687,,,1,15329,BAO_0000019,8,CHEMBL615732,,
296,,,,F,H,Expert,,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,12687,,,1,15329,BAO_0000019,8,CHEMBL615733,,
297,,,,F,H,Expert,,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,12687,,,1,15329,BAO_0000019,8,CHEMBL615734,,
298,,,,F,H,Autocuration,,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,12687,,,1,15329,BAO_0000019,8,CHEMBL615735,,
299,,,,F,H,Expert,,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,12687,,,1,15329,BAO_0000019,8,CHEMBL615736,,
300,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,20033,,,1,273,BAO_0000221,9,CHEMBL615737,,2116.0
301,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),20033,,,1,273,BAO_0000221,9,CHEMBL615738,,2116.0
302,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,20033,,,1,273,BAO_0000221,9,CHEMBL615739,,2116.0
303,,,,B,H,Autocuration,,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,10623,,,1,12092,BAO_0000357,8,CHEMBL615278,,
304,,Rattus norvegicus,,F,D,Expert,,10116.0,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,10623,,,1,1317,BAO_0000019,9,CHEMBL615279,,
305,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 4 receptor,168,,,1,12409,BAO_0000357,8,CHEMBL615280,,
306,,Gallus gallus,,B,U,Autocuration,,9031.0,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,22226,,,1,11126,BAO_0000019,0,CHEMBL615281,,
307,,Homo sapiens,,F,U,Autocuration,,9606.0,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,22226,,,1,11126,BAO_0000019,0,CHEMBL615282,,
308,,Homo sapiens,,F,U,Autocuration,,9606.0,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,22226,,,1,11126,BAO_0000019,0,CHEMBL615283,,
309,,Homo sapiens,,B,N,Autocuration,,9606.0,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,80156,,,1,11126,BAO_0000219,1,CHEMBL615284,649.0,
310,,Homo sapiens,,B,U,Autocuration,,9606.0,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,22226,,,1,11126,BAO_0000019,0,CHEMBL615285,,
311,,Homo sapiens,,B,U,Autocuration,,9606.0,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,22226,,,1,11126,BAO_0000019,0,CHEMBL615286,,
312,,Homo sapiens,,B,D,Autocuration,,9606.0,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,104703,,,1,17807,BAO_0000219,7,CHEMBL615287,,
313,,,,F,S,Intermediate,,,Chymotryptic inhibitory activity against 26S proteasome,100256,,,1,16575,BAO_0000220,2,CHEMBL615288,,
314,,,,B,S,Intermediate,,,Inhibitory activity against 26S proteasome degradation of IkB,100256,,,1,15407,BAO_0000220,2,CHEMBL615289,,
315,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibition of 2780/DOX ovarian cancer cell line,81034,,,1,10797,BAO_0000219,1,CHEMBL615290,478.0,
316,,Homo sapiens,,F,N,Intermediate,,9606.0,In vitro inhibition of 2780/S ovarian cancer cell line,81034,,,1,10797,BAO_0000219,1,CHEMBL884522,478.0,
317,,Homo sapiens,,F,U,Autocuration,,9606.0,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,22226,,,1,3469,BAO_0000019,0,CHEMBL615291,,
318,,,,B,M,Intermediate,,,Association constant for binding to AATT 28-mer AATT hairpin,22222,,,1,16037,BAO_0000225,3,CHEMBL615292,,
319,,,,B,M,Intermediate,,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,22222,,,1,16037,BAO_0000225,3,CHEMBL615293,,
320,,,,B,M,Intermediate,,,Reaction Rate Parameter for 28-mer AATT hairpin,22222,,,1,16037,BAO_0000225,3,CHEMBL615294,,
321,,,,B,M,Intermediate,,,Reaction Rate Parameter for 28-mer AATT hairpin,22222,,,1,16037,BAO_0000225,3,CHEMBL615295,,
322,,Homo sapiens,,F,U,Autocuration,,9606.0,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),22226,,,1,16524,BAO_0000019,0,CHEMBL825021,,
323,,Homo sapiens,,F,U,Autocuration,,9606.0,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),22226,,,1,16524,BAO_0000019,0,CHEMBL615296,,
324,,Homo sapiens,,F,U,Autocuration,,9606.0,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,22226,,,1,16524,BAO_0000019,0,CHEMBL615297,,
325,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Cytotoxicity against cell line 2SC/20 determined by MTT test,22226,,,1,16758,BAO_0000019,0,CHEMBL615298,,
326,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,22226,,,1,16758,BAO_0000019,0,CHEMBL615299,,
327,,Cricetulus griseus,,F,U,Autocuration,,10029.0,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,22226,,,1,16758,BAO_0000019,0,CHEMBL615300,,
328,,,,B,H,Autocuration,,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,241,,,1,14360,BAO_0000357,8,CHEMBL615301,,
329,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,241,,,1,14360,BAO_0000357,9,CHEMBL615302,,
330,,Rattus norvegicus,,B,U,Autocuration,,10116.0,Selectivity ratio of ID50 in liver and heart,22226,,,1,9964,BAO_0000019,0,CHEMBL615303,,
331,,,,B,H,Autocuration,,,"Selectivity, ratio of relative ID50 in liver and heart",12132,,,1,9964,BAO_0000019,8,CHEMBL615304,,
332,,,,B,H,Autocuration,,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,12132,,,1,9964,BAO_0000019,8,CHEMBL615305,,
333,,,,B,H,Autocuration,,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,,,1,9964,BAO_0000218,8,CHEMBL615306,,
334,,,,B,H,Autocuration,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,,,1,9964,BAO_0000218,8,CHEMBL615307,,
335,In vivo,,,B,H,Autocuration,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,,,1,9964,BAO_0000218,8,CHEMBL615308,,
336,In vivo,,,F,H,Autocuration,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,,,1,9964,BAO_0000218,8,CHEMBL615309,,
337,,,,B,U,Autocuration,,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",22226,,,1,9964,BAO_0000019,0,CHEMBL615310,,
338,,,,B,H,Autocuration,,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,12132,,,1,9964,BAO_0000019,8,CHEMBL615311,,
339,,Homo sapiens,,B,U,Autocuration,,9606.0,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",22226,,,1,9964,BAO_0000019,0,CHEMBL615312,,
340,,,,B,H,Autocuration,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,12132,,,1,9964,BAO_0000019,8,CHEMBL615313,,
341,,,,F,H,Autocuration,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,12132,,,1,9964,BAO_0000019,8,CHEMBL615314,,
342,,,,B,H,Autocuration,,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",12132,,,1,9964,BAO_0000019,8,CHEMBL615315,,
343,,Rattus norvegicus,,B,U,Autocuration,,10116.0,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",22226,,,1,9964,BAO_0000218,0,CHEMBL615316,,
344,In vivo,,,B,H,Autocuration,,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,12132,,,1,9964,BAO_0000218,8,CHEMBL615317,,
345,,,,B,H,Autocuration,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",12132,,,1,9964,BAO_0000218,8,CHEMBL615318,,
346,,Rattus norvegicus,,B,U,Autocuration,,10116.0,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",22226,,,1,9964,BAO_0000218,0,CHEMBL615319,,
347,,,,B,H,Autocuration,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",12132,,,1,9964,BAO_0000019,8,CHEMBL615320,,
348,,,,F,H,Autocuration,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",12132,,,1,9964,BAO_0000019,8,CHEMBL615321,,
349,,Rattus norvegicus,,B,U,Autocuration,,10116.0,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",22226,,,1,3796,BAO_0000019,0,CHEMBL615322,,
350,,Escherichia coli,,B,H,Autocuration,,562.0,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,19690,,,1,4251,BAO_0000357,8,CHEMBL615323,,
351,,Escherichia coli,,B,H,Autocuration,,562.0,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,19690,,,1,4251,BAO_0000357,8,CHEMBL615407,,
352,,Escherichia coli,,B,H,Autocuration,,562.0,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,19690,,,1,4251,BAO_0000357,8,CHEMBL857267,,
353,,Escherichia coli,,B,H,Autocuration,,562.0,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,19690,,,1,4251,BAO_0000357,8,CHEMBL615408,,
354,,,,B,H,Autocuration,,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,19690,,,1,166,BAO_0000357,8,CHEMBL615409,,
355,,,,B,H,Autocuration,,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,19690,,,1,17861,BAO_0000357,8,CHEMBL615410,,
356,,,,B,H,Autocuration,,,Inhibition constant against 3-dehydroquinate synthase,19690,,,1,166,BAO_0000357,8,CHEMBL615411,,
357,,,,B,H,Autocuration,,,Association rate constant against 3-dehydroquinate synthase,19690,,,1,166,BAO_0000357,8,CHEMBL615412,,
358,,,,B,H,Autocuration,,,Rate constant against 3-dehydroquinate synthase,19690,,,1,166,BAO_0000357,8,CHEMBL615413,,
359,,,,B,U,Autocuration,,,Inhibitory activity against fuc-TVII,22226,,,1,3548,BAO_0000019,0,CHEMBL615414,,
360,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,,,1,9877,BAO_0000251,9,CHEMBL615415,,2107.0
361,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,,,1,9877,BAO_0000251,9,CHEMBL615416,,2107.0
362,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,,,1,9877,BAO_0000251,9,CHEMBL615417,,2107.0
363,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,,,1,9877,BAO_0000251,9,CHEMBL615418,,2107.0
364,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,12236,,,1,9877,BAO_0000251,9,CHEMBL615419,,2107.0
365,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,12236,,,1,9877,BAO_0000251,9,CHEMBL615420,,2107.0
366,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,12236,,,1,9877,BAO_0000251,9,CHEMBL615421,,2107.0
367,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,12236,,,1,9877,BAO_0000251,9,CHEMBL615422,,2107.0
368,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,12236,,,1,9877,BAO_0000251,9,CHEMBL615423,,2107.0
369,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,12236,,,1,9877,BAO_0000251,9,CHEMBL872868,,2107.0
370,,Rattus norvegicus,,B,D,Autocuration,Liver,10116.0,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,12236,,,1,9877,BAO_0000251,9,CHEMBL615424,,2107.0
371,,,,B,H,Autocuration,,,Inhibitory activity against 3-phosphoglycerate kinase.,104832,,,1,3003,BAO_0000224,4,CHEMBL825022,,
372,,,,B,H,Autocuration,,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,104832,,,1,3003,BAO_0000224,4,CHEMBL615425,,
373,,,,B,H,Autocuration,,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",104832,,,1,3003,BAO_0000224,4,CHEMBL615426,,
374,,Homo sapiens,,B,D,Expert,,9606.0,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,10612,,,1,17185,BAO_0000357,9,CHEMBL615427,,
375,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity on 3677 melanoma cells,80616,,,1,6072,BAO_0000219,1,CHEMBL615428,844.0,
376,,Homo sapiens,,F,N,Intermediate,,9606.0,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,80616,,,1,6072,BAO_0000219,1,CHEMBL615429,844.0,
377,,Mus musculus,,F,N,Intermediate,,10090.0,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,80617,,,1,5018,BAO_0000219,1,CHEMBL615430,700.0,
378,,Homo sapiens,,F,U,Intermediate,,9606.0,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,22226,,,1,2852,BAO_0000019,0,CHEMBL615431,,
379,,,,F,U,Autocuration,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,22226,,,1,8663,BAO_0000218,0,CHEMBL615432,798.0,
380,,,,F,U,Autocuration,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,22226,,,1,8663,BAO_0000218,0,CHEMBL615433,798.0,
381,,Human rhinovirus 14,,F,D,Expert,,12131.0,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,12464,,,1,3245,BAO_0000019,9,CHEMBL615434,,
382,,Human rhinovirus sp.,,F,N,Intermediate,,169066.0,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,50085,,,1,3245,BAO_0000218,1,CHEMBL615435,,
383,,human rhinovirus type 14,,F,N,Intermediate,,169066.0,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,50679,,,1,3877,BAO_0000218,1,CHEMBL615436,,
384,,human rhinovirus type 14,,F,N,Intermediate,,169066.0,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,50679,,,1,3877,BAO_0000218,1,CHEMBL615437,,
385,,Human rhinovirus 14,,F,D,Expert,,12131.0,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12464,,,1,5861,BAO_0000019,9,CHEMBL615438,,
386,,Human rhinovirus 14,,F,D,Expert,,12131.0,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12464,,,1,5861,BAO_0000019,9,CHEMBL615439,,
387,,Human rhinovirus 14,,F,D,Expert,,12131.0,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,12464,,,1,5861,BAO_0000019,9,CHEMBL615440,,
388,,Human rhinovirus 14,,F,D,Expert,,12131.0,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,12464,,,1,5861,BAO_0000019,9,CHEMBL615441,,
389,,Enterovirus,,F,N,Intermediate,,12059.0,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,50665,,,1,13748,BAO_0000218,1,CHEMBL615641,,
390,,Enterovirus,,F,N,Intermediate,,12059.0,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,50665,,,1,13748,BAO_0000218,1,CHEMBL872065,,
391,,Enterovirus,,F,N,Intermediate,,12059.0,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,50665,,,1,13748,BAO_0000218,1,CHEMBL825023,,
392,,Enterovirus,,F,N,Intermediate,,12059.0,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,50665,,,1,13748,BAO_0000218,1,CHEMBL615642,,
393,,Human rhinovirus B,,B,H,Expert,,147712.0,Inhibition of human rhinovirus 3C protease,12464,,,1,13748,BAO_0000357,8,CHEMBL615643,,
394,,Homo sapiens,,B,U,Autocuration,,9606.0,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,22226,,,1,17699,BAO_0000019,0,CHEMBL615644,,
395,,Mus musculus,,F,N,Intermediate,,10090.0,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),80619,,,1,7145,BAO_0000218,1,CHEMBL615645,833.0,
396,,Mus musculus,,F,N,Intermediate,,10090.0,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),80619,,,1,7145,BAO_0000218,1,CHEMBL615646,833.0,
397,,Mus musculus,,F,N,Intermediate,,10090.0,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),80619,,,1,7145,BAO_0000218,1,CHEMBL615647,833.0,
398,,Mus musculus,,F,N,Intermediate,,10090.0,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),80619,,,1,7145,BAO_0000218,1,CHEMBL615648,833.0,
399,,Mus musculus,,F,N,Intermediate,,10090.0,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,80619,,,1,7145,BAO_0000218,1,CHEMBL615649,833.0,
400,,Mus musculus,,F,N,Intermediate,,10090.0,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,80619,,,1,7145,BAO_0000218,1,CHEMBL615650,833.0,
401,,Mus musculus,,F,N,Intermediate,,10090.0,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,80620,,,1,5325,BAO_0000218,1,CHEMBL615651,847.0,
402,,Mus musculus,,F,N,Intermediate,,10090.0,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,80620,,,1,5325,BAO_0000218,1,CHEMBL615652,847.0,
403,,Mus musculus,,F,N,Expert,,10090.0,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,80620,,,1,5325,BAO_0000218,1,CHEMBL615653,847.0,
404,,Mus musculus,,F,N,Intermediate,,10090.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,80620,,,1,16169,BAO_0000219,1,CHEMBL615654,847.0,
405,,Mus musculus,,F,N,Intermediate,,10090.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,80620,,,1,16169,BAO_0000219,1,CHEMBL615655,847.0,
406,,Mus musculus,,F,N,Intermediate,,10090.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,80620,,,1,16169,BAO_0000219,1,CHEMBL825024,847.0,
407,,Mus musculus,,F,N,Intermediate,,10090.0,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,80620,,,1,16169,BAO_0000219,1,CHEMBL615656,847.0,
408,,Mus musculus,,F,N,Intermediate,,10090.0,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,80620,,,1,16169,BAO_0000219,1,CHEMBL615657,847.0,
409,,Mus musculus,,F,N,Intermediate,,10090.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,80620,,,1,16169,BAO_0000219,1,CHEMBL615658,847.0,
410,,Mus musculus,,F,N,Intermediate,,10090.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,80620,,,1,16169,BAO_0000219,1,CHEMBL615659,847.0,
411,,Mus musculus,,F,N,Intermediate,,10090.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,80620,,,1,16169,BAO_0000219,1,CHEMBL615660,847.0,
412,,Mus musculus,,F,N,Intermediate,,10090.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,80620,,,1,16169,BAO_0000219,1,CHEMBL615661,847.0,
413,,Mus musculus,,F,N,Intermediate,,10090.0,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,80620,,,1,16169,BAO_0000219,1,CHEMBL615662,847.0,
414,,Mus musculus,,F,N,Intermediate,,10090.0,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,80620,,,1,16169,BAO_0000219,1,CHEMBL615663,847.0,
415,,Mus musculus,,F,N,Intermediate,,10090.0,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,80620,,,1,16169,BAO_0000219,1,CHEMBL615664,847.0,
416,,Mus musculus,,F,N,Intermediate,,10090.0,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,80620,,,1,16169,BAO_0000219,1,CHEMBL615665,847.0,
417,,Mus musculus,,F,N,Intermediate,,10090.0,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,80620,,,1,16169,BAO_0000219,1,CHEMBL615666,847.0,
418,,Mus musculus,,F,N,Intermediate,,10090.0,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,80620,,,1,16169,BAO_0000219,1,CHEMBL615667,847.0,
419,,Mus musculus,,F,N,Intermediate,,10090.0,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,80620,,,1,16169,BAO_0000219,1,CHEMBL615668,847.0,
420,,Mus musculus,,F,N,Intermediate,,10090.0,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,80620,,,1,16169,BAO_0000219,1,CHEMBL615669,847.0,
421,,Mus musculus,,F,N,Intermediate,,10090.0,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,80620,,,1,16169,BAO_0000219,1,CHEMBL615670,847.0,
422,,Mus musculus,,F,N,Intermediate,,10090.0,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,80620,,,1,16169,BAO_0000219,1,CHEMBL836739,847.0,
423,,Mus musculus,,F,N,Intermediate,,10090.0,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,80620,,,1,16169,BAO_0000219,1,CHEMBL615671,847.0,
424,,Mus musculus,,F,N,Intermediate,,10090.0,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,80620,,,1,16169,BAO_0000219,1,CHEMBL615672,847.0,
425,,Mus musculus,,F,N,Intermediate,,10090.0,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,80620,,,1,16169,BAO_0000219,1,CHEMBL615791,847.0,
426,,Mus musculus,,F,N,Intermediate,,10090.0,spermine levels in 3LL cells after the treatment of 1 uM of Compound,80620,,,1,16169,BAO_0000219,1,CHEMBL615792,847.0,
427,,Mus musculus,,F,N,Intermediate,,10090.0,spermine levels in 3LL cells after the treatment of 10 uM of Compound,80620,,,1,16169,BAO_0000219,1,CHEMBL615793,847.0,
428,,Mus musculus,,F,N,Intermediate,,10090.0,spermine levels in 3LL cells after the treatment of 250 uM of Compound,80620,,,1,16169,BAO_0000219,1,CHEMBL615794,847.0,
429,,Mus musculus,,F,N,Intermediate,,10090.0,spermine levels in 3LL cells after the treatment of 50 uM of Compound,80620,,,1,16169,BAO_0000219,1,CHEMBL615795,847.0,
430,,Homo sapiens,,F,N,Intermediate,,9606.0,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,80621,,,1,15547,BAO_0000219,1,CHEMBL615590,971.0,
431,,,,F,U,Autocuration,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,22226,,,1,8663,BAO_0000218,0,CHEMBL615591,,
432,,,,F,U,Autocuration,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,22226,,,1,8663,BAO_0000218,0,CHEMBL615592,,
433,,,,F,U,Autocuration,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,22226,,,1,8663,BAO_0000218,0,CHEMBL615593,,
434,,,,F,U,Autocuration,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,22226,,,1,8663,BAO_0000218,0,CHEMBL615594,,
435,,Mus musculus,,F,N,Intermediate,,10090.0,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,80951,,,1,4504,BAO_0000219,1,CHEMBL615595,723.0,
436,,Mus musculus,,F,N,Intermediate,,10090.0,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,80951,,,1,4504,BAO_0000219,1,CHEMBL615596,723.0,
437,,,,F,H,Expert,,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,11169,,,1,12695,BAO_0000219,8,CHEMBL615597,723.0,
438,,Mus musculus,,F,N,Intermediate,,10090.0,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,80951,,,1,12695,BAO_0000219,1,CHEMBL615598,723.0,
439,,Mus musculus,,F,N,Intermediate,,10090.0,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,80951,,,1,12695,BAO_0000219,1,CHEMBL615599,723.0,
440,,Mus musculus,,F,N,Expert,,10090.0,Effective dose against murine 3T3 fibroblasts cells,80951,,,1,17642,BAO_0000219,1,CHEMBL615600,723.0,
441,,Mus musculus,,F,N,Expert,,10090.0,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,80951,,,1,17642,BAO_0000219,1,CHEMBL615601,723.0,
442,,Mus musculus,,F,N,Expert,,10090.0,Cytotoxic effect on 3T3 cells,80951,,,1,12340,BAO_0000219,1,CHEMBL615602,723.0,
443,,Mus musculus,,F,N,Expert,,10090.0,Cytotoxic effect on 3T3 cells,80951,,,1,12340,BAO_0000219,1,CHEMBL615603,723.0,
444,,Mus musculus,,F,N,Intermediate,,10090.0,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,80951,,,1,12716,BAO_0000219,1,CHEMBL615604,723.0,
445,,Mus musculus,,F,N,Intermediate,,10090.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,80951,,,1,6277,BAO_0000219,1,CHEMBL615605,723.0,
446,,Mus musculus,,F,N,Intermediate,,10090.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,80951,,,1,6277,BAO_0000219,1,CHEMBL615606,723.0,
447,,Mus musculus,,F,N,Expert,,10090.0,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,80951,,,1,6277,BAO_0000219,1,CHEMBL884526,723.0,
448,,Mus musculus,,F,N,Expert,,10090.0,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,80951,,,1,6277,BAO_0000219,1,CHEMBL615607,723.0,
449,,Mus musculus,,F,N,Intermediate,,10090.0,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,80951,,,1,6277,BAO_0000219,1,CHEMBL615608,723.0,
450,,Mus musculus,,F,N,Expert,,10090.0,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,80951,,,1,6277,BAO_0000219,1,CHEMBL615609,723.0,
451,,Mus musculus,,F,N,Expert,,10090.0,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,80951,,,1,6277,BAO_0000219,1,CHEMBL615682,723.0,
452,,Mus musculus,,F,N,Intermediate,,10090.0,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,80951,,,1,6277,BAO_0000219,1,CHEMBL615683,723.0,
453,,Mus musculus,,F,N,Expert,,10090.0,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,80951,,,1,17780,BAO_0000218,1,CHEMBL615684,723.0,
454,,Mus musculus,,F,D,Autocuration,,10090.0,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,104860,,,1,12751,BAO_0000219,7,CHEMBL615685,,
455,,Mus musculus,,F,N,Expert,,10090.0,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,80951,,,1,12380,BAO_0000219,1,CHEMBL615686,723.0,
456,,Mus musculus,,F,N,Intermediate,,10090.0,Inhibitory activity against 3T3 cell line,80951,,,1,14892,BAO_0000219,1,CHEMBL615687,723.0,
457,,Mus musculus,,F,N,Intermediate,,10090.0,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,80951,,,1,12695,BAO_0000219,1,CHEMBL884523,723.0,
458,,,,F,H,Expert,,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,11169,,,1,12695,BAO_0000019,8,CHEMBL615688,,
459,,Mus musculus,,F,N,Intermediate,,10090.0,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,80951,,,1,12695,BAO_0000219,1,CHEMBL615689,723.0,
460,,Mus musculus,,F,N,Intermediate,,10090.0,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,80951,,,1,12695,BAO_0000219,1,CHEMBL615690,723.0,
461,,,,F,H,Expert,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,11169,,,1,12695,BAO_0000019,8,CHEMBL615691,,
462,,,,F,H,Expert,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,11169,,,1,12695,BAO_0000019,8,CHEMBL615692,,
463,,Mus musculus,,F,N,Intermediate,,10090.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,80951,,,1,6277,BAO_0000219,1,CHEMBL615693,723.0,
464,,Mus musculus,,F,N,Expert,,10090.0,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,80951,,,1,6277,BAO_0000219,1,CHEMBL615324,723.0,
465,,Homo sapiens,,F,D,Expert,,9606.0,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,9,,,1,4959,BAO_0000219,9,CHEMBL615325,723.0,
466,,Homo sapiens,,F,D,Expert,,9606.0,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),9,,,1,4959,BAO_0000219,9,CHEMBL615490,723.0,
467,,Homo sapiens,,F,D,Expert,,9606.0,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,188,,,1,4959,BAO_0000219,9,CHEMBL615491,723.0,
468,,Homo sapiens,,F,D,Expert,,9606.0,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),188,,,1,4959,BAO_0000219,9,CHEMBL615492,723.0,
469,,Mus musculus,,F,N,Intermediate,,10090.0,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,80951,,,1,12082,BAO_0000219,1,CHEMBL615493,723.0,
470,,Mus musculus,,F,N,Intermediate,,10090.0,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,80951,,,1,12082,BAO_0000219,1,CHEMBL615494,723.0,
471,,Mus musculus,,F,N,Intermediate,,10090.0,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,80951,,,1,12082,BAO_0000219,1,CHEMBL615495,723.0,
472,,Mus musculus,,F,N,Intermediate,,10090.0,Inhibitory concentration was calculated on 3T3 cells by using growth assay,80951,,,1,12082,BAO_0000219,1,CHEMBL615496,723.0,
473,,Mus musculus,,F,N,Intermediate,,10090.0,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,80951,,,1,2643,BAO_0000219,1,CHEMBL615497,723.0,
474,,Mus musculus,,F,N,Expert,,10090.0,Inhibition of Swiss 3T3 mouse fibroblast proliferation,80951,,,1,11926,BAO_0000219,1,CHEMBL615498,723.0,
475,,Mus musculus,,A,N,Intermediate,,10090.0,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,80951,,,1,15204,BAO_0000219,1,CHEMBL615499,723.0,
476,,Mus musculus,,F,N,Expert,,10090.0,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,80951,,,1,15992,BAO_0000219,1,CHEMBL835522,723.0,
477,,Mus musculus,,F,N,Intermediate,,10090.0,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,80951,,,1,16279,BAO_0000219,1,CHEMBL615500,723.0,
478,,Mus musculus,,F,N,Intermediate,,10090.0,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,,,1,16279,BAO_0000219,1,CHEMBL615501,723.0,
479,,Mus musculus,,F,N,Intermediate,,10090.0,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,,,1,16279,BAO_0000219,1,CHEMBL615502,723.0,
480,,Mus musculus,,F,N,Intermediate,,10090.0,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,,,1,16279,BAO_0000219,1,CHEMBL615503,723.0,
481,,Mus musculus,,F,N,Intermediate,,10090.0,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,,,1,16279,BAO_0000219,1,CHEMBL615504,723.0,
482,,Mus musculus,,F,N,Intermediate,,10090.0,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),80951,,,1,16279,BAO_0000219,1,CHEMBL615505,723.0,
483,,Mus musculus,,F,N,Expert,,10090.0,Inhibition of swiss 3T3 mouse fibroblast proliferation,80951,,,1,12831,BAO_0000219,1,CHEMBL615506,723.0,
484,,Mus musculus,,F,N,Intermediate,,10090.0,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,80951,,,1,13497,BAO_0000219,1,CHEMBL615507,723.0,
485,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,80006,,,1,13715,BAO_0000218,1,CHEMBL615508,620.0,
486,,Mus musculus,,F,N,Intermediate,,10090.0,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,80006,,,1,13618,BAO_0000219,1,CHEMBL615509,620.0,
487,,Mus musculus,,F,N,Intermediate,,10090.0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,80006,,,1,11902,BAO_0000219,1,CHEMBL615510,620.0,
488,,Mus musculus,,F,N,Intermediate,,10090.0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,80006,,,1,11902,BAO_0000219,1,CHEMBL615511,620.0,
489,,Mus musculus,,F,N,Intermediate,,10090.0,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,80006,,,1,11902,BAO_0000219,1,CHEMBL615512,620.0,
490,,Mus musculus,,F,N,Intermediate,,10090.0,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",80006,,,1,14840,BAO_0000218,1,CHEMBL615513,620.0,
491,,Mus musculus,,F,N,Intermediate,,10090.0,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",80006,,,1,14840,BAO_0000218,1,CHEMBL615514,620.0,
492,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,80006,,,1,13715,BAO_0000219,1,CHEMBL615515,620.0,
493,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,80006,,,1,13715,BAO_0000219,1,CHEMBL615516,620.0,
494,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,80006,,,1,13715,BAO_0000219,1,CHEMBL615517,620.0,
495,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,80006,,,1,13715,BAO_0000219,1,CHEMBL615518,620.0,
496,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,80006,,,1,13715,BAO_0000219,1,CHEMBL615519,620.0,
497,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,80006,,,1,13715,BAO_0000218,1,CHEMBL615520,620.0,
498,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,80006,,,1,13715,BAO_0000218,1,CHEMBL615521,620.0,
499,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,80006,,,1,13715,BAO_0000218,1,CHEMBL615522,620.0,
500,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,80006,,,1,13715,BAO_0000218,1,CHEMBL615523,620.0,
501,,,,F,N,Expert,,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,80006,,,1,13715,BAO_0000218,1,CHEMBL615524,620.0,
502,,,,F,N,Expert,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,80006,,,1,13715,BAO_0000218,1,CHEMBL615525,620.0,
503,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,80006,,,1,13715,BAO_0000218,1,CHEMBL615526,620.0,
504,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,80006,,,1,13715,BAO_0000218,1,CHEMBL615527,620.0,
505,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,80006,,,1,13715,BAO_0000218,1,CHEMBL615528,620.0,
506,,,,F,N,Expert,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,80006,,,1,13715,BAO_0000218,1,CHEMBL615529,620.0,
507,,,,F,N,Expert,,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,80006,,,1,13715,BAO_0000218,1,CHEMBL615530,620.0,
508,,,,F,N,Expert,,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,80006,,,1,13715,BAO_0000218,1,CHEMBL615531,620.0,
509,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,80006,,,1,13715,BAO_0000219,1,CHEMBL615532,620.0,
510,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,80006,,,1,13715,BAO_0000219,1,CHEMBL615533,620.0,
511,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,80006,,,1,13715,BAO_0000219,1,CHEMBL615534,620.0,
512,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,80006,,,1,13715,BAO_0000218,1,CHEMBL615535,620.0,
513,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,80006,,,1,13715,BAO_0000218,1,CHEMBL615536,620.0,
514,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,80006,,,1,13715,BAO_0000218,1,CHEMBL615537,620.0,
515,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,80006,,,1,13715,BAO_0000218,1,CHEMBL615538,620.0,
516,,,,F,N,Intermediate,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,80006,,,1,13715,BAO_0000218,1,CHEMBL836166,620.0,
517,,,,F,H,Expert,,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,11214,,,1,6411,BAO_0000219,8,CHEMBL615539,620.0,
518,,Mus musculus,,F,N,Intermediate,,10090.0,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,80006,,,1,6411,BAO_0000219,1,CHEMBL615540,620.0,
519,,,,F,H,Expert,,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,11214,,,1,6411,BAO_0000219,8,CHEMBL615541,620.0,
520,,Mus musculus,,F,N,Expert,,10090.0,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,80006,,,1,3966,BAO_0000219,1,CHEMBL615542,620.0,
521,,Mus musculus,,F,N,Intermediate,,10090.0,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,80006,,,1,3966,BAO_0000219,1,CHEMBL615543,620.0,
522,,Mus musculus,,F,N,Expert,,10090.0,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,80006,,,1,15556,BAO_0000219,1,CHEMBL615544,620.0,
523,,Mus musculus,,F,N,Expert,,10090.0,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,80006,,,1,5845,BAO_0000219,1,CHEMBL615545,620.0,
524,,Mus musculus,,F,N,Expert,,10090.0,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,80006,,,1,14422,BAO_0000219,1,CHEMBL615546,620.0,
525,,Mus musculus,,F,N,Expert,,10090.0,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,80006,,,1,5845,BAO_0000219,1,CHEMBL615547,620.0,
526,,Mus musculus,,F,N,Expert,,10090.0,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,80006,,,1,14508,BAO_0000219,1,CHEMBL615548,620.0,
527,,Mus musculus,,F,N,Expert,,10090.0,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,80006,,,1,14508,BAO_0000219,1,CHEMBL615549,620.0,
528,,Mus musculus,,F,N,Expert,,10090.0,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,80006,,,1,14508,BAO_0000219,1,CHEMBL615550,620.0,
529,,Rattus norvegicus,,F,N,Intermediate,,10116.0,Inhibitory activity against rat fibroblast (3Y1) cell line,80622,,,1,6349,BAO_0000219,1,CHEMBL615551,1118.0,
530,,Rattus norvegicus,,F,N,Expert,,10116.0,Mean concentration causing inhibition of cell growth in 3Y1 cells.,80622,,,1,15899,BAO_0000219,1,CHEMBL615552,1118.0,
531,,Rattus norvegicus,,F,N,Expert,,10116.0,Cytotoxicity in 3Y1 cells.,80622,,,1,15899,BAO_0000219,1,CHEMBL615553,1118.0,
532,,Rattus norvegicus,,F,N,Expert,,10116.0,Cytostatic effect in 3Y1 cells.,80622,,,1,15899,BAO_0000219,1,CHEMBL615554,1118.0,
533,,Rattus norvegicus,,F,N,Intermediate,,10116.0,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",80622,,,1,15899,BAO_0000219,1,CHEMBL615555,1118.0,
534,,Rattus norvegicus,,F,N,Expert,,10116.0,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,80622,,,1,17038,BAO_0000219,1,CHEMBL615556,1118.0,
535,,,,B,U,Autocuration,,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,22226,,,1,12421,BAO_0000019,0,CHEMBL615557,,
536,,,,B,U,Autocuration,,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,22226,,,1,12947,BAO_0000019,0,CHEMBL615558,,
537,,,,B,U,Autocuration,,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,22226,,,1,12947,BAO_0000019,0,CHEMBL872066,,
538,,Sus scrofa,,B,D,Expert,,9823.0,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,11607,,,1,4896,BAO_0000019,9,CHEMBL615559,,
539,,,,B,H,Autocuration,,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,11607,,,1,6148,BAO_0000019,8,CHEMBL615560,,
540,,,,B,H,Autocuration,,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,11607,,,1,16432,BAO_0000019,8,CHEMBL615561,,
541,,,,B,H,Expert,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,11607,,,1,4978,BAO_0000019,8,CHEMBL857062,,
542,,,,B,H,Expert,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),11607,,,1,4978,BAO_0000019,8,CHEMBL615562,,
543,,,,B,H,Autocuration,,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,11607,,,1,3723,BAO_0000019,8,CHEMBL615563,,
544,,,,B,H,Autocuration,,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),11607,,,1,3518,BAO_0000357,8,CHEMBL615564,,
545,,,,B,H,Autocuration,,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,11607,,,1,4164,BAO_0000019,8,CHEMBL615565,,
546,,,,B,H,Autocuration,,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,11607,,,1,3518,BAO_0000019,8,CHEMBL615566,,
547,,Sus scrofa,,B,D,Expert,,9823.0,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,11607,,,1,4164,BAO_0000019,9,CHEMBL615567,,
548,,,,B,H,Autocuration,,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,11607,,,1,3518,BAO_0000019,8,CHEMBL615568,,
549,,,,B,H,Autocuration,,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),11607,,,1,3518,BAO_0000357,8,CHEMBL615569,,
550,,,,B,H,Autocuration,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,11607,,,1,4978,BAO_0000019,8,CHEMBL615570,,
551,,,,B,H,Autocuration,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),11607,,,1,4978,BAO_0000019,8,CHEMBL615571,,
552,,,,B,H,Autocuration,,,Binding affinity against melatonin (MT1) receptor (pC1),104733,,,1,6455,BAO_0000224,4,CHEMBL615572,,
553,,,,B,U,Autocuration,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,22226,,,1,2222,BAO_0000019,0,CHEMBL615573,,
554,,,,B,U,Autocuration,,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,22226,,,1,13020,BAO_0000019,0,CHEMBL615574,,
555,,,,B,U,Autocuration,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,22226,,,1,13021,BAO_0000019,0,CHEMBL615575,,
556,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,10619,,,1,14532,BAO_0000357,8,CHEMBL615576,,
557,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,10619,,,1,14118,BAO_0000357,8,CHEMBL615577,,
558,,,,B,H,Autocuration,Hippocampus,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,51,,,1,11884,BAO_0000221,8,CHEMBL615578,,10000000.0
559,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,51,,,1,13969,BAO_0000357,8,CHEMBL615579,,
560,,,,B,H,Expert,,,Binding affinity for 5-hydroxytryptamine 1A receptor,51,,,1,13392,BAO_0000357,8,CHEMBL615580,,
561,,,,B,H,Expert,,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,51,,,1,14430,BAO_0000019,8,CHEMBL615581,,
562,,,,B,H,Autocuration,Hippocampus,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,,1,12248,BAO_0000221,8,CHEMBL615582,,10000000.0
563,,,,B,H,Autocuration,Hippocampus,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,,1,12249,BAO_0000221,8,CHEMBL615583,,10000000.0
564,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,8,CHEMBL615584,,10000000.0
565,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,8,CHEMBL833691,,10000000.0
566,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,8,CHEMBL615585,,10000000.0
567,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,8,CHEMBL615586,,10000000.0
568,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,8,CHEMBL884524,,10000000.0
569,,,,B,H,Autocuration,Hippocampus,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,,1,12249,BAO_0000221,8,CHEMBL615587,,10000000.0
570,,,,B,H,Autocuration,Hippocampus,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",51,,,1,11799,BAO_0000221,8,CHEMBL615588,,10000000.0
571,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,10576,,,1,14331,BAO_0000249,9,CHEMBL615589,,
572,,Bos taurus,,B,H,Expert,Hippocampus,9913.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,51,,,1,11884,BAO_0000221,8,CHEMBL615442,,10000000.0
573,,,,B,H,Autocuration,Hippocampus,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,51,,,1,14331,BAO_0000221,8,CHEMBL615443,,10000000.0
574,,,,B,H,Autocuration,Hippocampus,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,51,,,1,11701,BAO_0000221,8,CHEMBL615444,,10000000.0
575,,,,B,H,Expert,Hippocampus,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,51,,,1,11701,BAO_0000221,8,CHEMBL615445,,10000000.0
576,,,,B,H,Autocuration,Hippocampus,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,51,,,1,12248,BAO_0000221,8,CHEMBL615446,,10000000.0
577,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,51,,,1,12248,BAO_0000219,8,CHEMBL615447,449.0,
578,,,,B,H,Expert,Hippocampus,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,,1,12248,BAO_0000221,8,CHEMBL615448,,10000000.0
579,,,,B,H,Expert,Hippocampus,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,51,,,1,12249,BAO_0000221,8,CHEMBL615449,,10000000.0
580,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,51,,,1,12248,BAO_0000219,8,CHEMBL615450,449.0,
581,,,,B,H,Expert,Hippocampus,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",51,,,1,11799,BAO_0000221,8,CHEMBL615451,,10000000.0
582,,,,B,H,Autocuration,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,51,,,1,634,BAO_0000357,8,CHEMBL615452,,
583,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,8,CHEMBL615453,,10000000.0
584,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,8,CHEMBL615454,,10000000.0
585,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,8,CHEMBL615455,,10000000.0
586,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,8,CHEMBL615456,,10000000.0
587,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,51,,,1,9995,BAO_0000221,8,CHEMBL615457,,10000000.0
588,,,,B,H,Expert,Hippocampus,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,51,,,1,12210,BAO_0000218,8,CHEMBL615458,,10000000.0
589,,,,B,H,Expert,Hippocampus,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,,1,13311,BAO_0000221,8,CHEMBL615459,,10000000.0
590,,Homo sapiens,,B,D,Expert,,9606.0,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",51,,,1,2331,BAO_0000219,9,CHEMBL615460,449.0,
591,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,51,,,1,1375,BAO_0000019,8,CHEMBL615461,,
592,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,51,,,1,1375,BAO_0000019,8,CHEMBL615462,,
593,,Cavia porcellus,,F,H,Autocuration,Hippocampus,10141.0,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,51,,,1,11574,BAO_0000221,8,CHEMBL615463,,10000000.0
594,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,51,,,1,12867,BAO_0000221,8,CHEMBL615464,,2116.0
595,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,51,,,1,12867,BAO_0000221,8,CHEMBL615465,,2116.0
596,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,51,,,1,12867,BAO_0000221,8,CHEMBL615466,,2116.0
597,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,51,,,1,12867,BAO_0000221,8,CHEMBL615467,,2116.0
598,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,51,,,1,12867,BAO_0000221,8,CHEMBL615468,,2116.0
599,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,51,,,1,12867,BAO_0000221,8,CHEMBL615469,,2116.0
600,,Cavia porcellus,,B,H,Autocuration,,10141.0,Binding affinity against 5-hydroxytryptamine 1A receptor,51,,,1,11574,BAO_0000357,8,CHEMBL615470,,
601,,Cavia porcellus,,B,H,Autocuration,,10141.0,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,51,,,1,13114,BAO_0000357,8,CHEMBL615471,,
602,,Cavia porcellus,,B,H,Autocuration,,10141.0,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,51,,,1,13181,BAO_0000357,8,CHEMBL615472,,
603,,Cavia porcellus,,B,H,Autocuration,Hippocampus,10141.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,106,,,1,10639,BAO_0000221,8,CHEMBL883242,,10000000.0
604,,Cavia porcellus,,F,H,Autocuration,Hippocampus,10141.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,106,,,1,10639,BAO_0000221,8,CHEMBL615473,,10000000.0
605,,Cricetulus griseus,,B,H,Autocuration,,10029.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),11863,,,1,11883,BAO_0000218,8,CHEMBL615474,449.0,
606,,,,B,H,Autocuration,,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,51,,,1,17785,BAO_0000357,8,CHEMBL615475,,
607,,,,F,H,Autocuration,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,51,,,1,1558,BAO_0000219,8,CHEMBL615476,308.0,
608,,,,F,H,Autocuration,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,51,,,1,1558,BAO_0000219,8,CHEMBL615477,308.0,
609,,,,F,H,Autocuration,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,51,,,1,15740,BAO_0000019,8,CHEMBL615478,,
610,,,,F,H,Autocuration,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,51,,,1,17624,BAO_0000219,8,CHEMBL615160,449.0,
611,,,,F,H,Expert,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,51,,,1,17624,BAO_0000219,8,CHEMBL615161,449.0,
612,,,,F,H,Autocuration,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,51,,,1,17624,BAO_0000219,8,CHEMBL615162,449.0,
613,,,,F,H,Autocuration,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,51,,,1,17624,BAO_0000219,8,CHEMBL615163,449.0,
614,,,,B,H,Expert,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,,1,17624,BAO_0000219,8,CHEMBL615164,449.0,
615,,,,B,H,Expert,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,,1,17624,BAO_0000219,8,CHEMBL615165,449.0,
616,,,,B,H,Autocuration,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,51,,,1,17624,BAO_0000219,8,CHEMBL615166,449.0,
617,,,,F,H,Autocuration,,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,51,,,1,14256,BAO_0000219,8,CHEMBL615167,,
618,,Homo sapiens,,B,D,Expert,,9606.0,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,51,,,1,3445,BAO_0000219,9,CHEMBL615168,308.0,
619,,Homo sapiens,,B,D,Expert,,9606.0,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,51,,,1,3445,BAO_0000219,9,CHEMBL615169,308.0,
620,,Homo sapiens,,B,D,Expert,,9606.0,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,51,,,1,17200,BAO_0000219,9,CHEMBL615170,449.0,
621,,Homo sapiens,,B,D,Expert,,9606.0,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,51,,,1,17200,BAO_0000219,9,CHEMBL615171,449.0,
622,,,,F,H,Autocuration,,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,51,,,1,15180,BAO_0000019,8,CHEMBL615694,,
623,,,,F,H,Autocuration,,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,51,,,1,15180,BAO_0000019,8,CHEMBL615695,,
624,,,,F,H,Autocuration,,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",51,,,1,16026,BAO_0000019,8,CHEMBL615696,,
625,,,,F,H,Autocuration,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,51,,,1,2759,BAO_0000219,8,CHEMBL615697,449.0,
626,,Homo sapiens,,F,D,Expert,,9606.0,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),51,,,1,2759,BAO_0000219,9,CHEMBL859410,449.0,
627,,,,F,H,Autocuration,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),51,,,1,2759,BAO_0000219,8,CHEMBL615841,449.0,
628,,Homo sapiens,,F,D,Expert,,9606.0,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),51,,,1,2759,BAO_0000219,9,CHEMBL615842,449.0,
629,,,,F,H,Autocuration,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,51,,,1,2759,BAO_0000219,8,CHEMBL835003,449.0,
630,,,,F,H,Autocuration,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),51,,,1,2759,BAO_0000219,8,CHEMBL615843,449.0,
631,,Homo sapiens,,F,D,Expert,,9606.0,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),51,,,1,2759,BAO_0000219,9,CHEMBL615979,449.0,
632,,,,F,H,Autocuration,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),51,,,1,2759,BAO_0000219,8,CHEMBL615980,449.0,
633,,Homo sapiens,,F,D,Expert,,9606.0,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),51,,,1,2759,BAO_0000219,9,CHEMBL615981,449.0,
634,,Homo sapiens,,F,D,Expert,,9606.0,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,51,,,1,3445,BAO_0000019,9,CHEMBL615982,,
635,,Homo sapiens,,F,D,Expert,,9606.0,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",51,,,1,5272,BAO_0000019,9,CHEMBL615983,,
636,,Homo sapiens,,F,D,Expert,,9606.0,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",51,,,1,5272,BAO_0000019,9,CHEMBL615984,,
637,,Homo sapiens,,F,D,Expert,,9606.0,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",51,,,1,5272,BAO_0000019,9,CHEMBL615985,,
638,,,,F,H,Autocuration,,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,51,,,1,17624,BAO_0000219,8,CHEMBL615986,449.0,
639,,,,F,H,Autocuration,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,51,,,1,17624,BAO_0000219,8,CHEMBL615987,449.0,
640,,,,F,H,Autocuration,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,51,,,1,17624,BAO_0000219,8,CHEMBL615988,449.0,
641,,,,F,H,Expert,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,51,,,1,17624,BAO_0000219,8,CHEMBL615989,449.0,
642,,,,F,H,Autocuration,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,51,,,1,17624,BAO_0000219,8,CHEMBL615990,449.0,
643,,,,F,H,Autocuration,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,51,,,1,17624,BAO_0000219,8,CHEMBL615991,449.0,
644,,,,F,H,Autocuration,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,51,,,1,17624,BAO_0000219,8,CHEMBL615992,449.0,
645,,,,F,H,Autocuration,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,51,,,1,17624,BAO_0000219,8,CHEMBL615993,449.0,
646,,,,F,H,Expert,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,51,,,1,17624,BAO_0000219,8,CHEMBL615994,449.0,
647,,,,F,H,Autocuration,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,51,,,1,17624,BAO_0000219,8,CHEMBL615995,449.0,
648,,,,F,H,Autocuration,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,51,,,1,17624,BAO_0000219,8,CHEMBL615996,449.0,
649,,,,F,H,Autocuration,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,51,,,1,17624,BAO_0000219,8,CHEMBL615997,449.0,
650,,,,F,H,Autocuration,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,,1,6563,BAO_0000019,8,CHEMBL615998,,
651,,,,F,H,Autocuration,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,,1,6563,BAO_0000019,8,CHEMBL615999,,
652,,,,F,H,Autocuration,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,51,,,1,6563,BAO_0000019,8,CHEMBL616000,,
653,,,,F,H,Autocuration,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,,,1,17296,BAO_0000219,8,CHEMBL616001,722.0,
654,,Homo sapiens,,F,D,Expert,,9606.0,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",51,,,1,6876,BAO_0000019,9,CHEMBL616002,,
655,,,,F,H,Expert,,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",51,,,1,6876,BAO_0000019,8,CHEMBL616003,,
656,,Homo sapiens,,F,D,Expert,,9606.0,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,51,,,1,5272,BAO_0000019,9,CHEMBL616004,,
657,,Homo sapiens,,F,D,Expert,,9606.0,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,51,,,1,5272,BAO_0000019,9,CHEMBL616005,,
658,,,,F,H,Autocuration,,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",51,,,1,5548,BAO_0000019,8,CHEMBL616006,,
659,,,,F,H,Expert,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",51,,,1,5548,BAO_0000019,8,CHEMBL616007,,
660,,,,F,H,Autocuration,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",51,,,1,5548,BAO_0000019,8,CHEMBL616008,,
661,,,,F,H,Autocuration,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",51,,,1,5548,BAO_0000019,8,CHEMBL616009,,
662,,,,F,H,Expert,,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",51,,,1,5929,BAO_0000019,8,CHEMBL616010,,
663,,Homo sapiens,,F,D,Expert,,9606.0,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",51,,,1,5929,BAO_0000019,9,CHEMBL616011,,
664,,Homo sapiens,,F,D,Expert,,9606.0,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",51,,,1,5929,BAO_0000019,9,CHEMBL615740,,
665,,,,F,H,Autocuration,,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",51,,,1,16245,BAO_0000019,8,CHEMBL615741,,
666,,,,F,H,Expert,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",51,,,1,5640,BAO_0000019,8,CHEMBL615742,,
667,,,,F,H,Autocuration,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",51,,,1,5640,BAO_0000019,8,CHEMBL615743,,
668,,,,F,H,Autocuration,,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,51,,,1,14509,BAO_0000219,8,CHEMBL615744,449.0,
669,,,,F,H,Expert,,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,51,,,1,14509,BAO_0000219,8,CHEMBL615745,449.0,
670,,,,B,H,Autocuration,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,51,,,1,15331,BAO_0000357,8,CHEMBL615746,,
671,,,,B,H,Autocuration,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,51,,,1,15331,BAO_0000357,8,CHEMBL615747,,
672,,,,F,H,Autocuration,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,,1,6563,BAO_0000019,8,CHEMBL615748,,
673,,,,F,H,Autocuration,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",51,,,1,6563,BAO_0000019,8,CHEMBL615749,,
674,,,,F,H,Autocuration,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,51,,,1,6563,BAO_0000019,8,CHEMBL615750,,
675,,Homo sapiens,,F,D,Expert,,9606.0,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,51,,,1,6563,BAO_0000019,9,CHEMBL616259,,
676,,,,F,H,Autocuration,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,,1,6563,BAO_0000019,8,CHEMBL616260,,
677,,Homo sapiens,,F,D,Expert,,9606.0,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,51,,,1,5272,BAO_0000019,9,CHEMBL616261,,
678,,Homo sapiens,,F,D,Expert,,9606.0,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",51,,,1,5272,BAO_0000019,9,CHEMBL616262,,
679,,Homo sapiens,,F,D,Expert,,9606.0,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",51,,,1,5272,BAO_0000019,9,CHEMBL616263,,
680,,Homo sapiens,,F,D,Expert,,9606.0,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,51,,,1,5272,BAO_0000019,9,CHEMBL616264,,
681,,Homo sapiens,,F,D,Expert,,9606.0,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,51,,,1,5272,BAO_0000019,9,CHEMBL616265,,
682,,Homo sapiens,,F,D,Expert,,9606.0,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",51,,,1,5272,BAO_0000019,9,CHEMBL616266,,
683,,Homo sapiens,,F,D,Expert,,9606.0,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",51,,,1,5272,BAO_0000019,9,CHEMBL616267,,
684,,Homo sapiens,,F,D,Expert,,9606.0,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,51,,,1,5272,BAO_0000019,9,CHEMBL616268,,
685,,Homo sapiens,,B,D,Expert,,9606.0,Inhibition of human 5-hydroxytryptamine 1A receptor,51,,,1,16146,BAO_0000357,9,CHEMBL616269,,
686,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,,1,17624,BAO_0000219,8,CHEMBL884528,449.0,
687,,,,B,D,Expert,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,105,,,1,13706,BAO_0000219,9,CHEMBL616270,722.0,
688,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,51,,,1,15250,BAO_0000219,8,CHEMBL616271,449.0,
689,,,,F,H,Autocuration,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,51,,,1,17624,BAO_0000219,8,CHEMBL616272,449.0,
690,,,,B,H,Expert,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,51,,,1,6861,BAO_0000357,8,CHEMBL616273,,
691,,Homo sapiens,,B,D,Expert,,9606.0,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,51,,,1,17200,BAO_0000357,9,CHEMBL616274,,
692,,,,B,H,Autocuration,,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,51,,,1,17624,BAO_0000219,8,CHEMBL616275,449.0,
693,,,,B,H,Autocuration,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,,1,17624,BAO_0000219,8,CHEMBL616276,449.0,
694,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,22226,,,1,12058,BAO_0000218,0,CHEMBL616277,,
695,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,22226,,,1,12058,BAO_0000218,0,CHEMBL616278,,
696,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,22226,,,1,12058,BAO_0000218,0,CHEMBL616279,,
697,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,22226,,,1,12058,BAO_0000218,0,CHEMBL616280,,
698,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,22226,,,1,12058,BAO_0000218,0,CHEMBL616281,,
699,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,22226,,,1,12058,BAO_0000218,0,CHEMBL616282,,
700,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,22226,,,1,12058,BAO_0000218,0,CHEMBL616283,,
701,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,22226,,,1,12058,BAO_0000218,0,CHEMBL616284,,
702,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,22226,,,1,12058,BAO_0000218,0,CHEMBL616285,,
703,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,22226,,,1,12058,BAO_0000218,0,CHEMBL616286,,
704,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,22226,,,1,12058,BAO_0000218,0,CHEMBL616287,,
705,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,22226,,,1,12058,BAO_0000218,0,CHEMBL616288,,
706,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,22226,,,1,12058,BAO_0000218,0,CHEMBL616289,,
707,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,22226,,,1,12058,BAO_0000218,0,CHEMBL615610,,
708,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,22226,,,1,12058,BAO_0000218,0,CHEMBL615611,,
709,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,22226,,,1,12058,BAO_0000218,0,CHEMBL615612,,
710,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,22226,,,1,12058,BAO_0000218,0,CHEMBL615613,,
711,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,22226,,,1,12058,BAO_0000218,0,CHEMBL615614,,
712,In vivo,Rattus norvegicus,,F,U,Autocuration,,10116.0,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,22226,,,1,12058,BAO_0000218,0,CHEMBL615615,,
713,,,,B,H,Autocuration,,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,105093,,,1,11440,BAO_0000019,4,CHEMBL615616,,
714,,,,B,H,Autocuration,Hypothalamus,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,11923,,,1,6238,BAO_0000249,8,CHEMBL615617,,1898.0
715,,,,B,H,Autocuration,,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,10577,,,1,10046,BAO_0000019,8,CHEMBL615618,,
716,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,10577,,,1,10046,BAO_0000019,8,CHEMBL615619,,
717,,,,B,H,Expert,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,10577,,,1,10046,BAO_0000019,8,CHEMBL615620,,
718,,,,B,H,Autocuration,,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",55,,,1,167,BAO_0000357,8,CHEMBL615621,,
719,,,,B,H,Autocuration,,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",55,,,1,167,BAO_0000357,8,CHEMBL615622,,
720,,,,F,H,Autocuration,,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),12166,,,1,11520,BAO_0000019,8,CHEMBL615623,,
721,,,,F,H,Autocuration,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,12166,,,1,11520,BAO_0000019,8,CHEMBL615624,,
722,,,,F,H,Autocuration,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,12166,,,1,11520,BAO_0000019,8,CHEMBL615625,,
723,,,,F,H,Autocuration,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,12166,,,1,11520,BAO_0000019,8,CHEMBL767045,,
724,,Cavia porcellus,,F,H,Autocuration,,10141.0,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,55,,,1,135,BAO_0000019,8,CHEMBL615626,,
725,,Cavia porcellus,,F,H,Autocuration,,10141.0,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,55,,,1,135,BAO_0000019,8,CHEMBL615627,,
726,,Cavia porcellus,,B,H,Autocuration,,10141.0,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,55,,,1,11311,BAO_0000019,8,CHEMBL615628,,
727,,Cavia porcellus,,B,H,Autocuration,,10141.0,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,55,,,1,10193,BAO_0000357,8,CHEMBL615629,,
728,,Homo sapiens,,B,D,Expert,,9606.0,Inhibitory concentration against 5-lipoxygenase from human whole blood,55,,,1,12281,BAO_0000357,9,CHEMBL615630,,
729,,,,B,H,Autocuration,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],55,,,1,11311,BAO_0000219,8,CHEMBL615631,,
730,,,,F,H,Autocuration,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,17087,,,1,12576,BAO_0000218,8,CHEMBL615632,,
731,,,,B,H,Autocuration,,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,17087,,,1,12281,BAO_0000357,8,CHEMBL615633,,
732,,,,F,H,Autocuration,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,17087,,,1,12576,BAO_0000218,8,CHEMBL615634,,
733,,Sus scrofa,,B,H,Expert,,9823.0,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,55,,,1,11089,BAO_0000019,8,CHEMBL615635,,
734,,,,B,H,Expert,,,In vitro inhibition of rat 5-Lipoxygenase,12166,,,1,11006,BAO_0000357,8,CHEMBL615636,,
735,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibitory activity against 5-Lipoxygenase,12166,,,1,11481,BAO_0000357,9,CHEMBL615637,,
736,,,,B,H,Expert,,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,12166,,,1,10864,BAO_0000219,8,CHEMBL615638,702.0,
737,,,,B,H,Autocuration,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),12166,,,1,3595,BAO_0000219,8,CHEMBL615639,702.0,
738,,,,B,H,Autocuration,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,12166,,,1,11311,BAO_0000219,8,CHEMBL615640,702.0,
739,,,,B,H,Autocuration,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,12166,,,1,11311,BAO_0000019,8,CHEMBL615796,,
740,,,,B,H,Autocuration,,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],12166,,,1,11311,BAO_0000219,8,CHEMBL615845,,
741,,,,B,H,Autocuration,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,12166,,,1,11006,BAO_0000357,8,CHEMBL615846,,
742,,,,B,H,Autocuration,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,12166,,,1,3595,BAO_0000219,8,CHEMBL615847,702.0,
743,,,,B,H,Autocuration,,,The compound was tested for inhibition of isolated 5-Lipoxygenase,12166,,,1,11311,BAO_0000357,8,CHEMBL615848,,
744,,Rattus norvegicus,,B,U,Autocuration,,10116.0,Ratio of IC50 against 5-LO and COX,22226,,,1,11481,BAO_0000019,0,CHEMBL615849,,
745,,,,B,H,Autocuration,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,12166,,,1,11006,BAO_0000357,8,CHEMBL615850,,
746,,,,B,H,Autocuration,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,12166,,,1,11006,BAO_0000357,8,CHEMBL615851,,
747,,,,B,H,Autocuration,,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,12166,,,1,11311,BAO_0000219,8,CHEMBL615852,,
748,,,,F,H,Autocuration,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,12166,,,1,11006,BAO_0000019,8,CHEMBL615853,,
749,,,,B,H,Autocuration,Prostate gland,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,120,,,1,4288,BAO_0000357,8,CHEMBL884527,,2367.0
750,,Columba livia,,B,U,Autocuration,,8932.0,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,22226,,,1,7587,BAO_0000019,0,CHEMBL872871,,
751,,Columba livia,,B,U,Autocuration,,8932.0,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,22226,,,1,7587,BAO_0000019,0,CHEMBL615854,,
752,,Columba livia,,B,U,Autocuration,,8932.0,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,22226,,,1,7587,BAO_0000019,0,CHEMBL767046,,
753,,,,B,H,Autocuration,,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,10732,,,1,11249,BAO_0000357,8,CHEMBL615855,,
754,,Rattus norvegicus,,F,D,Expert,,10116.0,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,12198,,,1,8003,BAO_0000019,9,CHEMBL615856,,
755,,Rattus norvegicus,,F,D,Expert,,10116.0,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),12198,,,1,8003,BAO_0000019,9,CHEMBL615857,,
756,,Rattus norvegicus,,F,D,Expert,,10116.0,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),12198,,,1,8003,BAO_0000019,9,CHEMBL615858,,
757,,,,B,H,Expert,Hippocampus,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,10576,,,1,12416,BAO_0000221,8,CHEMBL615859,,10000000.0
758,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,51,,,1,16293,BAO_0000357,8,CHEMBL615860,,
759,,Oryctolagus cuniculus,,B,U,Autocuration,,9986.0,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,22226,,,1,13047,BAO_0000019,0,CHEMBL615861,,
760,,Oryctolagus cuniculus,,B,U,Autocuration,,9986.0,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,22226,,,1,13047,BAO_0000019,0,CHEMBL615862,,
761,,Oryctolagus cuniculus,,B,U,Autocuration,,9986.0,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,22226,,,1,13047,BAO_0000019,0,CHEMBL615863,,
762,,Oryctolagus cuniculus,,B,U,Autocuration,,9986.0,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,22226,,,1,13047,BAO_0000019,0,CHEMBL615864,,
763,,,,B,H,Autocuration,Hippocampus,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,104744,,,1,10085,BAO_0000221,4,CHEMBL615865,,10000000.0
764,,,,B,H,Autocuration,Hippocampus,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,104744,,,1,10085,BAO_0000221,4,CHEMBL615866,,10000000.0
765,,,,B,H,Autocuration,Hippocampus,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,104744,,,1,10085,BAO_0000221,4,CHEMBL615867,,10000000.0
766,,,,B,H,Autocuration,,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,104744,,,1,9841,BAO_0000249,4,CHEMBL615868,,
767,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,104744,,,1,8822,BAO_0000249,5,CHEMBL615869,,
768,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,104744,,,1,9806,BAO_0000019,5,CHEMBL615870,,
769,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,104744,,,1,9806,BAO_0000019,5,CHEMBL615871,,
770,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,104744,,,1,8868,BAO_0000224,4,CHEMBL615872,,
771,,,,B,H,Autocuration,Hippocampus,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,104744,,,1,9036,BAO_0000221,4,CHEMBL833492,,10000000.0
772,,,,B,H,Autocuration,Hippocampus,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,104744,,,1,11374,BAO_0000221,4,CHEMBL615873,,10000000.0
773,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,104744,,,1,10881,BAO_0000224,4,CHEMBL615479,,
774,,,,B,H,Autocuration,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,104744,,,1,8822,BAO_0000019,4,CHEMBL615480,,
775,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,104744,,,1,9806,BAO_0000249,5,CHEMBL615481,,
776,,,,B,H,Autocuration,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,,,1,15463,BAO_0000019,4,CHEMBL872869,,
777,,,,B,H,Autocuration,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,,,1,15463,BAO_0000019,4,CHEMBL615482,,
778,,,,B,H,Autocuration,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,104744,,,1,14542,BAO_0000221,4,CHEMBL615483,,955.0
779,,,,B,H,Autocuration,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,104744,,,1,14542,BAO_0000221,4,CHEMBL615484,,955.0
780,,,,B,H,Autocuration,,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,104744,,,1,8569,BAO_0000019,4,CHEMBL615485,,
781,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,104744,,,1,10062,BAO_0000224,5,CHEMBL615486,,
782,,,,B,H,Autocuration,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,104744,,,1,4771,BAO_0000224,4,CHEMBL615487,,
783,,,,B,H,Autocuration,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,104744,,,1,10062,BAO_0000224,4,CHEMBL615488,,
784,,,,B,H,Autocuration,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,104744,,,1,10062,BAO_0000224,4,CHEMBL615489,,
785,,,,B,H,Autocuration,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,104744,,,1,10062,BAO_0000224,4,CHEMBL615389,,
786,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,104744,,,1,15463,BAO_0000019,4,CHEMBL615390,,
787,,,,B,H,Autocuration,,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,104744,,,1,15463,BAO_0000019,4,CHEMBL615391,,
788,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,104744,,,1,9098,BAO_0000224,4,CHEMBL615392,,
789,,Rattus norvegicus,,B,U,Autocuration,,10116.0,Affinity for 5-hydroxytryptamine 1 receptor,22226,,,1,3070,BAO_0000019,0,CHEMBL615393,,
790,,,,B,H,Autocuration,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,104744,,,1,14542,BAO_0000221,4,CHEMBL615394,,955.0
791,,,,B,H,Autocuration,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,104744,,,1,14542,BAO_0000221,4,CHEMBL615395,,955.0
792,,,,B,H,Autocuration,,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,104744,,,1,6398,BAO_0000224,4,CHEMBL615396,,
793,,,,B,H,Autocuration,Brain,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,104744,,,1,1344,BAO_0000221,4,CHEMBL615397,,955.0
794,,,,B,H,Autocuration,,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,104744,,,1,11963,BAO_0000019,4,CHEMBL615398,,
795,,Rattus norvegicus,,B,U,Autocuration,,10116.0,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,22226,,,1,8908,BAO_0000019,0,CHEMBL615399,,
796,,,,B,H,Autocuration,,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,104744,,,1,9098,BAO_0000019,4,CHEMBL615400,,
797,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,104744,,,1,8841,BAO_0000019,5,CHEMBL615401,,
798,,Rattus norvegicus,,B,U,Autocuration,,10116.0,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,22226,,,1,8814,BAO_0000019,0,CHEMBL615402,,
799,,,,B,H,Autocuration,,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,104744,,,1,11752,BAO_0000019,4,CHEMBL615403,,
800,,,,B,H,Autocuration,Brain,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,104744,,,1,11642,BAO_0000221,4,CHEMBL615404,,955.0
801,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,104744,,,1,11642,BAO_0000019,4,CHEMBL615781,,
802,,,,B,H,Autocuration,Brain,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,104744,,,1,9231,BAO_0000220,4,CHEMBL615782,,955.0
803,,,,B,H,Autocuration,Brain,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,104744,,,1,11351,BAO_0000221,4,CHEMBL615783,,955.0
804,,,,B,U,Autocuration,,,Compound was tested for binding affinity against 5-HT1 receptor,22226,,,1,4639,BAO_0000019,0,CHEMBL873481,,
805,,,,B,U,Autocuration,,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,22226,,,1,1205,BAO_0000019,0,CHEMBL615784,,
806,,,,B,H,Expert,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,10576,,,1,10025,BAO_0000357,8,CHEMBL615785,,
807,,,,F,H,Autocuration,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",10576,,,1,13241,BAO_0000249,8,CHEMBL615786,,
808,In vivo,,,F,H,Autocuration,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,10576,,,1,16245,BAO_0000218,8,CHEMBL615787,,
809,In vivo,,,F,H,Autocuration,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,10576,,,1,16245,BAO_0000218,8,CHEMBL615788,,
810,,,,F,H,Autocuration,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,10576,,,1,12438,BAO_0000019,8,CHEMBL767044,,
811,In vivo,,,F,H,Autocuration,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,10576,,,1,16245,BAO_0000218,8,CHEMBL615789,,
812,In vivo,,,F,H,Autocuration,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,10576,,,1,16245,BAO_0000218,8,CHEMBL615790,,
813,,,,F,H,Autocuration,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,10576,,,1,15740,BAO_0000019,8,CHEMBL615813,,
814,,,,F,H,Autocuration,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,10576,,,1,15535,BAO_0000219,8,CHEMBL615814,,
815,,,,F,H,Expert,,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,51,,,1,15535,BAO_0000219,8,CHEMBL615815,,
816,,,,F,H,Autocuration,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,10576,,,1,15535,BAO_0000219,8,CHEMBL615816,,
817,,,,B,H,Expert,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,10576,,,1,9888,BAO_0000249,8,CHEMBL615817,,
818,,,,B,H,Autocuration,Hippocampus,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,10576,,,1,10085,BAO_0000221,8,CHEMBL615818,,10000000.0
819,,,,B,H,Autocuration,Hippocampus,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,10576,,,1,10085,BAO_0000221,8,CHEMBL615819,,10000000.0
820,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,10576,,,1,17331,BAO_0000249,8,CHEMBL615820,,
821,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,10576,,,1,10845,BAO_0000221,9,CHEMBL615821,,10000000.0
822,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10576,,,1,10845,BAO_0000221,9,CHEMBL615822,,10000000.0
823,,,,B,H,Expert,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,10576,,,1,10845,BAO_0000221,8,CHEMBL615823,,10000000.0
824,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,10576,,,1,10845,BAO_0000221,9,CHEMBL615824,,10000000.0
825,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,10576,,,1,10845,BAO_0000221,9,CHEMBL615825,,10000000.0
826,,,,B,H,Expert,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,10576,,,1,13730,BAO_0000357,8,CHEMBL615826,,
827,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,10576,,,1,13508,BAO_0000249,8,CHEMBL615827,,
828,,,,B,H,Expert,Hippocampus,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,10576,,,1,13508,BAO_0000249,8,CHEMBL615828,,10000000.0
829,,,,B,H,Expert,Hippocampus,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,1,12073,BAO_0000221,8,CHEMBL615829,,10000000.0
830,,,,B,H,Autocuration,Hippocampus,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,10576,,,1,4671,BAO_0000221,8,CHEMBL615830,,10000000.0
831,,,,B,H,Expert,Hippocampus,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,10576,,,1,13631,BAO_0000221,8,CHEMBL615831,,10000000.0
832,,,,B,H,Autocuration,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,10576,,,1,12438,BAO_0000357,8,CHEMBL615832,,
833,,,,B,H,Autocuration,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,10576,,,1,10483,BAO_0000019,8,CHEMBL615833,,
834,,,,B,H,Autocuration,Hippocampus,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,10576,,,1,10483,BAO_0000221,8,CHEMBL615834,,10000000.0
835,,,,B,H,Intermediate,,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,10576,,,1,12352,BAO_0000249,8,CHEMBL615835,,
836,,,,B,H,Autocuration,Hippocampus,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,10576,,,1,14732,BAO_0000249,8,CHEMBL615836,,10000000.0
837,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,10576,,,1,11049,BAO_0000019,9,CHEMBL615837,,
838,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,10576,,,1,11049,BAO_0000019,9,CHEMBL615838,,
839,,,,B,H,Expert,,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",10576,,,1,13657,BAO_0000249,8,CHEMBL615839,,
840,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,10576,,,1,11473,BAO_0000019,8,CHEMBL884525,,
841,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,10576,,,1,2014,BAO_0000249,8,CHEMBL615840,,
842,,,,B,H,Expert,Hippocampus,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,1,3086,BAO_0000221,8,CHEMBL615405,,10000000.0
843,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,10576,,,1,15854,BAO_0000019,8,CHEMBL615406,,
844,,,,B,H,Expert,Hippocampus,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,10576,,,1,10922,BAO_0000221,8,CHEMBL615900,,10000000.0
845,,,,B,H,Expert,Hippocampus,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,10576,,,1,13346,BAO_0000221,8,CHEMBL615901,,10000000.0
846,,,,B,H,Expert,,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,10576,,,1,15311,BAO_0000357,8,CHEMBL615902,,
847,,,,B,H,Autocuration,Hippocampus,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,10576,,,1,10922,BAO_0000221,8,CHEMBL615903,,10000000.0
848,,,,B,H,Autocuration,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,10576,,,1,10025,BAO_0000357,8,CHEMBL615904,,
849,,,,B,H,Expert,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,10576,,,1,10025,BAO_0000357,8,CHEMBL615905,,
850,,,,B,H,Autocuration,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,10576,,,1,9742,BAO_0000019,8,CHEMBL615906,,
851,,,,F,H,Autocuration,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,10576,,,1,9742,BAO_0000019,8,CHEMBL615907,,
852,,,,B,H,Expert,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,10576,,,1,12304,BAO_0000019,8,CHEMBL615908,,
853,,,,B,H,Autocuration,Hippocampus,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,10576,,,1,15789,BAO_0000221,8,CHEMBL615909,,10000000.0
854,,,,B,H,Autocuration,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",10576,,,1,9912,BAO_0000019,8,CHEMBL615910,,
855,,,,B,H,Autocuration,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",10576,,,1,9912,BAO_0000019,8,CHEMBL615911,,
856,,,,B,H,Autocuration,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",10576,,,1,9912,BAO_0000019,8,CHEMBL615912,,
857,,,,B,H,Expert,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,10576,,,1,16693,BAO_0000019,8,CHEMBL615913,,
858,,,,B,H,Expert,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,10576,,,1,13276,BAO_0000357,8,CHEMBL615914,,
859,,,,B,H,Autocuration,Hippocampus,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,10576,,,1,12678,BAO_0000221,8,CHEMBL615915,,10000000.0
860,,,,B,H,Autocuration,,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,10576,,,1,11825,BAO_0000357,8,CHEMBL615916,,
861,,,,B,H,Expert,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,10576,,,1,12443,BAO_0000357,8,CHEMBL615917,,
862,,,,B,H,Expert,,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,10576,,,1,13830,BAO_0000357,8,CHEMBL615918,,
863,,,,B,H,Expert,Hippocampus,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,10576,,,1,14286,BAO_0000249,8,CHEMBL615919,,10000000.0
864,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10576,,,1,14356,BAO_0000221,9,CHEMBL615920,,10000000.0
865,,,,B,H,Autocuration,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,10576,,,1,15306,BAO_0000357,8,CHEMBL615921,,
866,,,,B,H,Expert,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),10576,,,1,15306,BAO_0000357,8,CHEMBL615922,,
867,,Rattus norvegicus,,F,D,Expert,,10116.0,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",10576,,,1,16616,BAO_0000249,9,CHEMBL881290,,
868,,,,B,H,Autocuration,Hippocampus,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",10576,,,1,3651,BAO_0000221,8,CHEMBL615923,,10000000.0
869,,,,F,H,Autocuration,Hippocampus,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,1,14331,BAO_0000221,8,CHEMBL615924,,10000000.0
870,,,,F,H,Autocuration,Hippocampus,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,1,14331,BAO_0000221,8,CHEMBL615925,,10000000.0
871,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,10576,,,1,14178,BAO_0000357,9,CHEMBL615926,,
872,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,10576,,,1,10639,BAO_0000019,9,CHEMBL615927,,
873,,,,B,H,Autocuration,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,,1,12306,BAO_0000221,8,CHEMBL615928,,10000000.0
874,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,10576,,,1,1348,BAO_0000357,9,CHEMBL615929,,
875,,,,B,H,Autocuration,Hippocampus,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,10576,,,1,13605,BAO_0000221,8,CHEMBL615930,,10000000.0
876,,,,B,H,Autocuration,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,51,,,1,17624,BAO_0000219,8,CHEMBL615931,449.0,
877,,,,F,H,Autocuration,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,51,,,1,17624,BAO_0000219,8,CHEMBL615932,449.0,
878,,,,F,H,Autocuration,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,51,,,1,17624,BAO_0000219,8,CHEMBL615933,449.0,
879,,,,B,H,Autocuration,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,51,,,1,15267,BAO_0000357,8,CHEMBL615934,,
880,,,,B,H,Autocuration,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,51,,,1,16532,BAO_0000357,8,CHEMBL615935,,
881,,,,F,H,Autocuration,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",51,,,1,6563,BAO_0000019,8,CHEMBL615936,,
882,,,,B,H,Autocuration,,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,51,,,1,4751,BAO_0000219,8,CHEMBL615937,449.0,
883,,,,B,H,Autocuration,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,51,,,1,15463,BAO_0000357,8,CHEMBL615938,,
884,,,,B,H,Autocuration,,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),51,,,1,3805,BAO_0000357,8,CHEMBL615797,,
885,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,1,5640,BAO_0000357,8,CHEMBL615798,,
886,,,,B,H,Autocuration,,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,51,,,1,6563,BAO_0000357,8,CHEMBL872870,,
887,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,51,,,1,5548,BAO_0000357,8,CHEMBL615799,,
888,,,,B,H,Autocuration,,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,51,,,1,6347,BAO_0000357,8,CHEMBL615800,,
889,,,,F,H,Autocuration,,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,,,1,17296,BAO_0000219,8,CHEMBL615801,722.0,
890,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,51,,,1,13047,BAO_0000019,8,CHEMBL615802,,
891,,,,B,H,Autocuration,,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,51,,,1,15740,BAO_0000357,8,CHEMBL615803,,
892,,,,F,H,Expert,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",51,,,1,5640,BAO_0000019,8,CHEMBL835002,,
893,,,,F,H,Autocuration,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",51,,,1,5640,BAO_0000019,8,CHEMBL615804,,
894,,,,B,H,Expert,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,51,,,1,17211,BAO_0000219,8,CHEMBL615805,308.0,
895,,,,B,H,Autocuration,,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,51,,,1,4751,BAO_0000219,8,CHEMBL615806,449.0,
896,,Homo sapiens,,B,D,Expert,,9606.0,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,51,,,1,6491,BAO_0000357,9,CHEMBL615807,,
897,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,51,,,1,4707,BAO_0000357,8,CHEMBL615808,,
898,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against 5-hydroxytryptamine 1A receptor,51,,,1,13910,BAO_0000357,9,CHEMBL615809,,
899,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,51,,,1,16190,BAO_0000219,8,CHEMBL615810,308.0,
900,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,1,16633,BAO_0000357,8,CHEMBL615811,,
901,,,,B,H,Autocuration,,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,51,,,1,11898,BAO_0000219,8,CHEMBL615812,449.0,
902,,,,B,H,Autocuration,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,51,,,1,11898,BAO_0000219,8,CHEMBL615751,449.0,
903,,,,B,H,Autocuration,,,Binding affinity against human 5-hydroxytryptamine 1A receptor,51,,,1,14331,BAO_0000357,8,CHEMBL615752,,
904,,,,B,H,Expert,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,51,,,1,17624,BAO_0000219,8,CHEMBL615753,449.0,
905,,,,B,H,Autocuration,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,51,,,1,17624,BAO_0000219,8,CHEMBL615754,449.0,
906,,,,B,H,Autocuration,,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,51,,,1,3307,BAO_0000357,8,CHEMBL615755,,
907,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,51,,,1,6563,BAO_0000219,9,CHEMBL615756,449.0,
908,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,51,,,1,14165,BAO_0000019,8,CHEMBL615757,,
909,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,51,,,1,5732,BAO_0000357,8,CHEMBL615758,,
910,,,,B,H,Expert,,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,51,,,1,13366,BAO_0000357,8,CHEMBL615759,,
911,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,51,,,1,17626,BAO_0000357,8,CHEMBL615760,,
912,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,51,,,1,6588,BAO_0000219,8,CHEMBL615761,308.0,
913,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,51,,,1,16209,BAO_0000357,8,CHEMBL872104,,
914,,,,B,H,Autocuration,,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,51,,,1,15463,BAO_0000357,8,CHEMBL615762,,
915,,,,B,H,Autocuration,,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,51,,,1,15463,BAO_0000357,8,CHEMBL615763,,
916,,,,B,H,Autocuration,,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,51,,,1,14770,BAO_0000357,8,CHEMBL615764,,
917,,,,B,H,Autocuration,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),51,,,1,16245,BAO_0000219,8,CHEMBL615765,1167.0,
918,,,,B,H,Autocuration,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),51,,,1,16245,BAO_0000019,8,CHEMBL615766,,
919,,,,B,H,Autocuration,,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,51,,,1,5548,BAO_0000357,8,CHEMBL615767,,
920,,,,B,H,Expert,,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,1,5548,BAO_0000357,8,CHEMBL615768,,
921,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,1,5548,BAO_0000357,8,CHEMBL615769,,
922,,,,B,H,Expert,,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,51,,,1,6876,BAO_0000357,8,CHEMBL615770,,
923,,,,B,H,Autocuration,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,1,2598,BAO_0000357,8,CHEMBL615771,,
924,,,,B,H,Expert,,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,51,,,1,17785,BAO_0000357,8,CHEMBL615772,,
925,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,51,,,1,6013,BAO_0000357,8,CHEMBL615773,,
926,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,51,,,1,5929,BAO_0000357,8,CHEMBL615774,,
927,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,1,16633,BAO_0000357,8,CHEMBL615775,,
928,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,51,,,1,1558,BAO_0000357,8,CHEMBL615776,,
929,,,,B,H,Expert,,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,1,16026,BAO_0000357,8,CHEMBL615777,,
930,,,,B,H,Autocuration,,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,51,,,1,12469,BAO_0000219,8,CHEMBL615778,,
931,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,51,,,1,15874,BAO_0000357,9,CHEMBL615779,,
932,,,,B,H,Autocuration,,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,51,,,1,15874,BAO_0000357,8,CHEMBL615780,,
933,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,51,,,1,3935,BAO_0000357,8,CHEMBL616298,,
934,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,51,,,1,15818,BAO_0000357,8,CHEMBL616299,,
935,,,,B,H,Autocuration,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,51,,,1,13706,BAO_0000219,8,CHEMBL616300,485.0,
936,,,,F,H,Expert,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,51,,,1,13729,BAO_0000219,8,CHEMBL616301,485.0,
937,,,,B,H,Autocuration,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,51,,,1,15413,BAO_0000019,8,CHEMBL616302,,
938,,,,B,H,Autocuration,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),51,,,1,15413,BAO_0000019,8,CHEMBL616117,,
939,,,,B,H,Autocuration,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),51,,,1,15413,BAO_0000019,8,CHEMBL616118,,
940,,,,B,H,Autocuration,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,51,,,1,15413,BAO_0000019,8,CHEMBL616119,,
941,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,51,,,1,3445,BAO_0000219,9,CHEMBL616120,308.0,
942,,,,B,H,Autocuration,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,51,,,1,15740,BAO_0000357,8,CHEMBL616121,,
943,,,,B,H,Autocuration,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,51,,,1,15740,BAO_0000357,8,CHEMBL616122,,
944,,,,B,H,Autocuration,,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,51,,,1,17626,BAO_0000357,8,CHEMBL616123,,
945,,Homo sapiens,,B,D,Expert,,9606.0,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,51,,,1,4234,BAO_0000357,9,CHEMBL616124,,
946,,,,B,H,Expert,,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,51,,,1,5640,BAO_0000357,8,CHEMBL616125,,
947,,Rattus norvegicus,,B,H,Expert,,10116.0,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,51,,,1,5272,BAO_0000357,8,CHEMBL616126,,
948,,,,B,H,Autocuration,,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,51,,,1,4622,BAO_0000219,8,CHEMBL616127,449.0,
949,,,,B,H,Expert,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,51,,,1,17085,BAO_0000019,8,CHEMBL616128,,
950,,,,B,H,Autocuration,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,51,,,1,3025,BAO_0000357,8,CHEMBL616129,,
951,,,,B,H,Expert,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,51,,,1,15315,BAO_0000357,8,CHEMBL616130,,
952,,,,B,H,Autocuration,,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,51,,,1,15267,BAO_0000357,8,CHEMBL616131,,
953,,,,B,H,Autocuration,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,51,,,1,17158,BAO_0000219,8,CHEMBL616132,308.0,
954,,Homo sapiens,,B,D,Expert,,9606.0,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,51,,,1,14214,BAO_0000219,9,CHEMBL616133,308.0,
955,,,,B,H,Autocuration,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,1,17133,BAO_0000357,8,CHEMBL616134,,
956,,,,B,H,Autocuration,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,51,,,1,16532,BAO_0000357,8,CHEMBL616135,,
957,,Homo sapiens,,B,D,Expert,,9606.0,Affinity for 5-hydroxytryptamine 1A receptor subtype,51,,,1,2391,BAO_0000357,9,CHEMBL616136,,
958,,,,B,H,Autocuration,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,51,,,1,14447,BAO_0000019,8,CHEMBL616137,,
959,,,,B,H,Autocuration,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,51,,,1,14447,BAO_0000019,8,CHEMBL872105,,
960,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,51,,,1,15086,BAO_0000357,8,CHEMBL616138,,
961,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,51,,,1,13051,BAO_0000357,9,CHEMBL616139,,
962,,,,F,H,Autocuration,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",51,,,1,16026,BAO_0000019,8,CHEMBL616140,,
963,,,,B,H,Expert,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,51,,,1,17085,BAO_0000019,8,CHEMBL616141,,
964,,,,B,H,Autocuration,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,1,17133,BAO_0000357,8,CHEMBL616142,,
965,,,,B,H,Autocuration,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,51,,,1,17133,BAO_0000357,8,CHEMBL616143,,
966,,,,B,H,Autocuration,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,51,,,1,17211,BAO_0000219,8,CHEMBL616144,308.0,
967,,,,B,H,Autocuration,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,51,,,1,17211,BAO_0000219,8,CHEMBL616145,308.0,
968,,,,B,H,Autocuration,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,51,,,1,17211,BAO_0000219,8,CHEMBL616012,308.0,
969,,,,B,H,Autocuration,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,51,,,1,17211,BAO_0000219,8,CHEMBL616013,308.0,
970,,,,F,H,Autocuration,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",51,,,1,16394,BAO_0000019,8,CHEMBL616014,,
971,,,,F,H,Autocuration,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",51,,,1,16394,BAO_0000019,8,CHEMBL616015,,
972,,,,F,H,Autocuration,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",51,,,1,16394,BAO_0000019,8,CHEMBL616016,,
973,In vivo,,,F,H,Autocuration,,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,51,,,1,16394,BAO_0000218,8,CHEMBL616017,,
974,,,,B,H,Autocuration,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,51,,,1,16394,BAO_0000019,8,CHEMBL616018,,
975,,,,F,H,Autocuration,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,51,,,1,15740,BAO_0000019,8,CHEMBL616019,,
976,,,,F,H,Autocuration,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,51,,,1,15740,BAO_0000019,8,CHEMBL616020,,
977,,,,B,H,Autocuration,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,51,,,1,15740,BAO_0000357,8,CHEMBL858018,,
978,,,,F,H,Autocuration,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,,,1,17296,BAO_0000219,8,CHEMBL616021,722.0,
979,,,,F,H,Expert,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",51,,,1,5640,BAO_0000019,8,CHEMBL616022,,
980,,,,F,H,Autocuration,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",51,,,1,5640,BAO_0000019,8,CHEMBL616023,,
981,,,,F,H,Autocuration,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",51,,,1,5640,BAO_0000019,8,CHEMBL616024,,
982,,,,F,H,Autocuration,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",51,,,1,5640,BAO_0000019,8,CHEMBL616025,,
983,,,,F,H,Autocuration,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,51,,,1,2759,BAO_0000219,8,CHEMBL616026,449.0,
984,,,,F,H,Autocuration,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",51,,,1,16394,BAO_0000019,8,CHEMBL616027,,
985,,Homo sapiens,,F,D,Expert,,9606.0,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",51,,,1,16394,BAO_0000019,9,CHEMBL616028,,
986,,Homo sapiens,,F,D,Expert,,9606.0,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,51,,,1,3445,BAO_0000019,9,CHEMBL616029,,
987,,,,B,H,Expert,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,51,,,1,4316,BAO_0000219,8,CHEMBL616030,449.0,
988,,,,B,H,Expert,,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,51,,,1,4316,BAO_0000019,8,CHEMBL616031,,
989,,Homo sapiens,,F,D,Expert,,9606.0,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,51,,,1,15180,BAO_0000019,9,CHEMBL616032,,
990,,Homo sapiens,,F,D,Expert,,9606.0,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,51,,,1,15180,BAO_0000019,9,CHEMBL616033,,
991,,,,F,H,Autocuration,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,,1,15042,BAO_0000019,8,CHEMBL616034,,
992,,,,F,H,Autocuration,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,,1,15042,BAO_0000019,8,CHEMBL616035,,
993,,,,F,H,Autocuration,,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,51,,,1,15042,BAO_0000019,8,CHEMBL616036,,
994,,,,F,H,Autocuration,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,,1,15042,BAO_0000019,8,CHEMBL616037,,
995,,,,F,H,Autocuration,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,,1,15042,BAO_0000019,8,CHEMBL616038,,
996,,,,F,H,Autocuration,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,51,,,1,15042,BAO_0000019,8,CHEMBL616039,,
997,,,,F,H,Autocuration,,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,51,,,1,15042,BAO_0000019,8,CHEMBL616040,,
998,,Homo sapiens,,F,D,Expert,,9606.0,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,51,,,1,15180,BAO_0000219,9,CHEMBL616041,308.0,
999,,Homo sapiens,,F,D,Expert,,9606.0,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,51,,,1,15180,BAO_0000219,9,CHEMBL616042,308.0,
1000,,Homo sapiens,,F,D,Expert,,9606.0,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,51,,,1,15180,BAO_0000219,9,CHEMBL616043,308.0,
1001,,,,F,H,Autocuration,,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",51,,,1,16245,BAO_0000019,8,CHEMBL616044,,
1002,,,,F,H,Autocuration,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",51,,,1,16026,BAO_0000019,8,CHEMBL616045,,
1003,,,,F,H,Autocuration,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,51,,,1,17296,BAO_0000219,8,CHEMBL616046,722.0,
1004,,,,F,H,Autocuration,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),51,,,1,2759,BAO_0000219,8,CHEMBL616047,449.0,
1005,,,,F,H,Autocuration,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,51,,,1,2759,BAO_0000219,8,CHEMBL616048,449.0,
1006,,Homo sapiens,,F,D,Expert,,9606.0,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),51,,,1,2759,BAO_0000219,9,CHEMBL616049,449.0,
1007,,,,F,H,Autocuration,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),51,,,1,2759,BAO_0000219,8,CHEMBL616050,449.0,
1008,,,,F,H,Expert,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,51,,,1,15419,BAO_0000219,8,CHEMBL616051,,
1009,,,,F,H,Autocuration,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,51,,,1,15419,BAO_0000219,8,CHEMBL616212,,
1010,,,,F,H,Autocuration,,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",51,,,1,16026,BAO_0000019,8,CHEMBL616213,,
1011,In vitro,,,B,H,Expert,,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,51,,,1,1414,BAO_0000219,8,CHEMBL616214,,
1012,In vitro,,,B,H,Expert,,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,51,,,1,1414,BAO_0000219,8,CHEMBL616215,,
1013,,,,B,H,Autocuration,,,Binding activity radioligand.,51,,,1,12861,BAO_0000357,8,CHEMBL616216,,
1014,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,51,,,1,12861,BAO_0000019,8,CHEMBL616217,,
1015,,,,B,H,Autocuration,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,51,,,1,5104,BAO_0000357,8,CHEMBL616218,,
1016,,,,B,H,Autocuration,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,51,,,1,5105,BAO_0000357,8,CHEMBL616219,,
1017,,,,B,H,Autocuration,,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,51,,,1,16312,BAO_0000357,8,CHEMBL616220,,
1018,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,51,,,1,15180,BAO_0000357,9,CHEMBL833493,,
1019,,,,B,H,Autocuration,,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,51,,,1,5033,BAO_0000357,8,CHEMBL616221,,
1020,,Homo sapiens,,B,D,Expert,,9606.0,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,51,,,1,16909,BAO_0000219,9,CHEMBL616222,449.0,
1021,,,,F,H,Autocuration,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,51,,,1,2590,BAO_0000019,8,CHEMBL616223,,
1022,,,,F,H,Autocuration,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,51,,,1,2590,BAO_0000019,8,CHEMBL616224,,
1023,,,,B,H,Expert,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,51,,,1,16394,BAO_0000019,8,CHEMBL616225,,
1024,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,51,,,1,4540,BAO_0000219,9,CHEMBL616226,722.0,
1025,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,51,,,1,17296,BAO_0000219,8,CHEMBL616227,722.0,
1026,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,51,,,1,17296,BAO_0000219,8,CHEMBL616228,722.0,
1027,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,51,,,1,15779,BAO_0000219,8,CHEMBL616229,722.0,
1028,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,51,,,1,15779,BAO_0000219,8,CHEMBL616230,722.0,
1029,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,51,,,1,15779,BAO_0000219,8,CHEMBL616231,722.0,
1030,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,51,,,1,6166,BAO_0000357,8,CHEMBL616232,,
1031,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,51,,,1,15779,BAO_0000219,8,CHEMBL616233,722.0,
1032,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,51,,,1,4199,BAO_0000219,8,CHEMBL857973,722.0,
1033,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,51,,,1,15316,BAO_0000219,8,CHEMBL616234,,
1034,,,,B,H,Autocuration,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,51,,,1,14875,BAO_0000357,8,CHEMBL616235,,
1035,,,,B,H,Expert,,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,51,,,1,14727,BAO_0000219,8,CHEMBL616236,308.0,
1036,,,,B,H,Expert,,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,51,,,1,14727,BAO_0000019,8,CHEMBL616237,,
1037,,,,B,H,Autocuration,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,51,,,1,15146,BAO_0000219,8,CHEMBL616238,722.0,
1038,,,,B,H,Autocuration,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,51,,,1,5213,BAO_0000219,8,CHEMBL616239,722.0,
1039,,,,B,H,Autocuration,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,51,,,1,16429,BAO_0000219,8,CHEMBL616240,,
1040,,Homo sapiens,,B,D,Expert,,9606.0,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,51,,,1,15042,BAO_0000219,9,CHEMBL616241,308.0,
1041,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,51,,,1,14818,BAO_0000219,8,CHEMBL616242,722.0,
1042,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",51,,,1,4829,BAO_0000219,8,CHEMBL616243,722.0,
1043,,,,B,D,Expert,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,51,,,1,17200,BAO_0000357,9,CHEMBL616244,,
1044,,Homo sapiens,,B,D,Autocuration,,9606.0,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,51,,,1,13051,BAO_0000357,9,CHEMBL616245,,
1045,,,,B,H,Autocuration,,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,106,,,1,5486,BAO_0000357,8,CHEMBL616246,,
1046,,,,B,H,Autocuration,,,Binding affinity against 5-HT1D receptor,105,,,1,5254,BAO_0000357,8,CHEMBL616247,,
1047,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor,105,,,1,5254,BAO_0000357,8,CHEMBL616248,,
1048,,,,B,H,Autocuration,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,107,,,1,15331,BAO_0000357,8,CHEMBL616249,,
1049,,Homo sapiens,,B,H,Autocuration,,9606.0,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,10576,,,1,13506,BAO_0000357,8,CHEMBL616250,,
1050,,,,B,H,Autocuration,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,51,,,1,15267,BAO_0000357,8,CHEMBL616251,,
1051,In vivo,,,F,H,Autocuration,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,11863,,,1,16616,BAO_0000218,8,CHEMBL616252,,
1052,In vivo,,,F,H,Autocuration,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,11863,,,1,16616,BAO_0000218,8,CHEMBL616253,,
1053,In vivo,,,F,H,Autocuration,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,11863,,,1,16616,BAO_0000218,8,CHEMBL616254,,
1054,,Mus musculus,,F,D,Expert,,10090.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,11863,,,1,16616,BAO_0000218,9,CHEMBL616255,,
1055,,Mus musculus,,F,D,Expert,,10090.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,11863,,,1,16616,BAO_0000218,9,CHEMBL832872,,
1056,,Mus musculus,,F,D,Expert,,10090.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,11863,,,1,16616,BAO_0000218,9,CHEMBL616256,,
1057,,Mus musculus,,F,D,Expert,,10090.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,11863,,,1,16616,BAO_0000218,9,CHEMBL616257,,
1058,,Mus musculus,,F,D,Expert,,10090.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,11863,,,1,16616,BAO_0000218,9,CHEMBL616258,,
1059,,Mus musculus,,F,D,Expert,,10090.0,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,11863,,,1,16616,BAO_0000218,9,CHEMBL616384,,
1060,,,,B,H,Autocuration,Hippocampus,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,11863,,,1,10297,BAO_0000221,8,CHEMBL616385,,10000000.0
1061,,,,B,H,Expert,,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,11863,,,1,13704,BAO_0000357,8,CHEMBL616386,,
1062,,Mus musculus,,B,D,Expert,Hippocampus,10090.0,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,11863,,,1,10297,BAO_0000221,9,CHEMBL616387,,10000000.0
1063,,,,B,H,Autocuration,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,11863,,,1,10297,BAO_0000221,8,CHEMBL616388,,10000000.0
1064,,Mus musculus,,B,D,Expert,Hippocampus,10090.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,11863,,,1,10297,BAO_0000221,9,CHEMBL616389,,10000000.0
1065,,,,B,H,Autocuration,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,11863,,,1,10297,BAO_0000221,8,CHEMBL616390,,10000000.0
1066,,,,B,H,Autocuration,,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,11863,,,1,217,BAO_0000357,8,CHEMBL616391,,
1067,,Mus musculus,,B,D,Expert,Hippocampus,10090.0,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,11863,,,1,10297,BAO_0000221,9,CHEMBL616392,,10000000.0
1068,,Sus scrofa,,B,H,Autocuration,,9823.0,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,51,,,1,4921,BAO_0000357,8,CHEMBL616393,,
1069,,Sus scrofa,,B,H,Autocuration,,9823.0,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,51,,,1,4921,BAO_0000357,8,CHEMBL616394,,
1070,,Sus scrofa,,B,H,Autocuration,,9823.0,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,51,,,1,4996,BAO_0000019,8,CHEMBL616395,,
1071,,Sus scrofa,,B,H,Autocuration,,9823.0,Compound was evaluated for the binding affinity at 5- HT1A receptor,51,,,1,12918,BAO_0000357,8,CHEMBL616396,,
1072,,Sus scrofa,,B,H,Autocuration,,9823.0,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,51,,,1,5333,BAO_0000019,8,CHEMBL872907,,
1073,,Sus scrofa,,B,H,Autocuration,,9823.0,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,51,,,1,4437,BAO_0000019,8,CHEMBL616397,,
1074,,Sus scrofa,,B,H,Autocuration,,9823.0,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,51,,,1,1742,BAO_0000019,8,CHEMBL616398,,
1075,,Sus scrofa,,B,H,Expert,,9823.0,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,51,,,1,16688,BAO_0000357,8,CHEMBL616399,,
1076,,Sus scrofa,,B,H,Autocuration,,9823.0,Binding activity radioligand.,51,,,1,12861,BAO_0000357,8,CHEMBL857065,,
1077,,Sus scrofa,,B,H,Expert,,9823.0,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,51,,,1,12861,BAO_0000019,8,CHEMBL616400,,
1078,,Sus scrofa,,B,H,Autocuration,,9823.0,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,51,,,1,12861,BAO_0000019,8,CHEMBL616401,,
1079,,,,B,H,Expert,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,10624,,,1,12490,BAO_0000019,8,CHEMBL616402,,
1080,,Sus scrofa,,B,H,Expert,,9823.0,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,51,,,1,11828,BAO_0000019,8,CHEMBL616403,,
1081,,Sus scrofa,,B,H,Autocuration,Hippocampus,9823.0,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,51,,,1,11866,BAO_0000221,8,CHEMBL616404,,10000000.0
1082,,Sus scrofa,,B,H,Autocuration,,9823.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,51,,,1,12827,BAO_0000249,8,CHEMBL616405,,
1083,,Sus scrofa,,B,H,Autocuration,,9823.0,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,51,,,1,12918,BAO_0000019,8,CHEMBL616406,,
1084,,Sus scrofa,,F,H,Expert,,9823.0,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,51,,,1,12919,BAO_0000019,8,CHEMBL616407,,
1085,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,51,,,1,13047,BAO_0000019,8,CHEMBL616408,,
1086,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,10576,,,1,15796,BAO_0000249,9,CHEMBL616409,,
1087,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",10576,,,1,3651,BAO_0000221,9,CHEMBL616410,,10000000.0
1088,,,,B,H,Autocuration,,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,10576,,,1,188,BAO_0000357,8,CHEMBL616411,,
1089,,Rattus norvegicus,,F,D,Expert,,10116.0,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",10576,,,1,16616,BAO_0000249,9,CHEMBL616412,,
1090,,Rattus norvegicus,,F,D,Expert,Hippocampus,10116.0,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",10576,,,1,16616,BAO_0000249,9,CHEMBL616413,,10000000.0
1091,,,,B,H,Autocuration,Hippocampus,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,,1,12306,BAO_0000221,8,CHEMBL616414,,10000000.0
1092,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,10576,,,1,17167,BAO_0000221,9,CHEMBL616415,,10000000.0
1093,,,,B,H,Autocuration,,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,10576,,,1,14776,BAO_0000019,8,CHEMBL616416,,
1094,,,,B,H,Expert,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,10576,,,1,12158,BAO_0000357,8,CHEMBL616417,,
1095,,,,B,H,Autocuration,,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,10576,,,1,13481,BAO_0000357,8,CHEMBL616418,,
1096,In vitro,,,B,H,Autocuration,,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,10576,,,1,13427,BAO_0000219,8,CHEMBL616419,,
1097,,,,B,H,Autocuration,,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,10576,,,1,10210,BAO_0000357,8,CHEMBL616420,,
1098,,,,B,H,Autocuration,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,10576,,,1,10205,BAO_0000249,8,CHEMBL616421,,
1099,,,,B,H,Autocuration,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,10576,,,1,10205,BAO_0000249,8,CHEMBL616422,,
1100,,,,B,H,Expert,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,10576,,,1,10205,BAO_0000249,8,CHEMBL616423,,
1101,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,10576,,,1,12280,BAO_0000357,9,CHEMBL616424,,
1102,,,,B,H,Expert,,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,10576,,,1,17386,BAO_0000357,8,CHEMBL616425,,
1103,,,,B,H,Expert,,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,10576,,,1,13654,BAO_0000357,8,CHEMBL616426,,
1104,,,,B,H,Autocuration,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,10576,,,1,14423,BAO_0000221,8,CHEMBL616427,,10000000.0
1105,,,,B,H,Autocuration,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,10576,,,1,15412,BAO_0000221,8,CHEMBL616428,,10000000.0
1106,,,,B,H,Autocuration,Hippocampus,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,1,12073,BAO_0000221,8,CHEMBL616290,,10000000.0
1107,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,10576,,,1,4101,BAO_0000357,9,CHEMBL616052,,
1108,,,,B,H,Autocuration,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,10576,,,1,10062,BAO_0000357,8,CHEMBL616053,,
1109,,,,B,H,Autocuration,,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,10576,,,1,6238,BAO_0000249,8,CHEMBL616054,,
1110,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,10576,,,1,16273,BAO_0000357,8,CHEMBL616055,,
1111,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,10576,,,1,11139,BAO_0000357,8,CHEMBL616056,,
1112,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,10576,,,1,16796,BAO_0000019,8,CHEMBL616057,,
1113,,Rattus norvegicus,,B,D,Expert,Brain,10116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10576,,,1,9548,BAO_0000221,9,CHEMBL616058,,955.0
1114,,,,B,H,Autocuration,Brain,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10576,,,1,10381,BAO_0000221,8,CHEMBL616059,,955.0
1115,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,10576,,,1,13408,BAO_0000249,8,CHEMBL616060,,
1116,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,10576,,,1,13825,BAO_0000221,9,CHEMBL616061,,10000000.0
1117,,,,B,H,Expert,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,10576,,,1,11147,BAO_0000221,8,CHEMBL616062,,10000000.0
1118,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,10576,,,1,10552,BAO_0000249,8,CHEMBL616063,,
1119,,,,B,H,Autocuration,Striatum,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",10576,,,1,10552,BAO_0000249,8,CHEMBL616064,,2435.0
1120,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,10576,,,1,17136,BAO_0000249,9,CHEMBL616065,,
1121,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,10576,,,1,5778,BAO_0000249,9,CHEMBL616066,,
1122,,,,B,H,Autocuration,Hippocampus,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,10576,,,1,13481,BAO_0000221,8,CHEMBL616067,,10000000.0
1123,,,,B,H,Autocuration,Hippocampus,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,10576,,,1,13481,BAO_0000221,8,CHEMBL616068,,10000000.0
1124,,,,B,H,Intermediate,Hippocampus,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,10576,,,1,13630,BAO_0000221,8,CHEMBL616069,,10000000.0
1125,,,,B,H,Expert,,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,10576,,,1,16245,BAO_0000249,8,CHEMBL616070,,
1126,,,,B,H,Autocuration,Hippocampus,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,,,1,14509,BAO_0000221,8,CHEMBL616071,,10000000.0
1127,,,,B,H,Expert,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,10576,,,1,14509,BAO_0000221,8,CHEMBL616072,,10000000.0
1128,,,,B,H,Autocuration,Hippocampus,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,10576,,,1,14509,BAO_0000221,8,CHEMBL616073,,10000000.0
1129,,,,B,H,Autocuration,Hippocampus,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,10576,,,1,14509,BAO_0000221,8,CHEMBL616074,,10000000.0
1130,,,,B,H,Expert,,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,10576,,,1,14256,BAO_0000019,8,CHEMBL616075,,
1131,,,,B,H,Autocuration,,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,10576,,,1,11139,BAO_0000357,8,CHEMBL616076,,
1132,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,10576,,,1,11047,BAO_0000019,9,CHEMBL616077,,
1133,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,10576,,,1,11047,BAO_0000019,9,CHEMBL616078,,
1134,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,10576,,,1,11047,BAO_0000019,9,CHEMBL616079,,
1135,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,10576,,,1,2395,BAO_0000219,9,CHEMBL616080,485.0,
1136,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,10576,,,1,9699,BAO_0000357,8,CHEMBL616081,,
1137,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,10576,,,1,12028,BAO_0000221,9,CHEMBL616082,,10000000.0
1138,,,,B,H,Autocuration,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,10576,,,1,12028,BAO_0000221,8,CHEMBL616083,,10000000.0
1139,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,10576,,,1,5815,BAO_0000019,8,CHEMBL616084,,
1140,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,10576,,,1,16616,BAO_0000019,8,CHEMBL616085,,
1141,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,10576,,,1,5815,BAO_0000019,8,CHEMBL616086,,
1142,,,,B,H,Autocuration,Hippocampus,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",10576,,,1,2761,BAO_0000221,8,CHEMBL616087,,10000000.0
1143,,,,B,H,Expert,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,10576,,,1,13133,BAO_0000357,8,CHEMBL616088,,
1144,,,,B,H,Autocuration,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,10576,,,1,10444,BAO_0000019,8,CHEMBL616089,,
1145,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,10576,,,1,13278,BAO_0000357,9,CHEMBL616090,,
1146,,,,B,H,Autocuration,,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,10576,,,1,15874,BAO_0000357,8,CHEMBL616091,,
1147,,,,B,H,Autocuration,Striatum,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",10576,,,1,10552,BAO_0000249,8,CHEMBL616092,,2435.0
1148,,,,B,H,Autocuration,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),10576,,,1,11130,BAO_0000357,8,CHEMBL616093,,
1149,In vivo,,,B,H,Autocuration,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),10576,,,1,11130,BAO_0000218,8,CHEMBL616094,,
1150,,,,B,H,Autocuration,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,10576,,,1,14542,BAO_0000221,8,CHEMBL616095,,955.0
1151,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,10576,,,1,13670,BAO_0000357,9,CHEMBL616096,,
1152,,,,B,H,Expert,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,10576,,,1,9888,BAO_0000249,8,CHEMBL616097,,
1153,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,10576,,,1,3678,BAO_0000249,9,CHEMBL616098,,
1154,,,,B,H,Autocuration,Hippocampus,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,,,1,11332,BAO_0000221,8,CHEMBL616099,,10000000.0
1155,,,,B,H,Autocuration,Hippocampus,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,,,1,11332,BAO_0000221,8,CHEMBL616100,,10000000.0
1156,,,,B,H,Expert,,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,10576,,,1,1185,BAO_0000357,8,CHEMBL616101,,
1157,,,,B,H,Expert,,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,10576,,,1,2014,BAO_0000249,8,CHEMBL616102,,
1158,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,10576,,,1,1185,BAO_0000357,8,CHEMBL616103,,
1159,,,,B,H,Expert,,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,10576,,,1,14429,BAO_0000019,8,CHEMBL616104,,
1160,,,,B,H,Expert,,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",10576,,,1,16288,BAO_0000019,8,CHEMBL616105,,
1161,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,10576,,,1,5432,BAO_0000019,9,CHEMBL616106,,
1162,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,10576,,,1,14429,BAO_0000019,8,CHEMBL616107,,
1163,,,,B,H,Expert,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,10576,,,1,13672,BAO_0000357,8,CHEMBL616108,,
1164,,,,B,H,Expert,Hippocampus,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10576,,,1,11296,BAO_0000221,8,CHEMBL616109,,10000000.0
1165,,,,B,H,Autocuration,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,10576,,,1,11296,BAO_0000357,8,CHEMBL616110,,
1166,,,,B,H,Expert,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,10576,,,1,14749,BAO_0000219,8,CHEMBL616111,449.0,
1167,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,10576,,,1,15086,BAO_0000019,8,CHEMBL616112,,
1168,,,,B,H,Autocuration,Hippocampus,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,10576,,,1,13462,BAO_0000221,8,CHEMBL616113,,10000000.0
1169,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,10576,,,1,15363,BAO_0000019,8,CHEMBL616114,,
1170,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,10576,,,1,15363,BAO_0000019,8,CHEMBL616115,,
1171,,,,B,H,Autocuration,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,10576,,,1,10796,BAO_0000357,8,CHEMBL616116,,
1172,,,,B,H,Expert,Brain,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,10576,,,1,12816,BAO_0000221,8,CHEMBL615844,,955.0
1173,,,,B,H,Expert,Hippocampus,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10576,,,1,13542,BAO_0000221,8,CHEMBL615939,,10000000.0
1174,,,,B,H,Expert,,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,10576,,,1,13308,BAO_0000019,8,CHEMBL615940,,
1175,,,,B,H,Expert,Hippocampus,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,10576,,,1,13541,BAO_0000221,8,CHEMBL615941,,10000000.0
1176,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,10576,,,1,10058,BAO_0000221,8,CHEMBL615942,,10000000.0
1177,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10576,,,1,10058,BAO_0000221,8,CHEMBL615943,,10000000.0
1178,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,10576,,,1,10058,BAO_0000221,8,CHEMBL615944,,10000000.0
1179,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,10576,,,1,10058,BAO_0000221,8,CHEMBL615945,,10000000.0
1180,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,10576,,,1,10058,BAO_0000221,8,CHEMBL615946,,10000000.0
1181,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,10576,,,1,10058,BAO_0000221,8,CHEMBL615947,,10000000.0
1182,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,10576,,,1,10058,BAO_0000221,8,CHEMBL615948,,10000000.0
1183,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,10576,,,1,10058,BAO_0000221,8,CHEMBL615949,,10000000.0
1184,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,10576,,,1,10058,BAO_0000221,8,CHEMBL615950,,10000000.0
1185,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,10576,,,1,10058,BAO_0000221,8,CHEMBL615951,,10000000.0
1186,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,10576,,,1,10058,BAO_0000221,8,CHEMBL615952,,10000000.0
1187,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,10576,,,1,10058,BAO_0000221,8,CHEMBL615953,,10000000.0
1188,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,10576,,,1,10058,BAO_0000221,8,CHEMBL615954,,10000000.0
1189,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,10576,,,1,10058,BAO_0000221,9,CHEMBL615955,,10000000.0
1190,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,10576,,,1,10058,BAO_0000221,8,CHEMBL615956,,10000000.0
1191,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,10576,,,1,10058,BAO_0000221,8,CHEMBL615957,,10000000.0
1192,,,,B,H,Expert,,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,10576,,,1,12879,BAO_0000019,8,CHEMBL615958,,
1193,,,,B,H,Expert,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,10576,,,1,11964,BAO_0000019,8,CHEMBL615959,,
1194,,,,B,H,Autocuration,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),10576,,,1,11964,BAO_0000019,8,CHEMBL615960,,
1195,,,,B,H,Autocuration,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),10576,,,1,11964,BAO_0000019,8,CHEMBL615961,,
1196,,,,B,H,Expert,Brain,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,10576,,,1,9548,BAO_0000221,8,CHEMBL615962,,955.0
1197,,,,B,H,Expert,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,10576,,,1,9098,BAO_0000019,8,CHEMBL615963,,
1198,,,,B,H,Autocuration,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,10576,,,1,9098,BAO_0000019,8,CHEMBL615964,,
1199,,,,B,H,Autocuration,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,10576,,,1,9098,BAO_0000019,8,CHEMBL615965,,
1200,,,,B,H,Expert,,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,10576,,,1,13248,BAO_0000219,8,CHEMBL615966,449.0,
1201,,,,B,H,Expert,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,10576,,,1,3147,BAO_0000249,8,CHEMBL615967,,
1202,,,,B,H,Expert,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,10576,,,1,13949,BAO_0000019,8,CHEMBL615968,,
1203,,,,B,H,Autocuration,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),10576,,,1,11883,BAO_0000218,8,CHEMBL615969,449.0,
1204,,,,B,H,Autocuration,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),10576,,,1,11883,BAO_0000218,8,CHEMBL615970,,
1205,,Rattus norvegicus,,B,D,Expert,,10116.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,10576,,,1,11883,BAO_0000357,9,CHEMBL615971,,
1206,,,,B,H,Expert,,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,10576,,,1,15535,BAO_0000249,8,CHEMBL615972,,
1207,,,,B,H,Autocuration,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,10576,,,1,15535,BAO_0000249,8,CHEMBL615973,,
1208,,,,B,H,Autocuration,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,10576,,,1,15535,BAO_0000249,8,CHEMBL615974,,
1209,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,51,,,1,16372,BAO_0000219,9,CHEMBL615975,449.0,
1210,,,,B,H,Expert,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,10576,,,1,14608,BAO_0000249,8,CHEMBL615976,,
1211,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,10576,,,1,4795,BAO_0000221,9,CHEMBL872106,,10000000.0
1212,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,10576,,,1,13863,BAO_0000357,8,CHEMBL615977,,
1213,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,10576,,,1,13863,BAO_0000357,8,CHEMBL615978,,
1214,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,10576,,,1,13863,BAO_0000357,8,CHEMBL616166,,
1215,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,10576,,,1,13863,BAO_0000357,8,CHEMBL616167,,
1216,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,10576,,,1,13863,BAO_0000357,8,CHEMBL616168,,
1217,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,10576,,,1,13863,BAO_0000357,8,CHEMBL616169,,
1218,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,10576,,,1,13863,BAO_0000357,8,CHEMBL616170,,
1219,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,10576,,,1,13863,BAO_0000357,8,CHEMBL616171,,
1220,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,10576,,,1,13863,BAO_0000357,8,CHEMBL616172,,
1221,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,10576,,,1,13863,BAO_0000357,8,CHEMBL616173,,
1222,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,10576,,,1,13863,BAO_0000357,8,CHEMBL616174,,
1223,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,10576,,,1,13863,BAO_0000357,8,CHEMBL616175,,
1224,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,10576,,,1,13863,BAO_0000357,8,CHEMBL616176,,
1225,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,10576,,,1,13863,BAO_0000357,8,CHEMBL616177,,
1226,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,10576,,,1,13863,BAO_0000357,8,CHEMBL616178,,
1227,,,,B,H,Autocuration,,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,10576,,,1,9742,BAO_0000019,8,CHEMBL616179,,
1228,,,,B,H,Autocuration,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,10576,,,1,12073,BAO_0000357,8,CHEMBL616180,,
1229,,,,B,H,Autocuration,,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,10576,,,1,4101,BAO_0000357,8,CHEMBL616181,,
1230,,,,B,H,Autocuration,,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,10576,,,1,15360,BAO_0000019,8,CHEMBL616182,,
1231,,,,B,H,Autocuration,Hippocampus,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10576,,,1,11576,BAO_0000221,8,CHEMBL616183,,10000000.0
1232,,,,B,H,Expert,,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,10576,,,1,5834,BAO_0000019,8,CHEMBL615874,,
1233,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,10576,,,1,2395,BAO_0000219,9,CHEMBL615875,485.0,
1234,,,,B,H,Autocuration,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,10576,,,1,1375,BAO_0000019,8,CHEMBL615876,,
1235,,,,B,H,Autocuration,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,10576,,,1,1375,BAO_0000019,8,CHEMBL615877,,
1236,,,,B,H,Autocuration,,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),10576,,,1,3967,BAO_0000357,8,CHEMBL615878,,
1237,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,10576,,,1,12884,BAO_0000357,8,CHEMBL615879,,
1238,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,10576,,,1,2343,BAO_0000357,8,CHEMBL615880,,
1239,,,,B,H,Autocuration,,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",10576,,,1,11511,BAO_0000019,8,CHEMBL615881,,
1240,,Rattus norvegicus,,B,D,Expert,,10116.0,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",10576,,,1,11511,BAO_0000019,9,CHEMBL615882,,
1241,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,10576,,,1,16394,BAO_0000218,8,CHEMBL615883,,
1242,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),10576,,,1,16394,BAO_0000218,8,CHEMBL615884,,
1243,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),10576,,,1,16394,BAO_0000218,8,CHEMBL615885,,
1244,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),10576,,,1,16394,BAO_0000218,8,CHEMBL615886,,
1245,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),10576,,,1,16394,BAO_0000218,8,CHEMBL615887,,
1246,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),10576,,,1,16394,BAO_0000218,8,CHEMBL615888,,
1247,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),10576,,,1,16394,BAO_0000218,8,CHEMBL615889,,
1248,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),10576,,,1,16394,BAO_0000218,8,CHEMBL615890,,
1249,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),10576,,,1,16394,BAO_0000218,8,CHEMBL615891,,
1250,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),10576,,,1,16394,BAO_0000218,8,CHEMBL615892,,
1251,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),10576,,,1,16394,BAO_0000218,8,CHEMBL615893,,
1252,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),10576,,,1,16394,BAO_0000218,8,CHEMBL615894,,
1253,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),10576,,,1,16394,BAO_0000218,8,CHEMBL615895,,
1254,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),10576,,,1,16394,BAO_0000218,8,CHEMBL615896,,
1255,In vivo,,,F,H,Autocuration,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,10576,,,1,16394,BAO_0000218,8,CHEMBL615897,,
1256,,Rattus norvegicus,,F,D,Expert,,10116.0,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",10576,,,1,16616,BAO_0000249,9,CHEMBL615898,,
1257,,,,B,H,Autocuration,,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,10576,,,1,16796,BAO_0000019,8,CHEMBL615899,,
1258,,,,B,H,Autocuration,,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,10576,,,1,16796,BAO_0000019,8,CHEMBL616291,,
1259,,,,B,H,Autocuration,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,10576,,,1,15629,BAO_0000357,8,CHEMBL616292,,
1260,,,,F,H,Autocuration,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",10576,,,1,13241,BAO_0000249,8,CHEMBL616293,,
1261,,,,B,H,Expert,Hippocampus,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,1,12073,BAO_0000221,8,CHEMBL616294,,10000000.0
1262,,,,B,H,Autocuration,Hippocampus,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,10576,,,1,14286,BAO_0000249,8,CHEMBL616295,,10000000.0
1263,,,,B,H,Autocuration,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,10576,,,1,14542,BAO_0000221,8,CHEMBL616296,,955.0
1264,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,10576,,,1,13630,BAO_0000019,8,CHEMBL616297,,
1265,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,10576,,,1,13630,BAO_0000019,8,CHEMBL616605,,
1266,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,10576,,,1,13630,BAO_0000019,8,CHEMBL616606,,
1267,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,10576,,,1,13630,BAO_0000019,8,CHEMBL616607,,
1268,,,,F,H,Expert,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,10576,,,1,13630,BAO_0000019,8,CHEMBL616608,,
1269,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,10576,,,1,13630,BAO_0000019,8,CHEMBL616609,,
1270,,Rattus norvegicus,,F,D,Expert,,10116.0,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,10576,,,1,13630,BAO_0000019,9,CHEMBL616610,,
1271,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,10576,,,1,13630,BAO_0000019,8,CHEMBL616611,,
1272,,,,F,H,Expert,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,10576,,,1,13630,BAO_0000019,8,CHEMBL616612,,
1273,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,10576,,,1,13630,BAO_0000019,8,CHEMBL616613,,
1274,,,,F,H,Expert,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,10576,,,1,13630,BAO_0000019,8,CHEMBL616614,,
1275,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,10576,,,1,13630,BAO_0000019,8,CHEMBL616615,,
1276,,,,F,H,Expert,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,10576,,,1,13630,BAO_0000019,8,CHEMBL616616,,
1277,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,10576,,,1,13630,BAO_0000019,8,CHEMBL616617,,
1278,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,10576,,,1,13630,BAO_0000019,8,CHEMBL616618,,
1279,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,10576,,,1,13630,BAO_0000019,8,CHEMBL616619,,
1280,,,,F,H,Expert,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,10576,,,1,13630,BAO_0000019,8,CHEMBL616620,,
1281,,,,F,H,Expert,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,10576,,,1,13630,BAO_0000019,8,CHEMBL616621,,
1282,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,10576,,,1,13630,BAO_0000019,8,CHEMBL616622,,
1283,,,,F,H,Expert,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,10576,,,1,13630,BAO_0000019,8,CHEMBL616146,,
1284,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,10576,,,1,13630,BAO_0000019,8,CHEMBL832873,,
1285,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,10576,,,1,13630,BAO_0000019,8,CHEMBL616147,,
1286,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,10576,,,1,13630,BAO_0000019,8,CHEMBL872872,,
1287,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,10576,,,1,13630,BAO_0000019,8,CHEMBL616148,,
1288,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,10576,,,1,9783,BAO_0000221,8,CHEMBL616149,,10000000.0
1289,,,,B,H,Expert,Hippocampus,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,10576,,,1,9783,BAO_0000221,8,CHEMBL616150,,10000000.0
1290,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,10576,,,1,14331,BAO_0000249,9,CHEMBL616151,,
1291,,,,B,H,Expert,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,10576,,,1,15260,BAO_0000221,8,CHEMBL872873,,10000000.0
1292,,,,B,H,Autocuration,Hippocampus,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,10576,,,1,15260,BAO_0000221,8,CHEMBL616670,,10000000.0
1293,,,,B,H,Autocuration,Hippocampus,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,10576,,,1,15260,BAO_0000221,8,CHEMBL616671,,10000000.0
1294,,Rattus norvegicus,,F,D,Expert,,10116.0,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",10576,,,1,16616,BAO_0000249,9,CHEMBL884861,,
1295,,,,B,H,Autocuration,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,10576,,,1,15629,BAO_0000357,8,CHEMBL616672,,
1296,,,,B,H,Autocuration,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,10576,,,1,15086,BAO_0000019,8,CHEMBL616673,,
1297,,,,F,H,Expert,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,10576,,,1,5717,BAO_0000019,8,CHEMBL616674,,
1298,,,,B,H,Autocuration,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,10576,,,1,12652,BAO_0000357,8,CHEMBL616675,,
1299,,,,B,H,Autocuration,Hippocampus,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,10576,,,1,14608,BAO_0000221,8,CHEMBL616676,,10000000.0
1300,,,,B,H,Autocuration,Hippocampus,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,,1,12306,BAO_0000221,8,CHEMBL616677,,10000000.0
1301,,,,B,H,Autocuration,Hippocampus,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,,1,12306,BAO_0000221,8,CHEMBL616678,,10000000.0
1302,,Rattus norvegicus,,B,D,Expert,,10116.0,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,10576,,,1,15247,BAO_0000357,9,CHEMBL616679,,
1303,,,,B,H,Expert,Hippocampus,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,10576,,,1,17529,BAO_0000221,8,CHEMBL616680,,10000000.0
1304,,,,B,H,Autocuration,Hippocampus,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,1,14826,BAO_0000221,8,CHEMBL616681,,10000000.0
1305,,,,B,H,Autocuration,Hippocampus,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,1,14826,BAO_0000221,8,CHEMBL616682,,10000000.0
1306,,,,B,H,Autocuration,Hippocampus,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,10576,,,1,13241,BAO_0000221,8,CHEMBL616683,,10000000.0
1307,,,,B,H,Autocuration,Hippocampus,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,10576,,,1,14093,BAO_0000221,8,CHEMBL616684,,10000000.0
1308,,,,B,H,Autocuration,Hippocampus,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,10576,,,1,14093,BAO_0000221,8,CHEMBL616685,,10000000.0
1309,,,,B,H,Autocuration,Brain,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,10576,,,1,14442,BAO_0000221,8,CHEMBL616686,,955.0
1310,,,,B,H,Autocuration,,,Affinity for 5-hydroxytryptamine 1A receptor site,10576,,,1,9919,BAO_0000357,8,CHEMBL616687,,
1311,,,,B,H,Autocuration,,,Affinity for 5-hydroxytryptamine 1A receptor site,10576,,,1,9919,BAO_0000357,8,CHEMBL616688,,
1312,,,,B,H,Autocuration,Hippocampus,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,10576,,,1,11440,BAO_0000221,8,CHEMBL616689,,10000000.0
1313,,,,B,H,Autocuration,,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,10576,,,1,11257,BAO_0000357,8,CHEMBL616690,,
1314,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,10576,,,1,10330,BAO_0000357,8,CHEMBL616691,,
1315,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,10576,,,1,17331,BAO_0000221,9,CHEMBL616692,,10000000.0
1316,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,10576,,,1,16567,BAO_0000249,8,CHEMBL616693,,
1317,,Rattus norvegicus,,B,D,Expert,,10116.0,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",10576,,,1,12058,BAO_0000019,9,CHEMBL616694,,
1318,,,,B,H,Autocuration,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,10576,,,1,9699,BAO_0000221,8,CHEMBL616695,,10000000.0
1319,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,10576,,,1,9547,BAO_0000357,8,CHEMBL616696,,
1320,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,10576,,,1,10330,BAO_0000357,8,CHEMBL616697,,
1321,,,,B,H,Autocuration,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,10576,,,1,14331,BAO_0000357,8,CHEMBL616698,,
1322,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,10576,,,1,14060,BAO_0000019,9,CHEMBL616949,,
1323,,,,B,H,Autocuration,Hippocampus,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,10576,,,1,14744,BAO_0000221,8,CHEMBL616950,,10000000.0
1324,,,,B,H,Autocuration,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,10576,,,1,13506,BAO_0000357,8,CHEMBL832875,,
1325,,,,B,H,Expert,Brain,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10576,,,1,10862,BAO_0000221,8,CHEMBL616951,,955.0
1326,,,,B,H,Expert,Brain,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10576,,,1,10862,BAO_0000221,8,CHEMBL616952,,955.0
1327,,,,B,H,Expert,,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,10576,,,1,10062,BAO_0000357,8,CHEMBL616953,,
1328,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,10576,,,1,12073,BAO_0000357,8,CHEMBL616954,,
1329,,,,B,H,Autocuration,,,GTPgammaS radioligand binding assay,106,,,1,14875,BAO_0000357,8,CHEMBL616955,,
1330,,,,B,H,Autocuration,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,106,,,1,2391,BAO_0000357,8,CHEMBL616956,,
1331,,,,F,H,Autocuration,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,106,,,1,2391,BAO_0000019,8,CHEMBL616957,,
1332,,,,F,H,Autocuration,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,106,,,1,2391,BAO_0000019,8,CHEMBL616958,,
1333,,,,B,H,Autocuration,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,106,,,1,2391,BAO_0000357,8,CHEMBL616959,,
1334,,,,B,H,Autocuration,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,106,,,1,2391,BAO_0000357,8,CHEMBL616960,,
1335,,,,F,H,Autocuration,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,106,,,1,2391,BAO_0000019,8,CHEMBL616961,,
1336,,,,B,H,Expert,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,106,,,1,17211,BAO_0000219,8,CHEMBL616962,308.0,
1337,,,,B,H,Autocuration,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,106,,,1,17211,BAO_0000219,8,CHEMBL616963,308.0,
1338,,Homo sapiens,,B,D,Expert,,9606.0,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,106,,,1,6491,BAO_0000357,9,CHEMBL616524,,
1339,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,106,,,1,16190,BAO_0000219,8,CHEMBL616525,449.0,
1340,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,106,,,1,14165,BAO_0000019,8,CHEMBL872908,,
1341,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,106,,,1,14165,BAO_0000019,8,CHEMBL616526,,
1342,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,106,,,1,4234,BAO_0000357,9,CHEMBL616527,,
1343,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,106,,,1,6328,BAO_0000219,8,CHEMBL616528,,
1344,,,,B,H,Autocuration,,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,106,,,1,14770,BAO_0000357,8,CHEMBL616529,,
1345,,,,B,H,Autocuration,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,106,,,1,2598,BAO_0000357,8,CHEMBL616530,,
1346,,,,B,H,Expert,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,106,,,1,6897,BAO_0000357,8,CHEMBL616531,,
1347,,,,B,H,Autocuration,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,106,,,1,6897,BAO_0000357,8,CHEMBL616532,,
1348,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,106,,,1,6013,BAO_0000357,8,CHEMBL616533,,
1349,,,,B,H,Expert,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,106,,,1,5843,BAO_0000357,8,CHEMBL616534,,
1350,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,106,,,1,14454,BAO_0000357,8,CHEMBL616535,,
1351,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,106,,,1,16209,BAO_0000357,8,CHEMBL616536,,
1352,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,106,,,1,3935,BAO_0000357,8,CHEMBL616537,,
1353,,,,F,H,Expert,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,106,,,1,13729,BAO_0000219,8,CHEMBL616538,485.0,
1354,,,,F,H,Expert,,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,106,,,1,14251,BAO_0000019,8,CHEMBL616539,,
1355,,,,B,H,Expert,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,106,,,1,17085,BAO_0000019,8,CHEMBL616540,,
1356,,,,B,H,Autocuration,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,106,,,1,3025,BAO_0000357,8,CHEMBL616429,,
1357,,,,B,H,Expert,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,106,,,1,15315,BAO_0000357,8,CHEMBL616430,,
1358,,Homo sapiens,,B,D,Expert,,9606.0,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,106,,,1,14214,BAO_0000219,9,CHEMBL616431,,
1359,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,106,,,1,3804,BAO_0000357,9,CHEMBL616432,,
1360,,Homo sapiens,,B,D,Expert,,9606.0,Affinity for 5-hydroxytryptamine 1B receptor subtype,106,,,1,2391,BAO_0000357,9,CHEMBL616433,,
1361,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity for human 5-hydroxytryptamine 1B receptor,106,,,1,4175,BAO_0000357,9,CHEMBL616434,,
1362,,,,B,H,Autocuration,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,106,,,1,17296,BAO_0000219,8,CHEMBL616435,449.0,
1363,,,,B,H,Expert,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,106,,,1,17085,BAO_0000019,8,CHEMBL616436,,
1364,,,,B,H,Autocuration,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,106,,,1,17211,BAO_0000219,8,CHEMBL616437,308.0,
1365,,,,B,H,Autocuration,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,106,,,1,17211,BAO_0000219,8,CHEMBL616438,308.0,
1366,,,,B,H,Autocuration,,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,106,,,1,17211,BAO_0000219,8,CHEMBL616439,308.0,
1367,,Homo sapiens,,B,D,Expert,,9606.0,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,106,,,1,15926,BAO_0000357,9,CHEMBL616440,,
1368,,,,B,H,Autocuration,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,106,,,1,16312,BAO_0000219,8,CHEMBL616441,485.0,
1369,,,,B,H,Expert,,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,106,,,1,5843,BAO_0000357,8,CHEMBL616442,,
1370,,,,B,H,Autocuration,,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,106,,,1,5843,BAO_0000357,8,CHEMBL616443,,
1371,,,,B,H,Expert,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,106,,,1,16312,BAO_0000219,8,CHEMBL616444,485.0,
1372,,Homo sapiens,,B,D,Expert,,9606.0,Binding activity against human 5-hydroxytryptamine 1B receptor,106,,,1,15926,BAO_0000357,9,CHEMBL616445,,
1373,,Homo sapiens,,B,D,Expert,,9606.0,Binding activity against human 5-hydroxytryptamine 1B receptor,106,,,1,15926,BAO_0000357,9,CHEMBL616446,,
1374,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,106,,,1,4540,BAO_0000219,9,CHEMBL616447,449.0,
1375,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,106,,,1,6166,BAO_0000357,8,CHEMBL616448,,
1376,,,,B,H,Autocuration,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,106,,,1,17296,BAO_0000219,8,CHEMBL616449,449.0,
1377,,,,B,H,Autocuration,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,106,,,1,17296,BAO_0000219,8,CHEMBL616450,449.0,
1378,,,,B,H,Autocuration,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,106,,,1,17296,BAO_0000219,8,CHEMBL857974,449.0,
1379,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,106,,,1,15779,BAO_0000219,8,CHEMBL616451,449.0,
1380,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,106,,,1,15779,BAO_0000219,8,CHEMBL616452,449.0,
1381,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,106,,,1,15779,BAO_0000219,8,CHEMBL616453,449.0,
1382,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,106,,,1,4199,BAO_0000219,8,CHEMBL616454,449.0,
1383,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity for human 5-hydroxytryptamine 1B receptor,106,,,1,14875,BAO_0000357,9,CHEMBL616455,,
1384,,,,B,H,Autocuration,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,106,,,1,15146,BAO_0000219,8,CHEMBL616456,449.0,
1385,,,,B,H,Autocuration,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,106,,,1,5213,BAO_0000357,8,CHEMBL616457,,
1386,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,106,,,1,14818,BAO_0000219,8,CHEMBL616458,449.0,
1387,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",106,,,1,4829,BAO_0000219,8,CHEMBL616459,449.0,
1388,,,,F,H,Expert,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,106,,,1,14454,BAO_0000019,8,CHEMBL616460,,
1389,,,,F,H,Expert,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,106,,,1,14454,BAO_0000019,8,CHEMBL616461,,
1390,,,,F,H,Autocuration,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",106,,,1,14875,BAO_0000219,8,CHEMBL616462,449.0,
1391,,,,F,H,Autocuration,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",106,,,1,14875,BAO_0000219,8,CHEMBL616463,449.0,
1392,,,,F,H,Autocuration,,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",105,,,1,15250,BAO_0000019,8,CHEMBL616464,,
1393,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,105,,,1,15250,BAO_0000219,8,CHEMBL616465,449.0,
1394,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,17105,,,1,15086,BAO_0000357,8,CHEMBL832874,,
1395,,Oryctolagus cuniculus,,F,H,Autocuration,,9986.0,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,106,,,1,3025,BAO_0000019,8,CHEMBL616184,,
1396,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,106,,,1,14998,BAO_0000019,8,CHEMBL616185,,
1397,,Oryctolagus cuniculus,,B,H,Intermediate,,9986.0,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",106,,,1,14998,BAO_0000019,8,CHEMBL616186,,
1398,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,106,,,1,14998,BAO_0000019,8,CHEMBL616187,,
1399,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,10577,,,1,13969,BAO_0000357,8,CHEMBL616188,,
1400,,,,B,D,Intermediate,,,Binding affinity for 5-hydroxytryptamine 1B receptor,10577,,,1,13392,BAO_0000357,9,CHEMBL873475,,
1401,,Rattus norvegicus,,B,D,Expert,Striatum,10116.0,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,10577,,,1,3651,BAO_0000019,9,CHEMBL616189,,2435.0
1402,,,,B,H,Expert,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,10577,,,1,10025,BAO_0000357,8,CHEMBL616190,,
1403,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,10576,,,1,13863,BAO_0000357,8,CHEMBL616191,,
1404,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,10576,,,1,13863,BAO_0000357,8,CHEMBL616192,,
1405,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,10576,,,1,13863,BAO_0000357,8,CHEMBL616193,,
1406,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,10576,,,1,13863,BAO_0000357,8,CHEMBL616194,,
1407,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,10576,,,1,13863,BAO_0000357,8,CHEMBL616195,,
1408,,,,B,H,Autocuration,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,10576,,,1,13863,BAO_0000357,8,CHEMBL616196,,
1409,,,,B,H,Autocuration,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,10576,,,1,4622,BAO_0000249,8,CHEMBL616197,,10000000.0
1410,,,,B,H,Intermediate,,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,10576,,,1,14911,BAO_0000019,8,CHEMBL616198,,
1411,,,,B,H,Autocuration,Hippocampus,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,10576,,,1,12678,BAO_0000221,8,CHEMBL616199,,10000000.0
1412,,,,B,H,Expert,Hippocampus,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,10576,,,1,12678,BAO_0000221,8,CHEMBL616200,,10000000.0
1413,,,,B,H,Expert,Hippocampus,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,10576,,,1,14235,BAO_0000221,8,CHEMBL616201,,10000000.0
1414,,,,B,H,Expert,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,10576,,,1,14949,BAO_0000221,8,CHEMBL616202,,10000000.0
1415,,,,B,H,Expert,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,10576,,,1,14949,BAO_0000221,8,CHEMBL616203,,10000000.0
1416,,,,B,H,Expert,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,10576,,,1,14949,BAO_0000221,8,CHEMBL616204,,10000000.0
1417,,,,B,H,Expert,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,10576,,,1,14949,BAO_0000221,8,CHEMBL616205,,10000000.0
1418,,,,B,H,Expert,Hippocampus,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,10576,,,1,14949,BAO_0000221,8,CHEMBL616206,,10000000.0
1419,,,,B,H,Expert,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,10576,,,1,16118,BAO_0000249,8,CHEMBL616207,,
1420,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,10576,,,1,3268,BAO_0000249,8,CHEMBL616208,,
1421,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,10576,,,1,3268,BAO_0000249,8,CHEMBL616209,,
1422,,,,B,H,Expert,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,10576,,,1,16117,BAO_0000357,8,CHEMBL616210,,
1423,,,,B,H,Expert,Hippocampus,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,10576,,,1,9783,BAO_0000221,8,CHEMBL616211,,10000000.0
1424,,,,B,H,Autocuration,Hippocampus,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,10576,,,1,9783,BAO_0000221,8,CHEMBL616504,,10000000.0
1425,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,10576,,,1,14356,BAO_0000221,9,CHEMBL616505,,10000000.0
1426,,,,F,H,Autocuration,,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,10576,,,1,15740,BAO_0000019,8,CHEMBL616506,,
1427,,,,B,H,Autocuration,Hippocampus,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,10576,,,1,12306,BAO_0000221,8,CHEMBL872107,,10000000.0
1428,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,10576,,,1,13348,BAO_0000221,9,CHEMBL616507,,10000000.0
1429,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,10576,,,1,10394,BAO_0000249,8,CHEMBL616303,,
1430,,,,B,H,Autocuration,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,10576,,,1,15260,BAO_0000221,8,CHEMBL616304,,10000000.0
1431,,,,B,H,Expert,Hippocampus,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,10576,,,1,10046,BAO_0000221,8,CHEMBL616305,,10000000.0
1432,,,,F,H,Intermediate,Hippocampus,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,10576,,,1,15260,BAO_0000221,8,CHEMBL616306,,10000000.0
1433,,,,B,H,Autocuration,,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,10576,,,1,12851,BAO_0000357,8,CHEMBL616307,,
1434,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,10576,,,1,2148,BAO_0000221,9,CHEMBL881829,,10000000.0
1435,,,,B,H,Expert,,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,10576,,,1,13134,BAO_0000357,8,CHEMBL616308,,
1436,,,,B,H,Autocuration,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,10576,,,1,12462,BAO_0000019,8,CHEMBL616309,,
1437,,,,B,H,Expert,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,10576,,,1,12462,BAO_0000019,8,CHEMBL616310,,
1438,,,,B,H,Autocuration,,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,10576,,,1,12462,BAO_0000219,8,CHEMBL616311,449.0,
1439,,,,B,H,Expert,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,10576,,,1,11933,BAO_0000357,8,CHEMBL616312,,
1440,,,,B,H,Autocuration,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,10576,,,1,11933,BAO_0000357,8,CHEMBL616313,,
1441,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,10576,,,1,403,BAO_0000221,9,CHEMBL616314,,10000000.0
1442,,,,B,H,Autocuration,Hippocampus,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,1,15538,BAO_0000221,8,CHEMBL616315,,10000000.0
1443,,,,B,H,Autocuration,Hippocampus,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,10576,,,1,15538,BAO_0000221,8,CHEMBL616567,,10000000.0
1444,,,,B,H,Autocuration,Hippocampus,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,10576,,,1,15538,BAO_0000221,8,CHEMBL616568,,10000000.0
1445,,,,B,H,Intermediate,,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,10576,,,1,12464,BAO_0000019,8,CHEMBL616569,,
1446,,,,B,H,Expert,,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,10576,,,1,1455,BAO_0000357,8,CHEMBL616570,,
1447,,,,B,H,Autocuration,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,10576,,,1,12652,BAO_0000357,8,CHEMBL616571,,
1448,,,,B,H,Autocuration,Hippocampus,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,10576,,,1,12639,BAO_0000221,8,CHEMBL616572,,10000000.0
1449,,,,B,H,Expert,,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,10576,,,1,13949,BAO_0000249,8,CHEMBL616573,,
1450,,Rattus norvegicus,,B,D,Expert,,10116.0,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,10576,,,1,12463,BAO_0000357,9,CHEMBL616574,,
1451,,,,B,H,Expert,Hippocampus,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,10576,,,1,14829,BAO_0000221,8,CHEMBL616575,,10000000.0
1452,,,,B,H,Autocuration,Hippocampus,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,10576,,,1,14829,BAO_0000221,8,CHEMBL872108,,10000000.0
1453,,,,B,H,Autocuration,,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,10576,,,1,12092,BAO_0000357,8,CHEMBL616576,,
1454,,,,B,H,Autocuration,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,10576,,,1,403,BAO_0000249,8,CHEMBL616577,,
1455,,,,B,H,Autocuration,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,10576,,,1,403,BAO_0000249,8,CHEMBL616578,,
1456,,,,B,H,Expert,,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,10576,,,1,3967,BAO_0000357,8,CHEMBL616579,,
1457,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,10576,,,1,12771,BAO_0000019,9,CHEMBL616580,,
1458,,,,B,H,Autocuration,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,10576,,,1,15086,BAO_0000019,8,CHEMBL616581,,
1459,,,,B,H,Autocuration,Hippocampus,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,1,14909,BAO_0000221,8,CHEMBL616582,,10000000.0
1460,,,,B,H,Expert,Hippocampus,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,10576,,,1,14949,BAO_0000221,8,CHEMBL616583,,10000000.0
1461,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,10576,,,1,2309,BAO_0000221,9,CHEMBL616584,,10000000.0
1462,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,10576,,,1,4170,BAO_0000357,8,CHEMBL616585,,
1463,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,10576,,,1,11642,BAO_0000221,9,CHEMBL616586,,10000000.0
1464,,,,B,H,Autocuration,Hippocampus,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,10576,,,1,11642,BAO_0000221,8,CHEMBL616587,,10000000.0
1465,,,,B,H,Autocuration,Hippocampus,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,10576,,,1,12953,BAO_0000221,8,CHEMBL616588,,10000000.0
1466,,,,B,H,Autocuration,Hippocampus,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,10576,,,1,12953,BAO_0000221,8,CHEMBL616589,,10000000.0
1467,,,,B,H,Expert,Hippocampus,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,10576,,,1,12953,BAO_0000221,8,CHEMBL616590,,10000000.0
1468,,,,B,H,Expert,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",10576,,,1,12903,BAO_0000219,8,CHEMBL616591,449.0,
1469,,,,B,H,Expert,,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,10576,,,1,12536,BAO_0000357,8,CHEMBL616592,,
1470,,,,B,H,Autocuration,,,The inhibition activity of 5-HT1A at 1 uM,10576,,,1,10058,BAO_0000357,8,CHEMBL616593,,
1471,,,,B,H,Expert,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",10576,,,1,12902,BAO_0000219,8,CHEMBL616594,485.0,
1472,,,,B,H,Expert,,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,10576,,,1,14057,BAO_0000249,8,CHEMBL616595,,
1473,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,10576,,,1,11296,BAO_0000357,8,CHEMBL616596,,
1474,,,,B,H,Autocuration,Hippocampus,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10576,,,1,11296,BAO_0000221,8,CHEMBL616597,,10000000.0
1475,,,,B,H,Expert,Hippocampus,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,10576,,,1,11296,BAO_0000221,8,CHEMBL616598,,10000000.0
1476,,Rattus norvegicus,,F,D,Expert,,10116.0,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,10576,,,1,16616,BAO_0000249,9,CHEMBL616599,,
1477,,Rattus norvegicus,,F,D,Expert,Hippocampus,10116.0,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",10576,,,1,16616,BAO_0000249,9,CHEMBL616600,,10000000.0
1478,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,10576,,,1,16567,BAO_0000019,8,CHEMBL616601,,
1479,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,10576,,,1,16567,BAO_0000019,8,CHEMBL616602,,
1480,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,10576,,,1,16567,BAO_0000019,8,CHEMBL616603,,
1481,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,10576,,,1,16567,BAO_0000019,8,CHEMBL616604,,
1482,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,10576,,,1,17136,BAO_0000249,8,CHEMBL616316,,
1483,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,10576,,,1,17136,BAO_0000249,8,CHEMBL616317,,
1484,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,10576,,,1,16616,BAO_0000019,9,CHEMBL616318,,
1485,,,,B,H,Autocuration,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,10576,,,1,17331,BAO_0000221,8,CHEMBL616319,,10000000.0
1486,,,,B,H,Autocuration,Hippocampus,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,10576,,,1,17331,BAO_0000221,8,CHEMBL616320,,10000000.0
1487,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,10576,,,1,17167,BAO_0000221,9,CHEMBL616321,,10000000.0
1488,,,,F,H,Autocuration,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,10576,,,1,15740,BAO_0000019,8,CHEMBL616322,,
1489,,,,F,H,Autocuration,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,10576,,,1,15740,BAO_0000019,8,CHEMBL616323,,
1490,,,,B,H,Autocuration,,,Ratio of binding affinity to 5-HT 1A and D2 receptor,10576,,,1,4671,BAO_0000357,8,CHEMBL616324,,
1491,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,10576,,,1,10058,BAO_0000221,8,CHEMBL616325,,10000000.0
1492,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,10576,,,1,10058,BAO_0000221,8,CHEMBL616326,,10000000.0
1493,,,,B,H,Autocuration,Hippocampus,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,10576,,,1,10058,BAO_0000221,8,CHEMBL616327,,10000000.0
1494,,,,B,H,Autocuration,,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,10576,,,1,12073,BAO_0000357,8,CHEMBL616328,,
1495,,,,B,H,Autocuration,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),10576,,,1,2759,BAO_0000249,8,CHEMBL858110,,
1496,,,,F,H,Autocuration,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),10576,,,1,2759,BAO_0000249,8,CHEMBL616329,,
1497,,,,B,H,Autocuration,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),10576,,,1,2759,BAO_0000249,8,CHEMBL616330,,
1498,,,,F,H,Autocuration,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),10576,,,1,2759,BAO_0000249,8,CHEMBL616331,,
1499,,,,F,H,Autocuration,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,10576,,,1,2759,BAO_0000249,8,CHEMBL616332,,
1500,,,,B,H,Autocuration,Brain,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,10576,,,1,9737,BAO_0000249,8,CHEMBL857063,,955.0
1501,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,10576,,,1,9737,BAO_0000019,8,CHEMBL616333,,
1502,,,,F,H,Expert,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,10576,,,1,5717,BAO_0000019,8,CHEMBL616334,,
1503,,,,B,H,Autocuration,Hippocampus,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10576,,,1,12253,BAO_0000221,8,CHEMBL616335,,10000000.0
1504,,,,B,H,Autocuration,,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,10576,,,1,14025,BAO_0000019,8,CHEMBL616336,,
1505,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,10576,,,1,10425,BAO_0000249,8,CHEMBL616337,,
1506,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,10576,,,1,14998,BAO_0000019,8,CHEMBL616338,,
1507,,,,B,H,Autocuration,Hippocampus,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,10576,,,1,13694,BAO_0000221,8,CHEMBL616339,,10000000.0
1508,,,,B,H,Autocuration,Hippocampus,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,10576,,,1,13694,BAO_0000221,8,CHEMBL616340,,10000000.0
1509,,,,B,H,Autocuration,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,10576,,,1,4342,BAO_0000357,8,CHEMBL616341,,
1510,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity against rat 5-hydroxytryptamine 1A receptor,10576,,,1,12936,BAO_0000357,9,CHEMBL616342,,
1511,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,10576,,,1,13144,BAO_0000019,9,CHEMBL616343,,
1512,,,,B,H,Expert,,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,10576,,,1,13343,BAO_0000019,8,CHEMBL616344,,
1513,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,10576,,,1,12132,BAO_0000357,8,CHEMBL616345,,
1514,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,10576,,,1,15419,BAO_0000019,8,CHEMBL616346,,
1515,,,,B,H,Autocuration,Hippocampus,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,10576,,,1,1479,BAO_0000221,8,CHEMBL616347,,10000000.0
1516,,,,B,H,Expert,,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,10576,,,1,14287,BAO_0000019,8,CHEMBL616348,,
1517,,,,B,H,Expert,,,Binding affinity at 5-hydroxytryptamine 1A receptor,10576,,,1,13116,BAO_0000357,8,CHEMBL616349,,
1518,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,10576,,,1,2759,BAO_0000249,9,CHEMBL616152,,
1519,,,,B,H,Autocuration,,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,10576,,,1,2759,BAO_0000249,8,CHEMBL616153,,
1520,,,,B,H,Expert,,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",10576,,,1,14748,BAO_0000019,8,CHEMBL616154,,
1521,,,,B,H,Autocuration,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,10576,,,1,12304,BAO_0000019,8,CHEMBL616155,,
1522,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,10576,,,1,12409,BAO_0000221,9,CHEMBL616156,,10000000.0
1523,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,10576,,,1,12409,BAO_0000221,9,CHEMBL616157,,10000000.0
1524,,,,B,H,Autocuration,Hippocampus,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,10576,,,1,13267,BAO_0000221,8,CHEMBL616158,,10000000.0
1525,,,,B,H,Autocuration,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,10576,,,1,15194,BAO_0000357,8,CHEMBL616159,,
1526,,,,B,H,Expert,,,pKi value against rat 5-hydroxytryptamine 1A receptor.,10576,,,1,14256,BAO_0000357,8,CHEMBL616160,,
1527,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,10576,,,1,16567,BAO_0000019,8,CHEMBL616161,,
1528,,,,F,H,Autocuration,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,10576,,,1,15740,BAO_0000019,8,CHEMBL616162,,
1529,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,12687,,,1,13278,BAO_0000357,9,CHEMBL616163,,
1530,,,,B,H,Expert,,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,10626,,,1,1970,BAO_0000249,8,CHEMBL616164,,
1531,,,,B,H,Autocuration,Brain,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,10576,,,1,10034,BAO_0000221,8,CHEMBL616165,,955.0
1532,,Rattus norvegicus,,B,H,Autocuration,,10116.0,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,51,,,1,13348,BAO_0000019,8,CHEMBL616355,,
1533,,,,F,H,Autocuration,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,10576,,,1,13630,BAO_0000019,8,CHEMBL616356,,
1534,,,,B,H,Autocuration,Brain,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,10576,,,1,10862,BAO_0000221,8,CHEMBL616357,,955.0
1535,,,,B,H,Autocuration,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",10576,,,1,12058,BAO_0000019,8,CHEMBL616358,,
1536,,,,B,H,Autocuration,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,51,,,1,4639,BAO_0000357,8,CHEMBL616359,,
1537,,,,B,H,Expert,,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,51,,,1,15453,BAO_0000357,8,CHEMBL616360,,
1538,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,51,,,1,4820,BAO_0000357,8,CHEMBL616361,,
1539,,,,B,H,Autocuration,,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,51,,,1,1089,BAO_0000357,8,CHEMBL616362,,
1540,,,,B,H,Autocuration,,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,51,,,1,386,BAO_0000249,8,CHEMBL616363,,
1541,,,,B,H,Autocuration,,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,51,,,1,6011,BAO_0000357,8,CHEMBL616364,,
1542,,,,B,H,Autocuration,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,51,,,1,5014,BAO_0000357,8,CHEMBL616365,,
1543,,,,B,H,Expert,,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,51,,,1,4402,BAO_0000357,8,CHEMBL616366,,
1544,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,51,,,1,17066,BAO_0000357,8,CHEMBL872906,,
1545,,,,B,H,Autocuration,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,51,,,1,17515,BAO_0000357,8,CHEMBL616367,,
1546,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor,51,,,1,2474,BAO_0000357,8,CHEMBL616368,,
1547,,,,B,H,Autocuration,,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,51,,,1,4775,BAO_0000357,8,CHEMBL616369,,
1548,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,51,,,1,14294,BAO_0000357,9,CHEMBL616370,,
1549,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,51,,,1,14294,BAO_0000357,9,CHEMBL616371,,
1550,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,51,,,1,12249,BAO_0000219,8,CHEMBL616372,449.0,
1551,,,,B,H,Expert,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,51,,,1,11376,BAO_0000219,8,CHEMBL616373,,
1552,In vivo,,,B,H,Autocuration,,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,51,,,1,2474,BAO_0000218,8,CHEMBL616374,,
1553,,,,B,H,Autocuration,Hippocampus,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,51,,,1,13311,BAO_0000221,8,CHEMBL616375,,10000000.0
1554,,,,B,H,Autocuration,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,51,,,1,4373,BAO_0000357,8,CHEMBL616376,,
1555,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,51,,,1,1633,BAO_0000357,8,CHEMBL857064,,
1556,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,51,,,1,11866,BAO_0000357,8,CHEMBL616377,,
1557,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,51,,,1,4373,BAO_0000357,8,CHEMBL616378,,
1558,,,,B,H,Autocuration,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,51,,,1,4687,BAO_0000357,8,CHEMBL616379,,
1559,,,,B,H,Autocuration,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,11863,,,1,16946,BAO_0000357,8,CHEMBL616380,,
1560,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,11863,,,1,13291,BAO_0000357,8,CHEMBL616381,,
1561,,,,B,H,Autocuration,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,11863,,,1,14159,BAO_0000357,8,CHEMBL616382,,
1562,,,,B,H,Autocuration,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,11863,,,1,10812,BAO_0000357,8,CHEMBL616383,,
1563,,Mus musculus,,B,D,Expert,,10090.0,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,11863,,,1,3032,BAO_0000219,9,CHEMBL616350,449.0,
1564,,,,B,H,Autocuration,,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,11863,,,1,16655,BAO_0000357,8,CHEMBL616351,,
1565,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,11863,,,1,14532,BAO_0000357,8,CHEMBL616352,,
1566,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor,11863,,,1,13944,BAO_0000357,8,CHEMBL616353,,
1567,,,,B,H,Autocuration,,,Binding affinity against serotonergic 5-HT1a receptor,11863,,,1,13033,BAO_0000357,8,CHEMBL616354,,
1568,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,11863,,,1,10321,BAO_0000357,8,CHEMBL616508,,
1569,,Mus musculus,,B,D,Expert,,10090.0,Binding affinity for 5-hydroxytryptamine 1A receptor,11863,,,1,2968,BAO_0000357,9,CHEMBL616559,,
1570,,,,B,H,Autocuration,,,Binding affinity at 5-hydroxytryptamine 1A receptor,11863,,,1,13964,BAO_0000357,8,CHEMBL616560,,
1571,,,,B,H,Autocuration,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",11863,,,1,15527,BAO_0000357,8,CHEMBL616561,,
1572,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,11863,,,1,12248,BAO_0000219,8,CHEMBL616562,449.0,
1573,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,11863,,,1,12249,BAO_0000219,8,CHEMBL616563,449.0,
1574,,,,B,H,Autocuration,,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,11863,,,1,15120,BAO_0000357,8,CHEMBL616564,,
1575,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,11863,,,1,13313,BAO_0000357,8,CHEMBL616565,,
1576,,,,B,H,Autocuration,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,11863,,,1,2613,BAO_0000218,8,CHEMBL616566,,
1577,,,,B,H,Autocuration,,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,11863,,,1,16700,BAO_0000357,8,CHEMBL616989,,
1578,,,,B,H,Autocuration,,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,11863,,,1,2201,BAO_0000357,8,CHEMBL857975,,
1579,,Mus musculus,,B,D,Expert,,10090.0,Binding affinity against 5-hydroxytryptamine 1A receptor,11863,,,1,1274,BAO_0000357,9,CHEMBL616990,,
1580,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,11863,,,1,1317,BAO_0000357,8,CHEMBL616991,,
1581,,,,B,H,Autocuration,,,Tested against 5-hydroxytryptamine 1A receptor,11863,,,1,12146,BAO_0000357,8,CHEMBL616992,,
1582,,,,B,H,Autocuration,,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,11863,,,1,14059,BAO_0000357,8,CHEMBL616993,,
1583,,Oryctolagus cuniculus,,B,H,Expert,,9986.0,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,106,,,1,14025,BAO_0000019,8,CHEMBL616994,,
1584,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,106,,,1,14025,BAO_0000019,8,CHEMBL616995,,
1585,,Gorilla gorilla,,B,D,Intermediate,,9593.0,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,105571,,,1,14447,BAO_0000219,9,CHEMBL616996,722.0,
1586,In vivo,Cavia porcellus,,F,H,Autocuration,,10141.0,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,106,,,1,3025,BAO_0000218,8,CHEMBL616997,,
1587,In vivo,Cavia porcellus,,F,H,Autocuration,,10141.0,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,106,,,1,3025,BAO_0000218,8,CHEMBL616998,,
1588,,Cavia porcellus,,F,H,Autocuration,,10141.0,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,106,,,1,15329,BAO_0000019,8,CHEMBL616999,,
1589,,Cavia porcellus,,F,H,Autocuration,,10141.0,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,106,,,1,15329,BAO_0000019,8,CHEMBL617000,,
1590,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,106,,,1,15847,BAO_0000019,8,CHEMBL617001,,
1591,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,106,,,1,15847,BAO_0000019,8,CHEMBL858111,,
1592,,,,F,H,Autocuration,,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,106,,,1,14165,BAO_0000019,8,CHEMBL617002,,
1593,,,,F,H,Autocuration,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),106,,,1,14214,BAO_0000019,8,CHEMBL617003,,
1594,,,,F,H,Autocuration,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),106,,,1,14214,BAO_0000019,8,CHEMBL617004,,
1595,,Homo sapiens,,F,D,Expert,,9606.0,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,106,,,1,14214,BAO_0000019,9,CHEMBL617005,,
1596,,Homo sapiens,,F,D,Expert,,9606.0,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,106,,,1,13729,BAO_0000219,9,CHEMBL616623,485.0,
1597,,,,F,H,Autocuration,,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,106,,,1,3025,BAO_0000219,8,CHEMBL616624,449.0,
1598,,,,B,H,Autocuration,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,106,,,1,2391,BAO_0000357,8,CHEMBL883243,,
1599,,,,F,H,Autocuration,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,106,,,1,2391,BAO_0000019,8,CHEMBL616625,,
1600,,,,F,H,Expert,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",106,,,1,14956,BAO_0000219,8,CHEMBL616626,449.0,
1601,,,,F,H,Autocuration,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,106,,,1,2598,BAO_0000219,8,CHEMBL616627,449.0,
1602,,,,F,H,Autocuration,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,106,,,1,2598,BAO_0000219,8,CHEMBL616628,449.0,
1603,,,,F,H,Autocuration,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,106,,,1,2598,BAO_0000219,8,CHEMBL616629,449.0,
1604,,,,F,H,Autocuration,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,106,,,1,2598,BAO_0000219,8,CHEMBL616630,449.0,
1605,,,,F,H,Expert,,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",106,,,1,14956,BAO_0000019,8,CHEMBL616631,,
1606,,,,F,H,Autocuration,,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",106,,,1,14956,BAO_0000019,8,CHEMBL616632,,
1607,,Homo sapiens,,B,D,Expert,,9606.0,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,106,,,1,14214,BAO_0000357,9,CHEMBL616633,,
1608,,,,B,H,Expert,,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,106,,,1,3463,BAO_0000219,8,CHEMBL616634,449.0,
1609,,,,B,H,Autocuration,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,106,,,1,15331,BAO_0000357,8,CHEMBL616635,,
1610,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against 5-hydroxytryptamine 1B receptor,106,,,1,16146,BAO_0000357,9,CHEMBL885358,,
1611,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,106,,,1,14159,BAO_0000219,9,CHEMBL616636,449.0,
1612,,,,B,H,Expert,,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,106,,,1,14158,BAO_0000219,8,CHEMBL616637,449.0,
1613,,,,B,H,Autocuration,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,106,,,1,14159,BAO_0000357,8,CHEMBL616638,,
1614,,,,B,H,Expert,,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,106,,,1,15250,BAO_0000219,8,CHEMBL616639,449.0,
1615,,,,B,H,Expert,,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,106,,,1,15250,BAO_0000219,8,CHEMBL616640,449.0,
1616,,,,B,H,Expert,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,106,,,1,15331,BAO_0000219,8,CHEMBL616641,449.0,
1617,,,,B,H,Expert,,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,106,,,1,15332,BAO_0000219,8,CHEMBL616642,449.0,
1618,,,,B,H,Expert,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,106,,,1,14956,BAO_0000219,8,CHEMBL616643,449.0,
1619,,,,B,H,Autocuration,,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),106,,,1,3805,BAO_0000357,8,CHEMBL616644,,
1620,,,,B,H,Autocuration,,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,106,,,1,14875,BAO_0000357,8,CHEMBL616645,,
1621,,Oryctolagus cuniculus,,F,H,Autocuration,,9986.0,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),105,,,1,14454,BAO_0000019,8,CHEMBL616646,,
1622,,Oryctolagus cuniculus,,F,H,Expert,,9986.0,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),105,,,1,14454,BAO_0000019,8,CHEMBL616647,,
1623,,,,B,H,Autocuration,,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),105,,,1,16288,BAO_0000357,8,CHEMBL616509,,
1624,,,,B,H,Autocuration,,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),105,,,1,16288,BAO_0000357,8,CHEMBL616510,,
1625,,,,B,H,Autocuration,,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,105,,,1,16312,BAO_0000357,8,CHEMBL616511,,
1626,,Bos taurus,,B,H,Expert,,9913.0,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,105,,,1,1348,BAO_0000357,8,CHEMBL616512,,
1627,,Bos taurus,,B,H,Autocuration,,9913.0,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,105,,,1,5834,BAO_0000357,8,CHEMBL616513,,
1628,,Bos taurus,,B,H,Autocuration,Striatum,9913.0,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,105,,,1,13366,BAO_0000019,8,CHEMBL616514,,2435.0
1629,,Bos taurus,,B,H,Expert,,9913.0,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,105,,,1,1414,BAO_0000357,8,CHEMBL616515,,
1630,,Bos taurus,,B,H,Autocuration,,9913.0,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,105,,,1,14998,BAO_0000019,8,CHEMBL616516,,
1631,,Bos taurus,,B,H,Autocuration,,9913.0,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,105,,,1,11473,BAO_0000357,8,CHEMBL616517,,
1632,,Bos taurus,,B,H,Autocuration,,9913.0,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,105,,,1,11473,BAO_0000357,8,CHEMBL616518,,
1633,,Bos taurus,,B,H,Autocuration,,9913.0,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,105,,,1,10639,BAO_0000357,8,CHEMBL616519,,
1634,,Bos taurus,,B,H,Autocuration,,9913.0,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,105,,,1,10639,BAO_0000357,8,CHEMBL616520,,
1635,,Bos taurus,,B,H,Autocuration,,9913.0,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,105,,,1,1375,BAO_0000357,8,CHEMBL616521,,
1636,,Bos taurus,,B,H,Autocuration,,9913.0,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,105,,,1,1375,BAO_0000357,8,CHEMBL616522,,
1637,,Bos taurus,,B,H,Autocuration,,9913.0,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,105,,,1,16532,BAO_0000357,8,CHEMBL884531,,
1638,,Bos taurus,,B,H,Autocuration,,9913.0,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,105,,,1,11147,BAO_0000357,8,CHEMBL616523,,
1639,,Bos taurus,,B,H,Autocuration,Striatum,9913.0,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,105,,,1,13366,BAO_0000019,8,CHEMBL616731,,2435.0
1640,,Bos taurus,,B,H,Autocuration,,9913.0,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,105,,,1,10444,BAO_0000019,8,CHEMBL616732,,
1641,,Bos taurus,,B,H,Autocuration,,9913.0,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,105,,,1,16532,BAO_0000357,8,CHEMBL616733,,
1642,,Bos taurus,,B,H,Autocuration,,9913.0,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,105,,,1,16532,BAO_0000357,8,CHEMBL616734,,
1643,,Bos taurus,,B,H,Autocuration,,9913.0,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,105,,,1,12827,BAO_0000249,8,CHEMBL616735,,
1644,,Bos taurus,,B,H,Autocuration,,9913.0,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,105,,,1,12827,BAO_0000249,8,CHEMBL616736,,
1645,,Bos taurus,,F,H,Expert,,9913.0,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,,,1,12919,BAO_0000019,8,CHEMBL616737,,
1646,,Bos taurus,,B,H,Autocuration,,9913.0,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,105,,,1,14025,BAO_0000019,8,CHEMBL616738,,
1647,,Bos taurus,,F,H,Expert,,9913.0,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,,,1,12919,BAO_0000019,8,CHEMBL616739,,
1648,,Bos taurus,,F,H,Expert,,9913.0,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,,,1,12919,BAO_0000019,8,CHEMBL616740,,
1649,,Bos taurus,,F,H,Expert,,9913.0,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,105,,,1,12919,BAO_0000019,8,CHEMBL616741,,
1650,,Gorilla gorilla,,B,H,Autocuration,,9593.0,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,105,,,1,14447,BAO_0000219,8,CHEMBL616742,722.0,
1651,,Cavia porcellus,,B,D,Intermediate,,10141.0,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,105570,,,1,1375,BAO_0000019,9,CHEMBL616743,,
1652,,Cavia porcellus,,B,D,Intermediate,,10141.0,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,105570,,,1,1375,BAO_0000019,9,CHEMBL616744,,
1653,,Cavia porcellus,,F,D,Intermediate,,10141.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,105570,,,1,12409,BAO_0000019,9,CHEMBL616745,,
1654,,Cavia porcellus,,F,D,Intermediate,,10141.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,,,1,12409,BAO_0000019,9,CHEMBL616746,,
1655,,Cavia porcellus,,F,D,Intermediate,,10141.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,105570,,,1,12409,BAO_0000019,9,CHEMBL616747,,
1656,,Cavia porcellus,,F,D,Intermediate,,10141.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,105570,,,1,12409,BAO_0000019,9,CHEMBL616748,,
1657,,Cavia porcellus,,F,D,Intermediate,,10141.0,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,105570,,,1,12409,BAO_0000019,9,CHEMBL616648,,
1658,,Cavia porcellus,,B,D,Intermediate,,10141.0,Binding affinity against 5-hydroxytryptamine 1D receptor,105570,,,1,11574,BAO_0000357,9,CHEMBL616649,,
1659,,Cavia porcellus,,B,D,Intermediate,,10141.0,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,105570,,,1,1558,BAO_0000357,9,CHEMBL616650,,
1660,,Cavia porcellus,,F,D,Intermediate,,10141.0,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,,,1,12409,BAO_0000218,9,CHEMBL616651,,
1661,,Cavia porcellus,,F,D,Intermediate,,10141.0,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,,,1,12409,BAO_0000218,9,CHEMBL616652,,
1662,,Cavia porcellus,,F,D,Intermediate,,10141.0,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,105570,,,1,12409,BAO_0000218,9,CHEMBL616653,,
1663,,Cavia porcellus,,F,D,Intermediate,,10141.0,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,105570,,,1,12409,BAO_0000218,9,CHEMBL616654,,
1664,,Cavia porcellus,,B,D,Intermediate,,10141.0,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,105570,,,1,12253,BAO_0000019,9,CHEMBL616655,,
1665,,Cavia porcellus,,B,D,Intermediate,,10141.0,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,105570,,,1,12936,BAO_0000357,9,CHEMBL616656,,
1666,,Cavia porcellus,,B,H,Autocuration,,10141.0,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,105,,,1,13181,BAO_0000019,8,CHEMBL616657,,
1667,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,105570,,,1,12409,BAO_0000357,9,CHEMBL616658,,2435.0
1668,,Cavia porcellus,,B,D,Intermediate,,10141.0,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,105570,,,1,10639,BAO_0000357,9,CHEMBL616659,,
1669,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1D receptor,51,,,1,5254,BAO_0000357,8,CHEMBL616660,,
1670,,,,B,H,Autocuration,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,106,,,1,13051,BAO_0000357,8,CHEMBL616661,,
1671,,,,F,H,Expert,,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,105,,,1,3463,BAO_0000019,8,CHEMBL616662,,
1672,,,,F,H,Autocuration,,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,105,,,1,15315,BAO_0000019,8,CHEMBL616663,,
1673,,,,F,H,Autocuration,,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,105,,,1,6011,BAO_0000019,8,CHEMBL616664,,
1674,,Homo sapiens,,F,D,Expert,,9606.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",105,,,1,14159,BAO_0000219,9,CHEMBL881820,449.0,
1675,,,,F,H,Autocuration,,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",105,,,1,14159,BAO_0000219,8,CHEMBL616665,449.0,
1676,,,,B,H,Expert,,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,105,,,1,15250,BAO_0000219,8,CHEMBL616666,449.0,
1677,,,,B,H,Autocuration,,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,105,,,1,15250,BAO_0000219,8,CHEMBL616667,449.0,
1678,,,,F,H,Expert,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",105,,,1,15331,BAO_0000219,8,CHEMBL616668,449.0,
1679,,Homo sapiens,,F,D,Expert,,9606.0,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",105,,,1,15332,BAO_0000219,9,CHEMBL616669,449.0,
1680,,,,F,H,Expert,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",105,,,1,15332,BAO_0000219,8,CHEMBL617040,449.0,
1681,,,,F,H,Autocuration,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",105,,,1,3294,BAO_0000219,8,CHEMBL617041,449.0,
1682,,,,F,H,Expert,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",105,,,1,14158,BAO_0000219,8,CHEMBL617042,449.0,
1683,,,,F,H,Expert,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",105,,,1,14956,BAO_0000219,8,CHEMBL617043,449.0,
1684,,,,F,H,Autocuration,,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,105,,,1,12469,BAO_0000019,8,CHEMBL617044,,
1685,,,,F,H,Expert,,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,105,,,1,3463,BAO_0000219,8,CHEMBL617045,449.0,
1686,,Homo sapiens,,F,D,Expert,,9606.0,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",105,,,1,15250,BAO_0000219,9,CHEMBL617046,449.0,
1687,,Homo sapiens,,F,D,Expert,,9606.0,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",105,,,1,15250,BAO_0000219,9,CHEMBL617047,449.0,
1688,,,,F,H,Expert,,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",105,,,1,14956,BAO_0000019,8,CHEMBL617048,,
1689,,,,F,H,Autocuration,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",105,,,1,14159,BAO_0000019,8,CHEMBL616897,,
1690,,Homo sapiens,,F,D,Expert,,9606.0,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",105,,,1,14159,BAO_0000019,9,CHEMBL616898,,
1691,,Homo sapiens,,F,D,Expert,,9606.0,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,105,,,1,14499,BAO_0000219,9,CHEMBL858201,449.0,
1692,,,,F,H,Autocuration,,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,105,,,1,15315,BAO_0000019,8,CHEMBL616899,,
1693,In vitro,,,B,H,Autocuration,,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),105,,,1,3294,BAO_0000219,8,CHEMBL616900,,
1694,,,,B,H,Expert,,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,105,,,1,3463,BAO_0000219,8,CHEMBL616901,449.0,
1695,,,,B,H,Autocuration,,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,105,,,1,15331,BAO_0000357,8,CHEMBL616902,,
1696,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,,,1,14159,BAO_0000219,9,CHEMBL616903,449.0,
1697,,,,B,H,Expert,,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,105,,,1,14158,BAO_0000219,8,CHEMBL616904,449.0,
1698,,,,B,H,Autocuration,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,105,,,1,14159,BAO_0000357,8,CHEMBL616905,,
1699,,,,B,H,Expert,,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,105,,,1,15250,BAO_0000219,8,CHEMBL616906,449.0,
1700,,,,B,H,Expert,,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,105,,,1,15250,BAO_0000219,8,CHEMBL616907,449.0,
1701,,,,B,H,Expert,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,105,,,1,15331,BAO_0000219,8,CHEMBL616908,449.0,
1702,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,,,1,15332,BAO_0000219,9,CHEMBL616909,449.0,
1703,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,,,1,14499,BAO_0000219,9,CHEMBL616910,449.0,
1704,,,,B,H,Expert,,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,105,,,1,15332,BAO_0000219,8,CHEMBL616911,449.0,
1705,,,,B,H,Expert,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,105,,,1,14956,BAO_0000219,8,CHEMBL616912,449.0,
1706,,,,B,H,Autocuration,,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),105,,,1,3805,BAO_0000357,8,CHEMBL616913,,
1707,,Homo sapiens,,B,D,Expert,,9606.0,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,105,,,1,6011,BAO_0000219,9,CHEMBL616914,449.0,
1708,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,105,,,1,16190,BAO_0000219,8,CHEMBL616915,449.0,
1709,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,105,,,1,14165,BAO_0000019,8,CHEMBL616916,,
1710,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,105,,,1,4234,BAO_0000357,9,CHEMBL616917,,
1711,,,,B,H,Autocuration,,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",105,,,1,15527,BAO_0000357,8,CHEMBL616918,,
1712,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,105,,,1,6328,BAO_0000219,8,CHEMBL616919,,
1713,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,105,,,1,16209,BAO_0000357,8,CHEMBL616920,,
1714,,,,B,H,Autocuration,,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,105,,,1,14770,BAO_0000357,8,CHEMBL872914,,
1715,,,,B,H,Autocuration,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,105,,,1,2598,BAO_0000357,8,CHEMBL616921,,
1716,,,,B,H,Expert,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,105,,,1,6897,BAO_0000357,8,CHEMBL616922,,
1717,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1D receptor,105,,,1,6013,BAO_0000357,8,CHEMBL616923,,
1718,,,,B,H,Expert,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,105,,,1,5843,BAO_0000357,8,CHEMBL616924,,
1719,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,105,,,1,14454,BAO_0000357,8,CHEMBL875909,,
1720,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,105,,,1,14454,BAO_0000357,8,CHEMBL616925,,
1721,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,105,,,1,14454,BAO_0000357,8,CHEMBL616926,,
1722,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,105,,,1,15818,BAO_0000357,8,CHEMBL616927,,
1723,,,,F,H,Expert,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,105,,,1,13729,BAO_0000219,8,CHEMBL616928,485.0,
1724,In vitro,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),105,,,1,6011,BAO_0000219,9,CHEMBL616929,,
1725,,Homo sapiens,,B,D,Expert,,9606.0,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,105,,,1,4234,BAO_0000357,9,CHEMBL616930,,
1726,,,,B,H,Expert,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,105,,,1,17085,BAO_0000019,8,CHEMBL616931,,
1727,,,,B,H,Autocuration,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,105,,,1,3025,BAO_0000357,8,CHEMBL616932,,
1728,,,,B,H,Expert,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,105,,,1,15315,BAO_0000357,8,CHEMBL616933,,
1729,,Homo sapiens,,B,D,Expert,,9606.0,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,105,,,1,14214,BAO_0000219,9,CHEMBL616934,,
1730,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity for human 5-hydroxytryptamine 1D receptor,105,,,1,3804,BAO_0000357,9,CHEMBL616935,,
1731,,,,B,H,Autocuration,,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,105,,,1,16700,BAO_0000357,8,CHEMBL616936,,
1732,,Homo sapiens,,B,D,Expert,,9606.0,Affinity for 5-hydroxytryptamine 1D receptor subtype,105,,,1,2391,BAO_0000357,9,CHEMBL616937,,
1733,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity for human 5-hydroxytryptamine 1D receptor,105,,,1,4175,BAO_0000357,9,CHEMBL616938,,
1734,,,,B,H,Autocuration,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,105,,,1,17085,BAO_0000019,8,CHEMBL616939,,
1735,,,,B,H,Expert,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,105,,,1,17085,BAO_0000019,8,CHEMBL616940,,
1736,,Homo sapiens,,B,D,Expert,,9606.0,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,105,,,1,15926,BAO_0000357,9,CHEMBL616941,,
1737,,,,B,H,Autocuration,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,105,,,1,16312,BAO_0000219,8,CHEMBL616942,485.0,
1738,,,,B,H,Autocuration,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,105,,,1,16312,BAO_0000219,8,CHEMBL616943,485.0,
1739,,,,B,H,Autocuration,,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,104802,,,1,14956,BAO_0000219,4,CHEMBL616944,449.0,
1740,,,,F,H,Autocuration,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",105,,,1,3294,BAO_0000019,8,CHEMBL616945,,
1741,,,,B,H,Autocuration,,,Binding activity radioligand.,105,,,1,12861,BAO_0000357,8,CHEMBL616946,,
1742,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,105,,,1,12861,BAO_0000019,8,CHEMBL616947,,
1743,,,,B,H,Expert,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,105,,,1,16312,BAO_0000219,8,CHEMBL616948,485.0,
1744,,,,B,H,Autocuration,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,105,,,1,5104,BAO_0000357,8,CHEMBL616851,,
1745,,,,B,H,Autocuration,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,105,,,1,5105,BAO_0000357,8,CHEMBL616852,,
1746,,,,B,H,Autocuration,,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,105,,,1,14499,BAO_0000357,8,CHEMBL616853,,
1747,,Homo sapiens,,B,D,Expert,,9606.0,Binding activity against human 5-hydroxytryptamine 1D receptor,105,,,1,15926,BAO_0000357,9,CHEMBL616854,,
1748,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,105,,,1,4540,BAO_0000219,9,CHEMBL616855,449.0,
1749,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,105,,,1,15779,BAO_0000219,8,CHEMBL616856,449.0,
1750,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,105,,,1,15779,BAO_0000219,8,CHEMBL616857,449.0,
1751,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,105,,,1,6166,BAO_0000357,8,CHEMBL616858,,
1752,,,,B,H,Autocuration,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,105,,,1,15779,BAO_0000219,8,CHEMBL616859,449.0,
1753,,,,B,H,Autocuration,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,105,,,1,15779,BAO_0000219,8,CHEMBL616860,449.0,
1754,,,,B,H,Autocuration,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,105,,,1,17451,BAO_0000219,8,CHEMBL616861,722.0,
1755,,,,B,H,Autocuration,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,105,,,1,17451,BAO_0000219,8,CHEMBL616541,722.0,
1756,,,,B,H,Autocuration,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,105,,,1,17451,BAO_0000219,8,CHEMBL616542,722.0,
1757,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,105,,,1,4199,BAO_0000219,8,CHEMBL616543,449.0,
1758,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity for human 5-hydroxytryptamine 1D receptor,105,,,1,14875,BAO_0000357,9,CHEMBL616544,,
1759,,,,B,H,Autocuration,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,105,,,1,15146,BAO_0000219,8,CHEMBL616545,449.0,
1760,,,,B,H,Autocuration,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,105,,,1,5213,BAO_0000357,8,CHEMBL616546,,
1761,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,105,,,1,14818,BAO_0000219,8,CHEMBL616547,449.0,
1762,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",105,,,1,4829,BAO_0000219,8,CHEMBL616548,449.0,
1763,,,,F,H,Expert,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,105,,,1,14454,BAO_0000019,8,CHEMBL616549,,
1764,,,,F,H,Expert,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,105,,,1,14454,BAO_0000019,8,CHEMBL616550,,
1765,,,,B,H,Autocuration,,,Binding affinity against 5-HT2C receptor,108,,,1,5254,BAO_0000357,8,CHEMBL857066,,
1766,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1D receptor,108,,,1,5254,BAO_0000357,8,CHEMBL616551,,
1767,,,,B,H,Autocuration,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,10577,,,1,10639,BAO_0000357,8,CHEMBL616552,,
1768,,,,F,H,Autocuration,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,10577,,,1,10639,BAO_0000019,8,CHEMBL832876,,
1769,,,,B,H,Expert,,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",10577,,,1,12352,BAO_0000019,8,CHEMBL616553,,
1770,,,,B,H,Autocuration,,,Binding affinity towards 5-HT1B was determined,10577,,,1,9098,BAO_0000357,8,CHEMBL616554,,
1771,,,,B,H,Expert,,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,10577,,,1,14430,BAO_0000019,8,CHEMBL616555,,
1772,,,,B,H,Expert,,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",10577,,,1,13657,BAO_0000019,8,CHEMBL616556,,
1773,,,,B,H,Autocuration,,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",10577,,,1,13657,BAO_0000019,8,CHEMBL616557,,
1774,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,10577,,,1,15854,BAO_0000019,8,CHEMBL616558,,
1775,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,10577,,,1,10639,BAO_0000019,9,CHEMBL616749,,
1776,,,,B,H,Autocuration,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,10577,,,1,10025,BAO_0000357,8,CHEMBL616750,,
1777,,,,B,H,Autocuration,,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",10577,,,1,10025,BAO_0000357,8,CHEMBL616751,,
1778,,,,B,H,Autocuration,,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,10577,,,1,14286,BAO_0000249,8,CHEMBL616752,,
1779,,,,B,H,Autocuration,Striatum,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,10577,,,1,3651,BAO_0000019,8,CHEMBL616753,,2435.0
1780,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,10577,,,1,14178,BAO_0000357,9,CHEMBL616754,,
1781,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,10577,,,1,10639,BAO_0000019,8,CHEMBL616755,,
1782,,,,B,H,Autocuration,Striatum,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,10577,,,1,13605,BAO_0000019,8,CHEMBL616756,,2435.0
1783,,,,B,H,Autocuration,Striatum,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,10577,,,1,5834,BAO_0000019,8,CHEMBL616757,,2435.0
1784,,,,B,H,Autocuration,Striatum,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,10577,,,1,10922,BAO_0000357,8,CHEMBL616758,,2435.0
1785,,,,B,H,Autocuration,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,10577,,,1,14286,BAO_0000249,8,CHEMBL616759,,
1786,,,,B,H,Autocuration,,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,10577,,,1,11825,BAO_0000357,8,CHEMBL616760,,
1787,,,,B,H,Autocuration,Striatum,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,10577,,,1,14826,BAO_0000019,8,CHEMBL616761,,2435.0
1788,,,,B,H,Autocuration,Striatum,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,10577,,,1,9699,BAO_0000019,8,CHEMBL616762,,2435.0
1789,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,10577,,,1,14423,BAO_0000019,8,CHEMBL616763,,
1790,,,,B,H,Expert,,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,10577,,,1,10062,BAO_0000357,8,CHEMBL872909,,
1791,,,,B,H,Autocuration,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,10577,,,1,10062,BAO_0000357,8,CHEMBL616764,,
1792,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,10577,,,1,12280,BAO_0000357,9,CHEMBL616765,,
1793,,,,B,H,Autocuration,Striatum,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,10577,,,1,15412,BAO_0000357,8,CHEMBL616766,,2435.0
1794,,,,B,H,Autocuration,Striatum,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,10577,,,1,15412,BAO_0000357,8,CHEMBL616767,,2435.0
1795,,,,B,H,Autocuration,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,10577,,,1,10062,BAO_0000357,8,CHEMBL616768,,
1796,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,10577,,,1,11147,BAO_0000357,8,CHEMBL616769,,
1797,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,10577,,,1,9547,BAO_0000019,8,CHEMBL616770,,
1798,,,,B,H,Autocuration,,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,10577,,,1,10444,BAO_0000019,8,CHEMBL616771,,
1799,,,,B,H,Autocuration,Striatum,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,10577,,,1,12469,BAO_0000019,8,CHEMBL616772,,2435.0
1800,,,,B,H,Expert,,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,10577,,,1,9098,BAO_0000019,8,CHEMBL616773,,
1801,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,10577,,,1,9098,BAO_0000019,8,CHEMBL616774,,
1802,,,,B,H,Autocuration,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,10577,,,1,9699,BAO_0000357,8,CHEMBL616775,,
1803,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,10577,,,1,10394,BAO_0000249,8,CHEMBL616776,,
1804,,,,B,H,Autocuration,,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,10577,,,1,12092,BAO_0000357,8,CHEMBL616777,,
1805,,,,B,H,Autocuration,,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,10577,,,1,16700,BAO_0000357,8,CHEMBL616778,,
1806,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,10577,,,1,403,BAO_0000249,9,CHEMBL616779,,
1807,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity towards 5-hydroxytryptamine 1B receptor,10577,,,1,12771,BAO_0000357,9,CHEMBL616780,,
1808,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,10577,,,1,11642,BAO_0000019,8,CHEMBL616781,,
1809,,,,B,H,Autocuration,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,10577,,,1,12953,BAO_0000357,8,CHEMBL616782,,
1810,,,,B,H,Autocuration,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,10577,,,1,12953,BAO_0000357,8,CHEMBL616783,,
1811,,,,B,H,Expert,Striatum,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,10577,,,1,12953,BAO_0000019,8,CHEMBL616784,,2435.0
1812,,,,B,H,Autocuration,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,10577,,,1,12953,BAO_0000357,8,CHEMBL616785,,
1813,,,,B,H,Autocuration,Brain,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,10577,,,1,9737,BAO_0000249,8,CHEMBL857067,,955.0
1814,,,,B,H,Autocuration,,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,10577,,,1,9737,BAO_0000019,8,CHEMBL616786,,
1815,,,,B,H,Autocuration,Brain,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,10577,,,1,9737,BAO_0000249,8,CHEMBL616787,,955.0
1816,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,10577,,,1,12827,BAO_0000357,8,CHEMBL616788,,
1817,,,,B,H,Autocuration,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,10577,,,1,5033,BAO_0000357,8,CHEMBL616789,,
1818,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,10577,,,1,9786,BAO_0000019,9,CHEMBL616790,,
1819,,,,B,H,Expert,,,Binding affinity at 5-hydroxytryptamine 1B receptor,10577,,,1,13116,BAO_0000357,8,CHEMBL616791,,
1820,,,,B,H,Autocuration,,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,10577,,,1,16429,BAO_0000019,8,CHEMBL616792,,
1821,,Rattus norvegicus,,B,D,Expert,,10116.0,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,10577,,,1,12409,BAO_0000249,9,CHEMBL616793,,
1822,,,,B,H,Autocuration,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,10577,,,1,15194,BAO_0000357,8,CHEMBL616794,,
1823,,,,B,H,Autocuration,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,10577,,,1,15194,BAO_0000357,8,CHEMBL616795,,
1824,,,,B,H,Autocuration,,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,104686,,,1,5486,BAO_0000019,4,CHEMBL616796,,
1825,,,,B,H,Autocuration,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,106,,,1,4639,BAO_0000357,8,CHEMBL616797,,
1826,,,,B,H,Autocuration,,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,106,,,1,386,BAO_0000249,8,CHEMBL616798,,
1827,,,,B,H,Autocuration,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,106,,,1,2474,BAO_0000357,8,CHEMBL616799,,
1828,,,,B,H,Autocuration,,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,106,,,1,6011,BAO_0000357,8,CHEMBL616800,,
1829,,,,B,H,Autocuration,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,106,,,1,5014,BAO_0000357,8,CHEMBL616801,,
1830,,,,B,H,Autocuration,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,106,,,1,17515,BAO_0000357,8,CHEMBL616802,,
1831,,,,B,H,Autocuration,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,106,,,1,4373,BAO_0000357,8,CHEMBL616803,,
1832,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,106,,,1,1633,BAO_0000357,8,CHEMBL857068,,
1833,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,106,,,1,1633,BAO_0000357,8,CHEMBL616804,,
1834,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,106,,,1,4373,BAO_0000357,8,CHEMBL616805,,
1835,,,,B,H,Autocuration,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,106,,,1,4687,BAO_0000357,8,CHEMBL616806,,
1836,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1B receptor,106,,,1,11574,BAO_0000357,8,CHEMBL616807,,
1837,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,106,,,1,10321,BAO_0000357,8,CHEMBL616808,,
1838,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,106,,,1,15527,BAO_0000357,8,CHEMBL616809,,
1839,,,,B,H,Autocuration,,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,106,,,1,17200,BAO_0000357,8,CHEMBL616810,,
1840,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,104802,,,1,14423,BAO_0000224,4,CHEMBL616811,,
1841,,Bos taurus,,B,H,Autocuration,,9913.0,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,108,,,1,5834,BAO_0000357,8,CHEMBL616812,,
1842,,Sus scrofa,,B,H,Autocuration,,9823.0,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,108,,,1,11473,BAO_0000357,8,CHEMBL616813,,
1843,,Sus scrofa,,B,H,Autocuration,,9823.0,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,108,,,1,11473,BAO_0000357,8,CHEMBL616814,,
1844,,Sus scrofa,,B,H,Autocuration,,9823.0,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,108,,,1,10639,BAO_0000357,8,CHEMBL616815,,
1845,,Sus scrofa,,B,H,Autocuration,,9823.0,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,108,,,1,10639,BAO_0000357,8,CHEMBL616816,,
1846,,Sus scrofa,,B,H,Autocuration,,9823.0,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,108,,,1,14331,BAO_0000357,8,CHEMBL616817,,
1847,,Sus scrofa,,B,H,Autocuration,,9823.0,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,108,,,1,10796,BAO_0000357,8,CHEMBL616818,,
1848,,Sus scrofa,,B,H,Expert,,9823.0,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,108,,,1,9098,BAO_0000357,8,CHEMBL616819,,
1849,,Sus scrofa,,B,H,Expert,,9823.0,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,108,,,1,14331,BAO_0000357,8,CHEMBL616820,,
1850,,Sus scrofa,,B,H,Expert,,9823.0,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,108,,,1,11828,BAO_0000019,8,CHEMBL616821,,
1851,,Sus scrofa,,B,H,Autocuration,,9823.0,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,108,,,1,11866,BAO_0000357,8,CHEMBL616822,,
1852,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,108,,,1,13047,BAO_0000019,8,CHEMBL616823,,
1853,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,12689,,,1,188,BAO_0000357,9,CHEMBL616824,,
1854,,Rattus norvegicus,,B,D,Autocuration,,10116.0,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,12689,,,1,11825,BAO_0000357,9,CHEMBL616825,,
1855,,Rattus norvegicus,,B,D,Autocuration,,10116.0,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,12689,,,1,11825,BAO_0000357,9,CHEMBL616826,,
1856,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,12689,,,1,11624,BAO_0000019,9,CHEMBL616827,,
1857,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,12689,,,1,11139,BAO_0000357,9,CHEMBL616828,,
1858,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,12689,,,1,11147,BAO_0000357,9,CHEMBL616829,,
1859,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,12689,,,1,10444,BAO_0000019,9,CHEMBL616830,,
1860,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity against 5-hydroxytryptamine 1C receptor,12689,,,1,11624,BAO_0000357,9,CHEMBL616831,,
1861,,Rattus norvegicus,,B,D,Autocuration,,10116.0,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,,,1,11662,BAO_0000019,9,CHEMBL616832,,
1862,,Rattus norvegicus,,B,D,Autocuration,,10116.0,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,,,1,11662,BAO_0000019,9,CHEMBL616833,,
1863,,Rattus norvegicus,,B,D,Expert,,10116.0,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,,,1,11662,BAO_0000019,9,CHEMBL616834,,
1864,,Rattus norvegicus,,B,D,Autocuration,,10116.0,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",12689,,,1,11662,BAO_0000019,9,CHEMBL829595,,
1865,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,12689,,,1,9098,BAO_0000357,9,CHEMBL616835,,
1866,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,12689,,,1,10394,BAO_0000249,9,CHEMBL872910,,
1867,,,,B,H,Expert,,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,12689,,,1,11933,BAO_0000357,8,CHEMBL616836,,
1868,,Rattus norvegicus,,B,D,Autocuration,,10116.0,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,12689,,,1,12092,BAO_0000357,9,CHEMBL616837,,
1869,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,12689,,,1,12253,BAO_0000019,9,CHEMBL616466,,
1870,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,12689,,,1,12253,BAO_0000219,9,CHEMBL616467,722.0,
1871,,,,B,H,Autocuration,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,108,,,1,1558,BAO_0000357,8,CHEMBL616468,,
1872,,,,B,H,Autocuration,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,108,,,1,2474,BAO_0000357,8,CHEMBL616469,,
1873,,,,B,H,Autocuration,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,108,,,1,2474,BAO_0000357,8,CHEMBL616470,,
1874,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1C receptor,12689,,,1,11574,BAO_0000357,8,CHEMBL616471,,
1875,,,,B,H,Autocuration,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,12689,,,1,1558,BAO_0000357,8,CHEMBL616472,,
1876,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1C receptor,12689,,,1,13944,BAO_0000357,8,CHEMBL616473,,
1877,,,,B,H,Autocuration,,,Binding affinity against serotonergic 5-HT1c receptor,12689,,,1,13033,BAO_0000357,8,CHEMBL616474,,
1878,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,12689,,,1,10321,BAO_0000357,8,CHEMBL616475,,
1879,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,12689,,,1,11866,BAO_0000357,8,CHEMBL616476,,
1880,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),105,,,1,14454,BAO_0000019,8,CHEMBL616477,,
1881,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,104686,,,1,11574,BAO_0000224,4,CHEMBL616478,,
1882,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,104686,,,1,11574,BAO_0000224,4,CHEMBL616479,,
1883,,,,B,H,Autocuration,,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,104686,,,1,13631,BAO_0000019,4,CHEMBL616480,,
1884,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,104686,,,1,9630,BAO_0000019,5,CHEMBL616481,,
1885,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,104686,,,1,8822,BAO_0000249,5,CHEMBL616482,,
1886,,Rattus norvegicus,,B,D,Autocuration,Brain,10116.0,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,104686,,,1,9064,BAO_0000221,5,CHEMBL884713,,955.0
1887,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,104686,,,1,8868,BAO_0000224,4,CHEMBL616483,,
1888,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,104686,,,1,9064,BAO_0000224,4,CHEMBL616484,,
1889,,,,B,H,Autocuration,,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,104686,,,1,9806,BAO_0000019,4,CHEMBL616485,,
1890,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,104686,,,1,9098,BAO_0000224,4,CHEMBL616486,,
1891,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,104686,,,1,8868,BAO_0000224,4,CHEMBL616487,,
1892,,,,B,H,Autocuration,,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,104686,,,1,12765,BAO_0000224,4,CHEMBL616488,,
1893,,,,B,H,Autocuration,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,,1,11049,BAO_0000019,4,CHEMBL616489,,
1894,,,,B,H,Autocuration,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,,1,11049,BAO_0000019,4,CHEMBL616490,,
1895,,,,B,H,Autocuration,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,104686,,,1,11049,BAO_0000019,4,CHEMBL616491,,
1896,,,,B,H,Autocuration,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,104686,,,1,11049,BAO_0000019,4,CHEMBL616492,,
1897,,,,B,H,Autocuration,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,,1,11049,BAO_0000019,4,CHEMBL616493,,
1898,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,104686,,,1,11473,BAO_0000019,4,CHEMBL616494,,
1899,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,104686,,,1,11473,BAO_0000019,4,CHEMBL616495,,
1900,,,,B,H,Autocuration,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,104686,,,1,3086,BAO_0000019,4,CHEMBL616496,,
1901,,,,B,H,Autocuration,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,,1,11049,BAO_0000019,4,CHEMBL616497,,
1902,,,,B,H,Autocuration,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,104686,,,1,11049,BAO_0000019,4,CHEMBL616498,,
1903,,,,B,H,Autocuration,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,104686,,,1,10639,BAO_0000019,4,CHEMBL616499,,
1904,,,,B,H,Autocuration,,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,104686,,,1,10922,BAO_0000019,4,CHEMBL616500,,
1905,,Rattus norvegicus,,B,D,Autocuration,Brain,10116.0,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,104686,,,1,9064,BAO_0000221,5,CHEMBL616501,,955.0
1906,,,,B,H,Autocuration,Brain,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,104686,,,1,10748,BAO_0000221,4,CHEMBL616502,,955.0
1907,,,,B,H,Autocuration,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,104686,,,1,11614,BAO_0000249,4,CHEMBL884529,,
1908,,,,B,H,Autocuration,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,104686,,,1,11615,BAO_0000249,4,CHEMBL616503,,
1909,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,104686,,,1,11615,BAO_0000224,4,CHEMBL616964,,
1910,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,104686,,,1,11614,BAO_0000249,4,CHEMBL616965,,
1911,,,,B,H,Autocuration,,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,104686,,,1,11702,BAO_0000224,4,CHEMBL616966,,
1912,,,,B,H,Autocuration,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,104686,,,1,11702,BAO_0000224,4,CHEMBL616967,,
1913,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,104686,,,1,11702,BAO_0000224,5,CHEMBL616968,,
1914,,,,B,H,Autocuration,,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,104686,,,1,11702,BAO_0000224,4,CHEMBL616969,,
1915,,,,B,H,Autocuration,,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,104686,,,1,13346,BAO_0000019,4,CHEMBL884530,,
1916,,,,B,H,Autocuration,,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,104686,,,1,10025,BAO_0000224,4,CHEMBL616970,,
1917,,,,B,H,Autocuration,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,104686,,,1,10025,BAO_0000224,4,CHEMBL616971,,
1918,,,,B,H,Autocuration,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",104686,,,1,10025,BAO_0000224,4,CHEMBL616972,,
1919,,,,B,H,Autocuration,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,104686,,,1,9036,BAO_0000224,4,CHEMBL616973,,
1920,,,,B,H,Autocuration,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,104686,,,1,9036,BAO_0000224,4,CHEMBL616974,,
1921,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,104686,,,1,9161,BAO_0000019,4,CHEMBL616975,,
1922,,,,B,H,Autocuration,,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,104686,,,1,12304,BAO_0000019,4,CHEMBL616976,,
1923,,,,B,H,Autocuration,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,104686,,,1,13276,BAO_0000224,4,CHEMBL616977,,
1924,,,,B,H,Autocuration,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,104686,,,1,11825,BAO_0000224,4,CHEMBL616978,,
1925,,,,B,H,Autocuration,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,104686,,,1,12443,BAO_0000224,4,CHEMBL616979,,
1926,,,,B,H,Autocuration,,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,104686,,,1,13830,BAO_0000224,4,CHEMBL616980,,
1927,,,,B,H,Autocuration,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,104686,,,1,9592,BAO_0000249,4,CHEMBL616981,,
1928,,,,B,H,Autocuration,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,104686,,,1,9592,BAO_0000249,4,CHEMBL616982,,
1929,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,104686,,,1,10881,BAO_0000224,4,CHEMBL616983,,
1930,,,,B,H,Autocuration,,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,104686,,,1,13605,BAO_0000019,4,CHEMBL616984,,
1931,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibitory activity against 5-hydroxytryptamine 2 receptor,104686,,,1,11624,BAO_0000224,5,CHEMBL616985,,
1932,,,,B,H,Autocuration,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,104686,,,1,4101,BAO_0000224,4,CHEMBL616986,,
1933,,,,B,H,Autocuration,,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,104686,,,1,4101,BAO_0000224,4,CHEMBL616987,,
1934,,,,B,H,Autocuration,,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,104686,,,1,15360,BAO_0000019,4,CHEMBL616988,,
1935,,,,B,H,Autocuration,,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,104686,,,1,11576,BAO_0000019,4,CHEMBL617243,,
1936,,,,B,H,Autocuration,,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,104686,,,1,5834,BAO_0000019,4,CHEMBL617244,,
1937,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,104686,,,1,2395,BAO_0000219,5,CHEMBL617245,485.0,
1938,,,,B,H,Autocuration,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,104686,,,1,11965,BAO_0000249,4,CHEMBL617246,,
1939,,,,B,H,Autocuration,,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),104686,,,1,3967,BAO_0000224,4,CHEMBL617546,,
1940,,,,B,H,Autocuration,,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),104686,,,1,11130,BAO_0000249,4,CHEMBL617547,,
1941,In vitro,,,B,H,Autocuration,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,104686,,,1,13427,BAO_0000219,4,CHEMBL617548,,
1942,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,104686,,,1,9443,BAO_0000224,4,CHEMBL617549,,
1943,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,104686,,,1,9443,BAO_0000224,4,CHEMBL617550,,
1944,,,,B,H,Autocuration,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,104686,,,1,11825,BAO_0000224,4,CHEMBL617551,,
1945,,,,B,H,Autocuration,,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,104686,,,1,12120,BAO_0000249,4,CHEMBL617552,,
1946,,,,B,H,Autocuration,,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,104686,,,1,12120,BAO_0000249,4,CHEMBL617553,,
1947,,,,F,H,Autocuration,Thoracic aorta,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,104686,,,1,11963,BAO_0000019,4,CHEMBL617554,,1515.0
1948,,,,B,H,Autocuration,,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,104686,,,1,9069,BAO_0000019,4,CHEMBL617555,,
1949,,,,B,H,Autocuration,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,104686,,,1,8868,BAO_0000224,4,CHEMBL617556,,
1950,,,,B,H,Autocuration,,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,10624,,,1,17200,BAO_0000357,8,CHEMBL617557,,
1951,,,,B,H,Autocuration,,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,10624,,,1,17200,BAO_0000357,8,CHEMBL617558,,
1952,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,17106,,,1,13969,BAO_0000357,8,CHEMBL617559,,
1953,,,,B,D,Expert,,,Binding affinity for 5-hydroxytryptamine 1D receptor,17106,,,1,13392,BAO_0000357,9,CHEMBL617560,,
1954,,,,B,H,Autocuration,,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,17106,,,1,1742,BAO_0000249,8,CHEMBL617561,,
1955,,,,B,H,Autocuration,,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,17106,,,1,1742,BAO_0000249,8,CHEMBL617562,,
1956,,,,B,H,Autocuration,Striatum,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,17106,,,1,14331,BAO_0000357,8,CHEMBL617563,,2435.0
1957,,,,F,H,Autocuration,,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,17106,,,1,12861,BAO_0000019,8,CHEMBL617564,,
1958,,,,B,H,Expert,,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,17106,,,1,12861,BAO_0000019,8,CHEMBL617565,,
1959,,,,B,H,Autocuration,,,Binding activity radioligand.,17106,,,1,12861,BAO_0000357,8,CHEMBL856076,,
1960,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,17106,,,1,12861,BAO_0000019,8,CHEMBL617566,,
1961,,,,B,H,Expert,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,17106,,,1,12861,BAO_0000019,8,CHEMBL875911,,
1962,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,17106,,,1,12861,BAO_0000019,8,CHEMBL617567,,
1963,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,17106,,,1,675,BAO_0000249,8,CHEMBL617568,,
1964,,,,B,H,Expert,,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,17106,,,1,12490,BAO_0000019,8,CHEMBL617569,,
1965,,,,B,H,Expert,,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,17106,,,1,11828,BAO_0000249,8,CHEMBL617570,,
1966,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,17106,,,1,11866,BAO_0000357,8,CHEMBL617571,,
1967,,Sus scrofa,,B,H,Autocuration,,9823.0,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,105,,,1,773,BAO_0000357,8,CHEMBL617572,,
1968,,Oryctolagus cuniculus,,B,H,Expert,,9986.0,The compound was tested for intrinsic activity against 5-HT1D receptor,105,,,1,13047,BAO_0000357,8,CHEMBL617573,,
1969,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,105,,,1,13047,BAO_0000019,8,CHEMBL617574,,
1970,,Oryctolagus cuniculus,,B,H,Expert,,9986.0,The compound was tested for binding affinity against 5-HT1D receptor,105,,,1,13047,BAO_0000357,8,CHEMBL617575,,
1971,,,,B,H,Autocuration,,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,10578,,,1,188,BAO_0000357,8,CHEMBL617576,,
1972,,,,F,H,Autocuration,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,10578,,,1,10639,BAO_0000019,8,CHEMBL617577,,
1973,,,,F,H,Autocuration,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,10578,,,1,12438,BAO_0000019,8,CHEMBL617578,,
1974,,,,B,H,Autocuration,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,10578,,,1,12438,BAO_0000357,8,CHEMBL617579,,
1975,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,10578,,,1,15854,BAO_0000019,8,CHEMBL617580,,
1976,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,10578,,,1,10394,BAO_0000249,8,CHEMBL617581,,
1977,,,,B,H,Autocuration,,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,10578,,,1,12092,BAO_0000357,8,CHEMBL617582,,
1978,,,,B,H,Expert,,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,10578,,,1,3389,BAO_0000019,8,CHEMBL617583,,
1979,,,,B,H,Autocuration,,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,105,,,1,6011,BAO_0000357,8,CHEMBL617584,,
1980,,,,B,H,Autocuration,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,105,,,1,4639,BAO_0000357,8,CHEMBL617585,,
1981,,,,B,H,Autocuration,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,105,,,1,2474,BAO_0000357,8,CHEMBL875912,,
1982,,,,B,H,Autocuration,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,105,,,1,5014,BAO_0000357,8,CHEMBL617586,,
1983,,,,B,H,Autocuration,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,105,,,1,17515,BAO_0000357,8,CHEMBL617587,,
1984,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,105,,,1,11866,BAO_0000357,8,CHEMBL617588,,
1985,,,,B,H,Autocuration,,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,105,,,1,4687,BAO_0000357,8,CHEMBL857980,,
1986,,,,B,H,Autocuration,,,Tested against 5-hydroxytryptamine 1D receptor,105,,,1,12146,BAO_0000357,8,CHEMBL617589,,
1987,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,105,,,1,10321,BAO_0000357,8,CHEMBL617590,,
1988,,,,B,H,Autocuration,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,105,,,1,13267,BAO_0000219,8,CHEMBL617591,722.0,
1989,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against 5-Hydroxytryptamine 1D receptor,105,,,1,1274,BAO_0000357,9,CHEMBL617592,,
1990,,,,B,H,Autocuration,,,,105,,,1,15250,BAO_0000357,8,CHEMBL617593,,
1991,,,,B,H,Autocuration,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,106,,,1,13706,BAO_0000219,8,CHEMBL617594,485.0,
1992,,,,B,H,Autocuration,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,105,,,1,13706,BAO_0000219,8,CHEMBL617595,485.0,
1993,,,,B,H,Autocuration,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,105,,,1,13706,BAO_0000219,8,CHEMBL617596,722.0,
1994,,,,B,H,Autocuration,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,105,,,1,13706,BAO_0000219,8,CHEMBL617597,722.0,
1995,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,105,,,1,13047,BAO_0000019,8,CHEMBL617598,,
1996,,,,B,H,Autocuration,,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,105,,,1,13366,BAO_0000357,8,CHEMBL872916,,
1997,,,,B,H,Expert,,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,105,,,1,13366,BAO_0000357,8,CHEMBL617599,,
1998,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,105,,,1,1558,BAO_0000357,8,CHEMBL617091,,
1999,,,,B,H,Expert,,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",105,,,1,12902,BAO_0000219,8,CHEMBL617092,485.0,
2000,,,,B,H,Autocuration,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,105,,,1,13706,BAO_0000219,8,CHEMBL617093,485.0,
2001,,,,F,H,Autocuration,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,105,,,1,13706,BAO_0000019,8,CHEMBL617094,,
2002,,,,F,H,Autocuration,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,105,,,1,13706,BAO_0000019,8,CHEMBL617095,,
2003,,,,F,H,Autocuration,,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,105,,,1,14251,BAO_0000019,8,CHEMBL617096,,
2004,,,,F,H,Autocuration,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,105,,,1,14251,BAO_0000019,8,CHEMBL617097,,
2005,,,,F,H,Autocuration,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,105,,,1,14251,BAO_0000019,8,CHEMBL617098,,
2006,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,105,,,1,13313,BAO_0000357,8,CHEMBL617301,,
2007,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,105,,,1,13313,BAO_0000357,8,CHEMBL617302,,
2008,,,,B,H,Autocuration,,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,105,,,1,13366,BAO_0000357,8,CHEMBL617303,,
2009,,,,B,H,Expert,,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,105,,,1,13051,BAO_0000357,8,CHEMBL617304,,
2010,,,,B,H,Expert,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",105,,,1,12903,BAO_0000219,8,CHEMBL617305,449.0,
2011,,Homo sapiens,,B,D,Autocuration,,9606.0,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,105,,,1,12469,BAO_0000219,9,CHEMBL617306,,
2012,,,,B,H,Autocuration,,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,17106,,,1,5619,BAO_0000357,8,CHEMBL617307,,
2013,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,105,,,1,13047,BAO_0000019,8,CHEMBL617308,,
2014,,,,B,H,Autocuration,,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,105,,,1,16633,BAO_0000357,8,CHEMBL617309,,
2015,,,,B,H,Autocuration,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,105,,,1,16633,BAO_0000357,8,CHEMBL617310,,
2016,,,,B,H,Autocuration,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,105,,,1,16633,BAO_0000357,8,CHEMBL617311,,
2017,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,105,,,1,16633,BAO_0000357,8,CHEMBL617312,,
2018,,,,B,H,Autocuration,,,Affinity against 5-hydroxytryptamine 1D receptor alpha,105,,,1,3269,BAO_0000357,8,CHEMBL617313,,
2019,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,105,,,1,12409,BAO_0000357,8,CHEMBL617314,,
2020,,,,F,H,Autocuration,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,106,,,1,13706,BAO_0000019,8,CHEMBL617315,,
2021,,,,B,H,Autocuration,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,106,,,1,13706,BAO_0000219,8,CHEMBL617316,722.0,
2022,,,,B,H,Autocuration,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,106,,,1,13706,BAO_0000219,8,CHEMBL617317,722.0,
2023,,,,B,H,Autocuration,,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",106,,,1,12903,BAO_0000219,8,CHEMBL617318,449.0,
2024,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,106,,,1,13047,BAO_0000019,8,CHEMBL617319,,
2025,,,,B,D,Expert,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,106,,,1,13366,BAO_0000357,9,CHEMBL617320,,
2026,,,,B,D,Expert,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,106,,,1,13366,BAO_0000357,9,CHEMBL617321,,
2027,,,,B,D,Expert,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,106,,,1,13366,BAO_0000357,9,CHEMBL617322,,
2028,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,106,,,1,13366,BAO_0000357,8,CHEMBL616862,,
2029,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,106,,,1,13366,BAO_0000357,8,CHEMBL616863,,
2030,,,,B,H,Autocuration,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,106,,,1,12469,BAO_0000219,8,CHEMBL616864,449.0,
2031,,,,B,H,Autocuration,,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,106,,,1,13706,BAO_0000219,8,CHEMBL616865,485.0,
2032,,,,B,H,Autocuration,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,106,,,1,13706,BAO_0000219,8,CHEMBL616866,485.0,
2033,,,,F,H,Autocuration,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,106,,,1,13706,BAO_0000019,8,CHEMBL616867,,
2034,,,,B,H,Expert,,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",106,,,1,12902,BAO_0000219,8,CHEMBL616868,485.0,
2035,,,,B,H,Expert,,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,105,,,1,13051,BAO_0000357,8,CHEMBL616869,,
2036,,,,B,H,Expert,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",106,,,1,12903,BAO_0000219,8,CHEMBL616870,449.0,
2037,,,,F,H,Autocuration,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,105,,,1,1558,BAO_0000219,8,CHEMBL616871,485.0,
2038,,,,F,H,Autocuration,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,105,,,1,1558,BAO_0000219,8,CHEMBL616872,485.0,
2039,,,,F,H,Autocuration,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,105,,,1,1558,BAO_0000219,8,CHEMBL616873,485.0,
2040,,,,F,H,Autocuration,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,105,,,1,1558,BAO_0000219,8,CHEMBL616838,485.0,
2041,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,105,,,1,1558,BAO_0000357,8,CHEMBL616839,,
2042,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,106,,,1,13047,BAO_0000019,8,CHEMBL616840,,
2043,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,105,,,1,13313,BAO_0000357,8,CHEMBL616841,,
2044,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,105,,,1,13313,BAO_0000357,8,CHEMBL616842,,
2045,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,105,,,1,12409,BAO_0000357,8,CHEMBL857976,,
2046,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,10618,,,1,15250,BAO_0000219,8,CHEMBL616843,449.0,
2047,,Homo sapiens,,B,D,Expert,,9606.0,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,10618,,,1,1348,BAO_0000357,9,CHEMBL616844,,
2048,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,10618,,,1,1348,BAO_0000357,8,CHEMBL616845,,
2049,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,10618,,,1,4234,BAO_0000357,9,CHEMBL616846,,
2050,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,10618,,,1,16209,BAO_0000357,8,CHEMBL616847,,
2051,,,,B,H,Autocuration,,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,10618,,,1,10444,BAO_0000019,8,CHEMBL616848,,
2052,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,10618,,,1,3935,BAO_0000357,8,CHEMBL616849,,
2053,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,10618,,,1,15818,BAO_0000357,8,CHEMBL872911,,
2054,,,,B,H,Autocuration,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,10618,,,1,17085,BAO_0000019,8,CHEMBL616850,,
2055,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,10618,,,1,12936,BAO_0000219,9,CHEMBL616699,449.0,
2056,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,10618,,,1,6166,BAO_0000357,8,CHEMBL616700,,
2057,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,10618,,,1,15779,BAO_0000219,8,CHEMBL616701,449.0,
2058,,,,B,H,Autocuration,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,10618,,,1,15779,BAO_0000219,8,CHEMBL616702,449.0,
2059,,,,B,H,Autocuration,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,10618,,,1,15779,BAO_0000219,8,CHEMBL616703,449.0,
2060,,,,B,H,Autocuration,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,10618,,,1,13181,BAO_0000357,8,CHEMBL616704,,
2061,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,10618,,,1,4199,BAO_0000219,8,CHEMBL616705,449.0,
2062,,,,B,H,Autocuration,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,10618,,,1,14875,BAO_0000357,8,CHEMBL616706,,
2063,,,,B,H,Autocuration,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,10618,,,1,15146,BAO_0000219,8,CHEMBL616707,449.0,
2064,,,,B,H,Autocuration,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,10618,,,1,5213,BAO_0000357,8,CHEMBL616708,,
2065,,,,B,H,Autocuration,,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,10618,,,1,12146,BAO_0000357,8,CHEMBL616709,,
2066,,,,B,H,Autocuration,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,10618,,,1,13267,BAO_0000219,8,CHEMBL616710,449.0,
2067,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,10618,,,1,14818,BAO_0000219,8,CHEMBL616711,449.0,
2068,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",10618,,,1,4829,BAO_0000219,8,CHEMBL616712,449.0,
2069,,,,B,H,Autocuration,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,10618,,,1,4373,BAO_0000357,8,CHEMBL616713,,
2070,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,10618,,,1,4373,BAO_0000357,8,CHEMBL616714,,
2071,,,,B,H,Autocuration,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,10618,,,1,14159,BAO_0000357,8,CHEMBL616715,,
2072,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1E receptor,10618,,,1,16633,BAO_0000357,8,CHEMBL616716,,
2073,,,,F,H,Autocuration,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",279,,,1,17085,BAO_0000019,8,CHEMBL616717,,
2074,,,,F,H,Expert,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",279,,,1,17085,BAO_0000019,8,CHEMBL616718,,
2075,,,,F,H,Autocuration,,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,279,,,1,16209,BAO_0000019,8,CHEMBL875905,,
2076,,,,F,H,Autocuration,,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,279,,,1,16209,BAO_0000019,8,CHEMBL616719,,
2077,,,,F,H,Expert,,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",279,,,1,17085,BAO_0000019,8,CHEMBL616720,,
2078,,,,B,H,Autocuration,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,279,,,1,14159,BAO_0000357,8,CHEMBL616721,,
2079,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,279,,,1,15250,BAO_0000219,8,CHEMBL616722,449.0,
2080,,,,B,H,Autocuration,,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),279,,,1,3805,BAO_0000357,8,CHEMBL616723,,
2081,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,279,,,1,16190,BAO_0000219,8,CHEMBL616724,449.0,
2082,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,279,,,1,16190,BAO_0000357,8,CHEMBL616725,,
2083,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,279,,,1,16209,BAO_0000357,8,CHEMBL616726,,
2084,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,279,,,1,16209,BAO_0000357,8,CHEMBL616727,,
2085,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,279,,,1,16209,BAO_0000357,8,CHEMBL616728,,
2086,,,,B,H,Autocuration,,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,279,,,1,6866,BAO_0000357,8,CHEMBL616729,,
2087,,,,B,H,Expert,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,279,,,1,17085,BAO_0000019,8,CHEMBL616730,,
2088,,,,B,H,Autocuration,,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,279,,,1,16312,BAO_0000357,8,CHEMBL617125,,
2089,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,279,,,1,6166,BAO_0000357,8,CHEMBL857977,,
2090,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,279,,,1,15779,BAO_0000219,8,CHEMBL617126,449.0,
2091,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,279,,,1,4199,BAO_0000219,8,CHEMBL617127,449.0,
2092,,,,B,H,Autocuration,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,279,,,1,14875,BAO_0000357,8,CHEMBL617128,,
2093,,,,B,H,Autocuration,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,279,,,1,15146,BAO_0000219,8,CHEMBL617129,449.0,
2094,,,,B,H,Autocuration,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,279,,,1,5213,BAO_0000357,8,CHEMBL617130,,
2095,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,279,,,1,14818,BAO_0000219,8,CHEMBL617131,449.0,
2096,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",279,,,1,4829,BAO_0000219,8,CHEMBL617132,449.0,
2097,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",279,,,1,4829,BAO_0000219,8,CHEMBL617133,449.0,
2098,,,,B,H,Autocuration,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,279,,,1,4373,BAO_0000357,8,CHEMBL617134,,
2099,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,279,,,1,4373,BAO_0000357,8,CHEMBL617135,,
2100,,,,B,H,Autocuration,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,279,,,1,5014,BAO_0000357,8,CHEMBL617136,,
2101,,,,B,H,Autocuration,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",104686,,,1,11662,BAO_0000019,4,CHEMBL617137,,
2102,,,,B,H,Autocuration,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",104686,,,1,11662,BAO_0000019,4,CHEMBL617138,,
2103,,,,B,H,Autocuration,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",104686,,,1,11662,BAO_0000019,4,CHEMBL617139,,
2104,,,,B,H,Autocuration,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,12687,,,1,14093,BAO_0000019,8,CHEMBL617140,,
2105,In vivo,,,F,H,Autocuration,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",104686,,,1,11200,BAO_0000218,4,CHEMBL617141,,
2106,,,,F,H,Autocuration,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,,1,11200,BAO_0000019,4,CHEMBL858112,,
2107,,,,B,H,Intermediate,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,17005,,,1,12352,BAO_0000019,8,CHEMBL617142,,
2108,,Bos taurus,,B,U,Autocuration,,9913.0,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",22226,,,1,13657,BAO_0000019,0,CHEMBL617143,,
2109,,Bos taurus,,B,U,Autocuration,,9913.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,22226,,,1,14331,BAO_0000019,0,CHEMBL617144,,
2110,,Bos taurus,,B,U,Autocuration,,9913.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,22226,,,1,14331,BAO_0000019,0,CHEMBL617145,,
2111,,,,B,U,Autocuration,,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,22226,,,1,14331,BAO_0000019,0,CHEMBL617146,,
2112,,Cavia porcellus,,B,H,Autocuration,,10141.0,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,104784,,,1,12685,BAO_0000019,4,CHEMBL617147,,
2113,,Cavia porcellus,,B,H,Autocuration,,10141.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,104784,,,1,14389,BAO_0000019,4,CHEMBL617148,,
2114,,Cavia porcellus,,B,H,Autocuration,,10141.0,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,104784,,,1,14386,BAO_0000019,4,CHEMBL617149,,
2115,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,104784,,,1,5732,BAO_0000224,4,CHEMBL617150,,
2116,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,104784,,,1,16293,BAO_0000224,4,CHEMBL617151,,
2117,,,,B,H,Autocuration,,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,104784,,,1,2078,BAO_0000224,4,CHEMBL617201,,
2118,,,,B,H,Autocuration,,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,10209,,,1,5486,BAO_0000357,8,CHEMBL617202,,
2119,In vivo,,,B,H,Autocuration,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,104826,,,1,11820,BAO_0000218,4,CHEMBL617203,,
2120,,,,B,H,Autocuration,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,104826,,,1,10297,BAO_0000019,4,CHEMBL617204,,
2121,,,,B,H,Autocuration,,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,104826,,,1,13704,BAO_0000224,4,CHEMBL617205,,
2122,,Mus musculus,,B,D,Autocuration,,10090.0,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,104826,,,1,10297,BAO_0000019,5,CHEMBL617206,,
2123,In vivo,,,B,H,Autocuration,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,104826,,,1,11820,BAO_0000218,4,CHEMBL617207,,
2124,,Mus musculus,,B,D,Autocuration,,10090.0,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,104826,,,1,10297,BAO_0000019,5,CHEMBL617208,,
2125,,,,B,H,Autocuration,,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,104826,,,1,11555,BAO_0000224,4,CHEMBL617209,,
2126,,,,B,H,Autocuration,,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,104826,,,1,11555,BAO_0000224,4,CHEMBL617210,,
2127,,,,B,H,Autocuration,,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,104826,,,1,11555,BAO_0000224,4,CHEMBL617211,,
2128,,Mus musculus,,B,D,Autocuration,,10090.0,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,104826,,,1,10297,BAO_0000019,5,CHEMBL617212,,
2129,,Sus scrofa,,B,H,Autocuration,,9823.0,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,104784,,,1,16688,BAO_0000224,4,CHEMBL617213,,
2130,,Sus scrofa,,B,H,Autocuration,,9823.0,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,104784,,,1,16688,BAO_0000224,4,CHEMBL617214,,
2131,,,,B,U,Autocuration,,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,22226,,,1,5333,BAO_0000221,0,CHEMBL617215,,
2132,,,,B,U,Autocuration,,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,22226,,,1,4437,BAO_0000221,0,CHEMBL617216,,
2133,,Sus scrofa,,B,H,Autocuration,,9823.0,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,17005,,,1,5033,BAO_0000357,8,CHEMBL617217,,
2134,,,,B,H,Autocuration,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,104686,,,1,15267,BAO_0000019,4,CHEMBL617218,,
2135,,,,B,H,Autocuration,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,104686,,,1,15267,BAO_0000019,4,CHEMBL872913,,
2136,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,104826,,,1,11820,BAO_0000019,4,CHEMBL617219,,
2137,,,,B,H,Autocuration,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,104686,,,1,9069,BAO_0000224,4,CHEMBL873482,,
2138,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,104686,,,1,9162,BAO_0000019,5,CHEMBL617220,,
2139,,,,B,H,Autocuration,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,104686,,,1,9162,BAO_0000019,4,CHEMBL617221,,
2140,,,,B,H,Autocuration,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,104686,,,1,9162,BAO_0000019,4,CHEMBL617222,,
2141,,,,F,H,Autocuration,,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,104686,,,1,10428,BAO_0000019,4,CHEMBL875906,,
2142,,,,B,H,Autocuration,,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,104686,,,1,9628,BAO_0000019,4,CHEMBL617223,,
2143,,,,B,H,Autocuration,,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,104686,,,1,12704,BAO_0000224,4,CHEMBL617224,,
2144,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,104686,,,1,15453,BAO_0000224,5,CHEMBL617225,,
2145,,,,B,H,Autocuration,,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,104686,,,1,188,BAO_0000224,4,CHEMBL617226,,
2146,,,,B,H,Autocuration,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,104686,,,1,10349,BAO_0000224,4,CHEMBL617227,,
2147,,,,B,H,Autocuration,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,104686,,,1,10349,BAO_0000224,4,CHEMBL617228,,
2148,,,,B,H,Autocuration,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,104686,,,1,8868,BAO_0000224,4,CHEMBL617229,,
2149,,,,B,H,Autocuration,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,104686,,,1,10025,BAO_0000224,4,CHEMBL617230,,
2150,,,,B,H,Autocuration,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",104686,,,1,10025,BAO_0000224,4,CHEMBL617231,,
2151,,,,B,H,Autocuration,,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,104686,,,1,11702,BAO_0000224,4,CHEMBL617232,,
2152,,,,B,H,Autocuration,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,104686,,,1,11702,BAO_0000224,4,CHEMBL617233,,
2153,,,,B,H,Autocuration,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,104686,,,1,11702,BAO_0000224,4,CHEMBL617234,,
2154,,,,F,H,Autocuration,,,Compound was tested for the inhibition of quipazine induced head twitches in rats,104686,,,1,11702,BAO_0000019,4,CHEMBL617235,,
2155,,,,F,H,Autocuration,,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,104686,,,1,11702,BAO_0000019,4,CHEMBL617236,,
2156,,,,B,H,Autocuration,Hippocampus,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,104686,,,1,10085,BAO_0000221,4,CHEMBL617237,,10000000.0
2157,,,,B,H,Autocuration,Hippocampus,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,104686,,,1,10085,BAO_0000221,4,CHEMBL617238,,10000000.0
2158,,Rattus norvegicus,,B,D,Autocuration,Brain,10116.0,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,104686,,,1,9630,BAO_0000221,5,CHEMBL617239,,955.0
2159,,,,B,H,Autocuration,,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,104686,,,1,11070,BAO_0000019,4,CHEMBL617240,,
2160,,,,B,H,Autocuration,,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,104686,,,1,9841,BAO_0000249,4,CHEMBL617241,,
2161,,,,B,H,Autocuration,,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,104686,,,1,9841,BAO_0000249,4,CHEMBL875907,,
2162,,,,B,H,Autocuration,,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,104686,,,1,13291,BAO_0000019,4,CHEMBL617242,,
2163,,,,F,H,Autocuration,,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,104686,,,1,10590,BAO_0000019,4,CHEMBL617152,,
2164,,Rattus norvegicus,,B,D,Autocuration,Brain,10116.0,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,104686,,,1,9064,BAO_0000221,5,CHEMBL617153,,955.0
2165,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,104686,,,1,12268,BAO_0000249,5,CHEMBL617154,,
2166,,,,B,H,Autocuration,Brain,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,104686,,,1,13508,BAO_0000221,4,CHEMBL617155,,955.0
2167,,,,F,H,Autocuration,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,104686,,,1,11279,BAO_0000019,4,CHEMBL617156,,
2168,,,,F,H,Autocuration,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,104686,,,1,11200,BAO_0000019,4,CHEMBL617157,,
2169,,,,F,H,Autocuration,,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,,1,11200,BAO_0000019,4,CHEMBL617158,,
2170,,,,F,H,Autocuration,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,104686,,,1,11200,BAO_0000019,4,CHEMBL617159,,
2171,,,,F,H,Autocuration,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,104686,,,1,11200,BAO_0000019,4,CHEMBL617160,,
2172,,,,F,H,Autocuration,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,,1,11200,BAO_0000019,4,CHEMBL858113,,
2173,,,,B,H,Autocuration,Brain,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,104686,,,1,9231,BAO_0000220,4,CHEMBL617247,,955.0
2174,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,104686,,,1,9737,BAO_0000019,4,CHEMBL617248,,
2175,,,,B,H,Autocuration,Brain,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,104686,,,1,9737,BAO_0000249,4,CHEMBL617249,,955.0
2176,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,104686,,,1,9737,BAO_0000019,4,CHEMBL617250,,
2177,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,104686,,,1,9737,BAO_0000019,4,CHEMBL617251,,
2178,,Rattus norvegicus,,B,D,Autocuration,,10116.0,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,104686,,,1,11828,BAO_0000019,5,CHEMBL617252,,
2179,,,,B,H,Autocuration,,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,104686,,,1,12253,BAO_0000019,4,CHEMBL617006,,
2180,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,104686,,,1,12253,BAO_0000019,4,CHEMBL617007,,
2181,,,,F,H,Autocuration,,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",104686,,,1,11279,BAO_0000019,4,CHEMBL617008,,
2182,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,104686,,,1,11866,BAO_0000019,4,CHEMBL617009,,
2183,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,104686,,,1,14424,BAO_0000224,5,CHEMBL617010,,
2184,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,104686,,,1,15180,BAO_0000019,5,CHEMBL857978,,
2185,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,104686,,,1,15180,BAO_0000019,5,CHEMBL617011,,
2186,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,104686,,,1,9786,BAO_0000019,5,CHEMBL617012,,
2187,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,104686,,,1,12132,BAO_0000224,4,CHEMBL617013,,
2188,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,104686,,,1,5486,BAO_0000249,4,CHEMBL617014,,
2189,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,104686,,,1,15316,BAO_0000019,4,CHEMBL617015,,
2190,,,,B,H,Autocuration,,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,104686,,,1,16429,BAO_0000019,4,CHEMBL617016,,
2191,,,,B,H,Autocuration,,,pKi value for 5-hydroxytryptamine 2 receptor binding site,104686,,,1,14617,BAO_0000224,4,CHEMBL617017,,
2192,,,,B,H,Autocuration,Brain,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,104686,,,1,11351,BAO_0000221,4,CHEMBL617018,,955.0
2193,,,,F,H,Autocuration,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,104686,,,1,11279,BAO_0000019,4,CHEMBL617019,,
2194,,,,B,H,Autocuration,,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,,1,9523,BAO_0000019,4,CHEMBL617020,,
2195,,,,B,H,Autocuration,,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,,1,9523,BAO_0000019,4,CHEMBL617021,,
2196,,,,B,H,Autocuration,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,,1,9523,BAO_0000019,4,CHEMBL617022,,
2197,,,,B,H,Autocuration,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,,1,9523,BAO_0000019,4,CHEMBL617023,,
2198,,,,B,H,Autocuration,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,,1,9523,BAO_0000019,4,CHEMBL617024,,
2199,,,,B,H,Autocuration,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,105075,,,1,9523,BAO_0000019,4,CHEMBL617025,,
2200,,,,B,H,Autocuration,,,Hill coefficient of compound was determined,105075,,,1,9523,BAO_0000224,4,CHEMBL617026,,
2201,,,,B,U,Autocuration,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,22226,,,1,4771,BAO_0000019,0,CHEMBL617027,,
2202,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,104686,,,1,5033,BAO_0000019,5,CHEMBL617028,,
2203,,,,B,H,Expert,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,12687,,,1,10845,BAO_0000019,8,CHEMBL617029,,
2204,,,,B,H,Expert,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,12687,,,1,10845,BAO_0000019,8,CHEMBL875908,,
2205,,,,B,H,Autocuration,,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),12687,,,1,16288,BAO_0000357,8,CHEMBL617030,,
2206,,,,B,H,Autocuration,,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),12687,,,1,16288,BAO_0000019,8,CHEMBL617031,,
2207,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,12687,,,1,16190,BAO_0000019,8,CHEMBL617032,,
2208,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,104686,,,1,12463,BAO_0000224,5,CHEMBL617033,,
2209,,,,B,H,Autocuration,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",104686,,,1,9699,BAO_0000224,4,CHEMBL617034,,
2210,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,104686,,,1,9699,BAO_0000224,4,CHEMBL617035,,
2211,,,,B,H,Autocuration,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",104686,,,1,11662,BAO_0000019,4,CHEMBL617036,,
2212,,,,B,H,Autocuration,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,104784,,,1,1205,BAO_0000224,4,CHEMBL617037,,
2213,,,,B,U,Autocuration,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,22226,,,1,11376,BAO_0000219,0,CHEMBL617038,,
2214,,,,B,H,Autocuration,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",104784,,,1,11376,BAO_0000219,4,CHEMBL617039,,
2215,,,,B,H,Autocuration,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,104784,,,1,4639,BAO_0000224,4,CHEMBL617161,,
2216,,,,B,H,Autocuration,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,104784,,,1,2222,BAO_0000224,4,CHEMBL617162,,
2217,,,,B,H,Autocuration,,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,104784,,,1,1558,BAO_0000224,4,CHEMBL617163,,
2218,,,,B,H,Autocuration,,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,104784,,,1,1089,BAO_0000224,4,CHEMBL617164,,
2219,,,,B,H,Autocuration,,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,104784,,,1,386,BAO_0000249,4,CHEMBL617165,,
2220,,,,B,H,Autocuration,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,104784,,,1,2474,BAO_0000224,4,CHEMBL617166,,
2221,,,,B,H,Autocuration,,,Binding affinity towards 5-HT2 receptor,104784,,,1,17066,BAO_0000224,4,CHEMBL617167,,
2222,,,,B,H,Autocuration,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,104784,,,1,959,BAO_0000224,4,CHEMBL872912,,
2223,,,,B,H,Autocuration,,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,104784,,,1,6398,BAO_0000224,4,CHEMBL617168,,
2224,,,,B,H,Autocuration,,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,104686,,,1,11889,BAO_0000224,4,CHEMBL617169,,
2225,,,,B,H,Autocuration,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,104784,,,1,4221,BAO_0000224,4,CHEMBL617170,,
2226,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,104784,,,1,11026,BAO_0000224,4,CHEMBL617171,,
2227,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,104784,,,1,11866,BAO_0000224,4,CHEMBL617172,,
2228,,,,B,H,Autocuration,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,104784,,,1,4221,BAO_0000224,4,CHEMBL617173,,
2229,,,,B,U,Autocuration,,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,22226,,,1,13950,BAO_0000019,0,CHEMBL617174,,
2230,,,,B,H,Autocuration,,,5-hydroxytryptamine 2 receptor binding affinity,104784,,,1,1263,BAO_0000224,4,CHEMBL617175,,
2231,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,17005,,,1,13291,BAO_0000357,8,CHEMBL617176,,
2232,,,,B,H,Autocuration,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,17005,,,1,10812,BAO_0000357,8,CHEMBL617177,,
2233,,,,B,H,Autocuration,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,104784,,,1,13020,BAO_0000224,4,CHEMBL617178,,
2234,,,,B,H,Autocuration,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,104784,,,1,13021,BAO_0000224,4,CHEMBL617179,,
2235,,,,B,H,Autocuration,,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,104784,,,1,13020,BAO_0000224,4,CHEMBL617180,,
2236,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,17005,,,1,14532,BAO_0000357,8,CHEMBL617181,,
2237,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor,17005,,,1,13944,BAO_0000357,8,CHEMBL617182,,
2238,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor,17005,,,1,14331,BAO_0000357,8,CHEMBL617183,,
2239,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,17005,,,1,14118,BAO_0000357,8,CHEMBL617184,,
2240,,,,B,H,Autocuration,,,Binding affinity against serotonergic 5-HT2 receptor,17005,,,1,13033,BAO_0000357,8,CHEMBL617185,,
2241,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,17005,,,1,10321,BAO_0000357,8,CHEMBL617186,,
2242,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity at 5- HT2 receptor,17005,,,1,12918,BAO_0000357,8,CHEMBL617187,,
2243,,,,B,H,Autocuration,,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,17005,,,1,15120,BAO_0000357,8,CHEMBL617188,,
2244,,,,B,H,Autocuration,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,17005,,,1,2613,BAO_0000218,8,CHEMBL617189,,
2245,,Homo sapiens,,B,D,Autocuration,,9606.0,Inhibitory activity against cloned human 5-HT2 receptor,104784,,,1,13378,BAO_0000224,5,CHEMBL617190,,
2246,,Homo sapiens,,B,D,Autocuration,,9606.0,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",104784,,,1,2331,BAO_0000219,5,CHEMBL617191,449.0,
2247,,Homo sapiens,,B,D,Autocuration,,9606.0,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",104784,,,1,2331,BAO_0000219,5,CHEMBL617192,449.0,
2248,,Homo sapiens,,B,D,Autocuration,,9606.0,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",104784,,,1,2331,BAO_0000219,5,CHEMBL617193,449.0,
2249,,Homo sapiens,,B,D,Autocuration,,9606.0,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",104784,,,1,2331,BAO_0000219,5,CHEMBL617194,449.0,
2250,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,104784,,,1,4170,BAO_0000224,4,CHEMBL617195,,
2251,,,,B,H,Autocuration,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,104784,,,1,15453,BAO_0000224,4,CHEMBL881830,,
2252,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,17005,,,1,1479,BAO_0000357,8,CHEMBL617196,,
2253,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,104686,,,1,11139,BAO_0000224,4,CHEMBL617197,,
2254,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,17005,,,1,13969,BAO_0000357,8,CHEMBL617198,,
2255,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,17005,,,1,13392,BAO_0000357,8,CHEMBL873476,,
2256,,,,B,H,Expert,,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,17005,,,1,14430,BAO_0000019,8,CHEMBL617199,,
2257,,Cavia porcellus,,B,H,Autocuration,,10141.0,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,107,,,1,13181,BAO_0000357,8,CHEMBL617200,,
2258,,,,B,H,Autocuration,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,51,,,1,17200,BAO_0000357,8,CHEMBL617484,,
2259,,,,B,H,Autocuration,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,107,,,1,17200,BAO_0000357,8,CHEMBL617485,,
2260,,,,B,H,Autocuration,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,51,,,1,17200,BAO_0000357,8,CHEMBL617486,,
2261,,,,B,H,Autocuration,,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,107,,,1,13463,BAO_0000357,8,CHEMBL858022,,
2262,,,,B,H,Autocuration,,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,107,,,1,6347,BAO_0000219,8,CHEMBL617049,449.0,
2263,,Homo sapiens,,F,D,Expert,,9606.0,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,107,,,1,6857,BAO_0000219,9,CHEMBL617050,449.0,
2264,,,,F,H,Autocuration,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,107,,,1,4176,BAO_0000219,8,CHEMBL617051,,
2265,,,,F,H,Autocuration,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,107,,,1,4176,BAO_0000219,8,CHEMBL617052,,
2266,,,,F,H,Autocuration,,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,107,,,1,4176,BAO_0000219,8,CHEMBL617053,,
2267,,,,B,H,Autocuration,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",107,,,1,6347,BAO_0000219,8,CHEMBL617054,449.0,
2268,,,,B,H,Autocuration,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",107,,,1,6347,BAO_0000219,8,CHEMBL617055,449.0,
2269,,,,B,H,Autocuration,,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,107,,,1,15331,BAO_0000357,8,CHEMBL882924,,
2270,,Homo sapiens,,B,D,Expert,,9606.0,Inhibition of human 5-hydroxytryptamine 2A receptor,107,,,1,16146,BAO_0000357,9,CHEMBL617056,,
2271,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,107,,,1,15250,BAO_0000219,8,CHEMBL617057,449.0,
2272,,,,B,H,Expert,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,107,,,1,13631,BAO_0000219,8,CHEMBL617058,,
2273,,,,B,H,Autocuration,,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),107,,,1,3805,BAO_0000357,8,CHEMBL617059,,
2274,,,,B,H,Autocuration,,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,107,,,1,4011,BAO_0000219,8,CHEMBL617060,449.0,
2275,,,,B,H,Expert,,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,107,,,1,4012,BAO_0000219,8,CHEMBL617061,449.0,
2276,,,,B,H,Expert,,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,107,,,1,6366,BAO_0000219,8,CHEMBL617062,307.0,
2277,,,,B,H,Expert,,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,107,,,1,15949,BAO_0000219,8,CHEMBL617063,449.0,
2278,,,,F,H,Autocuration,,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,107,,,1,14093,BAO_0000019,8,CHEMBL617064,,
2279,,,,F,H,Autocuration,,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,107,,,1,13481,BAO_0000019,8,CHEMBL617065,,
2280,,,,B,H,Autocuration,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,107,,,1,6347,BAO_0000219,8,CHEMBL617066,449.0,
2281,,,,B,H,Autocuration,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,107,,,1,6347,BAO_0000219,8,CHEMBL617067,449.0,
2282,,,,F,H,Autocuration,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,107,,,1,14093,BAO_0000019,8,CHEMBL617068,,
2283,,,,F,H,Autocuration,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,107,,,1,14093,BAO_0000019,8,CHEMBL617069,,
2284,,,,F,H,Autocuration,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,107,,,1,13481,BAO_0000019,8,CHEMBL617070,,
2285,,,,B,H,Autocuration,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,107,,,1,14442,BAO_0000357,8,CHEMBL617071,,
2286,,,,B,H,Autocuration,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,107,,,1,14442,BAO_0000357,8,CHEMBL872915,,
2287,,,,B,H,Autocuration,,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,107,,,1,14755,BAO_0000357,8,CHEMBL617072,,
2288,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,107,,,1,16441,BAO_0000357,8,CHEMBL617073,,
2289,,,,B,H,Autocuration,,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,107,,,1,14744,BAO_0000357,8,CHEMBL617074,,
2290,,,,B,H,Expert,,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,107,,,1,16659,BAO_0000219,8,CHEMBL617075,449.0,
2291,,,,B,H,Autocuration,,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,107,,,1,3307,BAO_0000357,8,CHEMBL617076,,
2292,,Homo sapiens,,B,D,Expert,,9606.0,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,107,,,1,6857,BAO_0000019,9,CHEMBL617077,,
2293,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,107,,,1,5635,BAO_0000357,8,CHEMBL617078,,
2294,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,107,,,1,4234,BAO_0000357,9,CHEMBL617079,,
2295,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,107,,,1,15527,BAO_0000357,8,CHEMBL617080,,
2296,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,107,,,1,6588,BAO_0000219,8,CHEMBL617081,449.0,
2297,,,,B,H,Expert,,,Binding affinity towards human 5-HT2A receptor in BEK cells,107,,,1,13631,BAO_0000219,8,CHEMBL617082,,
2298,,,,B,H,Autocuration,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,107,,,1,17723,BAO_0000357,8,CHEMBL617083,,
2299,,,,B,H,Autocuration,,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,107,,,1,14770,BAO_0000357,8,CHEMBL617084,,
2300,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity for human 5-hydroxytryptamine 2A receptor,107,,,1,16293,BAO_0000357,9,CHEMBL617085,,
2301,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,107,,,1,16209,BAO_0000357,8,CHEMBL617086,,
2302,,,,B,H,Autocuration,,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,107,,,1,12469,BAO_0000219,8,CHEMBL617087,,
2303,,,,B,H,Autocuration,,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,107,,,1,15363,BAO_0000357,8,CHEMBL617088,,
2304,,,,B,H,Autocuration,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,107,,,1,15363,BAO_0000357,8,CHEMBL617089,,
2305,,,,B,H,Expert,,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",107,,,1,16441,BAO_0000019,8,CHEMBL617090,,
2306,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,107,,,1,8,BAO_0000357,8,CHEMBL617513,,
2307,,,,B,H,Autocuration,,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,107,,,1,4176,BAO_0000219,8,CHEMBL617514,722.0,
2308,,,,B,H,Autocuration,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,107,,,1,17085,BAO_0000019,8,CHEMBL617515,,
2309,,,,B,H,Autocuration,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,107,,,1,17200,BAO_0000357,8,CHEMBL617516,,
2310,,Homo sapiens,,B,D,Expert,,9606.0,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,107,,,1,17200,BAO_0000357,9,CHEMBL617517,,
2311,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,107,,,1,4013,BAO_0000219,9,CHEMBL617518,449.0,
2312,,,,B,H,Autocuration,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,107,,,1,5088,BAO_0000357,8,CHEMBL617519,,
2313,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,107,,,1,5088,BAO_0000357,9,CHEMBL617520,,
2314,,,,B,H,Autocuration,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,107,,,1,5088,BAO_0000357,8,CHEMBL617521,,
2315,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,107,,,1,5088,BAO_0000357,9,CHEMBL617522,,
2316,,,,B,H,Autocuration,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,107,,,1,5088,BAO_0000357,8,CHEMBL617523,,
2317,,,,B,H,Autocuration,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,107,,,1,5088,BAO_0000357,8,CHEMBL617524,,
2318,,,,B,H,Autocuration,,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,104686,,,1,9786,BAO_0000019,4,CHEMBL617525,,
2319,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,104686,,,1,9205,BAO_0000019,5,CHEMBL617526,,
2320,,,,B,H,Autocuration,,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,104686,,,1,11257,BAO_0000224,4,CHEMBL617527,,
2321,,,,B,H,Autocuration,,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,104686,,,1,9362,BAO_0000019,4,CHEMBL617528,,
2322,,,,B,H,Autocuration,,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,104686,,,1,9362,BAO_0000019,4,CHEMBL617529,,
2323,,,,B,H,Autocuration,,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,104686,,,1,10590,BAO_0000224,4,CHEMBL617530,,
2324,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,104686,,,1,10468,BAO_0000019,4,CHEMBL617531,,
2325,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,104686,,,1,13050,BAO_0000019,4,CHEMBL617532,,
2326,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,104686,,,1,11624,BAO_0000019,4,CHEMBL617533,,
2327,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,104686,,,1,10468,BAO_0000019,4,CHEMBL617534,,
2328,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,104686,,,1,10330,BAO_0000224,4,CHEMBL617535,,
2329,,,,B,H,Autocuration,,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,104686,,,1,10062,BAO_0000224,4,CHEMBL617536,,
2330,,,,B,H,Autocuration,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,104686,,,1,11642,BAO_0000224,4,CHEMBL617537,,
2331,,,,B,H,Autocuration,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,104686,,,1,10062,BAO_0000224,4,CHEMBL617538,,
2332,In vitro,,,B,H,Autocuration,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,104686,,,1,13427,BAO_0000219,4,CHEMBL617539,,
2333,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,104686,,,1,12280,BAO_0000224,5,CHEMBL617540,,
2334,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,104686,,,1,4101,BAO_0000224,5,CHEMBL617541,,
2335,,,,B,H,Autocuration,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,104686,,,1,10062,BAO_0000224,4,CHEMBL617542,,
2336,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,104686,,,1,11147,BAO_0000224,4,CHEMBL617543,,
2337,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,104686,,,1,2395,BAO_0000219,5,CHEMBL617544,485.0,
2338,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,104686,,,1,2395,BAO_0000219,5,CHEMBL617545,485.0,
2339,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,104686,,,1,9098,BAO_0000019,5,CHEMBL617413,,
2340,,,,B,H,Autocuration,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,104686,,,1,9098,BAO_0000019,4,CHEMBL617414,,
2341,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,104686,,,1,9098,BAO_0000019,5,CHEMBL617415,,
2342,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,104686,,,1,9443,BAO_0000224,4,CHEMBL617416,,
2343,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,104686,,,1,9443,BAO_0000224,4,CHEMBL617417,,
2344,,,,B,H,Autocuration,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",104686,,,1,9699,BAO_0000019,4,CHEMBL617418,,
2345,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,104686,,,1,9699,BAO_0000019,4,CHEMBL617419,,
2346,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,104686,,,1,9098,BAO_0000224,4,CHEMBL617420,,
2347,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Affinity for 5-hydroxytryptamine 2 receptor,104686,,,1,3070,BAO_0000224,5,CHEMBL617421,,
2348,,,,B,H,Autocuration,,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,104686,,,1,9547,BAO_0000224,4,CHEMBL617422,,
2349,,,,B,H,Autocuration,,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,104686,,,1,10444,BAO_0000019,4,CHEMBL617423,,
2350,,,,B,H,Autocuration,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,104686,,,1,14617,BAO_0000019,4,CHEMBL617424,,
2351,,,,B,H,Autocuration,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,104686,,,1,14617,BAO_0000019,4,CHEMBL617425,,
2352,,,,B,H,Autocuration,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),104686,,,1,11130,BAO_0000224,4,CHEMBL617426,,
2353,In vivo,,,B,H,Autocuration,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),104686,,,1,11130,BAO_0000218,4,CHEMBL617427,,
2354,,,,B,H,Autocuration,Brain,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,104686,,,1,14542,BAO_0000221,4,CHEMBL617428,,955.0
2355,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,104686,,,1,2797,BAO_0000224,4,CHEMBL617429,,
2356,,,,B,H,Autocuration,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,104686,,,1,11332,BAO_0000019,4,CHEMBL617430,,
2357,,,,B,H,Autocuration,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,104686,,,1,11332,BAO_0000019,4,CHEMBL617431,,
2358,,,,B,H,Autocuration,Frontal cortex,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,104686,,,1,10752,BAO_0000019,4,CHEMBL617432,,1870.0
2359,,,,B,H,Autocuration,,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,104686,,,1,1185,BAO_0000224,4,CHEMBL617433,,
2360,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,104686,,,1,1185,BAO_0000224,4,CHEMBL617434,,
2361,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,104686,,,1,11624,BAO_0000224,5,CHEMBL617435,,
2362,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,104686,,,1,1344,BAO_0000019,4,CHEMBL617436,,
2363,,Rattus norvegicus,,B,D,Autocuration,Striatum,10116.0,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,104686,,,1,15453,BAO_0000019,5,CHEMBL617437,,2435.0
2364,,,,B,H,Autocuration,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",104686,,,1,11662,BAO_0000019,4,CHEMBL617438,,
2365,,,,B,H,Autocuration,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",104686,,,1,11662,BAO_0000019,4,CHEMBL617439,,
2366,,,,B,H,Autocuration,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,104686,,,1,10796,BAO_0000224,4,CHEMBL617440,,
2367,,,,B,H,Autocuration,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,104686,,,1,9069,BAO_0000224,4,CHEMBL617441,,
2368,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,104686,,,1,8814,BAO_0000019,5,CHEMBL872918,,
2369,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,104686,,,1,8908,BAO_0000019,5,CHEMBL617442,,
2370,,,,B,H,Autocuration,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,104686,,,1,9098,BAO_0000019,4,CHEMBL617443,,
2371,,,,B,H,Autocuration,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,104686,,,1,9098,BAO_0000019,4,CHEMBL617444,,
2372,,,,B,H,Autocuration,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,104686,,,1,9098,BAO_0000019,4,CHEMBL617445,,
2373,,,,B,H,Autocuration,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,104686,,,1,9098,BAO_0000019,4,CHEMBL617446,,
2374,,,,B,H,Autocuration,,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,104686,,,1,9098,BAO_0000249,4,CHEMBL617447,,
2375,,,,B,H,Autocuration,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,104686,,,1,9098,BAO_0000019,4,CHEMBL617448,,
2376,,,,B,H,Autocuration,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,104686,,,1,9098,BAO_0000019,4,CHEMBL617449,,
2377,,,,B,H,Autocuration,,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,104686,,,1,9161,BAO_0000019,4,CHEMBL617450,,
2378,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,104686,,,1,9161,BAO_0000019,4,CHEMBL617451,,
2379,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,104686,,,1,9161,BAO_0000019,4,CHEMBL617452,,
2380,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,104686,,,1,9161,BAO_0000019,4,CHEMBL617453,,
2381,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,104686,,,1,9161,BAO_0000019,4,CHEMBL617660,,
2382,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,104686,,,1,9161,BAO_0000019,4,CHEMBL617661,,
2383,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,104686,,,1,9161,BAO_0000019,4,CHEMBL617662,,
2384,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,104686,,,1,9161,BAO_0000019,4,CHEMBL872919,,
2385,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,104686,,,1,9161,BAO_0000019,4,CHEMBL617663,,
2386,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,104686,,,1,9161,BAO_0000019,4,CHEMBL617664,,
2387,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,104686,,,1,9161,BAO_0000019,4,CHEMBL617665,,
2388,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,104686,,,1,9161,BAO_0000019,4,CHEMBL617666,,
2389,,,,B,H,Autocuration,,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,104686,,,1,12094,BAO_0000019,4,CHEMBL617667,,
2390,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,104686,,,1,12018,BAO_0000249,4,CHEMBL617668,,
2391,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,104686,,,1,10394,BAO_0000249,4,CHEMBL617669,,
2392,,,,B,H,Autocuration,,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,104686,,,1,15260,BAO_0000224,4,CHEMBL617670,,
2393,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibitory constant against 5-hydroxytryptamine 2 receptor,104686,,,1,11624,BAO_0000224,5,CHEMBL617671,,
2394,,,,B,H,Autocuration,,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,104686,,,1,13654,BAO_0000224,4,CHEMBL617672,,
2395,,,,B,H,Autocuration,,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,104686,,,1,9541,BAO_0000019,4,CHEMBL617673,,
2396,,,,B,H,Autocuration,,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,104686,,,1,11933,BAO_0000224,4,CHEMBL617674,,
2397,,,,B,H,Autocuration,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,104686,,,1,15538,BAO_0000019,4,CHEMBL617675,,
2398,,,,B,H,Autocuration,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,104686,,,1,15538,BAO_0000019,4,CHEMBL617676,,
2399,,,,B,H,Autocuration,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,104686,,,1,15538,BAO_0000019,4,CHEMBL617677,,
2400,,,,B,D,Autocuration,,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,104686,,,1,8841,BAO_0000019,5,CHEMBL617678,,
2401,,,,B,H,Autocuration,,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,104686,,,1,1455,BAO_0000224,4,CHEMBL617679,,
2402,,,,B,H,Autocuration,,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,104686,,,1,1455,BAO_0000224,4,CHEMBL617680,,
2403,,,,B,H,Autocuration,,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,104686,,,1,11752,BAO_0000019,4,CHEMBL617681,,
2404,,,,B,H,Autocuration,Brain,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,104686,,,1,11642,BAO_0000221,4,CHEMBL617682,,955.0
2405,,,,B,H,Autocuration,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,104686,,,1,12092,BAO_0000224,4,CHEMBL617683,,
2406,,,,B,H,Autocuration,,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,104686,,,1,3967,BAO_0000224,4,CHEMBL617684,,
2407,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity towards 5-hydroxytryptamine 2 receptor,104686,,,1,12771,BAO_0000224,5,CHEMBL617685,,
2408,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,104686,,,1,11642,BAO_0000019,4,CHEMBL617686,,
2409,,,,B,H,Autocuration,,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,104686,,,1,11628,BAO_0000224,4,CHEMBL617687,,
2410,,,,B,H,Autocuration,,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,104686,,,1,13654,BAO_0000224,4,CHEMBL617688,,
2411,,,,F,H,Autocuration,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,,1,11200,BAO_0000019,4,CHEMBL617689,,
2412,,,,F,H,Autocuration,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,104686,,,1,11200,BAO_0000019,4,CHEMBL617690,,
2413,In vivo,,,F,H,Autocuration,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",104686,,,1,11200,BAO_0000218,4,CHEMBL617691,,
2414,In vivo,,,F,H,Autocuration,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",104686,,,1,11200,BAO_0000218,4,CHEMBL617692,,
2415,In vivo,,,F,H,Autocuration,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",104686,,,1,11200,BAO_0000218,4,CHEMBL617693,,
2416,In vivo,,,F,H,Autocuration,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",104686,,,1,11200,BAO_0000218,4,CHEMBL617694,,
2417,,,,B,H,Expert,Brain,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,12687,,,1,15436,BAO_0000221,8,CHEMBL857985,,955.0
2418,,Rattus norvegicus,,B,D,Expert,,10116.0,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,12687,,,1,15436,BAO_0000019,9,CHEMBL617695,,
2419,,,,B,H,Autocuration,,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,12687,,,1,14025,BAO_0000019,8,CHEMBL617696,,
2420,,,,B,H,Autocuration,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,12687,,,1,4342,BAO_0000357,8,CHEMBL617697,,
2421,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,12687,,,1,13735,BAO_0000019,9,CHEMBL617257,,
2422,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,12687,,,1,5816,BAO_0000357,9,CHEMBL617258,,
2423,,,,B,H,Expert,,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,12687,,,1,14287,BAO_0000019,8,CHEMBL617259,,
2424,,,,B,H,Autocuration,,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,12687,,,1,15738,BAO_0000357,8,CHEMBL617260,,
2425,,Rattus norvegicus,,B,D,Expert,,10116.0,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,12687,,,1,15738,BAO_0000357,9,CHEMBL617261,,
2426,,,,B,H,Autocuration,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,12687,,,1,15026,BAO_0000019,8,CHEMBL617262,,
2427,,,,B,H,Expert,,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,12687,,,1,16647,BAO_0000019,8,CHEMBL617263,,
2428,,,,B,H,Autocuration,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,12687,,,1,16647,BAO_0000019,8,CHEMBL617264,,
2429,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,12687,,,1,13345,BAO_0000019,9,CHEMBL617265,,
2430,,,,B,H,Autocuration,,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,12687,,,1,1543,BAO_0000249,8,CHEMBL617266,,
2431,,,,B,H,Autocuration,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,12687,,,1,12444,BAO_0000019,8,CHEMBL617267,,
2432,,,,B,H,Expert,,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,12687,,,1,16404,BAO_0000019,8,CHEMBL617268,,
2433,,,,B,H,Autocuration,,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,12687,,,1,16404,BAO_0000219,8,CHEMBL617269,449.0,
2434,,,,B,H,Expert,,,Kinetic inhibition constant evaluated by measuring serotonergic activity,12687,,,1,15577,BAO_0000357,8,CHEMBL617323,,
2435,,,,B,H,Autocuration,,,Serotonergic activity of the compound.,12687,,,1,15577,BAO_0000357,8,CHEMBL617324,,
2436,,,,B,H,Autocuration,,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,12687,,,1,2495,BAO_0000249,8,CHEMBL617325,,
2437,,Rattus norvegicus,,B,D,Expert,,10116.0,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,12687,,,1,15042,BAO_0000019,9,CHEMBL617326,,
2438,,,,B,H,Expert,,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,12687,,,1,15026,BAO_0000249,8,CHEMBL617327,,
2439,,Rattus norvegicus,,F,D,Expert,,10116.0,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,,,1,12919,BAO_0000019,9,CHEMBL617328,,
2440,,Rattus norvegicus,,F,D,Expert,,10116.0,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,,,1,12919,BAO_0000019,9,CHEMBL617329,,
2441,,Rattus norvegicus,,F,D,Expert,,10116.0,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,,,1,12919,BAO_0000019,9,CHEMBL617330,,
2442,,,,B,H,Autocuration,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,,,1,15194,BAO_0000357,8,CHEMBL617331,,
2443,,,,B,H,Autocuration,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,12687,,,1,15194,BAO_0000357,8,CHEMBL617332,,
2444,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,107,,,1,4820,BAO_0000357,8,CHEMBL617333,,
2445,,,,B,H,Autocuration,,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,107,,,1,6736,BAO_0000357,8,CHEMBL617334,,
2446,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,107,,,1,5163,BAO_0000357,8,CHEMBL617335,,
2447,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,107,,,1,5163,BAO_0000357,8,CHEMBL617336,,
2448,,,,B,H,Autocuration,,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,107,,,1,6011,BAO_0000357,8,CHEMBL617337,,
2449,,Homo sapiens,,B,D,Expert,,9606.0,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,107,,,1,14294,BAO_0000357,9,CHEMBL617338,,
2450,,,,B,H,Autocuration,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,107,,,1,5014,BAO_0000357,8,CHEMBL617339,,
2451,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,107,,,1,17066,BAO_0000357,8,CHEMBL617340,,
2452,,,,B,H,Autocuration,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,107,,,1,17515,BAO_0000357,8,CHEMBL617341,,
2453,,,,B,H,Expert,,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,107,,,1,6736,BAO_0000357,8,CHEMBL617342,,
2454,,,,B,H,Expert,,,Affinity for 5-hydroxytryptamine 2A receptor,107,,,1,5163,BAO_0000357,8,CHEMBL617343,,
2455,,,,B,H,Expert,,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,107,,,1,16911,BAO_0000219,8,CHEMBL617344,723.0,
2456,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,107,,,1,6841,BAO_0000357,8,CHEMBL617345,,
2457,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,107,,,1,6119,BAO_0000357,8,CHEMBL617346,,
2458,,,,B,H,Autocuration,,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,107,,,1,3962,BAO_0000357,8,CHEMBL617347,,
2459,,,,B,H,Autocuration,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,107,,,1,4373,BAO_0000357,8,CHEMBL617348,,
2460,,,,B,H,Autocuration,,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,107,,,1,4373,BAO_0000357,8,CHEMBL617349,,
2461,,,,F,H,Autocuration,,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,107,,,1,3962,BAO_0000019,8,CHEMBL617350,,
2462,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,107,,,1,1633,BAO_0000357,8,CHEMBL872339,,
2463,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,107,,,1,4373,BAO_0000357,8,CHEMBL617351,,
2464,,,,B,H,Expert,,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,107,,,1,6576,BAO_0000357,8,CHEMBL617352,,
2465,,,,B,H,Autocuration,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,107,,,1,4687,BAO_0000357,8,CHEMBL617353,,
2466,,,,B,H,Autocuration,,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,107,,,1,16946,BAO_0000357,8,CHEMBL617354,,
2467,,,,B,H,Autocuration,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,107,,,1,14159,BAO_0000357,8,CHEMBL617355,,
2468,,Mus musculus,,B,H,Expert,,10090.0,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,107,,,1,3032,BAO_0000219,8,CHEMBL617356,449.0,
2469,,,,B,H,Autocuration,,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,107,,,1,16655,BAO_0000357,8,CHEMBL617357,,
2470,,,,B,H,Autocuration,,,Binding affinity at 5-hydroxytryptamine 2A receptor,107,,,1,13964,BAO_0000357,8,CHEMBL617358,,
2471,,,,B,H,Expert,,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,107,,,1,16989,BAO_0000357,8,CHEMBL617359,,
2472,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,107,,,1,16117,BAO_0000357,8,CHEMBL617360,,
2473,,,,B,H,Autocuration,,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,107,,,1,16700,BAO_0000357,8,CHEMBL875913,,
2474,,,,B,H,Autocuration,,,Affinity against 5-hydroxytryptamine 2A receptor,107,,,1,3269,BAO_0000357,8,CHEMBL617361,,
2475,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against 5-Hydroxytryptamine 2A receptor,107,,,1,1274,BAO_0000357,9,CHEMBL617362,,
2476,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,107,,,1,1317,BAO_0000357,8,CHEMBL617363,,
2477,,,,B,H,Autocuration,,,Tested against 5-hydroxytryptamine 2A receptor,107,,,1,12146,BAO_0000357,8,CHEMBL617364,,
2478,,,,B,H,Autocuration,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,105075,,,1,12652,BAO_0000224,4,CHEMBL617365,,
2479,,,,B,H,Autocuration,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,105075,,,1,12652,BAO_0000224,4,CHEMBL617366,,
2480,,,,B,H,Autocuration,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,105075,,,1,12652,BAO_0000224,4,CHEMBL617367,,
2481,,,,B,H,Autocuration,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,105075,,,1,12652,BAO_0000224,4,CHEMBL617368,,
2482,,,,B,H,Autocuration,,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),107,,,1,16647,BAO_0000357,8,CHEMBL617369,,
2483,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,227,,,1,15851,BAO_0000219,9,CHEMBL617370,722.0,
2484,,Homo sapiens,,F,D,Expert,,9606.0,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,227,,,1,6857,BAO_0000219,9,CHEMBL617371,449.0,
2485,,,,B,H,Autocuration,,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),227,,,1,3805,BAO_0000357,8,CHEMBL617372,,
2486,,Homo sapiens,,B,D,Expert,,9606.0,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,227,,,1,6491,BAO_0000357,9,CHEMBL617373,,
2487,,,,F,H,Autocuration,,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,227,,,1,14093,BAO_0000019,8,CHEMBL617374,,
2488,,,,F,H,Autocuration,,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,227,,,1,13481,BAO_0000019,8,CHEMBL617375,,
2489,,,,F,H,Autocuration,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,227,,,1,14093,BAO_0000019,8,CHEMBL617376,,
2490,,,,F,H,Autocuration,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,227,,,1,14093,BAO_0000019,8,CHEMBL617377,,
2491,,,,F,H,Autocuration,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,227,,,1,14093,BAO_0000019,8,CHEMBL617378,,
2492,,,,F,H,Autocuration,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,227,,,1,13481,BAO_0000019,8,CHEMBL617379,,
2493,,,,B,H,Autocuration,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,227,,,1,14442,BAO_0000357,8,CHEMBL617380,,
2494,,,,B,H,Autocuration,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,227,,,1,14442,BAO_0000357,8,CHEMBL617381,,
2495,,,,B,H,Autocuration,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,227,,,1,14442,BAO_0000357,8,CHEMBL617382,,
2496,,,,B,H,Autocuration,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,107,,,1,12369,BAO_0000357,8,CHEMBL617383,,
2497,,,,B,H,Expert,,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,107,,,1,12369,BAO_0000357,8,CHEMBL617384,,
2498,,,,B,H,Expert,,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,107,,,1,12369,BAO_0000357,8,CHEMBL617385,,
2499,,,,B,H,Autocuration,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,107,,,1,14447,BAO_0000019,8,CHEMBL617386,,
2500,,,,B,H,Autocuration,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,107,,,1,14447,BAO_0000019,8,CHEMBL617387,,
2501,,,,B,H,Autocuration,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,107,,,1,17451,BAO_0000219,8,CHEMBL617388,723.0,
2502,,,,F,H,Autocuration,,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,107,,,1,6857,BAO_0000219,8,CHEMBL617389,449.0,
2503,,Homo sapiens,,F,D,Expert,,9606.0,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,107,,,1,6857,BAO_0000219,9,CHEMBL617390,449.0,
2504,,,,B,H,Autocuration,,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,104817,,,1,5635,BAO_0000224,4,CHEMBL617391,,
2505,,,,B,H,Autocuration,,,Binding activity radioligand.,107,,,1,12861,BAO_0000357,8,CHEMBL617392,,
2506,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,107,,,1,12861,BAO_0000019,8,CHEMBL617393,,
2507,,,,B,H,Autocuration,,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,107,,,1,5105,BAO_0000219,8,CHEMBL617394,307.0,
2508,,,,B,H,Expert,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,107,,,1,5104,BAO_0000219,8,CHEMBL617395,307.0,
2509,,,,B,H,Expert,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,107,,,1,5105,BAO_0000219,8,CHEMBL617396,307.0,
2510,,,,B,H,Autocuration,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,107,,,1,5105,BAO_0000219,8,CHEMBL617397,307.0,
2511,,,,B,H,Autocuration,,,Binding affinity against 5-HT2A receptor,107,,,1,5254,BAO_0000357,8,CHEMBL617398,,
2512,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2A receptor,107,,,1,5254,BAO_0000357,8,CHEMBL617399,,
2513,,,,B,H,Autocuration,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,107,,,1,13267,BAO_0000219,8,CHEMBL617400,722.0,
2514,,,,B,H,Autocuration,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,107,,,1,13267,BAO_0000219,8,CHEMBL617401,722.0,
2515,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,107,,,1,14157,BAO_0000219,9,CHEMBL617402,722.0,
2516,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,,,1,12936,BAO_0000219,9,CHEMBL617403,722.0,
2517,,,,B,H,Expert,,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,107,,,1,14068,BAO_0000357,8,CHEMBL617404,,
2518,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,,,1,12936,BAO_0000219,9,CHEMBL857981,722.0,
2519,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,,,1,12936,BAO_0000219,9,CHEMBL617405,722.0,
2520,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,107,,,1,4540,BAO_0000219,9,CHEMBL617253,722.0,
2521,,,,B,H,Expert,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,107,,,1,6166,BAO_0000357,8,CHEMBL617254,,
2522,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,107,,,1,17296,BAO_0000219,8,CHEMBL617255,722.0,
2523,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,107,,,1,17296,BAO_0000219,8,CHEMBL617256,722.0,
2524,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,107,,,1,17296,BAO_0000219,8,CHEMBL616874,722.0,
2525,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,107,,,1,15779,BAO_0000219,9,CHEMBL616875,722.0,
2526,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,107,,,1,14391,BAO_0000219,8,CHEMBL616876,722.0,
2527,,,,B,H,Expert,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",107,,,1,15851,BAO_0000219,8,CHEMBL616877,722.0,
2528,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,107,,,1,15851,BAO_0000219,9,CHEMBL616878,722.0,
2529,,,,B,H,Expert,,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,107,,,1,3832,BAO_0000219,8,CHEMBL616879,722.0,
2530,,,,B,H,Expert,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,107,,,1,3833,BAO_0000219,8,CHEMBL616880,722.0,
2531,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,107,,,1,12936,BAO_0000219,9,CHEMBL616881,722.0,
2532,,,,B,H,Autocuration,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,107,,,1,17451,BAO_0000219,8,CHEMBL616882,723.0,
2533,,,,B,H,Autocuration,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,107,,,1,17451,BAO_0000219,8,CHEMBL616883,723.0,
2534,,,,B,H,Autocuration,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,107,,,1,17451,BAO_0000219,8,CHEMBL616884,723.0,
2535,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,107,,,1,4199,BAO_0000219,8,CHEMBL616885,722.0,
2536,,,,B,H,Autocuration,,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,107,,,1,1883,BAO_0000219,8,CHEMBL616886,485.0,
2537,,,,B,H,Expert,,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,107,,,1,1883,BAO_0000219,8,CHEMBL616887,485.0,
2538,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity for human 5-hydroxytryptamine 2A receptor,107,,,1,14875,BAO_0000357,9,CHEMBL616888,,
2539,,,,B,H,Autocuration,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,107,,,1,15146,BAO_0000219,8,CHEMBL616889,722.0,
2540,,,,B,H,Autocuration,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,107,,,1,5213,BAO_0000219,8,CHEMBL616890,722.0,
2541,,Homo sapiens,,B,D,Expert,,9606.0,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,107,,,1,16404,BAO_0000219,9,CHEMBL616891,449.0,
2542,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,107,,,1,14818,BAO_0000219,8,CHEMBL616892,722.0,
2543,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",107,,,1,4829,BAO_0000219,8,CHEMBL616893,722.0,
2544,,,,F,H,Autocuration,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,10620,,,1,12652,BAO_0000219,8,CHEMBL616894,723.0,
2545,,,,B,H,Expert,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,107,,,1,4682,BAO_0000219,8,CHEMBL616895,723.0,
2546,,,,F,H,Autocuration,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,10620,,,1,12652,BAO_0000019,8,CHEMBL616896,,
2547,,,,B,H,Autocuration,,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,10621,,,1,4921,BAO_0000357,8,CHEMBL617099,,
2548,,,,B,H,Autocuration,,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,10621,,,1,4921,BAO_0000357,8,CHEMBL617100,,
2549,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Binding affinity against rabbit aorta 5-HT2A receptor,107,,,1,16312,BAO_0000357,8,CHEMBL884532,,
2550,,Oryctolagus cuniculus,,B,H,Expert,,9986.0,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,107,,,1,14998,BAO_0000357,8,CHEMBL617101,,
2551,,Oryctolagus cuniculus,,B,H,Expert,,9986.0,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,107,,,1,14025,BAO_0000357,8,CHEMBL617102,,
2552,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,107,,,1,13047,BAO_0000019,8,CHEMBL617103,,
2553,,Oryctolagus cuniculus,,B,H,Expert,,9986.0,The compound was tested for binding affinity against 5-HT2A receptor,107,,,1,13047,BAO_0000357,8,CHEMBL617104,,
2554,,,,B,H,Autocuration,,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,10576,,,1,1883,BAO_0000219,8,CHEMBL857979,485.0,
2555,,,,B,H,Autocuration,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,12687,,,1,13463,BAO_0000019,8,CHEMBL857502,,
2556,,,,B,H,Autocuration,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,12687,,,1,13463,BAO_0000019,8,CHEMBL617105,,
2557,,,,B,H,Autocuration,Stomach,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,12687,,,1,13463,BAO_0000019,8,CHEMBL858021,,945.0
2558,,Rattus norvegicus,,B,D,Expert,Stomach,10116.0,Binding affinity for 5-HT 2A in rat stomach fundus,12687,,,1,13463,BAO_0000019,9,CHEMBL875910,,945.0
2559,,,,B,H,Autocuration,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,12687,,,1,13463,BAO_0000019,8,CHEMBL617106,,
2560,,,,B,H,Expert,,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,12687,,,1,16326,BAO_0000219,8,CHEMBL617107,723.0,
2561,,,,F,H,Autocuration,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,12687,,,1,14093,BAO_0000019,8,CHEMBL617108,,
2562,,,,F,H,Autocuration,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,12687,,,1,14093,BAO_0000019,8,CHEMBL617109,,
2563,,,,B,H,Autocuration,,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,12687,,,1,15740,BAO_0000357,8,CHEMBL617110,,
2564,,,,B,H,Autocuration,,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,12687,,,1,16633,BAO_0000357,8,CHEMBL617111,,
2565,,Rattus norvegicus,,F,D,Expert,,10116.0,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,12687,,,1,17200,BAO_0000019,9,CHEMBL617112,,
2566,,,,B,H,Autocuration,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,12687,,,1,17133,BAO_0000357,8,CHEMBL617113,,
2567,,,,B,H,Autocuration,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,12687,,,1,17133,BAO_0000357,8,CHEMBL617114,,
2568,,,,B,H,Autocuration,,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,12687,,,1,17133,BAO_0000357,8,CHEMBL617115,,
2569,,,,F,H,Autocuration,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,12687,,,1,17200,BAO_0000219,8,CHEMBL617116,,
2570,,,,F,H,Autocuration,,,Efficacy at 5-hydroxytryptamine 2A receptor,12687,,,1,15363,BAO_0000019,8,CHEMBL617117,,
2571,,,,B,H,Autocuration,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),12687,,,1,17200,BAO_0000357,8,CHEMBL617118,,
2572,,Rattus norvegicus,,B,D,Expert,,10116.0,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),12687,,,1,17200,BAO_0000357,9,CHEMBL617119,,
2573,,Rattus norvegicus,,B,D,Expert,,10116.0,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),12687,,,1,17200,BAO_0000357,9,CHEMBL617120,,
2574,,Rattus norvegicus,,F,D,Expert,,10116.0,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,12687,,,1,17200,BAO_0000219,9,CHEMBL617121,,
2575,,,,F,H,Autocuration,,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,12687,,,1,17200,BAO_0000219,8,CHEMBL617122,,
2576,,,,B,H,Autocuration,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,12687,,,1,17211,BAO_0000019,8,CHEMBL617123,,
2577,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,12687,,,1,17331,BAO_0000019,8,CHEMBL617124,,
2578,,,,B,H,Expert,,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,12687,,,1,13565,BAO_0000249,8,CHEMBL617600,,
2579,,,,B,H,Expert,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,12687,,,1,13730,BAO_0000357,8,CHEMBL617601,,
2580,,,,B,H,Expert,,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,12687,,,1,12416,BAO_0000019,8,CHEMBL882923,,
2581,,,,B,H,Autocuration,,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,12687,,,1,15295,BAO_0000357,8,CHEMBL617602,,
2582,,,,B,H,Autocuration,,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,12687,,,1,1742,BAO_0000019,8,CHEMBL617603,,
2583,,,,B,H,Autocuration,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,12687,,,1,15295,BAO_0000357,8,CHEMBL617604,,
2584,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,12687,,,1,14970,BAO_0000019,8,CHEMBL617605,,
2585,,,,B,H,Expert,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,12687,,,1,16693,BAO_0000019,8,CHEMBL617606,,
2586,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,12687,,,1,14776,BAO_0000019,9,CHEMBL617607,,
2587,,,,B,H,Autocuration,,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,,1,14286,BAO_0000249,8,CHEMBL617455,,
2588,,Rattus norvegicus,,B,D,Expert,,10116.0,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,12687,,,1,17200,BAO_0000019,9,CHEMBL617456,,
2589,,,,B,H,Expert,,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),12687,,,1,15306,BAO_0000357,8,CHEMBL617457,,
2590,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,12687,,,1,14178,BAO_0000357,9,CHEMBL617458,,
2591,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,12687,,,1,14229,BAO_0000019,9,CHEMBL617459,,
2592,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,12687,,,1,12884,BAO_0000357,8,CHEMBL617460,,
2593,,,,B,H,Expert,,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",12687,,,1,13149,BAO_0000357,8,CHEMBL617461,,
2594,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,12687,,,1,15295,BAO_0000019,9,CHEMBL617462,,
2595,,,,B,H,Autocuration,,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,12687,,,1,15740,BAO_0000357,8,CHEMBL617463,,
2596,,,,B,H,Autocuration,,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",12687,,,1,15185,BAO_0000019,8,CHEMBL617464,,
2597,,,,B,H,Autocuration,,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",12687,,,1,15185,BAO_0000019,8,CHEMBL617465,,
2598,,,,B,H,Expert,,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,12687,,,1,17529,BAO_0000019,8,CHEMBL617466,,
2599,,,,B,H,Autocuration,,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,12687,,,1,14826,BAO_0000019,8,CHEMBL617467,,
2600,,,,B,H,Expert,,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,12687,,,1,17211,BAO_0000019,8,CHEMBL617468,,
2601,,,,B,H,Autocuration,,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,12687,,,1,14826,BAO_0000019,8,CHEMBL617469,,
2602,,,,B,H,Autocuration,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,12687,,,1,14093,BAO_0000019,8,CHEMBL617470,,
2603,,,,B,H,Autocuration,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,12687,,,1,14093,BAO_0000019,8,CHEMBL617471,,
2604,,,,B,H,Expert,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,12687,,,1,13246,BAO_0000219,8,CHEMBL617472,723.0,
2605,,,,B,H,Expert,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,12687,,,1,13246,BAO_0000357,8,CHEMBL617473,,
2606,,Rattus norvegicus,,B,D,Expert,,10116.0,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,12687,,,1,15436,BAO_0000019,9,CHEMBL617474,,
2607,,Rattus norvegicus,,B,D,Expert,,10116.0,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,12687,,,1,15436,BAO_0000019,9,CHEMBL617475,,
2608,,,,B,H,Autocuration,Brain,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,12687,,,1,14442,BAO_0000221,8,CHEMBL617476,,955.0
2609,,,,B,H,Expert,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,12687,,,1,12457,BAO_0000357,8,CHEMBL617477,,
2610,,,,B,H,Expert,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,12687,,,1,12457,BAO_0000219,8,CHEMBL617478,723.0,
2611,,,,F,H,Autocuration,,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",12687,,,1,14755,BAO_0000221,8,CHEMBL617479,,
2612,,,,B,H,Autocuration,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,12687,,,1,4707,BAO_0000357,8,CHEMBL617480,,
2613,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 2A receptor,12687,,,1,13297,BAO_0000357,8,CHEMBL617481,,
2614,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,12687,,,1,17331,BAO_0000019,8,CHEMBL617482,,
2615,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,12687,,,1,4664,BAO_0000019,8,CHEMBL617483,,
2616,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,12687,,,1,16633,BAO_0000357,8,CHEMBL621528,,
2617,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,12687,,,1,4664,BAO_0000219,9,CHEMBL621529,723.0,
2618,,,,B,H,Expert,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,12687,,,1,16133,BAO_0000357,8,CHEMBL621530,,
2619,,,,B,H,Expert,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,,,1,16133,BAO_0000357,8,CHEMBL621531,,
2620,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,12687,,,1,14060,BAO_0000019,9,CHEMBL621532,,
2621,,,,B,H,Expert,,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,12687,,,1,16326,BAO_0000357,8,CHEMBL621533,,
2622,,,,B,H,Expert,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,12687,,,1,16659,BAO_0000219,8,CHEMBL621534,449.0,
2623,,,,B,H,Autocuration,,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,12687,,,1,14776,BAO_0000019,8,CHEMBL621535,,
2624,,,,B,H,Autocuration,,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,12687,,,1,13481,BAO_0000357,8,CHEMBL621536,,
2625,,,,B,H,Autocuration,,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,12687,,,1,17386,BAO_0000357,8,CHEMBL621537,,
2626,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity for 5-hydroxytryptamine 2A receptor,12687,,,1,6611,BAO_0000357,9,CHEMBL621538,,
2627,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,12687,,,1,14423,BAO_0000019,8,CHEMBL621539,,
2628,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,12687,,,1,15412,BAO_0000019,8,CHEMBL621540,,
2629,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,12687,,,1,15412,BAO_0000019,8,CHEMBL621541,,
2630,,,,B,H,Autocuration,,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,12687,,,1,6238,BAO_0000019,8,CHEMBL621542,,
2631,,,,B,H,Expert,,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,12687,,,1,6648,BAO_0000357,8,CHEMBL621543,,
2632,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,12687,,,1,5667,BAO_0000357,8,CHEMBL621544,,
2633,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,12687,,,1,6611,BAO_0000357,9,CHEMBL621545,,
2634,,,,B,H,Autocuration,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,,,1,13481,BAO_0000357,8,CHEMBL621546,,
2635,,,,B,H,Autocuration,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,12687,,,1,13481,BAO_0000357,8,CHEMBL621547,,
2636,,,,B,H,Expert,,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,12687,,,1,15558,BAO_0000219,8,CHEMBL618692,723.0,
2637,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,12687,,,1,6013,BAO_0000357,8,CHEMBL618693,,
2638,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,12687,,,1,16633,BAO_0000357,8,CHEMBL872922,,
2639,,,,B,H,Autocuration,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,12687,,,1,6013,BAO_0000357,8,CHEMBL618694,,
2640,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,12687,,,1,6013,BAO_0000357,9,CHEMBL618695,,
2641,,,,B,H,Autocuration,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,12687,,,1,6013,BAO_0000357,8,CHEMBL618696,,
2642,,,,B,H,Expert,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,12687,,,1,6013,BAO_0000357,8,CHEMBL618697,,
2643,,,,B,H,Autocuration,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,12687,,,1,6013,BAO_0000357,8,CHEMBL618892,,
2644,,,,B,H,Autocuration,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,12687,,,1,6013,BAO_0000357,8,CHEMBL618893,,
2645,,,,B,H,Autocuration,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,12687,,,1,16293,BAO_0000357,8,CHEMBL618894,,
2646,,,,B,H,Expert,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,12687,,,1,17175,BAO_0000219,8,CHEMBL618895,723.0,
2647,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,12687,,,1,13278,BAO_0000357,9,CHEMBL618896,,
2648,,,,B,H,Autocuration,Caudate-putamen,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,12687,,,1,3682,BAO_0000019,8,CHEMBL618897,,5383.0
2649,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,12687,,,1,2014,BAO_0000357,8,CHEMBL618898,,
2650,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,12687,,,1,2014,BAO_0000357,8,CHEMBL618899,,
2651,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,12687,,,1,4932,BAO_0000357,8,CHEMBL618900,,
2652,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,12687,,,1,4932,BAO_0000019,8,CHEMBL618901,,
2653,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,12687,,,1,3935,BAO_0000357,8,CHEMBL618902,,
2654,,Rattus norvegicus,,B,D,Expert,Hippocampus,10116.0,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,12687,,,1,5432,BAO_0000221,9,CHEMBL618903,,10000000.0
2655,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,12687,,,1,15818,BAO_0000357,8,CHEMBL618904,,
2656,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,12687,,,1,13672,BAO_0000357,8,CHEMBL618905,,
2657,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,12687,,,1,13672,BAO_0000357,8,CHEMBL618906,,
2658,,,,B,H,Expert,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,12687,,,1,14749,BAO_0000219,8,CHEMBL618907,723.0,
2659,,,,B,H,Autocuration,,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,12687,,,1,13462,BAO_0000019,8,CHEMBL618908,,
2660,,,,B,H,Autocuration,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,12687,,,1,15740,BAO_0000357,8,CHEMBL617909,,
2661,,,,B,H,Expert,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,12687,,,1,16647,BAO_0000019,8,CHEMBL617910,,
2662,,,,B,H,Autocuration,Brain,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,12687,,,1,13345,BAO_0000221,8,CHEMBL617911,,955.0
2663,,,,B,H,Autocuration,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,,1,16740,BAO_0000249,8,CHEMBL872923,,
2664,,,,B,H,Autocuration,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,,1,16740,BAO_0000249,8,CHEMBL617912,,
2665,,Rattus norvegicus,,B,D,Expert,,10116.0,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,12687,,,1,15535,BAO_0000019,9,CHEMBL617913,,
2666,,,,B,H,Expert,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,,1,16740,BAO_0000249,8,CHEMBL617914,,
2667,,,,B,H,Autocuration,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,,1,16740,BAO_0000249,8,CHEMBL617915,,
2668,,,,B,H,Autocuration,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,12687,,,1,16740,BAO_0000249,8,CHEMBL617916,,
2669,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,12687,,,1,4795,BAO_0000019,9,CHEMBL617917,,
2670,,,,B,H,Expert,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,12687,,,1,8,BAO_0000019,8,CHEMBL617918,,
2671,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,12687,,,1,8,BAO_0000019,8,CHEMBL617919,,
2672,,Rattus norvegicus,,B,D,Expert,,10116.0,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,12687,,,1,17200,BAO_0000019,9,CHEMBL617920,,
2673,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,12687,,,1,2148,BAO_0000019,9,CHEMBL617921,,
2674,,Rattus norvegicus,,B,D,Expert,,10116.0,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",105102,,,1,13345,BAO_0000224,5,CHEMBL617922,,
2675,,,,B,H,Autocuration,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,12687,,,1,5088,BAO_0000357,8,CHEMBL617923,,
2676,,,,B,H,Autocuration,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,12687,,,1,5088,BAO_0000357,8,CHEMBL617924,,
2677,,,,B,H,Autocuration,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,12687,,,1,17133,BAO_0000357,8,CHEMBL617925,,
2678,,Rattus norvegicus,,B,D,Expert,,10116.0,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,12687,,,1,17133,BAO_0000357,9,CHEMBL617926,,
2679,,,,B,H,Autocuration,,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,12687,,,1,16532,BAO_0000357,8,CHEMBL617927,,
2680,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,12687,,,1,15086,BAO_0000357,8,CHEMBL617928,,
2681,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,12687,,,1,2309,BAO_0000019,9,CHEMBL617929,,
2682,,,,B,H,Expert,,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,12687,,,1,12953,BAO_0000019,8,CHEMBL617930,,
2683,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,12687,,,1,12953,BAO_0000019,8,CHEMBL617931,,
2684,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,12687,,,1,12953,BAO_0000019,8,CHEMBL617932,,
2685,,,,B,H,Autocuration,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,12687,,,1,16659,BAO_0000219,8,CHEMBL617933,449.0,
2686,,,,B,H,Autocuration,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,12687,,,1,16740,BAO_0000019,8,CHEMBL617934,,
2687,,,,B,H,Autocuration,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,12687,,,1,16740,BAO_0000019,8,CHEMBL617935,,
2688,,,,B,H,Autocuration,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,12687,,,1,17133,BAO_0000357,8,CHEMBL617936,,
2689,,,,B,H,Autocuration,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,12687,,,1,17211,BAO_0000019,8,CHEMBL617937,,
2690,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,12687,,,1,17331,BAO_0000019,8,CHEMBL617938,,
2691,,,,B,H,Autocuration,,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,12687,,,1,16633,BAO_0000218,8,CHEMBL617939,,
2692,,,,B,H,Autocuration,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,12687,,,1,16633,BAO_0000218,8,CHEMBL617940,,
2693,,,,B,H,Autocuration,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,12687,,,1,16633,BAO_0000218,8,CHEMBL617941,,
2694,,,,B,H,Expert,,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,12687,,,1,15026,BAO_0000357,8,CHEMBL617942,,
2695,,,,B,H,Expert,,,Ratio of pKi of 5-HT2A to that of D2 receptor,12687,,,1,15026,BAO_0000357,8,CHEMBL617943,,
2696,,,,B,H,Expert,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,105093,,,1,16404,BAO_0000224,4,CHEMBL617944,,
2697,,,,B,H,Expert,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,105093,,,1,16404,BAO_0000224,4,CHEMBL617945,,
2698,,,,B,H,Expert,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,105075,,,1,16404,BAO_0000224,4,CHEMBL617946,,
2699,,,,B,H,Autocuration,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,12687,,,1,16404,BAO_0000357,8,CHEMBL617947,,
2700,,,,B,H,Expert,,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,12687,,,1,16326,BAO_0000357,8,CHEMBL617948,,
2701,,,,F,H,Autocuration,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,12687,,,1,15847,BAO_0000019,8,CHEMBL858116,,
2702,,,,F,H,Autocuration,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,12687,,,1,15847,BAO_0000019,8,CHEMBL617949,,
2703,,,,F,H,Autocuration,,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,12687,,,1,15329,BAO_0000019,8,CHEMBL617950,,
2704,,,,F,H,Expert,Thoracic aorta,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,12687,,,1,16404,BAO_0000019,8,CHEMBL617951,,1515.0
2705,,,,F,H,Expert,Thoracic aorta,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,12687,,,1,16404,BAO_0000019,8,CHEMBL617952,,1515.0
2706,,,,F,H,Autocuration,Thoracic aorta,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,12687,,,1,16404,BAO_0000019,8,CHEMBL617953,,1515.0
2707,,,,B,H,Autocuration,,,Binding activity radioligand.,12687,,,1,12861,BAO_0000357,8,CHEMBL617954,,
2708,,,,B,H,Expert,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,12687,,,1,12861,BAO_0000019,8,CHEMBL617955,,
2709,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,12687,,,1,12861,BAO_0000019,8,CHEMBL857071,,
2710,,,,B,H,Expert,,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,12687,,,1,12490,BAO_0000019,8,CHEMBL617270,,
2711,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,12687,,,1,12827,BAO_0000219,8,CHEMBL617271,339.0,
2712,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,12687,,,1,12827,BAO_0000219,8,CHEMBL617272,339.0,
2713,,,,B,H,Autocuration,,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,12687,,,1,12918,BAO_0000019,8,CHEMBL617273,,
2714,,Rattus norvegicus,,F,D,Expert,,10116.0,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,12687,,,1,12919,BAO_0000019,9,CHEMBL617274,,
2715,,,,B,H,Autocuration,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,108,,,1,17723,BAO_0000357,8,CHEMBL617275,,
2716,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,108,,,1,6013,BAO_0000357,8,CHEMBL617276,,
2717,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,108,,,1,16293,BAO_0000357,8,CHEMBL617277,,
2718,,,,B,H,Expert,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,108,,,1,3857,BAO_0000019,8,CHEMBL617278,,
2719,,,,B,H,Expert,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,108,,,1,3857,BAO_0000019,8,CHEMBL617279,,
2720,,,,B,H,Expert,,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,108,,,1,3857,BAO_0000019,8,CHEMBL617280,,
2721,,,,B,H,Autocuration,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,108,,,1,15363,BAO_0000357,8,CHEMBL617281,,
2722,,,,B,H,Autocuration,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,108,,,1,15363,BAO_0000357,8,CHEMBL617282,,
2723,,,,B,H,Expert,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,108,,,1,16441,BAO_0000019,8,CHEMBL617283,,
2724,,,,B,H,Expert,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,108,,,1,16441,BAO_0000019,8,CHEMBL617284,,
2725,,,,B,H,Autocuration,,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,108,,,1,4176,BAO_0000219,8,CHEMBL617285,722.0,
2726,,,,B,H,Autocuration,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,108,,,1,17085,BAO_0000019,8,CHEMBL617286,,
2727,,Homo sapiens,,B,D,Expert,,9606.0,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,108,,,1,17200,BAO_0000357,9,CHEMBL617287,,
2728,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,108,,,1,5088,BAO_0000357,8,CHEMBL617288,,
2729,,,,B,H,Autocuration,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,108,,,1,5088,BAO_0000357,8,CHEMBL617289,,
2730,,,,B,H,Autocuration,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,108,,,1,5088,BAO_0000357,8,CHEMBL872917,,
2731,,,,B,H,Autocuration,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,108,,,1,5088,BAO_0000357,8,CHEMBL617290,,
2732,,,,B,H,Autocuration,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,108,,,1,16659,BAO_0000219,8,CHEMBL617291,449.0,
2733,,,,B,H,Autocuration,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,108,,,1,16659,BAO_0000219,8,CHEMBL617292,449.0,
2734,,,,B,H,Autocuration,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,108,,,1,17451,BAO_0000219,8,CHEMBL617293,723.0,
2735,,Homo sapiens,,F,D,Expert,,9606.0,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,108,,,1,6857,BAO_0000219,9,CHEMBL617294,449.0,
2736,,,,B,H,Expert,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,108,,,1,3857,BAO_0000019,8,CHEMBL617295,,
2737,,,,B,H,Autocuration,,,Binding activity radioligand.,108,,,1,12861,BAO_0000357,8,CHEMBL617296,,
2738,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,108,,,1,12861,BAO_0000019,8,CHEMBL617297,,
2739,,,,B,H,Expert,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,108,,,1,5104,BAO_0000219,8,CHEMBL617298,449.0,
2740,,,,B,H,Expert,,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,108,,,1,5105,BAO_0000219,8,CHEMBL617299,449.0,
2741,,,,B,H,Autocuration,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,108,,,1,5105,BAO_0000219,8,CHEMBL617300,449.0,
2742,,,,B,H,Autocuration,,,Binding affinity against 5-HT2C receptor,108,,,1,5254,BAO_0000357,8,CHEMBL617454,,
2743,,,,B,H,Autocuration,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,108,,,1,13267,BAO_0000219,8,CHEMBL617505,722.0,
2744,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,108,,,1,14157,BAO_0000219,9,CHEMBL617506,722.0,
2745,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,108,,,1,12936,BAO_0000219,9,CHEMBL617507,722.0,
2746,,,,B,H,Expert,,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,108,,,1,14068,BAO_0000357,8,CHEMBL617508,,
2747,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,108,,,1,12936,BAO_0000219,9,CHEMBL857982,722.0,
2748,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,108,,,1,4540,BAO_0000219,9,CHEMBL617509,722.0,
2749,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,108,,,1,4540,BAO_0000219,9,CHEMBL617510,722.0,
2750,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,108,,,1,6166,BAO_0000357,8,CHEMBL617511,,
2751,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,108,,,1,17296,BAO_0000219,8,CHEMBL617512,722.0,
2752,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,108,,,1,17296,BAO_0000219,8,CHEMBL617749,722.0,
2753,,,,B,H,Autocuration,,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,108,,,1,15779,BAO_0000219,8,CHEMBL617750,722.0,
2754,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,108,,,1,15779,BAO_0000219,8,CHEMBL617751,722.0,
2755,,,,B,H,Expert,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,108,,,1,14391,BAO_0000219,8,CHEMBL617752,722.0,
2756,,,,B,H,Autocuration,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",108,,,1,15779,BAO_0000219,8,CHEMBL617753,722.0,
2757,,,,B,H,Expert,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",108,,,1,15851,BAO_0000219,8,CHEMBL617754,722.0,
2758,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,108,,,1,15851,BAO_0000219,9,CHEMBL617755,722.0,
2759,,,,B,H,Autocuration,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",108,,,1,15779,BAO_0000219,8,CHEMBL617756,722.0,
2760,,,,B,H,Expert,,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,108,,,1,3832,BAO_0000219,8,CHEMBL617757,722.0,
2761,,,,B,H,Expert,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,108,,,1,3833,BAO_0000219,8,CHEMBL617758,722.0,
2762,,,,B,H,Autocuration,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,108,,,1,17451,BAO_0000219,8,CHEMBL617759,723.0,
2763,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,108,,,1,4199,BAO_0000219,8,CHEMBL617760,722.0,
2764,,,,B,H,Expert,,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,108,,,1,1883,BAO_0000219,8,CHEMBL617761,485.0,
2765,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against 5-hydroxytryptamine 2C receptor,108,,,1,4321,BAO_0000357,9,CHEMBL617762,,
2766,,,,B,H,Autocuration,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,108,,,1,14875,BAO_0000357,8,CHEMBL617763,,
2767,,,,B,H,Autocuration,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,108,,,1,15146,BAO_0000219,8,CHEMBL857983,722.0,
2768,,,,B,H,Autocuration,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,108,,,1,5213,BAO_0000219,8,CHEMBL617764,722.0,
2769,,,,B,H,Autocuration,,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,108,,,1,16404,BAO_0000219,8,CHEMBL617765,308.0,
2770,,,,F,H,Autocuration,,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,108,,,1,13267,BAO_0000019,8,CHEMBL617766,,
2771,,,,F,H,Autocuration,Hippocampus,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,108,,,1,13267,BAO_0000221,8,CHEMBL617767,,10000000.0
2772,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,108,,,1,14818,BAO_0000219,8,CHEMBL617768,722.0,
2773,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",108,,,1,4829,BAO_0000219,8,CHEMBL617769,722.0,
2774,,,,B,H,Autocuration,,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,11864,,,1,13463,BAO_0000357,8,CHEMBL858023,,
2775,,,,B,H,Autocuration,Stomach,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,11864,,,1,13463,BAO_0000019,8,CHEMBL617770,,945.0
2776,,,,B,H,Autocuration,Stomach,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,11864,,,1,13463,BAO_0000019,8,CHEMBL617771,,945.0
2777,,,,F,H,Autocuration,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,11864,,,1,12652,BAO_0000219,8,CHEMBL617772,625.0,
2778,,,,B,H,Autocuration,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,11864,,,1,4682,BAO_0000219,8,CHEMBL617773,723.0,
2779,,,,B,H,Autocuration,,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,11864,,,1,4682,BAO_0000219,8,CHEMBL617850,723.0,
2780,,,,B,H,Autocuration,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,11864,,,1,4682,BAO_0000219,8,CHEMBL617851,723.0,
2781,,,,F,H,Autocuration,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,11864,,,1,12652,BAO_0000019,8,CHEMBL617852,,
2782,,Mus musculus,,B,H,Autocuration,Stomach,10090.0,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,12689,,,1,13463,BAO_0000019,8,CHEMBL858024,,945.0
2783,,Rattus norvegicus,,B,D,Expert,Stomach,10116.0,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,12689,,,1,13463,BAO_0000019,9,CHEMBL617853,,945.0
2784,,,,B,H,Expert,,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,108,,,1,13969,BAO_0000357,8,CHEMBL617854,,
2785,,Sus scrofa,,B,H,Expert,,9823.0,Binding affinity for 5-hydroxytryptamine 2C receptor,108,,,1,13392,BAO_0000357,8,CHEMBL873477,,
2786,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,108,,,1,13392,BAO_0000357,8,CHEMBL617855,,
2787,,,,B,H,Expert,,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,108,,,1,14430,BAO_0000019,8,CHEMBL617856,,
2788,,,,B,H,Autocuration,,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,108,,,1,1742,BAO_0000019,8,CHEMBL617857,,
2789,,,,B,H,Autocuration,,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,108,,,1,14286,BAO_0000249,8,CHEMBL617858,,
2790,,,,B,H,Autocuration,,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,108,,,1,5619,BAO_0000357,8,CHEMBL617859,,
2791,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,108,,,1,15086,BAO_0000357,8,CHEMBL617860,,
2792,,,,B,H,Autocuration,,,Binding activity radioligand.,108,,,1,12861,BAO_0000357,8,CHEMBL617861,,
2793,,,,B,H,Expert,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,108,,,1,12861,BAO_0000019,8,CHEMBL617862,,
2794,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,108,,,1,12861,BAO_0000019,8,CHEMBL617863,,
2795,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,108,,,1,12827,BAO_0000249,8,CHEMBL617864,,
2796,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,108,,,1,12827,BAO_0000249,8,CHEMBL617649,,
2797,,Sus scrofa,,F,H,Expert,,9823.0,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,108,,,1,12919,BAO_0000019,8,CHEMBL617650,,
2798,,Sus scrofa,,F,H,Expert,,9823.0,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,108,,,1,12919,BAO_0000019,8,CHEMBL617651,,
2799,,Sus scrofa,,B,H,Autocuration,,9823.0,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,108,,,1,16429,BAO_0000357,8,CHEMBL617652,,
2800,,Sus scrofa,,B,H,Autocuration,,9823.0,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,108,,,1,773,BAO_0000019,8,CHEMBL857072,,
2801,,Sus scrofa,,B,H,Autocuration,,9823.0,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,108,,,1,5033,BAO_0000357,8,CHEMBL617653,,
2802,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,12687,,,1,12861,BAO_0000019,8,CHEMBL617654,,
2803,,,,F,H,Autocuration,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,12689,,,1,14093,BAO_0000019,8,CHEMBL617655,,
2804,,,,B,H,Expert,,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,12689,,,1,14970,BAO_0000357,8,CHEMBL617656,,
2805,,,,B,H,Autocuration,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,12689,,,1,14970,BAO_0000357,8,CHEMBL617657,,
2806,,,,B,H,Autocuration,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,12689,,,1,14970,BAO_0000357,8,CHEMBL617658,,
2807,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,12689,,,1,14178,BAO_0000357,9,CHEMBL617659,,
2808,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,12689,,,1,14178,BAO_0000357,9,CHEMBL617838,,
2809,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,12689,,,1,14229,BAO_0000249,9,CHEMBL617839,,
2810,,,,B,H,Autocuration,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,12689,,,1,16532,BAO_0000357,8,CHEMBL617840,,
2811,,,,B,H,Autocuration,,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,12689,,,1,14826,BAO_0000019,8,CHEMBL617841,,
2812,,,,B,H,Autocuration,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,12689,,,1,17211,BAO_0000019,8,CHEMBL875915,,
2813,In vitro,,,B,H,Expert,,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,12689,,,1,17211,BAO_0000219,8,CHEMBL617842,,
2814,,,,B,H,Expert,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,12689,,,1,13246,BAO_0000219,8,CHEMBL617843,723.0,
2815,,,,B,H,Expert,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,12689,,,1,13246,BAO_0000357,8,CHEMBL617844,,
2816,,,,B,H,Expert,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,12689,,,1,12457,BAO_0000357,8,CHEMBL617845,,
2817,,,,B,H,Expert,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,12689,,,1,12457,BAO_0000219,8,CHEMBL617846,723.0,
2818,,,,B,H,Autocuration,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,12689,,,1,4707,BAO_0000357,8,CHEMBL617847,,
2819,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 2C receptor,12689,,,1,13297,BAO_0000357,8,CHEMBL617848,,
2820,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,12689,,,1,16633,BAO_0000357,8,CHEMBL617849,,
2821,,,,B,H,Expert,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,12689,,,1,16133,BAO_0000357,8,CHEMBL621507,,
2822,,,,B,H,Expert,,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,12689,,,1,16326,BAO_0000357,8,CHEMBL621508,,
2823,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,12689,,,1,14423,BAO_0000019,8,CHEMBL621509,,
2824,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,12689,,,1,15412,BAO_0000019,8,CHEMBL621510,,
2825,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,12689,,,1,15412,BAO_0000019,8,CHEMBL621511,,
2826,,,,B,H,Expert,,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,12689,,,1,15558,BAO_0000219,8,CHEMBL621512,625.0,
2827,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,12689,,,1,16633,BAO_0000357,8,CHEMBL621513,,
2828,,,,B,H,Expert,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,12689,,,1,6013,BAO_0000357,8,CHEMBL621514,,
2829,In vitro,,,B,H,Expert,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,12689,,,1,17175,BAO_0000219,8,CHEMBL621515,,
2830,,,,B,H,Autocuration,,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,12689,,,1,12469,BAO_0000219,8,CHEMBL621516,,
2831,,,,B,H,Autocuration,Caudate-putamen,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,12689,,,1,3682,BAO_0000019,8,CHEMBL621517,,5383.0
2832,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,12689,,,1,4932,BAO_0000357,8,CHEMBL621518,,
2833,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,12689,,,1,4932,BAO_0000019,8,CHEMBL621519,,
2834,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,12689,,,1,3935,BAO_0000357,8,CHEMBL621520,,
2835,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,12689,,,1,15818,BAO_0000357,8,CHEMBL621521,,
2836,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,12689,,,1,15818,BAO_0000357,8,CHEMBL621522,,
2837,,,,B,H,Expert,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,12689,,,1,14749,BAO_0000219,8,CHEMBL621523,,
2838,,,,B,H,Autocuration,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,12689,,,1,15740,BAO_0000357,8,CHEMBL621524,,
2839,,Rattus norvegicus,,B,D,Expert,,10116.0,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,12689,,,1,17133,BAO_0000357,9,CHEMBL621525,,
2840,,,,B,H,Autocuration,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,12689,,,1,16532,BAO_0000357,8,CHEMBL872921,,
2841,,,,B,H,Autocuration,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,12689,,,1,12369,BAO_0000357,8,CHEMBL621526,,
2842,,,,B,H,Expert,,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,12689,,,1,12369,BAO_0000219,8,CHEMBL621527,,
2843,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,12689,,,1,2309,BAO_0000019,9,CHEMBL617865,,
2844,,,,B,H,Autocuration,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,12689,,,1,12953,BAO_0000357,8,CHEMBL617866,,
2845,,,,B,H,Autocuration,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,12689,,,1,12953,BAO_0000019,8,CHEMBL617867,,
2846,,,,B,H,Autocuration,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,12689,,,1,12953,BAO_0000357,8,CHEMBL617487,,
2847,,,,B,H,Expert,,,Binding affinity for 5-hydroxytryptamine 2C receptor,12689,,,1,12953,BAO_0000357,8,CHEMBL617488,,
2848,,,,B,H,Autocuration,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,12689,,,1,17133,BAO_0000357,8,CHEMBL617489,,
2849,,,,B,H,Autocuration,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,12689,,,1,17211,BAO_0000019,8,CHEMBL617490,,
2850,,,,B,H,Autocuration,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,12689,,,1,17211,BAO_0000019,8,CHEMBL617491,,
2851,,,,B,H,Autocuration,,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,12689,,,1,14025,BAO_0000019,8,CHEMBL617492,,
2852,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,12689,,,1,14998,BAO_0000019,8,CHEMBL617493,,
2853,,,,B,H,Autocuration,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,12689,,,1,4342,BAO_0000357,8,CHEMBL617494,,
2854,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,12689,,,1,13735,BAO_0000019,9,CHEMBL617495,,
2855,,,,B,H,Autocuration,,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,12689,,,1,13181,BAO_0000357,8,CHEMBL617496,,
2856,,,,B,H,Autocuration,,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,12689,,,1,1883,BAO_0000219,8,CHEMBL617497,485.0,
2857,,,,B,H,Autocuration,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,12689,,,1,15194,BAO_0000357,8,CHEMBL617498,,
2858,,,,B,H,Autocuration,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,12689,,,1,15194,BAO_0000357,8,CHEMBL617499,,
2859,,,,F,H,Autocuration,,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,12689,,,1,14579,BAO_0000019,8,CHEMBL617500,,
2860,,,,B,H,Autocuration,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,108,,,1,4639,BAO_0000357,8,CHEMBL617501,,
2861,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,108,,,1,4820,BAO_0000357,8,CHEMBL617502,,
2862,,,,B,H,Autocuration,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,227,,,1,14442,BAO_0000357,8,CHEMBL617503,,
2863,,,,B,H,Autocuration,,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,227,,,1,14755,BAO_0000357,8,CHEMBL617504,,
2864,,,,B,H,Autocuration,,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,227,,,1,14744,BAO_0000357,8,CHEMBL617406,,
2865,,Homo sapiens,,B,D,Expert,,9606.0,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,227,,,1,6857,BAO_0000019,9,CHEMBL617407,,
2866,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,227,,,1,16209,BAO_0000357,8,CHEMBL617408,,
2867,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,227,,,1,15363,BAO_0000357,8,CHEMBL617409,,
2868,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,227,,,1,15363,BAO_0000357,8,CHEMBL617410,,
2869,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,227,,,1,15363,BAO_0000357,8,CHEMBL617411,,
2870,,,,B,H,Autocuration,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,227,,,1,17085,BAO_0000019,8,CHEMBL617412,,
2871,,Homo sapiens,,B,D,Expert,,9606.0,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,227,,,1,17200,BAO_0000357,9,CHEMBL617774,,
2872,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,227,,,1,15851,BAO_0000219,9,CHEMBL617775,722.0,
2873,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,227,,,1,15851,BAO_0000219,9,CHEMBL617776,722.0,
2874,,Homo sapiens,,F,D,Expert,,9606.0,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,227,,,1,6857,BAO_0000219,9,CHEMBL617777,449.0,
2875,,Homo sapiens,,F,D,Expert,,9606.0,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,227,,,1,6857,BAO_0000219,9,CHEMBL617778,449.0,
2876,,,,B,H,Autocuration,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",227,,,1,15779,BAO_0000219,8,CHEMBL617779,722.0,
2877,,,,B,H,Expert,,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,227,,,1,15851,BAO_0000219,8,CHEMBL617780,722.0,
2878,,,,B,H,Autocuration,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",227,,,1,15779,BAO_0000219,8,CHEMBL617781,722.0,
2879,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,227,,,1,14157,BAO_0000219,9,CHEMBL617782,722.0,
2880,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,227,,,1,4540,BAO_0000219,9,CHEMBL617783,722.0,
2881,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,227,,,1,6166,BAO_0000357,8,CHEMBL617784,,
2882,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,227,,,1,15779,BAO_0000219,8,CHEMBL617785,722.0,
2883,,,,B,H,Expert,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,227,,,1,14391,BAO_0000219,8,CHEMBL857984,722.0,
2884,,,,B,H,Expert,,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,227,,,1,3832,BAO_0000219,8,CHEMBL617786,722.0,
2885,,,,B,H,Expert,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,227,,,1,3833,BAO_0000219,8,CHEMBL617787,722.0,
2886,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,227,,,1,15851,BAO_0000219,9,CHEMBL617788,722.0,
2887,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,227,,,1,15851,BAO_0000219,9,CHEMBL617789,722.0,
2888,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,227,,,1,4199,BAO_0000219,8,CHEMBL617790,722.0,
2889,,,,B,H,Expert,,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,227,,,1,1883,BAO_0000219,8,CHEMBL617791,485.0,
2890,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 2B receptor,227,,,1,4321,BAO_0000357,8,CHEMBL617608,,
2891,,,,B,H,Autocuration,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,227,,,1,15146,BAO_0000219,8,CHEMBL617609,722.0,
2892,,,,B,H,Autocuration,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,227,,,1,5213,BAO_0000219,8,CHEMBL617610,722.0,
2893,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,227,,,1,14818,BAO_0000219,8,CHEMBL617611,722.0,
2894,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",227,,,1,4829,BAO_0000219,8,CHEMBL617612,722.0,
2895,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",227,,,1,4829,BAO_0000219,8,CHEMBL617613,722.0,
2896,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,227,,,1,14025,BAO_0000019,8,CHEMBL617614,,
2897,,,,B,H,Expert,Stomach,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,12688,,,1,13463,BAO_0000019,8,CHEMBL617615,,945.0
2898,,,,B,H,Expert,Stomach,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,12688,,,1,7259,BAO_0000357,8,CHEMBL858114,,945.0
2899,,,,B,H,Autocuration,Stomach,,Affinity against serotonergic receptor in the isolated rat stomach fundus,12688,,,1,7259,BAO_0000357,8,CHEMBL617616,,945.0
2900,,Rattus norvegicus,,F,D,Expert,Stomach,10116.0,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,12688,,,1,7185,BAO_0000019,9,CHEMBL617617,,945.0
2901,,Rattus norvegicus,,F,D,Expert,,10116.0,Antagonistic against 5-hydroxytryptamine 2B receptor,12688,,,1,7185,BAO_0000019,9,CHEMBL875914,,
2902,,,,F,H,Autocuration,Stomach,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,12688,,,1,13267,BAO_0000019,8,CHEMBL617618,,945.0
2903,,Rattus norvegicus,,B,D,Expert,Stomach,10116.0,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,12688,,,1,13735,BAO_0000357,9,CHEMBL617619,,945.0
2904,,,,F,H,Autocuration,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,12688,,,1,15738,BAO_0000019,8,CHEMBL617620,,
2905,,,,F,H,Autocuration,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,12688,,,1,15738,BAO_0000019,8,CHEMBL617621,,
2906,,,,F,H,Autocuration,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,12688,,,1,15738,BAO_0000019,8,CHEMBL617622,,
2907,,Rattus norvegicus,,B,D,Expert,Stomach,10116.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,,,1,12936,BAO_0000357,9,CHEMBL617623,,945.0
2908,,Rattus norvegicus,,B,D,Expert,Stomach,10116.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,,,1,12936,BAO_0000357,9,CHEMBL617624,,945.0
2909,,Rattus norvegicus,,B,D,Expert,Stomach,10116.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,,,1,12936,BAO_0000357,9,CHEMBL617625,,945.0
2910,,Rattus norvegicus,,B,D,Expert,Stomach,10116.0,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,12688,,,1,12936,BAO_0000357,9,CHEMBL617626,,945.0
2911,,,,F,H,Autocuration,Stomach,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,12688,,,1,16404,BAO_0000019,8,CHEMBL617627,,945.0
2912,,,,F,H,Expert,Stomach,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,12688,,,1,16404,BAO_0000019,8,CHEMBL617628,,945.0
2913,,,,F,H,Autocuration,Stomach,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,12688,,,1,16404,BAO_0000019,8,CHEMBL617629,,945.0
2914,,,,F,H,Autocuration,Stomach,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,12688,,,1,16404,BAO_0000019,8,CHEMBL858115,,945.0
2915,,Rattus norvegicus,,F,D,Expert,Stomach,10116.0,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,12688,,,1,16404,BAO_0000019,9,CHEMBL617630,,945.0
2916,,,,F,H,Autocuration,Thoracic aorta,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,12688,,,1,16404,BAO_0000019,8,CHEMBL617631,,1515.0
2917,,,,B,H,Autocuration,,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,12688,,,1,7483,BAO_0000357,8,CHEMBL617632,,
2918,,,,B,H,Expert,,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,12688,,,1,7483,BAO_0000357,8,CHEMBL617633,,
2919,,,,B,H,Autocuration,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,12688,,,1,7483,BAO_0000357,8,CHEMBL617634,,
2920,,,,B,H,Autocuration,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,12688,,,1,7483,BAO_0000357,8,CHEMBL617635,,
2922,,Rattus norvegicus,,F,D,Autocuration,Stomach,10116.0,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,12688,,,1,16404,BAO_0000019,9,CHEMBL617637,,945.0
2923,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 1A receptor,227,,,1,6347,BAO_0000357,8,CHEMBL617638,,
2924,,,,B,H,Autocuration,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,227,,,1,4373,BAO_0000357,8,CHEMBL617639,,
2925,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,227,,,1,4373,BAO_0000357,8,CHEMBL617640,,
2926,,,,B,H,Autocuration,,,Evaluated for the binding affinity to 5-HT 2B receptor,227,,,1,4687,BAO_0000357,8,CHEMBL617641,,
2927,,,,B,H,Autocuration,,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,227,,,1,16946,BAO_0000357,8,CHEMBL617642,,
2928,,,,B,H,Autocuration,,,Binding affinities against 5-hydroxytryptamine 2B receptor,227,,,1,16633,BAO_0000357,8,CHEMBL617643,,
2929,,,,B,H,Autocuration,,,Binding affinities towards 5-hydroxytryptamine 2B receptor,227,,,1,16633,BAO_0000357,8,CHEMBL617644,,
2930,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,227,,,1,16633,BAO_0000357,8,CHEMBL617645,,
2931,,,,B,H,Expert,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,108,,,1,15026,BAO_0000357,8,CHEMBL617646,,
2932,,Bos taurus,,B,H,Autocuration,,9913.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,108,,,1,15738,BAO_0000357,8,CHEMBL617647,,
2933,,Bos taurus,,B,H,Autocuration,,9913.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,108,,,1,15738,BAO_0000357,8,CHEMBL617648,,
2934,,Bos taurus,,B,H,Autocuration,,9913.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,108,,,1,15738,BAO_0000357,8,CHEMBL617875,,
2935,,Bos taurus,,B,H,Autocuration,,9913.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,108,,,1,15738,BAO_0000357,8,CHEMBL617876,,
2936,,Bos taurus,,B,H,Expert,,9913.0,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,108,,,1,16404,BAO_0000357,8,CHEMBL617877,,
2937,,Bos taurus,,B,H,Expert,,9913.0,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,108,,,1,15026,BAO_0000357,8,CHEMBL617878,,
2938,,Bos taurus,,B,H,Autocuration,,9913.0,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,108,,,1,15738,BAO_0000357,8,CHEMBL617879,,
2939,,Cavia porcellus,,B,H,Autocuration,,10141.0,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,108,,,1,16312,BAO_0000019,8,CHEMBL617880,,
2940,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,20033,,,1,5486,BAO_0000357,9,CHEMBL617881,,2435.0
2941,,,,B,H,Autocuration,,,Binding affinity against 5-HT1A receptor,51,,,1,5254,BAO_0000357,8,CHEMBL857073,,
2942,,,,F,H,Expert,,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,108,,,1,3857,BAO_0000219,8,CHEMBL617882,449.0,
2943,,Homo sapiens,,F,D,Expert,,9606.0,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,108,,,1,6857,BAO_0000219,9,CHEMBL617883,449.0,
2944,,,,F,H,Autocuration,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,108,,,1,4176,BAO_0000219,8,CHEMBL617884,,
2945,,,,B,H,Autocuration,,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,108,,,1,6347,BAO_0000219,8,CHEMBL617885,449.0,
2946,,,,B,H,Autocuration,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",108,,,1,6347,BAO_0000219,8,CHEMBL617886,449.0,
2947,,Homo sapiens,,B,D,Expert,,9606.0,Inhibition of human 5-hydroxytryptamine 2C receptor,108,,,1,16146,BAO_0000357,9,CHEMBL617887,,
2948,,,,B,H,Autocuration,,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),108,,,1,3805,BAO_0000357,8,CHEMBL617888,,
2949,,,,B,H,Autocuration,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,108,,,1,3857,BAO_0000019,8,CHEMBL617889,,
2950,,,,B,H,Autocuration,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,108,,,1,5635,BAO_0000357,8,CHEMBL617890,,
2951,,,,B,H,Autocuration,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,108,,,1,5635,BAO_0000357,8,CHEMBL617891,,
2952,,,,B,H,Autocuration,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,108,,,1,5635,BAO_0000357,8,CHEMBL617892,,
2953,,,,B,H,Expert,,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,108,,,1,4012,BAO_0000219,8,CHEMBL617893,449.0,
2954,,,,B,H,Expert,,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,108,,,1,6366,BAO_0000219,8,CHEMBL617894,449.0,
2955,,,,B,H,Expert,,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,108,,,1,15949,BAO_0000219,8,CHEMBL617895,449.0,
2956,,,,B,H,Autocuration,,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,108,,,1,17211,BAO_0000219,8,CHEMBL617896,449.0,
2957,,Homo sapiens,,B,D,Expert,,9606.0,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,108,,,1,6491,BAO_0000357,9,CHEMBL617897,,
2958,,,,F,H,Autocuration,,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,108,,,1,14093,BAO_0000019,8,CHEMBL617898,,
2959,,,,F,H,Autocuration,,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,108,,,1,13481,BAO_0000019,8,CHEMBL617899,,
2960,,Rattus norvegicus,,B,H,Expert,,10116.0,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,108,,,1,6347,BAO_0000219,8,CHEMBL617900,449.0,
2961,,,,F,H,Autocuration,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,108,,,1,14093,BAO_0000019,8,CHEMBL617901,,
2962,,,,F,H,Autocuration,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,108,,,1,14093,BAO_0000019,8,CHEMBL617902,,
2963,,,,F,H,Autocuration,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,108,,,1,13481,BAO_0000019,8,CHEMBL617903,,
2964,,,,B,H,Autocuration,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,108,,,1,14442,BAO_0000357,8,CHEMBL617904,,
2965,,,,B,H,Autocuration,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,108,,,1,14442,BAO_0000357,8,CHEMBL617905,,
2966,,,,B,H,Autocuration,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,108,,,1,14442,BAO_0000357,8,CHEMBL617906,,
2967,,,,B,H,Autocuration,,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,108,,,1,14755,BAO_0000357,8,CHEMBL617907,,
2968,,,,B,H,Autocuration,,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,108,,,1,14744,BAO_0000357,8,CHEMBL617908,,
2969,,,,B,H,Expert,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,108,,,1,16659,BAO_0000219,8,CHEMBL620617,449.0,
2970,,Homo sapiens,,B,D,Expert,,9606.0,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,108,,,1,6857,BAO_0000019,9,CHEMBL620618,,
2971,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,108,,,1,5635,BAO_0000357,8,CHEMBL620619,,
2972,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,108,,,1,4234,BAO_0000357,9,CHEMBL620620,,
2973,,,,B,H,Autocuration,,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,108,,,1,16209,BAO_0000357,8,CHEMBL620621,,
2974,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,104698,,,1,5778,BAO_0000249,7,CHEMBL872920,,
2975,,,,B,H,Autocuration,,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,104698,,,1,5094,BAO_0000223,6,CHEMBL620622,,
2976,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,104698,,,1,809,BAO_0000019,7,CHEMBL620623,,
2977,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,104698,,,1,1578,BAO_0000019,6,CHEMBL620624,,
2978,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,104698,,,1,809,BAO_0000019,6,CHEMBL620625,,
2979,,,,B,H,Autocuration,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,104698,,,1,12469,BAO_0000219,6,CHEMBL620626,,
2980,,,,B,H,Autocuration,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,104698,,,1,14290,BAO_0000019,6,CHEMBL621307,,
2981,,,,B,H,Autocuration,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,104698,,,1,14290,BAO_0000019,6,CHEMBL621308,,
2982,,,,B,H,Autocuration,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,104698,,,1,10609,BAO_0000223,6,CHEMBL621309,,
2983,,,,B,H,Autocuration,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,104698,,,1,10609,BAO_0000223,6,CHEMBL621310,,
2984,,,,B,H,Autocuration,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,104698,,,1,10609,BAO_0000223,6,CHEMBL621311,,
2985,,,,B,H,Autocuration,,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",104698,,,1,15253,BAO_0000249,6,CHEMBL621502,,
2986,,,,B,H,Autocuration,,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",104698,,,1,15253,BAO_0000249,6,CHEMBL621503,,
2987,,,,B,H,Autocuration,,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,104698,,,1,11683,BAO_0000249,6,CHEMBL621504,,
2988,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,104698,,,1,12092,BAO_0000223,6,CHEMBL621505,,
2989,,,,B,H,Autocuration,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,104698,,,1,1946,BAO_0000019,6,CHEMBL621506,,
2990,,,,B,H,Autocuration,,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,104698,,,1,11623,BAO_0000223,6,CHEMBL619781,,
2991,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,104698,,,1,11623,BAO_0000223,6,CHEMBL619782,,
2992,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,104698,,,1,14788,BAO_0000019,6,CHEMBL619783,,
2993,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,104698,,,1,5432,BAO_0000019,7,CHEMBL619784,,
2994,,,,B,H,Autocuration,,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,104698,,,1,14826,BAO_0000249,6,CHEMBL619785,,
2995,,,,B,H,Autocuration,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,104698,,,1,2222,BAO_0000223,6,CHEMBL619786,,
2996,,,,B,H,Autocuration,,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,104698,,,1,11963,BAO_0000019,6,CHEMBL619787,,
2997,,,,B,H,Autocuration,,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,104698,,,1,14145,BAO_0000019,6,CHEMBL872925,,
2998,,,,B,H,Autocuration,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,104698,,,1,17819,BAO_0000019,6,CHEMBL619788,,
2999,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,104698,,,1,10394,BAO_0000249,6,CHEMBL619789,,
3000,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,104698,,,1,10394,BAO_0000249,6,CHEMBL619790,,
3001,,,,B,H,Autocuration,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,104698,,,1,15034,BAO_0000019,6,CHEMBL619791,,
3002,,,,B,H,Autocuration,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,104698,,,1,691,BAO_0000019,6,CHEMBL619792,,
3003,,,,B,H,Autocuration,,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,104698,,,1,12092,BAO_0000249,6,CHEMBL619793,,
3004,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,104698,,,1,11752,BAO_0000223,7,CHEMBL619794,,
3005,,,,B,H,Autocuration,Brain,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,104698,,,1,11752,BAO_0000221,6,CHEMBL619795,,955.0
3006,,,,B,H,Autocuration,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,104698,,,1,301,BAO_0000019,6,CHEMBL619796,,
3007,,,,B,H,Autocuration,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,104698,,,1,16532,BAO_0000223,6,CHEMBL620448,,
3008,,,,B,H,Autocuration,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,104698,,,1,16532,BAO_0000223,6,CHEMBL620449,,
3009,,,,B,H,Autocuration,,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,104698,,,1,12092,BAO_0000223,6,CHEMBL620450,,
3010,,,,B,H,Autocuration,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,104698,,,1,11684,BAO_0000223,6,CHEMBL620451,,
3011,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,104698,,,1,11684,BAO_0000223,6,CHEMBL620631,,
3012,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,104698,,,1,12953,BAO_0000019,6,CHEMBL620632,,
3013,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,104698,,,1,12953,BAO_0000019,6,CHEMBL620633,,
3014,,,,B,H,Autocuration,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,104698,,,1,12953,BAO_0000223,6,CHEMBL620634,,
3015,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,104698,,,1,12861,BAO_0000019,6,CHEMBL620635,,
3016,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL620636,,
3017,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL620637,,
3018,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL620638,,
3019,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL620639,,
3020,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL620640,,
3021,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL620641,,
3022,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL620642,,
3023,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL620643,,
3024,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL620644,,
3025,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL620645,,
3026,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL620646,,
3027,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL620647,,
3028,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL620648,,
3029,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL620649,,
3030,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL620650,,
3031,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL620651,,
3032,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL872875,,
3033,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL620652,,
3034,,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,104698,,,1,10609,BAO_0000019,6,CHEMBL620653,,
3035,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,104698,,,1,12861,BAO_0000019,6,CHEMBL857076,,
3036,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,104698,,,1,12861,BAO_0000019,7,CHEMBL620654,,
3037,,,,B,H,Autocuration,,,Binding activity radioligand.,104698,,,1,12861,BAO_0000223,6,CHEMBL620655,,
3038,,,,B,H,Autocuration,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,104698,,,1,10728,BAO_0000249,6,CHEMBL620656,,
3039,,,,B,H,Autocuration,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,104698,,,1,10728,BAO_0000249,6,CHEMBL620657,,
3040,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,108,,,1,5163,BAO_0000357,8,CHEMBL620658,,
3041,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,108,,,1,5163,BAO_0000357,8,CHEMBL620659,,
3042,,,,B,H,Autocuration,,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,108,,,1,6011,BAO_0000357,8,CHEMBL620660,,
3043,,,,B,H,Autocuration,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,108,,,1,5014,BAO_0000357,8,CHEMBL620661,,
3044,,,,B,H,Autocuration,,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,108,,,1,5635,BAO_0000357,8,CHEMBL620662,,
3045,,,,B,H,Expert,,,Affinity for 5-hydroxytryptamine 2C receptor,108,,,1,5163,BAO_0000357,8,CHEMBL620663,,
3046,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,108,,,1,6841,BAO_0000357,8,CHEMBL620664,,
3047,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,108,,,1,6119,BAO_0000357,8,CHEMBL620665,,
3048,,,,B,H,Autocuration,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,108,,,1,4373,BAO_0000357,8,CHEMBL620666,,
3049,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,108,,,1,1633,BAO_0000357,8,CHEMBL620667,,
3050,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,108,,,1,1633,BAO_0000357,8,CHEMBL620668,,
3051,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,108,,,1,4373,BAO_0000357,8,CHEMBL620669,,
3052,,,,B,H,Expert,,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,108,,,1,6576,BAO_0000357,8,CHEMBL620670,,
3053,,,,B,H,Autocuration,,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,108,,,1,4687,BAO_0000357,8,CHEMBL620671,,
3054,,,,B,H,Autocuration,,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,108,,,1,12146,BAO_0000357,8,CHEMBL620672,,
3055,,,,B,H,Autocuration,,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,108,,,1,12146,BAO_0000357,8,CHEMBL620673,,
3056,,,,B,H,Autocuration,,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,108,,,1,16946,BAO_0000357,8,CHEMBL620674,,
3057,,,,B,H,Autocuration,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,108,,,1,14159,BAO_0000357,8,CHEMBL620675,,
3058,,,,B,H,Autocuration,,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,108,,,1,16700,BAO_0000357,8,CHEMBL620676,,
3059,,,,B,H,Autocuration,,,Affinity against 5-hydroxytryptamine 2C receptor,108,,,1,3269,BAO_0000357,8,CHEMBL621382,,
3060,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against 5-hydroxytryptamine 2C receptor,108,,,1,1274,BAO_0000357,9,CHEMBL621383,,
3061,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,108,,,1,1317,BAO_0000357,8,CHEMBL621384,,
3062,,Bos taurus,,B,H,Autocuration,,9913.0,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,144,,,1,5834,BAO_0000357,8,CHEMBL621385,,
3063,,Bos taurus,,B,H,Autocuration,,9913.0,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,144,,,1,11147,BAO_0000357,8,CHEMBL617989,,
3064,,Cavia porcellus,,F,H,Expert,,10141.0,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,104714,,,1,14145,BAO_0000019,4,CHEMBL617990,,
3065,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,104714,,,1,10561,BAO_0000221,4,CHEMBL875085,,2116.0
3066,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,104714,,,1,15847,BAO_0000019,4,CHEMBL617991,,
3067,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,104714,,,1,15847,BAO_0000019,4,CHEMBL617992,,
3068,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,104714,,,1,10561,BAO_0000221,4,CHEMBL617993,,2116.0
3069,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,104714,,,1,11454,BAO_0000221,4,CHEMBL617994,,2116.0
3070,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,104714,,,1,4639,BAO_0000019,4,CHEMBL617995,,
3071,,Cavia porcellus,,F,H,Autocuration,,10141.0,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,104714,,,1,4639,BAO_0000019,4,CHEMBL617996,,
3072,,Cavia porcellus,,F,H,Autocuration,,10141.0,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,104714,,,1,4639,BAO_0000019,4,CHEMBL617997,,
3073,,Cavia porcellus,,F,H,Autocuration,,10141.0,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,104714,,,1,4639,BAO_0000019,4,CHEMBL617998,,
3074,,Cavia porcellus,,F,H,Autocuration,,10141.0,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,104714,,,1,4639,BAO_0000019,4,CHEMBL617999,,
3075,,Cavia porcellus,,F,H,Autocuration,,10141.0,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,104714,,,1,4639,BAO_0000019,4,CHEMBL618000,,
3076,,Cavia porcellus,,F,H,Autocuration,Ileum,10141.0,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",104714,,,1,15253,BAO_0000221,4,CHEMBL617815,,2116.0
3077,,Cavia porcellus,,F,H,Autocuration,Ileum,10141.0,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",104714,,,1,15253,BAO_0000221,4,CHEMBL617816,,2116.0
3078,,Cavia porcellus,,F,H,Autocuration,Ileum,10141.0,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,104714,,,1,11963,BAO_0000221,4,CHEMBL617817,,2116.0
3079,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,104714,,,1,1946,BAO_0000221,4,CHEMBL617818,,2116.0
3080,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,104714,,,1,1946,BAO_0000221,4,CHEMBL617819,,2116.0
3081,,Cavia porcellus,,B,H,Autocuration,,10141.0,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,104714,,,1,12045,BAO_0000223,4,CHEMBL617820,,
3082,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,104714,,,1,1559,BAO_0000221,4,CHEMBL617821,,2116.0
3083,,Cavia porcellus,,F,H,Autocuration,Ileum,10141.0,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),104714,,,1,273,BAO_0000221,4,CHEMBL617822,,2116.0
3084,,Cavia porcellus,,F,H,Autocuration,Ileum,10141.0,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),104714,,,1,273,BAO_0000221,4,CHEMBL617823,,2116.0
3085,,Cavia porcellus,,F,H,Autocuration,Ileum,10141.0,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,104714,,,1,188,BAO_0000221,4,CHEMBL617824,,2116.0
3086,,Cavia porcellus,,F,H,Autocuration,Ileum,10141.0,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,104714,,,1,12919,BAO_0000221,4,CHEMBL617825,,2116.0
3087,,Cavia porcellus,,F,H,Autocuration,Ileum,10141.0,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,104714,,,1,12918,BAO_0000221,4,CHEMBL617826,,2116.0
3088,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,104714,,,1,1559,BAO_0000221,4,CHEMBL617827,,2116.0
3089,,Cavia porcellus,,F,H,Autocuration,Ileum,10141.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),104714,,,1,273,BAO_0000221,4,CHEMBL617828,,2116.0
3090,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,104714,,,1,1559,BAO_0000221,4,CHEMBL617829,,2116.0
3091,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,104714,,,1,1559,BAO_0000221,4,CHEMBL617830,,2116.0
3092,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,104714,,,1,1559,BAO_0000221,4,CHEMBL617831,,2116.0
3093,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,104714,,,1,14424,BAO_0000221,4,CHEMBL617832,,2116.0
3094,,Cavia porcellus,,B,U,Autocuration,,10141.0,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,22226,,,1,13181,BAO_0000019,0,CHEMBL617833,,
3095,,,,B,H,Autocuration,,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,51,,,1,5486,BAO_0000357,8,CHEMBL617834,,
3096,,Homo sapiens,,B,D,Expert,,9606.0,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,104714,,,1,6491,BAO_0000223,5,CHEMBL617835,,
3097,,,,B,H,Autocuration,,,Binding affinity towards 5-HT3 receptor,104714,,,1,6013,BAO_0000223,4,CHEMBL617836,,
3098,,,,B,H,Autocuration,,,Binding activity radioligand.,104714,,,1,12861,BAO_0000223,4,CHEMBL617837,,
3099,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,104714,,,1,12861,BAO_0000019,4,CHEMBL620392,,
3100,,,,B,H,Autocuration,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,104714,,,1,5104,BAO_0000223,4,CHEMBL620393,,
3101,,,,B,H,Autocuration,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,104714,,,1,5105,BAO_0000223,4,CHEMBL620394,,
3102,,,,B,H,Autocuration,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,104714,,,1,5104,BAO_0000223,4,CHEMBL620395,,
3103,,,,B,U,Autocuration,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,22226,,,1,3935,BAO_0000019,0,CHEMBL620396,,
3104,,,,B,H,Expert,,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,105030,,,1,13657,BAO_0000219,4,CHEMBL620582,433.0,
3105,In vivo,,,B,H,Autocuration,,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",105030,,,1,10369,BAO_0000218,4,CHEMBL620583,,
3106,,,,B,H,Autocuration,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),105030,,,1,10369,BAO_0000019,4,CHEMBL620584,,
3107,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,105030,,,1,12918,BAO_0000224,4,CHEMBL620585,,
3108,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity at 5- HT3 receptor,105030,,,1,12918,BAO_0000224,4,CHEMBL620586,,
3109,,,,B,H,Autocuration,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),105030,,,1,10369,BAO_0000019,4,CHEMBL620587,,
3110,,,,B,H,Autocuration,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,105030,,,1,773,BAO_0000019,4,CHEMBL620588,,
3111,,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor agonism in mouse,105030,,,1,12918,BAO_0000218,4,CHEMBL620589,,
3112,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,105030,,,1,10561,BAO_0000219,4,CHEMBL620590,,
3113,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,105030,,,1,12827,BAO_0000019,4,CHEMBL617956,,
3114,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,105030,,,1,12827,BAO_0000019,4,CHEMBL617957,,
3115,,,,B,H,Autocuration,,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,105030,,,1,12918,BAO_0000224,4,CHEMBL617958,,
3116,,,,B,H,Autocuration,,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,105030,,,1,273,BAO_0000219,4,CHEMBL617959,,
3117,,,,B,H,Autocuration,,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,105030,,,1,273,BAO_0000219,4,CHEMBL617960,,
3118,,,,B,H,Autocuration,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,105030,,,1,10561,BAO_0000224,4,CHEMBL617961,,
3119,In vitro,,,B,H,Autocuration,,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,105030,,,1,5033,BAO_0000219,4,CHEMBL617962,,
3120,,,,B,H,Autocuration,,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,105030,,,1,16429,BAO_0000219,4,CHEMBL617963,339.0,
3121,,,,B,H,Autocuration,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,11765,,,1,10322,BAO_0000019,8,CHEMBL617964,,
3122,,,,B,H,Autocuration,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,11765,,,1,14331,BAO_0000219,8,CHEMBL617965,,
3123,,Mus musculus,,B,D,Autocuration,,10090.0,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,10630,,,1,13462,BAO_0000357,9,CHEMBL617966,,
3124,,,,B,H,Autocuration,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,17106,,,1,12861,BAO_0000019,8,CHEMBL857074,,
3125,,Sus scrofa,,B,H,Autocuration,,9823.0,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,144,,,1,15086,BAO_0000357,8,CHEMBL617967,,
3126,,Sus scrofa,,B,H,Autocuration,,9823.0,Binding activity radioligand.,144,,,1,12861,BAO_0000357,8,CHEMBL617968,,
3127,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,104714,,,1,10561,BAO_0000223,4,CHEMBL617969,,
3128,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,104714,,,1,10561,BAO_0000223,4,CHEMBL617970,,
3129,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,104714,,,1,10561,BAO_0000223,4,CHEMBL617971,,
3130,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,104714,,,1,10561,BAO_0000019,4,CHEMBL617972,,
3131,,Oryctolagus cuniculus,,F,H,Autocuration,,9986.0,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),104714,,,1,273,BAO_0000019,4,CHEMBL617973,,
3132,,Oryctolagus cuniculus,,F,H,Autocuration,,9986.0,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),104714,,,1,273,BAO_0000019,4,CHEMBL617974,,
3133,,Oryctolagus cuniculus,,F,H,Autocuration,Ileum,9986.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),104714,,,1,273,BAO_0000221,4,CHEMBL617975,,2116.0
3134,,Oryctolagus cuniculus,,F,H,Autocuration,,9986.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),104714,,,1,273,BAO_0000019,4,CHEMBL617976,,
3135,,Oryctolagus cuniculus,,F,H,Autocuration,,9986.0,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),104714,,,1,273,BAO_0000019,4,CHEMBL617977,,
3136,,Oryctolagus cuniculus,,F,H,Autocuration,,9986.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),104714,,,1,273,BAO_0000019,4,CHEMBL617978,,
3137,,Oryctolagus cuniculus,,F,H,Autocuration,,9986.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),104714,,,1,273,BAO_0000019,4,CHEMBL617979,,
3138,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,104714,,,1,13047,BAO_0000219,4,CHEMBL617980,449.0,
3139,,Rattus norvegicus,,B,D,Autocuration,,10116.0,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,104698,,,1,1650,BAO_0000019,7,CHEMBL617981,,
3140,,,,B,H,Autocuration,,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),12020,,,1,16288,BAO_0000019,8,CHEMBL617982,,
3141,,,,B,H,Autocuration,,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),12020,,,1,16288,BAO_0000357,8,CHEMBL617983,,
3142,,Rattus norvegicus,,B,D,Autocuration,,10116.0,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,104698,,,1,10254,BAO_0000019,7,CHEMBL617984,,
3143,,,,B,H,Autocuration,,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",104698,,,1,14532,BAO_0000019,6,CHEMBL617985,,
3144,In vivo,,,F,H,Autocuration,Heart,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",104698,,,1,13392,BAO_0000218,6,CHEMBL617986,,948.0
3145,,,,F,H,Autocuration,Heart,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",104698,,,1,13392,BAO_0000019,6,CHEMBL617987,,948.0
3146,,,,F,H,Autocuration,Heart,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",104698,,,1,13392,BAO_0000019,6,CHEMBL617988,,948.0
3147,,,,F,H,Autocuration,Heart,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",104698,,,1,13392,BAO_0000019,6,CHEMBL617792,,948.0
3148,,,,F,H,Autocuration,Heart,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",104698,,,1,13392,BAO_0000019,6,CHEMBL617793,,948.0
3149,,,,F,H,Autocuration,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",104698,,,1,13392,BAO_0000019,6,CHEMBL617794,,
3150,,,,F,H,Autocuration,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",104698,,,1,13392,BAO_0000019,6,CHEMBL617795,,
3151,,,,F,H,Autocuration,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",104698,,,1,13392,BAO_0000019,6,CHEMBL617796,,
3152,,,,F,H,Autocuration,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",104698,,,1,13392,BAO_0000019,6,CHEMBL617797,,
3153,In vivo,Rattus norvegicus,,F,D,Autocuration,,10116.0,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),104698,,,1,1089,BAO_0000218,7,CHEMBL617798,,
3154,In vivo,,,F,H,Autocuration,,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),104698,,,1,1089,BAO_0000218,6,CHEMBL617799,,
3155,In vivo,Rattus norvegicus,,F,D,Autocuration,,10116.0,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,7,CHEMBL617800,,
3156,,Rattus norvegicus,,F,D,Autocuration,,10116.0,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,104698,,,1,11454,BAO_0000019,7,CHEMBL617801,,
3157,In vivo,Rattus norvegicus,,F,D,Autocuration,,10116.0,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,104698,,,1,12205,BAO_0000218,7,CHEMBL617802,,
3158,,Rattus norvegicus,,F,D,Autocuration,,10116.0,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),104698,,,1,1089,BAO_0000019,7,CHEMBL617803,,
3159,,,,B,H,Autocuration,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,104698,,,1,5094,BAO_0000019,6,CHEMBL617804,,
3160,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,104698,,,1,2622,BAO_0000019,7,CHEMBL617805,,
3161,,,,B,H,Autocuration,,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,104698,,,1,245,BAO_0000223,6,CHEMBL617806,,
3162,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,104698,,,1,14788,BAO_0000019,6,CHEMBL617807,,
3163,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,104698,,,1,14788,BAO_0000019,6,CHEMBL617808,,
3164,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,104698,,,1,3020,BAO_0000249,6,CHEMBL617809,,
3165,,,,B,H,Autocuration,,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,104698,,,1,1742,BAO_0000019,6,CHEMBL617810,,
3166,,,,B,H,Autocuration,Brain,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,104698,,,1,17394,BAO_0000249,6,CHEMBL617811,,955.0
3167,,,,B,H,Autocuration,Brain,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,104698,,,1,17394,BAO_0000221,6,CHEMBL617812,,955.0
3168,,,,B,H,Autocuration,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,104698,,,1,17394,BAO_0000249,6,CHEMBL617813,,
3169,,,,B,H,Autocuration,,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,104698,,,1,14286,BAO_0000249,6,CHEMBL617814,,
3170,,,,B,H,Autocuration,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,104698,,,1,14178,BAO_0000019,6,CHEMBL617698,,
3171,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,104698,,,1,14178,BAO_0000019,7,CHEMBL617699,,
3172,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,104698,,,1,14178,BAO_0000019,7,CHEMBL617700,,
3173,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,104698,,,1,14178,BAO_0000223,7,CHEMBL617701,,
3174,,,,B,H,Autocuration,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,104698,,,1,15034,BAO_0000019,6,CHEMBL617702,,
3175,,,,B,H,Autocuration,,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",104698,,,1,1089,BAO_0000249,6,CHEMBL617703,,
3176,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,104698,,,1,1089,BAO_0000019,7,CHEMBL617704,,
3177,,,,B,H,Autocuration,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,104698,,,1,16532,BAO_0000223,6,CHEMBL617705,,
3178,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,104698,,,1,12801,BAO_0000223,7,CHEMBL617706,,
3179,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),104698,,,1,15194,BAO_0000219,6,CHEMBL617707,433.0,
3180,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,104698,,,1,15194,BAO_0000219,6,CHEMBL617708,433.0,
3181,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,104698,,,1,15194,BAO_0000019,6,CHEMBL617709,,
3182,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,104698,,,1,15194,BAO_0000019,6,CHEMBL617710,,
3183,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,104698,,,1,15194,BAO_0000019,6,CHEMBL882925,,
3184,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,104698,,,1,15194,BAO_0000019,6,CHEMBL617711,,
3185,,,,F,H,Autocuration,,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,104698,,,1,10610,BAO_0000019,6,CHEMBL617712,,
3186,,Rattus norvegicus,,F,D,Autocuration,,10116.0,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,104698,,,1,10355,BAO_0000019,7,CHEMBL617713,,
3187,,,,F,H,Autocuration,,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",104698,,,1,691,BAO_0000019,6,CHEMBL617714,,
3188,,,,F,H,Autocuration,,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,104698,,,1,10611,BAO_0000218,6,CHEMBL617715,,
3189,In vivo,,,F,H,Autocuration,,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,104698,,,1,12801,BAO_0000218,6,CHEMBL617716,,
3190,,,,F,H,Autocuration,,,Inhibition of 5-HT evoked reflex bradycardia in rat.,104698,,,1,10609,BAO_0000218,6,CHEMBL617717,,
3191,In vivo,,,F,H,Autocuration,,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL617718,,
3192,In vivo,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL617719,,
3193,In vivo,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),104698,,,1,11454,BAO_0000218,6,CHEMBL617720,,
3194,In vivo,Rattus norvegicus,,F,D,Autocuration,,10116.0,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,7,CHEMBL617721,,
3195,In vivo,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL617722,,
3196,In vivo,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL617723,,
3197,In vivo,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL617724,,
3198,In vivo,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL617725,,
3199,In vivo,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL617726,,
3200,In vivo,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL617727,,
3201,In vivo,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL617728,,
3202,In vivo,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL617729,,
3203,In vivo,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL617730,,
3204,In vivo,,,F,H,Autocuration,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL617731,,
3205,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL617732,,
3206,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL617733,,
3207,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL617734,,
3208,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,104698,,,1,11454,BAO_0000218,6,CHEMBL872874,,
3209,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,104698,,,1,11454,BAO_0000218,6,CHEMBL617735,,
3210,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,104698,,,1,11454,BAO_0000218,6,CHEMBL617736,,
3211,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,104698,,,1,11454,BAO_0000218,6,CHEMBL617737,,
3212,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,104698,,,1,11454,BAO_0000218,6,CHEMBL617738,,
3213,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL617739,,
3214,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL617740,,
3215,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL617741,,
3216,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL617742,,
3217,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL617743,,
3218,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL617744,,
3219,In vivo,,,F,H,Autocuration,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,104698,,,1,11454,BAO_0000218,6,CHEMBL617745,,
3220,,,,F,H,Autocuration,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",104698,,,1,670,BAO_0000218,6,CHEMBL617746,,
3221,,,,F,H,Autocuration,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",104698,,,1,670,BAO_0000218,6,CHEMBL617747,,
3222,In vivo,,,F,H,Autocuration,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,104698,,,1,10321,BAO_0000218,6,CHEMBL617748,,
3223,In vivo,,,F,H,Autocuration,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,104698,,,1,10321,BAO_0000218,6,CHEMBL618909,,
3224,In vivo,,,F,H,Autocuration,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,104698,,,1,10321,BAO_0000218,6,CHEMBL618910,,
3225,In vivo,,,F,H,Autocuration,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,104698,,,1,10321,BAO_0000218,6,CHEMBL618911,,
3226,In vivo,,,F,H,Autocuration,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,104698,,,1,10321,BAO_0000218,6,CHEMBL618912,,
3227,In vivo,,,F,H,Autocuration,,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),104698,,,1,10322,BAO_0000218,6,CHEMBL618913,,
3228,,,,F,H,Autocuration,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,104698,,,1,15412,BAO_0000019,6,CHEMBL618914,,
3229,,,,F,H,Autocuration,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,104698,,,1,15412,BAO_0000019,6,CHEMBL618915,,
3230,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,104698,,,1,15412,BAO_0000223,7,CHEMBL618916,,
3231,,,,F,H,Autocuration,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,104698,,,1,15412,BAO_0000019,6,CHEMBL618917,,
3232,,,,B,D,Intermediate,Hippocampus,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,104698,,,1,15412,BAO_0000221,7,CHEMBL618918,,10000000.0
3233,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,104698,,,1,15412,BAO_0000019,7,CHEMBL618919,,
3234,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,104698,,,1,17394,BAO_0000019,7,CHEMBL618920,,
3235,,,,B,H,Autocuration,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,104698,,,1,12457,BAO_0000223,6,CHEMBL618921,,
3236,,,,B,H,Autocuration,,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,104698,,,1,12457,BAO_0000019,6,CHEMBL618922,,
3237,,,,B,H,Autocuration,,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,104698,,,1,12205,BAO_0000019,6,CHEMBL618923,,
3238,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,104698,,,1,14532,BAO_0000019,6,CHEMBL618924,,
3239,,,,B,H,Autocuration,,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,104698,,,1,1122,BAO_0000019,6,CHEMBL618925,,
3240,,,,B,H,Autocuration,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,104698,,,1,5094,BAO_0000019,6,CHEMBL618926,,
3241,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,20033,,,1,809,BAO_0000221,9,CHEMBL618927,,2116.0
3242,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,20033,,,1,809,BAO_0000221,9,CHEMBL618928,,2116.0
3243,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",20033,,,1,14290,BAO_0000221,9,CHEMBL618929,,2116.0
3244,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",20033,,,1,14290,BAO_0000221,9,CHEMBL618930,,2116.0
3245,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",20033,,,1,14290,BAO_0000221,9,CHEMBL618931,,2116.0
3246,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",20033,,,1,14290,BAO_0000221,9,CHEMBL619594,,2116.0
3247,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",20033,,,1,14290,BAO_0000221,9,CHEMBL619595,,2116.0
3248,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,20033,,,1,13961,BAO_0000221,9,CHEMBL619596,,2116.0
3249,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,20033,,,1,13961,BAO_0000221,9,CHEMBL619755,,2116.0
3250,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,20033,,,1,809,BAO_0000221,9,CHEMBL619756,,2116.0
3251,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,20033,,,1,809,BAO_0000221,9,CHEMBL619757,,2116.0
3252,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,20033,,,1,809,BAO_0000221,9,CHEMBL619758,,2116.0
3253,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",20033,,,1,14290,BAO_0000221,9,CHEMBL619759,,2116.0
3254,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",20033,,,1,14290,BAO_0000221,9,CHEMBL619760,,2116.0
3255,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",20033,,,1,14290,BAO_0000221,9,CHEMBL619761,,2116.0
3256,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,20033,,,1,14290,BAO_0000221,9,CHEMBL619762,,2116.0
3257,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",20033,,,1,14290,BAO_0000221,9,CHEMBL619763,,2116.0
3258,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",20033,,,1,14290,BAO_0000221,9,CHEMBL617868,,2116.0
3259,,Cavia porcellus,,B,D,Intermediate,,10141.0,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,20033,,,1,15034,BAO_0000357,9,CHEMBL617869,,
3260,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,,,1,5094,BAO_0000249,9,CHEMBL882926,,2435.0
3261,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,,,1,5094,BAO_0000249,9,CHEMBL617870,,2435.0
3262,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,20033,,,1,5399,BAO_0000357,9,CHEMBL617871,,2435.0
3263,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,20033,,,1,17394,BAO_0000357,9,CHEMBL617872,,2435.0
3264,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,20033,,,1,17394,BAO_0000357,9,CHEMBL617873,,2435.0
3265,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,20033,,,1,17394,BAO_0000357,9,CHEMBL617874,,2435.0
3266,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,20033,,,1,13961,BAO_0000221,9,CHEMBL619067,,2116.0
3267,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,20033,,,1,13961,BAO_0000221,9,CHEMBL619068,,2116.0
3268,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,20033,,,1,13961,BAO_0000221,9,CHEMBL619069,,2116.0
3269,,Cavia porcellus,,B,D,Intermediate,,10141.0,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,20033,,,1,16946,BAO_0000357,9,CHEMBL619070,,
3270,,Cavia porcellus,,B,D,Intermediate,,10141.0,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,20033,,,1,16946,BAO_0000357,9,CHEMBL619071,,
3271,,Cavia porcellus,,F,D,Intermediate,,10141.0,Agonistic activity against 5-hydroxytryptamine 4 receptor,20033,,,1,15034,BAO_0000019,9,CHEMBL619072,,
3272,,Cavia porcellus,,F,D,Intermediate,,10141.0,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,20033,,,1,15034,BAO_0000019,9,CHEMBL619073,,
3273,,Cavia porcellus,,F,D,Intermediate,,10141.0,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,20033,,,1,12918,BAO_0000019,9,CHEMBL619074,,
3274,,Cavia porcellus,,B,D,Intermediate,,10141.0,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,20033,,,1,16946,BAO_0000357,9,CHEMBL619075,,
3275,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,20033,,,1,17394,BAO_0000357,9,CHEMBL619076,,2435.0
3276,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,20033,,,1,15034,BAO_0000357,9,CHEMBL619077,,2435.0
3277,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,,,1,5094,BAO_0000249,9,CHEMBL619078,,2435.0
3278,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,20033,,,1,5094,BAO_0000249,9,CHEMBL619079,,2435.0
3279,,Cavia porcellus,,B,D,Intermediate,Ileum,10141.0,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,20033,,,1,17358,BAO_0000221,9,CHEMBL619080,,2116.0
3280,,Cavia porcellus,,B,D,Expert,,10141.0,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,20033,,,1,12953,BAO_0000357,9,CHEMBL619081,,
3281,,Cavia porcellus,,B,D,Intermediate,,10141.0,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,20033,,,1,12953,BAO_0000357,9,CHEMBL619082,,
3282,,Cavia porcellus,,B,D,Intermediate,,10141.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,20033,,,1,12953,BAO_0000357,9,CHEMBL619083,,
3283,,Cavia porcellus,,B,D,Intermediate,,10141.0,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,20033,,,1,12953,BAO_0000357,9,CHEMBL619084,,
3284,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,20033,,,1,273,BAO_0000221,9,CHEMBL859397,,2116.0
3285,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,20033,,,1,12918,BAO_0000221,9,CHEMBL619085,,2116.0
3286,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,20033,,,1,12919,BAO_0000221,9,CHEMBL619086,,2116.0
3287,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,20033,,,1,273,BAO_0000221,9,CHEMBL619087,,2116.0
3288,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,20033,,,1,273,BAO_0000221,9,CHEMBL619088,,2116.0
3289,,Cavia porcellus,,B,D,Intermediate,,10141.0,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,20033,,,1,13181,BAO_0000357,9,CHEMBL619089,,
3290,,Cavia porcellus,,B,H,Autocuration,,10141.0,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,168,,,1,13181,BAO_0000357,8,CHEMBL619090,,
3291,,Cavia porcellus,,F,D,Intermediate,,10141.0,Antagonistic activity against 5-hydroxytryptamine 4 receptor,20033,,,1,15034,BAO_0000019,9,CHEMBL619091,,
3292,,Cavia porcellus,,B,D,Intermediate,,10141.0,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,20033,,,1,5033,BAO_0000357,9,CHEMBL619092,,
3293,,Cavia porcellus,,B,D,Intermediate,,10141.0,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,20033,,,1,1980,BAO_0000019,9,CHEMBL619093,,
3294,,Cavia porcellus,,B,H,Autocuration,,10141.0,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,168,,,1,13181,BAO_0000219,8,CHEMBL619094,722.0,
3295,,Cavia porcellus,,B,D,Intermediate,,10141.0,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,20033,,,1,14287,BAO_0000019,9,CHEMBL619095,,
3296,,Cavia porcellus,,B,D,Intermediate,,10141.0,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,20033,,,1,1317,BAO_0000357,9,CHEMBL857988,,
3297,,Cavia porcellus,,B,D,Intermediate,,10141.0,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,20033,,,1,15316,BAO_0000357,9,CHEMBL619096,,
3298,,Cavia porcellus,,B,D,Intermediate,Striatum,10141.0,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,20033,,,1,16429,BAO_0000357,9,CHEMBL619097,,2435.0
3299,,Cavia porcellus,,B,D,Intermediate,Hippocampus,10141.0,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,20033,,,1,14818,BAO_0000221,9,CHEMBL619098,,10000000.0
3300,,Cavia porcellus,,B,D,Intermediate,,10141.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,20033,,,1,15194,BAO_0000357,9,CHEMBL619751,,
3301,,Cavia porcellus,,B,D,Intermediate,,10141.0,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,20033,,,1,15194,BAO_0000357,9,CHEMBL619752,,
3302,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,20033,,,1,13961,BAO_0000221,9,CHEMBL875096,,2116.0
3303,,,,B,H,Autocuration,,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,108,,,1,5486,BAO_0000357,8,CHEMBL619004,,
3304,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,168,,,1,16209,BAO_0000357,8,CHEMBL619005,,
3305,,,,B,H,Autocuration,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,168,,,1,17085,BAO_0000019,8,CHEMBL619006,,
3306,,,,B,H,Autocuration,,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,168,,,1,4199,BAO_0000219,8,CHEMBL619007,308.0,
3307,,,,B,H,Autocuration,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,168,,,1,15146,BAO_0000357,8,CHEMBL619008,,
3308,,,,B,H,Autocuration,,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,168,,,1,5213,BAO_0000357,8,CHEMBL619009,,
3309,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",168,,,1,4829,BAO_0000219,8,CHEMBL619010,308.0,
3310,,,,B,H,Autocuration,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,10622,,,1,17358,BAO_0000357,8,CHEMBL619011,,
3311,,,,B,H,Autocuration,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,10622,,,1,17358,BAO_0000357,8,CHEMBL619012,,
3312,,,,B,H,Autocuration,,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,10622,,,1,16946,BAO_0000219,8,CHEMBL619013,,
3313,,,,B,H,Autocuration,,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,10622,,,1,17358,BAO_0000357,8,CHEMBL619014,,
3314,,,,F,H,Autocuration,Cardiac atrium,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,11249,,,1,268,BAO_0000019,8,CHEMBL857503,,2081.0
3315,,,,F,H,Autocuration,Cardiac atrium,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,11249,,,1,268,BAO_0000019,8,CHEMBL619015,,2081.0
3316,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,11249,,,1,15086,BAO_0000357,8,CHEMBL619016,,
3317,,,,B,H,Autocuration,Hippocampus,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,11249,,,1,14875,BAO_0000221,8,CHEMBL619017,,10000000.0
3318,,Sus scrofa,,B,H,Autocuration,Hippocampus,9823.0,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,168,,,1,13267,BAO_0000221,8,CHEMBL619018,,10000000.0
3319,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,168,,,1,13047,BAO_0000019,8,CHEMBL619019,,
3320,,Rattus norvegicus,,B,D,Expert,,10116.0,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,10623,,,1,1650,BAO_0000357,9,CHEMBL619020,,
3321,,,,F,H,Autocuration,,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,10623,,,1,567,BAO_0000019,8,CHEMBL619021,,
3322,,,,B,H,Autocuration,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,10623,,,1,17358,BAO_0000357,8,CHEMBL619022,,
3323,,,,B,H,Autocuration,,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,10623,,,1,188,BAO_0000357,8,CHEMBL619023,,
3324,,,,F,H,Autocuration,,,lntrinsic activity relative to 5-HT receptor,10623,,,1,670,BAO_0000019,8,CHEMBL619024,,
3325,,,,F,H,Autocuration,,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,10623,,,1,204,BAO_0000019,8,CHEMBL619025,,
3326,,,,F,H,Expert,,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,10623,,,1,1946,BAO_0000019,8,CHEMBL619026,,
3327,,,,F,H,Autocuration,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,10623,,,1,6398,BAO_0000019,8,CHEMBL619027,,
3328,,,,F,H,Autocuration,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,10623,,,1,6398,BAO_0000019,8,CHEMBL619028,,
3329,,,,F,H,Autocuration,,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,10623,,,1,17358,BAO_0000019,8,CHEMBL619029,,
3330,,,,F,H,Autocuration,,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,10623,,,1,6398,BAO_0000019,8,CHEMBL619030,,
3331,,,,B,H,Expert,,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,10623,,,1,11752,BAO_0000357,8,CHEMBL619031,,
3332,,,,F,H,Autocuration,,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,10623,,,1,809,BAO_0000019,8,CHEMBL619032,,
3333,,Rattus norvegicus,,B,D,Expert,,10116.0,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,10623,,,1,14178,BAO_0000357,9,CHEMBL619033,,
3334,,,,B,H,Autocuration,,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,10623,,,1,567,BAO_0000357,8,CHEMBL619034,,
3335,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,10623,,,1,1946,BAO_0000357,8,CHEMBL619035,,
3336,,,,B,H,Autocuration,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,10623,,,1,1946,BAO_0000357,8,CHEMBL619036,,
3337,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,10623,,,1,13961,BAO_0000019,9,CHEMBL619037,,
3338,,,,B,H,Autocuration,Striatum,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,10623,,,1,6238,BAO_0000249,8,CHEMBL619038,,2435.0
3339,,,,B,H,Autocuration,,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,10623,,,1,14290,BAO_0000249,8,CHEMBL619039,,
3340,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,10623,,,1,14290,BAO_0000249,8,CHEMBL619040,,
3341,,Rattus norvegicus,,B,D,Expert,Striatum,10116.0,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,10623,,,1,809,BAO_0000019,9,CHEMBL619041,,2435.0
3342,,,,B,H,Autocuration,Striatum,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,10623,,,1,1578,BAO_0000019,8,CHEMBL619042,,2435.0
3343,,,,B,H,Expert,Striatum,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,10623,,,1,16709,BAO_0000249,8,CHEMBL619043,,2435.0
3344,,,,B,H,Expert,Striatum,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,10623,,,1,1946,BAO_0000019,8,CHEMBL619044,,2435.0
3345,,,,B,H,Expert,Striatum,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,10623,,,1,15253,BAO_0000249,8,CHEMBL619045,,2435.0
3346,,,,B,H,Expert,Striatum,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,10623,,,1,4535,BAO_0000249,8,CHEMBL619046,,2435.0
3347,,,,B,H,Expert,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,10623,,,1,13961,BAO_0000249,8,CHEMBL619047,,
3348,,,,F,H,Autocuration,Brain,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,10623,,,1,17358,BAO_0000221,8,CHEMBL619048,,955.0
3349,,,,F,H,Autocuration,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,10623,,,1,15847,BAO_0000019,8,CHEMBL859398,,
3350,,,,F,H,Autocuration,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,10623,,,1,15847,BAO_0000019,8,CHEMBL619049,,
3351,,,,F,H,Autocuration,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,10623,,,1,670,BAO_0000019,8,CHEMBL857886,,
3352,,,,F,H,Autocuration,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,10623,,,1,670,BAO_0000019,8,CHEMBL619050,,
3353,,,,F,H,Autocuration,,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,10623,,,1,1317,BAO_0000019,8,CHEMBL620591,,
3354,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity against rat 5-hydroxytryptamine 4 receptor,10623,,,1,12936,BAO_0000357,9,CHEMBL620592,,
3355,,,,B,H,Expert,Striatum,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,10623,,,1,4535,BAO_0000249,8,CHEMBL620593,,2435.0
3356,,Rattus norvegicus,,F,D,Expert,,10116.0,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,10623,,,1,14424,BAO_0000019,9,CHEMBL620594,,
3357,,,,F,H,Expert,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,10623,,,1,14424,BAO_0000019,8,CHEMBL875079,,
3358,,,,F,H,Expert,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,10623,,,1,14424,BAO_0000019,8,CHEMBL620595,,
3359,,Rattus norvegicus,,F,D,Expert,,10116.0,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,10623,,,1,14424,BAO_0000019,9,CHEMBL620596,,
3360,,,,F,H,Autocuration,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,10623,,,1,14424,BAO_0000019,8,CHEMBL620597,,
3361,,,,F,H,Expert,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,10623,,,1,14424,BAO_0000019,8,CHEMBL620598,,
3362,,,,F,H,Expert,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),10623,,,1,14424,BAO_0000218,8,CHEMBL620599,,
3363,,,,F,H,Autocuration,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,10623,,,1,14424,BAO_0000019,8,CHEMBL620600,,
3364,,Rattus norvegicus,,F,H,Autocuration,,10116.0,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,168,,,1,1980,BAO_0000019,8,CHEMBL620601,,
3365,,,,F,H,Autocuration,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,168,,,1,4639,BAO_0000019,8,CHEMBL620602,,
3366,,,,B,H,Autocuration,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,168,,,1,17358,BAO_0000357,8,CHEMBL620603,,
3367,,,,B,H,Autocuration,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,168,,,1,17358,BAO_0000357,8,CHEMBL620604,,
3368,,,,B,H,Autocuration,,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,168,,,1,17358,BAO_0000357,8,CHEMBL620605,,
3369,,,,B,H,Autocuration,,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,168,,,1,1558,BAO_0000357,8,CHEMBL620606,,
3370,,,,F,H,Autocuration,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,168,,,1,17358,BAO_0000019,8,CHEMBL620607,,
3371,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-HT4 receptor was determined,168,,,1,16117,BAO_0000357,8,CHEMBL620608,,
3372,,,,F,H,Autocuration,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,168,,,1,17358,BAO_0000019,8,CHEMBL620609,,
3373,,,,F,H,Autocuration,,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,168,,,1,17358,BAO_0000019,8,CHEMBL620610,,
3374,,,,B,H,Autocuration,,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,168,,,1,17358,BAO_0000357,8,CHEMBL620611,,
3375,,,,B,H,Autocuration,,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,168,,,1,17358,BAO_0000357,8,CHEMBL620612,,
3376,,,,B,H,Autocuration,,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,168,,,1,17358,BAO_0000357,8,CHEMBL620613,,
3377,,,,B,H,Autocuration,,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,168,,,1,17358,BAO_0000357,8,CHEMBL620614,,
3378,,,,B,H,Expert,,,Binding affinity against 5-Hydroxytryptamine 4 receptor,168,,,1,1274,BAO_0000357,8,CHEMBL620615,,
3379,,,,B,H,Autocuration,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,104698,,,1,10728,BAO_0000249,6,CHEMBL857075,,
3380,,,,B,H,Autocuration,,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,104698,,,1,11695,BAO_0000249,6,CHEMBL620616,,
3381,,,,B,H,Autocuration,,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,104698,,,1,11695,BAO_0000249,6,CHEMBL619411,,
3382,,,,B,H,Autocuration,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,104698,,,1,12490,BAO_0000019,6,CHEMBL619412,,
3383,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,104698,,,1,11828,BAO_0000019,7,CHEMBL619413,,
3384,,,,B,H,Autocuration,Hippocampus,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,104698,,,1,12253,BAO_0000221,6,CHEMBL619414,,10000000.0
3385,,,,B,H,Autocuration,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,104698,,,1,10561,BAO_0000019,6,CHEMBL619415,,
3386,,,,B,H,Autocuration,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,104698,,,1,10561,BAO_0000019,6,CHEMBL619416,,
3387,,,,F,H,Autocuration,,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,104698,,,1,14432,BAO_0000019,6,CHEMBL619417,,
3388,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity against rat 5-hydroxytryptamine 3 receptor,104698,,,1,12936,BAO_0000223,7,CHEMBL619418,,
3389,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity against 5-Hydroxytryptamine 3 receptor,104698,,,1,1274,BAO_0000223,7,CHEMBL619419,,
3390,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,104698,,,1,1980,BAO_0000019,6,CHEMBL619420,,
3391,,,,B,H,Autocuration,,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,104698,,,1,670,BAO_0000249,6,CHEMBL619421,,
3392,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,104698,,,1,968,BAO_0000019,7,CHEMBL619422,,
3393,,,,B,H,Autocuration,,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,104698,,,1,14287,BAO_0000019,6,CHEMBL619423,,
3394,,,,B,H,Autocuration,,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,104698,,,1,567,BAO_0000019,6,CHEMBL875080,,
3395,,,,B,H,Autocuration,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,104698,,,1,13267,BAO_0000019,6,CHEMBL619424,,
3396,,,,B,H,Autocuration,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,104698,,,1,14826,BAO_0000249,6,CHEMBL619425,,
3397,,,,B,H,Autocuration,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,104698,,,1,15194,BAO_0000223,6,CHEMBL619426,,
3398,,,,B,H,Autocuration,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,104698,,,1,15194,BAO_0000223,6,CHEMBL619427,,
3399,,Rattus norvegicus,,B,D,Autocuration,,10116.0,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,104698,,,1,10394,BAO_0000223,7,CHEMBL619645,,
3400,,,,B,D,Expert,,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",10576,,,1,13657,BAO_0000249,9,CHEMBL619646,,
3401,,,,F,H,Autocuration,Brain,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,12020,,,1,1879,BAO_0000221,8,CHEMBL619647,,955.0
3402,,,,F,H,Autocuration,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,12020,,,1,1879,BAO_0000019,8,CHEMBL619648,,
3403,,,,F,H,Autocuration,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,12020,,,1,1879,BAO_0000019,8,CHEMBL619165,,
3404,In vivo,,,F,H,Autocuration,,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,12020,,,1,204,BAO_0000218,8,CHEMBL620719,,
3405,,,,B,H,Autocuration,,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,12020,,,1,1879,BAO_0000019,8,CHEMBL872924,,
3406,,,,B,H,Autocuration,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,12020,,,1,1879,BAO_0000357,8,CHEMBL620720,,
3407,,,,B,H,Autocuration,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,12020,,,1,1879,BAO_0000019,8,CHEMBL620721,,
3408,,,,B,H,Autocuration,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,12020,,,1,1879,BAO_0000019,8,CHEMBL620722,,
3409,,,,B,H,Autocuration,,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",104698,,,1,10641,BAO_0000019,6,CHEMBL620723,,
3410,,,,B,H,Autocuration,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,12020,,,1,773,BAO_0000019,8,CHEMBL620724,,
3411,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,104698,,,1,11952,BAO_0000249,6,CHEMBL620725,,
3412,,Rattus norvegicus,,F,D,Autocuration,,10116.0,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,12020,,,1,14145,BAO_0000019,9,CHEMBL620726,,
3413,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,144,,,1,17066,BAO_0000357,8,CHEMBL620727,,
3414,,,,B,H,Autocuration,,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,104714,,,1,6398,BAO_0000223,4,CHEMBL620728,,
3415,,,,B,U,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,22226,,,1,10321,BAO_0000019,0,CHEMBL620729,,
3416,,,,F,H,Autocuration,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,104714,,,1,511,BAO_0000019,4,CHEMBL858288,,
3417,,,,B,H,Autocuration,,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,104714,,,1,4639,BAO_0000223,4,CHEMBL620730,,
3418,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,104714,,,1,4639,BAO_0000223,4,CHEMBL620731,,
3419,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,104714,,,1,4639,BAO_0000019,4,CHEMBL620732,,
3420,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,104714,,,1,4639,BAO_0000019,4,CHEMBL618042,,
3421,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,104714,,,1,4639,BAO_0000019,4,CHEMBL618043,,
3422,,,,B,H,Autocuration,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,104714,,,1,1558,BAO_0000223,4,CHEMBL618044,,
3423,,,,F,H,Autocuration,,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,104714,,,1,268,BAO_0000019,4,CHEMBL618045,,
3424,,,,B,H,Autocuration,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,104714,,,1,2474,BAO_0000223,4,CHEMBL618046,,
3425,,,,F,H,Autocuration,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,104714,,,1,5067,BAO_0000019,4,CHEMBL618047,,
3426,,,,F,H,Autocuration,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,104714,,,1,5067,BAO_0000019,4,CHEMBL875084,,
3427,,,,F,H,Autocuration,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,104714,,,1,5067,BAO_0000019,4,CHEMBL618048,,
3428,,,,B,H,Autocuration,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,104714,,,1,5067,BAO_0000223,4,CHEMBL618049,,
3429,,,,F,H,Autocuration,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,104714,,,1,5067,BAO_0000019,4,CHEMBL619764,,
3430,,,,F,H,Autocuration,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,104714,,,1,5067,BAO_0000019,4,CHEMBL619765,,
3431,,,,F,H,Autocuration,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,104714,,,1,5067,BAO_0000019,4,CHEMBL619766,,
3432,,,,B,H,Autocuration,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,104714,,,1,5067,BAO_0000223,4,CHEMBL619767,,
3433,,,,B,H,Autocuration,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,104714,,,1,5067,BAO_0000223,4,CHEMBL619768,,
3434,,,,F,H,Autocuration,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,104714,,,1,5067,BAO_0000019,4,CHEMBL619769,,
3435,,,,B,H,Autocuration,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,104714,,,1,5067,BAO_0000223,4,CHEMBL619770,,
3436,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,104714,,,1,5067,BAO_0000223,4,CHEMBL619771,,
3437,,,,B,H,Autocuration,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,104714,,,1,14331,BAO_0000219,4,CHEMBL619772,,
3438,,,,B,H,Autocuration,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,104714,,,1,5067,BAO_0000223,4,CHEMBL619773,,
3439,,,,B,H,Autocuration,,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,104714,,,1,6179,BAO_0000219,4,CHEMBL619774,433.0,
3440,,,,B,H,Autocuration,,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,104714,,,1,4265,BAO_0000019,4,CHEMBL875083,,
3441,,,,B,H,Autocuration,,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,104714,,,1,4265,BAO_0000219,4,CHEMBL620718,433.0,
3442,,,,B,H,Autocuration,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,104714,,,1,17358,BAO_0000223,4,CHEMBL618127,,
3443,,,,B,H,Autocuration,,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,104714,,,1,17358,BAO_0000223,4,CHEMBL618128,,
3444,In vitro,,,B,H,Autocuration,,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,104714,,,1,13628,BAO_0000219,4,CHEMBL618129,,
3445,,,,B,H,Autocuration,,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,104714,,,1,4612,BAO_0000223,4,CHEMBL618130,,
3446,,,,F,H,Autocuration,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,104714,,,1,17358,BAO_0000019,4,CHEMBL618131,,
3447,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,104714,,,1,4639,BAO_0000019,4,CHEMBL618132,,
3448,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,104714,,,1,4639,BAO_0000019,4,CHEMBL618133,,
3449,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,104714,,,1,4639,BAO_0000019,4,CHEMBL618134,,
3450,,Cavia porcellus,,F,H,Autocuration,,10141.0,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,104714,,,1,4639,BAO_0000019,4,CHEMBL618135,,
3451,,,,B,H,Autocuration,,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,104714,,,1,511,BAO_0000223,4,CHEMBL618136,,
3452,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,104714,,,1,1479,BAO_0000223,4,CHEMBL618137,,
3453,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,104714,,,1,1317,BAO_0000223,4,CHEMBL618138,,
3454,,,,B,H,Autocuration,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,104714,,,1,12146,BAO_0000223,4,CHEMBL618139,,
3455,,,,B,H,Autocuration,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,104714,,,1,12146,BAO_0000223,4,CHEMBL618140,,
3456,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,104714,,,1,13969,BAO_0000223,4,CHEMBL618141,,
3457,,,,B,H,Expert,,,Binding affinity for 5-hydroxytryptamine 2C receptor,108,,,1,13392,BAO_0000357,8,CHEMBL873478,,
3458,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,104698,,,1,13392,BAO_0000223,6,CHEMBL618142,,
3459,,,,B,H,Autocuration,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,144,,,1,14159,BAO_0000357,8,CHEMBL618143,,
3460,,,,B,H,Autocuration,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,144,,,1,1558,BAO_0000357,8,CHEMBL618144,,
3461,,,,B,H,Autocuration,,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,144,,,1,16655,BAO_0000357,8,CHEMBL618145,,
3462,,,,B,H,Autocuration,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,104714,,,1,13020,BAO_0000223,4,CHEMBL618146,,
3463,,,,B,H,Autocuration,,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,104714,,,1,13021,BAO_0000223,4,CHEMBL618147,,
3464,,,,B,H,Autocuration,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,104714,,,1,13020,BAO_0000223,4,CHEMBL618148,,
3465,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,144,,,1,10321,BAO_0000019,8,CHEMBL618149,,
3466,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,144,,,1,15818,BAO_0000357,8,CHEMBL872927,,
3467,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,144,,,1,15818,BAO_0000357,8,CHEMBL618150,,
3468,,,,B,H,Autocuration,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,144,,,1,17358,BAO_0000357,8,CHEMBL618151,,
3469,,,,B,H,Autocuration,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,144,,,1,2222,BAO_0000357,8,CHEMBL875094,,
3470,,,,B,H,Autocuration,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,144,,,1,10322,BAO_0000019,8,CHEMBL618152,,
3471,,,,B,H,Autocuration,,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,144,,,1,16117,BAO_0000357,8,CHEMBL618153,,
3472,,,,B,H,Autocuration,,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,144,,,1,17200,BAO_0000357,8,CHEMBL618888,,
3473,,,,F,H,Autocuration,,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,144,,,1,17358,BAO_0000019,8,CHEMBL618889,,
3474,,,,B,H,Autocuration,,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,144,,,1,16700,BAO_0000357,8,CHEMBL618890,,
3475,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,144,,,1,1980,BAO_0000019,8,CHEMBL618891,,
3476,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,144,,,1,1980,BAO_0000019,8,CHEMBL619054,,
3477,,,,B,H,Autocuration,,,Binding affinity against the 5-hydroxytryptamine 3 receptor,104714,,,1,12409,BAO_0000223,4,CHEMBL619055,,
3478,,,,B,H,Autocuration,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,144,,,1,4365,BAO_0000357,8,CHEMBL619056,,
3479,,,,F,H,Autocuration,,,Percent efficacy against 5-hydroxytryptamine 3A receptor,144,,,1,4365,BAO_0000019,8,CHEMBL619057,,
3480,,,,B,H,Autocuration,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,144,,,1,4365,BAO_0000357,8,CHEMBL619058,,
3481,,Rattus norvegicus,,F,D,Expert,,10116.0,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,12020,,,1,6769,BAO_0000219,9,CHEMBL619059,,
3482,,Rattus norvegicus,,F,D,Expert,,10116.0,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,12020,,,1,6769,BAO_0000219,9,CHEMBL619060,,
3483,,Rattus norvegicus,,F,D,Expert,,10116.0,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,12020,,,1,6769,BAO_0000219,9,CHEMBL875095,,
3484,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,20033,,,1,809,BAO_0000221,9,CHEMBL619061,,2116.0
3485,,Cavia porcellus,,F,D,Intermediate,Ileum,10141.0,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,20033,,,1,809,BAO_0000221,9,CHEMBL619062,,2116.0
3486,,Cavia porcellus,,F,D,Intermediate,,10141.0,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,20033,,,1,14290,BAO_0000019,9,CHEMBL619063,,
3487,,Cavia porcellus,,B,D,Intermediate,Ileum,10141.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,20033,,,1,17358,BAO_0000221,9,CHEMBL619064,,2116.0
3488,,Cavia porcellus,,B,D,Intermediate,,10141.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,20033,,,1,17358,BAO_0000357,9,CHEMBL619065,,
3489,,Cavia porcellus,,B,D,Intermediate,Ileum,10141.0,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,20033,,,1,17358,BAO_0000221,9,CHEMBL619066,,2116.0
3490,,,,B,H,Autocuration,Ileum,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,10209,,,1,17386,BAO_0000221,8,CHEMBL619775,,2116.0
3491,,,,B,H,Autocuration,,,Affinity against 5-hydroxytryptamine 7 receptor,10209,,,1,3269,BAO_0000357,8,CHEMBL619776,,
3492,,Cavia porcellus,,B,H,Autocuration,,10141.0,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,104841,,,1,7721,BAO_0000224,4,CHEMBL619777,,
3493,,Cavia porcellus,,B,H,Autocuration,,10141.0,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,104841,,,1,7721,BAO_0000224,4,CHEMBL619778,,
3494,,Cavia porcellus,,B,H,Autocuration,Ileum,10141.0,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,104841,,,1,9117,BAO_0000221,4,CHEMBL619779,,2116.0
3495,,Cavia porcellus,,B,H,Autocuration,,10141.0,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",104841,,,1,7721,BAO_0000224,4,CHEMBL619780,,
3496,,Cavia porcellus,,B,H,Autocuration,,10141.0,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",104841,,,1,7721,BAO_0000224,4,CHEMBL619166,,
3497,,Cavia porcellus,,F,H,Autocuration,,10141.0,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,104841,,,1,15796,BAO_0000019,4,CHEMBL619167,,
3498,,Cavia porcellus,,F,H,Autocuration,,10141.0,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,104841,,,1,15796,BAO_0000019,4,CHEMBL619168,,
3499,,Homo sapiens,,B,D,Expert,Cardiac atrium,9606.0,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,168,,,1,15650,BAO_0000219,9,CHEMBL619169,,2081.0
3500,,Homo sapiens,,B,D,Expert,Cardiac atrium,9606.0,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,168,,,1,15650,BAO_0000219,9,CHEMBL619170,,2081.0
3501,,Homo sapiens,,F,D,Autocuration,,9606.0,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",104841,,,1,6866,BAO_0000019,5,CHEMBL619171,,
3502,,Homo sapiens,,F,D,Expert,Cardiac atrium,9606.0,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",168,,,1,15650,BAO_0000219,9,CHEMBL619172,,2081.0
3503,,Mus musculus,,B,U,Autocuration,,10090.0,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,22226,,,1,10063,BAO_0000019,0,CHEMBL619173,,
3504,,Mus musculus,,B,U,Autocuration,,10090.0,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,22226,,,1,12665,BAO_0000019,0,CHEMBL619174,,
3505,,,,B,H,Autocuration,,,5-hydroxytryptamine receptor binding affinity was determined in rats,104705,,,1,7504,BAO_0000019,4,CHEMBL619175,,
3506,,,,B,H,Autocuration,,,Binding affinity at rat 5-hydroxytryptamine receptor.,104705,,,1,7504,BAO_0000224,4,CHEMBL619176,,
3507,,,,B,H,Autocuration,,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,104705,,,1,7038,BAO_0000019,4,CHEMBL619177,,
3508,,,,B,H,Autocuration,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,104705,,,1,7626,BAO_0000224,4,CHEMBL619178,,
3509,,,,B,H,Autocuration,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,104705,,,1,7626,BAO_0000224,4,CHEMBL619179,,
3510,,,,F,H,Autocuration,Stomach,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,104705,,,1,7185,BAO_0000019,4,CHEMBL619180,,945.0
3511,,,,F,H,Autocuration,Stomach,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,104705,,,1,7185,BAO_0000019,4,CHEMBL619181,,945.0
3512,,,,F,H,Autocuration,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,104705,,,1,7185,BAO_0000019,4,CHEMBL619182,,
3513,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,104705,,,1,6960,BAO_0000224,4,CHEMBL619183,,
3514,,,,B,H,Autocuration,,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",104705,,,1,6960,BAO_0000224,4,CHEMBL619184,,
3515,,,,B,H,Autocuration,Hippocampus,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,10576,,,1,12416,BAO_0000221,8,CHEMBL619185,,10000000.0
3516,,,,B,H,Expert,,,Binding affinity for rat 5-hydroxytryptamine transporter.,12198,,,1,15753,BAO_0000357,8,CHEMBL619186,,
3517,,,,B,H,Autocuration,,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,104705,,,1,8062,BAO_0000019,4,CHEMBL619187,,
3518,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,104705,,,1,9036,BAO_0000019,5,CHEMBL619188,,
3519,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,104705,,,1,15067,BAO_0000224,5,CHEMBL619189,,
3520,,Rattus norvegicus,,F,D,Expert,Brain,10116.0,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,12198,,,1,15753,BAO_0000019,9,CHEMBL619190,,955.0
3521,,Rattus norvegicus,,F,D,Expert,Cerebellum,10116.0,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,12198,,,1,15753,BAO_0000221,9,CHEMBL619191,,2037.0
3522,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,104705,,,1,15295,BAO_0000019,5,CHEMBL619192,,
3523,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Percent binding affinity against 5-hydroxytryptamine receptor,104705,,,1,6347,BAO_0000224,5,CHEMBL619193,,
3524,,,,B,U,Autocuration,,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,22226,,,1,6763,BAO_0000019,0,CHEMBL619194,,
3525,,Rattus norvegicus,,B,D,Autocuration,,10116.0,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,104705,,,1,12092,BAO_0000224,5,CHEMBL619195,,
3526,,Rattus norvegicus,,B,D,Autocuration,,10116.0,Affinity against 5-hydroxytryptamine receptor was determined,104705,,,1,1579,BAO_0000224,5,CHEMBL619196,,
3527,,Rattus norvegicus,,B,D,Autocuration,Stomach,10116.0,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,104705,,,1,1579,BAO_0000019,5,CHEMBL619197,,945.0
3528,In vitro,Homo sapiens,,B,D,Expert,,9606.0,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,121,,,1,5963,BAO_0000219,9,CHEMBL619198,,
3529,In vitro,Homo sapiens,,B,D,Expert,,9606.0,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,121,,,1,5963,BAO_0000219,9,CHEMBL875081,,
3530,,,,B,H,Autocuration,,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,18065,,,1,5030,BAO_0000357,8,CHEMBL884712,,
3531,,,,B,H,Expert,,,Inhibition of 5-hydroxytryptamine reuptake,121,,,1,15796,BAO_0000357,8,CHEMBL884710,,
3532,,,,F,H,Autocuration,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",18065,,,1,15413,BAO_0000019,8,CHEMBL619199,,
3533,,,,F,H,Autocuration,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",18065,,,1,15413,BAO_0000019,8,CHEMBL619200,,
3534,,,,F,H,Autocuration,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",18065,,,1,15413,BAO_0000019,8,CHEMBL619201,,
3535,,,,F,H,Autocuration,,,Tested for 5-hydroxytryptamine receptor uptake,18065,,,1,12409,BAO_0000019,8,CHEMBL619202,,
3536,,Homo sapiens,,B,D,Expert,,9606.0,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,51,,,1,16909,BAO_0000219,9,CHEMBL619203,449.0,
3537,,Homo sapiens,,F,D,Expert,,9606.0,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,51,,,1,16909,BAO_0000019,9,CHEMBL619204,,
3538,,Homo sapiens,,B,H,Autocuration,,9606.0,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,10576,,,1,15629,BAO_0000249,8,CHEMBL619205,,
3539,,,,B,H,Autocuration,,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,10576,,,1,15629,BAO_0000357,8,CHEMBL619206,,
3540,,,,B,H,Expert,,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,10576,,,1,15629,BAO_0000249,8,CHEMBL619207,,
3541,,,,F,H,Autocuration,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,10825,,,1,10034,BAO_0000019,8,CHEMBL619208,,2435.0
3542,,,,F,H,Autocuration,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,10825,,,1,10034,BAO_0000019,8,CHEMBL619209,,2435.0
3543,,,,F,H,Autocuration,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,10825,,,1,10034,BAO_0000019,8,CHEMBL619210,,2435.0
3544,,,,F,H,Autocuration,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,10825,,,1,10034,BAO_0000019,8,CHEMBL619211,,2435.0
3545,,,,F,H,Autocuration,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,10825,,,1,10034,BAO_0000019,8,CHEMBL619212,,2435.0
3546,,,,F,H,Autocuration,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,10825,,,1,10034,BAO_0000019,8,CHEMBL620681,,2435.0
3547,,,,F,H,Autocuration,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,10825,,,1,10034,BAO_0000019,8,CHEMBL620682,,2435.0
3548,,,,F,H,Autocuration,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,10825,,,1,10034,BAO_0000019,8,CHEMBL620683,,2435.0
3549,,,,F,H,Autocuration,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,10825,,,1,10034,BAO_0000019,8,CHEMBL620684,,2435.0
3550,,,,F,H,Autocuration,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,10825,,,1,10034,BAO_0000019,8,CHEMBL620685,,2435.0
3551,,,,F,H,Autocuration,Striatum,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,10825,,,1,10034,BAO_0000019,8,CHEMBL620686,,2435.0
3552,,,,F,H,Autocuration,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,10825,,,1,10034,BAO_0000019,8,CHEMBL620687,,349.0
3553,,,,F,H,Autocuration,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,10825,,,1,10034,BAO_0000019,8,CHEMBL620688,,349.0
3554,,,,F,H,Autocuration,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,10825,,,1,10034,BAO_0000019,8,CHEMBL620689,,349.0
3555,,,,F,H,Autocuration,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,10825,,,1,10034,BAO_0000019,8,CHEMBL620690,,349.0
3556,,,,F,H,Autocuration,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,10825,,,1,10034,BAO_0000019,8,CHEMBL620691,,349.0
3557,,,,F,H,Autocuration,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,10825,,,1,10034,BAO_0000019,8,CHEMBL620692,,349.0
3558,,,,F,H,Autocuration,Limbic system,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,10825,,,1,10034,BAO_0000019,8,CHEMBL620693,,349.0
3559,,,,B,H,Expert,,,Binding affinity against 5-hydroxytryptamine 4 receptor,168,,,1,1274,BAO_0000357,8,CHEMBL620694,,
3560,,,,F,H,Autocuration,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,168,,,1,17358,BAO_0000019,8,CHEMBL857986,,
3561,,,,B,H,Autocuration,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,168,,,1,14532,BAO_0000357,8,CHEMBL620695,,
3562,,,,B,H,Expert,,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,168,,,1,16989,BAO_0000357,8,CHEMBL620696,,
3563,,,,B,H,Autocuration,,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,168,,,1,17200,BAO_0000357,8,CHEMBL620697,,
3564,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 4 receptor,168,,,1,15779,BAO_0000357,8,CHEMBL620698,,
3565,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,168,,,1,15779,BAO_0000357,8,CHEMBL620699,,
3566,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,168,,,1,15779,BAO_0000357,8,CHEMBL620700,,
3567,,,,B,H,Autocuration,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,168,,,1,15650,BAO_0000219,8,CHEMBL620701,643.0,
3568,,,,B,H,Autocuration,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,168,,,1,15650,BAO_0000219,8,CHEMBL875082,643.0,
3569,,,,B,H,Autocuration,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,168,,,1,15650,BAO_0000219,8,CHEMBL620702,643.0,
3570,,,,B,H,Autocuration,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,168,,,1,15650,BAO_0000219,8,CHEMBL620703,643.0,
3571,,,,B,H,Autocuration,,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,168,,,1,17046,BAO_0000219,8,CHEMBL620704,673.0,
3572,,,,B,H,Expert,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,168,,,1,17046,BAO_0000219,8,CHEMBL620705,673.0,
3573,,,,B,H,Expert,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,168,,,1,15650,BAO_0000219,8,CHEMBL620706,673.0,
3574,,,,B,H,Expert,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,168,,,1,17046,BAO_0000219,8,CHEMBL620707,673.0,
3575,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 5 receptor,10624,,,1,17066,BAO_0000357,8,CHEMBL620708,,
3576,,,,B,H,Autocuration,,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,105,,,1,17200,BAO_0000357,8,CHEMBL620709,,
3577,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against 5-hydroxytryptamine 5A receptor,10624,,,1,16146,BAO_0000357,9,CHEMBL620710,,
3578,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,10624,,,1,15250,BAO_0000219,8,CHEMBL620711,449.0,
3579,,Homo sapiens,,B,D,Expert,,9606.0,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,10624,,,1,6491,BAO_0000357,9,CHEMBL620712,,
3580,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards human 5-hydroxytryptamine 5A receptor,10624,,,1,17066,BAO_0000357,9,CHEMBL620713,,
3581,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,10624,,,1,17066,BAO_0000357,9,CHEMBL620714,,
3582,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,10624,,,1,4234,BAO_0000357,9,CHEMBL620715,,
3583,,,,B,H,Autocuration,,,Binding affinity towards 5-HT5A receptor,10624,,,1,6013,BAO_0000357,8,CHEMBL620716,,
3584,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,10624,,,1,17175,BAO_0000357,8,CHEMBL620717,,
3585,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,10624,,,1,15818,BAO_0000357,8,CHEMBL618072,,
3586,,,,B,H,Autocuration,,,Binding affinity towards cloned human 5-HT5A receptor was determined,10624,,,1,6166,BAO_0000357,8,CHEMBL857987,,
3587,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,10624,,,1,15779,BAO_0000219,8,CHEMBL618073,722.0,
3588,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,10624,,,1,15779,BAO_0000219,8,CHEMBL618074,722.0,
3589,,,,B,H,Autocuration,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),10624,,,1,5213,BAO_0000219,8,CHEMBL618075,722.0,
3590,,Mus musculus,,B,D,Expert,,10090.0,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,10625,,,1,17066,BAO_0000357,9,CHEMBL618076,,
3591,,Mus musculus,,B,D,Expert,,10090.0,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,10625,,,1,17066,BAO_0000357,9,CHEMBL618077,,
3592,,Mus musculus,,B,D,Expert,,10090.0,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,10625,,,1,17066,BAO_0000357,9,CHEMBL618078,,
3593,,Mus musculus,,B,D,Expert,,10090.0,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,10625,,,1,17066,BAO_0000357,9,CHEMBL881821,,
3594,,Mus musculus,,B,D,Expert,,10090.0,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,10625,,,1,17066,BAO_0000357,9,CHEMBL618079,,
3595,,,,B,H,Expert,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,10625,,,1,17175,BAO_0000357,8,CHEMBL618080,,
3596,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,10576,,,1,16190,BAO_0000219,8,CHEMBL618081,722.0,
3597,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,10626,,,1,16190,BAO_0000219,8,CHEMBL618082,722.0,
3598,,,,B,H,Expert,,,Binding affinity towards 5-HT5a receptor,10624,,,1,4820,BAO_0000357,8,CHEMBL618083,,
3599,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards 5-hydroxytryptamine 5A receptor,10624,,,1,17066,BAO_0000357,9,CHEMBL618084,,
3600,,,,B,H,Expert,,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,10624,,,1,17066,BAO_0000357,8,CHEMBL618085,,
3601,,,,B,H,Expert,,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,10624,,,1,17175,BAO_0000357,8,CHEMBL618086,,
3602,,,,B,H,Autocuration,,,Binding affinities against 5-hydroxytryptamine 5A receptor,10624,,,1,16633,BAO_0000357,8,CHEMBL875092,,
3603,,,,B,H,Autocuration,,,Binding affinities towards 5-hydroxytryptamine 5A receptor,10624,,,1,16633,BAO_0000357,8,CHEMBL618087,,
3604,,,,B,H,Autocuration,,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,10624,,,1,16700,BAO_0000357,8,CHEMBL872926,,
3605,,Cavia porcellus,,F,H,Autocuration,,10141.0,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,104714,,,1,4639,BAO_0000019,4,CHEMBL618088,,
3606,,,,B,H,Autocuration,,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,104714,,,1,5486,BAO_0000223,4,CHEMBL618089,,
3607,,Homo sapiens,,B,D,Expert,,9606.0,Inhibition of human 5-hydroxytryptamine 6 receptor,10627,,,1,16146,BAO_0000357,9,CHEMBL618090,,
3608,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,10627,,,1,17273,BAO_0000357,9,CHEMBL618091,,
3609,,,,B,H,Autocuration,,,Inhibition against human 5-hydroxytryptamine 6 receptor,10627,,,1,17687,BAO_0000357,8,CHEMBL618092,,
3610,,Homo sapiens,,B,D,Expert,,9606.0,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,10627,,,1,6491,BAO_0000357,9,CHEMBL618093,,
3611,,,,B,H,Expert,,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,10627,,,1,16190,BAO_0000219,8,CHEMBL618094,308.0,
3612,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,10627,,,1,17066,BAO_0000357,9,CHEMBL618095,,
3613,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,1,17066,BAO_0000357,9,CHEMBL875093,,
3614,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,10627,,,1,17066,BAO_0000357,9,CHEMBL618096,,
3615,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,10627,,,1,17066,BAO_0000357,9,CHEMBL618118,,
3616,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against 5-hydroxytryptamine 6 receptor,10627,,,1,3555,BAO_0000357,9,CHEMBL618119,,
3617,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,1,5808,BAO_0000357,8,CHEMBL618120,,
3618,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,1,6013,BAO_0000357,8,CHEMBL618121,,
3619,,,,B,H,Expert,,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",10627,,,1,15818,BAO_0000219,8,CHEMBL618122,722.0,
3620,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,10627,,,1,16209,BAO_0000357,8,CHEMBL618123,,
3621,,,,B,H,Expert,,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,10627,,,1,3935,BAO_0000219,8,CHEMBL618124,722.0,
3622,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,1,15818,BAO_0000357,8,CHEMBL618125,,
3623,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,10627,,,1,3805,BAO_0000219,9,CHEMBL618126,722.0,
3624,,,,B,H,Expert,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,10627,,,1,16441,BAO_0000019,8,CHEMBL618236,,
3625,,,,B,H,Expert,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,10627,,,1,16441,BAO_0000019,8,CHEMBL618237,,
3626,,,,B,H,Expert,,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,10627,,,1,6786,BAO_0000219,8,CHEMBL618238,643.0,
3627,,Homo sapiens,,B,D,Expert,,9606.0,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,10627,,,1,4234,BAO_0000357,9,CHEMBL618239,,
3628,,,,B,H,Autocuration,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,10627,,,1,17085,BAO_0000019,8,CHEMBL618240,,
3629,,,,B,H,Autocuration,,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,10627,,,1,17200,BAO_0000357,8,CHEMBL618241,,
3630,,,,B,H,Autocuration,,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,10627,,,1,17451,BAO_0000219,8,CHEMBL859399,722.0,
3631,,,,F,H,Autocuration,,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,10627,,,1,3935,BAO_0000019,8,CHEMBL618242,,
3632,,,,B,H,Autocuration,,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,10627,,,1,5033,BAO_0000357,8,CHEMBL857991,,
3633,,,,B,H,Expert,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,10627,,,1,4540,BAO_0000357,8,CHEMBL619951,,
3634,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,10627,,,1,4540,BAO_0000219,9,CHEMBL619952,308.0,
3635,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,10627,,,1,4540,BAO_0000219,9,CHEMBL619953,308.0,
3636,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,10627,,,1,17296,BAO_0000219,8,CHEMBL619954,308.0,
3637,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,10627,,,1,17296,BAO_0000219,8,CHEMBL619955,308.0,
3638,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,10627,,,1,17296,BAO_0000219,8,CHEMBL619956,308.0,
3639,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,10627,,,1,15779,BAO_0000219,8,CHEMBL619957,449.0,
3640,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,10627,,,1,15779,BAO_0000219,8,CHEMBL619958,722.0,
3641,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,10627,,,1,15779,BAO_0000219,8,CHEMBL620627,722.0,
3642,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,10627,,,1,15779,BAO_0000219,8,CHEMBL620628,722.0,
3643,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,10627,,,1,15779,BAO_0000219,8,CHEMBL620629,308.0,
3644,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,1,6166,BAO_0000357,8,CHEMBL620630,,
3645,,,,B,H,Autocuration,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,10627,,,1,17451,BAO_0000219,8,CHEMBL620782,308.0,
3646,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,10627,,,1,15316,BAO_0000357,8,CHEMBL620783,,
3647,,,,B,H,Expert,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,10627,,,1,4199,BAO_0000357,8,CHEMBL620784,,
3648,,,,B,H,Expert,,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,10627,,,1,15146,BAO_0000219,8,CHEMBL620785,308.0,
3649,,,,B,H,Autocuration,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),10627,,,1,5213,BAO_0000357,8,CHEMBL857992,,
3650,,,,B,H,Autocuration,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,10627,,,1,16429,BAO_0000219,8,CHEMBL620786,,
3651,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,10627,,,1,14818,BAO_0000219,8,CHEMBL620787,308.0,
3652,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",10627,,,1,4829,BAO_0000219,8,CHEMBL620788,308.0,
3653,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",10627,,,1,4829,BAO_0000219,8,CHEMBL620789,308.0,
3654,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",10627,,,1,4829,BAO_0000219,8,CHEMBL620790,308.0,
3655,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,10628,,,1,15250,BAO_0000219,8,CHEMBL620791,449.0,
3656,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,10628,,,1,14423,BAO_0000019,8,CHEMBL620792,,
3657,,,,B,H,Autocuration,,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,10628,,,1,15086,BAO_0000357,8,CHEMBL620793,,
3658,,,,B,H,Autocuration,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,10628,,,1,4342,BAO_0000357,8,CHEMBL620794,,
3659,,Homo sapiens,,B,D,Autocuration,,9606.0,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,10627,,,1,16190,BAO_0000219,9,CHEMBL620795,308.0,
3660,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,1,4820,BAO_0000357,8,CHEMBL620796,,
3661,,,,B,H,Autocuration,,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,10627,,,1,4639,BAO_0000357,8,CHEMBL620797,,
3662,,Homo sapiens,,F,D,Expert,,9606.0,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,10627,,,1,17066,BAO_0000019,9,CHEMBL620798,,
3663,,,,B,H,Autocuration,,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,10627,,,1,6011,BAO_0000357,8,CHEMBL620799,,
3664,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,10627,,,1,17066,BAO_0000357,8,CHEMBL620800,,
3665,,,,B,H,Autocuration,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,10627,,,1,17515,BAO_0000357,8,CHEMBL620801,,
3666,,,,B,H,Autocuration,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,10627,,,1,5014,BAO_0000357,8,CHEMBL875100,,
3667,,,,B,H,Autocuration,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,10627,,,1,4373,BAO_0000357,8,CHEMBL620802,,
3668,,,,F,H,Expert,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,10627,,,1,17066,BAO_0000019,8,CHEMBL620803,,
3669,,,,F,H,Expert,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,10627,,,1,17066,BAO_0000019,8,CHEMBL620804,,
3670,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,10627,,,1,4373,BAO_0000357,8,CHEMBL620805,,
3671,,,,B,H,Autocuration,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,10627,,,1,4687,BAO_0000357,8,CHEMBL620806,,
3672,,,,B,H,Autocuration,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,10627,,,1,16946,BAO_0000357,8,CHEMBL620807,,
3673,,,,B,H,Autocuration,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,10627,,,1,16946,BAO_0000357,8,CHEMBL620808,,
3674,,,,B,H,Autocuration,,,Binding affinities against 5-hydroxytryptamine 6 receptor,10627,,,1,16633,BAO_0000357,8,CHEMBL620809,,
3675,,,,B,H,Autocuration,,,Binding affinities towards 5-hydroxytryptamine 6 receptor,10627,,,1,16633,BAO_0000357,8,CHEMBL620810,,
3676,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards 5-hydroxytryptamine 6 receptor,10627,,,1,17066,BAO_0000357,9,CHEMBL620811,,
3677,,,,B,H,Autocuration,,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,10627,,,1,16700,BAO_0000357,8,CHEMBL620812,,
3678,,,,B,H,Autocuration,,,Affinity against 5-hydroxytryptamine 6 receptor,10627,,,1,3269,BAO_0000357,8,CHEMBL620813,,
3679,,,,B,H,Autocuration,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],10627,,,1,5486,BAO_0000357,8,CHEMBL620814,,
3680,,Homo sapiens,,B,D,Expert,,9606.0,Inhibition of human 5-hydroxytryptamine 7 receptor,10209,,,1,16146,BAO_0000357,9,CHEMBL620815,,
3681,,,,B,H,Autocuration,,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,10209,,,1,5014,BAO_0000219,8,CHEMBL620816,722.0,
3682,,,,B,H,Autocuration,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,10209,,,1,15463,BAO_0000357,8,CHEMBL620817,,
3683,,,,B,H,Autocuration,,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),10209,,,1,3805,BAO_0000357,8,CHEMBL620818,,
3684,,,,B,H,Expert,,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,10209,,,1,5014,BAO_0000219,8,CHEMBL620819,722.0,
3685,,Homo sapiens,,B,D,Expert,,9606.0,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,10209,,,1,6491,BAO_0000357,9,CHEMBL620820,,
3686,,,,B,H,Autocuration,,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,10209,,,1,16190,BAO_0000219,8,CHEMBL620821,449.0,
3687,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards human 5-hydroxytryptamine 7 receptor,10209,,,1,17066,BAO_0000357,9,CHEMBL620822,,
3688,,Homo sapiens,,B,D,Expert,,9606.0,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,10209,,,1,17066,BAO_0000357,9,CHEMBL620823,,
3689,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity against 5-hydroxytryptamine 7 receptor,10209,,,1,3555,BAO_0000357,9,CHEMBL620824,,
3690,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,10209,,,1,6588,BAO_0000219,8,CHEMBL620825,449.0,
3691,,,,B,H,Autocuration,,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,10209,,,1,15463,BAO_0000357,8,CHEMBL872930,,
3692,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,10209,,,1,6013,BAO_0000357,8,CHEMBL620826,,
3693,,,,B,H,Autocuration,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,10209,,,1,16209,BAO_0000357,8,CHEMBL620827,,
3694,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,10209,,,1,3935,BAO_0000357,8,CHEMBL620828,,
3695,,,,B,H,Autocuration,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,10209,,,1,15818,BAO_0000357,8,CHEMBL620829,,
3696,,,,B,H,Expert,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,10209,,,1,5014,BAO_0000219,8,CHEMBL620830,722.0,
3697,,,,B,H,Expert,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,10209,,,1,16441,BAO_0000019,8,CHEMBL620831,,
3698,,,,B,H,Expert,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,10209,,,1,16441,BAO_0000019,8,CHEMBL620832,,
3699,,Homo sapiens,,B,D,Expert,,9606.0,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,10209,,,1,4234,BAO_0000357,9,CHEMBL621548,,
3700,,,,B,H,Autocuration,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,10209,,,1,17085,BAO_0000019,8,CHEMBL621549,,
3701,,,,B,H,Autocuration,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,10209,,,1,17200,BAO_0000357,8,CHEMBL621550,,
3702,,,,B,H,Autocuration,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,10209,,,1,17451,BAO_0000219,8,CHEMBL621551,449.0,
3703,,,,B,H,Autocuration,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,10209,,,1,17085,BAO_0000019,8,CHEMBL621552,,
3704,,,,B,H,Autocuration,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,10209,,,1,5104,BAO_0000357,8,CHEMBL857077,,
3705,,,,B,H,Autocuration,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,10209,,,1,5104,BAO_0000357,8,CHEMBL618158,,
3706,,Homo sapiens,,B,D,Expert,,9606.0,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,10209,,,1,5033,BAO_0000219,9,CHEMBL618159,643.0,
3707,,,,B,H,Autocuration,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,10209,,,1,5486,BAO_0000219,8,CHEMBL875101,643.0,
3708,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,10209,,,1,4540,BAO_0000219,9,CHEMBL618160,722.0,
3709,,,,B,H,Expert,,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,10209,,,1,6166,BAO_0000357,8,CHEMBL618161,,
3710,,,,B,H,Expert,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,10209,,,1,17342,BAO_0000219,8,CHEMBL618162,722.0,
3711,,,,B,H,Expert,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,10209,,,1,17342,BAO_0000357,8,CHEMBL618163,,
3712,,,,B,H,Autocuration,,,Binding affinity against 5-hydroxytryptamine 7 human receptors,10209,,,1,17296,BAO_0000357,8,CHEMBL618164,,
3713,,,,B,H,Expert,,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,10209,,,1,16429,BAO_0000219,8,CHEMBL618165,,
3714,,,,B,H,Autocuration,,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,10209,,,1,15779,BAO_0000219,8,CHEMBL618166,722.0,
3715,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,10209,,,1,15779,BAO_0000219,8,CHEMBL857989,722.0,
3716,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,10209,,,1,15779,BAO_0000219,8,CHEMBL619888,722.0,
3717,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,10209,,,1,15779,BAO_0000219,8,CHEMBL619889,722.0,
3718,,,,B,H,Autocuration,,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,10209,,,1,15779,BAO_0000219,8,CHEMBL619890,722.0,
3719,,,,B,H,Autocuration,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,10209,,,1,17451,BAO_0000219,8,CHEMBL619891,449.0,
3720,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),10209,,,1,4199,BAO_0000219,8,CHEMBL619892,722.0,
3721,,,,B,D,Expert,,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,10209,,,1,4199,BAO_0000219,9,CHEMBL619893,722.0,
3722,,,,B,H,Autocuration,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),10209,,,1,4199,BAO_0000219,8,CHEMBL619894,722.0,
3723,,,,B,D,Intermediate,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,10209,,,1,3680,BAO_0000219,9,CHEMBL619895,722.0,
3724,,,,B,D,Intermediate,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,10209,,,1,3680,BAO_0000357,9,CHEMBL619896,,
3725,,,,B,H,Autocuration,,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,10209,,,1,15316,BAO_0000219,8,CHEMBL619897,643.0,
3726,,,,B,H,Autocuration,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,10209,,,1,15146,BAO_0000219,8,CHEMBL619898,722.0,
3727,,,,B,H,Expert,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,10209,,,1,5213,BAO_0000219,8,CHEMBL619899,722.0,
3728,,,,B,H,Autocuration,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),10209,,,1,5213,BAO_0000219,8,CHEMBL619900,722.0,
3729,,Homo sapiens,,B,D,Expert,,9606.0,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,10209,,,1,14818,BAO_0000219,9,CHEMBL619901,722.0,
3730,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,10209,,,1,14818,BAO_0000219,8,CHEMBL620580,722.0,
3731,,,,B,H,Autocuration,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,10209,,,1,14818,BAO_0000219,8,CHEMBL620581,722.0,
3732,,,,B,H,Autocuration,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",10209,,,1,4829,BAO_0000219,8,CHEMBL620733,722.0,
3733,,Homo sapiens,,B,D,Autocuration,,9606.0,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,10209,,,1,17200,BAO_0000357,9,CHEMBL620734,,
3734,,Mus musculus,,B,D,Expert,,10090.0,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,10022,,,1,17066,BAO_0000357,9,CHEMBL620735,,
3735,,Oryctolagus cuniculus,,B,H,Autocuration,,9986.0,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,10209,,,1,14025,BAO_0000019,8,CHEMBL620736,,
3736,,,,B,H,Autocuration,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,11923,,,1,15250,BAO_0000219,8,CHEMBL620737,449.0,
3737,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,11923,,,1,16372,BAO_0000219,8,CHEMBL620738,449.0,
3738,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,11923,,,1,16372,BAO_0000219,8,CHEMBL620739,449.0,
3739,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,11923,,,1,16372,BAO_0000219,8,CHEMBL620740,449.0,
3740,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,11923,,,1,16372,BAO_0000219,8,CHEMBL620741,449.0,
3741,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,11923,,,1,16372,BAO_0000219,8,CHEMBL620742,449.0,
3742,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,11923,,,1,16372,BAO_0000219,8,CHEMBL620743,449.0,
3743,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,11923,,,1,16372,BAO_0000219,8,CHEMBL620744,449.0,
3744,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,11923,,,1,16372,BAO_0000219,8,CHEMBL620745,449.0,
3745,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,11923,,,1,16372,BAO_0000219,8,CHEMBL620746,449.0,
3746,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,11923,,,1,16372,BAO_0000219,8,CHEMBL620747,449.0,
3747,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,11923,,,1,16372,BAO_0000219,8,CHEMBL620748,449.0,
3748,,,,B,H,Autocuration,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,11923,,,1,16372,BAO_0000219,8,CHEMBL620749,449.0,
3749,,,,B,H,Expert,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,11923,,,1,17066,BAO_0000357,8,CHEMBL620750,,
3750,,Rattus norvegicus,,B,D,Expert,,10116.0,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,11923,,,1,17066,BAO_0000357,9,CHEMBL620751,,
3751,,,,B,H,Expert,,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,11923,,,1,17386,BAO_0000357,8,CHEMBL620752,,
